{"bf591e8759b1d4eefa15826f4d9ae11a7f227de4": [["IntroductionPneumonia is defi ned as infection and infl ammation of the lower respiratory tract in association with parenchymal radiographic opacity.", [["lower respiratory tract", "ANATOMY", 72, 95], ["parenchymal", "ANATOMY", 116, 127], ["IntroductionPneumonia", "DISEASE", 0, 21], ["infection", "DISEASE", 37, 46], ["lower", "ORGANISM_SUBDIVISION", 72, 77], ["respiratory tract", "ORGANISM_SUBDIVISION", 78, 95], ["IntroductionPneumonia", "PROBLEM", 0, 21], ["infection", "PROBLEM", 37, 46], ["infl ammation of the lower respiratory tract", "PROBLEM", 51, 95], ["parenchymal radiographic opacity", "PROBLEM", 116, 148], ["infection", "OBSERVATION", 37, 46], ["lower", "ANATOMY_MODIFIER", 72, 77], ["respiratory tract", "ANATOMY", 78, 95], ["parenchymal", "ANATOMY_MODIFIER", 116, 127], ["radiographic", "OBSERVATION_MODIFIER", 128, 140], ["opacity", "OBSERVATION", 141, 148]]], ["This defi nition excludes bronchiolitis, tracheitis, neonatal pneumonia, and noninfectious causes of pneumonia and pneumonitis, and these are not discussed in this chapter.IntroductionIn the pediatric intensive care unit (PICU), several pneumonia types may be encountered.", [["bronchiolitis", "DISEASE", 26, 39], ["tracheitis", "DISEASE", 41, 51], ["neonatal pneumonia", "DISEASE", 53, 71], ["pneumonia", "DISEASE", 101, 110], ["pneumonitis", "DISEASE", 115, 126], ["pneumonia", "DISEASE", 237, 246], ["This defi nition", "TREATMENT", 0, 16], ["bronchiolitis", "PROBLEM", 26, 39], ["tracheitis", "PROBLEM", 41, 51], ["neonatal pneumonia", "PROBLEM", 53, 71], ["noninfectious causes", "PROBLEM", 77, 97], ["pneumonia", "PROBLEM", 101, 110], ["pneumonitis", "PROBLEM", 115, 126], ["several pneumonia types", "PROBLEM", 229, 252], ["bronchiolitis", "OBSERVATION", 26, 39], ["tracheitis", "OBSERVATION", 41, 51], ["neonatal", "OBSERVATION_MODIFIER", 53, 61], ["pneumonia", "OBSERVATION", 62, 71], ["noninfectious", "OBSERVATION_MODIFIER", 77, 90], ["pneumonia", "OBSERVATION", 101, 110], ["pneumonitis", "OBSERVATION", 115, 126], ["pneumonia", "OBSERVATION", 237, 246]]], ["First, a previously healthy child may be admitted to the PICU because of severe community-acquired pneumonia (CAP).", [["pneumonia", "DISEASE", 99, 108], ["CAP", "DISEASE", 110, 113], ["child", "ORGANISM", 28, 33], ["severe community-acquired pneumonia (CAP)", "PROBLEM", 73, 114], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["pneumonia", "OBSERVATION", 99, 108]]], ["The pneumonia is usually caused by organisms that are prevalent in the out-of-hospital environment.", [["pneumonia", "DISEASE", 4, 13], ["The pneumonia", "PROBLEM", 0, 13], ["organisms", "PROBLEM", 35, 44], ["pneumonia", "OBSERVATION", 4, 13], ["usually caused", "UNCERTAINTY", 17, 31]]], ["Second, patients with genetic or acquired immune defi ciency commonly develop severe pneumonia with opportunistic infections that usually do not infect healthy children.", [["pneumonia", "DISEASE", 85, 94], ["opportunistic infections", "DISEASE", 100, 124], ["patients", "ORGANISM", 8, 16], ["children", "ORGANISM", 160, 168], ["patients", "SPECIES", 8, 16], ["children", "SPECIES", 160, 168], ["acquired immune defi ciency", "PROBLEM", 33, 60], ["severe pneumonia", "PROBLEM", 78, 94], ["opportunistic infections", "PROBLEM", 100, 124], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["pneumonia", "OBSERVATION", 85, 94], ["opportunistic", "OBSERVATION_MODIFIER", 100, 113], ["infections", "OBSERVATION", 114, 124]]], ["These immunocompromised patients commonly have been given chemo-radiotherapy for cancer or are receiving immune-suppressive agents to prevent rejection episodes following solid organ and hematopoietic stem cell transplantation.", [["cancer", "ANATOMY", 81, 87], ["solid organ", "ANATOMY", 171, 182], ["hematopoietic stem cell", "ANATOMY", 187, 210], ["cancer", "DISEASE", 81, 87], ["patients", "ORGANISM", 24, 32], ["cancer", "CANCER", 81, 87], ["organ", "ORGAN", 177, 182], ["hematopoietic stem cell", "CELL", 187, 210], ["patients", "SPECIES", 24, 32], ["chemo-radiotherapy", "TREATMENT", 58, 76], ["cancer", "PROBLEM", 81, 87], ["immune-suppressive agents", "TREATMENT", 105, 130], ["rejection episodes", "PROBLEM", 142, 160], ["solid organ", "TREATMENT", 171, 182], ["hematopoietic stem cell transplantation", "TREATMENT", 187, 226], ["immunocompromised", "OBSERVATION", 6, 23], ["rejection", "OBSERVATION", 142, 151], ["solid organ", "ANATOMY", 171, 182], ["hematopoietic stem cell transplantation", "OBSERVATION", 187, 226]]], ["Third, both previously healthy and immunocompromised patients may acquire nosocomial pneumonia during their hospital stay.", [["pneumonia", "DISEASE", 85, 94], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["nosocomial pneumonia", "PROBLEM", 74, 94], ["immunocompromised", "OBSERVATION", 35, 52], ["nosocomial", "OBSERVATION_MODIFIER", 74, 84], ["pneumonia", "OBSERVATION", 85, 94]]], ["Mechanically ventilated patients are at especially high risk to develop nosocomial ventilator-associated pneumonia (VAP).", [["ventilator-associated pneumonia", "DISEASE", 83, 114], ["VAP", "DISEASE", 116, 119], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["Mechanically ventilated", "TREATMENT", 0, 23], ["nosocomial ventilator-associated pneumonia", "PROBLEM", 72, 114], ["VAP", "PROBLEM", 116, 119], ["ventilated", "OBSERVATION", 13, 23], ["nosocomial ventilator", "OBSERVATION", 72, 93], ["pneumonia", "OBSERVATION", 105, 114]]], ["Finally, aspiration pneumonia caused by chronic inoculation of the lower respiratory tract with large amounts of less virulent bacteria in a susceptible host prone to aspiration is also observed in the PICU.IntroductionThis classifi cation of pneumonia types in the PICU is important because it has major implications on the causative microbial agent and, thus, the choice of initial empiric treatment that may be life saving.", [["lower respiratory tract", "ANATOMY", 67, 90], ["pneumonia", "DISEASE", 20, 29], ["pneumonia", "DISEASE", 243, 252], ["lower", "ORGANISM_SUBDIVISION", 67, 72], ["respiratory tract", "ORGANISM_SUBDIVISION", 73, 90], ["aspiration pneumonia", "PROBLEM", 9, 29], ["chronic inoculation of the lower respiratory tract", "PROBLEM", 40, 90], ["less virulent bacteria", "PROBLEM", 113, 135], ["aspiration", "PROBLEM", 167, 177], ["This classifi cation", "TREATMENT", 219, 239], ["pneumonia", "PROBLEM", 243, 252], ["initial empiric treatment", "TREATMENT", 376, 401], ["aspiration", "OBSERVATION_MODIFIER", 9, 19], ["pneumonia", "OBSERVATION", 20, 29], ["chronic", "OBSERVATION_MODIFIER", 40, 47], ["inoculation", "OBSERVATION", 48, 59], ["lower", "ANATOMY_MODIFIER", 67, 72], ["respiratory tract", "ANATOMY", 73, 90], ["large", "OBSERVATION_MODIFIER", 96, 101], ["amounts", "OBSERVATION_MODIFIER", 102, 109], ["less", "OBSERVATION_MODIFIER", 113, 117], ["virulent", "OBSERVATION_MODIFIER", 118, 126], ["bacteria", "OBSERVATION_MODIFIER", 127, 135], ["susceptible host prone", "OBSERVATION_MODIFIER", 141, 163], ["aspiration", "OBSERVATION", 167, 177], ["pneumonia", "OBSERVATION", 243, 252]]], ["This chapter reviews respiratory host defenses that maintain sterility of the lower respiratory tract.", [["respiratory", "ANATOMY", 21, 32], ["lower respiratory tract", "ANATOMY", 78, 101], ["lower", "ORGANISM_SUBDIVISION", 78, 83], ["respiratory tract", "ORGANISM_SUBDIVISION", 84, 101], ["sterility of the lower respiratory tract", "PROBLEM", 61, 101], ["lower", "ANATOMY_MODIFIER", 78, 83], ["respiratory tract", "ANATOMY", 84, 101]]], ["In addition, the pathogenesis, classifi cation, and treatment options for pneumonia and empyema in the PICU patient are briefl y discussed. potent expiratory maneuver is of fundamental importance in preventing material from being aspirated into the lungs.IntroductionThe conducting airways also contain several antimicrobial substances, including immunoglobulins (IgG and secretory IgA), and complement that bind and enhance the elimination of microbial agents.", [["lungs", "ANATOMY", 249, 254], ["airways", "ANATOMY", 282, 289], ["pneumonia", "DISEASE", 74, 83], ["empyema", "DISEASE", 88, 95], ["patient", "ORGANISM", 108, 115], ["lungs", "ORGAN", 249, 254], ["airways", "MULTI-TISSUE_STRUCTURE", 282, 289], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 347, 362], ["IgG", "GENE_OR_GENE_PRODUCT", 364, 367], ["secretory IgA", "GENE_OR_GENE_PRODUCT", 372, 385], ["immunoglobulins", "PROTEIN", 347, 362], ["IgG", "PROTEIN", 364, 367], ["secretory IgA", "PROTEIN", 372, 385], ["patient", "SPECIES", 108, 115], ["classifi cation", "TREATMENT", 31, 46], ["treatment options", "TREATMENT", 52, 69], ["pneumonia", "PROBLEM", 74, 83], ["empyema", "PROBLEM", 88, 95], ["potent expiratory maneuver", "TREATMENT", 140, 166], ["several antimicrobial substances", "TREATMENT", 303, 335], ["immunoglobulins (IgG", "TEST", 347, 367], ["secretory IgA", "TEST", 372, 385], ["microbial agents", "TREATMENT", 444, 460], ["pneumonia", "OBSERVATION", 74, 83], ["empyema", "OBSERVATION", 88, 95], ["expiratory maneuver", "OBSERVATION", 147, 166], ["lungs", "ANATOMY", 249, 254], ["airways", "ANATOMY", 282, 289], ["several", "OBSERVATION_MODIFIER", 303, 310], ["antimicrobial substances", "OBSERVATION", 311, 335]]], ["In addition, airway epithelial and alveolar type (AT) II cells secrete several antimicrobial peptides.", [["airway epithelial", "ANATOMY", 13, 30], ["alveolar type (AT) II cells", "ANATOMY", 35, 62], ["airway epithelial", "CELL", 13, 30], ["alveolar type (AT) II cells", "CELL", 35, 62], ["airway epithelial and alveolar type (AT) II cells", "CELL_TYPE", 13, 62], ["airway epithelial and alveolar type (AT) II cells", "PROBLEM", 13, 62], ["several antimicrobial peptides", "TREATMENT", 71, 101], ["airway epithelial", "ANATOMY", 13, 30], ["alveolar", "ANATOMY_MODIFIER", 35, 43], ["several", "OBSERVATION_MODIFIER", 71, 78], ["antimicrobial peptides", "OBSERVATION", 79, 101]]], ["One of the best characterized families of antimicrobial peptides are the defensins, which are cysteine-rich peptides possessing broad antimicrobial activity [4] .", [["cysteine", "CHEMICAL", 94, 102], ["cysteine", "CHEMICAL", 94, 102], ["defensins", "GENE_OR_GENE_PRODUCT", 73, 82], ["antimicrobial peptides", "TREATMENT", 42, 64], ["cysteine-rich peptides", "TREATMENT", 94, 116]]], ["An important recent discovery is the expanding role of respiratory airway epithelium in innate immune defenses by mechanisms that mimic those noted in phagocytic cells.", [["respiratory airway epithelium", "ANATOMY", 55, 84], ["phagocytic cells", "ANATOMY", 151, 167], ["airway epithelium", "TISSUE", 67, 84], ["phagocytic cells", "CELL", 151, 167], ["phagocytic cells", "CELL_TYPE", 151, 167], ["respiratory airway epithelium", "PROBLEM", 55, 84], ["respiratory airway epithelium", "OBSERVATION", 55, 84], ["phagocytic cells", "OBSERVATION", 151, 167]]], ["Respiratory epithelial cells, including ATII cells, express TLR and are capable of expressing a variety of cytokines that amplify infl ammation.", [["Respiratory epithelial cells", "ANATOMY", 0, 28], ["ATII cells", "ANATOMY", 40, 50], ["Respiratory epithelial cells", "CELL", 0, 28], ["ATII cells", "CELL", 40, 50], ["TLR", "GENE_OR_GENE_PRODUCT", 60, 63], ["infl", "GENE_OR_GENE_PRODUCT", 130, 134], ["Respiratory epithelial cells", "CELL_TYPE", 0, 28], ["ATII cells", "CELL_TYPE", 40, 50], ["TLR", "PROTEIN", 60, 63], ["cytokines", "PROTEIN", 107, 116], ["Respiratory epithelial cells", "PROBLEM", 0, 28], ["ATII cells", "PROBLEM", 40, 50], ["epithelial cells", "OBSERVATION", 12, 28], ["ATII cells", "OBSERVATION", 40, 50]]], ["The importance of innate immunity in epithelial cells was confi rmed in mice with specifi c inhibition of nuclear factor (NF) \u03baB activation that was restricted to distal airway epithelial cells.", [["epithelial cells", "ANATOMY", 37, 53], ["distal airway epithelial cells", "ANATOMY", 163, 193], ["epithelial cells", "CELL", 37, 53], ["mice", "ORGANISM", 72, 76], ["nuclear factor (NF) \u03baB", "GENE_OR_GENE_PRODUCT", 106, 128], ["airway epithelial cells", "CELL", 170, 193], ["epithelial cells", "CELL_TYPE", 37, 53], ["nuclear factor (NF) \u03baB", "PROTEIN", 106, 128], ["distal airway epithelial cells", "CELL_TYPE", 163, 193], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["epithelial cells", "PROBLEM", 37, 53], ["epithelial cells", "OBSERVATION", 37, 53], ["distal", "ANATOMY_MODIFIER", 163, 169], ["airway", "ANATOMY", 170, 176], ["epithelial cells", "OBSERVATION", 177, 193]]], ["Mice lacking the ability to activate NF\u03baB in epithelial cells exhibited impaired infl ammatory response to inhaled LPS [5] .", [["epithelial cells", "ANATOMY", 45, 61], ["LPS", "CHEMICAL", 115, 118], ["Mice", "ORGANISM", 0, 4], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 37, 41], ["epithelial cells", "CELL", 45, 61], ["LPS", "SIMPLE_CHEMICAL", 115, 118], ["NF\u03baB", "PROTEIN", 37, 41], ["epithelial cells", "CELL_TYPE", 45, 61], ["Mice", "SPECIES", 0, 4], ["inhaled LPS", "TREATMENT", 107, 118]]], ["These data provide evidence that distal airway epithelial cells and the signals they transduce play a key physiologic role in lung infl ammation in vivo.", [["distal airway epithelial cells", "ANATOMY", 33, 63], ["lung", "ANATOMY", 126, 130], ["airway epithelial cells", "CELL", 40, 63], ["lung", "ORGAN", 126, 130], ["distal airway epithelial cells", "CELL_TYPE", 33, 63], ["distal airway epithelial cells", "PROBLEM", 33, 63], ["distal", "ANATOMY_MODIFIER", 33, 39], ["airway", "ANATOMY", 40, 46], ["epithelial cells", "OBSERVATION", 47, 63], ["lung", "ANATOMY", 126, 130]]], ["Alveolar type II cells also secrete surfactant proteins (SP)-A and D. Both SP-A and SP-D are collagen-like lectins (collectins) that agglutinate and/or opsonize pathogens and enhance their phagocytosis by innate immune cells such as alveolar macrophages and neutrophils [6] .", [["Alveolar type II cells", "ANATOMY", 0, 22], ["immune cells", "ANATOMY", 212, 224], ["alveolar macrophages", "ANATOMY", 233, 253], ["neutrophils", "ANATOMY", 258, 269], ["Alveolar type II cells", "CELL", 0, 22], ["surfactant proteins (SP)-A", "GENE_OR_GENE_PRODUCT", 36, 62], ["SP-A", "GENE_OR_GENE_PRODUCT", 75, 79], ["SP-D", "GENE_OR_GENE_PRODUCT", 84, 88], ["collagen-like lectins", "GENE_OR_GENE_PRODUCT", 93, 114], ["collectins", "GENE_OR_GENE_PRODUCT", 116, 126], ["immune cells", "CELL", 212, 224], ["alveolar macrophages", "CELL", 233, 253], ["neutrophils", "CELL", 258, 269], ["Alveolar type II cells", "CELL_TYPE", 0, 22], ["surfactant proteins", "PROTEIN", 36, 55], ["SP", "PROTEIN", 57, 59], ["SP", "PROTEIN", 75, 77], ["SP", "PROTEIN", 84, 86], ["collagen", "PROTEIN", 93, 101], ["lectins", "PROTEIN", 107, 114], ["collectins", "PROTEIN", 116, 126], ["innate immune cells", "CELL_TYPE", 205, 224], ["alveolar macrophages", "CELL_TYPE", 233, 253], ["neutrophils", "CELL_TYPE", 258, 269], ["Alveolar type II cells", "PROBLEM", 0, 22], ["surfactant proteins", "TEST", 36, 55], ["agglutinate", "PROBLEM", 133, 144], ["opsonize pathogens", "PROBLEM", 152, 170], ["alveolar macrophages", "PROBLEM", 233, 253], ["neutrophils", "TEST", 258, 269], ["II cells", "OBSERVATION", 14, 22], ["alveolar macrophages", "OBSERVATION", 233, 253]]], ["Surfactant proteins A and D may have additional immunoregulatory functions [7] and also may exhibit direct bactericidal effects by inducing damage to the bacterial cell membrane [8] .", [["cell membrane", "ANATOMY", 164, 177], ["Surfactant proteins A", "GENE_OR_GENE_PRODUCT", 0, 21], ["D", "SIMPLE_CHEMICAL", 26, 27], ["cell membrane", "CELLULAR_COMPONENT", 164, 177], ["Surfactant proteins A and D", "PROTEIN", 0, 27], ["Surfactant proteins", "TREATMENT", 0, 19], ["direct bactericidal effects", "PROBLEM", 100, 127], ["damage to the bacterial cell membrane", "PROBLEM", 140, 177], ["bacterial cell membrane", "OBSERVATION", 154, 177]]], ["The functions of SP-A and SP-D in host defense are listed in Table 17 .1.IntroductionIn the distal airspaces, alveolar macrophages are the fi rst phagocytic cell type encountered by pathogens entering the lung.", [["distal airspaces", "ANATOMY", 92, 108], ["alveolar macrophages", "ANATOMY", 110, 130], ["cell", "ANATOMY", 157, 161], ["lung", "ANATOMY", 205, 209], ["SP-A", "GENE_OR_GENE_PRODUCT", 17, 21], ["SP-D", "GENE_OR_GENE_PRODUCT", 26, 30], ["airspaces", "MULTI-TISSUE_STRUCTURE", 99, 108], ["alveolar macrophages", "CELL", 110, 130], ["rst phagocytic cell type", "CELL", 142, 166], ["lung", "ORGAN", 205, 209], ["SP", "PROTEIN", 17, 19], ["SP", "PROTEIN", 26, 28], ["alveolar macrophages", "CELL_TYPE", 110, 130], ["SP", "TEST", 17, 19], ["alveolar macrophages", "PROBLEM", 110, 130], ["distal", "ANATOMY_MODIFIER", 92, 98], ["airspaces", "ANATOMY_MODIFIER", 99, 108], ["alveolar macrophages", "OBSERVATION", 110, 130], ["fi rst", "OBSERVATION_MODIFIER", 139, 145], ["phagocytic cell type", "OBSERVATION", 146, 166], ["pathogens", "OBSERVATION", 182, 191], ["lung", "ANATOMY", 205, 209]]], ["Macrophages have the capacity to induce the generation of large amounts of cytokines, chemokines, matrix metalloproteinases (MMP), nitric oxide, and potent oxidants that participate in antimicrobial defenses.", [["Macrophages", "ANATOMY", 0, 11], ["nitric oxide", "CHEMICAL", 131, 143], ["nitric oxide", "CHEMICAL", 131, 143], ["Macrophages", "CELL", 0, 11], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 98, 123], ["MMP", "GENE_OR_GENE_PRODUCT", 125, 128], ["nitric oxide", "SIMPLE_CHEMICAL", 131, 143], ["Macrophages", "CELL_TYPE", 0, 11], ["cytokines", "PROTEIN", 75, 84], ["chemokines", "PROTEIN", 86, 96], ["matrix metalloproteinases", "PROTEIN", 98, 123], ["MMP", "PROTEIN", 125, 128], ["Macrophages", "TREATMENT", 0, 11], ["the capacity", "PROBLEM", 17, 29], ["cytokines", "TREATMENT", 75, 84], ["chemokines, matrix metalloproteinases", "TREATMENT", 86, 123], ["MMP)", "TREATMENT", 125, 129], ["nitric oxide", "TREATMENT", 131, 143], ["potent oxidants", "TREATMENT", 149, 164], ["large", "OBSERVATION_MODIFIER", 58, 63], ["amounts", "OBSERVATION_MODIFIER", 64, 71]]], ["In contrast, interstitial macrophages are located in the lung connective tissue and serve as both phagocytic cells and antigen-processing cells.", [["interstitial macrophages", "ANATOMY", 13, 37], ["lung connective tissue", "ANATOMY", 57, 79], ["phagocytic cells", "ANATOMY", 98, 114], ["cells", "ANATOMY", 138, 143], ["interstitial macrophages", "CELL", 13, 37], ["lung connective tissue", "TISSUE", 57, 79], ["phagocytic cells", "CELL", 98, 114], ["antigen", "GENE_OR_GENE_PRODUCT", 119, 126], ["cells", "CELL", 138, 143], ["interstitial macrophages", "CELL_TYPE", 13, 37], ["phagocytic cells", "CELL_TYPE", 98, 114], ["antigen-processing cells", "CELL_TYPE", 119, 143], ["interstitial macrophages", "PROBLEM", 13, 37], ["interstitial", "ANATOMY_MODIFIER", 13, 25], ["macrophages", "OBSERVATION", 26, 37], ["lung", "ANATOMY", 57, 61], ["connective tissue", "ANATOMY", 62, 79], ["phagocytic cells", "OBSERVATION", 98, 114], ["processing cells", "OBSERVATION", 127, 143]]], ["Tumor necrosis factor (TNF)-\u03b1, a macrophage-derived multifunctional cytokine, is expressed early in both patients with and animal models of pneumonia [9] .", [["macrophage", "ANATOMY", 33, 43], ["necrosis", "DISEASE", 6, 14], ["pneumonia", "DISEASE", 140, 149], ["Tumor necrosis factor (TNF)-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 29], ["macrophage", "CELL", 33, 43], ["patients", "ORGANISM", 105, 113], ["Tumor necrosis factor (TNF)-\u03b1", "PROTEIN", 0, 29], ["macrophage-derived multifunctional cytokine", "PROTEIN", 33, 76], ["patients", "SPECIES", 105, 113], ["Tumor necrosis factor", "PROBLEM", 0, 21], ["TNF", "TEST", 23, 26], ["a macrophage", "PROBLEM", 31, 43], ["pneumonia", "PROBLEM", 140, 149], ["necrosis", "OBSERVATION", 6, 14], ["pneumonia", "OBSERVATION", 140, 149]]], ["Microbes also induce macrophages to generate potent chemokines that attract circulating neutrophils and monocytes into the lungs.", [["macrophages", "ANATOMY", 21, 32], ["neutrophils", "ANATOMY", 88, 99], ["monocytes", "ANATOMY", 104, 113], ["lungs", "ANATOMY", 123, 128], ["macrophages", "CELL", 21, 32], ["neutrophils", "CELL", 88, 99], ["monocytes", "CELL", 104, 113], ["lungs", "ORGAN", 123, 128], ["macrophages", "CELL_TYPE", 21, 32], ["chemokines", "PROTEIN", 52, 62], ["circulating neutrophils", "CELL_TYPE", 76, 99], ["monocytes", "CELL_TYPE", 104, 113], ["macrophages", "PROBLEM", 21, 32], ["potent chemokines", "PROBLEM", 45, 62], ["circulating neutrophils", "TEST", 76, 99], ["macrophages", "OBSERVATION", 21, 32], ["potent", "OBSERVATION_MODIFIER", 45, 51], ["monocytes", "OBSERVATION", 104, 113], ["lungs", "ANATOMY", 123, 128]]], ["Cytokines/ chemokines amplify infl ammatory responses and orchestrate the polarization and transition of innate to adaptive immunity that function to eliminate invading microorganisms [10] .", [["infl", "GENE_OR_GENE_PRODUCT", 30, 34], ["Cytokines", "PROTEIN", 0, 9], ["chemokines", "PROTEIN", 11, 21], ["Cytokines/ chemokines", "TREATMENT", 0, 21], ["invading microorganisms", "PROBLEM", 160, 183]]], ["Figure 17 .2 summarizes the cellular and secretory peptides that are components of host defense against microbes in the lower respiratory tract.", [["cellular", "ANATOMY", 28, 36], ["lower respiratory tract", "ANATOMY", 120, 143], ["cellular", "CELL", 28, 36], ["lower", "ORGANISM_SUBDIVISION", 120, 125], ["respiratory tract", "ORGANISM_SUBDIVISION", 126, 143], ["Figure", "TEST", 0, 6], ["secretory peptides", "OBSERVATION", 41, 59], ["host defense", "OBSERVATION", 83, 95], ["lower", "ANATOMY_MODIFIER", 120, 125], ["respiratory tract", "ANATOMY", 126, 143]]], ["Disorders associated with impaired mechanical, innate, and adaptive host responses that may lead to the development of pneumonia in a susceptible host are listed in Table 17 .2.PathogenesisThe upper respiratory tract is normally colonized with nonpathogenic bacterial fl ora, but physical and immunologic host defenses generally ensure that bacteria that gain access to the lower respiratory tract are cleared.", [["upper respiratory tract", "ANATOMY", 193, 216], ["lower respiratory tract", "ANATOMY", 374, 397], ["pneumonia", "DISEASE", 119, 128], ["upper respiratory", "ORGANISM_SUBDIVISION", 193, 210], ["tract", "ORGANISM_SUBDIVISION", 211, 216], ["bacterial fl ora", "ORGANISM", 258, 274], ["lower", "ORGANISM_SUBDIVISION", 374, 379], ["respiratory tract", "ORGANISM_SUBDIVISION", 380, 397], ["Disorders", "PROBLEM", 0, 9], ["pneumonia", "PROBLEM", 119, 128], ["The upper respiratory tract", "PROBLEM", 189, 216], ["nonpathogenic bacterial fl ora", "PROBLEM", 244, 274], ["bacteria", "PROBLEM", 341, 349], ["impaired", "OBSERVATION_MODIFIER", 26, 34], ["mechanical", "OBSERVATION_MODIFIER", 35, 45], ["pneumonia", "OBSERVATION", 119, 128], ["upper", "ANATOMY_MODIFIER", 193, 198], ["respiratory tract", "ANATOMY", 199, 216], ["colonized", "OBSERVATION_MODIFIER", 229, 238], ["nonpathogenic", "OBSERVATION_MODIFIER", 244, 257], ["bacterial fl", "OBSERVATION", 258, 270], ["lower", "ANATOMY_MODIFIER", 374, 379], ["respiratory tract", "ANATOMY", 380, 397]]], ["Pneumonia occurs because of an impairment of host defenses (as discussed earlier), invasion by a virulent organism, or invasion by an overwhelming inoculum of less virulent organisms.", [["Pneumonia", "DISEASE", 0, 9], ["Pneumonia", "PROBLEM", 0, 9], ["an impairment of host defenses", "PROBLEM", 28, 58], ["a virulent organism", "PROBLEM", 95, 114], ["invasion", "PROBLEM", 119, 127], ["an overwhelming inoculum of less virulent organisms", "PROBLEM", 131, 182], ["impairment", "OBSERVATION_MODIFIER", 31, 41], ["host defenses", "OBSERVATION", 45, 58], ["overwhelming", "OBSERVATION_MODIFIER", 134, 146], ["inoculum", "OBSERVATION_MODIFIER", 147, 155], ["less", "OBSERVATION_MODIFIER", 159, 163], ["virulent organisms", "OBSERVATION", 164, 182]]], ["There are fi ve main modes of pathogen entry into the lower respiratory tract.Inhalation and DropletsInhalation of infectious particles is probably the most important pathogenic mechanism in the development of CAP, with particular importance in pneumonia of those caused by Legionella species and Mycobacterium tuberculosis.", [["lower respiratory tract", "ANATOMY", 54, 77], ["CAP", "DISEASE", 210, 213], ["pneumonia", "DISEASE", 245, 254], ["Mycobacterium tuberculosis", "DISEASE", 297, 323], ["lower", "ORGANISM_SUBDIVISION", 54, 59], ["respiratory tract", "ORGANISM_SUBDIVISION", 60, 77], ["Legionella species", "ORGANISM", 274, 292], ["Mycobacterium tuberculosis", "ORGANISM", 297, 323], ["Mycobacterium tuberculosis", "SPECIES", 297, 323], ["Mycobacterium tuberculosis", "SPECIES", 297, 323], ["Inhalation", "TREATMENT", 78, 88], ["DropletsInhalation", "TREATMENT", 93, 111], ["infectious particles", "PROBLEM", 115, 135], ["CAP", "PROBLEM", 210, 213], ["pneumonia", "PROBLEM", 245, 254], ["Legionella species", "PROBLEM", 274, 292], ["Mycobacterium tuberculosis", "PROBLEM", 297, 323], ["main", "OBSERVATION_MODIFIER", 16, 20], ["pathogen entry", "OBSERVATION", 30, 44], ["lower", "ANATOMY_MODIFIER", 54, 59], ["respiratory tract", "ANATOMY", 60, 77], ["infectious particles", "OBSERVATION", 115, 135], ["probably the", "UNCERTAINTY", 139, 151], ["most important", "OBSERVATION_MODIFIER", 152, 166], ["CAP", "OBSERVATION_MODIFIER", 210, 213], ["pneumonia", "OBSERVATION", 245, 254], ["Legionella species", "OBSERVATION", 274, 292], ["Mycobacterium tuberculosis", "OBSERVATION", 297, 323]]], ["Contact with contaminated fomites also may be important in the acquisition of viral agents, especially respiratory syncytial virus.", [["fomites", "ANATOMY", 26, 33], ["respiratory syncytial virus", "DISEASE", 103, 130], ["respiratory syncytial virus", "ORGANISM", 103, 130], ["respiratory syncytial virus", "SPECIES", 103, 130], ["respiratory syncytial virus", "SPECIES", 103, 130], ["viral agents", "TREATMENT", 78, 90], ["respiratory syncytial virus", "PROBLEM", 103, 130]]], ["The viral agents that cause pneumonia proliferate and spread by contiguity to involve lower and more distal portions of the respiratory tract.", [["distal portions", "ANATOMY", 101, 116], ["respiratory tract", "ANATOMY", 124, 141], ["pneumonia", "DISEASE", 28, 37], ["respiratory tract", "ORGANISM_SUBDIVISION", 124, 141], ["The viral agents", "TREATMENT", 0, 16], ["pneumonia proliferate", "PROBLEM", 28, 49], ["viral agents", "OBSERVATION", 4, 16], ["pneumonia", "OBSERVATION", 28, 37], ["lower", "ANATOMY_MODIFIER", 86, 91], ["distal", "ANATOMY_MODIFIER", 101, 107], ["portions", "ANATOMY_MODIFIER", 108, 116], ["respiratory tract", "ANATOMY", 124, 141]]], ["Inhalation is also a common cause of pneumonia caused by contaminated ventilator tubes.", [["pneumonia", "DISEASE", 37, 46], ["Inhalation", "TREATMENT", 0, 10], ["pneumonia", "PROBLEM", 37, 46], ["contaminated ventilator tubes", "TREATMENT", 57, 86], ["pneumonia", "OBSERVATION", 37, 46], ["contaminated", "OBSERVATION_MODIFIER", 57, 69], ["ventilator tubes", "OBSERVATION", 70, 86]]], ["Endosome TLR5 TLR7/ TRL8 TLR9 TLR10 TLR11 TLR12 TLR13 CD14 FIGURE 17.1.", [["TLR7", "GENE_OR_GENE_PRODUCT", 14, 18], ["TRL8", "GENE_OR_GENE_PRODUCT", 20, 24], ["Endosome TLR5 TLR7/ TRL8 TLR9 TLR10", "PROTEIN", 0, 35], ["TLR11", "PROTEIN", 36, 41], ["TLR12", "PROTEIN", 42, 47], ["CD14", "PROTEIN", 54, 58], ["CD14 FIGURE", "TEST", 54, 65], ["TLR5 TLR7", "ANATOMY", 9, 18]]], ["Toll-like receptors (TLR) and their ligands.", [["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 0, 19], ["TLR", "GENE_OR_GENE_PRODUCT", 21, 24], ["Toll-like receptors", "PROTEIN", 0, 19], ["TLR", "PROTEIN", 21, 24]]], ["LPS, lipopolysaccharide; HSPs, heat shock proteins.AspirationIn addition to inhalation, pneumonia arises following the aspiration of microorganisms from the oral cavity or nasopharynx.", [["oral cavity", "ANATOMY", 157, 168], ["nasopharynx", "ANATOMY", 172, 183], ["LPS", "CHEMICAL", 0, 3], ["lipopolysaccharide", "CHEMICAL", 5, 23], ["pneumonia", "DISEASE", 88, 97], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 5, 23], ["HSPs", "GENE_OR_GENE_PRODUCT", 25, 29], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 31, 50], ["oral cavity", "ORGAN", 157, 168], ["nasopharynx", "ORGAN", 172, 183], ["HSPs", "PROTEIN", 25, 29], ["heat shock proteins", "PROTEIN", 31, 50], ["LPS", "TEST", 0, 3], ["lipopolysaccharide", "TEST", 5, 23], ["HSPs", "PROBLEM", 25, 29], ["heat shock proteins", "PROBLEM", 31, 50], ["AspirationIn", "TREATMENT", 51, 63], ["inhalation", "TREATMENT", 76, 86], ["pneumonia", "PROBLEM", 88, 97], ["microorganisms from the oral cavity or nasopharynx", "PROBLEM", 133, 183], ["pneumonia", "OBSERVATION", 88, 97], ["oral cavity", "ANATOMY", 157, 168], ["nasopharynx", "ANATOMY", 172, 183]]], ["Invasive disease most commonly occurs upon acquisition of a new serotype of the organism with which the patient has not had previous experience.", [["Invasive disease", "DISEASE", 0, 16], ["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["Invasive disease", "PROBLEM", 0, 16], ["disease", "OBSERVATION", 9, 16]]], ["Most episodes of VAP are thought to develop from the aspiration of oropharyngeal secretions containing potentially pathogenic organisms.", [["oropharyngeal secretions", "ANATOMY", 67, 91], ["VAP", "DISEASE", 17, 20], ["oropharyngeal secretions", "ORGANISM_SUBDIVISION", 67, 91], ["VAP", "PROBLEM", 17, 20], ["oropharyngeal secretions", "PROBLEM", 67, 91], ["potentially pathogenic organisms", "PROBLEM", 103, 135], ["VAP", "OBSERVATION", 17, 20], ["aspiration", "OBSERVATION", 53, 63], ["oropharyngeal", "ANATOMY", 67, 80], ["secretions", "OBSERVATION", 81, 91]]], ["Aspiration of gastric secretions may also contribute, although likely to a lesser degree.", [["gastric secretions", "ANATOMY", 14, 32], ["gastric secretions", "ORGAN", 14, 32], ["Aspiration of gastric secretions", "PROBLEM", 0, 32], ["gastric", "ANATOMY", 14, 21], ["secretions", "OBSERVATION", 22, 32], ["lesser degree", "OBSERVATION_MODIFIER", 75, 88]]], ["Tracheal intubation interrupts the body's anatomic and physiologic defenses against aspiration, making mechanical ventilation a major risk factor for VAP.", [["Tracheal", "ANATOMY", 0, 8], ["body", "ANATOMY", 35, 39], ["VAP", "DISEASE", 150, 153], ["Tracheal", "ORGAN", 0, 8], ["body", "ORGANISM_SUBDIVISION", 35, 39], ["Tracheal intubation", "TREATMENT", 0, 19], ["aspiration", "PROBLEM", 84, 94], ["mechanical ventilation", "TREATMENT", 103, 125], ["VAP", "PROBLEM", 150, 153], ["intubation", "OBSERVATION", 9, 19], ["aspiration", "OBSERVATION", 84, 94], ["mechanical ventilation", "OBSERVATION", 103, 125]]], ["The term aspiration pneumonia should be reserved for pneumonia or pneumonitis resulting from the aspiration of large amounts of gastric or oropharyngeal contents that may contain a large inoculum of relatively nonvirulent bacteria.", [["gastric", "ANATOMY", 128, 135], ["oropharyngeal", "ANATOMY", 139, 152], ["aspiration pneumonia", "DISEASE", 9, 29], ["pneumonia", "DISEASE", 53, 62], ["pneumonitis", "DISEASE", 66, 77], ["gastric", "ORGAN", 128, 135], ["oropharyngeal", "ORGANISM_SUBDIVISION", 139, 152], ["The term aspiration pneumonia", "PROBLEM", 0, 29], ["pneumonia", "PROBLEM", 53, 62], ["pneumonitis", "PROBLEM", 66, 77], ["the aspiration of large amounts of gastric or oropharyngeal contents", "PROBLEM", 93, 161], ["a large inoculum of relatively nonvirulent bacteria", "PROBLEM", 179, 230], ["term", "OBSERVATION_MODIFIER", 4, 8], ["aspiration", "OBSERVATION_MODIFIER", 9, 19], ["pneumonia", "OBSERVATION", 20, 29], ["pneumonia", "OBSERVATION", 53, 62], ["pneumonitis", "OBSERVATION", 66, 77], ["aspiration", "OBSERVATION", 97, 107], ["large", "OBSERVATION_MODIFIER", 111, 116], ["amounts", "OBSERVATION_MODIFIER", 117, 124], ["gastric", "ANATOMY", 128, 135], ["oropharyngeal contents", "ANATOMY", 139, 161], ["large", "OBSERVATION_MODIFIER", 181, 186], ["inoculum", "OBSERVATION_MODIFIER", 187, 195], ["relatively", "OBSERVATION_MODIFIER", 199, 209], ["nonvirulent bacteria", "OBSERVATION", 210, 230]]], ["The pathogens that commonly produce CAP or VAP, such as Streptococcus pneumoniae, Gram-negative bacilli, and Staphylococcus aureus, are relatively virulent bacteria so that only a small inoculum is required and the aspiration is usually subtle.Hematogenous SpreadIn immunocompromised individuals, an additional mode of pneumonia acquisition is bacteremia and sepsis.", [["CAP", "CHEMICAL", 36, 39], ["VAP", "DISEASE", 43, 46], ["Streptococcus pneumoniae", "DISEASE", 56, 80], ["Staphylococcus aureus", "DISEASE", 109, 130], ["pneumonia", "DISEASE", 319, 328], ["bacteremia", "DISEASE", 344, 354], ["sepsis", "DISEASE", 359, 365], ["Streptococcus pneumoniae", "ORGANISM", 56, 80], ["Gram-negative bacilli", "GENE_OR_GENE_PRODUCT", 82, 103], ["Staphylococcus aureus", "ORGANISM", 109, 130], ["Streptococcus pneumoniae", "SPECIES", 56, 80], ["Staphylococcus aureus", "SPECIES", 109, 130], ["Streptococcus pneumoniae", "SPECIES", 56, 80], ["Staphylococcus aureus", "SPECIES", 109, 130], ["The pathogens", "PROBLEM", 0, 13], ["CAP", "PROBLEM", 36, 39], ["VAP", "PROBLEM", 43, 46], ["Streptococcus pneumoniae", "PROBLEM", 56, 80], ["Gram-negative bacilli", "PROBLEM", 82, 103], ["Staphylococcus aureus", "PROBLEM", 109, 130], ["relatively virulent bacteria", "PROBLEM", 136, 164], ["a small inoculum", "PROBLEM", 178, 194], ["the aspiration", "PROBLEM", 211, 225], ["Hematogenous SpreadIn immunocompromised individuals", "PROBLEM", 244, 295], ["pneumonia acquisition", "PROBLEM", 319, 340], ["bacteremia", "PROBLEM", 344, 354], ["sepsis", "PROBLEM", 359, 365], ["CAP", "OBSERVATION_MODIFIER", 36, 39], ["negative bacilli", "OBSERVATION", 87, 103], ["Staphylococcus aureus", "OBSERVATION", 109, 130], ["virulent bacteria", "OBSERVATION", 147, 164], ["small", "OBSERVATION_MODIFIER", 180, 185], ["inoculum", "OBSERVATION", 186, 194], ["aspiration", "OBSERVATION", 215, 225], ["immunocompromised", "OBSERVATION", 266, 283], ["pneumonia", "OBSERVATION", 319, 328], ["bacteremia", "OBSERVATION", 344, 354], ["sepsis", "OBSERVATION", 359, 365]]], ["Hematogenous deposition of bacteria is responsible for some cases of pneumonia caused by Staph. aureus, Pseudomonas aeruginosa, and Escherichia coli.ReactivationReactivation of pathogens can take place in the setting of defi cits of cell-mediated immunity.", [["cell", "ANATOMY", 233, 237], ["pneumonia", "DISEASE", 69, 78], ["aureus", "ORGANISM", 96, 102], ["Pseudomonas aeruginosa", "ORGANISM", 104, 126], ["Escherichia coli", "ORGANISM", 132, 148], ["cell", "CELL", 233, 237], ["aureus", "SPECIES", 96, 102], ["Pseudomonas aeruginosa", "SPECIES", 104, 126], ["Escherichia coli", "SPECIES", 132, 148], ["aureus", "SPECIES", 96, 102], ["Pseudomonas aeruginosa", "SPECIES", 104, 126], ["Escherichia coli", "SPECIES", 132, 148], ["Hematogenous deposition of bacteria", "PROBLEM", 0, 35], ["pneumonia", "PROBLEM", 69, 78], ["Staph", "PROBLEM", 89, 94], ["aureus", "PROBLEM", 96, 102], ["Pseudomonas aeruginosa", "PROBLEM", 104, 126], ["Escherichia coli", "PROBLEM", 132, 148], ["ReactivationReactivation of pathogens", "PROBLEM", 149, 186], ["cell-mediated immunity", "TREATMENT", 233, 255], ["bacteria", "OBSERVATION", 27, 35], ["responsible for", "UNCERTAINTY", 39, 54], ["pneumonia", "OBSERVATION", 69, 78], ["Staph", "OBSERVATION", 89, 94], ["Pseudomonas aeruginosa", "OBSERVATION", 104, 126], ["Escherichia coli", "OBSERVATION", 132, 148]]], ["Pathogens such as Pneumocystis carinii/jiroveci, M. tuberculosis, and cytomegalovirus (CMV) may remain latent for many years after exposure, with fl ares of active disease in the face of immune compromise.", [["Pneumocystis carinii/jiroveci", "DISEASE", 18, 47], ["M. tuberculosis", "DISEASE", 49, 64], ["cytomegalovirus (CMV)", "DISEASE", 70, 91], ["Pneumocystis carinii", "ORGANISM", 18, 38], ["jiroveci", "ORGANISM", 39, 47], ["M. tuberculosis", "ORGANISM", 49, 64], ["cytomegalovirus", "ORGANISM", 70, 85], ["CMV", "ORGANISM", 87, 90], ["Pneumocystis carinii", "SPECIES", 18, 38], ["/jiroveci", "SPECIES", 38, 47], ["M. tuberculosis", "SPECIES", 49, 64], ["Pneumocystis carinii/jiroveci", "SPECIES", 18, 47], ["M. tuberculosis", "SPECIES", 49, 64], ["CMV", "SPECIES", 87, 90], ["Pathogens", "PROBLEM", 0, 9], ["Pneumocystis carinii", "PROBLEM", 18, 38], ["jiroveci", "PROBLEM", 39, 47], ["M. tuberculosis", "PROBLEM", 49, 64], ["cytomegalovirus", "PROBLEM", 70, 85], ["active disease", "PROBLEM", 157, 171], ["immune compromise", "PROBLEM", 187, 204], ["Pneumocystis carinii", "OBSERVATION", 18, 38], ["jiroveci", "OBSERVATION", 39, 47], ["tuberculosis", "OBSERVATION", 52, 64], ["cytomegalovirus", "OBSERVATION", 70, 85], ["active", "OBSERVATION_MODIFIER", 157, 163], ["disease", "OBSERVATION", 164, 171], ["immune compromise", "OBSERVATION", 187, 204]]], ["Reactivation tuberculosis occasionally occurs in immunocompetent hosts.Direct Injury and InflammationDirect inoculation rarely occurs as a result of surgery or bronchoscopy but may play a role in the development of pneumonia in patients supported with mechanical ventilation.", [["tuberculosis", "DISEASE", 13, 25], ["Injury", "DISEASE", 78, 84], ["pneumonia", "DISEASE", 215, 224], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["Reactivation tuberculosis", "PROBLEM", 0, 25], ["Direct Injury", "PROBLEM", 71, 84], ["InflammationDirect inoculation", "PROBLEM", 89, 119], ["surgery", "TREATMENT", 149, 156], ["bronchoscopy", "TREATMENT", 160, 172], ["pneumonia", "PROBLEM", 215, 224], ["mechanical ventilation", "TREATMENT", 252, 274], ["tuberculosis", "OBSERVATION", 13, 25], ["immunocompetent hosts", "OBSERVATION", 49, 70], ["Injury", "OBSERVATION", 78, 84], ["pneumonia", "OBSERVATION", 215, 224], ["mechanical ventilation", "OBSERVATION", 252, 274]]], ["The direct extension of infection to the lung from contiguous areas such as the pleural or subdiaphragmatic spaces is rare.Pneumonia Types in the Pediatric Intensive Care UnitCommunity-Acquired PneumoniaDefinitions and Main FeaturesCommunity-acquired pneumonia refers to pneumonia in a previously healthy person who acquired the infection outside a hospital.", [["lung", "ANATOMY", 41, 45], ["pleural", "ANATOMY", 80, 87], ["subdiaphragmatic spaces", "ANATOMY", 91, 114], ["infection", "DISEASE", 24, 33], ["Pneumonia", "DISEASE", 123, 132], ["PneumoniaDefinitions", "DISEASE", 194, 214], ["pneumonia", "DISEASE", 251, 260], ["pneumonia", "DISEASE", 271, 280], ["infection", "DISEASE", 329, 338], ["lung", "ORGAN", 41, 45], ["pleural", "ORGAN", 80, 87], ["person", "SPECIES", 305, 311], ["infection to the lung", "PROBLEM", 24, 45], ["the pleural or subdiaphragmatic spaces", "PROBLEM", 76, 114], ["Pneumonia", "PROBLEM", 123, 132], ["Acquired PneumoniaDefinitions", "PROBLEM", 185, 214], ["Main FeaturesCommunity", "PROBLEM", 219, 241], ["acquired pneumonia", "PROBLEM", 242, 260], ["pneumonia", "PROBLEM", 271, 280], ["the infection", "PROBLEM", 325, 338], ["infection", "OBSERVATION", 24, 33], ["lung", "ANATOMY", 41, 45], ["pleural", "ANATOMY", 80, 87], ["subdiaphragmatic", "ANATOMY", 91, 107], ["Main FeaturesCommunity", "OBSERVATION", 219, 241], ["pneumonia", "OBSERVATION", 251, 260], ["pneumonia", "OBSERVATION", 271, 280], ["infection", "OBSERVATION", 329, 338]]], ["It is one of the most common serious infections in children, with an incidence of 34 to 40 cases per 1,000 children in the industrialized world [11] .", [["infections", "DISEASE", 37, 47], ["children", "ORGANISM", 51, 59], ["children", "SPECIES", 51, 59], ["children", "SPECIES", 107, 115], ["most common", "OBSERVATION_MODIFIER", 17, 28], ["serious", "OBSERVATION_MODIFIER", 29, 36], ["infections", "OBSERVATION", 37, 47]]], ["A subset of these patients will require PICU admission.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["Admission to the intensive care unit should be considered for patients with persistent hypoxemia despite oxygen therapy, recurrent apnea, signs of respiratory fatigue with or without mental status changes, or evidence of compensated or decompensated shock.", [["respiratory", "ANATOMY", 147, 158], ["hypoxemia", "DISEASE", 87, 96], ["oxygen", "CHEMICAL", 105, 111], ["apnea", "DISEASE", 131, 136], ["respiratory fatigue", "DISEASE", 147, 166], ["shock", "DISEASE", 250, 255], ["oxygen", "CHEMICAL", 105, 111], ["patients", "ORGANISM", 62, 70], ["oxygen", "SIMPLE_CHEMICAL", 105, 111], ["patients", "SPECIES", 62, 70], ["persistent hypoxemia", "PROBLEM", 76, 96], ["oxygen therapy", "TREATMENT", 105, 119], ["recurrent apnea", "PROBLEM", 121, 136], ["respiratory fatigue", "PROBLEM", 147, 166], ["mental status changes", "PROBLEM", 183, 204], ["decompensated shock", "PROBLEM", 236, 255], ["persistent", "OBSERVATION_MODIFIER", 76, 86], ["hypoxemia", "OBSERVATION", 87, 96], ["oxygen therapy", "OBSERVATION", 105, 119], ["respiratory fatigue", "OBSERVATION", 147, 166], ["decompensated", "OBSERVATION_MODIFIER", 236, 249], ["shock", "OBSERVATION", 250, 255]]], ["Infants less than 6 months of age and children with comorbid conditions such as bronchopulmonary dysplasia, cystic fi brosis, neuromuscular disorders, congenital heart disease, and immunodefi ciency disorders have limited respiratory reserves and, therefore, are at increased risk for respiratory failure during a pneumonia episode.Definitions and Main FeaturesFor the adult population, the American and British Thoracic Societies have developed guidelines for hospital and ICU admissions for patients with severe CAP [12] .", [["bronchopulmonary dysplasia", "ANATOMY", 80, 106], ["cystic", "ANATOMY", 108, 114], ["neuromuscular", "ANATOMY", 126, 139], ["heart", "ANATOMY", 162, 167], ["respiratory", "ANATOMY", 222, 233], ["respiratory", "ANATOMY", 285, 296], ["bronchopulmonary dysplasia", "DISEASE", 80, 106], ["cystic fi brosis", "DISEASE", 108, 124], ["neuromuscular disorders", "DISEASE", 126, 149], ["congenital heart disease", "DISEASE", 151, 175], ["immunodefi ciency disorders", "DISEASE", 181, 208], ["respiratory failure", "DISEASE", 285, 304], ["pneumonia", "DISEASE", 314, 323], ["CAP", "DISEASE", 514, 517], ["children", "ORGANISM", 38, 46], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 80, 106], ["heart", "ORGAN", 162, 167], ["patients", "ORGANISM", 493, 501], ["Infants", "SPECIES", 0, 7], ["children", "SPECIES", 38, 46], ["patients", "SPECIES", 493, 501], ["comorbid conditions", "PROBLEM", 52, 71], ["bronchopulmonary dysplasia", "PROBLEM", 80, 106], ["cystic fi brosis", "PROBLEM", 108, 124], ["neuromuscular disorders", "PROBLEM", 126, 149], ["congenital heart disease", "PROBLEM", 151, 175], ["immunodefi ciency disorders", "PROBLEM", 181, 208], ["limited respiratory reserves", "PROBLEM", 214, 242], ["respiratory failure", "PROBLEM", 285, 304], ["a pneumonia episode", "PROBLEM", 312, 331], ["severe CAP", "PROBLEM", 507, 517], ["bronchopulmonary", "ANATOMY", 80, 96], ["dysplasia", "OBSERVATION", 97, 106], ["cystic", "OBSERVATION_MODIFIER", 108, 114], ["neuromuscular", "ANATOMY", 126, 139], ["heart", "ANATOMY", 162, 167], ["disease", "OBSERVATION", 168, 175], ["respiratory reserves", "OBSERVATION", 222, 242], ["respiratory failure", "OBSERVATION", 285, 304], ["pneumonia", "OBSERVATION", 314, 323], ["Main", "OBSERVATION_MODIFIER", 348, 352], ["Thoracic", "ANATOMY", 412, 420]]], ["According to the American Thoracic Society Guidelines, admission to the ICU is needed for patients with severe CAP, defi ned as the presence of either one of two major criteria, or the presence of two of three minor criteria.", [["CAP", "DISEASE", 111, 114], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["severe CAP", "PROBLEM", 104, 114], ["Thoracic", "ANATOMY", 26, 34]]], ["The major criteria include need for mechanical ventilation and septic shock; the minor criteria include systolic blood pressure \u226490 mm Hg, multilobar disease, and a PaO 2 /FiO 2 ratio <250.", [["blood", "ANATOMY", 113, 118], ["multilobar", "ANATOMY", 139, 149], ["septic shock", "DISEASE", 63, 75], ["multilobar disease", "DISEASE", 139, 157], ["Hg", "CHEMICAL", 135, 137], ["PaO 2", "CHEMICAL", 165, 170], ["FiO 2", "CHEMICAL", 172, 177], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["mechanical ventilation", "TREATMENT", 36, 58], ["septic shock", "PROBLEM", 63, 75], ["systolic blood pressure", "TEST", 104, 127], ["multilobar disease", "PROBLEM", 139, 157], ["a PaO", "TEST", 163, 168], ["FiO 2 ratio", "TEST", 172, 183], ["mechanical ventilation", "OBSERVATION", 36, 58], ["septic shock", "OBSERVATION", 63, 75], ["multilobar disease", "OBSERVATION", 139, 157]]], ["In addition, a Pneumonia Severity Index (PSI) score identifi es adults at increased risk of medical complications and death [13] .", [["Pneumonia", "DISEASE", 15, 24], ["death", "DISEASE", 118, 123], ["a Pneumonia Severity Index", "PROBLEM", 13, 39], ["medical complications", "PROBLEM", 92, 113], ["death", "PROBLEM", 118, 123], ["Pneumonia", "OBSERVATION", 15, 24]]], ["However, similar guidelines or scores to grade the severity of pneumonia in children have not been developed.Specific PathogensChildren admitted to the PICU because of CAP are more commonly infected with bacterial than viral pathogens.", [["pneumonia", "DISEASE", 63, 72], ["CAP", "DISEASE", 168, 171], ["children", "ORGANISM", 76, 84], ["children", "SPECIES", 76, 84], ["Children", "SPECIES", 127, 135], ["pneumonia", "PROBLEM", 63, 72], ["CAP", "PROBLEM", 168, 171], ["bacterial than viral pathogens", "PROBLEM", 204, 234], ["pneumonia", "OBSERVATION", 63, 72]]], ["Streptococcus pneumoniae is the most commonly identifi ed bacterial cause of CAP in infants and children older than 1 month.", [["Streptococcus pneumoniae", "DISEASE", 0, 24], ["CAP", "DISEASE", 77, 80], ["Streptococcus pneumoniae", "ORGANISM", 0, 24], ["infants", "ORGANISM", 84, 91], ["children", "ORGANISM", 96, 104], ["Streptococcus pneumoniae", "SPECIES", 0, 24], ["infants", "SPECIES", 84, 91], ["children", "SPECIES", 96, 104], ["Streptococcus pneumoniae", "SPECIES", 0, 24], ["Streptococcus pneumoniae", "PROBLEM", 0, 24], ["pneumoniae", "OBSERVATION", 14, 24], ["most commonly", "OBSERVATION_MODIFIER", 32, 45], ["bacterial", "OBSERVATION_MODIFIER", 58, 67], ["CAP", "OBSERVATION_MODIFIER", 77, 80]]], ["Pneumonias caused by group A Streptococcus and Staph. aureus are less frequent.", [["Pneumonias", "DISEASE", 0, 10], ["group A Streptococcus", "ORGANISM", 21, 42], ["aureus", "ORGANISM", 54, 60], ["aureus", "SPECIES", 54, 60], ["aureus", "SPECIES", 54, 60], ["Pneumonias", "PROBLEM", 0, 10], ["group A Streptococcus", "PROBLEM", 21, 42], ["Staph", "PROBLEM", 47, 52], ["aureus", "PROBLEM", 54, 60], ["Streptococcus", "OBSERVATION", 29, 42], ["less", "OBSERVATION_MODIFIER", 65, 69], ["frequent", "OBSERVATION_MODIFIER", 70, 78]]], ["Haemophilus infl uenzae pneumonia has become uncommon following the widespread use of Haemophilus infl uenza type B immunization.", [["Haemophilus infl uenzae pneumonia", "DISEASE", 0, 33], ["Haemophilus infl uenza type B", "CHEMICAL", 86, 115], ["Haemophilus infl uenzae", "ORGANISM", 0, 23], ["Haemophilus infl uenza type B", "ORGANISM", 86, 115], ["Haemophilus infl uenzae", "SPECIES", 0, 23], ["Haemophilus infl uenzae", "SPECIES", 0, 23], ["Haemophilus infl uenza type B", "SPECIES", 86, 115], ["Haemophilus infl uenzae pneumonia", "PROBLEM", 0, 33], ["Haemophilus infl uenza type B immunization", "TREATMENT", 86, 128], ["pneumonia", "OBSERVATION", 24, 33]]], ["Viruses are identifi ed most often in children <5 years of age.", [["children", "ORGANISM", 38, 46], ["children", "SPECIES", 38, 46], ["Viruses", "PROBLEM", 0, 7]]], ["Respiratory syncytial virus is the most common viral etiology during infancy, with adenovirus, infl uenza virus, parainfl uenza virus, and the recently described human metapneumonovirus (14) also not infrequently detected.", [["Respiratory syncytial virus", "DISEASE", 0, 27], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["adenovirus", "ORGANISM", 83, 93], ["infl uenza virus", "ORGANISM", 95, 111], ["parainfl uenza virus", "ORGANISM", 113, 133], ["human", "ORGANISM", 162, 167], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["uenza virus", "SPECIES", 100, 111], ["parainfl uenza virus", "SPECIES", 113, 133], ["human", "SPECIES", 162, 167], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["infl uenza virus", "SPECIES", 95, 111], ["parainfl uenza virus", "SPECIES", 113, 133], ["human", "SPECIES", 162, 167], ["Respiratory syncytial virus", "PROBLEM", 0, 27], ["adenovirus", "PROBLEM", 83, 93], ["infl uenza virus", "PROBLEM", 95, 111], ["parainfl uenza virus", "PROBLEM", 113, 133], ["syncytial virus", "OBSERVATION", 12, 27], ["most common", "OBSERVATION_MODIFIER", 35, 46]]], ["Mycoplasma pneumoniae and Chlamydia pneumoniae are more common in older children and adolescents [11] .Specific PathogensIn May 1993 an outbreak of an acute febrile illness associated with respiratory failure, shock, and high mortality was identifi ed by investigators from the Centers for Disease Control and Prevention (CDC) as being caused by a hantavirus.", [["respiratory", "ANATOMY", 189, 200], ["Mycoplasma pneumoniae", "DISEASE", 0, 21], ["Chlamydia pneumoniae", "DISEASE", 26, 46], ["febrile illness", "DISEASE", 157, 172], ["respiratory failure", "DISEASE", 189, 208], ["shock", "DISEASE", 210, 215], ["hantavirus", "DISEASE", 348, 358], ["Mycoplasma pneumoniae", "ORGANISM", 0, 21], ["Chlamydia pneumoniae", "ORGANISM", 26, 46], ["children", "ORGANISM", 72, 80], ["Mycoplasma pneumoniae", "SPECIES", 0, 21], ["Chlamydia pneumoniae", "SPECIES", 26, 46], ["children", "SPECIES", 72, 80], ["adolescents", "SPECIES", 85, 96], ["Mycoplasma pneumoniae", "SPECIES", 0, 21], ["Chlamydia pneumoniae", "SPECIES", 26, 46], ["Mycoplasma pneumoniae", "PROBLEM", 0, 21], ["Chlamydia pneumoniae", "PROBLEM", 26, 46], ["an acute febrile illness", "PROBLEM", 148, 172], ["respiratory failure", "PROBLEM", 189, 208], ["shock", "PROBLEM", 210, 215], ["high mortality", "PROBLEM", 221, 235], ["Disease Control", "TREATMENT", 290, 305], ["a hantavirus", "PROBLEM", 346, 358], ["pneumoniae", "OBSERVATION", 11, 21], ["Chlamydia pneumoniae", "OBSERVATION", 26, 46], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["febrile", "OBSERVATION_MODIFIER", 157, 164], ["illness", "OBSERVATION", 165, 172], ["respiratory failure", "OBSERVATION", 189, 208], ["shock", "OBSERVATION", 210, 215], ["hantavirus", "OBSERVATION", 348, 358]]], ["In the United States, 95% of the cases occurred west of the Mississippi after environmental exposure to infected deer mouse saliva, urine, or feces.", [["saliva", "ANATOMY", 124, 130], ["urine", "ANATOMY", 132, 137], ["feces", "ANATOMY", 142, 147], ["deer", "ORGANISM", 113, 117], ["mouse", "ORGANISM", 118, 123], ["saliva", "ORGANISM_SUBSTANCE", 124, 130], ["urine", "ORGANISM_SUBSTANCE", 132, 137], ["feces", "ORGANISM_SUBSTANCE", 142, 147], ["deer", "SPECIES", 113, 117], ["mouse", "SPECIES", 118, 123], ["deer", "SPECIES", 113, 117], ["mouse", "SPECIES", 118, 123]]], ["In addition, a novel coronavirus was identifi ed as the causative agent of severe acute respiratory syndrome (SARS), a new respiratory illness that affects adults and children, although the severity of the disease is less in children than in adults [15] .", [["respiratory", "ANATOMY", 123, 134], ["acute respiratory syndrome", "DISEASE", 82, 108], ["SARS", "DISEASE", 110, 114], ["respiratory illness", "DISEASE", 123, 142], ["coronavirus", "ORGANISM", 21, 32], ["children", "ORGANISM", 167, 175], ["children", "ORGANISM", 225, 233], ["coronavirus", "SPECIES", 21, 32], ["children", "SPECIES", 167, 175], ["children", "SPECIES", 225, 233], ["a novel coronavirus", "PROBLEM", 13, 32], ["severe acute respiratory syndrome", "PROBLEM", 75, 108], ["a new respiratory illness", "PROBLEM", 117, 142], ["the disease", "PROBLEM", 202, 213], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["respiratory syndrome", "OBSERVATION", 88, 108], ["new", "OBSERVATION_MODIFIER", 119, 122], ["respiratory illness", "OBSERVATION", 123, 142], ["disease", "OBSERVATION", 206, 213]]], ["Another cause of severe pneumonia that should be considered is tuberculosis.", [["pneumonia", "DISEASE", 24, 33], ["tuberculosis", "DISEASE", 63, 75], ["severe pneumonia", "PROBLEM", 17, 33], ["tuberculosis", "PROBLEM", 63, 75], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["pneumonia", "OBSERVATION", 24, 33], ["should be considered", "UNCERTAINTY", 39, 59], ["tuberculosis", "OBSERVATION", 63, 75]]], ["A history of contact with a person with pulmonary tuberculosis is usually elicited.", [["pulmonary", "ANATOMY", 40, 49], ["pulmonary tuberculosis", "DISEASE", 40, 62], ["pulmonary", "ORGAN", 40, 49], ["person", "SPECIES", 28, 34], ["pulmonary tuberculosis", "PROBLEM", 40, 62], ["pulmonary", "ANATOMY", 40, 49], ["tuberculosis", "OBSERVATION", 50, 62]]], ["Finally, uncommon causes of CAP in otherwise healthy children are fungal infections including Coccidiodes immitis, Histoplasma capsulatum, and Blastomyces dermatitidis.", [["CAP", "DISEASE", 28, 31], ["fungal infections", "DISEASE", 66, 83], ["Coccidiodes immitis", "DISEASE", 94, 113], ["Histoplasma capsulatum", "DISEASE", 115, 137], ["Blastomyces dermatitidis", "DISEASE", 143, 167], ["children", "ORGANISM", 53, 61], ["Coccidiodes immitis", "ORGANISM", 94, 113], ["Histoplasma capsulatum", "ORGANISM", 115, 137], ["Blastomyces dermatitidis", "ORGANISM", 143, 167], ["children", "SPECIES", 53, 61], ["Coccidiodes immitis", "SPECIES", 94, 113], ["Histoplasma capsulatum", "SPECIES", 115, 137], ["Blastomyces dermatitidis", "SPECIES", 143, 167], ["Coccidiodes immitis", "SPECIES", 94, 113], ["Histoplasma capsulatum", "SPECIES", 115, 137], ["Blastomyces dermatitidis", "SPECIES", 143, 167], ["CAP", "PROBLEM", 28, 31], ["fungal infections", "PROBLEM", 66, 83], ["Coccidiodes immitis", "PROBLEM", 94, 113], ["Histoplasma capsulatum", "PROBLEM", 115, 137], ["Blastomyces dermatitidis", "PROBLEM", 143, 167], ["CAP", "OBSERVATION_MODIFIER", 28, 31], ["fungal infections", "OBSERVATION", 66, 83], ["Histoplasma capsulatum", "OBSERVATION", 115, 137], ["Blastomyces dermatitidis", "OBSERVATION", 143, 167]]], ["These organisms should be included in the differential diagnosis as a cause of pneumonia only if there is a history of residence or travel to an area of endemic infection.Specific PathogensOccasionally, infection with Strep. pneumoniae [16] and Mycoplasma pneumoniae [17] can cause necrotic pneumonia secondary to an invasive organism or exaggerated host immune response.", [["pneumonia", "DISEASE", 79, 88], ["infection", "DISEASE", 161, 170], ["infection", "DISEASE", 203, 212], ["Mycoplasma pneumoniae", "DISEASE", 245, 266], ["pneumonia", "DISEASE", 291, 300], ["Strep. pneumoniae [16]", "ORGANISM", 218, 240], ["Mycoplasma pneumoniae", "ORGANISM", 245, 266], ["Strep. pneumoniae", "SPECIES", 218, 235], ["Mycoplasma pneumoniae", "SPECIES", 245, 266], ["Strep. pneumoniae", "SPECIES", 218, 235], ["Mycoplasma pneumoniae", "SPECIES", 245, 266], ["These organisms", "PROBLEM", 0, 15], ["pneumonia", "PROBLEM", 79, 88], ["endemic infection", "PROBLEM", 153, 170], ["infection", "PROBLEM", 203, 212], ["Strep. pneumoniae", "PROBLEM", 218, 235], ["Mycoplasma pneumoniae", "PROBLEM", 245, 266], ["necrotic pneumonia", "PROBLEM", 282, 300], ["an invasive organism", "PROBLEM", 314, 334], ["exaggerated host immune response", "PROBLEM", 338, 370], ["pneumonia", "OBSERVATION", 79, 88], ["endemic", "OBSERVATION_MODIFIER", 153, 160], ["infection", "OBSERVATION", 161, 170], ["infection", "OBSERVATION", 203, 212], ["necrotic", "OBSERVATION_MODIFIER", 282, 290], ["pneumonia", "OBSERVATION", 291, 300], ["invasive", "OBSERVATION_MODIFIER", 317, 325], ["organism", "OBSERVATION", 326, 334], ["exaggerated", "OBSERVATION_MODIFIER", 338, 349], ["host immune response", "OBSERVATION", 350, 370]]], ["Compared to patients with pneumonia and parapneumonic effusions, children who developed necrotizing pneumonia exhibited a more protracted hospital course associated with higher rates of complications, including bronchopleural fi stulas and need for thoracotomy for fi stula repair or lobectomy.", [["stula", "ANATOMY", 268, 273], ["pneumonia", "DISEASE", 26, 35], ["parapneumonic effusions", "DISEASE", 40, 63], ["pneumonia", "DISEASE", 100, 109], ["bronchopleural fi stulas", "DISEASE", 211, 235], ["patients", "ORGANISM", 12, 20], ["children", "ORGANISM", 65, 73], ["patients", "SPECIES", 12, 20], ["children", "SPECIES", 65, 73], ["pneumonia", "PROBLEM", 26, 35], ["parapneumonic effusions", "PROBLEM", 40, 63], ["necrotizing pneumonia", "PROBLEM", 88, 109], ["complications", "PROBLEM", 186, 199], ["bronchopleural fi stulas", "PROBLEM", 211, 235], ["thoracotomy", "TREATMENT", 249, 260], ["fi stula repair", "TREATMENT", 265, 280], ["lobectomy", "TREATMENT", 284, 293], ["pneumonia", "OBSERVATION", 26, 35], ["parapneumonic", "OBSERVATION_MODIFIER", 40, 53], ["effusions", "OBSERVATION", 54, 63], ["necrotizing", "OBSERVATION_MODIFIER", 88, 99], ["pneumonia", "OBSERVATION", 100, 109], ["complications", "OBSERVATION", 186, 199], ["bronchopleural", "ANATOMY", 211, 225], ["thoracotomy", "OBSERVATION", 249, 260], ["lobectomy", "OBSERVATION", 284, 293]]], ["None of the necrotizing pneumonia patients were immune defi cient [18] .ApproachThe diagnosis of CAP is usually made based on the presence of respiratory symptoms (cough, retractions) in a febrile and tachypneic child.", [["respiratory", "ANATOMY", 142, 153], ["pneumonia", "DISEASE", 24, 33], ["CAP", "DISEASE", 97, 100], ["respiratory symptoms", "DISEASE", 142, 162], ["cough", "DISEASE", 164, 169], ["febrile", "DISEASE", 189, 196], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["the necrotizing pneumonia", "PROBLEM", 8, 33], ["CAP", "PROBLEM", 97, 100], ["respiratory symptoms", "PROBLEM", 142, 162], ["cough", "PROBLEM", 164, 169], ["retractions", "PROBLEM", 171, 182], ["a febrile and tachypneic child", "PROBLEM", 187, 217], ["necrotizing", "OBSERVATION_MODIFIER", 12, 23], ["pneumonia", "OBSERVATION", 24, 33], ["CAP", "OBSERVATION", 97, 100]]], ["The presence of infi ltrates on chest radiographs confi rms the diagnosis of pneumonia.", [["pneumonia", "DISEASE", 77, 86], ["infi ltrates", "PROBLEM", 16, 28], ["chest radiographs", "TEST", 32, 49], ["pneumonia", "PROBLEM", 77, 86], ["chest", "ANATOMY", 32, 37], ["pneumonia", "OBSERVATION", 77, 86]]], ["Infi ltrates are generally either interstitial or alveolar.", [["interstitial", "ANATOMY", 34, 46], ["alveolar", "ANATOMY", 50, 58], ["Infi ltrates", "GENE_OR_GENE_PRODUCT", 0, 12], ["alveolar", "MULTI-TISSUE_STRUCTURE", 50, 58], ["generally", "OBSERVATION_MODIFIER", 17, 26], ["interstitial", "OBSERVATION", 34, 46], ["alveolar", "ANATOMY_MODIFIER", 50, 58]]], ["Although alveolar infi ltrates are more commonly observed during bacterial pneumonia [19] , in most studies, the pattern of infi ltrates has not been shown to correctly differentiate viral from bacterial pneumonia [20] .", [["alveolar", "ANATOMY", 9, 17], ["pneumonia", "DISEASE", 75, 84], ["pneumonia", "DISEASE", 204, 213], ["alveolar infi ltrates", "PROBLEM", 9, 30], ["bacterial pneumonia", "PROBLEM", 65, 84], ["infi ltrates", "PROBLEM", 124, 136], ["bacterial pneumonia", "PROBLEM", 194, 213], ["alveolar", "ANATOMY_MODIFIER", 9, 17], ["bacterial", "OBSERVATION_MODIFIER", 65, 74], ["pneumonia", "OBSERVATION", 75, 84], ["bacterial", "OBSERVATION_MODIFIER", 194, 203], ["pneumonia", "OBSERVATION", 204, 213]]], ["Chest radiographs will also detect the presence of pleural effusions, pneumatoceles which are observed during staphylococcal pneumonia, or presence of air-fl uid levels indicative of abscess formation.ApproachAfter initial stabilization, diagnostic testing should be performed rapidly, avoiding delays in the administration of initial empiric therapy.", [["pleural effusions", "ANATOMY", 51, 68], ["pneumatoceles", "ANATOMY", 70, 83], ["abscess", "ANATOMY", 183, 190], ["pleural effusions", "DISEASE", 51, 68], ["pneumatoceles", "DISEASE", 70, 83], ["staphylococcal pneumonia", "DISEASE", 110, 134], ["abscess", "DISEASE", 183, 190], ["pleural effusions", "PATHOLOGICAL_FORMATION", 51, 68], ["pneumatoceles", "CANCER", 70, 83], ["air-fl uid", "SIMPLE_CHEMICAL", 151, 161], ["abscess", "PATHOLOGICAL_FORMATION", 183, 190], ["Chest radiographs", "TEST", 0, 17], ["pleural effusions", "PROBLEM", 51, 68], ["pneumatoceles", "PROBLEM", 70, 83], ["staphylococcal pneumonia", "PROBLEM", 110, 134], ["air-fl uid levels", "TEST", 151, 168], ["abscess formation", "PROBLEM", 183, 200], ["diagnostic testing", "TEST", 238, 256], ["initial empiric therapy", "TREATMENT", 327, 350], ["pleural", "ANATOMY", 51, 58], ["effusions", "OBSERVATION", 59, 68], ["staphylococcal", "OBSERVATION_MODIFIER", 110, 124], ["pneumonia", "OBSERVATION", 125, 134], ["air", "OBSERVATION", 151, 154], ["fl uid", "OBSERVATION", 155, 161], ["indicative of", "UNCERTAINTY", 169, 182], ["abscess", "OBSERVATION", 183, 190]]], ["In addition to a chest radiograph, an admitted patient should have a complete blood count and differential and routine blood chemistry testing (including glucose, serum sodium, liver and renal function tests, and electrolytes).", [["chest", "ANATOMY", 17, 22], ["blood", "ANATOMY", 78, 83], ["blood", "ANATOMY", 119, 124], ["serum", "ANATOMY", 163, 168], ["liver", "ANATOMY", 177, 182], ["renal", "ANATOMY", 187, 192], ["glucose", "CHEMICAL", 154, 161], ["sodium", "CHEMICAL", 169, 175], ["glucose", "CHEMICAL", 154, 161], ["sodium", "CHEMICAL", 169, 175], ["patient", "ORGANISM", 47, 54], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["glucose", "SIMPLE_CHEMICAL", 154, 161], ["serum", "ORGANISM_SUBSTANCE", 163, 168], ["sodium", "SIMPLE_CHEMICAL", 169, 175], ["liver", "ORGAN", 177, 182], ["renal", "ORGAN", 187, 192], ["patient", "SPECIES", 47, 54], ["a chest radiograph", "TEST", 15, 33], ["a complete blood count", "TEST", 67, 89], ["differential", "TEST", 94, 106], ["routine blood chemistry testing", "TEST", 111, 142], ["glucose", "TEST", 154, 161], ["serum sodium", "TEST", 163, 175], ["liver", "TEST", 177, 182], ["renal function tests", "TEST", 187, 207], ["electrolytes", "TEST", 213, 225], ["chest", "ANATOMY", 17, 22], ["liver", "ANATOMY", 177, 182], ["renal", "ANATOMY", 187, 192]]], ["All admitted patients should have oxygen saturation assessed by pulse oximetry and supplemental oxygen administered as needed.", [["oxygen", "CHEMICAL", 34, 40], ["oxygen", "CHEMICAL", 96, 102], ["oxygen", "CHEMICAL", 34, 40], ["oxygen", "CHEMICAL", 96, 102], ["patients", "ORGANISM", 13, 21], ["oxygen", "SIMPLE_CHEMICAL", 34, 40], ["oxygen", "SIMPLE_CHEMICAL", 96, 102], ["patients", "SPECIES", 13, 21], ["oxygen saturation", "TEST", 34, 51], ["pulse oximetry", "TEST", 64, 78], ["supplemental oxygen", "TREATMENT", 83, 102]]], ["Arterial blood gas should be measured in any patient with severe illness to assess both the level oxygenation and the degree of carbon dioxide retention.ApproachFor critically ill patients with pneumonia, an aggressive approach to determine the causative microbial agent is warranted.", [["Arterial blood", "ANATOMY", 0, 14], ["carbon dioxide", "CHEMICAL", 128, 142], ["critically ill", "DISEASE", 165, 179], ["pneumonia", "DISEASE", 194, 203], ["carbon dioxide", "CHEMICAL", 128, 142], ["Arterial", "ORGANISM_SUBSTANCE", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["patient", "ORGANISM", 45, 52], ["carbon dioxide", "SIMPLE_CHEMICAL", 128, 142], ["patients", "ORGANISM", 180, 188], ["patient", "SPECIES", 45, 52], ["patients", "SPECIES", 180, 188], ["Arterial blood gas", "TEST", 0, 18], ["severe illness", "PROBLEM", 58, 72], ["the level oxygenation", "TEST", 88, 109], ["carbon dioxide retention", "PROBLEM", 128, 152], ["pneumonia", "PROBLEM", 194, 203], ["an aggressive approach", "TREATMENT", 205, 227], ["the causative microbial agent", "TREATMENT", 241, 270], ["carbon dioxide retention", "OBSERVATION", 128, 152], ["pneumonia", "OBSERVATION", 194, 203]]], ["Microbiologic confi rmation is ultimately obtained for approximately 30%-50% of children with CAP [21].", [["CAP", "DISEASE", 94, 97], ["children", "ORGANISM", 80, 88], ["children", "SPECIES", 80, 88], ["CAP", "TEST", 94, 97]]], ["If a pleural effusion is present, aspiration of pleural fl uid for Gram stain and culture prior to starting antibiotics is valuable.", [["pleural effusion", "ANATOMY", 5, 21], ["pleural", "ANATOMY", 48, 55], ["pleural effusion", "DISEASE", 5, 21], ["pleural", "ORGAN", 5, 12], ["a pleural effusion", "PROBLEM", 3, 21], ["aspiration of pleural fl uid", "TEST", 34, 62], ["Gram stain", "TEST", 67, 77], ["culture", "TEST", 82, 89], ["antibiotics", "TREATMENT", 108, 119], ["pleural", "ANATOMY", 5, 12], ["effusion", "OBSERVATION", 13, 21], ["pleural", "ANATOMY", 48, 55]]], ["Blood culture may reveal organisms in up to 30% of patients with bacterial pneumonia [22] .", [["Blood culture", "ANATOMY", 0, 13], ["bacterial pneumonia", "DISEASE", 65, 84], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["Blood culture", "TEST", 0, 13], ["organisms", "PROBLEM", 25, 34], ["bacterial pneumonia", "PROBLEM", 65, 84], ["bacterial", "OBSERVATION_MODIFIER", 65, 74], ["pneumonia", "OBSERVATION", 75, 84]]], ["Sputum collection is usually not practical for infants and children, and bacterial organisms recovered from the nasopharynx do not accurately predict the etiology of pneumonia.", [["Sputum", "ANATOMY", 0, 6], ["nasopharynx", "ANATOMY", 112, 123], ["pneumonia", "DISEASE", 166, 175], ["infants", "ORGANISM", 47, 54], ["children", "ORGANISM", 59, 67], ["nasopharynx", "ORGAN", 112, 123], ["infants", "SPECIES", 47, 54], ["children", "SPECIES", 59, 67], ["Sputum collection", "TEST", 0, 17], ["bacterial organisms", "PROBLEM", 73, 92], ["pneumonia", "PROBLEM", 166, 175], ["nasopharynx", "ANATOMY", 112, 123], ["pneumonia", "OBSERVATION", 166, 175]]], ["However, recovery of viruses and other atypical pathogens from the nasopharynx is more predictive.", [["nasopharynx", "ANATOMY", 67, 78], ["nasopharynx", "ORGAN", 67, 78], ["viruses", "PROBLEM", 21, 28], ["other atypical pathogens from the nasopharynx", "PROBLEM", 33, 78], ["viruses", "OBSERVATION", 21, 28], ["atypical", "OBSERVATION_MODIFIER", 39, 47], ["pathogens", "OBSERVATION", 48, 57], ["nasopharynx", "ANATOMY", 67, 78], ["more predictive", "OBSERVATION_MODIFIER", 82, 97]]], ["Bacterial organisms recovered from tracheal secretions obtained through an endotracheal tube may or may not refl ect the causative agent(s) responsible for lower respiratory tract infection.", [["tracheal secretions", "ANATOMY", 35, 54], ["endotracheal tube", "ANATOMY", 75, 92], ["lower respiratory tract", "ANATOMY", 156, 179], ["respiratory tract infection", "DISEASE", 162, 189], ["tracheal secretions", "MULTI-TISSUE_STRUCTURE", 35, 54], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 75, 92], ["lower", "ORGANISM", 156, 161], ["respiratory tract", "ORGANISM_SUBDIVISION", 162, 179], ["Bacterial organisms", "PROBLEM", 0, 19], ["tracheal secretions", "PROBLEM", 35, 54], ["an endotracheal tube", "TREATMENT", 72, 92], ["lower respiratory tract infection", "PROBLEM", 156, 189], ["organisms", "OBSERVATION", 10, 19], ["tracheal", "ANATOMY", 35, 43], ["secretions", "OBSERVATION", 44, 54], ["endotracheal tube", "OBSERVATION", 75, 92], ["lower", "ANATOMY_MODIFIER", 156, 161], ["respiratory tract", "ANATOMY", 162, 179], ["infection", "OBSERVATION", 180, 189]]], ["Specimens are considered appropriate for examination if they contain \u226410 epithelial cells and \u226525 polymorphonuclear leukocytes under low power [23] .", [["Specimens", "ANATOMY", 0, 9], ["epithelial cells", "ANATOMY", 73, 89], ["polymorphonuclear leukocytes", "ANATOMY", 98, 126], ["epithelial cells", "CELL", 73, 89], ["polymorphonuclear leukocytes", "CELL", 98, 126], ["epithelial cells", "CELL_TYPE", 73, 89], ["polymorphonuclear leukocytes", "CELL_TYPE", 98, 126], ["Specimens", "TEST", 0, 9], ["examination", "TEST", 41, 52], ["epithelial cells", "TEST", 73, 89], ["polymorphonuclear leukocytes", "TEST", 98, 126]]], ["The primary purpose of tracheal aspirate samples is to visualize a bacterial morphology of an organism that was not anticipated so that appropriate drugs can be added to the initial antibiotic regimen (e.g., Staph. aureus or an enteric Gram-negative antibiotic).", [["tracheal aspirate samples", "ANATOMY", 23, 48], ["tracheal aspirate samples", "CANCER", 23, 48], ["aureus", "ORGANISM", 215, 221], ["Gram", "GENE_OR_GENE_PRODUCT", 236, 240], ["aureus", "SPECIES", 215, 221], ["aureus", "SPECIES", 215, 221], ["tracheal aspirate samples", "TEST", 23, 48], ["a bacterial morphology", "PROBLEM", 65, 87], ["an organism", "PROBLEM", 91, 102], ["appropriate drugs", "TREATMENT", 136, 153], ["the initial antibiotic regimen", "TREATMENT", 170, 200], ["Staph", "PROBLEM", 208, 213], ["aureus", "PROBLEM", 215, 221], ["an enteric Gram", "TEST", 225, 240], ["tracheal", "ANATOMY", 23, 31], ["aspirate", "OBSERVATION", 32, 40], ["bacterial morphology", "OBSERVATION_MODIFIER", 67, 87], ["enteric", "ANATOMY", 228, 235], ["negative antibiotic", "OBSERVATION", 241, 260]]], ["Bronchoalveolar lavage (BAL) has been shown to be a rapid, relatively safe, and relatively noninvasive diagnostic procedure to obtain lower respiratory tract samples for microbial identifi cation and analysis.ApproachOther techniques that can be used to identify pathogens include antigen detection of bacteria and viruses using immunofl uorescence, polymerase chain reaction, and serology such as cold agglutination test for M. pneumonia.", [["Bronchoalveolar lavage", "ANATOMY", 0, 22], ["BAL", "ANATOMY", 24, 27], ["lower respiratory tract samples", "ANATOMY", 134, 165], ["pneumonia", "DISEASE", 429, 438], ["Bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 0, 22], ["BAL", "MULTI-TISSUE_STRUCTURE", 24, 27], ["cation", "SIMPLE_CHEMICAL", 189, 195], ["M. pneumonia", "SPECIES", 426, 438], ["Bronchoalveolar lavage (BAL", "TEST", 0, 27], ["relatively noninvasive diagnostic procedure", "TREATMENT", 80, 123], ["lower respiratory tract samples", "PROBLEM", 134, 165], ["microbial identifi cation", "TREATMENT", 170, 195], ["analysis", "TEST", 200, 208], ["ApproachOther techniques", "TREATMENT", 209, 233], ["pathogens", "PROBLEM", 263, 272], ["antigen detection", "TEST", 281, 298], ["bacteria", "PROBLEM", 302, 310], ["viruses", "PROBLEM", 315, 322], ["immunofl uorescence", "PROBLEM", 329, 348], ["polymerase chain reaction", "PROBLEM", 350, 375], ["serology", "TEST", 381, 389], ["cold agglutination test", "TEST", 398, 421], ["M. pneumonia", "PROBLEM", 426, 438], ["respiratory tract", "ANATOMY", 140, 157], ["pneumonia", "OBSERVATION", 429, 438]]], ["The specifi city of the cold agglutination test for M. pneumonia is almost absolute, although the sensitivity is only about 50%.", [["pneumonia", "DISEASE", 55, 64], ["M. pneumonia", "SPECIES", 52, 64], ["the cold agglutination test", "TEST", 20, 47], ["M. pneumonia", "PROBLEM", 52, 64], ["the sensitivity", "TEST", 94, 109], ["pneumonia", "OBSERVATION", 55, 64], ["absolute", "OBSERVATION_MODIFIER", 75, 83]]], ["Detection of Mycoplasma IgM by enzyme-linked immunoabsorbant assay (ELISA) is a sensitive technique and should be considered for children [24] .Definitions and Main FeaturesImmunocompromised patients are those whose immune mechanisms are defi cient because of congenital immune defi ciency syndromes, acquired immunologic disorders, or exposure to cytotoxic chemotherapy and steroids.", [["immunologic disorders", "DISEASE", 310, 331], ["steroids", "CHEMICAL", 375, 383], ["steroids", "CHEMICAL", 375, 383], ["Mycoplasma IgM", "GENE_OR_GENE_PRODUCT", 13, 27], ["children", "ORGANISM", 129, 137], ["patients", "ORGANISM", 191, 199], ["steroids", "SIMPLE_CHEMICAL", 375, 383], ["Mycoplasma IgM", "PROTEIN", 13, 27], ["children", "SPECIES", 129, 137], ["patients", "SPECIES", 191, 199], ["Mycoplasma IgM", "TEST", 13, 27], ["enzyme", "TEST", 31, 37], ["congenital immune defi ciency syndromes", "PROBLEM", 260, 299], ["acquired immunologic disorders", "PROBLEM", 301, 331], ["cytotoxic chemotherapy", "TREATMENT", 348, 370], ["steroids", "TREATMENT", 375, 383], ["Mycoplasma IgM", "OBSERVATION", 13, 27], ["Main", "OBSERVATION_MODIFIER", 160, 164], ["Immunocompromised", "OBSERVATION", 173, 190], ["cytotoxic chemotherapy", "OBSERVATION", 348, 370]]], ["In addition, recipients of solid organ and hematopoietic stem cell transplantation (HSCT) are frequently given life-long treatment with immunosuppressive agents designed to prevent graft rejection or graft-versus-host disease.", [["solid organ", "ANATOMY", 27, 38], ["hematopoietic stem cell", "ANATOMY", 43, 66], ["graft", "ANATOMY", 181, 186], ["graft", "ANATOMY", 200, 205], ["graft-versus-host disease", "DISEASE", 200, 225], ["recipients", "ORGANISM", 13, 23], ["solid organ", "CELL", 27, 38], ["hematopoietic stem cell", "CELL", 43, 66], ["graft", "TISSUE", 181, 186], ["graft", "TISSUE", 200, 205], ["solid organ", "PROBLEM", 27, 38], ["hematopoietic stem cell transplantation", "TREATMENT", 43, 82], ["long treatment", "TREATMENT", 116, 130], ["immunosuppressive agents", "TREATMENT", 136, 160], ["graft rejection", "PROBLEM", 181, 196], ["graft-versus-host disease", "PROBLEM", 200, 225], ["solid organ", "ANATOMY", 27, 38], ["hematopoietic stem cell transplantation", "OBSERVATION", 43, 82], ["graft rejection", "OBSERVATION", 181, 196], ["graft", "OBSERVATION", 200, 205], ["host disease", "OBSERVATION", 213, 225]]], ["Patients who develop severe neutropenia (i.e., an absolute neutrophil count \u2264500 cells/mL) or lymphopenia for prolonged periods of time are at greatest risk to develop a variety of infectious complications, including life-threatening pneumonia.", [["neutrophil", "ANATOMY", 59, 69], ["cells", "ANATOMY", 81, 86], ["neutropenia", "DISEASE", 28, 39], ["lymphopenia", "DISEASE", 94, 105], ["pneumonia", "DISEASE", 234, 243], ["Patients", "ORGANISM", 0, 8], ["neutrophil", "CELL", 59, 69], ["Patients", "SPECIES", 0, 8], ["severe neutropenia", "PROBLEM", 21, 39], ["an absolute neutrophil count", "TEST", 47, 75], ["lymphopenia", "PROBLEM", 94, 105], ["infectious complications", "PROBLEM", 181, 205], ["life-threatening pneumonia", "PROBLEM", 217, 243], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["neutropenia", "OBSERVATION", 28, 39], ["lymphopenia", "OBSERVATION", 94, 105], ["variety", "OBSERVATION_MODIFIER", 170, 177], ["infectious", "OBSERVATION_MODIFIER", 181, 191], ["threatening", "OBSERVATION_MODIFIER", 222, 233], ["pneumonia", "OBSERVATION", 234, 243]]], ["The lung is the predominant site of opportunistic infection in the immunocompromised patient [25] .PathogensImmunosuppressed patients are predisposed to develop infections by ubiquitous microorganisms that do not normally cause disease in healthy people.", [["lung", "ANATOMY", 4, 8], ["opportunistic infection", "DISEASE", 36, 59], ["infections", "DISEASE", 161, 171], ["lung", "ORGAN", 4, 8], ["patient", "ORGANISM", 85, 92], ["patients", "ORGANISM", 125, 133], ["people", "ORGANISM", 247, 253], ["patient", "SPECIES", 85, 92], ["patients", "SPECIES", 125, 133], ["people", "SPECIES", 247, 253], ["opportunistic infection", "PROBLEM", 36, 59], ["infections", "PROBLEM", 161, 171], ["ubiquitous microorganisms", "PROBLEM", 175, 200], ["lung", "ANATOMY", 4, 8], ["predominant", "OBSERVATION_MODIFIER", 16, 27], ["site", "OBSERVATION_MODIFIER", 28, 32], ["opportunistic", "OBSERVATION_MODIFIER", 36, 49], ["infection", "OBSERVATION", 50, 59], ["immunocompromised", "OBSERVATION_MODIFIER", 67, 84], ["infections", "OBSERVATION", 161, 171]]], ["They are also more susceptible to the usual causes of pneumonia, which can affect anyone.", [["pneumonia", "DISEASE", 54, 63], ["pneumonia", "PROBLEM", 54, 63], ["pneumonia", "OBSERVATION", 54, 63]]], ["The sequence in which different organisms appear in the immunosuppressed and post-transplant recipients is fairly characteristic.", [["The sequence", "TEST", 0, 12], ["different organisms", "PROBLEM", 22, 41], ["immunosuppressed", "OBSERVATION", 56, 72], ["post-transplant recipients", "OBSERVATION", 77, 103]]], ["Nosocomial bacterial infections remain the most common cause of pneumonia during the early posttransplant, neutropenic phase.", [["bacterial infections", "DISEASE", 11, 31], ["pneumonia", "DISEASE", 64, 73], ["neutropenic", "DISEASE", 107, 118], ["Nosocomial bacterial infections", "PROBLEM", 0, 31], ["pneumonia", "PROBLEM", 64, 73], ["neutropenic phase", "PROBLEM", 107, 124], ["bacterial", "OBSERVATION_MODIFIER", 11, 20], ["infections", "OBSERVATION", 21, 31], ["most common", "OBSERVATION_MODIFIER", 43, 54], ["pneumonia", "OBSERVATION", 64, 73]]], ["Staphylococcus aureus and Gramnegative pathogens predominate.", [["Staphylococcus aureus", "DISEASE", 0, 21], ["Staphylococcus aureus", "ORGANISM", 0, 21], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Staphylococcus aureus", "PROBLEM", 0, 21], ["Gramnegative pathogens", "PROBLEM", 26, 48], ["aureus", "OBSERVATION", 15, 21], ["Gramnegative pathogens", "OBSERVATION", 26, 48]]], ["In addition, fungal infections with Candida and Aspergillus species are not uncommonly seen during a severe neutropenic phase.", [["fungal infections", "DISEASE", 13, 30], ["neutropenic", "DISEASE", 108, 119], ["Aspergillus species", "ORGANISM", 48, 67], ["fungal infections", "PROBLEM", 13, 30], ["Candida", "PROBLEM", 36, 43], ["Aspergillus species", "PROBLEM", 48, 67], ["a severe neutropenic phase", "PROBLEM", 99, 125], ["fungal", "OBSERVATION_MODIFIER", 13, 19], ["infections", "OBSERVATION", 20, 30], ["Candida", "OBSERVATION_MODIFIER", 36, 43], ["Aspergillus species", "OBSERVATION", 48, 67], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["neutropenic", "OBSERVATION", 108, 119]]], ["The second period, from 1 to 6 months after solid organ transplant, is the time when opportunistic infections more commonly associated with transplantation, including Nocardia, P. carinii/jiroveci, and CMV are observed [26] .", [["organ", "ANATOMY", 50, 55], ["opportunistic infections", "DISEASE", 85, 109], ["Nocardia, P. carinii/jiroveci", "DISEASE", 167, 196], ["organ", "ORGAN", 50, 55], ["P. carinii", "ORGANISM", 177, 187], ["jiroveci", "ORGANISM", 188, 196], ["CMV", "ORGANISM", 202, 205], ["P. carinii", "SPECIES", 177, 187], ["jiroveci", "SPECIES", 188, 196], ["P. carinii/jiroveci", "SPECIES", 177, 196], ["CMV", "SPECIES", 202, 205], ["solid organ transplant", "TREATMENT", 44, 66], ["opportunistic infections", "PROBLEM", 85, 109], ["transplantation", "TREATMENT", 140, 155], ["Nocardia", "PROBLEM", 167, 175], ["P. carinii/jiroveci", "PROBLEM", 177, 196], ["CMV", "PROBLEM", 202, 205], ["transplant", "OBSERVATION", 56, 66], ["jiroveci", "OBSERVATION", 188, 196]]], ["During the third period, after 6 months, patients are categorized into different risk groups depending on the level of function of their allograft and the degree of immunosuppression they have received.", [["allograft", "ANATOMY", 137, 146], ["patients", "ORGANISM", 41, 49], ["allograft", "TISSUE", 137, 146], ["patients", "SPECIES", 41, 49], ["their allograft", "TREATMENT", 131, 146], ["immunosuppression", "TREATMENT", 165, 182], ["allograft", "OBSERVATION", 137, 146], ["immunosuppression", "OBSERVATION", 165, 182]]], ["Those who are on minimal immunosuppression therapy are subject mainly to the same pathogens as the rest of the community.", [["minimal immunosuppression therapy", "TREATMENT", 17, 50]]], ["Those with allograft dysfunction and ongoing heavy immunosuppressive therapy remain subject to all of the opportunistic infections seen during the second period.", [["allograft", "ANATOMY", 11, 20], ["allograft dysfunction", "DISEASE", 11, 32], ["opportunistic infections", "DISEASE", 106, 130], ["allograft", "TISSUE", 11, 20], ["allograft dysfunction", "PROBLEM", 11, 32], ["ongoing heavy immunosuppressive therapy", "TREATMENT", 37, 76], ["the opportunistic infections", "PROBLEM", 102, 130], ["allograft", "OBSERVATION", 11, 20], ["heavy", "OBSERVATION_MODIFIER", 45, 50], ["immunosuppressive therapy", "OBSERVATION", 51, 76], ["opportunistic", "OBSERVATION_MODIFIER", 106, 119], ["infections", "OBSERVATION", 120, 130]]], ["Lung transplant recipients who develop bronchiolitis obliterans and HSCT recipients who develop graft-versus-host disease remain especially at risk for infections [26] .ApproachPulmonary infi ltrates in the immunocompromised host may be caused by a variety of organisms, and may have noninfectious causes.", [["Lung", "ANATOMY", 0, 4], ["graft", "ANATOMY", 96, 101], ["bronchiolitis obliterans", "DISEASE", 39, 63], ["graft-versus-host disease", "DISEASE", 96, 121], ["infections", "DISEASE", 152, 162], ["Lung", "ORGAN", 0, 4], ["recipients", "ORGANISM", 16, 26], ["recipients", "ORGANISM", 73, 83], ["graft", "TISSUE", 96, 101], ["Lung transplant recipients", "TREATMENT", 0, 26], ["bronchiolitis obliterans", "PROBLEM", 39, 63], ["HSCT recipients", "TREATMENT", 68, 83], ["graft-versus-host disease", "PROBLEM", 96, 121], ["infections", "PROBLEM", 152, 162], ["ApproachPulmonary infi ltrates", "TREATMENT", 169, 199], ["the immunocompromised host", "PROBLEM", 203, 229], ["a variety of organisms", "PROBLEM", 247, 269], ["noninfectious causes", "PROBLEM", 284, 304], ["transplant", "OBSERVATION", 5, 15], ["bronchiolitis obliterans", "OBSERVATION", 39, 63], ["graft", "OBSERVATION", 96, 101], ["versus-host", "OBSERVATION_MODIFIER", 102, 113], ["disease", "OBSERVATION", 114, 121], ["infections", "OBSERVATION", 152, 162], ["immunocompromised host", "OBSERVATION", 207, 229], ["noninfectious", "OBSERVATION_MODIFIER", 284, 297]]], ["Because progression to respiratory failure may be rapid, an aggressive approach to diagnosis and treatment is necessary to limit morbidity and mortality.", [["respiratory", "ANATOMY", 23, 34], ["respiratory failure", "DISEASE", 23, 42], ["respiratory failure", "PROBLEM", 23, 42], ["treatment", "TREATMENT", 97, 106], ["respiratory failure", "OBSERVATION", 23, 42], ["may be", "UNCERTAINTY", 43, 49], ["rapid", "OBSERVATION_MODIFIER", 50, 55]]], ["Initial broad-spectrum therapy is important, with alterations of the empiric regimen once the clinical situation has stabilized and more diagnostic information has been obtained.", [["Initial broad-spectrum therapy", "TREATMENT", 0, 30], ["the empiric regimen", "TREATMENT", 65, 84]]], ["In the immunocompromised host, BAL procedure should be performed promptly to rule out infectious etiologies. lists suggested BAL fl uids analysis studies and cultures.", [["BAL", "ANATOMY", 31, 34], ["BAL procedure", "TREATMENT", 31, 44], ["infectious etiologies", "PROBLEM", 86, 107], ["BAL fl uids analysis studies", "TEST", 125, 153], ["cultures", "TEST", 158, 166], ["immunocompromised host", "OBSERVATION", 7, 29], ["infectious", "OBSERVATION", 86, 96]]], ["Bronchoalveolar lavage is very helpful in the diagnosis of P. carinii/jiroveci, CMV, tuberculosis, and some fungal infections.", [["Bronchoalveolar lavage", "ANATOMY", 0, 22], ["P. carinii/jiroveci, CMV, tuberculosis", "DISEASE", 59, 97], ["fungal infections", "DISEASE", 108, 125], ["P. carinii", "ORGANISM", 59, 69], ["jiroveci", "ORGANISM", 70, 78], ["CMV", "ORGANISM", 80, 83], ["P. carinii", "SPECIES", 59, 69], ["P. carinii/jiroveci", "SPECIES", 59, 78], ["CMV", "SPECIES", 80, 83], ["Bronchoalveolar lavage", "TEST", 0, 22], ["P. carinii", "PROBLEM", 59, 69], ["jiroveci", "PROBLEM", 70, 78], ["CMV", "PROBLEM", 80, 83], ["tuberculosis", "PROBLEM", 85, 97], ["some fungal infections", "PROBLEM", 103, 125], ["lavage", "OBSERVATION", 16, 22], ["carinii", "OBSERVATION", 62, 69], ["jiroveci", "OBSERVATION", 70, 78], ["tuberculosis", "OBSERVATION", 85, 97], ["some", "OBSERVATION_MODIFIER", 103, 107], ["fungal", "OBSERVATION_MODIFIER", 108, 114], ["infections", "OBSERVATION", 115, 125]]], ["However, the ability of BAL fl uids analysis and culture to detect invasive aspergillosis, one of the most lethal infectious complication after transplantation, is limited [27] .", [["invasive aspergillosis", "ANATOMY", 67, 89], ["aspergillosis", "DISEASE", 76, 89], ["aspergillosis", "CANCER", 76, 89], ["BAL fl uids analysis", "TEST", 24, 44], ["culture", "TEST", 49, 56], ["invasive aspergillosis", "PROBLEM", 67, 89], ["the most lethal infectious complication", "PROBLEM", 98, 137], ["transplantation", "TREATMENT", 144, 159], ["invasive", "OBSERVATION_MODIFIER", 67, 75], ["aspergillosis", "OBSERVATION", 76, 89]]], ["The diagnostic yield for Aspergillus species infection has been enhanced by the recently developed ELISA that detects galactomannan, a fungal cell wall component released during invasive disease [28] .", [["cell wall", "ANATOMY", 142, 151], ["Aspergillus species infection", "DISEASE", 25, 54], ["Aspergillus species", "ORGANISM", 25, 44], ["galactomannan", "GENE_OR_GENE_PRODUCT", 118, 131], ["cell wall", "TISSUE", 142, 151], ["Aspergillus species infection", "PROBLEM", 25, 54], ["ELISA", "TEST", 99, 104], ["galactomannan", "TEST", 118, 131], ["a fungal cell wall component", "PROBLEM", 133, 161], ["invasive disease", "PROBLEM", 178, 194], ["fungal cell", "OBSERVATION", 135, 146], ["wall", "ANATOMY_MODIFIER", 147, 151], ["component", "OBSERVATION_MODIFIER", 152, 161], ["invasive", "OBSERVATION_MODIFIER", 178, 186]]], ["Histopathologic analysis and culture of open lung biopsy specimens may provide accurate determination for the cause of pulmonary infi ltrates in pediatric patients [29] .", [["lung biopsy specimens", "ANATOMY", 45, 66], ["pulmonary", "ANATOMY", 119, 128], ["pulmonary infi ltrates", "DISEASE", 119, 141], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 45, 56], ["pulmonary", "ORGAN", 119, 128], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["Histopathologic analysis", "TEST", 0, 24], ["culture", "TEST", 29, 36], ["open lung biopsy specimens", "TEST", 40, 66], ["pulmonary infi ltrates", "PROBLEM", 119, 141], ["lung", "ANATOMY", 45, 49], ["pulmonary", "ANATOMY", 119, 128]]], ["However, open lung biopsy is associated with a signifi cant surgical risk in critically ill patients.", [["lung", "ANATOMY", 14, 18], ["critically ill", "DISEASE", 77, 91], ["lung", "ORGAN", 14, 18], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["open lung biopsy", "TEST", 9, 25], ["a signifi cant surgical risk", "PROBLEM", 45, 73], ["lung", "ANATOMY", 14, 18], ["biopsy", "OBSERVATION", 19, 25]]], ["Open lung biopsy is most effective and least risky when performed early in the course of patients who develop nodular infi ltrates that require rapid differentiation between fungal infections and more benign lesions [30] .", [["lung", "ANATOMY", 5, 9], ["benign lesions", "ANATOMY", 201, 215], ["fungal infections", "DISEASE", 174, 191], ["lung", "ORGAN", 5, 9], ["patients", "ORGANISM", 89, 97], ["benign lesions", "CANCER", 201, 215], ["patients", "SPECIES", 89, 97], ["Open lung biopsy", "TEST", 0, 16], ["nodular infi ltrates", "PROBLEM", 110, 130], ["fungal infections", "PROBLEM", 174, 191], ["more benign lesions", "PROBLEM", 196, 215], ["lung", "ANATOMY", 5, 9], ["biopsy", "OBSERVATION", 10, 16], ["most effective", "OBSERVATION_MODIFIER", 20, 34], ["nodular", "OBSERVATION_MODIFIER", 110, 117], ["fungal", "OBSERVATION_MODIFIER", 174, 180], ["infections", "OBSERVATION", 181, 191], ["benign", "OBSERVATION_MODIFIER", 201, 207], ["lesions", "OBSERVATION", 208, 215]]], ["Chemoprophylaxis against opportunistic infections is an important component of management of the post-transplant immunosuppressed patients.", [["opportunistic infections", "DISEASE", 25, 49], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["Chemoprophylaxis", "TREATMENT", 0, 16], ["opportunistic infections", "PROBLEM", 25, 49], ["the post-transplant immunosuppressed patients", "TREATMENT", 93, 138]]], ["Before the widespread introduction of chemoprophylaxis, P. carinii pneumonia (PCP) was observed to be a common opportunistic infection among transplant recipients.", [["P. carinii pneumonia", "DISEASE", 56, 76], ["PCP", "DISEASE", 78, 81], ["opportunistic infection", "DISEASE", 111, 134], ["P. carinii", "ORGANISM", 56, 66], ["recipients", "ORGANISM", 152, 162], ["P. carinii", "SPECIES", 56, 66], ["P. carinii", "SPECIES", 56, 66], ["chemoprophylaxis", "TREATMENT", 38, 54], ["P. carinii pneumonia", "PROBLEM", 56, 76], ["a common opportunistic infection", "PROBLEM", 102, 134], ["transplant recipients", "TREATMENT", 141, 162], ["carinii", "OBSERVATION_MODIFIER", 59, 66], ["pneumonia", "OBSERVATION", 67, 76], ["opportunistic", "OBSERVATION_MODIFIER", 111, 124], ["infection", "OBSERVATION", 125, 134]]], ["With the administration of low-dose trimethoprim-sulfamethoxazole or an alternative prophylactic agent such as pentamidine, PCP can be effectively prevented [31] .", [["trimethoprim-sulfamethoxazole", "CHEMICAL", 36, 65], ["pentamidine", "CHEMICAL", 111, 122], ["PCP", "CHEMICAL", 124, 127], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 36, 65], ["pentamidine", "CHEMICAL", 111, 122], ["PCP", "CHEMICAL", 124, 127], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 36, 65], ["pentamidine", "SIMPLE_CHEMICAL", 111, 122], ["PCP", "SIMPLE_CHEMICAL", 124, 127], ["low-dose trimethoprim", "TREATMENT", 27, 48], ["sulfamethoxazole", "TREATMENT", 49, 65], ["an alternative prophylactic agent", "TREATMENT", 69, 102], ["pentamidine", "TREATMENT", 111, 122], ["PCP", "TREATMENT", 124, 127]]], ["Prophylaxis is also recommended for CMV in high-risk CMV seronegative recipients.", [["CMV", "ORGANISM", 36, 39], ["CMV", "ORGANISM", 53, 56], ["recipients", "ORGANISM", 70, 80], ["CMV", "SPECIES", 36, 39], ["Prophylaxis", "TREATMENT", 0, 11], ["CMV", "PROBLEM", 36, 39], ["CMV seronegative recipients", "TREATMENT", 53, 80], ["CMV seronegative recipients", "OBSERVATION", 53, 80]]], ["Such prophylaxis includes intravenous ganciclovir for 14 days, followed by oral ganciclovir capsules for three months [32] .Definitions and Main FeaturesAspiration pneumonia refers to the pulmonary consequences resulting from the abnormal entry of fl uid, formula, or endogenous secretions into the lower airways.", [["intravenous", "ANATOMY", 26, 37], ["oral", "ANATOMY", 75, 79], ["pulmonary", "ANATOMY", 188, 197], ["secretions", "ANATOMY", 279, 289], ["lower airways", "ANATOMY", 299, 312], ["ganciclovir", "CHEMICAL", 38, 49], ["ganciclovir", "CHEMICAL", 80, 91], ["pneumonia", "DISEASE", 164, 173], ["ganciclovir", "CHEMICAL", 38, 49], ["ganciclovir", "CHEMICAL", 80, 91], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 26, 37], ["ganciclovir", "SIMPLE_CHEMICAL", 38, 49], ["oral", "ORGANISM_SUBDIVISION", 75, 79], ["ganciclovir", "SIMPLE_CHEMICAL", 80, 91], ["pulmonary", "ORGAN", 188, 197], ["fl uid", "GENE_OR_GENE_PRODUCT", 248, 254], ["lower airways", "MULTI-TISSUE_STRUCTURE", 299, 312], ["Such prophylaxis", "TREATMENT", 0, 16], ["intravenous ganciclovir", "TREATMENT", 26, 49], ["oral ganciclovir capsules", "TREATMENT", 75, 100], ["Main FeaturesAspiration pneumonia", "PROBLEM", 140, 173], ["the abnormal entry of fl uid", "PROBLEM", 226, 254], ["endogenous secretions into the lower airways", "PROBLEM", 268, 312], ["Main", "OBSERVATION_MODIFIER", 140, 144], ["FeaturesAspiration", "OBSERVATION_MODIFIER", 145, 163], ["pneumonia", "OBSERVATION", 164, 173], ["pulmonary", "ANATOMY", 188, 197], ["abnormal", "OBSERVATION_MODIFIER", 230, 238], ["endogenous", "OBSERVATION_MODIFIER", 268, 278], ["secretions", "OBSERVATION", 279, 289], ["lower", "ANATOMY_MODIFIER", 299, 304], ["airways", "ANATOMY", 305, 312]]], ["There is usually compromise in host defenses that protect the lower airways, including glottic closure, cough refl ex, and other clearing mechanisms.", [["lower airways", "ANATOMY", 62, 75], ["glottic", "ANATOMY", 87, 94], ["lower airways", "ORGANISM_SUBDIVISION", 62, 75], ["glottic", "ORGAN", 87, 94], ["usually compromise in host defenses", "PROBLEM", 9, 44], ["glottic closure", "TREATMENT", 87, 102], ["cough refl ex", "PROBLEM", 104, 117], ["compromise", "OBSERVATION", 17, 27], ["host defenses", "OBSERVATION", 31, 44], ["lower", "ANATOMY_MODIFIER", 62, 67], ["airways", "ANATOMY", 68, 75], ["glottic closure", "OBSERVATION", 87, 102], ["cough", "OBSERVATION", 104, 109]]], ["Histories of seizure, anesthesia, or other episode of reduced level of consciousness, neurologic disease, dysphagia, or gastroesophageal refl ux are all risk factors for aspiration.", [["neurologic", "ANATOMY", 86, 96], ["gastroesophageal", "ANATOMY", 120, 136], ["seizure", "DISEASE", 13, 20], ["neurologic disease", "DISEASE", 86, 104], ["dysphagia", "DISEASE", 106, 115], ["gastroesophageal refl ux", "DISEASE", 120, 144], ["seizure", "PROBLEM", 13, 20], ["anesthesia", "TREATMENT", 22, 32], ["reduced level of consciousness", "PROBLEM", 54, 84], ["neurologic disease", "PROBLEM", 86, 104], ["dysphagia", "PROBLEM", 106, 115], ["gastroesophageal refl ux", "PROBLEM", 120, 144], ["aspiration", "PROBLEM", 170, 180], ["seizure", "OBSERVATION", 13, 20], ["gastroesophageal", "ANATOMY", 120, 136], ["aspiration", "OBSERVATION", 170, 180]]], ["The risk of aspiration is especially high after removal of an endotracheal tube because of the residual effects of sedative drugs, the presence of a nasogastric tube, and swallowing dysfunction related to alterations of upper-airway sensitivity, glottic injury, and laryngeal muscular dysfunction [33] .", [["endotracheal tube", "ANATOMY", 62, 79], ["nasogastric tube", "ANATOMY", 149, 165], ["upper-airway", "ANATOMY", 220, 232], ["glottic", "ANATOMY", 246, 253], ["laryngeal muscular", "ANATOMY", 266, 284], ["swallowing dysfunction", "DISEASE", 171, 193], ["glottic injury", "DISEASE", 246, 260], ["laryngeal muscular dysfunction", "DISEASE", 266, 296], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 62, 79], ["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 149, 165], ["glottic", "ORGAN", 246, 253], ["muscular", "ORGAN", 276, 284], ["aspiration", "PROBLEM", 12, 22], ["removal", "TREATMENT", 48, 55], ["an endotracheal tube", "TREATMENT", 59, 79], ["sedative drugs", "TREATMENT", 115, 129], ["a nasogastric tube", "TREATMENT", 147, 165], ["swallowing dysfunction", "PROBLEM", 171, 193], ["upper-airway sensitivity", "PROBLEM", 220, 244], ["glottic injury", "PROBLEM", 246, 260], ["laryngeal muscular dysfunction", "PROBLEM", 266, 296], ["aspiration", "OBSERVATION", 12, 22], ["endotracheal tube", "OBSERVATION", 62, 79], ["sedative drugs", "OBSERVATION", 115, 129], ["nasogastric tube", "OBSERVATION", 149, 165], ["glottic injury", "OBSERVATION", 246, 260], ["laryngeal muscular", "ANATOMY", 266, 284]]], ["Aspiration pneumonia may be classifi ed into three clinical syndromes: chemical pneumonitis, bacterial infection, and airway obstruction.", [["airway", "ANATOMY", 118, 124], ["Aspiration pneumonia", "DISEASE", 0, 20], ["pneumonitis", "DISEASE", 80, 91], ["bacterial infection", "DISEASE", 93, 112], ["airway obstruction", "DISEASE", 118, 136], ["airway obstruction", "PATHOLOGICAL_FORMATION", 118, 136], ["Aspiration pneumonia", "PROBLEM", 0, 20], ["three clinical syndromes", "PROBLEM", 45, 69], ["chemical pneumonitis", "PROBLEM", 71, 91], ["bacterial infection", "PROBLEM", 93, 112], ["airway obstruction", "PROBLEM", 118, 136], ["pneumonia", "OBSERVATION", 11, 20], ["chemical", "OBSERVATION_MODIFIER", 71, 79], ["pneumonitis", "OBSERVATION", 80, 91], ["bacterial", "OBSERVATION_MODIFIER", 93, 102], ["infection", "OBSERVATION", 103, 112], ["airway", "ANATOMY", 118, 124], ["obstruction", "OBSERVATION", 125, 136]]], ["In animal models, development of chemical pneumonitis requires a 1 to 4 mL/kg inoculum of fl uid with a pH of 2.5 to initiate an infl ammatory reaction that may lead to pulmonary fi brosis [34] .", [["pulmonary", "ANATOMY", 169, 178], ["pneumonitis", "DISEASE", 42, 53], ["chemical pneumonitis", "PROBLEM", 33, 53], ["a pH", "TEST", 102, 106], ["an infl ammatory reaction", "PROBLEM", 126, 151], ["pulmonary fi brosis", "PROBLEM", 169, 188], ["chemical", "OBSERVATION_MODIFIER", 33, 41], ["pneumonitis", "OBSERVATION", 42, 53], ["may lead to", "UNCERTAINTY", 157, 168], ["pulmonary", "ANATOMY", 169, 178]]], ["Bacteria, present in the aspirated oropharyngeal and gastric secretions, may also lead to pneumonia.", [["oropharyngeal", "ANATOMY", 35, 48], ["gastric secretions", "ANATOMY", 53, 71], ["pneumonia", "DISEASE", 90, 99], ["oropharyngeal", "ORGANISM_SUBDIVISION", 35, 48], ["gastric secretions", "ORGAN", 53, 71], ["Bacteria", "PROBLEM", 0, 8], ["the aspirated oropharyngeal and gastric secretions", "PROBLEM", 21, 71], ["pneumonia", "PROBLEM", 90, 99], ["oropharyngeal", "ANATOMY", 35, 48], ["gastric", "ANATOMY", 53, 60], ["secretions", "OBSERVATION", 61, 71], ["may also lead to", "UNCERTAINTY", 73, 89], ["pneumonia", "OBSERVATION", 90, 99]]], ["Aspiration pneumonia may involve particulate matter or foreign body, which, in addition to causing airway obstruction or refl ux airway closure, may synergistically contribute to acid-induced lung injury [34] .PathogensTrue aspiration pneumonia, by convention, usually refers to an infection caused by less virulent bacteria, primarily anaerobes, which are common constituents of the normal fl ora in a susceptible host prone to aspiration.", [["particulate matter", "ANATOMY", 33, 51], ["body", "ANATOMY", 63, 67], ["airway", "ANATOMY", 99, 105], ["airway", "ANATOMY", 129, 135], ["lung", "ANATOMY", 192, 196], ["pneumonia", "DISEASE", 11, 20], ["airway obstruction", "DISEASE", 99, 117], ["lung injury", "DISEASE", 192, 203], ["aspiration pneumonia", "DISEASE", 224, 244], ["infection", "DISEASE", 282, 291], ["airway", "MULTI-TISSUE_STRUCTURE", 99, 105], ["airway", "MULTI-TISSUE_STRUCTURE", 129, 135], ["lung", "ORGAN", 192, 196], ["fl ora", "ORGANISM", 391, 397], ["Aspiration pneumonia", "PROBLEM", 0, 20], ["particulate matter", "PROBLEM", 33, 51], ["foreign body", "PROBLEM", 55, 67], ["airway obstruction", "PROBLEM", 99, 117], ["refl ux airway closure", "TREATMENT", 121, 143], ["acid-induced lung injury", "PROBLEM", 179, 203], ["True aspiration pneumonia", "PROBLEM", 219, 244], ["an infection", "PROBLEM", 279, 291], ["less virulent bacteria", "PROBLEM", 302, 324], ["anaerobes", "PROBLEM", 336, 345], ["aspiration", "PROBLEM", 429, 439], ["pneumonia", "OBSERVATION", 11, 20], ["particulate matter", "OBSERVATION_MODIFIER", 33, 51], ["foreign body", "OBSERVATION", 55, 67], ["airway", "ANATOMY", 99, 105], ["obstruction", "OBSERVATION", 106, 117], ["airway", "ANATOMY", 129, 135], ["closure", "OBSERVATION", 136, 143], ["acid-induced", "OBSERVATION_MODIFIER", 179, 191], ["lung", "ANATOMY", 192, 196], ["injury", "OBSERVATION", 197, 203], ["aspiration", "OBSERVATION_MODIFIER", 224, 234], ["pneumonia", "OBSERVATION", 235, 244], ["infection", "OBSERVATION", 282, 291], ["less", "OBSERVATION_MODIFIER", 302, 306], ["virulent bacteria", "OBSERVATION_MODIFIER", 307, 324], ["anaerobes", "OBSERVATION", 336, 345], ["normal", "OBSERVATION", 384, 390], ["fl ora", "OBSERVATION", 391, 397], ["aspiration", "OBSERVATION", 429, 439]]], ["Pneumonia is commonly caused by oropharyngeal fl ora, including anaerobic Gram-negative bacilli (Bacteroides fragilis, Fusobacterium nucleatum, Peptostreptococcus, and Prevotella) and anaerobic Gram-positive bacilli (Clostridium, Eubacterium, Actinomyces, Lactobacillus, and Propionibacterium).ApproachAspiration usually occurs when the patient is supine during or immediately after feeding.", [["oropharyngeal fl ora", "ANATOMY", 32, 52], ["Pneumonia", "DISEASE", 0, 9], ["Clostridium, Eubacterium, Actinomyces, Lactobacillus", "CHEMICAL", 217, 269], ["oropharyngeal fl ora", "ORGANISM", 32, 52], ["Gram-", "GENE_OR_GENE_PRODUCT", 74, 79], ["Bacteroides fragilis", "ORGANISM", 97, 117], ["Fusobacterium nucleatum", "ORGANISM", 119, 142], ["Prevotella", "SIMPLE_CHEMICAL", 168, 178], ["Gram-positive bacilli", "SIMPLE_CHEMICAL", 194, 215], ["Lactobacillus", "SIMPLE_CHEMICAL", 256, 269], ["patient", "ORGANISM", 337, 344], ["Bacteroides fragilis", "SPECIES", 97, 117], ["Fusobacterium nucleatum", "SPECIES", 119, 142], ["patient", "SPECIES", 337, 344], ["Bacteroides fragilis", "SPECIES", 97, 117], ["Fusobacterium nucleatum", "SPECIES", 119, 142], ["Pneumonia", "PROBLEM", 0, 9], ["oropharyngeal fl ora", "TEST", 32, 52], ["anaerobic Gram-negative bacilli (Bacteroides fragilis", "PROBLEM", 64, 117], ["Fusobacterium nucleatum", "PROBLEM", 119, 142], ["Peptostreptococcus", "PROBLEM", 144, 162], ["Prevotella", "PROBLEM", 168, 178], ["anaerobic Gram-positive bacilli", "PROBLEM", 184, 215], ["Clostridium", "TEST", 217, 228], ["Eubacterium", "PROBLEM", 230, 241], ["Actinomyces", "PROBLEM", 243, 254], ["Lactobacillus", "PROBLEM", 256, 269], ["Propionibacterium", "PROBLEM", 275, 292], ["oropharyngeal fl", "ANATOMY", 32, 48], ["negative bacilli", "OBSERVATION", 79, 95], ["positive bacilli", "OBSERVATION", 199, 215]]], ["In the supine position the right upper lobe is the most dependent part of the lung and is most frequently affected.", [["right upper lobe", "ANATOMY", 27, 43], ["lung", "ANATOMY", 78, 82], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 33, 43], ["lung", "ORGAN", 78, 82], ["supine", "ANATOMY_MODIFIER", 7, 13], ["right upper lobe", "ANATOMY", 27, 43], ["most dependent", "OBSERVATION_MODIFIER", 51, 65], ["lung", "ANATOMY", 78, 82], ["most", "OBSERVATION_MODIFIER", 90, 94], ["frequently", "OBSERVATION_MODIFIER", 95, 105]]], ["Commonly, impaired airway protective responses are observed.", [["airway", "ANATOMY", 19, 25], ["airway", "MULTI-TISSUE_STRUCTURE", 19, 25], ["impaired airway protective responses", "PROBLEM", 10, 46], ["impaired", "OBSERVATION_MODIFIER", 10, 18], ["airway", "ANATOMY", 19, 25]]], ["The presence of tracheoesophageal malformations should be investigated if recurrent aspiration is noted in an otherwise healthy infant.ApproachThe clinical presentation and course of chemical pneumonitis after inhalation of gastric contents ranges from mild and selflimited to severe and life threatening, depending on the nature of the aspirate and the underlying condition of the host.", [["tracheoesophageal", "ANATOMY", 16, 33], ["gastric", "ANATOMY", 224, 231], ["aspirate", "ANATOMY", 337, 345], ["tracheoesophageal malformations", "DISEASE", 16, 47], ["pneumonitis", "DISEASE", 192, 203], ["tracheoesophageal malformations", "PATHOLOGICAL_FORMATION", 16, 47], ["infant", "ORGANISM", 128, 134], ["gastric", "ORGAN", 224, 231], ["infant", "SPECIES", 128, 134], ["tracheoesophageal malformations", "PROBLEM", 16, 47], ["recurrent aspiration", "PROBLEM", 74, 94], ["chemical pneumonitis", "PROBLEM", 183, 203], ["gastric contents", "PROBLEM", 224, 240], ["mild and selflimited to severe and life threatening", "PROBLEM", 253, 304], ["the aspirate", "TEST", 333, 345], ["tracheoesophageal", "ANATOMY", 16, 33], ["malformations", "OBSERVATION", 34, 47], ["aspiration", "OBSERVATION", 84, 94], ["chemical", "OBSERVATION_MODIFIER", 183, 191], ["pneumonitis", "OBSERVATION", 192, 203], ["gastric", "ANATOMY", 224, 231], ["contents", "OBSERVATION", 232, 240], ["mild", "OBSERVATION_MODIFIER", 253, 257], ["severe", "OBSERVATION_MODIFIER", 277, 283], ["aspirate", "OBSERVATION", 337, 345]]], ["In the absence of witnessed inhalation of vomit, diagnosis is diffi cult and requires a high index of suspicion in a patient who has risk factors for aspiration.", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["vomit", "PROBLEM", 42, 47], ["diffi cult", "TEST", 62, 72], ["aspiration", "PROBLEM", 150, 160], ["aspiration", "OBSERVATION", 150, 160]]], ["In the absence of an obvious predisposition, the abrupt onset of a self-limited illness characterized by dyspnea, cyanosis, and low-grade fever associated with diffuse rales, hypoxemia, and alveolar infi ltrates in dependent lobes should suggest aspiration [35] .", [["alveolar", "ANATOMY", 190, 198], ["lobes", "ANATOMY", 225, 230], ["illness", "DISEASE", 80, 87], ["dyspnea", "DISEASE", 105, 112], ["cyanosis", "DISEASE", 114, 122], ["low-grade fever", "DISEASE", 128, 143], ["hypoxemia", "DISEASE", 175, 184], ["lobes", "ORGAN", 225, 230], ["a self-limited illness", "PROBLEM", 65, 87], ["dyspnea", "PROBLEM", 105, 112], ["cyanosis", "PROBLEM", 114, 122], ["low-grade fever", "PROBLEM", 128, 143], ["diffuse rales", "PROBLEM", 160, 173], ["hypoxemia", "PROBLEM", 175, 184], ["alveolar infi ltrates in dependent lobes", "PROBLEM", 190, 230], ["aspiration", "PROBLEM", 246, 256], ["obvious", "OBSERVATION_MODIFIER", 21, 28], ["predisposition", "OBSERVATION", 29, 43], ["abrupt", "OBSERVATION_MODIFIER", 49, 55], ["dyspnea", "OBSERVATION", 105, 112], ["cyanosis", "OBSERVATION", 114, 122], ["low-grade", "OBSERVATION_MODIFIER", 128, 137], ["fever", "OBSERVATION", 138, 143], ["diffuse", "OBSERVATION_MODIFIER", 160, 167], ["rales", "OBSERVATION", 168, 173], ["hypoxemia", "OBSERVATION", 175, 184], ["alveolar", "ANATOMY_MODIFIER", 190, 198], ["infi ltrates", "OBSERVATION", 199, 211], ["dependent lobes", "ANATOMY", 215, 230], ["aspiration", "OBSERVATION", 246, 256]]], ["If BAL is performed, assessment of lipid-laden macrophage index using Oil-Red-O stain is helpful in confi rming the diagnosis [36] .", [["BAL", "ANATOMY", 3, 6], ["macrophage", "ANATOMY", 47, 57], ["BAL", "ORGANISM_SUBSTANCE", 3, 6], ["lipid", "SIMPLE_CHEMICAL", 35, 40], ["macrophage", "CELL", 47, 57], ["BAL", "TEST", 3, 6], ["assessment", "TEST", 21, 31], ["lipid", "TEST", 35, 40], ["O stain", "TEST", 78, 85]]], ["The presence of foul-smelling putrid discharge in sputum or pleural fl uid is regarded as diagnostic of anaerobic infection.", [["sputum", "ANATOMY", 50, 56], ["pleural fl uid", "ANATOMY", 60, 74], ["anaerobic infection", "DISEASE", 104, 123], ["sputum", "ORGANISM_SUBSTANCE", 50, 56], ["foul-smelling putrid discharge in sputum", "PROBLEM", 16, 56], ["pleural fl uid", "PROBLEM", 60, 74], ["anaerobic infection", "PROBLEM", 104, 123], ["foul", "OBSERVATION_MODIFIER", 16, 20], ["smelling putrid", "OBSERVATION", 21, 36], ["sputum", "OBSERVATION", 50, 56], ["pleural", "ANATOMY", 60, 67], ["fl", "OBSERVATION", 68, 70], ["anaerobic", "OBSERVATION_MODIFIER", 104, 113], ["infection", "OBSERVATION", 114, 123]]], ["Patients often have prolonged fever and productive cough, frequently showing blood in the sputum, which indicates necrosis (tissue death) in the lung.", [["blood", "ANATOMY", 77, 82], ["sputum", "ANATOMY", 90, 96], ["tissue", "ANATOMY", 124, 130], ["lung", "ANATOMY", 145, 149], ["fever", "DISEASE", 30, 35], ["cough", "DISEASE", 51, 56], ["necrosis", "DISEASE", 114, 122], ["death", "DISEASE", 131, 136], ["Patients", "ORGANISM", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["sputum", "ORGANISM_SUBSTANCE", 90, 96], ["tissue", "TISSUE", 124, 130], ["lung", "ORGAN", 145, 149], ["Patients", "SPECIES", 0, 8], ["prolonged fever", "PROBLEM", 20, 35], ["productive cough", "PROBLEM", 40, 56], ["blood in the sputum", "PROBLEM", 77, 96], ["necrosis (tissue death) in the lung", "PROBLEM", 114, 149], ["prolonged", "OBSERVATION_MODIFIER", 20, 29], ["fever", "OBSERVATION", 30, 35], ["productive", "OBSERVATION_MODIFIER", 40, 50], ["cough", "OBSERVATION", 51, 56], ["sputum", "OBSERVATION", 90, 96], ["necrosis", "OBSERVATION", 114, 122], ["tissue death", "OBSERVATION", 124, 136], ["lung", "ANATOMY", 145, 149]]], ["If aspiration is persistent, fi brosis and bronchiectasis may result.ApproachA number of interventions (e.g., positioning, dietary changes, drugs, oral hygiene, tube feeding) have been proposed to prevent aspiration Patients with an observed aspiration should have immediate tracheal suction or bronchoscopy to clear fl uids and particulate matter that may cause obstruction.", [["oral", "ANATOMY", 147, 151], ["tube", "ANATOMY", 161, 165], ["tracheal", "ANATOMY", 275, 283], ["bronchiectasis", "DISEASE", 43, 57], ["obstruction", "DISEASE", 363, 374], ["oral", "ORGANISM_SUBDIVISION", 147, 151], ["tube", "TISSUE", 161, 165], ["Patients", "ORGANISM", 216, 224], ["tracheal", "MULTI-TISSUE_STRUCTURE", 275, 283], ["Patients", "SPECIES", 216, 224], ["aspiration", "PROBLEM", 3, 13], ["persistent", "PROBLEM", 17, 27], ["fi brosis", "PROBLEM", 29, 38], ["bronchiectasis", "PROBLEM", 43, 57], ["interventions (e.g., positioning, dietary changes", "TREATMENT", 89, 138], ["drugs", "TREATMENT", 140, 145], ["oral hygiene", "TREATMENT", 147, 159], ["tube feeding", "TREATMENT", 161, 173], ["aspiration", "PROBLEM", 205, 215], ["an observed aspiration", "PROBLEM", 230, 252], ["immediate tracheal suction", "TREATMENT", 265, 291], ["bronchoscopy", "TREATMENT", 295, 307], ["obstruction", "PROBLEM", 363, 374], ["aspiration", "OBSERVATION", 3, 13], ["persistent", "OBSERVATION_MODIFIER", 17, 27], ["bronchiectasis", "OBSERVATION", 43, 57], ["aspiration", "OBSERVATION", 205, 215], ["aspiration", "OBSERVATION", 242, 252], ["tracheal", "ANATOMY", 275, 283], ["suction", "OBSERVATION", 284, 291], ["may cause", "UNCERTAINTY", 353, 362], ["obstruction", "OBSERVATION", 363, 374]]], ["The use of corticosteroids in the treatment of chemical pneumonitis is controversial [37] , and antibiotics should not be used early in the course unless a superimposed bacterial infection is suspected.Definitions and Main FeaturesThe National Nosocomial Infection Surveillance (NNIS) program sponsored by the CDC defi nes VAP as pneumonia in patients who have been on mechanical ventilation for >48 hr and have developed new and persistent radiographic evidence of focal infi ltrates.", [["corticosteroids", "CHEMICAL", 11, 26], ["pneumonitis", "DISEASE", 56, 67], ["bacterial infection", "DISEASE", 169, 188], ["Nosocomial Infection", "DISEASE", 244, 264], ["VAP", "DISEASE", 323, 326], ["pneumonia", "DISEASE", 330, 339], ["corticosteroids", "CHEMICAL", 11, 26], ["patients", "ORGANISM", 343, 351], ["patients", "SPECIES", 343, 351], ["corticosteroids", "TREATMENT", 11, 26], ["chemical pneumonitis", "PROBLEM", 47, 67], ["antibiotics", "TREATMENT", 96, 107], ["a superimposed bacterial infection", "PROBLEM", 154, 188], ["The National Nosocomial Infection", "PROBLEM", 231, 264], ["VAP", "PROBLEM", 323, 326], ["pneumonia", "PROBLEM", 330, 339], ["mechanical ventilation", "TREATMENT", 369, 391], ["focal infi ltrates", "PROBLEM", 466, 484], ["chemical", "OBSERVATION_MODIFIER", 47, 55], ["pneumonitis", "OBSERVATION", 56, 67], ["superimposed", "OBSERVATION_MODIFIER", 156, 168], ["bacterial", "OBSERVATION_MODIFIER", 169, 178], ["infection", "OBSERVATION", 179, 188], ["Main", "OBSERVATION_MODIFIER", 218, 222], ["Nosocomial", "OBSERVATION_MODIFIER", 244, 254], ["Infection", "OBSERVATION", 255, 264], ["pneumonia", "OBSERVATION", 330, 339], ["new", "OBSERVATION_MODIFIER", 422, 425], ["persistent", "OBSERVATION_MODIFIER", 430, 440], ["evidence of", "UNCERTAINTY", 454, 465], ["focal", "OBSERVATION_MODIFIER", 466, 471], ["infi ltrates", "OBSERVATION", 472, 484]]], ["In addition, patients had to have two of the following: temperature >38\u2032C, leukocytosis (white blood cell >12,000/mm 3 ), and purulent sputum (>25 white blood cells/high-powered fi eld on tracheal aspirate Gram stain).", [["white blood cell", "ANATOMY", 89, 105], ["purulent sputum", "ANATOMY", 126, 141], ["white blood cells", "ANATOMY", 147, 164], ["tracheal", "ANATOMY", 188, 196], ["leukocytosis", "DISEASE", 75, 87], ["patients", "ORGANISM", 13, 21], ["blood cell", "CELL", 95, 105], ["sputum", "ORGANISM_SUBSTANCE", 135, 141], ["blood cells", "CELL", 153, 164], ["white blood cells", "CELL_TYPE", 147, 164], ["patients", "SPECIES", 13, 21], ["temperature", "TEST", 56, 67], ["leukocytosis", "PROBLEM", 75, 87], ["white blood cell", "TEST", 89, 105], ["purulent sputum", "PROBLEM", 126, 141], ["white blood cells", "TEST", 147, 164], ["tracheal aspirate Gram stain", "TEST", 188, 216], ["purulent", "OBSERVATION_MODIFIER", 126, 134], ["sputum", "OBSERVATION", 135, 141], ["tracheal", "ANATOMY", 188, 196]]], ["After blood stream infections, VAP is the second most common cause of nosocomial infections in PICUs.", [["blood stream", "ANATOMY", 6, 18], ["blood stream infections", "DISEASE", 6, 29], ["VAP", "DISEASE", 31, 34], ["infections", "DISEASE", 81, 91], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["PICUs", "CANCER", 95, 100], ["blood stream infections", "PROBLEM", 6, 29], ["VAP", "PROBLEM", 31, 34], ["nosocomial infections", "PROBLEM", 70, 91], ["stream", "OBSERVATION_MODIFIER", 12, 18], ["infections", "OBSERVATION", 19, 29], ["nosocomial", "OBSERVATION_MODIFIER", 70, 80], ["infections", "OBSERVATION", 81, 91]]], ["The mean VAP rate in children ranges from 6 to 12/1,000 ventilator days, accounting for 20%-50% of hospital-acquired infections [38, 39] .", [["VAP", "DISEASE", 9, 12], ["infections", "DISEASE", 117, 127], ["children", "ORGANISM", 21, 29], ["children", "SPECIES", 21, 29], ["The mean VAP rate", "TEST", 0, 17], ["acquired infections", "PROBLEM", 108, 127], ["mean VAP", "OBSERVATION", 4, 12]]], ["Infections acquired in the PICU are associated with a signifi cantly increased risk of death [40] .PathogensNosocomial pneumonia and VAP are typically categorized as either early onset (occurring in the fi rst 3-4 days of mechanical ventilation) or late onset.", [["Infections", "DISEASE", 0, 10], ["death", "DISEASE", 87, 92], ["pneumonia", "DISEASE", 119, 128], ["VAP", "DISEASE", 133, 136], ["Infections", "PROBLEM", 0, 10], ["death", "PROBLEM", 87, 92], ["PathogensNosocomial pneumonia", "PROBLEM", 99, 128], ["VAP", "PROBLEM", 133, 136], ["mechanical ventilation", "TREATMENT", 222, 244], ["Nosocomial", "OBSERVATION_MODIFIER", 108, 118], ["pneumonia", "OBSERVATION", 119, 128], ["VAP", "OBSERVATION", 133, 136], ["early", "OBSERVATION_MODIFIER", 173, 178], ["onset", "OBSERVATION_MODIFIER", 179, 184]]], ["Early-onset nosocomial pneumonia and VAP are commonly caused by antibiotic-sensitive, community-acquired organisms (e.g., Strep. pneumoniae, and Staph. aureus).", [["pneumonia", "DISEASE", 23, 32], ["VAP", "DISEASE", 37, 40], ["pneumoniae", "ORGANISM", 129, 139], ["aureus", "ORGANISM", 152, 158], ["pneumoniae", "SPECIES", 129, 139], ["aureus", "SPECIES", 152, 158], ["pneumoniae", "SPECIES", 129, 139], ["aureus", "SPECIES", 152, 158], ["Early-onset nosocomial pneumonia", "PROBLEM", 0, 32], ["VAP", "PROBLEM", 37, 40], ["antibiotic", "TEST", 64, 74], ["acquired organisms", "PROBLEM", 96, 114], ["pneumoniae", "PROBLEM", 129, 139], ["Staph", "PROBLEM", 145, 150], ["aureus", "PROBLEM", 152, 158], ["onset", "OBSERVATION_MODIFIER", 6, 11], ["nosocomial", "OBSERVATION_MODIFIER", 12, 22], ["pneumonia", "OBSERVATION", 23, 32], ["VAP", "OBSERVATION", 37, 40], ["Staph", "OBSERVATION", 145, 150]]], ["Late-onset nosocomial pneumonia and VAP are commonly caused by anti-biotic-resistant nosocomial organisms (e.g., P. aeruginosa, methicillin-resistant Staph. aureus, Acinetobacter species, and Enterobacter species).", [["nosocomial pneumonia", "DISEASE", 11, 31], ["VAP", "DISEASE", 36, 39], ["nosocomial organisms", "DISEASE", 85, 105], ["methicillin", "CHEMICAL", 128, 139], ["methicillin", "CHEMICAL", 128, 139], ["P. aeruginosa", "ORGANISM", 113, 126], ["methicillin", "SIMPLE_CHEMICAL", 128, 139], ["aureus", "ORGANISM", 157, 163], ["Acinetobacter species", "ORGANISM", 165, 186], ["Enterobacter species", "ORGANISM", 192, 212], ["P. aeruginosa", "SPECIES", 113, 126], ["aureus", "SPECIES", 157, 163], ["P. aeruginosa", "SPECIES", 113, 126], ["aureus", "SPECIES", 157, 163], ["Late-onset nosocomial pneumonia", "PROBLEM", 0, 31], ["VAP", "PROBLEM", 36, 39], ["anti-biotic-resistant nosocomial organisms", "PROBLEM", 63, 105], ["P. aeruginosa", "PROBLEM", 113, 126], ["methicillin", "PROBLEM", 128, 139], ["resistant Staph", "PROBLEM", 140, 155], ["aureus", "PROBLEM", 157, 163], ["Acinetobacter species", "PROBLEM", 165, 186], ["Enterobacter species", "PROBLEM", 192, 212], ["onset", "OBSERVATION_MODIFIER", 5, 10], ["nosocomial", "OBSERVATION_MODIFIER", 11, 21], ["pneumonia", "OBSERVATION", 22, 31], ["VAP", "OBSERVATION", 36, 39], ["Staph", "OBSERVATION", 150, 155], ["Acinetobacter species", "OBSERVATION", 165, 186], ["Enterobacter species", "OBSERVATION", 192, 212]]], ["During the winter respiratory viral season, all patients in a medical care environment are at risk for disease due to respiratory syncytial virus, parainfl uenza, and infl uenza viruses.", [["respiratory syncytial virus", "DISEASE", 118, 145], ["patients", "ORGANISM", 48, 56], ["respiratory syncytial virus", "ORGANISM", 118, 145], ["infl uenza viruses", "ORGANISM", 167, 185], ["patients", "SPECIES", 48, 56], ["respiratory syncytial virus", "SPECIES", 118, 145], ["infl uenza viruses", "SPECIES", 167, 185], ["disease", "PROBLEM", 103, 110], ["respiratory syncytial virus", "PROBLEM", 118, 145], ["parainfl uenza", "PROBLEM", 147, 161], ["infl uenza viruses", "PROBLEM", 167, 185], ["respiratory", "ANATOMY", 118, 129], ["syncytial virus", "OBSERVATION", 130, 145], ["uenza viruses", "OBSERVATION", 172, 185]]], ["Legionnaire's disease is a multisystem illness with pneumonia caused by Legionella species usually present in contaminated water.", [["Legionnaire's disease", "DISEASE", 0, 21], ["multisystem illness", "DISEASE", 27, 46], ["pneumonia", "DISEASE", 52, 61], ["Legionnaire's disease", "PROBLEM", 0, 21], ["a multisystem illness", "PROBLEM", 25, 46], ["pneumonia", "PROBLEM", 52, 61], ["Legionella species", "PROBLEM", 72, 90], ["disease", "OBSERVATION", 14, 21], ["multisystem", "OBSERVATION_MODIFIER", 27, 38], ["illness", "OBSERVATION", 39, 46], ["pneumonia", "OBSERVATION", 52, 61], ["Legionella species", "OBSERVATION", 72, 90]]], ["Legionnaire's disease is less common in children than adults.ApproachCompared with postmortem lung biopsies and culture results, the use of clinical criteria to diagnose VAP (lung infi ltrates, leukocytosis, purulent secretions, fever) had a sensitivity of 69% and a specifi city of 75% [41] .", [["lung", "ANATOMY", 94, 98], ["lung", "ANATOMY", 175, 179], ["purulent secretions", "ANATOMY", 208, 227], ["Legionnaire's disease", "DISEASE", 0, 21], ["VAP", "DISEASE", 170, 173], ["lung infi ltrates", "DISEASE", 175, 192], ["leukocytosis", "DISEASE", 194, 206], ["fever", "DISEASE", 229, 234], ["children", "ORGANISM", 40, 48], ["lung biopsies", "MULTI-TISSUE_STRUCTURE", 94, 107], ["lung", "ORGAN", 175, 179], ["children", "SPECIES", 40, 48], ["Legionnaire's disease", "PROBLEM", 0, 21], ["postmortem lung biopsies", "TEST", 83, 107], ["culture", "TEST", 112, 119], ["VAP", "PROBLEM", 170, 173], ["lung infi ltrates", "TEST", 175, 192], ["leukocytosis", "PROBLEM", 194, 206], ["purulent secretions", "PROBLEM", 208, 227], ["fever", "PROBLEM", 229, 234], ["a sensitivity", "TEST", 240, 253], ["a specifi city", "TEST", 265, 279], ["disease", "OBSERVATION", 14, 21], ["less common", "OBSERVATION_MODIFIER", 25, 36], ["lung", "ANATOMY", 94, 98], ["biopsies", "OBSERVATION", 99, 107], ["lung", "ANATOMY", 175, 179], ["leukocytosis", "OBSERVATION_MODIFIER", 194, 206], ["purulent", "OBSERVATION_MODIFIER", 208, 216]]], ["Clearly, a number of noninfectious causes of fever and pulmonary infi ltrates can also occur in these patients, making the above clinical criteria nonspecifi c for the diagnosis of VAP.", [["pulmonary", "ANATOMY", 55, 64], ["fever", "DISEASE", 45, 50], ["pulmonary infi ltrates", "DISEASE", 55, 77], ["VAP", "DISEASE", 181, 184], ["pulmonary", "ORGAN", 55, 64], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["fever", "PROBLEM", 45, 50], ["pulmonary infi ltrates", "PROBLEM", 55, 77], ["VAP", "PROBLEM", 181, 184], ["noninfectious", "OBSERVATION", 21, 34], ["fever", "OBSERVATION", 45, 50], ["pulmonary", "ANATOMY", 55, 64], ["VAP", "OBSERVATION", 181, 184]]], ["Lung infi ltrates may be caused by pulmonary hemorrhage, chemical aspiration, or atelectasis.", [["Lung", "ANATOMY", 0, 4], ["pulmonary", "ANATOMY", 35, 44], ["pulmonary hemorrhage", "DISEASE", 35, 55], ["atelectasis", "DISEASE", 81, 92], ["Lung", "ORGAN", 0, 4], ["pulmonary", "ORGAN", 35, 44], ["pulmonary hemorrhage", "PROBLEM", 35, 55], ["chemical aspiration", "PROBLEM", 57, 76], ["atelectasis", "PROBLEM", 81, 92], ["may be caused", "UNCERTAINTY", 18, 31], ["pulmonary", "ANATOMY", 35, 44], ["hemorrhage", "OBSERVATION", 45, 55], ["chemical", "OBSERVATION_MODIFIER", 57, 65], ["aspiration", "OBSERVATION", 66, 76], ["atelectasis", "OBSERVATION", 81, 92]]], ["Fever may be caused by a drug reaction, extrapulmonary infection, or blood transfusion.", [["extrapulmonary", "ANATOMY", 40, 54], ["blood", "ANATOMY", 69, 74], ["Fever", "DISEASE", 0, 5], ["extrapulmonary infection", "DISEASE", 40, 64], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["Fever", "PROBLEM", 0, 5], ["a drug reaction", "PROBLEM", 23, 38], ["extrapulmonary infection", "PROBLEM", 40, 64], ["blood transfusion", "TREATMENT", 69, 86], ["may be caused", "UNCERTAINTY", 6, 19], ["drug reaction", "OBSERVATION", 25, 38], ["extrapulmonary", "ANATOMY", 40, 54], ["infection", "OBSERVATION", 55, 64]]], ["Autopsy results in a series of patients with acute lung injury demonstrated that clinical criteria alone led to an incorrect diagnosis of VAP in 29% of clinically suspected cases [42] .", [["lung", "ANATOMY", 51, 55], ["acute lung injury", "DISEASE", 45, 62], ["VAP", "DISEASE", 138, 141], ["patients", "ORGANISM", 31, 39], ["lung", "ORGAN", 51, 55], ["patients", "SPECIES", 31, 39], ["Autopsy", "TEST", 0, 7], ["acute lung injury", "PROBLEM", 45, 62], ["VAP", "PROBLEM", 138, 141], ["lung", "ANATOMY", 51, 55], ["injury", "OBSERVATION", 56, 62]]], ["These limitations have encouraged the use of invasive approaches to sample and culture material from the lower respiratory tract for accurate diagnosis of VAP.ApproachVentilator-associated pneumonia is most accurately diagnosed by quantitative culture and microscopic examination of lower respiratory tract secretions, which are best obtained by bronchoscopy and BAL [43] .", [["sample", "ANATOMY", 68, 74], ["lower respiratory tract", "ANATOMY", 105, 128], ["lower respiratory tract secretions", "ANATOMY", 283, 317], ["VAP", "DISEASE", 155, 158], ["ApproachVentilator", "CHEMICAL", 159, 177], ["pneumonia", "DISEASE", 189, 198], ["lower respiratory", "ORGANISM_SUBDIVISION", 105, 122], ["tract", "ORGANISM_SUBDIVISION", 123, 128], ["ApproachVentilator", "SIMPLE_CHEMICAL", 159, 177], ["lower", "ORGANISM_SUBDIVISION", 283, 288], ["respiratory tract", "ORGANISM_SUBDIVISION", 289, 306], ["secretions", "ORGANISM_SUBSTANCE", 307, 317], ["invasive approaches", "TREATMENT", 45, 64], ["culture material", "TEST", 79, 95], ["the lower respiratory tract", "PROBLEM", 101, 128], ["VAP", "PROBLEM", 155, 158], ["pneumonia", "PROBLEM", 189, 198], ["quantitative culture", "TEST", 231, 251], ["microscopic examination", "TEST", 256, 279], ["lower respiratory tract secretions", "PROBLEM", 283, 317], ["bronchoscopy", "TEST", 346, 358], ["BAL", "TEST", 363, 366], ["lower", "ANATOMY_MODIFIER", 105, 110], ["respiratory tract", "ANATOMY", 111, 128], ["VAP", "OBSERVATION", 155, 158], ["pneumonia", "OBSERVATION", 189, 198], ["lower", "ANATOMY_MODIFIER", 283, 288], ["respiratory tract", "ANATOMY", 289, 306], ["secretions", "OBSERVATION", 307, 317]]], ["Cultures of tracheal aspirates are not very useful in establishing the cause of VAP [44] .", [["tracheal aspirates", "ANATOMY", 12, 30], ["VAP", "DISEASE", 80, 83], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 12, 30], ["Cultures of tracheal aspirates", "TEST", 0, 30], ["VAP", "PROBLEM", 80, 83], ["tracheal", "ANATOMY", 12, 20], ["aspirates", "OBSERVATION", 21, 30]]], ["Although such cultures are highly sensitive, their specifi city is low even when they are cultured quantitatively [45] .", [["such cultures", "TEST", 9, 22]]], ["Combining clinical and bacteriologic evaluation is probably the best way to achieve the objectives of correctly diagnosing VAP and appropriately using antimicrobial agents.", [["VAP", "DISEASE", 123, 126], ["bacteriologic evaluation", "TEST", 23, 47], ["VAP", "PROBLEM", 123, 126], ["antimicrobial agents", "TREATMENT", 151, 171]]], ["The main aims of this diagnostic approach are to rapidly identify patients with true lung bacterial infection, to select appropriate initial antimicrobial therapy, to adjust therapy based on antibiotic sensitivities, and to withhold antibiotics from patients without VAP.", [["lung", "ANATOMY", 85, 89], ["lung bacterial infection", "DISEASE", 85, 109], ["VAP", "DISEASE", 267, 270], ["patients", "ORGANISM", 66, 74], ["lung", "ORGAN", 85, 89], ["patients", "ORGANISM", 250, 258], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 250, 258], ["true lung bacterial infection", "PROBLEM", 80, 109], ["appropriate initial antimicrobial therapy", "TREATMENT", 121, 162], ["therapy", "TREATMENT", 174, 181], ["antibiotic sensitivities", "TREATMENT", 191, 215], ["antibiotics", "TREATMENT", 233, 244], ["VAP", "PROBLEM", 267, 270], ["lung", "ANATOMY", 85, 89], ["bacterial", "OBSERVATION_MODIFIER", 90, 99], ["infection", "OBSERVATION", 100, 109]]], ["Guidelines for the prevention of VAP in children are lacking, but data extrapolated from adult studies support routine elevation of head of bed 30\u00b0, appropriate use of sedatives and muscle relaxants, and adequate oral and circuit hygiene [46] .Definitions and Main FeaturesEmpyema is the presence of purulent material containing polymorphonuclear leukocytes and fi brin in the pleural cavity.", [["head", "ANATOMY", 132, 136], ["muscle", "ANATOMY", 182, 188], ["oral", "ANATOMY", 213, 217], ["polymorphonuclear leukocytes", "ANATOMY", 329, 357], ["pleural cavity", "ANATOMY", 377, 391], ["VAP", "DISEASE", 33, 36], ["Empyema", "DISEASE", 273, 280], ["children", "ORGANISM", 40, 48], ["head", "ORGANISM_SUBDIVISION", 132, 136], ["muscle", "ORGAN", 182, 188], ["oral", "ORGANISM_SUBDIVISION", 213, 217], ["polymorphonuclear leukocytes", "CELL", 329, 357], ["fi brin", "CELL", 362, 369], ["pleural cavity", "MULTI-TISSUE_STRUCTURE", 377, 391], ["polymorphonuclear leukocytes", "CELL_TYPE", 329, 357], ["children", "SPECIES", 40, 48], ["VAP", "PROBLEM", 33, 36], ["adult studies", "TEST", 89, 102], ["routine elevation of head of bed", "TREATMENT", 111, 143], ["sedatives", "TREATMENT", 168, 177], ["muscle relaxants", "TREATMENT", 182, 198], ["Empyema", "PROBLEM", 273, 280], ["purulent material", "PROBLEM", 300, 317], ["polymorphonuclear leukocytes", "PROBLEM", 329, 357], ["fi brin in the pleural cavity", "PROBLEM", 362, 391], ["head", "ANATOMY", 132, 136], ["Main", "OBSERVATION_MODIFIER", 260, 264], ["Empyema", "OBSERVATION", 273, 280], ["purulent", "OBSERVATION_MODIFIER", 300, 308], ["polymorphonuclear leukocytes", "OBSERVATION", 329, 357], ["fi", "OBSERVATION_MODIFIER", 362, 364], ["brin", "OBSERVATION_MODIFIER", 365, 369], ["pleural", "ANATOMY", 377, 384], ["cavity", "ANATOMY_MODIFIER", 385, 391]]], ["Empyema is usually a complication of inadequately treated bacterial CAP, although it may occur after trauma, thoracic surgery, or intrathoracic esophageal perforation.", [["thoracic", "ANATOMY", 109, 117], ["intrathoracic esophageal", "ANATOMY", 130, 154], ["Empyema", "DISEASE", 0, 7], ["CAP", "DISEASE", 68, 71], ["trauma", "DISEASE", 101, 107], ["intrathoracic esophageal perforation", "DISEASE", 130, 166], ["thoracic", "ORGAN", 109, 117], ["esophageal", "ORGAN", 144, 154], ["Empyema", "PROBLEM", 0, 7], ["inadequately treated bacterial CAP", "PROBLEM", 37, 71], ["trauma", "PROBLEM", 101, 107], ["thoracic surgery", "TREATMENT", 109, 125], ["intrathoracic esophageal perforation", "PROBLEM", 130, 166], ["inadequately treated", "OBSERVATION_MODIFIER", 37, 57], ["bacterial CAP", "OBSERVATION", 58, 71], ["thoracic", "ANATOMY", 109, 117], ["surgery", "OBSERVATION", 118, 125], ["intrathoracic", "ANATOMY", 130, 143], ["esophageal", "ANATOMY", 144, 154], ["perforation", "OBSERVATION", 155, 166]]], ["Although parapneumonic pleural effusions are noted in up to 34&-40% of children with pneumonia, empyema is rare, present in 1%-2% of cases [47] .", [["parapneumonic pleural effusions", "ANATOMY", 9, 40], ["parapneumonic pleural effusions", "DISEASE", 9, 40], ["pneumonia", "DISEASE", 85, 94], ["empyema", "DISEASE", 96, 103], ["pleural effusions", "PATHOLOGICAL_FORMATION", 23, 40], ["children", "ORGANISM", 71, 79], ["children", "SPECIES", 71, 79], ["parapneumonic pleural effusions", "PROBLEM", 9, 40], ["pneumonia", "PROBLEM", 85, 94], ["empyema", "PROBLEM", 96, 103], ["parapneumonic", "OBSERVATION_MODIFIER", 9, 22], ["pleural", "ANATOMY", 23, 30], ["effusions", "OBSERVATION", 31, 40], ["pneumonia", "OBSERVATION", 85, 94], ["empyema", "OBSERVATION", 96, 103], ["rare", "OBSERVATION_MODIFIER", 107, 111]]], ["The formation of an empyema can be divided into three stages: exudative, fi brinopurulent, and organizing.", [["empyema", "DISEASE", 20, 27], ["exudative", "DISEASE", 62, 71], ["an empyema", "PROBLEM", 17, 27], ["exudative", "PROBLEM", 62, 71], ["empyema", "OBSERVATION", 20, 27], ["exudative", "OBSERVATION", 62, 71], ["fi brinopurulent", "OBSERVATION_MODIFIER", 73, 89]]], ["During the exudative stage, pus accumu-lates.", [["the exudative stage", "PROBLEM", 7, 26], ["pus accumu-lates", "PROBLEM", 28, 44], ["exudative", "OBSERVATION_MODIFIER", 11, 20], ["pus", "OBSERVATION", 28, 31]]], ["This is followed by fi brin deposition and loculation of pleural fl uid known as the fi brinopurulent stage.", [["pleural fl uid", "ANATOMY", 57, 71], ["fi brin deposition", "TREATMENT", 20, 38], ["loculation of pleural fl uid", "PROBLEM", 43, 71], ["loculation", "OBSERVATION_MODIFIER", 43, 53], ["pleural", "ANATOMY", 57, 64], ["fl uid", "OBSERVATION", 65, 71], ["fi", "OBSERVATION_MODIFIER", 85, 87], ["brinopurulent", "OBSERVATION_MODIFIER", 88, 101], ["stage", "OBSERVATION", 102, 107]]], ["The organizing stage is characterized by fi broblast proliferation; at this time there is the potential for lung entrapment by scarring [48] .Definitions and Main FeaturesTypically, the pleural fl uid in empyema is exudative, caused by protein leakage from the capillaries because of increased permeability and increased hydrostatic pressure during the infl ammatory process.", [["broblast", "ANATOMY", 44, 52], ["lung", "ANATOMY", 108, 112], ["pleural fl uid", "ANATOMY", 186, 200], ["capillaries", "ANATOMY", 261, 272], ["lung entrapment", "DISEASE", 108, 123], ["empyema", "DISEASE", 204, 211], ["exudative", "DISEASE", 215, 224], ["fi broblast", "CELL", 41, 52], ["lung", "ORGAN", 108, 112], ["capillaries", "TISSUE", 261, 272], ["fi broblast proliferation", "PROBLEM", 41, 66], ["lung entrapment", "PROBLEM", 108, 123], ["scarring", "PROBLEM", 127, 135], ["empyema", "PROBLEM", 204, 211], ["exudative", "PROBLEM", 215, 224], ["protein leakage from the capillaries", "PROBLEM", 236, 272], ["increased permeability", "PROBLEM", 284, 306], ["increased hydrostatic pressure", "PROBLEM", 311, 341], ["the infl ammatory process", "TREATMENT", 349, 374], ["fi", "OBSERVATION_MODIFIER", 41, 43], ["broblast proliferation", "OBSERVATION", 44, 66], ["potential for", "UNCERTAINTY", 94, 107], ["lung", "ANATOMY", 108, 112], ["entrapment", "OBSERVATION", 113, 123], ["scarring", "OBSERVATION", 127, 135], ["Main", "OBSERVATION_MODIFIER", 158, 162], ["pleural", "ANATOMY", 186, 193], ["fl", "OBSERVATION", 194, 196], ["empyema", "OBSERVATION", 204, 211], ["exudative", "OBSERVATION", 215, 224], ["protein leakage", "OBSERVATION", 236, 251], ["capillaries", "ANATOMY", 261, 272], ["increased", "OBSERVATION_MODIFIER", 284, 293], ["permeability", "OBSERVATION_MODIFIER", 294, 306], ["increased", "OBSERVATION_MODIFIER", 311, 320], ["hydrostatic pressure", "OBSERVATION", 321, 341]]], ["Although the distinction between transudates and exudates is sometimes diffi cult to make, several features favor an exudative process.", [["exudates", "ANATOMY", 49, 57], ["transudates", "CANCER", 33, 44], ["transudates", "PROBLEM", 33, 44], ["exudates", "PROBLEM", 49, 57], ["an exudative process", "PROBLEM", 114, 134], ["transudates", "OBSERVATION", 33, 44], ["exudates", "OBSERVATION_MODIFIER", 49, 57], ["exudative", "OBSERVATION_MODIFIER", 117, 126], ["process", "OBSERVATION", 127, 134]]], ["If at least one of the following three criteria is present, the fl uid is virtually always an exudate: (1) pleural fl uid protein >2.9 g/dL or protein/serum protein ratio greater than 0.5;Definitions and Main Features(2) pleural fl uid lactate dehydrogenase (LDH)/serum LDH ratio greater than 0.6; and/or (3) pleural fl uid LDH greater than two thirds the serum LDH [49, 50] .PathogensThe most common organisms that cause empyema in children are Strep. pneumoniae, Staph. aureus, and group A streptococci.", [["exudate", "ANATOMY", 94, 101], ["serum", "ANATOMY", 151, 156], ["serum", "ANATOMY", 264, 269], ["serum", "ANATOMY", 356, 361], ["lactate", "CHEMICAL", 236, 243], ["empyema", "DISEASE", 422, 429], ["lactate", "CHEMICAL", 236, 243], ["exudate", "TISSUE", 94, 101], ["serum", "ORGANISM_SUBSTANCE", 151, 156], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 236, 257], ["LDH", "GENE_OR_GENE_PRODUCT", 259, 262], ["serum", "ORGANISM_SUBSTANCE", 264, 269], ["LDH", "GENE_OR_GENE_PRODUCT", 270, 273], ["LDH", "GENE_OR_GENE_PRODUCT", 324, 327], ["serum", "ORGANISM_SUBSTANCE", 356, 361], ["LDH", "SIMPLE_CHEMICAL", 362, 365], ["children", "ORGANISM", 433, 441], ["pneumoniae", "ORGANISM", 453, 463], ["aureus", "ORGANISM", 472, 478], ["pleural fl uid protein", "PROTEIN", 107, 129], ["dL", "PROTEIN", 137, 139], ["serum protein", "PROTEIN", 151, 164], ["lactate dehydrogenase", "PROTEIN", 236, 257], ["LDH", "PROTEIN", 259, 262], ["children", "SPECIES", 433, 441], ["pneumoniae", "SPECIES", 453, 463], ["aureus", "SPECIES", 472, 478], ["pneumoniae", "SPECIES", 453, 463], ["aureus", "SPECIES", 472, 478], ["the fl uid", "TEST", 60, 70], ["pleural fl uid protein", "TEST", 107, 129], ["g/dL", "TEST", 135, 139], ["protein/serum protein ratio", "TEST", 143, 170], ["Main Features", "TEST", 204, 217], ["pleural fl uid lactate dehydrogenase", "TEST", 221, 257], ["LDH)", "TEST", 259, 263], ["serum LDH ratio", "TEST", 264, 279], ["pleural fl uid LDH", "TEST", 309, 327], ["the serum LDH", "TEST", 352, 365], ["Pathogens", "PROBLEM", 376, 385], ["empyema", "PROBLEM", 422, 429], ["Strep", "PROBLEM", 446, 451], ["pneumoniae", "PROBLEM", 453, 463], ["Staph", "PROBLEM", 465, 470], ["aureus", "PROBLEM", 472, 478], ["group A streptococci", "PROBLEM", 484, 504], ["exudate", "OBSERVATION", 94, 101], ["pleural", "ANATOMY", 107, 114], ["pleural", "ANATOMY", 221, 228], ["pleural", "ANATOMY", 309, 316], ["most common", "OBSERVATION_MODIFIER", 389, 400], ["empyema", "OBSERVATION", 422, 429], ["Strep", "OBSERVATION", 446, 451], ["Staph", "OBSERVATION", 465, 470], ["streptococci", "OBSERVATION", 492, 504]]], ["Haemophilus infl uenzae is rarely encountered since the advent of the H. infl uenzae B vaccine.", [["Haemophilus infl uenzae", "DISEASE", 0, 23], ["Haemophilus infl uenzae", "ORGANISM", 0, 23], ["H. infl uenzae B", "ORGANISM", 70, 86], ["Haemophilus infl uenzae", "SPECIES", 0, 23], ["H. infl uenzae", "SPECIES", 70, 84], ["Haemophilus infl uenzae", "SPECIES", 0, 23], ["H. infl uenzae", "SPECIES", 70, 84], ["Haemophilus infl uenzae", "PROBLEM", 0, 23], ["the H. infl uenzae B vaccine", "TREATMENT", 66, 94]]], ["Mycoplasma pneumoniae and viruses can rarely result in exudative pleural effusions.", [["exudative pleural effusions", "ANATOMY", 55, 82], ["Mycoplasma pneumoniae", "DISEASE", 0, 21], ["pleural effusions", "DISEASE", 65, 82], ["Mycoplasma pneumoniae", "ORGANISM", 0, 21], ["pleural effusions", "PATHOLOGICAL_FORMATION", 65, 82], ["Mycoplasma pneumoniae", "SPECIES", 0, 21], ["Mycoplasma pneumoniae", "SPECIES", 0, 21], ["Mycoplasma pneumoniae", "PROBLEM", 0, 21], ["viruses", "PROBLEM", 26, 33], ["exudative pleural effusions", "PROBLEM", 55, 82], ["pneumoniae", "OBSERVATION", 11, 21], ["viruses", "OBSERVATION", 26, 33], ["exudative", "OBSERVATION_MODIFIER", 55, 64], ["pleural", "ANATOMY", 65, 72], ["effusions", "OBSERVATION", 73, 82]]], ["In a series of 72 pediatric patients with empyema, 24% were secondary to anaerobic infection [51] .", [["empyema", "DISEASE", 42, 49], ["infection", "DISEASE", 83, 92], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["empyema", "PROBLEM", 42, 49], ["anaerobic infection", "PROBLEM", 73, 92], ["empyema", "OBSERVATION", 42, 49], ["infection", "OBSERVATION", 83, 92]]], ["These data highlight the importance of anaerobic bacteria in selected cases of empyema in children and adolescents.", [["empyema", "DISEASE", 79, 86], ["children", "ORGANISM", 90, 98], ["children", "SPECIES", 90, 98], ["adolescents", "SPECIES", 103, 114], ["anaerobic bacteria", "PROBLEM", 39, 57], ["empyema", "PROBLEM", 79, 86], ["empyema", "OBSERVATION", 79, 86]]], ["In addition, tuberculosis should always be considered in the differential diagnosis, and a purifi ed protein derivative test should be performed.ApproachThe differential diagnosis of patients with pleural effusions is shown in Table 17 .4.", [["pleural effusions", "ANATOMY", 197, 214], ["tuberculosis", "DISEASE", 13, 25], ["pleural effusions", "DISEASE", 197, 214], ["patients", "ORGANISM", 183, 191], ["pleural effusions", "CANCER", 197, 214], ["patients", "SPECIES", 183, 191], ["tuberculosis", "PROBLEM", 13, 25], ["a purifi ed protein derivative test", "TEST", 89, 124], ["pleural effusions", "PROBLEM", 197, 214], ["tuberculosis", "OBSERVATION", 13, 25], ["pleural", "ANATOMY", 197, 204], ["effusions", "OBSERVATION", 205, 214]]], ["The presence of fever associated with clinical signs of bacterial pneumonia is a clue to an underlying pneumonia as the cause of the effusion.", [["fever", "DISEASE", 16, 21], ["bacterial pneumonia", "DISEASE", 56, 75], ["pneumonia", "DISEASE", 103, 112], ["effusion", "DISEASE", 133, 141], ["fever", "PROBLEM", 16, 21], ["bacterial pneumonia", "PROBLEM", 56, 75], ["an underlying pneumonia", "PROBLEM", 89, 112], ["the effusion", "PROBLEM", 129, 141], ["fever", "OBSERVATION", 16, 21], ["bacterial", "OBSERVATION_MODIFIER", 56, 65], ["pneumonia", "OBSERVATION", 66, 75], ["pneumonia", "OBSERVATION", 103, 112], ["effusion", "OBSERVATION", 133, 141]]], ["A lateral decubitus radiograph, ultrasonography, or computed tomography may differentiate whether the fl uid is loculated.", [["fl uid", "DNA", 102, 108], ["A lateral decubitus radiograph", "TEST", 0, 30], ["ultrasonography", "TEST", 32, 47], ["computed tomography", "TEST", 52, 71], ["loculated", "PROBLEM", 112, 121], ["fl", "OBSERVATION", 102, 104], ["loculated", "OBSERVATION", 112, 121]]], ["A sample of the fl uid should be obtained by thoracentesis in order to determine if the effusion is a transudate versus exudate.", [["sample", "ANATOMY", 2, 8], ["transudate", "ANATOMY", 102, 112], ["exudate", "ANATOMY", 120, 127], ["effusion", "DISEASE", 88, 96], ["exudate", "TISSUE", 120, 127], ["A sample of the fl uid", "TEST", 0, 22], ["thoracentesis", "TREATMENT", 45, 58], ["the effusion", "PROBLEM", 84, 96], ["a transudate", "PROBLEM", 100, 112], ["exudate", "PROBLEM", 120, 127], ["effusion", "OBSERVATION", 88, 96], ["transudate", "OBSERVATION", 102, 112], ["exudate", "OBSERVATION", 120, 127]]], ["Pleural cultures are positive in approximately one half of pediatric patients with empyema.", [["Pleural cultures", "ANATOMY", 0, 16], ["empyema", "DISEASE", 83, 90], ["Pleural cultures", "CELL", 0, 16], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["Pleural cultures", "TEST", 0, 16], ["empyema", "PROBLEM", 83, 90], ["cultures", "OBSERVATION", 8, 16], ["positive", "OBSERVATION", 21, 29], ["empyema", "OBSERVATION", 83, 90]]], ["Blood culture and urine latex agglutination may help to identify a bacterial pathogen.", [["Blood", "ANATOMY", 0, 5], ["urine", "ANATOMY", 18, 23], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["urine", "ORGANISM_SUBSTANCE", 18, 23], ["Blood culture", "TEST", 0, 13], ["urine latex agglutination", "TEST", 18, 43], ["a bacterial pathogen", "PROBLEM", 65, 85], ["bacterial pathogen", "OBSERVATION", 67, 85]]], ["A pneumatocele or pneumothorax seen on chest fi lm suggests Staph. aureus as the cause of the empyema.ApproachUntil a specifi c organism is identifi ed, empiric antibiotic therapy should be instituted.", [["pneumatocele", "ANATOMY", 2, 14], ["chest fi lm", "ANATOMY", 39, 50], ["pneumatocele", "DISEASE", 2, 14], ["pneumothorax", "DISEASE", 18, 30], ["empyema", "DISEASE", 94, 101], ["pneumatocele", "CANCER", 2, 14], ["aureus", "ORGANISM", 67, 73], ["aureus", "SPECIES", 67, 73], ["aureus", "SPECIES", 67, 73], ["A pneumatocele", "PROBLEM", 0, 14], ["pneumothorax", "PROBLEM", 18, 30], ["chest fi lm", "TEST", 39, 50], ["Staph", "PROBLEM", 60, 65], ["aureus", "PROBLEM", 67, 73], ["the empyema", "PROBLEM", 90, 101], ["a specifi c organism", "PROBLEM", 116, 136], ["empiric antibiotic therapy", "TREATMENT", 153, 179], ["pneumatocele", "OBSERVATION", 2, 14], ["pneumothorax", "OBSERVATION", 18, 30], ["chest", "ANATOMY", 39, 44], ["Staph", "OBSERVATION", 60, 65], ["empyema", "OBSERVATION", 94, 101]]], ["This might include a third-generation cephalosporin and antistaphylococcal \u03b2-lactamase-resistant penicillin.", [["cephalosporin", "CHEMICAL", 38, 51], ["\u03b2-lactamase", "CHEMICAL", 75, 86], ["penicillin", "CHEMICAL", 97, 107], ["cephalosporin", "CHEMICAL", 38, 51], ["penicillin", "CHEMICAL", 97, 107], ["cephalosporin", "SIMPLE_CHEMICAL", 38, 51], ["antistaphylococcal \u03b2-lactamase", "SIMPLE_CHEMICAL", 56, 86], ["penicillin", "SIMPLE_CHEMICAL", 97, 107], ["a third-generation cephalosporin", "TREATMENT", 19, 51], ["antistaphylococcal \u03b2-lactamase", "TREATMENT", 56, 86], ["resistant penicillin", "TREATMENT", 87, 107]]], ["Antibiotics can be adjusted once an organism is identifi ed.", [["Antibiotics", "TREATMENT", 0, 11]]], ["Antibiotic therapy should be intravenous until the patient becomes afebrile and then should be continued orally for an additional 2-3 weeks.", [["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 40], ["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58], ["Antibiotic therapy", "TREATMENT", 0, 18], ["intravenous", "TREATMENT", 29, 40], ["afebrile", "PROBLEM", 67, 75]]], ["There is major debate as to the proper adjuvant treatment of children with empyema.", [["empyema", "DISEASE", 75, 82], ["children", "ORGANISM", 61, 69], ["children", "SPECIES", 61, 69], ["empyema", "PROBLEM", 75, 82], ["empyema", "OBSERVATION", 75, 82]]], ["Prospective, randomized and controlled studies of children with empyema are lacking.", [["empyema", "DISEASE", 64, 71], ["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58], ["empyema", "PROBLEM", 64, 71], ["empyema", "OBSERVATION", 64, 71]]], ["With the exception of starting appropriate or empiric antibiotics, there is no consensus on when and in whom to place a chest tube, instill fi brinolytic agents, or take to the operating room [52] .", [["chest tube", "ANATOMY", 120, 130], ["chest tube", "TISSUE", 120, 130], ["empiric antibiotics", "TREATMENT", 46, 65], ["a chest tube", "TREATMENT", 118, 130], ["instill fi brinolytic agents", "TREATMENT", 132, 160], ["no", "UNCERTAINTY", 76, 78], ["chest", "ANATOMY", 120, 125], ["tube", "OBSERVATION", 126, 130]]], ["In 1992, Light suggested that chest tubes should be inserted if the pleural fl uid is gross pus, if the Gram stain of the pleural fl uid is positive, if the pleural fl uid glucose level is below 40 mg/dL, or if the pleural fl uid pH level is less than 7.00 [53] .", [["chest tubes", "ANATOMY", 30, 41], ["pleural", "ANATOMY", 68, 75], ["pus", "ANATOMY", 92, 95], ["pleural", "ANATOMY", 122, 129], ["pleural", "ANATOMY", 157, 164], ["pleural", "ANATOMY", 215, 222], ["glucose", "CHEMICAL", 172, 179], ["glucose", "CHEMICAL", 172, 179], ["chest tubes", "MULTI-TISSUE_STRUCTURE", 30, 41], ["pus", "ORGANISM_SUBSTANCE", 92, 95], ["glucose", "SIMPLE_CHEMICAL", 172, 179], ["chest tubes", "TREATMENT", 30, 41], ["the pleural fl uid", "TEST", 64, 82], ["gross pus", "PROBLEM", 86, 95], ["the Gram stain", "TEST", 100, 114], ["the pleural fl uid", "TEST", 118, 136], ["the pleural fl uid glucose level", "TEST", 153, 185], ["the pleural fl uid pH level", "TEST", 211, 238], ["chest", "ANATOMY", 30, 35], ["tubes", "OBSERVATION", 36, 41], ["pleural", "ANATOMY", 68, 75], ["gross", "OBSERVATION_MODIFIER", 86, 91], ["pus", "OBSERVATION", 92, 95], ["pleural", "ANATOMY", 122, 129], ["pleural", "ANATOMY", 157, 164], ["pleural", "ANATOMY", 215, 222]]], ["If drainage with a chest tube is unsatisfactory, either urokinase or tissue plasminogen activator (tPA) should be injected intrapleurally [54, 55] .", [["chest tube", "ANATOMY", 19, 29], ["chest tube", "MULTI-TISSUE_STRUCTURE", 19, 29], ["urokinase", "GENE_OR_GENE_PRODUCT", 56, 65], ["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 69, 97], ["tPA", "SIMPLE_CHEMICAL", 99, 102], ["urokinase", "PROTEIN", 56, 65], ["drainage", "TREATMENT", 3, 11], ["a chest tube", "TREATMENT", 17, 29], ["urokinase or tissue plasminogen activator (tPA)", "TREATMENT", 56, 103], ["drainage", "OBSERVATION", 3, 11], ["chest", "ANATOMY", 19, 24], ["tube", "OBSERVATION", 25, 29]]], ["If drainage is still unsatisfactory, a decortication should be considered [56] .", [["drainage", "TREATMENT", 3, 11], ["a decortication", "TREATMENT", 37, 52], ["drainage", "OBSERVATION", 3, 11], ["decortication", "OBSERVATION", 39, 52]]], ["A stage-related approach to the management of empyema is perhaps most effi cacious and cost-effective [57] .", [["empyema", "DISEASE", 46, 53], ["A stage-related approach", "PROBLEM", 0, 24], ["the management", "TREATMENT", 28, 42], ["empyema", "PROBLEM", 46, 53], ["empyema", "OBSERVATION", 46, 53], ["most effi", "OBSERVATION_MODIFIER", 65, 74]]], ["In the exudative stage, conservative treatment using tube drainage may suffi ce.", [["tube", "ANATOMY", 53, 57], ["tube", "TISSUE", 53, 57], ["the exudative stage", "PROBLEM", 3, 22], ["conservative treatment", "TREATMENT", 24, 46], ["tube drainage", "TREATMENT", 53, 66], ["exudative", "OBSERVATION_MODIFIER", 7, 16], ["stage", "OBSERVATION_MODIFIER", 17, 22]]], ["Fibrinolytic treatment may be useful during the fi brinopurulent stage.", [["Fibrinolytic treatment", "TREATMENT", 0, 22]]], ["In contrast, aggressive treatment using surgical decortication may be necessary during the organizing stage.ApproachWith the advent of video-assisted thoracoscopy (VATS), these traditional approaches to management of empyema in children are being challenged.", [["empyema", "DISEASE", 217, 224], ["children", "ORGANISM", 228, 236], ["children", "SPECIES", 228, 236], ["aggressive treatment", "TREATMENT", 13, 33], ["surgical decortication", "TREATMENT", 40, 62], ["video-assisted thoracoscopy", "TREATMENT", 135, 162], ["VATS", "TREATMENT", 164, 168], ["management", "TREATMENT", 203, 213], ["empyema", "PROBLEM", 217, 224], ["decortication", "OBSERVATION", 49, 62], ["thoracoscopy", "OBSERVATION", 150, 162], ["empyema", "OBSERVATION", 217, 224]]], ["Video-assisted techniques offer distinct advantages in the accurate staging of the disease process, effectiveness of management of organizing pleural disease, and post-operative patient comfort [58] .", [["pleural", "ANATOMY", 142, 149], ["pleural disease", "DISEASE", 142, 157], ["pleural", "ORGAN", 142, 149], ["patient", "ORGANISM", 178, 185], ["patient", "SPECIES", 178, 185], ["Video-assisted techniques", "TREATMENT", 0, 25], ["the disease process", "PROBLEM", 79, 98], ["management", "TREATMENT", 117, 127], ["organizing pleural disease", "PROBLEM", 131, 157], ["organizing", "OBSERVATION_MODIFIER", 131, 141], ["pleural", "ANATOMY", 142, 149], ["disease", "OBSERVATION", 150, 157]]], ["In a retrospective study, the performance of early VATS (<48 hr after admission) in children with empyema was associated with signifi cantly decreased length of hospital stay compared with performance of late VATS (>48 hr after admission) [59] .ApproachChildren treated for empyema generally recover and have no residual sequelae.", [["empyema", "DISEASE", 98, 105], ["empyema", "DISEASE", 274, 281], ["children", "ORGANISM", 84, 92], ["children", "SPECIES", 84, 92], ["a retrospective study", "TEST", 3, 24], ["early VATS", "TREATMENT", 45, 55], ["empyema", "PROBLEM", 98, 105], ["late VATS", "TREATMENT", 204, 213], ["ApproachChildren", "TREATMENT", 245, 261], ["empyema", "PROBLEM", 274, 281], ["residual sequelae", "PROBLEM", 312, 329], ["early", "OBSERVATION_MODIFIER", 45, 50], ["VATS", "OBSERVATION", 51, 55], ["empyema", "OBSERVATION", 98, 105], ["empyema", "OBSERVATION", 274, 281], ["no", "UNCERTAINTY", 309, 311], ["residual", "OBSERVATION_MODIFIER", 312, 320], ["sequelae", "OBSERVATION", 321, 329]]], ["Radiographs at the time of discharge usually show pleural thickening that later resolves.", [["pleural", "ANATOMY", 50, 57], ["pleural thickening", "DISEASE", 50, 68], ["pleural", "PATHOLOGICAL_FORMATION", 50, 57], ["Radiographs", "TEST", 0, 11], ["pleural thickening", "PROBLEM", 50, 68], ["pleural", "ANATOMY", 50, 57], ["thickening", "OBSERVATION", 58, 68]]], ["Follow-up pulmonary function tests and physical examination are also usually normal or consistent with mild restrictive disease [60] .General Treatment Principles Antimicrobial TherapyMost epidemiologic investigations have clearly demonstrated that the indiscriminate administration of antibiotic agents to patients in the PICU has contributed to the emergence of multiresistant pathogens with potentially increased morbidity and mortality.", [["pulmonary", "ANATOMY", 10, 19], ["pulmonary", "ORGAN", 10, 19], ["patients", "ORGANISM", 307, 315], ["patients", "SPECIES", 307, 315], ["Follow-up pulmonary function tests", "TEST", 0, 34], ["physical examination", "TEST", 39, 59], ["mild restrictive disease", "PROBLEM", 103, 127], ["General Treatment Principles", "TREATMENT", 134, 162], ["Antimicrobial Therapy", "TREATMENT", 163, 184], ["Most epidemiologic investigations", "TEST", 184, 217], ["antibiotic agents", "TREATMENT", 286, 303], ["multiresistant pathogens", "PROBLEM", 364, 388], ["potentially increased morbidity", "PROBLEM", 394, 425], ["pulmonary", "ANATOMY", 10, 19], ["consistent with", "UNCERTAINTY", 87, 102], ["mild", "OBSERVATION_MODIFIER", 103, 107], ["restrictive disease", "OBSERVATION", 108, 127], ["Antimicrobial Therapy", "OBSERVATION", 163, 184], ["increased", "OBSERVATION_MODIFIER", 406, 415], ["morbidity", "OBSERVATION", 416, 425]]], ["The prevalence of penicillin-resistant strains of Strep. pneumoniae, methicillin-resistant Staph. aureus, vancomycin-resistant Enterococcus, and Gram-negative bacteria producing extended-spectrum \u03b2-lactamase is increasing.", [["penicillin", "CHEMICAL", 18, 28], ["methicillin", "CHEMICAL", 69, 80], ["vancomycin", "CHEMICAL", 106, 116], ["Enterococcus", "CHEMICAL", 127, 139], ["penicillin", "CHEMICAL", 18, 28], ["methicillin", "CHEMICAL", 69, 80], ["vancomycin", "CHEMICAL", 106, 116], ["penicillin", "SIMPLE_CHEMICAL", 18, 28], ["pneumoniae", "ORGANISM", 57, 67], ["methicillin", "SIMPLE_CHEMICAL", 69, 80], ["aureus", "ORGANISM", 98, 104], ["vancomycin", "SIMPLE_CHEMICAL", 106, 116], ["extended-spectrum \u03b2-lactamase", "PROTEIN", 178, 207], ["pneumoniae", "SPECIES", 57, 67], ["aureus", "SPECIES", 98, 104], ["pneumoniae", "SPECIES", 57, 67], ["aureus", "SPECIES", 98, 104], ["penicillin", "TREATMENT", 18, 28], ["Strep", "PROBLEM", 50, 55], ["pneumoniae", "PROBLEM", 57, 67], ["methicillin", "PROBLEM", 69, 80], ["resistant Staph", "PROBLEM", 81, 96], ["aureus", "PROBLEM", 98, 104], ["vancomycin", "TEST", 106, 116], ["resistant Enterococcus", "PROBLEM", 117, 139], ["Gram", "TEST", 145, 149], ["negative bacteria", "PROBLEM", 150, 167], ["Strep", "OBSERVATION", 50, 55], ["methicillin", "OBSERVATION", 69, 80], ["resistant", "OBSERVATION_MODIFIER", 81, 90], ["Staph", "OBSERVATION", 91, 96], ["vancomycin", "OBSERVATION", 106, 116], ["resistant Enterococcus", "OBSERVATION", 117, 139], ["negative bacteria", "OBSERVATION_MODIFIER", 150, 167], ["increasing", "OBSERVATION_MODIFIER", 211, 221]]], ["Despite these concerns, it is clear that patient survival may improve if pneumonia is correctly and rapidly treated.", [["pneumonia", "DISEASE", 73, 82], ["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48], ["pneumonia", "PROBLEM", 73, 82], ["pneumonia", "OBSERVATION", 73, 82]]], ["In adults, inappropriate initial antibiotic therapy is strongly associated with fatality [61] .", [["inappropriate initial antibiotic therapy", "TREATMENT", 11, 51]]], ["Therefore, it may be concluded that empiric antibiotics for the treatment of severe pneumonia are indicated.General Treatment Principles Antimicrobial TherapyThe choice of antibiotics is based on several factors, including the age of the patient, the type of pneumonia, and the local resistant patterns of predominant bacterial pathogens.", [["pneumonia", "DISEASE", 84, 93], ["pneumonia", "DISEASE", 259, 268], ["patient", "ORGANISM", 238, 245], ["patient", "SPECIES", 238, 245], ["empiric antibiotics", "TREATMENT", 36, 55], ["severe pneumonia", "PROBLEM", 77, 93], ["General Treatment Principles", "TREATMENT", 108, 136], ["Antimicrobial Therapy", "TREATMENT", 137, 158], ["antibiotics", "TREATMENT", 172, 183], ["pneumonia", "PROBLEM", 259, 268], ["predominant bacterial pathogens", "PROBLEM", 306, 337], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["pneumonia", "OBSERVATION", 84, 93], ["Antimicrobial Therapy", "OBSERVATION", 137, 158], ["pneumonia", "OBSERVATION", 259, 268], ["predominant", "OBSERVATION_MODIFIER", 306, 317], ["bacterial pathogens", "OBSERVATION", 318, 337]]], ["Suggested choices for initial empiric antibiotic coverage for pneumonia in the PICU are listed in Table 17 .5.", [["pneumonia", "DISEASE", 62, 71], ["initial empiric antibiotic coverage", "TREATMENT", 22, 57], ["pneumonia", "PROBLEM", 62, 71], ["pneumonia", "OBSERVATION", 62, 71]]], ["Aspiration pneumonia occurring in the community can be treated with ampicillin-sulbactam.", [["Aspiration pneumonia", "DISEASE", 0, 20], ["ampicillin-sulbactam", "CHEMICAL", 68, 88], ["ampicillin", "CHEMICAL", 68, 78], ["sulbactam", "CHEMICAL", 79, 88], ["ampicillin-sulbactam", "SIMPLE_CHEMICAL", 68, 88], ["Aspiration pneumonia", "PROBLEM", 0, 20], ["ampicillin", "TREATMENT", 68, 78], ["sulbactam", "TREATMENT", 79, 88], ["pneumonia", "OBSERVATION", 11, 20]]], ["Empiric treatment for pneumonia in immunocompromised hosts requires broad-spectrum Gram-positive and Gram-negative coverage.General Treatment Principles Antimicrobial TherapyImmunocompromised patients are especially susceptible to a variety of life-threatening opportunistic viral and fungal pneumonias that require prompt diagnosis and aggressive treatment.", [["pneumonia", "DISEASE", 22, 31], ["opportunistic viral and fungal pneumonias", "DISEASE", 261, 302], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 192, 200], ["Empiric treatment", "TREATMENT", 0, 17], ["pneumonia", "PROBLEM", 22, 31], ["immunocompromised hosts", "PROBLEM", 35, 58], ["Gram", "TEST", 101, 105], ["opportunistic viral and fungal pneumonias", "PROBLEM", 261, 302], ["aggressive treatment", "TREATMENT", 337, 357], ["pneumonia", "OBSERVATION", 22, 31], ["negative coverage", "OBSERVATION", 106, 123], ["fungal pneumonias", "OBSERVATION", 285, 302]]], ["For example, trimethoprim-sulfamethoxazole or pentamidine should be given for P. carinii/jiroveci, amphotericin B or caspofungin for Candida and Aspergillus species, acyclovir for herpes, amantadine for infl uenza, ganciclovir or foscarnet for CMV, and ribavirin for severe respiratory syncytial virus.", [["trimethoprim-sulfamethoxazole", "CHEMICAL", 13, 42], ["pentamidine", "CHEMICAL", 46, 57], ["jiroveci", "DISEASE", 89, 97], ["amphotericin B", "CHEMICAL", 99, 113], ["caspofungin", "CHEMICAL", 117, 128], ["acyclovir", "CHEMICAL", 166, 175], ["herpes", "DISEASE", 180, 186], ["amantadine", "CHEMICAL", 188, 198], ["infl uenza", "CHEMICAL", 203, 213], ["ganciclovir", "CHEMICAL", 215, 226], ["foscarnet", "CHEMICAL", 230, 239], ["ribavirin", "CHEMICAL", 253, 262], ["respiratory syncytial virus", "DISEASE", 274, 301], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 13, 42], ["pentamidine", "CHEMICAL", 46, 57], ["amphotericin B", "CHEMICAL", 99, 113], ["caspofungin", "CHEMICAL", 117, 128], ["acyclovir", "CHEMICAL", 166, 175], ["amantadine", "CHEMICAL", 188, 198], ["ganciclovir", "CHEMICAL", 215, 226], ["foscarnet", "CHEMICAL", 230, 239], ["ribavirin", "CHEMICAL", 253, 262], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 13, 42], ["pentamidine", "SIMPLE_CHEMICAL", 46, 57], ["P. carinii", "ORGANISM", 78, 88], ["jiroveci", "ORGANISM", 89, 97], ["amphotericin B", "SIMPLE_CHEMICAL", 99, 113], ["caspofungin", "SIMPLE_CHEMICAL", 117, 128], ["Candida", "ORGANISM", 133, 140], ["Aspergillus species", "ORGANISM", 145, 164], ["acyclovir", "SIMPLE_CHEMICAL", 166, 175], ["herpes", "ORGANISM", 180, 186], ["amantadine", "SIMPLE_CHEMICAL", 188, 198], ["infl uenza", "SIMPLE_CHEMICAL", 203, 213], ["ganciclovir", "SIMPLE_CHEMICAL", 215, 226], ["foscarnet", "SIMPLE_CHEMICAL", 230, 239], ["CMV", "ORGANISM", 244, 247], ["ribavirin", "SIMPLE_CHEMICAL", 253, 262], ["respiratory syncytial virus", "ORGANISM", 274, 301], ["P. carinii", "SPECIES", 78, 88], ["P. carinii", "SPECIES", 78, 88], ["CMV", "SPECIES", 244, 247], ["respiratory syncytial virus", "SPECIES", 274, 301], ["trimethoprim", "TREATMENT", 13, 25], ["sulfamethoxazole", "TREATMENT", 26, 42], ["pentamidine", "TREATMENT", 46, 57], ["carinii", "PROBLEM", 81, 88], ["jiroveci", "TREATMENT", 89, 97], ["amphotericin B", "TREATMENT", 99, 113], ["caspofungin", "TREATMENT", 117, 128], ["Candida", "PROBLEM", 133, 140], ["Aspergillus species", "PROBLEM", 145, 164], ["acyclovir", "TREATMENT", 166, 175], ["herpes", "PROBLEM", 180, 186], ["amantadine", "TREATMENT", 188, 198], ["infl uenza", "TREATMENT", 203, 213], ["ganciclovir", "TREATMENT", 215, 226], ["foscarnet", "TREATMENT", 230, 239], ["CMV", "TREATMENT", 244, 247], ["ribavirin", "TREATMENT", 253, 262], ["severe respiratory syncytial virus", "PROBLEM", 267, 301], ["jiroveci", "OBSERVATION", 89, 97], ["respiratory syncytial virus", "OBSERVATION", 274, 301]]], ["Empiric regimens may need to be modifi ed once results of cultures and antibiotic susceptibility testing are available.Antiinflammatory ApproachThe infl ammatory response to infection is necessary for host defense but can contribute to the systemic toxicity and lung injury that may result from pneumonia.", [["lung", "ANATOMY", 262, 266], ["infection", "DISEASE", 174, 183], ["toxicity", "DISEASE", 249, 257], ["lung injury", "DISEASE", 262, 273], ["pneumonia", "DISEASE", 295, 304], ["lung", "ORGAN", 262, 266], ["Empiric regimens", "TREATMENT", 0, 16], ["cultures", "TEST", 58, 66], ["antibiotic susceptibility testing", "TEST", 71, 104], ["Antiinflammatory Approach", "TREATMENT", 119, 144], ["infection", "PROBLEM", 174, 183], ["the systemic toxicity", "PROBLEM", 236, 257], ["lung injury", "PROBLEM", 262, 273], ["pneumonia", "PROBLEM", 295, 304], ["infection", "OBSERVATION", 174, 183], ["systemic", "OBSERVATION_MODIFIER", 240, 248], ["toxicity", "OBSERVATION", 249, 257], ["lung", "ANATOMY", 262, 266], ["injury", "OBSERVATION", 267, 273], ["pneumonia", "OBSERVATION", 295, 304]]], ["In some settings, adjunctive treatment of lower respiratory infections with antiinfl ammatory agents can reduce morbidity.", [["respiratory", "ANATOMY", 48, 59], ["respiratory infections", "DISEASE", 48, 70], ["antiinfl ammatory agents", "SIMPLE_CHEMICAL", 76, 100], ["adjunctive treatment", "TREATMENT", 18, 38], ["lower respiratory infections", "PROBLEM", 42, 70], ["antiinfl ammatory agents", "TREATMENT", 76, 100], ["morbidity", "PROBLEM", 112, 121], ["lower", "ANATOMY_MODIFIER", 42, 47], ["respiratory", "ANATOMY", 48, 59], ["infections", "OBSERVATION", 60, 70]]], ["Corticosteroids have a well-documented role in the management of P. carinii/jiroveci pneumonia.", [["P. carinii/jiroveci pneumonia", "DISEASE", 65, 94], ["P. carinii", "ORGANISM", 65, 75], ["jiroveci", "ORGANISM", 76, 84], ["P. carinii", "SPECIES", 65, 75], ["P. carinii", "SPECIES", 65, 75], ["Corticosteroids", "TREATMENT", 0, 15], ["the management", "TREATMENT", 47, 61], ["P. carinii", "PROBLEM", 65, 75], ["jiroveci pneumonia", "PROBLEM", 76, 94], ["carinii", "OBSERVATION", 68, 75], ["jiroveci pneumonia", "OBSERVATION", 76, 94]]], ["In a multicenter trial, infusion of hydrocortisone signifi cantly decreased length of hospital stay and prevented mortality in adult patients with CAP [62] .", [["hydrocortisone", "CHEMICAL", 36, 50], ["CAP", "DISEASE", 147, 150], ["hydrocortisone", "CHEMICAL", 36, 50], ["hydrocortisone", "SIMPLE_CHEMICAL", 36, 50], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["hydrocortisone", "TREATMENT", 36, 50], ["CAP", "TEST", 147, 150]]], ["Corticosteroids also may be effective under some circumstances in the treatment of infl ammatory sequelae of respiratory tract infection, such as tuberculous pleurisy and bronchiolitis obliterans organizing pneumonia (BOOP).", [["respiratory tract", "ANATOMY", 109, 126], ["respiratory tract infection", "DISEASE", 109, 136], ["tuberculous pleurisy", "DISEASE", 146, 166], ["bronchiolitis obliterans organizing pneumonia", "DISEASE", 171, 216], ["BOOP", "DISEASE", 218, 222], ["respiratory tract", "ORGANISM_SUBDIVISION", 109, 126], ["Corticosteroids", "TREATMENT", 0, 15], ["infl ammatory sequelae", "PROBLEM", 83, 105], ["respiratory tract infection", "PROBLEM", 109, 136], ["tuberculous pleurisy", "PROBLEM", 146, 166], ["bronchiolitis obliterans organizing pneumonia", "PROBLEM", 171, 216], ["BOOP", "PROBLEM", 218, 222], ["may be", "UNCERTAINTY", 21, 27], ["effective", "OBSERVATION_MODIFIER", 28, 37], ["respiratory tract", "ANATOMY", 109, 126], ["infection", "OBSERVATION", 127, 136], ["tuberculous", "OBSERVATION_MODIFIER", 146, 157], ["pleurisy", "OBSERVATION", 158, 166], ["bronchiolitis obliterans", "OBSERVATION", 171, 195], ["organizing", "OBSERVATION_MODIFIER", 196, 206], ["pneumonia", "OBSERVATION", 207, 216], ["BOOP", "OBSERVATION", 218, 222]]], ["Strategies targeting specifi c cytokines have not been effective to date but remain active areas of investigation.", [["specifi c", "GENE_OR_GENE_PRODUCT", 21, 30], ["specifi c cytokines", "PROTEIN", 21, 40], ["Strategies targeting specifi c cytokines", "PROBLEM", 0, 40], ["active", "OBSERVATION_MODIFIER", 84, 90]]], ["Enhanced understanding of the interactions of pathogen components with TLRs may be helpful one day in controlling and containing infectious diseases.VaccinesImmunization has reduced the incidence of several serious childhood diseases.", [["infectious diseases", "DISEASE", 129, 148], ["VaccinesImmunization", "CHEMICAL", 149, 169], ["TLRs", "GENE_OR_GENE_PRODUCT", 71, 75], ["TLRs", "PROTEIN", 71, 75], ["TLRs", "TREATMENT", 71, 75], ["infectious diseases", "PROBLEM", 129, 148], ["VaccinesImmunization", "TREATMENT", 149, 169], ["several serious childhood diseases", "PROBLEM", 199, 233], ["infectious", "OBSERVATION", 129, 139], ["reduced", "OBSERVATION_MODIFIER", 174, 181], ["several", "OBSERVATION_MODIFIER", 199, 206], ["serious", "OBSERVATION_MODIFIER", 207, 214], ["childhood", "OBSERVATION_MODIFIER", 215, 224], ["diseases", "OBSERVATION", 225, 233]]], ["Immunization against infl uenza and increasingly resistant pneumococci can play a critical role in the prevention of pneumonia, particularly in immunocompromised patients.", [["uenza", "CHEMICAL", 26, 31], ["pneumococci", "CHEMICAL", 59, 70], ["pneumonia", "DISEASE", 117, 126], ["infl uenza", "ORGANISM", 21, 31], ["pneumococci", "ORGANISM", 59, 70], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["infl uenza", "SPECIES", 21, 31], ["Immunization", "TREATMENT", 0, 12], ["infl uenza", "TREATMENT", 21, 31], ["increasingly resistant pneumococci", "PROBLEM", 36, 70], ["pneumonia", "PROBLEM", 117, 126], ["pneumococci", "OBSERVATION", 59, 70], ["pneumonia", "OBSERVATION", 117, 126]]]], "d0c2ac63240ec41899b1dd80e399ffb47a04be3a": [["IntroductionDiseases that affect the health and productivity of food animals directly impact the cost and supply of high-quality protein available for human consumption.", [["IntroductionDiseases", "DISEASE", 0, 20], ["human", "ORGANISM", 151, 156], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["IntroductionDiseases", "PROBLEM", 0, 20], ["high-quality protein", "TREATMENT", 116, 136], ["human consumption", "TREATMENT", 151, 168]]], ["In addition to the expense resulting from animal treatments and deaths, diseases also cause economic losses by decreasing meat, milk or egg production, reducing feed conversion, slowing weight gain, and increasing the time the animal must remain on the farm prior to marketing.", [["meat", "ANATOMY", 122, 126], ["milk", "ANATOMY", 128, 132], ["egg", "ANATOMY", 136, 139], ["deaths", "DISEASE", 64, 70], ["weight gain", "DISEASE", 186, 197], ["meat", "ORGANISM_SUBDIVISION", 122, 126], ["milk", "ORGANISM_SUBSTANCE", 128, 132], ["egg", "ORGANISM_SUBSTANCE", 136, 139], ["animal treatments", "TREATMENT", 42, 59], ["diseases", "PROBLEM", 72, 80], ["economic losses", "PROBLEM", 92, 107], ["decreasing meat", "PROBLEM", 111, 126], ["egg production", "TREATMENT", 136, 150], ["reducing feed conversion", "TREATMENT", 152, 176], ["slowing weight gain", "PROBLEM", 178, 197]]], ["This article will briefly discuss many of the important diseases that affect the production of livestock, poultry and fish for meat.", [["meat", "ANATOMY", 127, 131], ["poultry", "ORGANISM_SUBDIVISION", 106, 113], ["fish", "ORGANISM_SUBDIVISION", 118, 122], ["meat", "ORGANISM_SUBDIVISION", 127, 131], ["the important diseases", "PROBLEM", 42, 64]]], ["It is worth noting that a number of diseases included in this article are notifiable and/or zoonotic (discussed in greater detail in Infectious diseases of meat animals:IntroductionNotifiable and zoonotic diseases).", [["Infectious diseases of meat", "DISEASE", 133, 160], ["zoonotic diseases", "DISEASE", 196, 213], ["diseases", "PROBLEM", 36, 44], ["diseases", "OBSERVATION", 36, 44]]], ["A good review of the use of antibiotics for the treatment of infections diseases can be found in Antibiotics: Use in animal husbandry.Diseases Affecting Livestock and PoultryDiseases of importance to ruminants and swine are listed in Table 1 , while Table 2 lists diseases that are of importance for poultry.Actinobacillosis (Wooden Tongue; Actinobacillus spp.)Actinobacillosis is characterized by firm, nodular swellings of the tongue, head and other tissues.", [["tongue", "ANATOMY", 429, 435], ["head", "ANATOMY", 437, 441], ["tissues", "ANATOMY", 452, 459], ["infections diseases", "DISEASE", 61, 80], ["Actinobacillosis", "CHEMICAL", 308, 324], ["Actinobacillosis", "DISEASE", 361, 377], ["Wooden Tongue", "ORGANISM", 326, 339], ["Actinobacillus spp.", "ORGANISM", 341, 360], ["tongue", "ORGAN", 429, 435], ["head", "ORGANISM_SUBDIVISION", 437, 441], ["tissues", "TISSUE", 452, 459], ["swine", "SPECIES", 214, 219], ["Actinobacillus spp.", "SPECIES", 341, 360], ["swine", "SPECIES", 214, 219], ["Actinobacillus spp.)", "SPECIES", 341, 361], ["antibiotics", "TREATMENT", 28, 39], ["infections diseases", "PROBLEM", 61, 80], ["Diseases", "PROBLEM", 134, 142], ["Actinobacillosis", "PROBLEM", 308, 324], ["Actinobacillus spp.", "PROBLEM", 341, 360], ["Actinobacillosis", "PROBLEM", 361, 377], ["firm, nodular swellings of the tongue, head and other tissues", "PROBLEM", 398, 459], ["good", "OBSERVATION_MODIFIER", 2, 6], ["infections", "OBSERVATION", 61, 71], ["Tongue", "ANATOMY", 333, 339], ["firm", "OBSERVATION_MODIFIER", 398, 402], ["nodular", "OBSERVATION_MODIFIER", 404, 411], ["swellings", "OBSERVATION", 412, 421], ["tongue", "ANATOMY", 429, 435], ["head", "ANATOMY", 437, 441], ["other tissues", "ANATOMY", 446, 459]]], ["Losses associated with this infection are due to incapacitation of the affected animal and condemnation of affected tissue.Actinomycosis (Lumpy Jaw; Actinomyces spp.)Actinomycosis most often causes a slow-growing swelling on the jaw.", [["tissue", "ANATOMY", 116, 122], ["jaw", "ANATOMY", 229, 232], ["Losses", "DISEASE", 0, 6], ["infection", "DISEASE", 28, 37], ["Actinomycosis", "DISEASE", 123, 136], ["Actinomycosis", "DISEASE", 166, 179], ["swelling", "DISEASE", 213, 221], ["tissue", "TISSUE", 116, 122], ["Lumpy Jaw; Actinomyces spp.", "ORGANISM", 138, 165], ["jaw", "ORGAN", 229, 232], ["Actinomyces spp.", "SPECIES", 149, 165], ["this infection", "PROBLEM", 23, 37], ["incapacitation", "PROBLEM", 49, 63], ["the affected animal", "PROBLEM", 67, 86], ["affected tissue", "PROBLEM", 107, 122], ["Actinomycosis (Lumpy Jaw", "PROBLEM", 123, 147], ["Actinomyces spp.", "TREATMENT", 149, 165], ["Actinomycosis", "PROBLEM", 166, 179], ["a slow-growing swelling on the jaw", "PROBLEM", 198, 232], ["infection", "OBSERVATION", 28, 37], ["affected tissue", "OBSERVATION", 107, 122], ["Jaw", "ANATOMY", 144, 147], ["slow", "OBSERVATION_MODIFIER", 200, 204], ["growing", "OBSERVATION_MODIFIER", 205, 212], ["swelling", "OBSERVATION", 213, 221], ["jaw", "ANATOMY", 229, 232]]], ["Incapacitation of the affected animal and condemnation of affected tissue result.Anaplasmosis (Anaplasma spp.)The course of illness can range from chronic to peracute, with animals exhibiting clinical signs related to anaemia (icterus, depression, inappetence, fever, weight loss, decreased milk production, death).", [["tissue", "ANATOMY", 67, 73], ["milk", "ANATOMY", 291, 295], ["illness", "DISEASE", 124, 131], ["anaemia", "DISEASE", 218, 225], ["icterus", "DISEASE", 227, 234], ["depression", "DISEASE", 236, 246], ["inappetence", "DISEASE", 248, 259], ["fever", "DISEASE", 261, 266], ["weight loss", "DISEASE", 268, 279], ["death", "DISEASE", 308, 313], ["tissue", "TISSUE", 67, 73], ["Anaplasma spp.", "ORGANISM", 95, 109], ["milk", "ORGANISM_SUBSTANCE", 291, 295], ["Anaplasma spp.", "SPECIES", 95, 109], ["Anaplasma spp.)", "SPECIES", 95, 110], ["Incapacitation", "PROBLEM", 0, 14], ["affected tissue result", "PROBLEM", 58, 80], ["Anaplasmosis (Anaplasma spp.", "PROBLEM", 81, 109], ["chronic to peracute", "PROBLEM", 147, 166], ["clinical signs", "PROBLEM", 192, 206], ["anaemia (icterus", "PROBLEM", 218, 234], ["depression", "PROBLEM", 236, 246], ["inappetence", "PROBLEM", 248, 259], ["fever", "PROBLEM", 261, 266], ["weight loss", "PROBLEM", 268, 279], ["decreased milk production", "PROBLEM", 281, 306], ["death", "PROBLEM", 308, 313], ["affected tissue", "OBSERVATION", 58, 73], ["chronic", "OBSERVATION_MODIFIER", 147, 154], ["icterus", "OBSERVATION", 227, 234]]], ["On necropsy, the blood is watery and icterus can be prominent.Anthrax (Bacillus anthracis)Anthrax affects an extremely wide range of mammals, including humans.", [["blood", "ANATOMY", 17, 22], ["watery", "ANATOMY", 26, 32], ["icterus", "DISEASE", 37, 44], ["Anthrax", "DISEASE", 62, 69], ["Anthrax", "DISEASE", 90, 97], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["watery", "ORGANISM_SUBSTANCE", 26, 32], ["Anthrax", "ORGANISM", 62, 69], ["Bacillus anthracis", "ORGANISM", 71, 89], ["humans", "ORGANISM", 152, 158], ["Bacillus anthracis", "SPECIES", 71, 89], ["humans", "SPECIES", 152, 158], ["Bacillus anthracis", "SPECIES", 71, 89], ["humans", "SPECIES", 152, 158], ["necropsy", "TREATMENT", 3, 11], ["watery", "PROBLEM", 26, 32], ["icterus", "PROBLEM", 37, 44], ["Anthrax (Bacillus anthracis", "TREATMENT", 62, 89], ["blood", "ANATOMY", 17, 22], ["watery", "OBSERVATION", 26, 32], ["icterus", "OBSERVATION", 37, 44], ["prominent", "OBSERVATION_MODIFIER", 52, 61]]], ["The clinical course ranges from chronic to peracute (death with few if any clinical signs).", [["death", "DISEASE", 53, 58], ["chronic to peracute (death", "PROBLEM", 32, 58], ["chronic", "OBSERVATION_MODIFIER", 32, 39]]], ["Acutely affected animals develop high fever, depression, respiratory and/or cardiac distress, convulsions, bloody discharges from body openings and death.", [["respiratory", "ANATOMY", 57, 68], ["cardiac", "ANATOMY", 76, 83], ["body", "ANATOMY", 130, 134], ["fever", "DISEASE", 38, 43], ["depression", "DISEASE", 45, 55], ["respiratory and/or cardiac distress", "DISEASE", 57, 92], ["convulsions", "DISEASE", 94, 105], ["death", "DISEASE", 148, 153], ["cardiac", "ORGAN", 76, 83], ["body", "ORGANISM_SUBDIVISION", 130, 134], ["Acutely affected animals", "PROBLEM", 0, 24], ["high fever", "PROBLEM", 33, 43], ["depression", "PROBLEM", 45, 55], ["respiratory and/or cardiac distress", "PROBLEM", 57, 92], ["convulsions", "PROBLEM", 94, 105], ["bloody discharges", "PROBLEM", 107, 124], ["body openings", "PROBLEM", 130, 143], ["death", "PROBLEM", 148, 153], ["high", "OBSERVATION_MODIFIER", 33, 37], ["fever", "OBSERVATION", 38, 43], ["respiratory", "ANATOMY", 57, 68], ["cardiac", "ANATOMY", 76, 83], ["distress", "OBSERVATION", 84, 92]]], ["Cases that are more chronic may develop oedema in the ventral portions of the head, neck, thorax and abdomen.", [["ventral portions", "ANATOMY", 54, 70], ["head", "ANATOMY", 78, 82], ["neck", "ANATOMY", 84, 88], ["thorax", "ANATOMY", 90, 96], ["abdomen", "ANATOMY", 101, 108], ["oedema", "DISEASE", 40, 46], ["oedema", "PATHOLOGICAL_FORMATION", 40, 46], ["ventral portions", "MULTI-TISSUE_STRUCTURE", 54, 70], ["head", "ORGANISM_SUBDIVISION", 78, 82], ["neck", "ORGANISM_SUBDIVISION", 84, 88], ["thorax", "ORGAN", 90, 96], ["abdomen", "ORGAN", 101, 108], ["oedema in the ventral portions of the head, neck, thorax and abdomen", "PROBLEM", 40, 108], ["more chronic", "OBSERVATION_MODIFIER", 15, 27], ["oedema", "OBSERVATION", 40, 46], ["ventral", "ANATOMY_MODIFIER", 54, 61], ["portions", "ANATOMY_MODIFIER", 62, 70], ["head", "ANATOMY", 78, 82], ["neck", "ANATOMY", 84, 88], ["thorax", "ANATOMY", 90, 96], ["abdomen", "ANATOMY", 101, 108]]], ["Anthrax should be considered whenever there is a carcass in which the blood fails to clot and rigor mortis does not occur.", [["blood", "ANATOMY", 70, 75], ["clot", "ANATOMY", 85, 89], ["Anthrax", "DISEASE", 0, 7], ["carcass", "ORGANISM_SUBDIVISION", 49, 56], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["clot", "ORGANISM_SUBSTANCE", 85, 89], ["Anthrax", "TREATMENT", 0, 7], ["clot", "PROBLEM", 85, 89], ["rigor mortis", "PROBLEM", 94, 106], ["clot", "OBSERVATION", 85, 89]]], ["Upon necropsy, enlarged spleens and lesions consistent with septicaemia are seen.Atrophic RhinitisThis disease is characterized by atrophy of the nasal turbinates of swine, which in moderate to severe cases causes distortion of the snout.", [["spleens", "ANATOMY", 24, 31], ["lesions", "ANATOMY", 36, 43], ["nasal turbinates", "ANATOMY", 146, 162], ["septicaemia", "DISEASE", 60, 71], ["Rhinitis", "DISEASE", 90, 98], ["distortion of the snout", "DISEASE", 214, 237], ["spleens", "ORGAN", 24, 31], ["lesions", "PATHOLOGICAL_FORMATION", 36, 43], ["nasal turbinates", "MULTI-TISSUE_STRUCTURE", 146, 162], ["swine", "ORGANISM", 166, 171], ["snout", "ORGANISM_SUBDIVISION", 232, 237], ["enlarged spleens", "PROBLEM", 15, 31], ["lesions", "PROBLEM", 36, 43], ["septicaemia", "PROBLEM", 60, 71], ["Atrophic Rhinitis", "PROBLEM", 81, 98], ["This disease", "PROBLEM", 98, 110], ["atrophy of the nasal turbinates of swine", "PROBLEM", 131, 171], ["distortion of the snout", "PROBLEM", 214, 237], ["necropsy", "OBSERVATION", 5, 13], ["enlarged", "OBSERVATION_MODIFIER", 15, 23], ["spleens", "ANATOMY", 24, 31], ["lesions", "OBSERVATION", 36, 43], ["consistent with", "UNCERTAINTY", 44, 59], ["septicaemia", "OBSERVATION", 60, 71], ["Rhinitis", "OBSERVATION", 90, 98], ["disease", "OBSERVATION", 103, 110], ["atrophy", "OBSERVATION", 131, 138], ["nasal turbinates", "ANATOMY", 146, 162], ["swine", "OBSERVATION", 166, 171], ["moderate", "OBSERVATION_MODIFIER", 182, 190], ["severe", "OBSERVATION_MODIFIER", 194, 200], ["cases", "OBSERVATION", 201, 206], ["distortion", "OBSERVATION_MODIFIER", 214, 224], ["snout", "ANATOMY", 232, 237]]], ["Development of the disease is related to infection with Bordetella bronchiseptica and Pasteurella multocida in addition to environmental and management factors.", [["infection", "DISEASE", 41, 50], ["Bordetella bronchiseptica", "DISEASE", 56, 81], ["Bordetella bronchiseptica", "ORGANISM", 56, 81], ["Pasteurella multocida", "ORGANISM", 86, 107], ["Bordetella bronchiseptica", "SPECIES", 56, 81], ["Pasteurella multocida", "SPECIES", 86, 107], ["Bordetella bronchiseptica", "SPECIES", 56, 81], ["Pasteurella multocida", "SPECIES", 86, 107], ["the disease", "PROBLEM", 15, 26], ["infection", "PROBLEM", 41, 50], ["Bordetella bronchiseptica", "TREATMENT", 56, 81], ["Pasteurella multocida", "PROBLEM", 86, 107], ["management factors", "TREATMENT", 141, 159], ["disease", "OBSERVATION", 19, 26], ["related to", "UNCERTAINTY", 30, 40], ["infection", "OBSERVATION", 41, 50]]], ["Economic losses can be severe as affected animals consume less feed, leading to a slower rate of weight gain and stunting.", [["weight gain", "DISEASE", 97, 108], ["stunting", "DISEASE", 113, 121], ["Economic losses", "PROBLEM", 0, 15], ["weight gain", "PROBLEM", 97, 108], ["stunting", "PROBLEM", 113, 121], ["severe", "OBSERVATION_MODIFIER", 23, 29]]], ["Atrophic rhinitis is widespread in the swine industry of many countries.", [["Atrophic rhinitis", "DISEASE", 0, 17], ["swine", "SPECIES", 39, 44], ["swine", "SPECIES", 39, 44], ["Atrophic rhinitis", "PROBLEM", 0, 17], ["rhinitis", "OBSERVATION", 9, 17], ["widespread", "OBSERVATION_MODIFIER", 21, 31]]], ["Aujeszky's disease affects a wide range of animals with the infection resulting in death in all species but swine.", [["Aujeszky's disease", "DISEASE", 0, 18], ["infection", "DISEASE", 60, 69], ["death", "DISEASE", 83, 88], ["Aujeszky", "ORGANISM", 0, 8], ["Aujeszky", "SPECIES", 0, 8], ["swine", "SPECIES", 108, 113], ["Aujeszky", "SPECIES", 0, 8], ["swine", "SPECIES", 108, 113], ["Aujeszky's disease", "PROBLEM", 0, 18], ["the infection", "PROBLEM", 56, 69], ["death", "PROBLEM", 83, 88], ["all species", "PROBLEM", 92, 103], ["disease", "OBSERVATION", 11, 18], ["wide range", "OBSERVATION_MODIFIER", 29, 39], ["infection", "OBSERVATION", 60, 69]]], ["With swine, clinical signs can vary from inapparent infection to death, depending on the state of immunity, age of the animals and the strain of the virus.", [["infection", "DISEASE", 52, 61], ["death", "DISEASE", 65, 70], ["swine", "SPECIES", 5, 10], ["swine", "SPECIES", 5, 10], ["clinical signs", "PROBLEM", 12, 26], ["inapparent infection", "PROBLEM", 41, 61], ["death", "PROBLEM", 65, 70], ["the strain of the virus", "PROBLEM", 131, 154], ["inapparent", "OBSERVATION_MODIFIER", 41, 51], ["infection", "OBSERVATION", 52, 61]]], ["Clinical signs in young pigs are fever, inappetence and depression, followed by trembling, incoordination, convulsions, coma and death.", [["fever", "DISEASE", 33, 38], ["inappetence", "DISEASE", 40, 51], ["depression", "DISEASE", 56, 66], ["incoordination", "DISEASE", 91, 105], ["convulsions", "DISEASE", 107, 118], ["coma", "DISEASE", 120, 124], ["death", "DISEASE", 129, 134], ["pigs", "ORGANISM", 24, 28], ["pigs", "SPECIES", 24, 28], ["fever", "PROBLEM", 33, 38], ["inappetence", "PROBLEM", 40, 51], ["depression", "PROBLEM", 56, 66], ["incoordination", "PROBLEM", 91, 105], ["convulsions", "PROBLEM", 107, 118], ["coma", "PROBLEM", 120, 124], ["death", "PROBLEM", 129, 134]]], ["Sows frequently exhibit increases in abortion, stillbirths and/or mummies.", [["stillbirths", "DISEASE", 47, 58], ["increases in abortion", "PROBLEM", 24, 45], ["increases", "OBSERVATION_MODIFIER", 24, 33], ["abortion", "OBSERVATION", 37, 45]]], ["The course of this disease in all other species is short (<48 h) and begins with a brief excitement phase characterized by trembling, anxiety and aggressive behaviour.", [["anxiety", "DISEASE", 134, 141], ["aggressive behaviour", "DISEASE", 146, 166], ["this disease in all other species", "PROBLEM", 14, 47], ["a brief excitement phase", "PROBLEM", 81, 105], ["trembling", "PROBLEM", 123, 132], ["anxiety", "PROBLEM", 134, 141], ["aggressive behaviour", "PROBLEM", 146, 166], ["disease", "OBSERVATION", 19, 26]]], ["This is followed by intense pruritis and culminates with incoordination, convulsions, coma and death.Avian Chlamydiosis (Psittacosis, Ornithosis, Chlamydia psittaci)Avian Chlamydiosis is a systemic and occasionally fatal disease of most birds caused by several different strains of Chlamydia psittici.", [["pruritis", "DISEASE", 28, 36], ["incoordination", "DISEASE", 57, 71], ["convulsions", "DISEASE", 73, 84], ["coma", "DISEASE", 86, 90], ["death", "DISEASE", 95, 100], ["Chlamydiosis", "CHEMICAL", 107, 119], ["Chlamydia psittaci", "DISEASE", 146, 164], ["Avian Chlamydiosis", "DISEASE", 165, 183], ["Chlamydia psittici", "DISEASE", 282, 300], ["Avian Chlamydiosis", "ORGANISM", 101, 119], ["Psittacosis, Ornithosis", "ORGANISM", 121, 144], ["Chlamydia psittaci", "ORGANISM", 146, 164], ["Avian Chlamydiosis", "ORGANISM", 165, 183], ["birds", "ORGANISM", 237, 242], ["Chlamydia psittici", "ORGANISM", 282, 300], ["Avian", "SPECIES", 101, 106], ["Chlamydia psittaci", "SPECIES", 146, 164], ["Chlamydia psittici", "SPECIES", 282, 300], ["Chlamydia psittaci", "SPECIES", 146, 164], ["Chlamydia psittici", "SPECIES", 282, 300], ["intense pruritis", "PROBLEM", 20, 36], ["incoordination", "PROBLEM", 57, 71], ["convulsions", "PROBLEM", 73, 84], ["coma", "PROBLEM", 86, 90], ["death", "PROBLEM", 95, 100], ["Avian Chlamydiosis", "PROBLEM", 101, 119], ["Psittacosis", "PROBLEM", 121, 132], ["Ornithosis", "PROBLEM", 134, 144], ["Chlamydia psittaci", "PROBLEM", 146, 164], ["a systemic and occasionally fatal disease", "PROBLEM", 187, 228], ["Chlamydia psittici", "PROBLEM", 282, 300], ["intense", "OBSERVATION_MODIFIER", 20, 27], ["pruritis", "OBSERVATION", 28, 36], ["Chlamydiosis", "OBSERVATION", 107, 119], ["Psittacosis", "OBSERVATION", 121, 132], ["systemic", "OBSERVATION_MODIFIER", 189, 197], ["occasionally", "OBSERVATION_MODIFIER", 202, 214], ["fatal", "OBSERVATION_MODIFIER", 215, 220], ["disease", "OBSERVATION", 221, 228], ["most birds", "OBSERVATION_MODIFIER", 232, 242], ["Chlamydia psittici", "OBSERVATION", 282, 300]]], ["The lungs of affected birds are diffusely congested.", [["lungs", "ANATOMY", 4, 9], ["lungs", "ORGAN", 4, 9], ["birds", "ORGANISM", 22, 27], ["diffusely congested", "PROBLEM", 32, 51], ["lungs", "ANATOMY", 4, 9], ["affected", "OBSERVATION_MODIFIER", 13, 21], ["birds", "OBSERVATION_MODIFIER", 22, 27], ["diffusely", "OBSERVATION_MODIFIER", 32, 41], ["congested", "OBSERVATION", 42, 51]]], ["The thoracic and peritonial cavities show fibrinous exudates.", [["thoracic", "ANATOMY", 4, 12], ["peritonial cavities", "ANATOMY", 17, 36], ["fibrinous exudates", "ANATOMY", 42, 60], ["thoracic", "MULTI-TISSUE_STRUCTURE", 4, 12], ["peritonial cavities", "PATHOLOGICAL_FORMATION", 17, 36], ["fibrinous exudates", "PATHOLOGICAL_FORMATION", 42, 60], ["fibrinous exudates", "PROBLEM", 42, 60], ["thoracic", "ANATOMY", 4, 12], ["peritonial cavities", "ANATOMY", 17, 36], ["fibrinous", "OBSERVATION_MODIFIER", 42, 51], ["exudates", "OBSERVATION", 52, 60]]], ["The pericardial and air sacs are thickened and covered by fibrinous exudates.", [["pericardial", "ANATOMY", 4, 15], ["air sacs", "ANATOMY", 20, 28], ["fibrinous exudates", "ANATOMY", 58, 76], ["pericardial", "MULTI-TISSUE_STRUCTURE", 4, 15], ["air sacs", "MULTI-TISSUE_STRUCTURE", 20, 28], ["fibrinous exudates", "PATHOLOGICAL_FORMATION", 58, 76], ["thickened", "PROBLEM", 33, 42], ["fibrinous exudates", "PROBLEM", 58, 76], ["pericardial", "ANATOMY", 4, 15], ["air sacs", "ANATOMY", 20, 28], ["thickened", "OBSERVATION", 33, 42], ["fibrinous", "OBSERVATION_MODIFIER", 58, 67], ["exudates", "OBSERVATION", 68, 76]]], ["The heart may be enlarged with fibrin plaques or yellowish flakey exudate on the surface.", [["heart", "ANATOMY", 4, 9], ["fibrin plaques", "ANATOMY", 31, 45], ["yellowish flakey exudate", "ANATOMY", 49, 73], ["surface", "ANATOMY", 81, 88], ["heart", "ORGAN", 4, 9], ["fibrin", "GENE_OR_GENE_PRODUCT", 31, 37], ["surface", "CELLULAR_COMPONENT", 81, 88], ["fibrin plaques", "PROBLEM", 31, 45], ["yellowish flakey exudate on the surface", "PROBLEM", 49, 88], ["heart", "ANATOMY", 4, 9], ["may be", "UNCERTAINTY", 10, 16], ["enlarged", "OBSERVATION", 17, 25], ["fibrin", "OBSERVATION_MODIFIER", 31, 37], ["plaques", "OBSERVATION", 38, 45], ["yellowish", "OBSERVATION_MODIFIER", 49, 58], ["flakey", "OBSERVATION_MODIFIER", 59, 65], ["exudate", "OBSERVATION", 66, 73], ["surface", "OBSERVATION_MODIFIER", 81, 88]]], ["The liver and spleen are frequently enlarged and discoloured.Avian Infectious Bronchitis (Coronavirus spp.)Avian infectious bronchitis is an acute, highly contagious respiratory disease associated with coughing, sneezing and tracheal rales.", [["liver", "ANATOMY", 4, 9], ["spleen", "ANATOMY", 14, 20], ["respiratory", "ANATOMY", 166, 177], ["tracheal", "ANATOMY", 225, 233], ["Infectious Bronchitis", "DISEASE", 67, 88], ["Avian infectious bronchitis", "DISEASE", 107, 134], ["respiratory disease", "DISEASE", 166, 185], ["coughing", "DISEASE", 202, 210], ["sneezing", "DISEASE", 212, 220], ["liver", "ORGAN", 4, 9], ["spleen", "ORGAN", 14, 20], ["Avian Infectious Bronchitis", "ORGANISM", 61, 88], ["Coronavirus spp.", "ORGANISM", 90, 106], ["Avian", "SPECIES", 61, 66], ["Avian", "SPECIES", 107, 112], ["discoloured", "PROBLEM", 49, 60], ["Avian Infectious Bronchitis (Coronavirus spp.", "PROBLEM", 61, 106], ["Avian infectious bronchitis", "PROBLEM", 107, 134], ["highly contagious respiratory disease", "PROBLEM", 148, 185], ["coughing", "PROBLEM", 202, 210], ["sneezing", "PROBLEM", 212, 220], ["tracheal rales", "PROBLEM", 225, 239], ["liver", "ANATOMY", 4, 9], ["spleen", "ANATOMY", 14, 20], ["frequently", "OBSERVATION_MODIFIER", 25, 35], ["enlarged", "OBSERVATION", 36, 44], ["Infectious", "OBSERVATION_MODIFIER", 67, 77], ["Bronchitis", "OBSERVATION", 78, 88], ["infectious", "OBSERVATION_MODIFIER", 113, 123], ["bronchitis", "OBSERVATION", 124, 134], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["highly", "OBSERVATION_MODIFIER", 148, 154], ["contagious", "OBSERVATION_MODIFIER", 155, 165], ["respiratory disease", "OBSERVATION", 166, 185], ["coughing", "OBSERVATION", 202, 210], ["tracheal", "ANATOMY", 225, 233], ["rales", "OBSERVATION", 234, 239]]], ["Gross lesions include a serous, catarrhal or caseous exudate in the trachea, nasal passages, sinuses and air sacs.", [["Gross lesions", "ANATOMY", 0, 13], ["serous", "ANATOMY", 24, 30], ["caseous exudate", "ANATOMY", 45, 60], ["trachea", "ANATOMY", 68, 75], ["nasal", "ANATOMY", 77, 82], ["sinuses", "ANATOMY", 93, 100], ["air sacs", "ANATOMY", 105, 113], ["catarrhal", "DISEASE", 32, 41], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["trachea", "MULTI-TISSUE_STRUCTURE", 68, 75], ["sinuses", "MULTI-TISSUE_STRUCTURE", 93, 100], ["air sacs", "MULTI-TISSUE_STRUCTURE", 105, 113], ["Gross lesions", "PROBLEM", 0, 13], ["a serous, catarrhal or caseous exudate in the trachea, nasal passages, sinuses and air sacs", "PROBLEM", 22, 113], ["lesions", "OBSERVATION", 6, 13], ["serous", "OBSERVATION_MODIFIER", 24, 30], ["catarrhal", "OBSERVATION_MODIFIER", 32, 41], ["caseous", "OBSERVATION_MODIFIER", 45, 52], ["exudate", "OBSERVATION", 53, 60], ["trachea", "ANATOMY", 68, 75], ["nasal passages", "ANATOMY", 77, 91], ["sinuses", "ANATOMY", 93, 100], ["air sacs", "OBSERVATION", 105, 113]]], ["Laying chickens frequently exhibit fluid yolk material in the abdominal cavity.", [["fluid yolk", "ANATOMY", 35, 45], ["abdominal cavity", "ANATOMY", 62, 78], ["chickens", "ORGANISM", 7, 15], ["fluid yolk material", "MULTI-TISSUE_STRUCTURE", 35, 54], ["abdominal cavity", "MULTI-TISSUE_STRUCTURE", 62, 78], ["chickens", "SPECIES", 7, 15], ["chickens", "SPECIES", 7, 15], ["fluid yolk material in the abdominal cavity", "PROBLEM", 35, 78], ["fluid yolk material", "OBSERVATION", 35, 54], ["abdominal cavity", "ANATOMY", 62, 78]]], ["Egg quality is severely affected in recovered birds.Avian Pox (Avipoxvirus spp.)There are a number of distinct avian pox viruses, which vary in their species specificity and pathogenicity.", [["Avian Pox", "ORGANISM", 52, 61], ["Avipoxvirus spp.", "ORGANISM", 63, 79], ["avian", "ORGANISM", 111, 116], ["pox viruses", "ORGANISM", 117, 128], ["Avian", "SPECIES", 52, 57], ["Avipoxvirus spp.", "SPECIES", 63, 79], ["avian pox", "SPECIES", 111, 120], ["pox viruses", "SPECIES", 117, 128], ["severely affected", "PROBLEM", 15, 32], ["Avian Pox (Avipoxvirus spp.", "TREATMENT", 52, 79], ["distinct avian pox viruses", "PROBLEM", 102, 128], ["severely", "OBSERVATION_MODIFIER", 15, 23], ["affected", "OBSERVATION", 24, 32], ["number", "OBSERVATION_MODIFIER", 92, 98], ["distinct", "OBSERVATION_MODIFIER", 102, 110], ["avian", "OBSERVATION_MODIFIER", 111, 116], ["pox viruses", "OBSERVATION", 117, 128], ["species", "OBSERVATION_MODIFIER", 150, 157], ["pathogenicity", "OBSERVATION_MODIFIER", 174, 187]]], ["Pox lesions typically affect the non-feathered areas of the bird.", [["Pox lesions", "ANATOMY", 0, 11], ["Pox lesions", "PATHOLOGICAL_FORMATION", 0, 11], ["bird", "ORGANISM_SUBDIVISION", 60, 64], ["Pox lesions", "PROBLEM", 0, 11], ["lesions", "OBSERVATION", 4, 11], ["bird", "ANATOMY", 60, 64]]], ["Diphtheritic lesions of the oral cavity and oesophagus and/or infection of the nasal cavities may also be present.", [["Diphtheritic lesions", "ANATOMY", 0, 20], ["oral cavity", "ANATOMY", 28, 39], ["oesophagus", "ANATOMY", 44, 54], ["nasal cavities", "ANATOMY", 79, 93], ["infection", "DISEASE", 62, 71], ["Diphtheritic lesions", "PATHOLOGICAL_FORMATION", 0, 20], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 28, 39], ["oesophagus", "ORGAN", 44, 54], ["nasal cavities", "MULTI-TISSUE_STRUCTURE", 79, 93], ["Diphtheritic lesions of the oral cavity and oesophagus", "PROBLEM", 0, 54], ["infection of the nasal cavities", "PROBLEM", 62, 93], ["lesions", "OBSERVATION", 13, 20], ["oral cavity", "ANATOMY", 28, 39], ["oesophagus", "ANATOMY", 44, 54], ["infection", "OBSERVATION", 62, 71], ["nasal cavities", "ANATOMY", 79, 93], ["may also be", "UNCERTAINTY", 94, 105]]], ["There are no internal lesions.Blackleg (Clostridium chauvoei)This disease is named for the emphysematous swelling most often seen in the large muscles of cattle and sheep.", [["internal lesions", "ANATOMY", 13, 29], ["emphysematous", "ANATOMY", 91, 104], ["muscles", "ANATOMY", 143, 150], ["Blackleg", "CHEMICAL", 30, 38], ["emphysematous swelling", "DISEASE", 91, 113], ["lesions", "PATHOLOGICAL_FORMATION", 22, 29], ["Blackleg", "SIMPLE_CHEMICAL", 30, 38], ["Clostridium chauvoei", "ORGANISM", 40, 60], ["muscles", "ORGAN", 143, 150], ["cattle", "ORGANISM", 154, 160], ["sheep", "ORGANISM", 165, 170], ["cattle", "SPECIES", 154, 160], ["sheep", "SPECIES", 165, 170], ["Clostridium chauvoei", "SPECIES", 40, 60], ["cattle", "SPECIES", 154, 160], ["sheep", "SPECIES", 165, 170], ["internal lesions", "PROBLEM", 13, 29], ["Blackleg (Clostridium chauvoei)", "TREATMENT", 30, 61], ["This disease", "PROBLEM", 61, 73], ["the emphysematous swelling", "PROBLEM", 87, 113], ["no", "UNCERTAINTY", 10, 12], ["internal", "OBSERVATION_MODIFIER", 13, 21], ["lesions", "OBSERVATION", 22, 29], ["disease", "OBSERVATION", 66, 73], ["emphysematous", "OBSERVATION_MODIFIER", 91, 104], ["swelling", "OBSERVATION", 105, 113], ["large", "OBSERVATION_MODIFIER", 137, 142], ["muscles", "ANATOMY", 143, 150], ["cattle", "OBSERVATION", 154, 160]]], ["The affected muscle is dark, dry and spongy in appearance with a sweet smell.", [["muscle", "ANATOMY", 13, 19], ["muscle", "ORGAN", 13, 19], ["dark", "PROBLEM", 23, 27], ["a sweet smell", "PROBLEM", 63, 76], ["muscle", "ANATOMY", 13, 19], ["dark", "OBSERVATION_MODIFIER", 23, 27], ["dry", "OBSERVATION", 29, 32], ["spongy", "OBSERVATION_MODIFIER", 37, 43], ["sweet smell", "OBSERVATION", 65, 76]]], ["Blackleg usually develops in beef breed animals in excellent health and weight.Bluetongue (BT virus)This viral disease of ruminants, especially sheep, is spread by biting insects (Culicoides spp.).", [["Blackleg", "CHEMICAL", 0, 8], ["Bluetongue", "CHEMICAL", 79, 89], ["viral disease of ruminants", "DISEASE", 105, 131], ["Bluetongue (BT virus", "ORGANISM", 79, 99], ["sheep", "ORGANISM", 144, 149], ["Culicoides spp.", "ORGANISM", 180, 195], ["beef", "SPECIES", 29, 33], ["sheep", "SPECIES", 144, 149], ["Culicoides spp.", "SPECIES", 180, 195], ["beef", "SPECIES", 29, 33], ["sheep", "SPECIES", 144, 149], ["Culicoides spp.", "SPECIES", 180, 195], ["Bluetongue (BT virus", "PROBLEM", 79, 99], ["This viral disease of ruminants", "PROBLEM", 100, 131], ["viral disease", "OBSERVATION", 105, 118]]], ["Clinical signs include fever, listlessness, reddening of the face, and erosion, ulceration and necrosis of the mouth.", [["face", "ANATOMY", 61, 65], ["mouth", "ANATOMY", 111, 116], ["fever", "DISEASE", 23, 28], ["listlessness", "DISEASE", 30, 42], ["reddening of the face", "DISEASE", 44, 65], ["erosion", "DISEASE", 71, 78], ["ulceration", "DISEASE", 80, 90], ["necrosis", "DISEASE", 95, 103], ["mouth", "ORGAN", 111, 116], ["Clinical signs", "TEST", 0, 14], ["fever", "PROBLEM", 23, 28], ["listlessness", "PROBLEM", 30, 42], ["reddening of the face", "PROBLEM", 44, 65], ["erosion", "PROBLEM", 71, 78], ["ulceration", "PROBLEM", 80, 90], ["necrosis of the mouth", "PROBLEM", 95, 116], ["fever", "OBSERVATION", 23, 28], ["reddening", "OBSERVATION_MODIFIER", 44, 53], ["face", "ANATOMY", 61, 65], ["erosion", "OBSERVATION", 71, 78], ["ulceration", "OBSERVATION", 80, 90], ["necrosis", "OBSERVATION", 95, 103], ["mouth", "ANATOMY", 111, 116]]], ["Swelling and cyanosis of the tongue may be seen along with lameness, conjunctivitis and pneumonia.BotulismBotulism is caused by a toxin produced by the bacteria Clostridium botulinum.", [["tongue", "ANATOMY", 29, 35], ["Swelling", "DISEASE", 0, 8], ["cyanosis of the tongue", "DISEASE", 13, 35], ["lameness", "DISEASE", 59, 67], ["conjunctivitis", "DISEASE", 69, 83], ["pneumonia", "DISEASE", 88, 97], ["BotulismBotulism", "CHEMICAL", 98, 114], ["tongue", "ORGAN", 29, 35], ["BotulismBotulism", "SIMPLE_CHEMICAL", 98, 114], ["Clostridium botulinum", "ORGANISM", 161, 182], ["Clostridium botulinum", "SPECIES", 161, 182], ["Clostridium botulinum", "SPECIES", 161, 182], ["Swelling", "PROBLEM", 0, 8], ["cyanosis of the tongue", "PROBLEM", 13, 35], ["lameness", "PROBLEM", 59, 67], ["conjunctivitis", "PROBLEM", 69, 83], ["pneumonia", "PROBLEM", 88, 97], ["a toxin", "PROBLEM", 128, 135], ["the bacteria Clostridium botulinum", "PROBLEM", 148, 182], ["cyanosis", "OBSERVATION", 13, 21], ["tongue", "ANATOMY", 29, 35], ["may be seen", "UNCERTAINTY", 36, 47], ["lameness", "OBSERVATION", 59, 67], ["conjunctivitis", "OBSERVATION", 69, 83], ["pneumonia", "OBSERVATION", 88, 97]]], ["A wide variety of species are affected including livestock, poultry and humans.", [["humans", "ORGANISM", 72, 78], ["humans", "SPECIES", 72, 78], ["humans", "SPECIES", 72, 78], ["A wide variety of species", "PROBLEM", 0, 25], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["variety", "OBSERVATION_MODIFIER", 7, 14], ["species", "OBSERVATION", 18, 25]]], ["This disease manifests as an ascending muscle paralysis with death occurring due to respiratory or cardiac paralysis.", [["muscle", "ANATOMY", 39, 45], ["respiratory", "ANATOMY", 84, 95], ["cardiac", "ANATOMY", 99, 106], ["muscle paralysis", "DISEASE", 39, 55], ["death", "DISEASE", 61, 66], ["respiratory or cardiac paralysis", "DISEASE", 84, 116], ["muscle", "ORGAN", 39, 45], ["cardiac", "ORGAN", 99, 106], ["This disease", "PROBLEM", 0, 12], ["an ascending muscle paralysis", "PROBLEM", 26, 55], ["death", "PROBLEM", 61, 66], ["respiratory or cardiac paralysis", "PROBLEM", 84, 116], ["ascending", "ANATOMY_MODIFIER", 29, 38], ["muscle", "ANATOMY", 39, 45], ["paralysis", "OBSERVATION", 46, 55], ["cardiac", "ANATOMY", 99, 106], ["paralysis", "OBSERVATION", 107, 116]]], ["More information on Clostridium botulinum can be found in Microbiological safety of meat: Clostridium botulinum.Bovine Viral Diarrhoea (Pestivirus spp.)Clinical signs are variable and include fever, inappetence, lethargy, diarrhoea, dehydration, purulent nasal discharge, oral erosions, respiratory signs and corneal opacity.", [["meat", "ANATOMY", 84, 88], ["nasal", "ANATOMY", 255, 260], ["oral", "ANATOMY", 272, 276], ["respiratory", "ANATOMY", 287, 298], ["corneal", "ANATOMY", 309, 316], ["Clostridium botulinum", "DISEASE", 20, 41], ["Viral Diarrhoea", "DISEASE", 119, 134], ["fever", "DISEASE", 192, 197], ["inappetence", "DISEASE", 199, 210], ["lethargy", "DISEASE", 212, 220], ["diarrhoea", "DISEASE", 222, 231], ["dehydration", "DISEASE", 233, 244], ["erosions", "DISEASE", 277, 285], ["corneal opacity", "DISEASE", 309, 324], ["Clostridium botulinum", "ORGANISM", 20, 41], ["meat", "ORGANISM_SUBDIVISION", 84, 88], ["Clostridium botulinum", "ORGANISM", 90, 111], ["Bovine", "ORGANISM", 112, 118], ["Viral Diarrhoea", "ORGANISM", 119, 134], ["Pestivirus spp.", "ORGANISM", 136, 151], ["nasal", "ORGANISM_SUBDIVISION", 255, 260], ["oral", "ORGANISM_SUBDIVISION", 272, 276], ["corneal", "TISSUE", 309, 316], ["Clostridium botulinum", "SPECIES", 20, 41], ["Clostridium botulinum", "SPECIES", 90, 111], ["Bovine", "SPECIES", 112, 118], ["Clostridium botulinum", "SPECIES", 20, 41], ["Clostridium botulinum", "SPECIES", 90, 111], ["Bovine", "SPECIES", 112, 118], ["Clostridium botulinum", "PROBLEM", 20, 41], ["Clostridium botulinum", "PROBLEM", 90, 111], ["Bovine Viral Diarrhoea (Pestivirus spp.", "PROBLEM", 112, 151], ["Clinical signs", "TEST", 152, 166], ["fever", "PROBLEM", 192, 197], ["inappetence", "PROBLEM", 199, 210], ["lethargy", "PROBLEM", 212, 220], ["diarrhoea", "PROBLEM", 222, 231], ["dehydration", "PROBLEM", 233, 244], ["purulent nasal discharge", "PROBLEM", 246, 270], ["oral erosions", "PROBLEM", 272, 285], ["respiratory signs", "PROBLEM", 287, 304], ["corneal opacity", "PROBLEM", 309, 324], ["Viral Diarrhoea", "OBSERVATION", 119, 134], ["diarrhoea", "OBSERVATION", 222, 231], ["dehydration", "OBSERVATION_MODIFIER", 233, 244], ["purulent", "OBSERVATION_MODIFIER", 246, 254], ["nasal", "ANATOMY", 255, 260], ["discharge", "OBSERVATION", 261, 270], ["oral", "ANATOMY", 272, 276], ["erosions", "OBSERVATION", 277, 285], ["respiratory", "ANATOMY", 287, 298], ["signs", "OBSERVATION", 299, 304], ["corneal", "ANATOMY", 309, 316], ["opacity", "OBSERVATION", 317, 324]]], ["Erosions may occur on the coronary band and interdigital spaces of the foot, causing lameness.", [["coronary band", "ANATOMY", 26, 39], ["interdigital spaces", "ANATOMY", 44, 63], ["foot", "ANATOMY", 71, 75], ["Erosions", "DISEASE", 0, 8], ["lameness", "DISEASE", 85, 93], ["coronary band", "MULTI-TISSUE_STRUCTURE", 26, 39], ["foot", "ORGANISM_SUBDIVISION", 71, 75], ["Erosions", "PROBLEM", 0, 8], ["lameness", "PROBLEM", 85, 93], ["coronary", "ANATOMY", 26, 34], ["band", "ANATOMY_MODIFIER", 35, 39], ["interdigital", "ANATOMY_MODIFIER", 44, 56], ["spaces", "ANATOMY_MODIFIER", 57, 63], ["foot", "ANATOMY", 71, 75], ["lameness", "OBSERVATION", 85, 93]]], ["Gross lesions may include erosions with little evidence of inflammation in the mouth, pharynx, oesophagus, stomachs, caecum and small intestine.Brucellosis (Brucella spp.)Several species of Brucella cause illness in ruminants, swine, and humans.", [["Gross lesions", "ANATOMY", 0, 13], ["mouth", "ANATOMY", 79, 84], ["pharynx", "ANATOMY", 86, 93], ["oesophagus", "ANATOMY", 95, 105], ["stomachs", "ANATOMY", 107, 115], ["caecum", "ANATOMY", 117, 123], ["small intestine", "ANATOMY", 128, 143], ["erosions", "DISEASE", 26, 34], ["inflammation", "DISEASE", 59, 71], ["Brucellosis", "DISEASE", 144, 155], ["Brucella cause illness", "DISEASE", 190, 212], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["mouth", "ORGANISM_SUBDIVISION", 79, 84], ["pharynx", "ORGAN", 86, 93], ["oesophagus", "ORGAN", 95, 105], ["stomachs", "ORGAN", 107, 115], ["caecum", "MULTI-TISSUE_STRUCTURE", 117, 123], ["small intestine", "ORGAN", 128, 143], ["Brucella spp.", "ORGANISM", 157, 170], ["Brucella", "ORGANISM", 190, 198], ["humans", "ORGANISM", 238, 244], ["Brucella spp.", "SPECIES", 157, 170], ["swine", "SPECIES", 227, 232], ["humans", "SPECIES", 238, 244], ["swine", "SPECIES", 227, 232], ["humans", "SPECIES", 238, 244], ["Gross lesions", "PROBLEM", 0, 13], ["erosions", "PROBLEM", 26, 34], ["inflammation in the mouth, pharynx, oesophagus, stomachs, caecum and small intestine", "PROBLEM", 59, 143], ["Brucellosis (Brucella spp.", "PROBLEM", 144, 170], ["Brucella", "PROBLEM", 190, 198], ["illness", "PROBLEM", 205, 212], ["lesions", "OBSERVATION", 6, 13], ["erosions", "OBSERVATION", 26, 34], ["little evidence of", "UNCERTAINTY", 40, 58], ["inflammation", "OBSERVATION", 59, 71], ["mouth", "ANATOMY", 79, 84], ["pharynx", "ANATOMY", 86, 93], ["oesophagus", "ANATOMY", 95, 105], ["stomachs", "ANATOMY", 107, 115], ["caecum", "ANATOMY", 117, 123], ["small intestine", "ANATOMY", 128, 143], ["Brucella cause", "OBSERVATION", 190, 204]]], ["Clinical signs include fever, abortion, stillbirths and retained placentas.", [["placentas", "ANATOMY", 65, 74], ["fever", "DISEASE", 23, 28], ["abortion", "DISEASE", 30, 38], ["stillbirths", "DISEASE", 40, 51], ["placentas", "MULTI-TISSUE_STRUCTURE", 65, 74], ["Clinical signs", "TEST", 0, 14], ["fever", "PROBLEM", 23, 28], ["abortion", "PROBLEM", 30, 38], ["stillbirths", "PROBLEM", 40, 51], ["retained placentas", "PROBLEM", 56, 74], ["fever", "OBSERVATION", 23, 28], ["retained placentas", "OBSERVATION", 56, 74]]], ["Humans may be infected through handling infected tissue or consumption of milk from infected animals.Campylobacteriosis (Campylobacter spp.)Campylobacter cause diarrhoea in a variety of animals, with younger animals most severely affected.", [["tissue", "ANATOMY", 49, 55], ["milk", "ANATOMY", 74, 78], ["Campylobacteriosis", "CHEMICAL", 101, 119], ["Campylobacter spp.", "DISEASE", 121, 139], ["Campylobacter", "CHEMICAL", 140, 153], ["diarrhoea", "DISEASE", 160, 169], ["Humans", "ORGANISM", 0, 6], ["tissue", "TISSUE", 49, 55], ["milk", "ORGANISM_SUBSTANCE", 74, 78], ["Campylobacter spp.", "ORGANISM", 121, 139], ["Campylobacter spp.", "SPECIES", 121, 139], ["Campylobacter spp.)", "SPECIES", 121, 140], ["handling infected tissue", "PROBLEM", 31, 55], ["Campylobacteriosis (Campylobacter spp.", "PROBLEM", 101, 139], ["Campylobacter", "PROBLEM", 140, 153], ["diarrhoea", "PROBLEM", 160, 169], ["may be", "UNCERTAINTY", 7, 13], ["infected", "OBSERVATION", 14, 22], ["infected", "OBSERVATION", 40, 48], ["infected", "OBSERVATION_MODIFIER", 84, 92], ["Campylobacter spp.", "OBSERVATION", 121, 139], ["diarrhoea", "OBSERVATION", 160, 169], ["most severely", "OBSERVATION_MODIFIER", 216, 229]]], ["The prevalence of this disease has been increasing in both animals and humans in recent years.", [["humans", "ORGANISM", 71, 77], ["humans", "SPECIES", 71, 77], ["humans", "SPECIES", 71, 77], ["this disease", "PROBLEM", 18, 30], ["disease", "OBSERVATION", 23, 30], ["increasing", "OBSERVATION_MODIFIER", 40, 50], ["both", "OBSERVATION_MODIFIER", 54, 58], ["animals", "OBSERVATION_MODIFIER", 59, 66]]], ["More information on Campylobacter spp. can be found in Microbiological safety of meat: Thermotolerant Campylobacter.Caseous Lymphadenitis (Corynebacterium pseudotuberculosis)This chronic disease primarily affecting sheep and goats is characterized by caseous abscesses of the lymph nodes, lungs and other organs.", [["meat", "ANATOMY", 81, 85], ["caseous abscesses", "ANATOMY", 251, 268], ["lymph nodes", "ANATOMY", 276, 287], ["lungs", "ANATOMY", 289, 294], ["organs", "ANATOMY", 305, 311], ["Campylobacter spp.", "DISEASE", 20, 38], ["Lymphadenitis", "DISEASE", 124, 137], ["Corynebacterium pseudotuberculosis", "DISEASE", 139, 173], ["chronic disease", "DISEASE", 179, 194], ["abscesses", "DISEASE", 259, 268], ["Campylobacter spp.", "ORGANISM", 20, 38], ["meat", "ORGANISM_SUBDIVISION", 81, 85], ["Corynebacterium pseudotuberculosis", "ORGANISM", 139, 173], ["sheep", "ORGANISM", 215, 220], ["goats", "ORGANISM", 225, 230], ["caseous abscesses", "PATHOLOGICAL_FORMATION", 251, 268], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 276, 287], ["lungs", "ORGAN", 289, 294], ["organs", "ORGAN", 305, 311], ["Campylobacter spp.", "SPECIES", 20, 38], ["Corynebacterium pseudotuberculosis", "SPECIES", 139, 173], ["sheep", "SPECIES", 215, 220], ["goats", "SPECIES", 225, 230], ["Campylobacter spp.", "SPECIES", 20, 38], ["Corynebacterium pseudotuberculosis", "SPECIES", 139, 173], ["sheep", "SPECIES", 215, 220], ["goats", "SPECIES", 225, 230], ["Campylobacter spp.", "TREATMENT", 20, 38], ["Thermotolerant Campylobacter", "PROBLEM", 87, 115], ["Caseous Lymphadenitis (Corynebacterium pseudotuberculosis", "PROBLEM", 116, 173], ["This chronic disease", "PROBLEM", 174, 194], ["caseous abscesses of the lymph nodes, lungs and other organs", "PROBLEM", 251, 311], ["Thermotolerant Campylobacter", "OBSERVATION", 87, 115], ["Lymphadenitis", "OBSERVATION", 124, 137], ["Corynebacterium pseudotuberculosis", "OBSERVATION", 139, 173], ["chronic", "OBSERVATION_MODIFIER", 179, 186], ["disease", "OBSERVATION", 187, 194], ["caseous", "OBSERVATION_MODIFIER", 251, 258], ["abscesses", "OBSERVATION", 259, 268], ["lymph nodes", "OBSERVATION", 276, 287], ["lungs", "ANATOMY", 289, 294], ["organs", "ANATOMY", 305, 311]]], ["Economic losses result from decreased weight gain and productivity, condemnation of tissues or the whole carcass and decreased value of the hide as abscesses rupture to the outside.Clostridium perfringensClostridium perfringens causes enteritis, dysentery, toxaemia and death in cattle, sheep, swine, goats and deer.", [["tissues", "ANATOMY", 84, 91], ["whole carcass", "ANATOMY", 99, 112], ["abscesses", "ANATOMY", 148, 157], ["weight gain", "DISEASE", 38, 49], ["rupture", "DISEASE", 158, 165], ["Clostridium perfringens", "DISEASE", 181, 204], ["Clostridium perfringens", "DISEASE", 204, 227], ["enteritis", "DISEASE", 235, 244], ["dysentery", "DISEASE", 246, 255], ["toxaemia", "DISEASE", 257, 265], ["death", "DISEASE", 270, 275], ["tissues", "TISSUE", 84, 91], ["carcass", "ORGANISM_SUBDIVISION", 105, 112], ["abscesses", "PATHOLOGICAL_FORMATION", 148, 157], ["Clostridium perfringens", "ORGANISM", 181, 204], ["Clostridium perfringens", "ORGANISM", 204, 227], ["cattle", "ORGANISM", 279, 285], ["sheep", "ORGANISM", 287, 292], ["swine", "ORGANISM", 294, 299], ["goats", "ORGANISM", 301, 306], ["Clostridium perfringens", "SPECIES", 181, 204], ["Clostridium perfringens", "SPECIES", 204, 227], ["cattle", "SPECIES", 279, 285], ["sheep", "SPECIES", 287, 292], ["swine", "SPECIES", 294, 299], ["goats", "SPECIES", 301, 306], ["deer", "SPECIES", 311, 315], ["Clostridium perfringens", "SPECIES", 181, 204], ["Clostridium perfringens", "SPECIES", 204, 227], ["cattle", "SPECIES", 279, 285], ["sheep", "SPECIES", 287, 292], ["swine", "SPECIES", 294, 299], ["goats", "SPECIES", 301, 306], ["Economic losses", "PROBLEM", 0, 15], ["decreased weight gain", "PROBLEM", 28, 49], ["condemnation of tissues", "PROBLEM", 68, 91], ["the whole carcass", "PROBLEM", 95, 112], ["abscesses rupture", "PROBLEM", 148, 165], ["Clostridium perfringens", "PROBLEM", 181, 204], ["Clostridium perfringens", "PROBLEM", 204, 227], ["enteritis", "PROBLEM", 235, 244], ["dysentery", "PROBLEM", 246, 255], ["toxaemia", "PROBLEM", 257, 265], ["death", "PROBLEM", 270, 275], ["decreased", "OBSERVATION_MODIFIER", 28, 37], ["weight gain", "OBSERVATION", 38, 49], ["tissues", "ANATOMY", 84, 91], ["decreased", "OBSERVATION_MODIFIER", 117, 126], ["abscesses", "OBSERVATION", 148, 157], ["perfringens", "OBSERVATION", 193, 204], ["enteritis", "OBSERVATION", 235, 244], ["dysentery", "OBSERVATION_MODIFIER", 246, 255]]], ["Further discussion of Clostridium perfringens can be found in Microbiological safety of meat: Clostridium perfringens.CoccidiosisVarious genera of coccidia affect a wide variety of animals.", [["Clostridium perfringens", "DISEASE", 22, 45], ["Clostridium perfringens", "DISEASE", 94, 117], ["coccidia", "DISEASE", 147, 155], ["Clostridium perfringens", "ORGANISM", 22, 45], ["meat", "ORGANISM_SUBDIVISION", 88, 92], ["Clostridium perfringens", "ORGANISM", 94, 117], ["Clostridium perfringens", "SPECIES", 22, 45], ["Clostridium perfringens", "SPECIES", 94, 117], ["Clostridium perfringens", "SPECIES", 22, 45], ["Clostridium perfringens", "SPECIES", 94, 117], ["Clostridium perfringens", "PROBLEM", 22, 45], ["Clostridium perfringens", "PROBLEM", 94, 117], ["coccidia affect", "PROBLEM", 147, 162], ["Clostridium perfringens", "OBSERVATION", 94, 117], ["coccidia", "OBSERVATION", 147, 155], ["wide", "OBSERVATION_MODIFIER", 165, 169], ["variety", "OBSERVATION_MODIFIER", 170, 177]]], ["Clinical signs range from inapparent infection to depression, weight loss, haemorrhagic diarrhoea and death.", [["infection", "DISEASE", 37, 46], ["depression", "DISEASE", 50, 60], ["weight loss", "DISEASE", 62, 73], ["haemorrhagic diarrhoea", "DISEASE", 75, 97], ["death", "DISEASE", 102, 107], ["Clinical signs range", "TEST", 0, 20], ["inapparent infection", "PROBLEM", 26, 46], ["depression", "PROBLEM", 50, 60], ["weight loss", "PROBLEM", 62, 73], ["haemorrhagic diarrhoea", "PROBLEM", 75, 97], ["death", "PROBLEM", 102, 107], ["inapparent", "OBSERVATION_MODIFIER", 26, 36], ["infection", "OBSERVATION", 37, 46], ["haemorrhagic", "OBSERVATION_MODIFIER", 75, 87], ["diarrhoea", "OBSERVATION", 88, 97]]], ["In general, young animals are the most severely affected.", [["animals", "ORGANISM", 18, 25], ["most severely", "OBSERVATION_MODIFIER", 34, 47]]], ["In poultry, lesions may be seen upon careful examination of the intestinal tract, where thickening of the wall and whitish plaques or cysts may be seen.Duck Viral Enteritis (Duck Plague; Herpesvirus spp.)Clinical signs of this disease vary with the age and species of waterfowl infected and vary from listlessness, inappetence, nasal discharge, ataxia, decreased production and diarrhoea to acute death.", [["lesions", "ANATOMY", 12, 19], ["intestinal tract", "ANATOMY", 64, 80], ["wall", "ANATOMY", 106, 110], ["whitish plaques", "ANATOMY", 115, 130], ["cysts", "ANATOMY", 134, 139], ["nasal", "ANATOMY", 328, 333], ["plaques", "DISEASE", 123, 130], ["cysts", "DISEASE", 134, 139], ["Viral Enteritis", "DISEASE", 157, 172], ["Duck Plague", "DISEASE", 174, 185], ["waterfowl infected", "DISEASE", 268, 286], ["listlessness", "DISEASE", 301, 313], ["inappetence", "DISEASE", 315, 326], ["ataxia", "DISEASE", 345, 351], ["diarrhoea", "DISEASE", 378, 387], ["death", "DISEASE", 397, 402], ["lesions", "PATHOLOGICAL_FORMATION", 12, 19], ["intestinal tract", "ORGANISM_SUBDIVISION", 64, 80], ["wall", "TISSUE", 106, 110], ["whitish plaques", "PATHOLOGICAL_FORMATION", 115, 130], ["Duck Viral Enteritis", "ORGANISM", 152, 172], ["Duck Plague", "ORGANISM", 174, 185], ["Herpesvirus spp.", "ORGANISM", 187, 203], ["nasal", "ORGANISM_SUBDIVISION", 328, 333], ["Herpesvirus", "SPECIES", 187, 198], ["lesions", "PROBLEM", 12, 19], ["careful examination", "TEST", 37, 56], ["thickening of the wall", "PROBLEM", 88, 110], ["whitish plaques", "PROBLEM", 115, 130], ["cysts", "PROBLEM", 134, 139], ["Duck Viral Enteritis", "PROBLEM", 152, 172], ["this disease", "PROBLEM", 222, 234], ["waterfowl infected", "PROBLEM", 268, 286], ["listlessness", "PROBLEM", 301, 313], ["inappetence", "PROBLEM", 315, 326], ["nasal discharge", "PROBLEM", 328, 343], ["ataxia", "PROBLEM", 345, 351], ["decreased production", "PROBLEM", 353, 373], ["diarrhoea", "PROBLEM", 378, 387], ["acute death", "PROBLEM", 391, 402], ["lesions", "OBSERVATION", 12, 19], ["may be seen", "UNCERTAINTY", 20, 31], ["intestinal tract", "ANATOMY", 64, 80], ["thickening", "OBSERVATION", 88, 98], ["wall", "ANATOMY_MODIFIER", 106, 110], ["whitish", "OBSERVATION_MODIFIER", 115, 122], ["plaques", "OBSERVATION", 123, 130], ["cysts", "OBSERVATION", 134, 139], ["may be seen", "UNCERTAINTY", 140, 151], ["Viral Enteritis", "OBSERVATION", 157, 172], ["disease", "OBSERVATION", 227, 234], ["waterfowl", "OBSERVATION_MODIFIER", 268, 277], ["infected", "OBSERVATION", 278, 286], ["nasal", "ANATOMY", 328, 333]]], ["In general, haemorrhages can be found in the intestines, liver, pancreas, kidneys and lungs.", [["intestines", "ANATOMY", 45, 55], ["liver", "ANATOMY", 57, 62], ["pancreas", "ANATOMY", 64, 72], ["kidneys", "ANATOMY", 74, 81], ["lungs", "ANATOMY", 86, 91], ["haemorrhages", "DISEASE", 12, 24], ["haemorrhages", "PATHOLOGICAL_FORMATION", 12, 24], ["intestines", "ORGAN", 45, 55], ["liver", "ORGAN", 57, 62], ["pancreas", "ORGAN", 64, 72], ["kidneys", "ORGAN", 74, 81], ["lungs", "ORGAN", 86, 91], ["haemorrhages", "PROBLEM", 12, 24], ["haemorrhages", "OBSERVATION", 12, 24], ["intestines", "ANATOMY", 45, 55], ["liver", "ANATOMY", 57, 62], ["pancreas", "ANATOMY", 64, 72], ["kidneys", "ANATOMY", 74, 81], ["lungs", "ANATOMY", 86, 91]]], ["The lumens of the intestine and ventriculus (gizzard) are frequently blood-filled.Erysipelas (Erysipelothrix rhusiopathiae)Although erysipelas can affect a number of species, it is usually of significance only in swine, turkeys and humans.", [["lumens", "ANATOMY", 4, 10], ["intestine", "ANATOMY", 18, 27], ["ventriculus", "ANATOMY", 32, 43], ["gizzard", "ANATOMY", 45, 52], ["blood", "ANATOMY", 69, 74], ["erysipelas", "DISEASE", 132, 142], ["lumens", "MULTI-TISSUE_STRUCTURE", 4, 10], ["intestine", "ORGAN", 18, 27], ["ventriculus", "MULTI-TISSUE_STRUCTURE", 32, 43], ["gizzard", "ORGANISM_SUBDIVISION", 45, 52], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["Erysipelas", "SIMPLE_CHEMICAL", 82, 92], ["Erysipelothrix rhusiopathiae", "ORGANISM", 94, 122], ["turkeys", "ORGANISM", 220, 227], ["humans", "ORGANISM", 232, 238], ["Erysipelothrix rhusiopathiae", "SPECIES", 94, 122], ["swine", "SPECIES", 213, 218], ["turkeys", "SPECIES", 220, 227], ["humans", "SPECIES", 232, 238], ["swine", "SPECIES", 213, 218], ["turkeys", "SPECIES", 220, 227], ["humans", "SPECIES", 232, 238], ["Erysipelas (Erysipelothrix rhusiopathiae", "TREATMENT", 82, 122], ["erysipelas", "PROBLEM", 132, 142], ["lumens", "ANATOMY_MODIFIER", 4, 10], ["intestine", "ANATOMY", 18, 27], ["ventriculus", "ANATOMY", 32, 43], ["gizzard", "ANATOMY", 45, 52], ["filled", "OBSERVATION_MODIFIER", 75, 81], ["Erysipelothrix rhusiopathiae", "OBSERVATION", 94, 122], ["erysipelas", "OBSERVATION", 132, 142], ["species", "OBSERVATION", 166, 173]]], ["Swine suffer septicaemia and skin lesions.", [["skin lesions", "ANATOMY", 29, 41], ["septicaemia", "DISEASE", 13, 24], ["skin lesions", "DISEASE", 29, 41], ["skin lesions", "PATHOLOGICAL_FORMATION", 29, 41], ["Swine", "SPECIES", 0, 5], ["septicaemia", "PROBLEM", 13, 24], ["skin lesions", "PROBLEM", 29, 41], ["septicaemia", "OBSERVATION", 13, 24], ["skin", "ANATOMY", 29, 33], ["lesions", "OBSERVATION", 34, 41]]], ["The disease can range from chronic to acute or may be inapparent.", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11], ["chronic", "OBSERVATION_MODIFIER", 27, 34], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["may be", "UNCERTAINTY", 47, 53], ["inapparent", "OBSERVATION_MODIFIER", 54, 64]]], ["Clinical signs include fever, listlessness, inappetence, painful lameness and, in pregnant sows, abortion.", [["fever", "DISEASE", 23, 28], ["listlessness", "DISEASE", 30, 42], ["inappetence", "DISEASE", 44, 55], ["lameness", "DISEASE", 65, 73], ["abortion", "DISEASE", 97, 105], ["sows", "ORGANISM_SUBDIVISION", 91, 95], ["Clinical signs", "TEST", 0, 14], ["fever", "PROBLEM", 23, 28], ["listlessness", "PROBLEM", 30, 42], ["inappetence", "PROBLEM", 44, 55], ["painful lameness", "PROBLEM", 57, 73], ["abortion", "PROBLEM", 97, 105], ["fever", "OBSERVATION", 23, 28]]], ["Raised, firm, discoloured (pink to purple), urticarial (frequently diamond-shaped) skin lesions are characteristic.", [["skin lesions", "ANATOMY", 83, 95], ["urticarial", "DISEASE", 44, 54], ["skin lesions", "PATHOLOGICAL_FORMATION", 83, 95], ["urticarial (frequently diamond-shaped) skin lesions", "PROBLEM", 44, 95], ["firm", "OBSERVATION_MODIFIER", 8, 12], ["pink", "OBSERVATION_MODIFIER", 27, 31], ["to purple", "OBSERVATION_MODIFIER", 32, 41], ["urticarial", "OBSERVATION_MODIFIER", 44, 54], ["frequently diamond", "OBSERVATION_MODIFIER", 56, 74], ["shaped", "OBSERVATION_MODIFIER", 75, 81], ["skin", "ANATOMY", 83, 87], ["lesions", "OBSERVATION", 88, 95]]], ["In turkeys, erysipelas is associated with death and male sterility.", [["erysipelas", "DISEASE", 12, 22], ["death", "DISEASE", 42, 47], ["turkeys", "ORGANISM", 3, 10], ["turkeys", "SPECIES", 3, 10], ["turkeys", "SPECIES", 3, 10], ["erysipelas", "PROBLEM", 12, 22], ["death", "PROBLEM", 42, 47], ["erysipelas", "OBSERVATION", 12, 22]]], ["Clinical signs include listlessness, ataxia, weight loss, skin and snood lesions and death.", [["skin", "ANATOMY", 58, 62], ["snood lesions", "ANATOMY", 67, 80], ["listlessness", "DISEASE", 23, 35], ["ataxia", "DISEASE", 37, 43], ["weight loss", "DISEASE", 45, 56], ["skin and snood lesions", "DISEASE", 58, 80], ["death", "DISEASE", 85, 90], ["skin", "ORGAN", 58, 62], ["snood lesions", "PATHOLOGICAL_FORMATION", 67, 80], ["Clinical signs", "TEST", 0, 14], ["listlessness", "PROBLEM", 23, 35], ["ataxia", "PROBLEM", 37, 43], ["weight loss", "PROBLEM", 45, 56], ["skin and snood lesions", "PROBLEM", 58, 80], ["death", "PROBLEM", 85, 90], ["skin", "ANATOMY", 58, 62], ["snood", "ANATOMY", 67, 72], ["lesions", "OBSERVATION", 73, 80]]], ["Gross lesions in turkeys are related to septicaemia.", [["Gross lesions", "ANATOMY", 0, 13], ["septicaemia", "DISEASE", 40, 51], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["turkeys", "ORGANISM", 17, 24], ["turkeys", "SPECIES", 17, 24], ["turkeys", "SPECIES", 17, 24], ["Gross lesions in turkeys", "PROBLEM", 0, 24], ["septicaemia", "PROBLEM", 40, 51], ["lesions", "OBSERVATION", 6, 13], ["related to", "UNCERTAINTY", 29, 39], ["septicaemia", "OBSERVATION", 40, 51]]], ["In humans, erysipelas causes a local skin lesion and is associated with the handling of live swine and turkeys and the processing of meat, poultry or fish (where it is a contaminant).Fowl Cholera (Pasteurella multocida)The course of this disease is most often acute and fatal.", [["skin lesion", "ANATOMY", 37, 48], ["meat", "ANATOMY", 133, 137], ["erysipelas", "DISEASE", 11, 21], ["skin lesion", "DISEASE", 37, 48], ["Cholera", "DISEASE", 188, 195], ["humans", "ORGANISM", 3, 9], ["skin", "ORGAN", 37, 41], ["turkeys", "ORGANISM", 103, 110], ["meat", "ORGANISM_SUBDIVISION", 133, 137], ["fish", "ORGANISM_SUBDIVISION", 150, 154], ["Pasteurella multocida", "ORGANISM", 197, 218], ["humans", "SPECIES", 3, 9], ["swine", "SPECIES", 93, 98], ["turkeys", "SPECIES", 103, 110], ["Pasteurella multocida", "SPECIES", 197, 218], ["humans", "SPECIES", 3, 9], ["swine", "SPECIES", 93, 98], ["turkeys", "SPECIES", 103, 110], ["Pasteurella multocida", "SPECIES", 197, 218], ["erysipelas", "PROBLEM", 11, 21], ["a local skin lesion", "PROBLEM", 29, 48], ["Fowl Cholera (Pasteurella multocida", "PROBLEM", 183, 218], ["this disease", "PROBLEM", 233, 245], ["erysipelas", "OBSERVATION", 11, 21], ["local", "OBSERVATION_MODIFIER", 31, 36], ["skin", "ANATOMY", 37, 41], ["lesion", "OBSERVATION", 42, 48], ["disease", "OBSERVATION", 238, 245], ["most often", "UNCERTAINTY", 249, 259], ["acute", "OBSERVATION_MODIFIER", 260, 265], ["fatal", "OBSERVATION", 270, 275]]], ["Affected birds display fever, anorexia, depression, mucoid oral discharge, diarrhoea and respiratory distress.", [["oral", "ANATOMY", 59, 63], ["respiratory", "ANATOMY", 89, 100], ["fever", "DISEASE", 23, 28], ["anorexia", "DISEASE", 30, 38], ["depression", "DISEASE", 40, 50], ["diarrhoea", "DISEASE", 75, 84], ["respiratory distress", "DISEASE", 89, 109], ["birds", "ORGANISM", 9, 14], ["oral", "ORGANISM_SUBDIVISION", 59, 63], ["fever", "PROBLEM", 23, 28], ["anorexia", "PROBLEM", 30, 38], ["depression", "PROBLEM", 40, 50], ["mucoid oral discharge", "PROBLEM", 52, 73], ["diarrhoea", "PROBLEM", 75, 84], ["respiratory distress", "PROBLEM", 89, 109], ["fever", "OBSERVATION", 23, 28], ["anorexia", "OBSERVATION", 30, 38], ["mucoid", "OBSERVATION_MODIFIER", 52, 58], ["diarrhoea", "OBSERVATION", 75, 84], ["respiratory distress", "OBSERVATION", 89, 109]]], ["Acute death without any previously noted clinical signs is common.", [["death", "DISEASE", 6, 11], ["Acute death", "PROBLEM", 0, 11]]], ["Lesions are associated with vascular disturbances.", [["vascular", "ANATOMY", 28, 36], ["vascular disturbances", "DISEASE", 28, 49], ["vascular", "MULTI-TISSUE_STRUCTURE", 28, 36], ["Lesions", "PROBLEM", 0, 7], ["vascular disturbances", "PROBLEM", 28, 49], ["vascular", "ANATOMY", 28, 36], ["disturbances", "OBSERVATION", 37, 49]]], ["Frequently, congestion and haemorrhages are seen in the intestine, with increased levels of peritoneal and pericardial fluids.", [["intestine", "ANATOMY", 56, 65], ["peritoneal", "ANATOMY", 92, 102], ["pericardial fluids", "ANATOMY", 107, 125], ["congestion", "DISEASE", 12, 22], ["haemorrhages", "DISEASE", 27, 39], ["intestine", "ORGAN", 56, 65], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 92, 102], ["pericardial fluids", "PATHOLOGICAL_FORMATION", 107, 125], ["congestion", "PROBLEM", 12, 22], ["haemorrhages", "PROBLEM", 27, 39], ["increased levels of peritoneal and pericardial fluids", "PROBLEM", 72, 125], ["congestion", "OBSERVATION", 12, 22], ["haemorrhages", "OBSERVATION", 27, 39], ["intestine", "ANATOMY", 56, 65], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["levels", "OBSERVATION_MODIFIER", 82, 88], ["peritoneal", "ANATOMY", 92, 102], ["pericardial", "ANATOMY", 107, 118], ["fluids", "OBSERVATION", 119, 125]]], ["The liver may be swollen with many small areas of necrosis.", [["liver", "ANATOMY", 4, 9], ["necrosis", "DISEASE", 50, 58], ["liver", "ORGAN", 4, 9], ["swollen", "PROBLEM", 17, 24], ["necrosis", "PROBLEM", 50, 58], ["liver", "ANATOMY", 4, 9], ["may be", "UNCERTAINTY", 10, 16], ["swollen", "OBSERVATION", 17, 24], ["many", "OBSERVATION_MODIFIER", 30, 34], ["small", "OBSERVATION_MODIFIER", 35, 40], ["areas", "OBSERVATION_MODIFIER", 41, 46], ["necrosis", "OBSERVATION", 50, 58]]], ["In turkeys, pneumonia is common.Infectious Bovine Rhinotracheitis (Herpesvirus spp.)Clinical signs vary greatly with this disease depending on the strain of organism and age of the affected animal.", [["pneumonia", "DISEASE", 12, 21], ["Bovine Rhinotracheitis", "DISEASE", 43, 65], ["turkeys", "ORGANISM", 3, 10], ["Bovine Rhinotracheitis", "ORGANISM", 43, 65], ["Herpesvirus spp.", "ORGANISM", 67, 83], ["turkeys", "SPECIES", 3, 10], ["Bovine", "SPECIES", 43, 49], ["Herpesvirus spp.", "SPECIES", 67, 83], ["turkeys", "SPECIES", 3, 10], ["pneumonia", "PROBLEM", 12, 21], ["Infectious Bovine Rhinotracheitis (Herpesvirus spp.", "PROBLEM", 32, 83], ["Clinical signs", "PROBLEM", 84, 98], ["this disease", "PROBLEM", 117, 129], ["the strain of organism", "PROBLEM", 143, 165], ["pneumonia", "OBSERVATION", 12, 21], ["Rhinotracheitis", "OBSERVATION", 50, 65]]], ["Feedlot animals generally develop high fever, inappetence, lethargy, respiratory signs, nasal reddening and discharge, conjunctivitis and papules or ulcers on the nasal mucosa.", [["respiratory", "ANATOMY", 69, 80], ["nasal", "ANATOMY", 88, 93], ["papules", "ANATOMY", 138, 145], ["ulcers", "ANATOMY", 149, 155], ["nasal mucosa", "ANATOMY", 163, 175], ["fever", "DISEASE", 39, 44], ["inappetence", "DISEASE", 46, 57], ["lethargy", "DISEASE", 59, 67], ["respiratory signs", "DISEASE", 69, 86], ["nasal reddening", "DISEASE", 88, 103], ["conjunctivitis", "DISEASE", 119, 133], ["papules", "DISEASE", 138, 145], ["ulcers", "DISEASE", 149, 155], ["nasal", "ORGANISM_SUBDIVISION", 88, 93], ["papules", "PATHOLOGICAL_FORMATION", 138, 145], ["ulcers", "PATHOLOGICAL_FORMATION", 149, 155], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 163, 175], ["high fever", "PROBLEM", 34, 44], ["inappetence", "PROBLEM", 46, 57], ["lethargy", "PROBLEM", 59, 67], ["respiratory signs", "PROBLEM", 69, 86], ["nasal reddening", "PROBLEM", 88, 103], ["conjunctivitis", "PROBLEM", 119, 133], ["papules", "PROBLEM", 138, 145], ["ulcers on the nasal mucosa", "PROBLEM", 149, 175], ["high", "OBSERVATION_MODIFIER", 34, 38], ["fever", "OBSERVATION", 39, 44], ["respiratory", "ANATOMY", 69, 80], ["nasal", "ANATOMY", 88, 93], ["reddening", "OBSERVATION", 94, 103], ["conjunctivitis", "OBSERVATION", 119, 133], ["papules", "OBSERVATION", 138, 145], ["ulcers", "OBSERVATION", 149, 155], ["nasal mucosa", "ANATOMY", 163, 175]]], ["Breeding animals can abort or develop inflammation, pustules, erosions and ulcers on the prepuce and penis of males and the vulva and vagina of females.", [["pustules", "ANATOMY", 52, 60], ["ulcers", "ANATOMY", 75, 81], ["prepuce", "ANATOMY", 89, 96], ["penis", "ANATOMY", 101, 106], ["vulva", "ANATOMY", 124, 129], ["vagina", "ANATOMY", 134, 140], ["inflammation", "DISEASE", 38, 50], ["pustules", "DISEASE", 52, 60], ["erosions", "DISEASE", 62, 70], ["ulcers", "DISEASE", 75, 81], ["pustules", "PATHOLOGICAL_FORMATION", 52, 60], ["erosions", "PATHOLOGICAL_FORMATION", 62, 70], ["ulcers", "PATHOLOGICAL_FORMATION", 75, 81], ["prepuce", "ORGANISM_SUBDIVISION", 89, 96], ["penis", "ORGAN", 101, 106], ["vulva", "ORGAN", 124, 129], ["vagina", "ORGAN", 134, 140], ["inflammation", "PROBLEM", 38, 50], ["pustules", "PROBLEM", 52, 60], ["erosions", "PROBLEM", 62, 70], ["ulcers on the prepuce and penis of males and the vulva and vagina of females", "PROBLEM", 75, 151], ["inflammation", "OBSERVATION", 38, 50], ["pustules", "OBSERVATION", 52, 60], ["erosions", "OBSERVATION", 62, 70], ["ulcers", "OBSERVATION", 75, 81], ["prepuce", "ANATOMY", 89, 96], ["penis", "ANATOMY", 101, 106], ["males", "OBSERVATION", 110, 115], ["vulva", "ANATOMY", 124, 129], ["vagina", "ANATOMY", 134, 140], ["females", "OBSERVATION", 144, 151]]], ["Young animals frequently develop fever, ocular and nasal discharges, respiratory signs, diarrhoea and encephalitis.", [["ocular", "ANATOMY", 40, 46], ["nasal", "ANATOMY", 51, 56], ["respiratory", "ANATOMY", 69, 80], ["fever", "DISEASE", 33, 38], ["ocular and nasal discharges", "DISEASE", 40, 67], ["respiratory signs", "DISEASE", 69, 86], ["diarrhoea", "DISEASE", 88, 97], ["encephalitis", "DISEASE", 102, 114], ["ocular", "ORGANISM_SUBDIVISION", 40, 46], ["nasal", "ORGANISM_SUBDIVISION", 51, 56], ["fever", "PROBLEM", 33, 38], ["ocular and nasal discharges", "PROBLEM", 40, 67], ["respiratory signs", "PROBLEM", 69, 86], ["diarrhoea", "PROBLEM", 88, 97], ["encephalitis", "PROBLEM", 102, 114], ["fever", "OBSERVATION", 33, 38], ["ocular", "ANATOMY", 40, 46], ["nasal", "ANATOMY", 51, 56], ["discharges", "OBSERVATION", 57, 67], ["respiratory signs", "OBSERVATION", 69, 86], ["diarrhoea", "OBSERVATION", 88, 97], ["encephalitis", "OBSERVATION", 102, 114]]], ["Lesions also vary and may include inflammation, haemorrhage and necrotic foci in the respiratory tract, bronchopneumonia and erosions or ulcers in the nasal passages.Infectious Coryza (Haemophilus paragallinarium)This subacute or acute respiratory disease affects primarily chickens, causing depression, sneezing, rales, nasal discharge, and swelling under the eyes that may extend to all of the face and wattles.", [["necrotic foci", "ANATOMY", 64, 77], ["respiratory tract", "ANATOMY", 85, 102], ["ulcers", "ANATOMY", 137, 143], ["nasal", "ANATOMY", 151, 156], ["respiratory", "ANATOMY", 236, 247], ["nasal", "ANATOMY", 321, 326], ["eyes", "ANATOMY", 361, 365], ["face", "ANATOMY", 396, 400], ["wattles", "ANATOMY", 405, 412], ["inflammation", "DISEASE", 34, 46], ["haemorrhage", "DISEASE", 48, 59], ["necrotic", "DISEASE", 64, 72], ["bronchopneumonia", "DISEASE", 104, 120], ["erosions", "DISEASE", 125, 133], ["ulcers", "DISEASE", 137, 143], ["respiratory disease", "DISEASE", 236, 255], ["depression", "DISEASE", 292, 302], ["sneezing", "DISEASE", 304, 312], ["swelling", "DISEASE", 342, 350], ["respiratory tract", "ORGANISM_SUBDIVISION", 85, 102], ["erosions", "PATHOLOGICAL_FORMATION", 125, 133], ["ulcers", "PATHOLOGICAL_FORMATION", 137, 143], ["Haemophilus paragallinarium", "ORGANISM", 185, 212], ["chickens", "ORGANISM", 274, 282], ["nasal", "ORGANISM_SUBDIVISION", 321, 326], ["eyes", "ORGAN", 361, 365], ["face", "ORGANISM_SUBDIVISION", 396, 400], ["Haemophilus paragallinarium", "SPECIES", 185, 212], ["chickens", "SPECIES", 274, 282], ["Haemophilus paragallinarium", "SPECIES", 185, 212], ["chickens", "SPECIES", 274, 282], ["Lesions", "PROBLEM", 0, 7], ["inflammation", "PROBLEM", 34, 46], ["haemorrhage", "PROBLEM", 48, 59], ["necrotic foci in the respiratory tract", "PROBLEM", 64, 102], ["bronchopneumonia", "PROBLEM", 104, 120], ["erosions", "PROBLEM", 125, 133], ["ulcers in the nasal passages", "PROBLEM", 137, 165], ["Infectious Coryza (Haemophilus paragallinarium)", "PROBLEM", 166, 213], ["acute respiratory disease", "PROBLEM", 230, 255], ["depression", "PROBLEM", 292, 302], ["sneezing", "PROBLEM", 304, 312], ["rales", "PROBLEM", 314, 319], ["nasal discharge", "PROBLEM", 321, 336], ["swelling under the eyes", "PROBLEM", 342, 365], ["may include", "UNCERTAINTY", 22, 33], ["inflammation", "OBSERVATION", 34, 46], ["haemorrhage", "OBSERVATION", 48, 59], ["necrotic", "OBSERVATION_MODIFIER", 64, 72], ["foci", "OBSERVATION", 73, 77], ["respiratory tract", "ANATOMY", 85, 102], ["bronchopneumonia", "OBSERVATION", 104, 120], ["erosions", "OBSERVATION", 125, 133], ["ulcers", "OBSERVATION", 137, 143], ["nasal", "ANATOMY", 151, 156], ["passages", "OBSERVATION", 157, 165], ["subacute", "OBSERVATION_MODIFIER", 218, 226], ["acute", "OBSERVATION_MODIFIER", 230, 235], ["respiratory disease", "OBSERVATION", 236, 255], ["sneezing", "OBSERVATION", 304, 312], ["rales", "OBSERVATION", 314, 319], ["nasal", "ANATOMY", 321, 326], ["discharge", "OBSERVATION", 327, 336], ["swelling", "OBSERVATION", 342, 350], ["eyes", "ANATOMY", 361, 365], ["face", "ANATOMY", 396, 400]]], ["Egg production is greatly curtailed.", [["Egg", "SIMPLE_CHEMICAL", 0, 3], ["greatly", "OBSERVATION_MODIFIER", 18, 25], ["curtailed", "OBSERVATION_MODIFIER", 26, 35]]], ["Gross lesions consist of sinusitis and may include conjunctivitis, tracheitis, bronchitis and airsacculitis.InfluenzaInfection with type A influenza viruses is a problem for swine, poultry and humans.", [["Gross lesions", "ANATOMY", 0, 13], ["sinusitis", "DISEASE", 25, 34], ["conjunctivitis", "DISEASE", 51, 65], ["tracheitis", "DISEASE", 67, 77], ["bronchitis", "DISEASE", 79, 89], ["airsacculitis", "DISEASE", 94, 107], ["InfluenzaInfection", "DISEASE", 108, 126], ["type A influenza viruses", "DISEASE", 132, 156], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["type A influenza viruses", "ORGANISM", 132, 156], ["swine", "ORGANISM", 174, 179], ["humans", "ORGANISM", 193, 199], ["A influenza viruses", "SPECIES", 137, 156], ["swine", "SPECIES", 174, 179], ["humans", "SPECIES", 193, 199], ["type A influenza viruses", "SPECIES", 132, 156], ["swine", "SPECIES", 174, 179], ["humans", "SPECIES", 193, 199], ["Gross lesions", "PROBLEM", 0, 13], ["sinusitis", "PROBLEM", 25, 34], ["conjunctivitis", "PROBLEM", 51, 65], ["tracheitis", "PROBLEM", 67, 77], ["bronchitis", "PROBLEM", 79, 89], ["airsacculitis", "PROBLEM", 94, 107], ["InfluenzaInfection", "PROBLEM", 108, 126], ["type A influenza viruses", "PROBLEM", 132, 156], ["lesions", "OBSERVATION", 6, 13], ["sinusitis", "OBSERVATION", 25, 34], ["may include", "UNCERTAINTY", 39, 50], ["conjunctivitis", "OBSERVATION", 51, 65], ["tracheitis", "OBSERVATION", 67, 77], ["bronchitis", "OBSERVATION", 79, 89]]], ["This disease is characterized by a sudden onset of fever, coughing, sneezing, respiratory distress and listlessness, with the affected animals either recovering or dying, quickly.", [["respiratory", "ANATOMY", 78, 89], ["fever", "DISEASE", 51, 56], ["coughing", "DISEASE", 58, 66], ["sneezing", "DISEASE", 68, 76], ["respiratory distress", "DISEASE", 78, 98], ["listlessness", "DISEASE", 103, 115], ["This disease", "PROBLEM", 0, 12], ["fever", "PROBLEM", 51, 56], ["coughing", "PROBLEM", 58, 66], ["sneezing", "PROBLEM", 68, 76], ["respiratory distress", "PROBLEM", 78, 98], ["listlessness", "PROBLEM", 103, 115], ["the affected animals", "PROBLEM", 122, 142], ["disease", "OBSERVATION", 5, 12], ["fever", "OBSERVATION", 51, 56], ["coughing", "OBSERVATION", 58, 66], ["respiratory distress", "OBSERVATION", 78, 98]]], ["Gross lesions in poultry include sinusitis, periocular oedema and cyanosis, diphtheritic plaques in the trachea, and haemorrhages in the proventriculus, small intestine and cloaca.", [["Gross lesions", "ANATOMY", 0, 13], ["sinusitis", "ANATOMY", 33, 42], ["periocular", "ANATOMY", 44, 54], ["diphtheritic plaques", "ANATOMY", 76, 96], ["trachea", "ANATOMY", 104, 111], ["proventriculus", "ANATOMY", 137, 151], ["small intestine", "ANATOMY", 153, 168], ["cloaca", "ANATOMY", 173, 179], ["sinusitis", "DISEASE", 33, 42], ["periocular oedema", "DISEASE", 44, 61], ["cyanosis", "DISEASE", 66, 74], ["diphtheritic plaques", "DISEASE", 76, 96], ["haemorrhages", "DISEASE", 117, 129], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["periocular oedema", "PATHOLOGICAL_FORMATION", 44, 61], ["trachea", "ORGAN", 104, 111], ["proventriculus", "ORGAN", 137, 151], ["small intestine", "ORGAN", 153, 168], ["cloaca", "ORGAN", 173, 179], ["Gross lesions in poultry", "PROBLEM", 0, 24], ["sinusitis", "PROBLEM", 33, 42], ["periocular oedema", "PROBLEM", 44, 61], ["cyanosis", "PROBLEM", 66, 74], ["diphtheritic plaques in the trachea", "PROBLEM", 76, 111], ["haemorrhages in the proventriculus", "PROBLEM", 117, 151], ["small intestine and cloaca", "PROBLEM", 153, 179], ["lesions", "OBSERVATION", 6, 13], ["poultry", "OBSERVATION_MODIFIER", 17, 24], ["sinusitis", "OBSERVATION", 33, 42], ["periocular", "ANATOMY", 44, 54], ["oedema", "OBSERVATION", 55, 61], ["cyanosis", "OBSERVATION", 66, 74], ["diphtheritic", "OBSERVATION_MODIFIER", 76, 88], ["plaques", "OBSERVATION", 89, 96], ["trachea", "ANATOMY", 104, 111], ["haemorrhages", "OBSERVATION", 117, 129], ["proventriculus", "ANATOMY", 137, 151], ["small", "OBSERVATION_MODIFIER", 153, 158], ["intestine", "ANATOMY", 159, 168], ["cloaca", "ANATOMY", 173, 179]]], ["Economic losses are incurred through loss of weight during illness, reproductive problems (abortions in swine; loss of egg production in poultry) and deaths.", [["egg", "ANATOMY", 119, 122], ["loss of weight during illness", "DISEASE", 37, 66], ["abortions", "DISEASE", 91, 100], ["deaths", "DISEASE", 150, 156], ["egg", "ORGANISM_SUBDIVISION", 119, 122], ["swine", "SPECIES", 104, 109], ["swine", "SPECIES", 104, 109], ["Economic losses", "PROBLEM", 0, 15], ["loss of weight during illness", "PROBLEM", 37, 66], ["reproductive problems", "PROBLEM", 68, 89], ["loss of egg production", "PROBLEM", 111, 133], ["losses", "OBSERVATION", 9, 15]]], ["Poultry, especially chickens, have suffered far greater losses than swine.InfluenzaIn recent years, this disease has taken on additional significance as it has become apparent that poultry and swine play an important role in the reassortment of genetic material and the development of influenza strains that affect humans.Mycobacterium avium subsp. paratuberculosis)Clinical disease is rarely seen in young animals.", [["influenza", "DISEASE", 285, 294], ["chickens", "ORGANISM", 20, 28], ["influenza strains", "ORGANISM", 285, 302], ["humans", "ORGANISM", 315, 321], ["Mycobacterium avium", "ORGANISM", 322, 341], ["paratuberculosis", "ORGANISM", 349, 365], ["chickens", "SPECIES", 20, 28], ["swine", "SPECIES", 68, 73], ["swine", "SPECIES", 193, 198], ["humans", "SPECIES", 315, 321], ["Mycobacterium avium", "SPECIES", 322, 341], ["subsp", "SPECIES", 342, 347], ["paratuberculosis", "SPECIES", 349, 365], ["chickens", "SPECIES", 20, 28], ["swine", "SPECIES", 68, 73], ["swine", "SPECIES", 193, 198], ["humans", "SPECIES", 315, 321], ["Mycobacterium avium", "SPECIES", 322, 341], ["paratuberculosis", "SPECIES", 349, 365], ["this disease", "PROBLEM", 100, 112], ["influenza strains", "PROBLEM", 285, 302], ["Mycobacterium avium subsp", "PROBLEM", 322, 347], ["paratuberculosis", "PROBLEM", 349, 365], ["Clinical disease", "PROBLEM", 366, 382], ["greater", "OBSERVATION_MODIFIER", 48, 55], ["losses", "OBSERVATION", 56, 62], ["influenza", "OBSERVATION", 285, 294], ["disease", "OBSERVATION", 375, 382]]], ["Affected animals show progressive weight loss leading to emaciation and death.", [["weight loss", "DISEASE", 34, 45], ["emaciation", "DISEASE", 57, 67], ["death", "DISEASE", 72, 77], ["Affected animals", "PROBLEM", 0, 16], ["progressive weight loss", "PROBLEM", 22, 45], ["emaciation", "PROBLEM", 57, 67], ["death", "PROBLEM", 72, 77], ["progressive", "OBSERVATION_MODIFIER", 22, 33], ["weight loss", "OBSERVATION", 34, 45]]], ["The weight loss caused by the accordian-like, corrugated thickening of the intestinal wall and mucosa is accompanied by a profuse diarrhoea.", [["intestinal wall", "ANATOMY", 75, 90], ["mucosa", "ANATOMY", 95, 101], ["weight loss", "DISEASE", 4, 15], ["diarrhoea", "DISEASE", 130, 139], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 75, 90], ["mucosa", "MULTI-TISSUE_STRUCTURE", 95, 101], ["The weight loss", "PROBLEM", 0, 15], ["corrugated thickening of the intestinal wall and mucosa", "PROBLEM", 46, 101], ["a profuse diarrhoea", "PROBLEM", 120, 139], ["weight loss", "OBSERVATION", 4, 15], ["corrugated", "OBSERVATION_MODIFIER", 46, 56], ["thickening", "OBSERVATION", 57, 67], ["intestinal wall", "ANATOMY", 75, 90], ["mucosa", "ANATOMY", 95, 101], ["profuse", "OBSERVATION_MODIFIER", 122, 129], ["diarrhoea", "OBSERVATION", 130, 139]]], ["This disease in goats has a somewhat different appearance as usually only a focal or diffuse thickening of intestinal walls is seen.", [["intestinal walls", "ANATOMY", 107, 123], ["goats", "ORGANISM", 16, 21], ["intestinal walls", "PATHOLOGICAL_FORMATION", 107, 123], ["goats", "SPECIES", 16, 21], ["goats", "SPECIES", 16, 21], ["This disease in goats", "PROBLEM", 0, 21], ["a focal or diffuse thickening of intestinal walls", "PROBLEM", 74, 123], ["disease", "OBSERVATION", 5, 12], ["somewhat different", "OBSERVATION_MODIFIER", 28, 46], ["focal", "OBSERVATION_MODIFIER", 76, 81], ["diffuse", "OBSERVATION_MODIFIER", 85, 92], ["thickening", "OBSERVATION", 93, 103], ["intestinal walls", "ANATOMY", 107, 123]]], ["Diarrhoea is rare in goats.", [["Diarrhoea", "DISEASE", 0, 9], ["goats", "ORGANISM", 21, 26], ["goats", "SPECIES", 21, 26], ["goats", "SPECIES", 21, 26], ["Diarrhoea", "PROBLEM", 0, 9], ["rare", "OBSERVATION_MODIFIER", 13, 17]]], ["Losses occur through decreased productivity and the eventual death of affected animals.Laryngotracheitis (Herpesvirus spp.)This acute upper respiratory disease of chickens is characterized by nasal discharge, gasping, coughing with expulsion of bloody exudates, respiratory distress and death.", [["respiratory", "ANATOMY", 140, 151], ["nasal", "ANATOMY", 192, 197], ["respiratory", "ANATOMY", 262, 273], ["Losses", "DISEASE", 0, 6], ["death", "DISEASE", 61, 66], ["upper respiratory disease", "DISEASE", 134, 159], ["coughing", "DISEASE", 218, 226], ["respiratory distress", "DISEASE", 262, 282], ["death", "DISEASE", 287, 292], ["Laryngotracheitis", "ORGANISM", 87, 104], ["Herpesvirus spp.", "ORGANISM", 106, 122], ["chickens", "ORGANISM", 163, 171], ["nasal", "ORGANISM_SUBDIVISION", 192, 197], ["Herpesvirus spp.", "SPECIES", 106, 122], ["chickens", "SPECIES", 163, 171], ["chickens", "SPECIES", 163, 171], ["decreased productivity", "PROBLEM", 21, 43], ["affected animals", "PROBLEM", 70, 86], ["Laryngotracheitis (Herpesvirus spp.", "PROBLEM", 87, 122], ["This acute upper respiratory disease of chickens", "PROBLEM", 123, 171], ["nasal discharge", "PROBLEM", 192, 207], ["gasping", "PROBLEM", 209, 216], ["coughing", "PROBLEM", 218, 226], ["bloody exudates", "PROBLEM", 245, 260], ["respiratory distress", "PROBLEM", 262, 282], ["death", "PROBLEM", 287, 292], ["decreased", "OBSERVATION_MODIFIER", 21, 30], ["productivity", "OBSERVATION_MODIFIER", 31, 43], ["Herpesvirus spp.", "OBSERVATION", 106, 122], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["upper", "ANATOMY_MODIFIER", 134, 139], ["respiratory", "ANATOMY", 140, 151], ["disease", "OBSERVATION", 152, 159], ["chickens", "OBSERVATION", 163, 171], ["nasal", "ANATOMY", 192, 197], ["discharge", "OBSERVATION", 198, 207], ["respiratory distress", "OBSERVATION", 262, 282]]], ["The trachea and larynx are inflamed and oedematous.", [["trachea", "ANATOMY", 4, 11], ["larynx", "ANATOMY", 16, 22], ["trachea", "MULTI-TISSUE_STRUCTURE", 4, 11], ["larynx", "ORGAN", 16, 22], ["inflamed", "PROBLEM", 27, 35], ["oedematous", "PROBLEM", 40, 50], ["trachea", "ANATOMY", 4, 11], ["larynx", "ANATOMY", 16, 22], ["inflamed", "OBSERVATION", 27, 35], ["oedematous", "OBSERVATION", 40, 50]]], ["In more severe cases, there is haemorrhage and necrosis of the trachea and larynx.", [["trachea", "ANATOMY", 63, 70], ["larynx", "ANATOMY", 75, 81], ["haemorrhage", "DISEASE", 31, 42], ["necrosis", "DISEASE", 47, 55], ["trachea", "ORGAN", 63, 70], ["larynx", "ORGAN", 75, 81], ["haemorrhage", "PROBLEM", 31, 42], ["necrosis of the trachea and larynx", "PROBLEM", 47, 81], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["cases", "OBSERVATION", 15, 20], ["haemorrhage", "OBSERVATION", 31, 42], ["necrosis", "OBSERVATION", 47, 55], ["trachea", "ANATOMY", 63, 70], ["larynx", "ANATOMY", 75, 81]]], ["Inflammation may extend to the bronchi, lungs and air sacs.Leptospirosis (Leptospira interrogans multiple serotypes)Leptospira are in the tissues and urine of infected animals and can survive for months outside a host.", [["bronchi", "ANATOMY", 31, 38], ["lungs", "ANATOMY", 40, 45], ["air sacs", "ANATOMY", 50, 58], ["tissues", "ANATOMY", 138, 145], ["urine", "ANATOMY", 150, 155], ["Inflammation", "DISEASE", 0, 12], ["Leptospirosis", "DISEASE", 59, 72], ["bronchi", "MULTI-TISSUE_STRUCTURE", 31, 38], ["lungs", "ORGAN", 40, 45], ["air sacs", "MULTI-TISSUE_STRUCTURE", 50, 58], ["Leptospira interrogans multiple serotypes", "ORGANISM", 74, 115], ["Leptospira", "ORGANISM", 116, 126], ["tissues", "TISSUE", 138, 145], ["urine", "ORGANISM_SUBSTANCE", 150, 155], ["Leptospira interrogans", "SPECIES", 74, 96], ["Leptospira interrogans", "SPECIES", 74, 96], ["Inflammation", "PROBLEM", 0, 12], ["Leptospirosis (Leptospira interrogans multiple serotypes", "PROBLEM", 59, 115], ["Leptospira", "PROBLEM", 116, 126], ["bronchi", "ANATOMY", 31, 38], ["lungs", "ANATOMY", 40, 45], ["air sacs", "OBSERVATION", 50, 58], ["tissues", "ANATOMY", 138, 145], ["infected", "OBSERVATION", 159, 167]]], ["Infection occurs in animals and humans when the agent contacts abraded skin or the mucous membranes of the mouth, nose or eye.", [["skin", "ANATOMY", 71, 75], ["mucous membranes", "ANATOMY", 83, 99], ["mouth", "ANATOMY", 107, 112], ["nose", "ANATOMY", 114, 118], ["eye", "ANATOMY", 122, 125], ["humans", "ORGANISM", 32, 38], ["skin", "ORGAN", 71, 75], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 83, 99], ["mouth", "ORGANISM_SUBDIVISION", 107, 112], ["nose", "ORGANISM_SUBDIVISION", 114, 118], ["eye", "ORGAN", 122, 125], ["humans", "SPECIES", 32, 38], ["humans", "SPECIES", 32, 38], ["Infection", "PROBLEM", 0, 9], ["skin", "ANATOMY", 71, 75], ["mucous membranes", "ANATOMY", 83, 99], ["mouth", "ANATOMY", 107, 112], ["nose", "ANATOMY", 114, 118], ["eye", "ANATOMY", 122, 125]]], ["Clinical signs include fever, anaemia, icterus, blood in the urine, abortion and, occasionally, death.", [["blood", "ANATOMY", 48, 53], ["urine", "ANATOMY", 61, 66], ["fever", "DISEASE", 23, 28], ["anaemia", "DISEASE", 30, 37], ["icterus, blood in the urine", "DISEASE", 39, 66], ["abortion", "DISEASE", 68, 76], ["death", "DISEASE", 96, 101], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["urine", "ORGANISM_SUBSTANCE", 61, 66], ["Clinical signs", "TEST", 0, 14], ["fever", "PROBLEM", 23, 28], ["anaemia", "PROBLEM", 30, 37], ["icterus", "PROBLEM", 39, 46], ["blood in the urine", "PROBLEM", 48, 66], ["abortion", "PROBLEM", 68, 76], ["fever", "OBSERVATION", 23, 28], ["anaemia", "OBSERVATION", 30, 37], ["icterus", "OBSERVATION", 39, 46], ["urine", "ANATOMY", 61, 66]]], ["Chronically infected animals may show no signs other than slow weight gain.", [["weight gain", "DISEASE", 63, 74], ["animals", "ORGANISM", 21, 28], ["Chronically infected animals", "PROBLEM", 0, 28], ["slow weight gain", "PROBLEM", 58, 74], ["infected", "OBSERVATION", 12, 20], ["no signs", "UNCERTAINTY", 38, 46]]], ["Gross lesions include haemorrhages on the surface of the abdominal organs, heart and lungs.Listeria (Circling Disease; Listeria monocytogenes)Listeria affects a wide range of animals, most often cattle and sheep.", [["Gross lesions", "ANATOMY", 0, 13], ["surface", "ANATOMY", 42, 49], ["abdominal organs", "ANATOMY", 57, 73], ["heart", "ANATOMY", 75, 80], ["lungs", "ANATOMY", 85, 90], ["haemorrhages", "DISEASE", 22, 34], ["Listeria", "CHEMICAL", 91, 99], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["surface", "CELLULAR_COMPONENT", 42, 49], ["abdominal organs", "MULTI-TISSUE_STRUCTURE", 57, 73], ["heart", "ORGAN", 75, 80], ["lungs", "ORGAN", 85, 90], ["Listeria", "ORGANISM", 91, 99], ["Circling Disease; Listeria monocytogenes", "ORGANISM", 101, 141], ["cattle", "ORGANISM", 195, 201], ["sheep", "ORGANISM", 206, 211], ["Listeria monocytogenes", "SPECIES", 119, 141], ["cattle", "SPECIES", 195, 201], ["sheep", "SPECIES", 206, 211], ["Listeria monocytogenes", "SPECIES", 119, 141], ["cattle", "SPECIES", 195, 201], ["sheep", "SPECIES", 206, 211], ["Gross lesions", "PROBLEM", 0, 13], ["haemorrhages", "PROBLEM", 22, 34], ["Listeria (Circling Disease", "PROBLEM", 91, 117], ["Listeria monocytogenes", "PROBLEM", 119, 141], ["Listeria", "PROBLEM", 142, 150], ["lesions", "OBSERVATION", 6, 13], ["haemorrhages", "OBSERVATION", 22, 34], ["surface", "ANATOMY_MODIFIER", 42, 49], ["abdominal", "ANATOMY_MODIFIER", 57, 66], ["organs", "ANATOMY", 67, 73], ["heart", "ANATOMY", 75, 80], ["lungs", "ANATOMY", 85, 90], ["Circling Disease", "OBSERVATION", 101, 117], ["Listeria monocytogenes", "OBSERVATION", 119, 141], ["wide range", "OBSERVATION_MODIFIER", 161, 171]]], ["Neurological disturbances, most notably walking in a circle, but also abortions, septicaemia and death, may be seen with this disease.", [["Neurological", "ANATOMY", 0, 12], ["Neurological disturbances", "DISEASE", 0, 25], ["abortions", "DISEASE", 70, 79], ["septicaemia", "DISEASE", 81, 92], ["death", "DISEASE", 97, 102], ["Neurological disturbances", "PROBLEM", 0, 25], ["septicaemia", "PROBLEM", 81, 92], ["death", "PROBLEM", 97, 102], ["this disease", "PROBLEM", 121, 133], ["septicaemia", "OBSERVATION", 81, 92], ["may be seen", "UNCERTAINTY", 104, 115]]], ["More information on Listeria monocytogenes, the causative agent of this disease, can be found in Microbiological safety of meat: Listeria monocytogenes.Lymphoid Leukosis (Retroviridae family)Whitish nodules in the bursa, liver, spleen, kidney, and occasionally in the heart, gonads and pancreas, are typically seen with this disease.", [["Lymphoid", "ANATOMY", 152, 160], ["nodules", "ANATOMY", 199, 206], ["bursa", "ANATOMY", 214, 219], ["liver", "ANATOMY", 221, 226], ["spleen", "ANATOMY", 228, 234], ["kidney", "ANATOMY", 236, 242], ["heart", "ANATOMY", 268, 273], ["gonads", "ANATOMY", 275, 281], ["pancreas", "ANATOMY", 286, 294], ["Listeria monocytogenes", "ORGANISM", 20, 42], ["meat", "ORGANISM_SUBDIVISION", 123, 127], ["Listeria monocytogenes", "ORGANISM", 129, 151], ["Lymphoid Leukosis", "CANCER", 152, 169], ["Retroviridae", "GENE_OR_GENE_PRODUCT", 171, 183], ["Whitish nodules", "CANCER", 191, 206], ["bursa", "ORGAN", 214, 219], ["liver", "ORGAN", 221, 226], ["spleen", "ORGAN", 228, 234], ["kidney", "ORGAN", 236, 242], ["heart", "ORGAN", 268, 273], ["gonads", "ORGAN", 275, 281], ["pancreas", "ORGAN", 286, 294], ["Listeria monocytogenes", "SPECIES", 20, 42], ["Listeria monocytogenes", "SPECIES", 129, 151], ["Listeria monocytogenes", "SPECIES", 20, 42], ["Listeria monocytogenes", "SPECIES", 129, 151], ["Listeria monocytogenes", "PROBLEM", 20, 42], ["this disease", "PROBLEM", 67, 79], ["Listeria monocytogenes", "PROBLEM", 129, 151], ["Lymphoid Leukosis", "PROBLEM", 152, 169], ["Whitish nodules in the bursa, liver, spleen, kidney, and occasionally in the heart, gonads and pancreas", "PROBLEM", 191, 294], ["this disease", "PROBLEM", 320, 332], ["Listeria monocytogenes", "OBSERVATION", 129, 151], ["Leukosis", "OBSERVATION", 161, 169], ["Whitish", "OBSERVATION_MODIFIER", 191, 198], ["nodules", "OBSERVATION", 199, 206], ["bursa", "ANATOMY", 214, 219], ["liver", "ANATOMY", 221, 226], ["spleen", "ANATOMY", 228, 234], ["kidney", "ANATOMY", 236, 242], ["heart", "ANATOMY", 268, 273], ["gonads", "ANATOMY", 275, 281], ["pancreas", "ANATOMY", 286, 294], ["disease", "OBSERVATION", 325, 332]]], ["These nodules grossly resemble those seen with Marek's disease, although lesions seldom are seen in birds <16 weeks of age, whereas Marek's can affect birds as young as 3-4 weeks old.LymphosarcomaLymphosarcoma is caused by a virus in cattle, while the cause in other species is unknown.", [["nodules", "ANATOMY", 6, 13], ["lesions", "ANATOMY", 73, 80], ["Marek's disease", "DISEASE", 47, 62], ["LymphosarcomaLymphosarcoma", "DISEASE", 183, 209], ["nodules", "CANCER", 6, 13], ["lesions", "PATHOLOGICAL_FORMATION", 73, 80], ["Marek", "ORGANISM", 132, 137], ["birds", "ORGANISM", 151, 156], ["cattle", "ORGANISM", 234, 240], ["cattle", "SPECIES", 234, 240], ["Marek", "SPECIES", 132, 137], ["cattle", "SPECIES", 234, 240], ["These nodules", "PROBLEM", 0, 13], ["Marek's disease", "PROBLEM", 47, 62], ["lesions seldom", "PROBLEM", 73, 87], ["LymphosarcomaLymphosarcoma", "PROBLEM", 183, 209], ["a virus in cattle", "PROBLEM", 223, 240], ["nodules", "OBSERVATION", 6, 13], ["disease", "OBSERVATION", 55, 62], ["lesions", "OBSERVATION", 73, 80], ["virus", "OBSERVATION", 225, 230]]], ["Clinical signs of lymphosarcoma include greatly enlarged lymph nodes that bulge from the cut surface.Malignant Catarrhal Fever (Herpesvirus spp.)This disease can be caused by two or more different alcelaphine herpes viruses (AHV).This disease primarily affects cattle and deer that are exposed to either sheep (AHV-2) or wildebeests (AHV-1) that carry the infective agent.", [["lymphosarcoma", "ANATOMY", 18, 31], ["lymph nodes", "ANATOMY", 57, 68], ["surface", "ANATOMY", 93, 100], ["lymphosarcoma", "DISEASE", 18, 31], ["Malignant Catarrhal Fever", "DISEASE", 101, 126], ["alcelaphine herpes viruses", "DISEASE", 197, 223], ["lymphosarcoma", "CANCER", 18, 31], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 57, 68], ["surface", "CELLULAR_COMPONENT", 93, 100], ["Herpesvirus spp.", "ORGANISM", 128, 144], ["alcelaphine herpes viruses", "ORGANISM", 197, 223], ["AHV", "CANCER", 225, 228], ["cattle", "ORGANISM", 261, 267], ["deer", "ORGANISM", 272, 276], ["sheep", "ORGANISM", 304, 309], ["AHV-2", "ORGANISM", 311, 316], ["AHV-1", "ORGANISM", 334, 339], ["cattle", "SPECIES", 261, 267], ["deer", "SPECIES", 272, 276], ["sheep", "SPECIES", 304, 309], ["AHV", "SPECIES", 225, 228], ["cattle", "SPECIES", 261, 267], ["deer", "SPECIES", 272, 276], ["sheep", "SPECIES", 304, 309], ["AHV-1", "SPECIES", 334, 339], ["lymphosarcoma", "PROBLEM", 18, 31], ["greatly enlarged lymph nodes", "PROBLEM", 40, 68], ["Malignant Catarrhal Fever (Herpesvirus spp.", "PROBLEM", 101, 144], ["This disease", "PROBLEM", 145, 157], ["different alcelaphine herpes viruses", "PROBLEM", 187, 223], ["This disease", "PROBLEM", 230, 242], ["the infective agent", "TREATMENT", 352, 371], ["lymphosarcoma", "OBSERVATION", 18, 31], ["greatly", "OBSERVATION_MODIFIER", 40, 47], ["enlarged", "OBSERVATION_MODIFIER", 48, 56], ["lymph nodes", "OBSERVATION", 57, 68], ["bulge", "OBSERVATION_MODIFIER", 74, 79], ["cut", "OBSERVATION_MODIFIER", 89, 92], ["surface", "OBSERVATION_MODIFIER", 93, 100], ["disease", "OBSERVATION", 150, 157], ["herpes viruses", "OBSERVATION", 209, 223], ["disease", "OBSERVATION", 235, 242], ["infective", "OBSERVATION", 356, 365]]], ["Infected cattle and deer develop a high fever, depression, swollen lymph nodes, serous discharges from the eyes and nose, erosions in the mouth, diarrhoea and death.", [["lymph nodes", "ANATOMY", 67, 78], ["serous", "ANATOMY", 80, 86], ["eyes", "ANATOMY", 107, 111], ["nose", "ANATOMY", 116, 120], ["mouth", "ANATOMY", 138, 143], ["fever", "DISEASE", 40, 45], ["depression", "DISEASE", 47, 57], ["erosions in the mouth", "DISEASE", 122, 143], ["diarrhoea", "DISEASE", 145, 154], ["death", "DISEASE", 159, 164], ["cattle", "ORGANISM", 9, 15], ["deer", "ORGANISM", 20, 24], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 67, 78], ["serous", "ORGANISM_SUBSTANCE", 80, 86], ["eyes", "ORGAN", 107, 111], ["nose", "ORGANISM_SUBDIVISION", 116, 120], ["mouth", "ORGANISM_SUBDIVISION", 138, 143], ["cattle", "SPECIES", 9, 15], ["deer", "SPECIES", 20, 24], ["cattle", "SPECIES", 9, 15], ["deer", "SPECIES", 20, 24], ["a high fever", "PROBLEM", 33, 45], ["depression", "PROBLEM", 47, 57], ["swollen lymph nodes", "PROBLEM", 59, 78], ["serous discharges from the eyes and nose", "PROBLEM", 80, 120], ["erosions in the mouth", "PROBLEM", 122, 143], ["diarrhoea", "PROBLEM", 145, 154], ["death", "PROBLEM", 159, 164], ["high", "OBSERVATION_MODIFIER", 35, 39], ["fever", "OBSERVATION", 40, 45], ["swollen", "OBSERVATION_MODIFIER", 59, 66], ["lymph nodes", "OBSERVATION", 67, 78], ["serous discharges", "OBSERVATION", 80, 97], ["eyes", "ANATOMY", 107, 111], ["nose", "ANATOMY", 116, 120], ["erosions", "OBSERVATION", 122, 130], ["mouth", "ANATOMY", 138, 143], ["diarrhoea", "OBSERVATION", 145, 154]]], ["Lesions include necrosis of the epithelium of the gastrointestinal, respiratory and/or urinary tracts.Malignant Oedema (Clostridium septicum)Malignant oedema results from contaminating a wound with a Clostridium sp., most commonly Cl. septicum.", [["epithelium", "ANATOMY", 32, 42], ["gastrointestinal", "ANATOMY", 50, 66], ["respiratory", "ANATOMY", 68, 79], ["urinary tracts", "ANATOMY", 87, 101], ["Malignant Oedema", "ANATOMY", 102, 118], ["Malignant oedema", "ANATOMY", 141, 157], ["wound", "ANATOMY", 187, 192], ["necrosis", "DISEASE", 16, 24], ["gastrointestinal, respiratory and/or urinary tracts", "DISEASE", 50, 101], ["Malignant Oedema", "DISEASE", 102, 118], ["Clostridium septicum", "DISEASE", 120, 140], ["Malignant oedema", "DISEASE", 141, 157], ["Clostridium sp.", "DISEASE", 200, 215], ["Cl. septicum", "DISEASE", 231, 243], ["epithelium", "TISSUE", 32, 42], ["gastrointestinal", "ORGAN", 50, 66], ["urinary tracts", "PATHOLOGICAL_FORMATION", 87, 101], ["Malignant Oedema", "CANCER", 102, 118], ["Clostridium septicum", "ORGANISM", 120, 140], ["wound", "PATHOLOGICAL_FORMATION", 187, 192], ["Clostridium sp.", "ORGANISM", 200, 215], ["Cl. septicum", "ORGANISM", 231, 243], ["Clostridium septicum", "SPECIES", 120, 140], ["Clostridium sp.", "SPECIES", 200, 215], ["Cl. septicum", "SPECIES", 231, 243], ["Clostridium septicum", "SPECIES", 120, 140], ["Clostridium sp.", "SPECIES", 200, 215], ["Cl. septicum", "SPECIES", 231, 243], ["Lesions", "PROBLEM", 0, 7], ["necrosis of the epithelium of the gastrointestinal, respiratory and/or urinary tracts", "PROBLEM", 16, 101], ["Malignant Oedema", "PROBLEM", 102, 118], ["Clostridium septicum)", "PROBLEM", 120, 141], ["Malignant oedema", "PROBLEM", 141, 157], ["a wound", "PROBLEM", 185, 192], ["a Clostridium sp.", "PROBLEM", 198, 215], ["septicum", "PROBLEM", 235, 243], ["necrosis", "OBSERVATION", 16, 24], ["epithelium", "ANATOMY_MODIFIER", 32, 42], ["gastrointestinal", "ANATOMY", 50, 66], ["respiratory", "ANATOMY", 68, 79], ["urinary tracts", "ANATOMY", 87, 101], ["Oedema", "OBSERVATION", 112, 118], ["Clostridium septicum", "OBSERVATION_MODIFIER", 120, 140], ["Malignant", "OBSERVATION_MODIFIER", 141, 150], ["oedema", "OBSERVATION", 151, 157], ["wound", "ANATOMY", 187, 192], ["septicum", "OBSERVATION", 235, 243]]], ["A soft, oedematous, rapidly growing swelling develops at the injury site.", [["swelling", "DISEASE", 36, 44], ["oedematous", "PROBLEM", 8, 18], ["rapidly growing swelling", "PROBLEM", 20, 44], ["the injury site", "PROBLEM", 57, 72], ["soft", "ANATOMY", 2, 6], ["oedematous", "OBSERVATION_MODIFIER", 8, 18], ["rapidly", "OBSERVATION_MODIFIER", 20, 27], ["growing", "OBSERVATION_MODIFIER", 28, 35], ["swelling", "OBSERVATION", 36, 44], ["injury", "OBSERVATION", 61, 67]]], ["The muscle in affected areas is dark brown to black (similar to blackleg).", [["muscle", "ANATOMY", 4, 10], ["muscle", "ORGAN", 4, 10], ["dark brown", "PROBLEM", 32, 42], ["muscle", "ANATOMY", 4, 10], ["affected", "OBSERVATION_MODIFIER", 14, 22], ["areas", "OBSERVATION_MODIFIER", 23, 28], ["dark", "OBSERVATION_MODIFIER", 32, 36], ["brown to black", "OBSERVATION_MODIFIER", 37, 51]]], ["High fever, anorexia and muscle tremor precede death.Marek's Disease (Herpesvirus spp.)Chickens are the only important natural host of Marek's disease.", [["muscle", "ANATOMY", 25, 31], ["fever", "DISEASE", 5, 10], ["anorexia", "DISEASE", 12, 20], ["muscle tremor", "DISEASE", 25, 38], ["death", "DISEASE", 47, 52], ["Marek's Disease", "DISEASE", 53, 68], ["Marek's disease", "DISEASE", 135, 150], ["muscle", "ORGAN", 25, 31], ["Marek's Disease", "ORGANISM", 53, 68], ["Herpesvirus spp.", "ORGANISM", 70, 86], ["Chickens", "ORGANISM", 87, 95], ["Marek", "ORGANISM", 135, 140], ["Marek", "SPECIES", 53, 58], ["Chickens", "SPECIES", 87, 95], ["Marek", "SPECIES", 135, 140], ["Chickens", "SPECIES", 87, 95], ["High fever", "PROBLEM", 0, 10], ["anorexia", "PROBLEM", 12, 20], ["muscle tremor precede death", "PROBLEM", 25, 52], ["Marek's Disease (Herpesvirus spp.", "PROBLEM", 53, 86], ["Marek's disease", "PROBLEM", 135, 150], ["fever", "OBSERVATION", 5, 10], ["anorexia", "OBSERVATION", 12, 20], ["muscle", "ANATOMY", 25, 31], ["tremor", "OBSERVATION", 32, 38], ["Disease", "OBSERVATION", 61, 68]]], ["Enlargement of peripheral nerves, especially the vagus, brachial and sciatic, is diagnostic for this lymphoproliferative disease.", [["peripheral nerves", "ANATOMY", 15, 32], ["vagus", "ANATOMY", 49, 54], ["brachial", "ANATOMY", 56, 64], ["sciatic", "ANATOMY", 69, 76], ["Enlargement of peripheral nerves", "DISEASE", 0, 32], ["lymphoproliferative disease", "DISEASE", 101, 128], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 15, 32], ["vagus", "MULTI-TISSUE_STRUCTURE", 49, 54], ["brachial", "MULTI-TISSUE_STRUCTURE", 56, 64], ["sciatic", "MULTI-TISSUE_STRUCTURE", 69, 76], ["Enlargement of peripheral nerves", "PROBLEM", 0, 32], ["this lymphoproliferative disease", "PROBLEM", 96, 128], ["peripheral", "ANATOMY_MODIFIER", 15, 25], ["nerves", "ANATOMY", 26, 32], ["vagus", "ANATOMY", 49, 54], ["brachial", "ANATOMY", 56, 64], ["sciatic", "ANATOMY", 69, 76], ["lymphoproliferative", "OBSERVATION", 101, 120]]], ["Paralysis of areas innervated by the affected nerves is common.", [["nerves", "ANATOMY", 46, 52], ["Paralysis", "DISEASE", 0, 9], ["nerves", "MULTI-TISSUE_STRUCTURE", 46, 52], ["Paralysis of areas", "PROBLEM", 0, 18], ["affected nerves", "ANATOMY", 37, 52]]], ["Also seen are whitish nodules involving the thoracic and abdominal organs, enlarged feather follicles and a blue or grey discoloration of the iris.Newcastle Disease (Paramyxovirus spp.)This acute respiratory disease affects a wide range of avian species.", [["whitish nodules", "ANATOMY", 14, 29], ["thoracic", "ANATOMY", 44, 52], ["abdominal organs", "ANATOMY", 57, 73], ["feather follicles", "ANATOMY", 84, 101], ["iris", "ANATOMY", 142, 146], ["respiratory", "ANATOMY", 196, 207], ["Newcastle Disease", "DISEASE", 147, 164], ["respiratory disease", "DISEASE", 196, 215], ["whitish nodules", "PATHOLOGICAL_FORMATION", 14, 29], ["thoracic", "ORGAN", 44, 52], ["abdominal organs", "ORGAN", 57, 73], ["feather follicles", "MULTI-TISSUE_STRUCTURE", 84, 101], ["iris", "ORGAN", 142, 146], ["Paramyxovirus spp.", "ORGANISM", 166, 184], ["avian", "ORGANISM", 240, 245], ["whitish nodules involving the thoracic and abdominal organs", "PROBLEM", 14, 73], ["enlarged feather follicles", "PROBLEM", 75, 101], ["a blue or grey discoloration of the iris", "PROBLEM", 106, 146], ["Newcastle Disease (Paramyxovirus spp.", "PROBLEM", 147, 184], ["This acute respiratory disease", "PROBLEM", 185, 215], ["avian species", "PROBLEM", 240, 253], ["whitish", "OBSERVATION_MODIFIER", 14, 21], ["nodules", "OBSERVATION", 22, 29], ["thoracic", "ANATOMY", 44, 52], ["abdominal organs", "ANATOMY", 57, 73], ["enlarged", "OBSERVATION_MODIFIER", 75, 83], ["feather follicles", "OBSERVATION", 84, 101], ["blue", "OBSERVATION_MODIFIER", 108, 112], ["grey", "OBSERVATION_MODIFIER", 116, 120], ["discoloration", "OBSERVATION", 121, 134], ["iris", "ANATOMY", 142, 146], ["Disease", "OBSERVATION", 157, 164], ["Paramyxovirus spp.", "OBSERVATION", 166, 184], ["acute", "OBSERVATION_MODIFIER", 190, 195], ["respiratory disease", "OBSERVATION", 196, 215], ["wide range", "OBSERVATION_MODIFIER", 226, 236], ["avian species", "OBSERVATION", 240, 253]]], ["Clinical signs and lesions depend on the age and species affected and the strain of the virus.", [["lesions", "ANATOMY", 19, 26], ["lesions", "PATHOLOGICAL_FORMATION", 19, 26], ["Clinical signs", "PROBLEM", 0, 14], ["lesions", "PROBLEM", 19, 26], ["species affected", "PROBLEM", 49, 65], ["the virus", "PROBLEM", 84, 93], ["lesions", "OBSERVATION", 19, 26]]], ["Severity of disease ranges from inapparent infection to acute death.", [["infection", "DISEASE", 43, 52], ["death", "DISEASE", 62, 67], ["disease ranges", "PROBLEM", 12, 26], ["inapparent infection", "PROBLEM", 32, 52], ["acute death", "PROBLEM", 56, 67], ["disease", "OBSERVATION", 12, 19], ["inapparent", "OBSERVATION_MODIFIER", 32, 42], ["infection", "OBSERVATION", 43, 52], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["death", "OBSERVATION", 62, 67]]], ["Affected animals may display gastrointestinal, respiratory and/or nervous system signs.", [["gastrointestinal", "ANATOMY", 29, 45], ["respiratory", "ANATOMY", 47, 58], ["nervous system", "ANATOMY", 66, 80], ["gastrointestinal, respiratory and/or nervous system signs", "DISEASE", 29, 86], ["gastrointestinal", "ORGAN", 29, 45], ["nervous", "ANATOMICAL_SYSTEM", 66, 73], ["system", "ANATOMICAL_SYSTEM", 74, 80], ["Affected animals", "PROBLEM", 0, 16], ["gastrointestinal, respiratory and/or nervous system signs", "PROBLEM", 29, 86], ["gastrointestinal", "ANATOMY", 29, 45], ["respiratory", "ANATOMY", 47, 58]]], ["Clinical signs may include depression, diarrhoea, respiratory distress, paralysis, twisting of the neck, head thrown back, swelling of the head and death.", [["respiratory", "ANATOMY", 50, 61], ["neck", "ANATOMY", 99, 103], ["head", "ANATOMY", 105, 109], ["back", "ANATOMY", 117, 121], ["head", "ANATOMY", 139, 143], ["depression", "DISEASE", 27, 37], ["diarrhoea", "DISEASE", 39, 48], ["respiratory distress", "DISEASE", 50, 70], ["paralysis", "DISEASE", 72, 81], ["swelling of the head", "DISEASE", 123, 143], ["death", "DISEASE", 148, 153], ["neck", "ORGANISM_SUBDIVISION", 99, 103], ["head", "ORGANISM_SUBDIVISION", 105, 109], ["head", "ORGANISM_SUBDIVISION", 139, 143], ["Clinical signs", "PROBLEM", 0, 14], ["depression", "PROBLEM", 27, 37], ["diarrhoea", "PROBLEM", 39, 48], ["respiratory distress", "PROBLEM", 50, 70], ["paralysis", "PROBLEM", 72, 81], ["twisting of the neck", "PROBLEM", 83, 103], ["head thrown back", "PROBLEM", 105, 121], ["swelling of the head", "PROBLEM", 123, 143], ["death", "PROBLEM", 148, 153], ["may include", "UNCERTAINTY", 15, 26], ["depression", "OBSERVATION", 27, 37], ["respiratory distress", "OBSERVATION", 50, 70], ["paralysis", "OBSERVATION", 72, 81], ["neck", "ANATOMY", 99, 103], ["head", "ANATOMY", 105, 109], ["swelling", "OBSERVATION", 123, 131], ["head", "ANATOMY", 139, 143]]], ["Gross lesions are variable and may include haemorrhages and necrosis of the intestine, tracheal haemorrhages and airsacculitis.", [["Gross lesions", "ANATOMY", 0, 13], ["intestine", "ANATOMY", 76, 85], ["tracheal", "ANATOMY", 87, 95], ["haemorrhages", "DISEASE", 43, 55], ["necrosis", "DISEASE", 60, 68], ["tracheal haemorrhages", "DISEASE", 87, 108], ["airsacculitis", "DISEASE", 113, 126], ["Gross lesions", "CANCER", 0, 13], ["intestine", "ORGAN", 76, 85], ["tracheal", "ORGAN", 87, 95], ["Gross lesions", "PROBLEM", 0, 13], ["haemorrhages", "PROBLEM", 43, 55], ["necrosis of the intestine", "PROBLEM", 60, 85], ["tracheal haemorrhages", "PROBLEM", 87, 108], ["airsacculitis", "PROBLEM", 113, 126], ["lesions", "OBSERVATION", 6, 13], ["may include", "UNCERTAINTY", 31, 42], ["haemorrhages", "OBSERVATION", 43, 55], ["necrosis", "OBSERVATION", 60, 68], ["intestine", "ANATOMY", 76, 85], ["tracheal", "ANATOMY", 87, 95], ["haemorrhages", "OBSERVATION", 96, 108]]], ["Occasionally, humans exposed to Newcastle virus develop conjunctivitis.Pasteurella Pneumonia (Shipping Fever)Shipping Fever is primarily a respiratory disease of ruminants, especially cattle and sheep in feedlots.", [["respiratory", "ANATOMY", 139, 150], ["conjunctivitis", "DISEASE", 56, 70], ["Pasteurella Pneumonia", "DISEASE", 71, 92], ["Fever", "DISEASE", 103, 108], ["Fever", "DISEASE", 118, 123], ["respiratory disease of ruminants", "DISEASE", 139, 171], ["humans", "ORGANISM", 14, 20], ["Newcastle virus", "ORGANISM", 32, 47], ["Pasteurella Pneumonia", "ORGANISM", 71, 92], ["cattle", "ORGANISM", 184, 190], ["sheep", "ORGANISM", 195, 200], ["humans", "SPECIES", 14, 20], ["Pasteurella Pneumonia", "SPECIES", 71, 92], ["cattle", "SPECIES", 184, 190], ["sheep", "SPECIES", 195, 200], ["humans", "SPECIES", 14, 20], ["Newcastle virus", "SPECIES", 32, 47], ["cattle", "SPECIES", 184, 190], ["sheep", "SPECIES", 195, 200], ["Newcastle virus", "PROBLEM", 32, 47], ["conjunctivitis", "PROBLEM", 56, 70], ["Pasteurella Pneumonia", "PROBLEM", 71, 92], ["Shipping Fever", "PROBLEM", 94, 108], ["Shipping Fever", "PROBLEM", 109, 123], ["a respiratory disease of ruminants", "PROBLEM", 137, 171], ["conjunctivitis", "OBSERVATION", 56, 70], ["Pneumonia", "OBSERVATION", 83, 92], ["respiratory disease", "OBSERVATION", 139, 158], ["ruminants", "OBSERVATION_MODIFIER", 162, 171]]], ["Clinical signs include depression, inappetence, fever, and difficulty in breathing.", [["depression", "DISEASE", 23, 33], ["inappetence", "DISEASE", 35, 46], ["fever", "DISEASE", 48, 53], ["depression", "PROBLEM", 23, 33], ["inappetence", "PROBLEM", 35, 46], ["fever", "PROBLEM", 48, 53], ["difficulty in breathing", "PROBLEM", 59, 82], ["depression", "OBSERVATION", 23, 33], ["fever", "OBSERVATION", 48, 53]]], ["Gross lesions include a fibrinous pleuropneumonia and/or bronchopneumonia.", [["Gross lesions", "ANATOMY", 0, 13], ["fibrinous pleuropneumonia", "ANATOMY", 24, 49], ["pleuropneumonia", "DISEASE", 34, 49], ["bronchopneumonia", "DISEASE", 57, 73], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["Gross lesions", "PROBLEM", 0, 13], ["a fibrinous pleuropneumonia", "PROBLEM", 22, 49], ["bronchopneumonia", "PROBLEM", 57, 73], ["lesions", "OBSERVATION", 6, 13], ["fibrinous", "OBSERVATION_MODIFIER", 24, 33], ["pleuropneumonia", "OBSERVATION", 34, 49], ["bronchopneumonia", "OBSERVATION", 57, 73]]], ["Affected animals exhibit stunting, poor weight gain, and frequently die.", [["stunting", "DISEASE", 25, 33], ["weight gain", "DISEASE", 40, 51], ["Affected animals", "PROBLEM", 0, 16], ["stunting", "PROBLEM", 25, 33], ["poor weight gain", "PROBLEM", 35, 51], ["stunting", "OBSERVATION", 25, 33]]], ["Shipping fever is most frequently seen in animals that have been recently stressed (such as through transportation).", [["fever", "DISEASE", 9, 14], ["Shipping fever", "PROBLEM", 0, 14], ["fever", "OBSERVATION", 9, 14], ["most frequently", "OBSERVATION_MODIFIER", 18, 33]]], ["This disease can be caused by a number of different agents but is usually associated with stress (such as occurs with shipping), a viral infection, followed by a bacterial infection.", [["viral infection", "DISEASE", 131, 146], ["bacterial infection", "DISEASE", 162, 181], ["This disease", "PROBLEM", 0, 12], ["stress", "PROBLEM", 90, 96], ["a viral infection", "PROBLEM", 129, 146], ["a bacterial infection", "PROBLEM", 160, 181], ["disease", "OBSERVATION", 5, 12], ["viral", "OBSERVATION_MODIFIER", 131, 136], ["infection", "OBSERVATION", 137, 146], ["bacterial", "OBSERVATION_MODIFIER", 162, 171], ["infection", "OBSERVATION", 172, 181]]], ["The bacteria most commonly associated with shipping fever is Mannheimia haemolytica (previously Pasteurella haemolytica).", [["shipping fever", "DISEASE", 43, 57], ["Mannheimia haemolytica", "ORGANISM", 61, 83], ["Pasteurella haemolytica", "ORGANISM", 96, 119], ["Mannheimia haemolytica", "SPECIES", 61, 83], ["Pasteurella haemolytica", "SPECIES", 96, 119], ["Mannheimia haemolytica", "SPECIES", 61, 83], ["Pasteurella haemolytica", "SPECIES", 96, 119], ["The bacteria", "PROBLEM", 0, 12], ["shipping fever", "PROBLEM", 43, 57], ["Mannheimia haemolytica", "PROBLEM", 61, 83], ["previously Pasteurella haemolytica", "PROBLEM", 85, 119], ["bacteria", "OBSERVATION", 4, 12], ["Mannheimia haemolytica", "OBSERVATION", 61, 83]]], ["This disease causes great economic losses due to reduced rate of gain of body weight, inefficient feed conversion, cost of treatments, condemnation of carcasses and death of the animals.Porcine Reproductive and Respiratory Syndrome (Mystery Swine Disease, Swine Infertility and Respiratory Syndrome, Porcine Epidemic Abortion and Respiratory Syndrome, Blue Ear, Arterivirus spp.)This disease is characterized by fever, reproductive problems (stillbirths, abortions, mummies, weak piglets) and/or respiratory problems (sneezing, difficulty breathing, pneumonia).", [["body", "ANATOMY", 73, 77], ["respiratory", "ANATOMY", 496, 507], ["death", "DISEASE", 165, 170], ["Porcine Reproductive and Respiratory Syndrome", "DISEASE", 186, 231], ["Mystery Swine Disease", "DISEASE", 233, 254], ["Swine Infertility and Respiratory Syndrome", "DISEASE", 256, 298], ["Porcine Epidemic Abortion and Respiratory Syndrome", "DISEASE", 300, 350], ["fever", "DISEASE", 412, 417], ["reproductive problems", "DISEASE", 419, 440], ["stillbirths", "DISEASE", 442, 453], ["abortions", "DISEASE", 455, 464], ["respiratory problems", "DISEASE", 496, 516], ["sneezing", "DISEASE", 518, 526], ["difficulty breathing", "DISEASE", 528, 548], ["pneumonia", "DISEASE", 550, 559], ["body", "ORGANISM_SUBDIVISION", 73, 77], ["piglets", "ORGANISM_SUBDIVISION", 480, 487], ["Porcine", "SPECIES", 186, 193], ["Porcine", "SPECIES", 300, 307], ["piglets", "SPECIES", 480, 487], ["This disease", "PROBLEM", 0, 12], ["great economic losses", "PROBLEM", 20, 41], ["reduced rate of gain of body weight", "PROBLEM", 49, 84], ["inefficient feed conversion", "TREATMENT", 86, 113], ["treatments", "TREATMENT", 123, 133], ["Porcine Reproductive and Respiratory Syndrome", "PROBLEM", 186, 231], ["Mystery Swine Disease", "PROBLEM", 233, 254], ["Swine Infertility", "PROBLEM", 256, 273], ["Respiratory Syndrome", "PROBLEM", 278, 298], ["Porcine Epidemic Abortion", "PROBLEM", 300, 325], ["Respiratory Syndrome", "PROBLEM", 330, 350], ["Blue Ear, Arterivirus spp.", "PROBLEM", 352, 378], ["This disease", "PROBLEM", 379, 391], ["fever", "PROBLEM", 412, 417], ["reproductive problems", "PROBLEM", 419, 440], ["stillbirths", "PROBLEM", 442, 453], ["abortions", "PROBLEM", 455, 464], ["weak piglets)", "PROBLEM", 475, 488], ["respiratory problems", "PROBLEM", 496, 516], ["sneezing", "PROBLEM", 518, 526], ["difficulty breathing", "PROBLEM", 528, 548], ["pneumonia", "PROBLEM", 550, 559], ["great", "OBSERVATION_MODIFIER", 20, 25], ["economic losses", "OBSERVATION", 26, 41], ["reduced", "OBSERVATION_MODIFIER", 49, 56], ["Respiratory Syndrome", "OBSERVATION", 211, 231], ["Respiratory Syndrome", "OBSERVATION", 278, 298], ["Respiratory Syndrome", "OBSERVATION", 330, 350], ["disease", "OBSERVATION", 384, 391], ["fever", "OBSERVATION", 412, 417], ["respiratory", "ANATOMY", 496, 507], ["pneumonia", "OBSERVATION", 550, 559]]], ["Gross lesions are much more common in younger animals and may include enlargement of lymph nodes, cyanosis (bluing) of the skin especially noticeable on the ears, pneumonia, and clear fluid in the chest, abdomen or pericardial sac.", [["Gross lesions", "ANATOMY", 0, 13], ["lymph nodes", "ANATOMY", 85, 96], ["skin", "ANATOMY", 123, 127], ["ears", "ANATOMY", 157, 161], ["fluid", "ANATOMY", 184, 189], ["chest", "ANATOMY", 197, 202], ["abdomen", "ANATOMY", 204, 211], ["pericardial sac", "ANATOMY", 215, 230], ["enlargement of lymph nodes", "DISEASE", 70, 96], ["cyanosis", "DISEASE", 98, 106], ["pneumonia", "DISEASE", 163, 172], ["Gross lesions", "CANCER", 0, 13], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 85, 96], ["skin", "ORGAN", 123, 127], ["ears", "ORGAN", 157, 161], ["fluid", "ORGANISM_SUBSTANCE", 184, 189], ["chest", "ORGAN", 197, 202], ["abdomen", "ORGAN", 204, 211], ["pericardial sac", "MULTI-TISSUE_STRUCTURE", 215, 230], ["Gross lesions", "PROBLEM", 0, 13], ["enlargement of lymph nodes", "PROBLEM", 70, 96], ["cyanosis (bluing) of the skin", "PROBLEM", 98, 127], ["pneumonia", "PROBLEM", 163, 172], ["clear fluid in the chest, abdomen or pericardial sac", "PROBLEM", 178, 230], ["lesions", "OBSERVATION", 6, 13], ["much", "OBSERVATION_MODIFIER", 18, 22], ["more common", "OBSERVATION_MODIFIER", 23, 34], ["may include", "UNCERTAINTY", 58, 69], ["enlargement", "OBSERVATION_MODIFIER", 70, 81], ["lymph nodes", "OBSERVATION", 85, 96], ["cyanosis", "OBSERVATION", 98, 106], ["skin", "ANATOMY", 123, 127], ["ears", "ANATOMY", 157, 161], ["pneumonia", "OBSERVATION", 163, 172], ["clear", "OBSERVATION_MODIFIER", 178, 183], ["fluid", "OBSERVATION", 184, 189], ["chest", "ANATOMY", 197, 202], ["abdomen", "ANATOMY", 204, 211], ["pericardial sac", "ANATOMY", 215, 230]]], ["Differences in viral strains account for the variety and extent of clinical signs and lesions.Progressive Pneumonia (Maedi-Visna; Lentivirus spp.)Progressive pneumonia is a chronic disease of sheep and goats.", [["lesions", "ANATOMY", 86, 93], ["Pneumonia", "DISEASE", 106, 115], ["pneumonia", "DISEASE", 158, 167], ["lesions", "PATHOLOGICAL_FORMATION", 86, 93], ["Lentivirus", "ORGANISM", 130, 140], ["sheep", "ORGANISM", 192, 197], ["goats", "ORGANISM_SUBDIVISION", 202, 207], ["sheep", "SPECIES", 192, 197], ["goats", "SPECIES", 202, 207], ["sheep", "SPECIES", 192, 197], ["goats", "SPECIES", 202, 207], ["viral strains", "PROBLEM", 15, 28], ["clinical signs", "PROBLEM", 67, 81], ["lesions", "PROBLEM", 86, 93], ["Progressive Pneumonia", "PROBLEM", 94, 115], ["Lentivirus spp.", "TREATMENT", 130, 145], ["Progressive pneumonia", "PROBLEM", 146, 167], ["a chronic disease of sheep and goats", "PROBLEM", 171, 207], ["viral strains", "OBSERVATION", 15, 28], ["lesions", "OBSERVATION", 86, 93], ["Pneumonia", "OBSERVATION", 106, 115], ["pneumonia", "OBSERVATION", 158, 167], ["chronic", "OBSERVATION_MODIFIER", 173, 180], ["disease", "OBSERVATION", 181, 188]]], ["Clinical signs are rarely seen in animals less than 2 years of age.", [["Clinical signs", "PROBLEM", 0, 14]]], ["As the pneumonia progresses, weight loss, respiratory distress and weakness are seen.", [["respiratory", "ANATOMY", 42, 53], ["pneumonia", "DISEASE", 7, 16], ["weight loss", "DISEASE", 29, 40], ["respiratory distress", "DISEASE", 42, 62], ["weakness", "DISEASE", 67, 75], ["the pneumonia", "PROBLEM", 3, 16], ["weight loss", "PROBLEM", 29, 40], ["respiratory distress", "PROBLEM", 42, 62], ["weakness", "PROBLEM", 67, 75], ["pneumonia", "OBSERVATION", 7, 16], ["weight loss", "OBSERVATION", 29, 40], ["respiratory distress", "OBSERVATION", 42, 62], ["weakness", "OBSERVATION", 67, 75]]], ["At slaughter, the lungs are firm and do not collapse.", [["lungs", "ANATOMY", 18, 23], ["lungs", "ORGAN", 18, 23], ["collapse", "PROBLEM", 44, 52], ["lungs", "ANATOMY", 18, 23], ["firm", "OBSERVATION", 28, 32], ["collapse", "OBSERVATION", 44, 52]]], ["The lung lobes are adhered to one another and to the thoracic wall.Salmonellosis (Salmonella spp.)Salmonella spp. affect the enteric tract of most, if not all, animal species.", [["lung lobes", "ANATOMY", 4, 14], ["thoracic wall", "ANATOMY", 53, 66], ["enteric tract", "ANATOMY", 125, 138], ["Salmonellosis", "DISEASE", 67, 80], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 4, 14], ["thoracic wall", "MULTI-TISSUE_STRUCTURE", 53, 66], ["Salmonella spp.", "ORGANISM", 82, 97], ["Salmonella spp.", "ORGANISM", 98, 113], ["enteric tract", "ORGANISM_SUBDIVISION", 125, 138], ["Salmonella spp.", "SPECIES", 82, 97], ["Salmonella spp.", "SPECIES", 98, 113], ["Salmonella spp.", "SPECIES", 98, 113], ["Salmonellosis (Salmonella spp.", "TREATMENT", 67, 97], ["Salmonella spp.", "PROBLEM", 98, 113], ["lung", "ANATOMY", 4, 8], ["lobes", "ANATOMY_MODIFIER", 9, 14], ["thoracic", "ANATOMY", 53, 61], ["wall", "ANATOMY_MODIFIER", 62, 66], ["enteric tract", "OBSERVATION_MODIFIER", 125, 138]]], ["Clinical signs include fever, diarrhoea and dehydration and can range from inapparent infection to death from septicaemia.", [["fever", "DISEASE", 23, 28], ["diarrhoea", "DISEASE", 30, 39], ["dehydration", "DISEASE", 44, 55], ["infection", "DISEASE", 86, 95], ["death", "DISEASE", 99, 104], ["septicaemia", "DISEASE", 110, 121], ["Clinical signs", "TEST", 0, 14], ["fever", "PROBLEM", 23, 28], ["diarrhoea", "PROBLEM", 30, 39], ["dehydration", "PROBLEM", 44, 55], ["inapparent infection", "PROBLEM", 75, 95], ["death", "PROBLEM", 99, 104], ["septicaemia", "PROBLEM", 110, 121], ["fever", "OBSERVATION", 23, 28], ["diarrhoea", "OBSERVATION", 30, 39], ["inapparent", "OBSERVATION_MODIFIER", 75, 85], ["infection", "OBSERVATION", 86, 95], ["septicaemia", "OBSERVATION", 110, 121]]], ["Young animals are usually the most severely affected.", [["most severely", "OBSERVATION_MODIFIER", 30, 43]]], ["The occurrence of this disease in animals and humans has increased greatly in recent years.", [["humans", "ORGANISM", 46, 52], ["humans", "SPECIES", 46, 52], ["humans", "SPECIES", 46, 52], ["this disease", "PROBLEM", 18, 30], ["disease", "OBSERVATION", 23, 30], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["greatly", "OBSERVATION_MODIFIER", 67, 74]]], ["Intensification of the livestock and poultry industries and contamination of feedstuffs through the use of animal by-products are thought to be contributing factors to the increase in disease.", [["poultry industries", "TREATMENT", 37, 55], ["contamination of feedstuffs", "TREATMENT", 60, 87], ["the increase in disease", "PROBLEM", 168, 191], ["livestock", "OBSERVATION_MODIFIER", 23, 32], ["thought to be", "UNCERTAINTY", 130, 143], ["increase", "OBSERVATION_MODIFIER", 172, 180], ["disease", "OBSERVATION", 184, 191]]], ["Further information on Salmonella spp. can be found in Microbiological safety of meat: Salmonella spp.Sarcocystosis (Sarcocystis spp.)Infection with these protozoans is usually asymptomatic with diagnosis made at slaughter.", [["Sarcocystosis", "DISEASE", 102, 115], ["Salmonella spp", "ORGANISM", 23, 37], ["meat", "ORGANISM_SUBDIVISION", 81, 85], ["Salmonella spp", "ORGANISM", 87, 101], ["Sarcocystis spp.", "ORGANISM", 117, 133], ["Sarcocystis spp.", "SPECIES", 117, 133], ["Salmonella spp", "TEST", 23, 37], ["Salmonella spp", "PROBLEM", 87, 101], ["Sarcocystosis (Sarcocystis spp.", "PROBLEM", 102, 133], ["Infection", "PROBLEM", 134, 143], ["these protozoans", "PROBLEM", 149, 165], ["Salmonella spp", "OBSERVATION", 87, 101], ["Sarcocystis spp.", "OBSERVATION", 117, 133]]], ["Losses occur due to trimming away of infected tissue or condemnation of the carcass if the condition is generalized.ScrapieScrapie generally occurs in animals over 2 years of age.", [["tissue", "ANATOMY", 46, 52], ["Losses", "DISEASE", 0, 6], ["tissue", "TISSUE", 46, 52], ["carcass", "ORGANISM_SUBDIVISION", 76, 83], ["infected tissue", "PROBLEM", 37, 52], ["infected", "OBSERVATION", 37, 45], ["generalized", "OBSERVATION_MODIFIER", 104, 115]]], ["Affected animals lag behind the herd, are easily excited, develop ataxia and, despite a good appetite, progressively lose weight.", [["ataxia", "DISEASE", 66, 72], ["ataxia", "PROBLEM", 66, 72]]], ["Fine tremors of the head and neck become apparent.", [["head", "ANATOMY", 20, 24], ["neck", "ANATOMY", 29, 33], ["tremors", "DISEASE", 5, 12], ["head", "ORGANISM_SUBDIVISION", 20, 24], ["neck", "ORGAN", 29, 33], ["Fine tremors of the head and neck", "PROBLEM", 0, 33], ["tremors", "OBSERVATION", 5, 12], ["head", "ANATOMY", 20, 24], ["neck", "ANATOMY", 29, 33]]], ["The classic clinical sign of scrapie is extreme pruritis resulting in animals scraping their bodies on surfaces in an effort to relieve the itchiness.", [["scrapie", "DISEASE", 29, 36], ["pruritis", "DISEASE", 48, 56], ["itchiness", "DISEASE", 140, 149], ["pruritis", "CANCER", 48, 56], ["scrapie", "SPECIES", 29, 36], ["scrapie", "PROBLEM", 29, 36], ["extreme pruritis", "PROBLEM", 40, 56], ["the itchiness", "PROBLEM", 136, 149], ["scrapie", "OBSERVATION", 29, 36], ["extreme", "OBSERVATION_MODIFIER", 40, 47], ["pruritis", "OBSERVATION", 48, 56], ["itchiness", "OBSERVATION", 140, 149]]], ["Bilateral alopecia and erosions result from this intense scratching behaviour.", [["alopecia", "DISEASE", 10, 18], ["erosions", "DISEASE", 23, 31], ["erosions", "PATHOLOGICAL_FORMATION", 23, 31], ["Bilateral alopecia", "PROBLEM", 0, 18], ["erosions", "PROBLEM", 23, 31], ["this intense scratching behaviour", "PROBLEM", 44, 77], ["alopecia", "OBSERVATION", 10, 18], ["erosions", "OBSERVATION", 23, 31], ["intense", "OBSERVATION_MODIFIER", 49, 56], ["scratching", "OBSERVATION", 57, 67]]], ["Some strains of scrapie do not cause pruritis.", [["scrapie", "DISEASE", 16, 23], ["pruritis", "DISEASE", 37, 45], ["scrapie", "SPECIES", 16, 23], ["Some strains of scrapie", "PROBLEM", 0, 23], ["pruritis", "PROBLEM", 37, 45], ["scrapie", "OBSERVATION", 16, 23], ["pruritis", "OBSERVATION", 37, 45]]], ["More information on scrapie and other transmissible spongiform encephalopathies can be found in Microbiological safety of meat: Prions and viruses.Tetanus (Lockjaw; Clostridium tetani)Tetanus affects swine, horses and all ruminant animals.", [["meat", "ANATOMY", 122, 126], ["scrapie", "DISEASE", 20, 27], ["transmissible spongiform encephalopathies", "DISEASE", 38, 79], ["Tetanus", "DISEASE", 147, 154], ["Tetanus", "DISEASE", 184, 191], ["meat", "ORGANISM_SUBDIVISION", 122, 126], ["Lockjaw;", "ORGANISM", 156, 164], ["Clostridium tetani", "ORGANISM", 165, 183], ["swine", "ORGANISM", 200, 205], ["horses", "ORGANISM", 207, 213], ["Clostridium tetani", "SPECIES", 165, 183], ["swine", "SPECIES", 200, 205], ["horses", "SPECIES", 207, 213], ["scrapie", "SPECIES", 20, 27], ["swine", "SPECIES", 200, 205], ["scrapie", "PROBLEM", 20, 27], ["other transmissible spongiform encephalopathies", "PROBLEM", 32, 79], ["Tetanus (Lockjaw; Clostridium tetani", "TREATMENT", 147, 183]]], ["The clinical manifestation begins as muscle stiffness and tremors, which progresses to convulsions and death.Transmissible Gastroenteritis (Coronavirus spp.)This disease causes vomiting, severe diarrhoea and death in young pigs (< 5 weeks old).", [["muscle", "ANATOMY", 37, 43], ["muscle stiffness", "DISEASE", 37, 53], ["tremors", "DISEASE", 58, 65], ["convulsions", "DISEASE", 87, 98], ["death", "DISEASE", 103, 108], ["Gastroenteritis", "DISEASE", 123, 138], ["vomiting", "DISEASE", 177, 185], ["diarrhoea", "DISEASE", 194, 203], ["death", "DISEASE", 208, 213], ["muscle", "ORGAN", 37, 43], ["Coronavirus spp.", "ORGANISM", 140, 156], ["pigs", "ORGANISM", 223, 227], ["pigs", "SPECIES", 223, 227], ["pigs", "SPECIES", 223, 227], ["muscle stiffness", "PROBLEM", 37, 53], ["tremors", "PROBLEM", 58, 65], ["convulsions", "PROBLEM", 87, 98], ["death", "PROBLEM", 103, 108], ["Transmissible Gastroenteritis (Coronavirus spp.", "PROBLEM", 109, 156], ["This disease", "PROBLEM", 157, 169], ["vomiting", "PROBLEM", 177, 185], ["severe diarrhoea", "PROBLEM", 187, 203], ["death", "PROBLEM", 208, 213], ["muscle", "ANATOMY", 37, 43], ["tremors", "OBSERVATION", 58, 65], ["Gastroenteritis", "OBSERVATION", 123, 138], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["diarrhoea", "OBSERVATION", 194, 203]]], ["Older swine usually suffer only a short bout of vomiting and diarrhoea.", [["vomiting", "DISEASE", 48, 56], ["diarrhoea", "DISEASE", 61, 70], ["swine", "ORGANISM", 6, 11], ["swine", "SPECIES", 6, 11], ["vomiting", "PROBLEM", 48, 56], ["diarrhoea", "PROBLEM", 61, 70], ["diarrhoea", "OBSERVATION", 61, 70]]], ["Gross lesions may include reddening of the gastrointestinal tract and thinning of the wall of the small intestine.Tuberculosis (Mycobacterium spp.)Tuberculosis can be caused either by the bovine (M. bovis), avian (M. avium), or human (M. tuberculosis) strains of Mycobacterium.", [["Gross lesions", "ANATOMY", 0, 13], ["gastrointestinal tract", "ANATOMY", 43, 65], ["wall", "ANATOMY", 86, 90], ["small intestine", "ANATOMY", 98, 113], ["reddening of the gastrointestinal tract", "DISEASE", 26, 65], ["Tuberculosis", "DISEASE", 114, 126], ["Tuberculosis", "DISEASE", 147, 159], ["M. tuberculosis", "DISEASE", 235, 250], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 43, 65], ["wall", "TISSUE", 86, 90], ["small intestine", "ORGAN", 98, 113], ["Mycobacterium spp.", "ORGANISM", 128, 146], ["bovine", "ORGANISM", 188, 194], ["M. bovis", "ORGANISM", 196, 204], ["M. avium", "ORGANISM", 214, 222], ["human", "ORGANISM", 228, 233], ["M. tuberculosis", "ORGANISM", 235, 250], ["Mycobacterium spp.", "SPECIES", 128, 146], ["bovine", "SPECIES", 188, 194], ["M. bovis", "SPECIES", 196, 204], ["avian", "SPECIES", 207, 212], ["M. avium", "SPECIES", 214, 222], ["human", "SPECIES", 228, 233], ["M. tuberculosis", "SPECIES", 235, 250], ["Mycobacterium spp.)", "SPECIES", 128, 147], ["bovine", "SPECIES", 188, 194], ["M. bovis", "SPECIES", 196, 204], ["M. avium", "SPECIES", 214, 222], ["human", "SPECIES", 228, 233], ["M. tuberculosis", "SPECIES", 235, 250], ["Gross lesions", "PROBLEM", 0, 13], ["reddening of the gastrointestinal tract", "PROBLEM", 26, 65], ["thinning of the wall of the small intestine", "PROBLEM", 70, 113], ["Tuberculosis (Mycobacterium spp.", "PROBLEM", 114, 146], ["Tuberculosis", "PROBLEM", 147, 159], ["the bovine (M. bovis)", "PROBLEM", 184, 205], ["avian (M. avium)", "PROBLEM", 207, 223], ["Mycobacterium", "PROBLEM", 263, 276], ["lesions", "OBSERVATION", 6, 13], ["reddening", "OBSERVATION", 26, 35], ["gastrointestinal tract", "ANATOMY", 43, 65], ["thinning", "OBSERVATION", 70, 78], ["wall", "ANATOMY_MODIFIER", 86, 90], ["small intestine", "ANATOMY", 98, 113], ["Mycobacterium spp.", "OBSERVATION", 128, 146], ["Mycobacterium", "OBSERVATION", 263, 276]]], ["Cattle, sheep, goats and deer are readily infected by M. bovis but are rarely affected by the avian or human strains.", [["sheep", "ORGANISM", 8, 13], ["goats", "ORGANISM", 15, 20], ["deer", "ORGANISM", 25, 29], ["M. bovis", "ORGANISM", 54, 62], ["avian", "ORGANISM", 94, 99], ["human", "ORGANISM", 103, 108], ["Cattle", "SPECIES", 0, 6], ["sheep", "SPECIES", 8, 13], ["goats", "SPECIES", 15, 20], ["deer", "SPECIES", 25, 29], ["M. bovis", "SPECIES", 54, 62], ["avian", "SPECIES", 94, 99], ["human", "SPECIES", 103, 108], ["Cattle", "SPECIES", 0, 6], ["sheep", "SPECIES", 8, 13], ["goats", "SPECIES", 15, 20], ["deer", "SPECIES", 25, 29], ["M. bovis", "SPECIES", 54, 62], ["human", "SPECIES", 103, 108]]], ["Swine are affected by all three types of tuberculosis.", [["tuberculosis", "DISEASE", 41, 53], ["Swine", "SPECIES", 0, 5], ["tuberculosis", "PROBLEM", 41, 53], ["all", "OBSERVATION_MODIFIER", 22, 25], ["three types", "OBSERVATION_MODIFIER", 26, 37], ["tuberculosis", "OBSERVATION", 41, 53]]], ["Tuberculosis is a chronic disease causing decreased productivity, respiratory distress and eventually death.", [["respiratory", "ANATOMY", 66, 77], ["Tuberculosis", "DISEASE", 0, 12], ["respiratory distress", "DISEASE", 66, 86], ["death", "DISEASE", 102, 107], ["Tuberculosis", "PROBLEM", 0, 12], ["a chronic disease", "PROBLEM", 16, 33], ["decreased productivity", "PROBLEM", 42, 64], ["respiratory distress", "PROBLEM", 66, 86], ["eventually death", "PROBLEM", 91, 107], ["chronic", "OBSERVATION_MODIFIER", 18, 25], ["disease", "OBSERVATION", 26, 33], ["decreased", "OBSERVATION_MODIFIER", 42, 51], ["productivity", "OBSERVATION_MODIFIER", 52, 64], ["respiratory distress", "OBSERVATION", 66, 86]]], ["Caseous, granulomatous lesions (tubercles) in the lungs and/or lymph nodes are characteristic.", [["granulomatous lesions", "ANATOMY", 9, 30], ["tubercles", "ANATOMY", 32, 41], ["lungs", "ANATOMY", 50, 55], ["lymph nodes", "ANATOMY", 63, 74], ["granulomatous lesions", "PATHOLOGICAL_FORMATION", 9, 30], ["tubercles", "ORGAN", 32, 41], ["lungs", "ORGAN", 50, 55], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 63, 74], ["Caseous, granulomatous lesions (tubercles) in the lungs and/or lymph nodes", "PROBLEM", 0, 74], ["granulomatous", "OBSERVATION_MODIFIER", 9, 22], ["lesions", "OBSERVATION", 23, 30], ["tubercles", "OBSERVATION_MODIFIER", 32, 41], ["lungs", "ANATOMY", 50, 55], ["/", "ANATOMY", 59, 60], ["lymph nodes", "OBSERVATION", 63, 74]]], ["Poultry, especially chickens, are readily infected by avian tuberculosis but resistant to the bovine and human strains.", [["avian tuberculosis", "DISEASE", 54, 72], ["chickens", "ORGANISM", 20, 28], ["avian tuberculosis", "ORGANISM", 54, 72], ["bovine", "ORGANISM", 94, 100], ["human", "ORGANISM", 105, 110], ["chickens", "SPECIES", 20, 28], ["avian tuberculosis", "SPECIES", 54, 72], ["bovine", "SPECIES", 94, 100], ["human", "SPECIES", 105, 110], ["chickens", "SPECIES", 20, 28], ["avian tuberculosis", "SPECIES", 54, 72], ["bovine", "SPECIES", 94, 100], ["human", "SPECIES", 105, 110], ["chickens", "PROBLEM", 20, 28], ["avian tuberculosis", "PROBLEM", 54, 72], ["the bovine and human strains", "TREATMENT", 90, 118], ["infected", "OBSERVATION", 42, 50], ["tuberculosis", "OBSERVATION", 60, 72]]], ["Affected poultry suffer poor productivity and are unthrifty.", [["poor productivity", "OBSERVATION", 24, 41]]], ["Tubercles are found most often in the intestines, liver, spleen and bone marrow of affected animals.Diseases Affecting FishDisease of importance to fish are listed in Table 3 .Diseases Affecting FishThe diseases are discussed briefly below.Bacterial Gill Disease (Flavobacterium branchiophila)Clinical signs include lethargy, inappetence, flared opercula and/or laboured opercula movements.", [["Tubercles", "ANATOMY", 0, 9], ["intestines", "ANATOMY", 38, 48], ["liver", "ANATOMY", 50, 55], ["spleen", "ANATOMY", 57, 63], ["bone marrow", "ANATOMY", 68, 79], ["opercula", "ANATOMY", 346, 354], ["opercula", "ANATOMY", 371, 379], ["FishThe diseases", "DISEASE", 195, 211], ["lethargy", "DISEASE", 316, 324], ["inappetence", "DISEASE", 326, 337], ["Tubercles", "GENE_OR_GENE_PRODUCT", 0, 9], ["intestines", "ORGAN", 38, 48], ["liver", "ORGAN", 50, 55], ["spleen", "ORGAN", 57, 63], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 68, 79], ["fish", "ORGANISM", 148, 152], ["Flavobacterium branchiophila", "ORGANISM", 264, 292], ["Flavobacterium branchiophila", "SPECIES", 264, 292], ["Flavobacterium branchiophila", "SPECIES", 264, 292], ["Tubercles", "PROBLEM", 0, 9], ["affected animals", "PROBLEM", 83, 99], ["Diseases", "PROBLEM", 100, 108], ["FishThe diseases", "PROBLEM", 195, 211], ["Bacterial Gill Disease (Flavobacterium branchiophila)", "PROBLEM", 240, 293], ["Clinical signs", "TEST", 293, 307], ["lethargy", "PROBLEM", 316, 324], ["inappetence", "PROBLEM", 326, 337], ["flared opercula", "PROBLEM", 339, 354], ["laboured opercula movements", "PROBLEM", 362, 389], ["intestines", "ANATOMY", 38, 48], ["liver", "ANATOMY", 50, 55], ["spleen", "ANATOMY", 57, 63], ["bone", "ANATOMY", 68, 72], ["marrow", "OBSERVATION", 73, 79], ["Gill", "ANATOMY", 250, 254], ["Disease", "OBSERVATION", 255, 262], ["flared", "OBSERVATION_MODIFIER", 339, 345], ["opercula movements", "OBSERVATION", 371, 389]]], ["The gills may be pale with thickened tips or reddened and swollen with mucus strands trailing from the gills.", [["gills", "ANATOMY", 4, 9], ["mucus", "ANATOMY", 71, 76], ["gills", "ANATOMY", 103, 108], ["gills", "ORGAN", 4, 9], ["gills", "ORGAN", 103, 108], ["pale", "PROBLEM", 17, 21], ["thickened tips", "PROBLEM", 27, 41], ["reddened and swollen", "PROBLEM", 45, 65], ["mucus strands", "PROBLEM", 71, 84], ["gills", "ANATOMY", 4, 9], ["may be", "UNCERTAINTY", 10, 16], ["pale", "OBSERVATION_MODIFIER", 17, 21], ["thickened", "OBSERVATION_MODIFIER", 27, 36], ["tips", "OBSERVATION_MODIFIER", 37, 41], ["reddened", "OBSERVATION_MODIFIER", 45, 53], ["swollen", "OBSERVATION_MODIFIER", 58, 65], ["mucus strands", "OBSERVATION", 71, 84], ["gills", "ANATOMY", 103, 108]]], ["Onset of illness frequently follows environmental deterioration (overcrowding, low oxygen, excessive turbidity, high ammonia levels).Bacterial Kidney Disease (Renibacterium salmoninarum)Affected fish may appear normal or they may be inappetent, depressed, darker in colour, fluid-filled abdomen, exophthalmic and/or haemorrhagic at the base of the fins and vent.", [["Kidney", "ANATOMY", 143, 149], ["fluid", "ANATOMY", 274, 279], ["abdomen", "ANATOMY", 287, 294], ["fins", "ANATOMY", 348, 352], ["illness", "DISEASE", 9, 16], ["oxygen", "CHEMICAL", 83, 89], ["ammonia", "CHEMICAL", 117, 124], ["Kidney Disease", "DISEASE", 143, 157], ["depressed", "DISEASE", 245, 254], ["haemorrhagic", "DISEASE", 316, 328], ["oxygen", "CHEMICAL", 83, 89], ["ammonia", "CHEMICAL", 117, 124], ["oxygen", "SIMPLE_CHEMICAL", 83, 89], ["ammonia", "SIMPLE_CHEMICAL", 117, 124], ["Renibacterium salmoninarum", "ORGANISM", 159, 185], ["fish", "ORGANISM", 195, 199], ["abdomen", "ORGANISM_SUBDIVISION", 287, 294], ["fins", "ORGANISM_SUBDIVISION", 348, 352], ["Renibacterium salmoninarum", "SPECIES", 159, 185], ["Renibacterium salmoninarum", "SPECIES", 159, 185], ["illness", "PROBLEM", 9, 16], ["environmental deterioration", "PROBLEM", 36, 63], ["low oxygen", "PROBLEM", 79, 89], ["excessive turbidity", "PROBLEM", 91, 110], ["high ammonia levels", "PROBLEM", 112, 131], ["Bacterial Kidney Disease", "PROBLEM", 133, 157], ["Renibacterium salmoninarum)", "TREATMENT", 159, 186], ["depressed", "PROBLEM", 245, 254], ["fluid-filled abdomen", "PROBLEM", 274, 294], ["exophthalmic", "PROBLEM", 296, 308], ["haemorrhagic", "PROBLEM", 316, 328], ["vent", "TREATMENT", 357, 361], ["illness", "OBSERVATION", 9, 16], ["Kidney", "ANATOMY", 143, 149], ["Disease", "OBSERVATION", 150, 157], ["normal", "OBSERVATION", 211, 217], ["depressed", "OBSERVATION_MODIFIER", 245, 254], ["darker", "OBSERVATION_MODIFIER", 256, 262], ["fluid", "OBSERVATION", 274, 279], ["filled", "OBSERVATION", 280, 286], ["abdomen", "ANATOMY", 287, 294], ["haemorrhagic", "OBSERVATION", 316, 328], ["base", "ANATOMY_MODIFIER", 336, 340], ["fins", "ANATOMY", 348, 352]]], ["Grossly, the kidneys are pale and swollen, with whitish nodules.Channel Catfish Disease (Herpes spp.)This disease primarily affects young catfish.", [["kidneys", "ANATOMY", 13, 20], ["whitish nodules", "ANATOMY", 48, 63], ["Herpes spp.)", "DISEASE", 89, 101], ["kidneys", "ORGAN", 13, 20], ["whitish nodules", "CANCER", 48, 63], ["Herpes spp.", "ORGANISM", 89, 100], ["catfish", "ORGANISM", 138, 145], ["pale", "PROBLEM", 25, 29], ["swollen", "PROBLEM", 34, 41], ["whitish nodules", "PROBLEM", 48, 63], ["Channel Catfish Disease (Herpes spp.", "PROBLEM", 64, 100], ["This disease", "PROBLEM", 101, 113], ["kidneys", "ANATOMY", 13, 20], ["pale", "OBSERVATION", 25, 29], ["swollen", "OBSERVATION", 34, 41], ["whitish", "OBSERVATION_MODIFIER", 48, 55], ["nodules", "OBSERVATION", 56, 63], ["Catfish Disease", "OBSERVATION", 72, 87], ["disease", "OBSERVATION", 106, 113], ["young catfish", "OBSERVATION", 132, 145]]], ["Clinical signs include erratic swimming, swimming tail-down at the surface, fluid-filled abdomen, exophthalmia, haemorrhages on the skin, gills and the base of the fins.", [["surface", "ANATOMY", 67, 74], ["fluid", "ANATOMY", 76, 81], ["abdomen", "ANATOMY", 89, 96], ["skin", "ANATOMY", 132, 136], ["gills", "ANATOMY", 138, 143], ["fins", "ANATOMY", 164, 168], ["exophthalmia", "DISEASE", 98, 110], ["haemorrhages", "DISEASE", 112, 124], ["abdomen", "ORGANISM_SUBDIVISION", 89, 96], ["skin", "ORGAN", 132, 136], ["gills", "ORGAN", 138, 143], ["fins", "ORGANISM_SUBDIVISION", 164, 168], ["Clinical signs", "TEST", 0, 14], ["erratic swimming", "PROBLEM", 23, 39], ["swimming tail", "TEST", 41, 54], ["fluid-filled abdomen", "PROBLEM", 76, 96], ["exophthalmia", "PROBLEM", 98, 110], ["haemorrhages on the skin", "PROBLEM", 112, 136], ["fluid", "OBSERVATION", 76, 81], ["filled", "OBSERVATION", 82, 88], ["abdomen", "ANATOMY", 89, 96], ["haemorrhages", "OBSERVATION", 112, 124], ["skin", "ANATOMY", 132, 136], ["gills", "ANATOMY", 138, 143], ["base", "ANATOMY_MODIFIER", 152, 156], ["fins", "ANATOMY", 164, 168]]], ["Upon necropsy, petechial haemorrhages are found throughout the muscle.Columnaris Disease (Flexibacter columnaris)This widespread disease causes lesions in the skin, gills and fins.", [["petechial", "ANATOMY", 15, 24], ["muscle", "ANATOMY", 63, 69], ["lesions", "ANATOMY", 144, 151], ["skin", "ANATOMY", 159, 163], ["gills", "ANATOMY", 165, 170], ["fins", "ANATOMY", 175, 179], ["haemorrhages", "DISEASE", 25, 37], ["petechial haemorrhages", "PATHOLOGICAL_FORMATION", 15, 37], ["muscle", "ORGAN", 63, 69], ["Flexibacter columnaris", "ORGANISM", 90, 112], ["lesions", "PATHOLOGICAL_FORMATION", 144, 151], ["skin", "ORGAN", 159, 163], ["gills", "ORGAN", 165, 170], ["fins", "ORGAN", 175, 179], ["Flexibacter columnaris", "SPECIES", 90, 112], ["Flexibacter columnaris", "SPECIES", 90, 112], ["necropsy", "TEST", 5, 13], ["petechial haemorrhages", "PROBLEM", 15, 37], ["Columnaris Disease (Flexibacter columnaris", "PROBLEM", 70, 112], ["This widespread disease", "PROBLEM", 113, 136], ["lesions in the skin, gills and fins", "PROBLEM", 144, 179], ["petechial", "OBSERVATION_MODIFIER", 15, 24], ["haemorrhages", "OBSERVATION", 25, 37], ["muscle", "ANATOMY", 63, 69], ["widespread", "OBSERVATION_MODIFIER", 118, 128], ["disease", "OBSERVATION", 129, 136], ["lesions", "OBSERVATION", 144, 151], ["skin", "ANATOMY", 159, 163], ["gills", "ANATOMY", 165, 170], ["fins", "ANATOMY", 175, 179]]], ["The gills exhibit light to dark brown discoloration and necrosis.", [["gills", "ANATOMY", 4, 9], ["necrosis", "DISEASE", 56, 64], ["gills", "ORGAN", 4, 9], ["dark brown discoloration", "PROBLEM", 27, 51], ["necrosis", "PROBLEM", 56, 64], ["gills", "ANATOMY", 4, 9], ["light to dark", "OBSERVATION_MODIFIER", 18, 31], ["brown discoloration", "OBSERVATION", 32, 51], ["necrosis", "OBSERVATION", 56, 64]]], ["Fins become frayed; the skin becomes dull and loses coloration.", [["skin", "ANATOMY", 24, 28], ["skin", "ORGAN", 24, 28], ["dull", "PROBLEM", 37, 41], ["frayed", "OBSERVATION", 12, 18], ["skin", "ANATOMY", 24, 28], ["dull", "OBSERVATION", 37, 41], ["coloration", "OBSERVATION_MODIFIER", 52, 62]]], ["Skin ulcers develop and can progress to affect the underlying muscle.Enteric Septicaemia of Catfish (Edwardsiellosis; Edwardsiella ictaluri)The clinical presentation of this disease is variable in catfish.", [["Skin ulcers", "ANATOMY", 0, 11], ["muscle", "ANATOMY", 62, 68], ["ulcers", "DISEASE", 5, 11], ["Skin ulcers", "PATHOLOGICAL_FORMATION", 0, 11], ["muscle", "ORGAN", 62, 68], ["Edwardsiella ictaluri", "ORGANISM", 118, 139], ["catfish", "ORGANISM", 197, 204], ["Edwardsiella ictaluri", "SPECIES", 118, 139], ["Edwardsiella ictaluri", "SPECIES", 118, 139], ["Skin ulcers", "PROBLEM", 0, 11], ["Enteric Septicaemia of Catfish (Edwardsiellosis", "PROBLEM", 69, 116], ["Edwardsiella ictaluri", "PROBLEM", 118, 139], ["this disease", "PROBLEM", 169, 181], ["ulcers", "OBSERVATION", 5, 11], ["muscle", "ANATOMY", 62, 68], ["Septicaemia", "OBSERVATION", 77, 88], ["Catfish", "OBSERVATION_MODIFIER", 92, 99], ["Edwardsiella ictaluri", "OBSERVATION_MODIFIER", 118, 139], ["disease", "OBSERVATION", 174, 181], ["variable", "OBSERVATION_MODIFIER", 185, 193]]], ["Peracutely affected fish may die prior to the development of clinical signs.", [["fish", "ORGANISM", 20, 24], ["clinical signs", "PROBLEM", 61, 75]]], ["Acutely affected fish hang tail-down from the surface or swim in a corkscrew pattern.", [["tail", "ANATOMY", 27, 31], ["surface", "ANATOMY", 46, 53], ["fish", "ORGANISM", 17, 21], ["tail", "ORGANISM_SUBDIVISION", 27, 31], ["surface", "CELLULAR_COMPONENT", 46, 53], ["Acutely affected fish hang tail", "PROBLEM", 0, 31], ["affected", "OBSERVATION_MODIFIER", 8, 16], ["fish", "OBSERVATION", 17, 21], ["tail", "OBSERVATION_MODIFIER", 27, 31], ["corkscrew", "OBSERVATION", 67, 76]]], ["External examination may reveal petechial haemorrhages on the ventral surface of the body and around the mouth, raised lesions or ulcers on the upper midline near the eyes, and whitish ulcers on the skin.", [["petechial", "ANATOMY", 32, 41], ["ventral surface", "ANATOMY", 62, 77], ["body", "ANATOMY", 85, 89], ["mouth", "ANATOMY", 105, 110], ["lesions", "ANATOMY", 119, 126], ["ulcers", "ANATOMY", 130, 136], ["upper midline", "ANATOMY", 144, 157], ["eyes", "ANATOMY", 167, 171], ["whitish ulcers", "ANATOMY", 177, 191], ["skin", "ANATOMY", 199, 203], ["haemorrhages", "DISEASE", 42, 54], ["ulcers", "DISEASE", 130, 136], ["ulcers", "DISEASE", 185, 191], ["petechial haemorrhages", "PATHOLOGICAL_FORMATION", 32, 54], ["ventral surface", "MULTI-TISSUE_STRUCTURE", 62, 77], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["mouth", "ORGANISM_SUBDIVISION", 105, 110], ["lesions", "CANCER", 119, 126], ["ulcers", "PATHOLOGICAL_FORMATION", 130, 136], ["upper midline", "ORGANISM_SUBDIVISION", 144, 157], ["eyes", "ORGAN", 167, 171], ["whitish ulcers", "PATHOLOGICAL_FORMATION", 177, 191], ["skin", "ORGAN", 199, 203], ["External examination", "TEST", 0, 20], ["petechial haemorrhages", "PROBLEM", 32, 54], ["raised lesions", "PROBLEM", 112, 126], ["ulcers on the upper midline", "PROBLEM", 130, 157], ["whitish ulcers on the skin", "PROBLEM", 177, 203], ["petechial", "OBSERVATION_MODIFIER", 32, 41], ["haemorrhages", "OBSERVATION", 42, 54], ["ventral", "ANATOMY_MODIFIER", 62, 69], ["surface", "ANATOMY_MODIFIER", 70, 77], ["body", "ANATOMY", 85, 89], ["mouth", "ANATOMY", 105, 110], ["raised", "OBSERVATION_MODIFIER", 112, 118], ["lesions", "OBSERVATION", 119, 126], ["ulcers", "OBSERVATION", 130, 136], ["upper", "ANATOMY_MODIFIER", 144, 149], ["midline", "ANATOMY_MODIFIER", 150, 157], ["eyes", "ANATOMY", 167, 171], ["whitish", "OBSERVATION_MODIFIER", 177, 184], ["ulcers", "OBSERVATION", 185, 191], ["skin", "ANATOMY", 199, 203]]], ["Gross lesions include bloody or clear yellow fluid in the abdomen, swollen kidneys and spleen and swollen, discolored liver with areas of necrosis or haemorrhage.", [["Gross lesions", "ANATOMY", 0, 13], ["yellow fluid", "ANATOMY", 38, 50], ["abdomen", "ANATOMY", 58, 65], ["swollen kidneys", "ANATOMY", 67, 82], ["spleen", "ANATOMY", 87, 93], ["liver", "ANATOMY", 118, 123], ["necrosis", "DISEASE", 138, 146], ["haemorrhage", "DISEASE", 150, 161], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["fluid", "ORGANISM_SUBSTANCE", 45, 50], ["abdomen", "ORGAN", 58, 65], ["kidneys", "ORGAN", 75, 82], ["spleen", "ORGAN", 87, 93], ["liver", "ORGAN", 118, 123], ["Gross lesions", "PROBLEM", 0, 13], ["bloody or clear yellow fluid in the abdomen", "PROBLEM", 22, 65], ["swollen kidneys and spleen", "PROBLEM", 67, 93], ["swollen, discolored liver", "PROBLEM", 98, 123], ["necrosis", "PROBLEM", 138, 146], ["haemorrhage", "PROBLEM", 150, 161], ["lesions", "OBSERVATION", 6, 13], ["bloody", "OBSERVATION", 22, 28], ["clear", "OBSERVATION_MODIFIER", 32, 37], ["yellow fluid", "OBSERVATION", 38, 50], ["abdomen", "ANATOMY", 58, 65], ["swollen", "OBSERVATION", 67, 74], ["kidneys", "ANATOMY", 75, 82], ["spleen", "ANATOMY", 87, 93], ["swollen", "OBSERVATION", 98, 105], ["discolored", "OBSERVATION", 107, 117], ["liver", "ANATOMY", 118, 123], ["areas", "OBSERVATION_MODIFIER", 129, 134], ["necrosis", "OBSERVATION", 138, 146], ["haemorrhage", "OBSERVATION", 150, 161]]], ["Chronically infected fish may develop a raised cranial lesion or ulcer that eventually penetrates the skull.Furunculosis (Aeromonas salmonicida)The clinical picture varies with the age and species of fish and strain of Aeromonas salmonicida.", [["cranial lesion", "ANATOMY", 47, 61], ["ulcer", "ANATOMY", 65, 70], ["skull", "ANATOMY", 102, 107], ["cranial lesion", "DISEASE", 47, 61], ["ulcer", "DISEASE", 65, 70], ["fish", "ORGANISM", 21, 25], ["cranial lesion", "PATHOLOGICAL_FORMATION", 47, 61], ["ulcer", "PATHOLOGICAL_FORMATION", 65, 70], ["skull", "ORGAN", 102, 107], ["Aeromonas salmonicida", "ORGANISM", 122, 143], ["fish", "ORGANISM_SUBDIVISION", 200, 204], ["Aeromonas salmonicida", "ORGANISM", 219, 240], ["Aeromonas salmonicida", "SPECIES", 122, 143], ["Aeromonas salmonicida", "SPECIES", 219, 240], ["Aeromonas salmonicida", "SPECIES", 122, 143], ["Aeromonas salmonicida", "SPECIES", 219, 240], ["Chronically infected fish", "PROBLEM", 0, 25], ["a raised cranial lesion", "PROBLEM", 38, 61], ["ulcer", "PROBLEM", 65, 70], ["Furunculosis (Aeromonas salmonicida", "PROBLEM", 108, 143], ["Aeromonas salmonicida", "PROBLEM", 219, 240], ["infected", "OBSERVATION", 12, 20], ["raised", "OBSERVATION_MODIFIER", 40, 46], ["cranial", "ANATOMY", 47, 54], ["lesion", "OBSERVATION", 55, 61], ["ulcer", "OBSERVATION", 65, 70], ["skull", "ANATOMY", 102, 107]]], ["In salmon this disease is usually acute (anorexia and discoloration of the skin 2-3 days before death) to peracute (death without prior clinical signs).", [["skin", "ANATOMY", 75, 79], ["anorexia", "DISEASE", 41, 49], ["death", "DISEASE", 96, 101], ["death", "DISEASE", 116, 121], ["skin", "ORGAN", 75, 79], ["anorexia", "PROBLEM", 41, 49], ["discoloration of the skin", "PROBLEM", 54, 79], ["prior clinical signs", "TEST", 130, 150], ["disease", "OBSERVATION", 15, 22], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["anorexia", "OBSERVATION", 41, 49], ["discoloration", "OBSERVATION_MODIFIER", 54, 67], ["skin", "ANATOMY", 75, 79]]], ["Gross lesions include pale liver, soft kidneys, enlarged spleen and haemorrhages in the viscera.", [["Gross lesions", "ANATOMY", 0, 13], ["pale liver", "ANATOMY", 22, 32], ["soft kidneys", "ANATOMY", 34, 46], ["spleen", "ANATOMY", 57, 63], ["viscera", "ANATOMY", 88, 95], ["haemorrhages", "DISEASE", 68, 80], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["liver", "ORGAN", 27, 32], ["kidneys", "ORGAN", 39, 46], ["spleen", "ORGAN", 57, 63], ["viscera", "ORGAN", 88, 95], ["Gross lesions", "PROBLEM", 0, 13], ["pale liver", "PROBLEM", 22, 32], ["enlarged spleen", "PROBLEM", 48, 63], ["haemorrhages in the viscera", "PROBLEM", 68, 95], ["lesions", "OBSERVATION", 6, 13], ["pale", "OBSERVATION", 22, 26], ["liver", "ANATOMY", 27, 32], ["soft", "ANATOMY_MODIFIER", 34, 38], ["kidneys", "ANATOMY", 39, 46], ["enlarged", "OBSERVATION", 48, 56], ["spleen", "ANATOMY", 57, 63], ["haemorrhages", "OBSERVATION", 68, 80], ["viscera", "ANATOMY", 88, 95]]], ["When the course of the disease is subacute, classic ulcerative lesions (furuncles) are seen.Haemorrhagic Septicaemia (Aeromonas hydrophila, A. punctata, A. sobria, Pseudomonas fluorescens, Pseudomonas spp.)Signs of disease include haemorrhages and ulcers of the skin, exophthalmia, haemorrhages involving the eye, fluid-filled abdomen and reddening of the fins and the bases of the fins.", [["ulcerative lesions", "ANATOMY", 52, 70], ["furuncles", "ANATOMY", 72, 81], ["skin", "ANATOMY", 262, 266], ["eye", "ANATOMY", 309, 312], ["fluid", "ANATOMY", 314, 319], ["abdomen", "ANATOMY", 327, 334], ["fins", "ANATOMY", 356, 360], ["fins", "ANATOMY", 382, 386], ["furuncles", "DISEASE", 72, 81], ["Haemorrhagic Septicaemia", "DISEASE", 92, 116], ["Aeromonas hydrophila", "DISEASE", 118, 138], ["haemorrhages", "DISEASE", 231, 243], ["ulcers", "DISEASE", 248, 254], ["exophthalmia", "DISEASE", 268, 280], ["haemorrhages", "DISEASE", 282, 294], ["ulcerative lesions", "PATHOLOGICAL_FORMATION", 52, 70], ["furuncles", "CANCER", 72, 81], ["Haemorrhagic Septicaemia", "ORGANISM", 92, 116], ["Aeromonas hydrophila", "ORGANISM", 118, 138], ["A. punctata", "ORGANISM", 140, 151], ["A. sobria", "ORGANISM", 153, 162], ["Pseudomonas fluorescens", "ORGANISM", 164, 187], ["Pseudomonas spp.", "ORGANISM", 189, 205], ["ulcers", "PATHOLOGICAL_FORMATION", 248, 254], ["skin", "ORGAN", 262, 266], ["eye", "ORGAN", 309, 312], ["abdomen", "ORGANISM_SUBDIVISION", 327, 334], ["fins", "ORGAN", 356, 360], ["fins", "ORGANISM_SUBDIVISION", 382, 386], ["Aeromonas hydrophila", "SPECIES", 118, 138], ["A. punctata", "SPECIES", 140, 151], ["A. sobria", "SPECIES", 153, 162], ["Pseudomonas fluorescens", "SPECIES", 164, 187], ["Pseudomonas spp.", "SPECIES", 189, 205], ["Aeromonas hydrophila", "SPECIES", 118, 138], ["A. punctata", "SPECIES", 140, 151], ["A. sobria", "SPECIES", 153, 162], ["Pseudomonas fluorescens", "SPECIES", 164, 187], ["Pseudomonas spp.)", "SPECIES", 189, 206], ["subacute", "PROBLEM", 34, 42], ["classic ulcerative lesions (furuncles)", "PROBLEM", 44, 82], ["Haemorrhagic Septicaemia", "PROBLEM", 92, 116], ["Aeromonas hydrophila", "PROBLEM", 118, 138], ["A. punctata", "PROBLEM", 140, 151], ["A. sobria", "PROBLEM", 153, 162], ["Pseudomonas fluorescens", "PROBLEM", 164, 187], ["Pseudomonas spp.", "PROBLEM", 189, 205], ["disease", "PROBLEM", 215, 222], ["haemorrhages", "PROBLEM", 231, 243], ["ulcers of the skin", "PROBLEM", 248, 266], ["exophthalmia", "PROBLEM", 268, 280], ["haemorrhages involving the eye, fluid-filled abdomen", "PROBLEM", 282, 334], ["reddening of the fins and the bases of the fins", "PROBLEM", 339, 386], ["disease", "OBSERVATION", 23, 30], ["subacute", "OBSERVATION_MODIFIER", 34, 42], ["classic", "OBSERVATION_MODIFIER", 44, 51], ["ulcerative", "OBSERVATION_MODIFIER", 52, 62], ["lesions", "OBSERVATION", 63, 70], ["Septicaemia", "OBSERVATION", 105, 116], ["Aeromonas hydrophila", "OBSERVATION_MODIFIER", 118, 138], ["disease", "OBSERVATION", 215, 222], ["haemorrhages", "OBSERVATION", 231, 243], ["ulcers", "OBSERVATION", 248, 254], ["skin", "ANATOMY", 262, 266], ["haemorrhages", "OBSERVATION", 282, 294], ["eye", "ANATOMY", 309, 312], ["fluid", "OBSERVATION", 314, 319], ["filled", "OBSERVATION", 320, 326], ["abdomen", "ANATOMY", 327, 334], ["reddening", "OBSERVATION", 339, 348], ["fins", "ANATOMY_MODIFIER", 356, 360], ["bases", "ANATOMY_MODIFIER", 369, 374], ["fins", "ANATOMY", 382, 386]]], ["Internally, swollen kidneys, a pale or greenish liver and intestinal and vent haemorrhages may be seen.", [["swollen kidneys", "ANATOMY", 12, 27], ["liver", "ANATOMY", 48, 53], ["intestinal", "ANATOMY", 58, 68], ["haemorrhages", "DISEASE", 78, 90], ["kidneys", "ORGAN", 20, 27], ["liver", "ORGAN", 48, 53], ["intestinal", "ORGAN", 58, 68], ["Internally, swollen kidneys", "PROBLEM", 0, 27], ["a pale or greenish liver and intestinal and vent haemorrhages", "PROBLEM", 29, 90], ["swollen", "OBSERVATION", 12, 19], ["kidneys", "ANATOMY", 20, 27], ["pale", "OBSERVATION_MODIFIER", 31, 35], ["greenish", "OBSERVATION", 39, 47], ["liver", "ANATOMY", 48, 53], ["intestinal", "ANATOMY", 58, 68], ["vent", "ANATOMY", 73, 77], ["haemorrhages", "OBSERVATION", 78, 90], ["may be seen", "UNCERTAINTY", 91, 102]]], ["This disease is more frequently seen when temperatures are warmer.Infectious Hematopoietic Necrosis (IHN virus)Clinical signs in young fish include pale gills, exophthalmia, haemorrhages at the base of the fins and vent, darkening of the skin and white faecal material trailing from the vent.", [["Hematopoietic", "ANATOMY", 77, 90], ["pale gills", "ANATOMY", 148, 158], ["fins", "ANATOMY", 206, 210], ["skin", "ANATOMY", 238, 242], ["Hematopoietic Necrosis", "DISEASE", 77, 99], ["exophthalmia", "DISEASE", 160, 172], ["haemorrhages", "DISEASE", 174, 186], ["fish", "ORGANISM", 135, 139], ["gills", "ORGAN", 153, 158], ["fins", "ORGANISM_SUBDIVISION", 206, 210], ["skin", "ORGAN", 238, 242], ["This disease", "PROBLEM", 0, 12], ["Infectious Hematopoietic Necrosis (IHN virus", "PROBLEM", 66, 110], ["Clinical signs", "TEST", 111, 125], ["pale gills", "PROBLEM", 148, 158], ["exophthalmia", "PROBLEM", 160, 172], ["haemorrhages", "PROBLEM", 174, 186], ["vent", "TREATMENT", 215, 219], ["darkening of the skin and white faecal material", "PROBLEM", 221, 268], ["the vent", "TREATMENT", 283, 291], ["disease", "OBSERVATION", 5, 12], ["more frequently", "OBSERVATION_MODIFIER", 16, 31], ["Necrosis", "OBSERVATION", 91, 99], ["gills", "ANATOMY", 153, 158], ["haemorrhages", "OBSERVATION", 174, 186], ["base", "ANATOMY_MODIFIER", 194, 198], ["fins", "ANATOMY", 206, 210], ["darkening", "OBSERVATION_MODIFIER", 221, 230], ["skin", "ANATOMY", 238, 242], ["white", "OBSERVATION_MODIFIER", 247, 252], ["faecal material", "OBSERVATION", 253, 268]]], ["Subdermal haemorrhage may occur in the area between the head and dorsal fin.", [["Subdermal", "ANATOMY", 0, 9], ["area", "ANATOMY", 39, 43], ["head", "ANATOMY", 56, 60], ["dorsal fin", "ANATOMY", 65, 75], ["haemorrhage", "DISEASE", 10, 21], ["head", "ORGANISM_SUBDIVISION", 56, 60], ["dorsal fin", "TISSUE", 65, 75], ["Subdermal haemorrhage", "PROBLEM", 0, 21], ["haemorrhage", "OBSERVATION", 10, 21], ["head", "ANATOMY", 56, 60], ["dorsal", "ANATOMY_MODIFIER", 65, 71], ["fin", "ANATOMY", 72, 75]]], ["Grossly, the kidney, liver, spleen and pancreas are necrotic.Infectious Pancreatic Necrosis (IPN virus)Young salmon and trout are clinically affected with IPN while older animals can be carriers.", [["kidney", "ANATOMY", 13, 19], ["liver", "ANATOMY", 21, 26], ["spleen", "ANATOMY", 28, 34], ["pancreas", "ANATOMY", 39, 47], ["Pancreatic", "ANATOMY", 72, 82], ["necrotic", "DISEASE", 52, 60], ["Infectious Pancreatic Necrosis", "DISEASE", 61, 91], ["kidney", "ORGAN", 13, 19], ["liver", "ORGAN", 21, 26], ["spleen", "ORGAN", 28, 34], ["pancreas", "ORGAN", 39, 47], ["Pancreatic", "ORGAN", 72, 82], ["IPN virus", "ORGANISM", 93, 102], ["salmon", "ORGANISM", 109, 115], ["trout", "ORGANISM", 120, 125], ["IPN", "CANCER", 155, 158], ["salmon and trout", "SPECIES", 109, 125], ["Young salmon", "SPECIES", 103, 115], ["trout", "SPECIES", 120, 125], ["necrotic", "PROBLEM", 52, 60], ["Infectious Pancreatic Necrosis (IPN virus", "PROBLEM", 61, 102], ["kidney", "ANATOMY", 13, 19], ["liver", "ANATOMY", 21, 26], ["spleen", "ANATOMY", 28, 34], ["pancreas", "ANATOMY", 39, 47], ["necrotic", "OBSERVATION", 52, 60], ["Pancreatic", "ANATOMY", 72, 82], ["Necrosis", "OBSERVATION", 83, 91]]], ["Clinical signs include erratic swimming, exophthalmia, abdominal distension and darkened bodies.", [["abdominal", "ANATOMY", 55, 64], ["exophthalmia", "DISEASE", 41, 53], ["abdominal distension", "DISEASE", 55, 75], ["abdominal", "ORGANISM_SUBDIVISION", 55, 64], ["Clinical signs", "TEST", 0, 14], ["erratic swimming", "PROBLEM", 23, 39], ["exophthalmia", "PROBLEM", 41, 53], ["abdominal distension", "PROBLEM", 55, 75], ["darkened bodies", "PROBLEM", 80, 95], ["erratic swimming", "OBSERVATION", 23, 39], ["abdominal", "ANATOMY", 55, 64], ["distension", "OBSERVATION", 65, 75], ["darkened bodies", "OBSERVATION", 80, 95]]], ["Grossly the pancreas contains numerous petechial haemorrhages while the liver and spleen are pale.Proliferative Gill Disease (Hamburger Gill Disease; Myxospora protozoan)This disease is caused by a protozoan parasite.", [["pancreas", "ANATOMY", 12, 20], ["petechial", "ANATOMY", 39, 48], ["liver", "ANATOMY", 72, 77], ["spleen", "ANATOMY", 82, 88], ["haemorrhages", "DISEASE", 49, 61], ["Gill Disease", "DISEASE", 112, 124], ["Hamburger Gill Disease", "DISEASE", 126, 148], ["protozoan parasite", "DISEASE", 198, 216], ["pancreas", "ORGAN", 12, 20], ["petechial haemorrhages", "PATHOLOGICAL_FORMATION", 39, 61], ["liver", "ORGAN", 72, 77], ["spleen", "ORGAN", 82, 88], ["numerous petechial haemorrhages", "PROBLEM", 30, 61], ["Proliferative Gill Disease (Hamburger Gill Disease", "PROBLEM", 98, 148], ["Myxospora protozoan)", "PROBLEM", 150, 170], ["This disease", "PROBLEM", 170, 182], ["a protozoan parasite", "PROBLEM", 196, 216], ["pancreas", "ANATOMY", 12, 20], ["numerous", "OBSERVATION_MODIFIER", 30, 38], ["petechial", "OBSERVATION_MODIFIER", 39, 48], ["haemorrhages", "OBSERVATION", 49, 61], ["liver", "ANATOMY", 72, 77], ["spleen", "ANATOMY", 82, 88], ["pale", "OBSERVATION", 93, 97], ["Gill", "ANATOMY", 112, 116], ["Disease", "OBSERVATION", 117, 124], ["Hamburger Gill Disease", "OBSERVATION", 126, 148], ["disease", "OBSERVATION", 175, 182], ["protozoan parasite", "OBSERVATION", 198, 216]]], ["Clinical signs include anorexia and lethargy, and the gills exhibit pale, swollen, clubbed and/or broken lamellae.Proliferative Kidney Disease (Myxospora protozoan)Affected fish exhibit abdominal swelling, exophthalmia, pale gills and a darkening in colour.", [["gills", "ANATOMY", 54, 59], ["lamellae", "ANATOMY", 105, 113], ["Kidney", "ANATOMY", 128, 134], ["abdominal", "ANATOMY", 186, 195], ["pale gills", "ANATOMY", 220, 230], ["anorexia", "DISEASE", 23, 31], ["lethargy", "DISEASE", 36, 44], ["Kidney Disease", "DISEASE", 128, 142], ["abdominal swelling", "DISEASE", 186, 204], ["exophthalmia", "DISEASE", 206, 218], ["gills", "ORGAN", 54, 59], ["Kidney", "ORGAN", 128, 134], ["fish", "ORGANISM", 173, 177], ["abdominal", "ORGANISM_SUBDIVISION", 186, 195], ["gills", "ORGAN", 225, 230], ["Clinical signs", "TEST", 0, 14], ["anorexia", "PROBLEM", 23, 31], ["lethargy", "PROBLEM", 36, 44], ["the gills exhibit pale", "PROBLEM", 50, 72], ["swollen", "PROBLEM", 74, 81], ["clubbed", "PROBLEM", 83, 90], ["broken lamellae", "PROBLEM", 98, 113], ["Proliferative Kidney Disease", "PROBLEM", 114, 142], ["Myxospora protozoan)", "PROBLEM", 144, 164], ["Affected fish", "PROBLEM", 164, 177], ["abdominal swelling", "PROBLEM", 186, 204], ["exophthalmia", "PROBLEM", 206, 218], ["pale gills", "PROBLEM", 220, 230], ["a darkening in colour", "PROBLEM", 235, 256], ["anorexia", "OBSERVATION", 23, 31], ["gills", "ANATOMY", 54, 59], ["pale", "OBSERVATION_MODIFIER", 68, 72], ["swollen", "OBSERVATION", 74, 81], ["lamellae", "OBSERVATION_MODIFIER", 105, 113], ["Kidney", "ANATOMY", 128, 134], ["Disease", "OBSERVATION", 135, 142], ["abdominal", "ANATOMY", 186, 195], ["swelling", "OBSERVATION", 196, 204], ["pale", "OBSERVATION_MODIFIER", 220, 224], ["gills", "ANATOMY", 225, 230], ["darkening", "OBSERVATION_MODIFIER", 237, 246], ["colour", "OBSERVATION_MODIFIER", 250, 256]]], ["Lesions include swollen, mottled kidneys and spleen.Proliferative Kidney Disease (Myxospora protozoan)Saprolegnia (Saprolegnia spp., Achlya spp., Dictuyuchus spp.)Proliferative Kidney Disease (Myxospora protozoan)Several fungal species (water moulds) affect fish and fish eggs, causing cottony tufts or greyish white patches to appear on the affected tissue.Vibriosis (Hitra; Vibrio spp.)Clinical signs range from mortality without prior clinical signs to a chronic course.", [["kidneys", "ANATOMY", 33, 40], ["spleen", "ANATOMY", 45, 51], ["Kidney", "ANATOMY", 66, 72], ["Kidney", "ANATOMY", 177, 183], ["eggs", "ANATOMY", 272, 276], ["cottony tufts", "ANATOMY", 286, 299], ["tissue", "ANATOMY", 351, 357], ["Kidney Disease", "DISEASE", 66, 80], ["Kidney Disease", "DISEASE", 177, 191], ["Vibriosis", "DISEASE", 358, 367], ["kidneys", "ORGAN", 33, 40], ["spleen", "ORGAN", 45, 51], ["Kidney", "ORGAN", 66, 72], ["Saprolegnia spp.", "ORGANISM", 115, 131], ["Achlya spp.", "ORGANISM", 133, 144], ["Dictuyuchus spp", "ORGANISM", 146, 161], ["Kidney", "ORGAN", 177, 183], ["fish", "ORGANISM_SUBDIVISION", 258, 262], ["fish", "ORGANISM", 267, 271], ["eggs", "ORGANISM_SUBSTANCE", 272, 276], ["tissue", "TISSUE", 351, 357], ["Hitra; Vibrio spp.", "ORGANISM", 369, 387], ["Saprolegnia spp.", "SPECIES", 115, 131], ["Achlya spp.", "SPECIES", 133, 144], ["Dictuyuchus spp", "SPECIES", 146, 161], ["Vibrio spp.", "SPECIES", 376, 387], ["Saprolegnia spp.", "SPECIES", 115, 131], ["Achlya spp.", "SPECIES", 133, 144], ["Lesions", "PROBLEM", 0, 7], ["swollen, mottled kidneys and spleen", "PROBLEM", 16, 51], ["Proliferative Kidney Disease", "PROBLEM", 52, 80], ["Myxospora protozoan)", "PROBLEM", 82, 102], ["Saprolegnia (Saprolegnia spp.", "TREATMENT", 102, 131], ["Proliferative Kidney Disease", "PROBLEM", 163, 191], ["Myxospora protozoan", "PROBLEM", 193, 212], ["Several fungal species", "PROBLEM", 213, 235], ["fish eggs", "PROBLEM", 267, 276], ["cottony tufts", "PROBLEM", 286, 299], ["greyish white patches", "PROBLEM", 303, 324], ["Vibriosis", "PROBLEM", 358, 367], ["prior clinical signs", "PROBLEM", 432, 452], ["swollen", "OBSERVATION", 16, 23], ["mottled", "OBSERVATION", 25, 32], ["kidneys", "ANATOMY", 33, 40], ["spleen", "ANATOMY", 45, 51], ["Kidney", "ANATOMY", 66, 72], ["Disease", "OBSERVATION", 73, 80], ["Kidney", "ANATOMY", 177, 183], ["Disease", "OBSERVATION", 184, 191], ["Several", "OBSERVATION_MODIFIER", 213, 220], ["fungal species", "OBSERVATION", 221, 235], ["fish eggs", "OBSERVATION", 267, 276], ["chronic", "OBSERVATION_MODIFIER", 458, 465]]], ["In the acute form, subdermal cavities develop which ulcerate releasing serosanguinous fluid.", [["subdermal cavities", "ANATOMY", 19, 37], ["serosanguinous fluid", "ANATOMY", 71, 91], ["subdermal cavities", "MULTI-TISSUE_STRUCTURE", 19, 37], ["subdermal cavities", "PROBLEM", 19, 37], ["serosanguinous fluid", "PROBLEM", 71, 91], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["subdermal", "ANATOMY", 19, 28], ["cavities", "OBSERVATION", 29, 37], ["serosanguinous fluid", "OBSERVATION", 71, 91]]], ["In the chronic form, eye lesions (exophthalmos, corneal edema and ulceration) and granulomatous lesions in the muscle predominate.Viral Haemorrhagic Septicaemia (VHS virus)Clinical signs and lesions vary greatly.", [["eye lesions", "ANATOMY", 21, 32], ["corneal", "ANATOMY", 48, 55], ["granulomatous lesions", "ANATOMY", 82, 103], ["muscle", "ANATOMY", 111, 117], ["lesions", "ANATOMY", 191, 198], ["eye lesions", "DISEASE", 21, 32], ["exophthalmos", "DISEASE", 34, 46], ["corneal edema", "DISEASE", 48, 61], ["ulceration", "DISEASE", 66, 76], ["Viral Haemorrhagic Septicaemia", "DISEASE", 130, 160], ["eye lesions", "PATHOLOGICAL_FORMATION", 21, 32], ["corneal edema", "PATHOLOGICAL_FORMATION", 48, 61], ["ulceration", "PATHOLOGICAL_FORMATION", 66, 76], ["granulomatous lesions", "PATHOLOGICAL_FORMATION", 82, 103], ["muscle", "ORGAN", 111, 117], ["lesions", "PATHOLOGICAL_FORMATION", 191, 198], ["Viral Haemorrhagic Septicaemia (VHS virus", "SPECIES", 130, 171], ["eye lesions", "PROBLEM", 21, 32], ["exophthalmos", "PROBLEM", 34, 46], ["corneal edema", "PROBLEM", 48, 61], ["ulceration", "PROBLEM", 66, 76], ["granulomatous lesions in the muscle predominate", "PROBLEM", 82, 129], ["Viral Haemorrhagic Septicaemia (VHS virus", "PROBLEM", 130, 171], ["Clinical signs", "TEST", 172, 186], ["lesions", "PROBLEM", 191, 198], ["chronic", "OBSERVATION_MODIFIER", 7, 14], ["eye", "ANATOMY", 21, 24], ["lesions", "OBSERVATION", 25, 32], ["exophthalmos", "OBSERVATION", 34, 46], ["corneal", "ANATOMY", 48, 55], ["edema", "OBSERVATION", 56, 61], ["ulceration", "OBSERVATION", 66, 76], ["granulomatous", "OBSERVATION_MODIFIER", 82, 95], ["lesions", "OBSERVATION", 96, 103], ["muscle", "ANATOMY", 111, 117], ["Haemorrhagic", "OBSERVATION_MODIFIER", 136, 148], ["Septicaemia", "OBSERVATION", 149, 160], ["lesions", "OBSERVATION", 191, 198]]], ["Lethargy, exophthalmia, anaemia, abdominal distension, darkening of the body, and haemorrhagic skin, eyes, gills, and fin bases may be seen.", [["abdominal", "ANATOMY", 33, 42], ["body", "ANATOMY", 72, 76], ["skin", "ANATOMY", 95, 99], ["eyes", "ANATOMY", 101, 105], ["gills", "ANATOMY", 107, 112], ["fin bases", "ANATOMY", 118, 127], ["Lethargy", "DISEASE", 0, 8], ["exophthalmia", "DISEASE", 10, 22], ["anaemia", "DISEASE", 24, 31], ["abdominal distension", "DISEASE", 33, 53], ["haemorrhagic", "DISEASE", 82, 94], ["abdominal", "ORGANISM_SUBDIVISION", 33, 42], ["body", "ORGANISM_SUBDIVISION", 72, 76], ["skin", "ORGAN", 95, 99], ["eyes", "ORGAN", 101, 105], ["gills", "ORGAN", 107, 112], ["fin", "ORGAN", 118, 121], ["Lethargy", "PROBLEM", 0, 8], ["exophthalmia", "PROBLEM", 10, 22], ["anaemia", "PROBLEM", 24, 31], ["abdominal distension", "PROBLEM", 33, 53], ["darkening of the body", "PROBLEM", 55, 76], ["haemorrhagic skin, eyes, gills, and fin bases", "PROBLEM", 82, 127], ["anaemia", "OBSERVATION", 24, 31], ["abdominal", "ANATOMY", 33, 42], ["distension", "OBSERVATION", 43, 53], ["darkening", "OBSERVATION_MODIFIER", 55, 64], ["body", "ANATOMY", 72, 76], ["haemorrhagic", "OBSERVATION_MODIFIER", 82, 94], ["skin", "ANATOMY", 95, 99], ["eyes", "ANATOMY", 101, 105], ["gills", "ANATOMY", 107, 112], ["fin", "ANATOMY_MODIFIER", 118, 121], ["bases", "ANATOMY_MODIFIER", 122, 127]]], ["Grossly, the abdomen is haemorrhagic and the liver, kidneys, and spleen are oedematous.Whirling Disease (Black Tail; Myxobolus cerebralis)This chronic debilitating disease affects younger fish to a much greater degree than older fish.", [["abdomen", "ANATOMY", 13, 20], ["liver", "ANATOMY", 45, 50], ["kidneys", "ANATOMY", 52, 59], ["spleen", "ANATOMY", 65, 71], ["haemorrhagic", "DISEASE", 24, 36], ["abdomen", "ORGAN", 13, 20], ["liver", "ORGAN", 45, 50], ["kidneys", "ORGAN", 52, 59], ["spleen", "ORGAN", 65, 71], ["fish", "ORGANISM", 188, 192], ["fish", "ORGANISM_SUBDIVISION", 229, 233], ["haemorrhagic", "PROBLEM", 24, 36], ["oedematous", "PROBLEM", 76, 86], ["Whirling Disease (Black Tail", "PROBLEM", 87, 115], ["This chronic debilitating disease", "PROBLEM", 138, 171], ["abdomen", "ANATOMY", 13, 20], ["haemorrhagic", "OBSERVATION", 24, 36], ["liver", "ANATOMY", 45, 50], ["kidneys", "ANATOMY", 52, 59], ["spleen", "ANATOMY", 65, 71], ["oedematous", "OBSERVATION", 76, 86], ["Black Tail", "OBSERVATION_MODIFIER", 105, 115], ["chronic", "OBSERVATION_MODIFIER", 143, 150], ["debilitating", "OBSERVATION_MODIFIER", 151, 163], ["disease", "OBSERVATION", 164, 171]]], ["The characteristic behaviour, for which this disease is named, results from damage to the tail cartilage.", [["tail cartilage", "ANATOMY", 90, 104], ["damage to the tail cartilage", "DISEASE", 76, 104], ["tail cartilage", "TISSUE", 90, 104], ["this disease", "PROBLEM", 40, 52], ["damage to the tail cartilage", "PROBLEM", 76, 104], ["characteristic", "OBSERVATION_MODIFIER", 4, 18], ["behaviour", "OBSERVATION_MODIFIER", 19, 28], ["tail cartilage", "ANATOMY", 90, 104]]], ["This disease also causes the tail to become very dark.", [["tail", "ANATOMY", 29, 33], ["tail", "ORGANISM_SUBDIVISION", 29, 33], ["This disease", "PROBLEM", 0, 12], ["disease", "OBSERVATION", 5, 12], ["tail", "OBSERVATION_MODIFIER", 29, 33], ["very", "OBSERVATION_MODIFIER", 44, 48], ["dark", "OBSERVATION", 49, 53]]], ["Damage can also occur to jaw, head, opercula and other areas of the spine.", [["jaw", "ANATOMY", 25, 28], ["head", "ANATOMY", 30, 34], ["opercula", "ANATOMY", 36, 44], ["spine", "ANATOMY", 68, 73], ["jaw", "ORGAN", 25, 28], ["head", "ORGANISM_SUBDIVISION", 30, 34], ["opercula", "CANCER", 36, 44], ["spine", "ORGAN", 68, 73], ["Damage", "PROBLEM", 0, 6], ["jaw", "ANATOMY", 25, 28], ["head", "ANATOMY", 30, 34], ["opercula", "ANATOMY", 36, 44], ["spine", "ANATOMY", 68, 73]]], ["There are no internal lesions.", [["internal lesions", "ANATOMY", 13, 29], ["lesions", "PATHOLOGICAL_FORMATION", 22, 29], ["internal lesions", "PROBLEM", 13, 29], ["no", "UNCERTAINTY", 10, 12], ["internal", "OBSERVATION_MODIFIER", 13, 21], ["lesions", "OBSERVATION", 22, 29]]], ["Weight loss and death occur owing to the inability of the fish to move and feed properly.IntroductionThe use of ionizing radiation as a means of controlling microorganisms has been extensively researched for many years.", [["Weight loss", "DISEASE", 0, 11], ["death", "DISEASE", 16, 21], ["fish", "ORGANISM", 58, 62], ["Weight loss", "PROBLEM", 0, 11], ["death", "PROBLEM", 16, 21], ["ionizing radiation", "TREATMENT", 112, 130]]], ["In one, a radioactive substance, e.g. Cobalt 60, gives off the radiation.", [["Cobalt", "CHEMICAL", 38, 44], ["Cobalt 60", "CHEMICAL", 38, 47], ["Cobalt 60", "SIMPLE_CHEMICAL", 38, 47], ["the radiation", "TREATMENT", 59, 72]]], ["It gives off high-energy photons, called c-rays, which can penetrate foods to a depth of more than 50 cm.", [["high-energy photons", "TREATMENT", 13, 32]]], ["The electrons can only penetrate food to a depth of 3 cm, so the thickness of material, which can be treated effectively, is limited.", [["3 cm", "OBSERVATION_MODIFIER", 52, 56], ["thickness", "OBSERVATION_MODIFIER", 65, 74], ["material", "OBSERVATION", 78, 86]]], ["These technologies have been used commercially for a long time (c-rays for more than thirty years), e.g. to sterilize disposable medical equipment.IntroductionIonizing radiation inactivates microorganisms by one of two mechanisms, described as direct and indirect inactivation.", [["IntroductionIonizing radiation", "TREATMENT", 147, 177]]], ["Direct inactivation refers to the collision of a photon or an electron with the genetic material of a cell.", [["cell", "ANATOMY", 102, 106], ["cell", "CELL", 102, 106], ["Direct inactivation", "PROBLEM", 0, 19], ["a photon", "TREATMENT", 47, 55]]], ["If this collision results in damage to the genetic material that cannot be repaired, the cell is inactivated.", [["cell", "ANATOMY", 89, 93], ["cell", "CELL", 89, 93], ["this collision", "PROBLEM", 3, 17], ["damage to the genetic material", "PROBLEM", 29, 59]]], ["Indirect inactivation results when a photon or electron passes very near to the genetic material and ionizes a molecule of another substance (usually water).", [["electron", "SIMPLE_CHEMICAL", 47, 55], ["Indirect inactivation", "PROBLEM", 0, 21], ["a photon", "TREATMENT", 35, 43]]], ["The free radical resulting from this ionization reacts with the genetic material of the cell and results in inactivation.", [["cell", "ANATOMY", 88, 92], ["free radical", "SIMPLE_CHEMICAL", 4, 16], ["cell", "CELL", 88, 92], ["this ionization reacts", "TREATMENT", 32, 54], ["free", "OBSERVATION_MODIFIER", 4, 8], ["radical", "OBSERVATION_MODIFIER", 9, 16]]], ["Microorganisms vary in their sensitivity to the direct effects of ionizing radiation, with bacterial spores and viruses being most resistant.", [["spores", "ANATOMY", 101, 107], ["Microorganisms", "PROBLEM", 0, 14], ["ionizing radiation", "TREATMENT", 66, 84], ["bacterial spores", "PROBLEM", 91, 107], ["viruses", "PROBLEM", 112, 119], ["ionizing radiation", "OBSERVATION", 66, 84], ["bacterial spores", "OBSERVATION", 91, 107]]], ["Indirect inactivation is influenced by envi-ronmental factors, such as temperature and moisture content.Food ApplicationsIrradiation may be applied to foods to accomplish different technical objectives.", [["envi-ronmental factors", "PROTEIN", 39, 61], ["Indirect inactivation", "PROBLEM", 0, 21], ["envi-ronmental factors", "PROBLEM", 39, 61], ["Food ApplicationsIrradiation", "TREATMENT", 104, 132], ["inactivation", "OBSERVATION", 9, 21]]], ["Meats may be 'pasteurized', to eliminate vegetative pathogenic bacteria, or may be completely sterilized, as is done by NASA in the United States, for the production of high-quality, sterile foods for the space programme.", [["Meats", "ANATOMY", 0, 5], ["vegetative pathogenic bacteria", "PROBLEM", 41, 71], ["the space programme", "TREATMENT", 201, 220]]], ["The World Health Organization has concluded that food irradiated to any dose appropriate to achieve the intended technological objective is both safe to consume and nutritionally adequate.Irradiation of Meat and Meat ProductsMeat and meat products are irradiated primarily to improve the safety of the products by reducing the potential presence of pathogenic bacteria.", [["meat", "ANATOMY", 234, 238], ["Meat", "ORGANISM_SUBSTANCE", 225, 229], ["meat", "ORGANISM", 234, 238], ["Irradiation of Meat", "TREATMENT", 188, 207], ["Meat Products", "TREATMENT", 212, 225], ["Meat and meat products", "TREATMENT", 225, 247], ["the products", "TREATMENT", 298, 310], ["pathogenic bacteria", "PROBLEM", 349, 368], ["pathogenic", "OBSERVATION_MODIFIER", 349, 359], ["bacteria", "OBSERVATION", 360, 368]]], ["Most of the pathogenic bacteria that have been associated with meat, including Salmonella, Campylobacter, and the pathogenic Escherichia coli species, are readily inactivated by irradiation.", [["meat", "ANATOMY", 63, 67], ["meat", "ORGANISM_SUBDIVISION", 63, 67], ["Escherichia coli", "ORGANISM", 125, 141], ["Escherichia coli", "SPECIES", 125, 141], ["Salmonella", "SPECIES", 79, 89], ["Escherichia coli", "SPECIES", 125, 141], ["the pathogenic bacteria", "PROBLEM", 8, 31], ["Salmonella", "PROBLEM", 79, 89], ["Campylobacter", "PROBLEM", 91, 104], ["the pathogenic Escherichia coli species", "PROBLEM", 110, 149], ["pathogenic", "OBSERVATION_MODIFIER", 12, 22], ["bacteria", "OBSERVATION", 23, 31], ["pathogenic", "OBSERVATION_MODIFIER", 114, 124], ["Escherichia coli species", "OBSERVATION", 125, 149]]], ["The technology of irradiation provides the meat industry with the ability to provide a fresh, non-heat-treated product to consumers that is essentially free of pathogenic food-borne bacteria.Irradiation of Meat and Meat ProductsAlong with the reduction or elimination of pathogenic bacteria, there is a significant reduction in the populations of spoilage bacteria.", [["meat", "ANATOMY", 43, 47], ["meat", "ORGANISM_SUBDIVISION", 43, 47], ["irradiation", "TREATMENT", 18, 29], ["a fresh, non-heat-treated product", "TREATMENT", 85, 118], ["borne bacteria", "PROBLEM", 176, 190], ["Irradiation of Meat", "TREATMENT", 191, 210], ["Meat Products", "TREATMENT", 215, 228], ["the reduction", "TREATMENT", 239, 252], ["pathogenic bacteria", "PROBLEM", 271, 290], ["a significant reduction", "PROBLEM", 301, 324], ["spoilage bacteria", "PROBLEM", 347, 364], ["reduction", "OBSERVATION_MODIFIER", 243, 252], ["pathogenic", "OBSERVATION_MODIFIER", 271, 281], ["bacteria", "OBSERVATION", 282, 290], ["significant", "OBSERVATION_MODIFIER", 303, 314], ["reduction", "OBSERVATION_MODIFIER", 315, 324], ["populations", "OBSERVATION_MODIFIER", 332, 343], ["spoilage bacteria", "OBSERVATION", 347, 364]]], ["This results in an extension of shelf-life of the fresh product, which is related to the dose at which the product is processed.", [["the fresh product", "TREATMENT", 46, 63]]], ["Irradiated meats stored at refrigeration temperatures may have an extension of shelf-life of up to 2 weeks.", [["meats", "ANATOMY", 11, 16]]]], "PMC7267311": [["BACKGROUNDThe severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102 virus) which causes coronavirus disease 2019 (COVID\u201019) infection has dramatically changed the way that physicians approach airway procedures.", [["airway", "ANATOMY", 198, 204], ["acute respiratory syndrome coronavirus", "DISEASE", 21, 59], ["coronavirus disease", "DISEASE", 94, 113], ["COVID\u201019", "CHEMICAL", 120, 128], ["infection", "DISEASE", 130, 139], ["SARS\u2010CoV\u20102 virus", "ORGANISM", 63, 79], ["airway", "MULTI-TISSUE_STRUCTURE", 198, 204], ["CoV\u20102 virus", "SPECIES", 68, 79], ["severe acute respiratory syndrome coronavirus", "SPECIES", 14, 59], ["SARS\u2010CoV\u20102 virus", "SPECIES", 63, 79], ["BACKGROUNDThe severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 59], ["SARS\u2010CoV\u20102 virus)", "PROBLEM", 63, 80], ["coronavirus disease", "PROBLEM", 94, 113], ["infection", "PROBLEM", 130, 139], ["airway procedures", "TREATMENT", 198, 215], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["respiratory syndrome coronavirus", "OBSERVATION", 27, 59], ["coronavirus disease", "OBSERVATION", 94, 113], ["infection", "OBSERVATION", 130, 139], ["airway", "ANATOMY", 198, 204]]], ["SARS\u2010CoV\u20102 affects multiple levels of the aerodigestive tract.", [["aerodigestive tract", "ANATOMY", 42, 61], ["SARS", "DISEASE", 0, 4], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 5, 10], ["aerodigestive tract", "ORGAN", 42, 61], ["CoV\u20102", "DNA", 5, 10], ["multiple", "OBSERVATION_MODIFIER", 19, 27], ["levels", "OBSERVATION_MODIFIER", 28, 34], ["aerodigestive tract", "ANATOMY", 42, 61]]], ["Viral loads in the lower respiratory tract samples (sputum) appear to be significantly higher compared to those from nasal or throat swabs.1Although the exact route of transmission is not well defined, SARS\u2010CoV\u20102 is thought to be spread via a combination of contact, droplet, and airborne routes.2The Centers for Disease Control and Prevention has recommended use of personal protective equipment (PPE) for both patients and healthcare personnel in order to decrease risk of transmission; this entails that patients use facemasks and providers utilize isolation gowns, gloves, N95 respirators, and face shields or goggles.3Commonly performed airway procedures including intubation, direct laryngoscopy, bronchoscopy, and tracheostomy placement have a high risk of aerosol generation.", [["lower respiratory tract samples", "ANATOMY", 19, 50], ["sputum", "ANATOMY", 52, 58], ["nasal", "ANATOMY", 117, 122], ["throat swabs", "ANATOMY", 126, 138], ["airway", "ANATOMY", 642, 648], ["CoV\u20102", "CHEMICAL", 207, 212], ["Viral", "ORGANISM", 0, 5], ["lower", "ORGANISM_SUBDIVISION", 19, 24], ["respiratory tract", "ORGANISM_SUBDIVISION", 25, 42], ["samples", "ORGANISM_SUBSTANCE", 43, 50], ["sputum", "ORGANISM_SUBSTANCE", 52, 58], ["nasal", "ORGANISM_SUBDIVISION", 117, 122], ["patients", "ORGANISM", 412, 420], ["patients", "ORGANISM", 507, 515], ["airway", "MULTI-TISSUE_STRUCTURE", 642, 648], ["SARS\u2010CoV\u20102", "PROTEIN", 202, 212], ["patients", "SPECIES", 412, 420], ["patients", "SPECIES", 507, 515], ["Viral loads", "TEST", 0, 11], ["sputum", "TEST", 52, 58], ["nasal or throat swabs", "TEST", 117, 138], ["Disease Control", "TREATMENT", 313, 328], ["personal protective equipment", "TREATMENT", 367, 396], ["facemasks", "TREATMENT", 520, 529], ["isolation gowns", "TREATMENT", 552, 567], ["gloves", "TREATMENT", 569, 575], ["N95 respirators", "TREATMENT", 577, 592], ["face shields", "TREATMENT", 598, 610], ["goggles", "PROBLEM", 614, 621], ["airway procedures", "TREATMENT", 642, 659], ["intubation", "TREATMENT", 670, 680], ["direct laryngoscopy", "TEST", 682, 701], ["bronchoscopy", "TREATMENT", 703, 715], ["tracheostomy placement", "TREATMENT", 721, 743], ["aerosol generation", "TREATMENT", 764, 782], ["loads", "OBSERVATION_MODIFIER", 6, 11], ["lower", "ANATOMY_MODIFIER", 19, 24], ["respiratory tract", "ANATOMY", 25, 42], ["significantly", "OBSERVATION_MODIFIER", 73, 86], ["higher", "OBSERVATION_MODIFIER", 87, 93], ["throat", "ANATOMY", 126, 132], ["thought to be", "UNCERTAINTY", 216, 229], ["airway", "ANATOMY", 642, 648], ["aerosol generation", "OBSERVATION", 764, 782]]], ["Airway providers have reflected on ways to mitigate the transmission risks especially when approaching a surgical airway.", [["Airway", "ANATOMY", 0, 6], ["airway", "ANATOMY", 114, 120], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["airway", "MULTI-TISSUE_STRUCTURE", 114, 120], ["a surgical airway", "TREATMENT", 103, 120], ["airway", "ANATOMY", 114, 120]]], ["Several academic organizations have outlined new recommendations for tracheostomy placement in the setting of the COVID\u201019 pandemic.4, 5, 6, 7 To standardize institutional safety measures with tracheostomy, we advocate using a dedicated tracheostomy time\u2010out applicable to all patients including those suspected of having COVID\u201019 (Figure 1).", [["patients", "ORGANISM", 277, 285], ["patients", "SPECIES", 277, 285], ["tracheostomy placement", "TREATMENT", 69, 91], ["pandemic", "PROBLEM", 123, 131], ["tracheostomy", "TREATMENT", 193, 205], ["a dedicated tracheostomy time\u2010out", "TREATMENT", 225, 258]]], ["The aim of this specific tracheostomy time\u2010out is to reduce preventable errors that may increase the risk of transmission of SARS\u2010CoV\u20102.ELEMENTS OF TRANSMISSION RISK REDUCTIONIn a tracheostomy procedure, risk reduction of SARS\u2010CoV\u20102 transmission can be broken down into three components: preparation, personnel, and process (Figure 2).Preparation.", [["SARS", "DISEASE", 125, 129], ["SARS", "DISEASE", 222, 226], ["SARS\u2010CoV", "SPECIES", 125, 133], ["this specific tracheostomy time\u2010out", "TREATMENT", 11, 46], ["preventable errors", "PROBLEM", 60, 78], ["SARS", "PROBLEM", 125, 129], ["a tracheostomy procedure", "TREATMENT", 178, 202], ["SARS", "PROBLEM", 222, 226], ["CoV\u20102 transmission", "TREATMENT", 227, 245], ["tracheostomy", "OBSERVATION", 180, 192]]], ["Patients who undergo an elective tracheostomy should receive preoperative SARS\u2010CoV\u20102 testing.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["an elective tracheostomy", "TREATMENT", 21, 45], ["preoperative SARS", "TEST", 61, 78], ["CoV\u20102 testing", "TEST", 79, 92], ["tracheostomy", "OBSERVATION", 33, 45]]], ["In emergent airway settings, however, this is not feasible.", [["airway", "ANATOMY", 12, 18], ["airway", "MULTI-TISSUE_STRUCTURE", 12, 18], ["airway", "ANATOMY", 12, 18]]], ["Several days before the procedure, the operating room or ICU coordinator must ensure that a negative pressure room is available and that appropriate PPE will be available for the entire OR staff.", [["the procedure", "TREATMENT", 20, 33]]], ["Before the procedure is started, we advocate that a dedicated tracheostomy time\u2010out should be conducted.", [["the procedure", "TREATMENT", 7, 20], ["a dedicated tracheostomy time\u2010out", "TREATMENT", 50, 83]]], ["Key aspects of the case should be discussed at that moment including operative plan, paralytic and reversal plans, and expected sequences for holding ventilation or changing circuits.", [["paralytic", "TREATMENT", 85, 94], ["reversal plans", "TREATMENT", 99, 113], ["holding ventilation", "TREATMENT", 142, 161], ["changing circuits", "TREATMENT", 165, 182]]], ["When the surgical team is close to entering the airway, there should again be a discussion with the anesthesia team regarding the expected next steps.", [["airway", "ANATOMY", 48, 54], ["airway", "MULTI-TISSUE_STRUCTURE", 48, 54], ["airway", "ANATOMY", 48, 54]]], ["A part of the tracheostomy time\u2010out is focused on intraoperative safety measures (Figure 1, light magenta background); this portion of the time\u2010out should be repeated when close to entering the airway.Personnel.", [["airway", "ANATOMY", 194, 200], ["airway", "MULTI-TISSUE_STRUCTURE", 194, 200], ["the tracheostomy time\u2010out", "TREATMENT", 10, 35], ["tracheostomy", "OBSERVATION", 14, 26], ["airway", "ANATOMY", 194, 200]]], ["The surgical team personnel should be proficient at donning and removing PPE carefully.", [["PPE carefully", "TREATMENT", 73, 86]]], ["It is recommended that a spotter be assigned to ensure that providers are properly wearing PPE and do not accidently contaminate themselves while removing the PPE.", [["the PPE", "TREATMENT", 155, 162]]], ["Only the needed personnel should be present for the tracheostomy.", [["the tracheostomy", "TREATMENT", 48, 64], ["tracheostomy", "OBSERVATION", 52, 64]]], ["Both the surgical and anesthesiology teams must take steps to reduce the aerosolization of respiratory secretions during the case.", [["respiratory secretions", "ANATOMY", 91, 113], ["respiratory secretions", "PROBLEM", 91, 113], ["surgical", "OBSERVATION", 9, 17], ["respiratory", "ANATOMY", 91, 102], ["secretions", "OBSERVATION", 103, 113]]], ["One must also ensure that the ventilator does not become contaminated.", [["the ventilator", "TREATMENT", 26, 40]]], ["Whenever the respiratory circuit is open, ventilation should be held.", [["respiratory", "ANATOMY", 13, 24], ["the respiratory circuit", "TREATMENT", 9, 32], ["ventilation", "TREATMENT", 42, 53], ["respiratory circuit", "OBSERVATION", 13, 32]]], ["This is especially important after the tracheotomy incision is made.", [["the tracheotomy incision", "TREATMENT", 35, 59], ["tracheotomy incision", "OBSERVATION", 39, 59]]], ["Ventilation should be held for the following sequence: endotracheal tube (ETT) advancement distally before tracheal incision, tracheal incision and withdrawal of ETT, tracheostomy tube insertion and cuff inflation, ventilation tubing attachment, and closing of circuit.", [["tracheal", "ANATOMY", 107, 115], ["tracheal", "ANATOMY", 126, 134], ["cuff", "ANATOMY", 199, 203], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 55, 72], ["tracheal", "MULTI-TISSUE_STRUCTURE", 126, 134], ["tube", "TISSUE", 180, 184], ["cuff", "MULTI-TISSUE_STRUCTURE", 199, 203], ["Ventilation", "TREATMENT", 0, 11], ["endotracheal tube (ETT) advancement distally", "TREATMENT", 55, 99], ["tracheal incision", "PROBLEM", 107, 124], ["tracheal incision", "TREATMENT", 126, 143], ["withdrawal of ETT", "TREATMENT", 148, 165], ["tracheostomy tube insertion", "TREATMENT", 167, 194], ["cuff inflation", "TREATMENT", 199, 213], ["ventilation tubing attachment", "TREATMENT", 215, 244], ["closing of circuit", "TREATMENT", 250, 268], ["endotracheal tube", "OBSERVATION", 55, 72], ["tracheal", "ANATOMY", 107, 115], ["incision", "OBSERVATION", 116, 124], ["tracheal", "ANATOMY", 126, 134], ["incision", "OBSERVATION", 135, 143], ["tracheostomy tube", "OBSERVATION", 167, 184], ["cuff inflation", "OBSERVATION", 199, 213], ["ventilation tubing", "OBSERVATION", 215, 233]]], ["If ventilation is needed during this sequence, the surgical and anesthesiology teams should ensure that the cuff of the ETT or tracheostomy tube is first inflated.", [["ventilation", "TREATMENT", 3, 14], ["the cuff of the ETT", "TREATMENT", 104, 123], ["tracheostomy tube", "TREATMENT", 127, 144], ["ETT", "OBSERVATION", 120, 123], ["tracheostomy tube", "OBSERVATION", 127, 144]]], ["With any circuit changes, the anesthesia team clamps the ETT before reconnecting the circuit.", [["the anesthesia", "TREATMENT", 26, 40], ["the ETT", "TREATMENT", 53, 60], ["the circuit", "TREATMENT", 81, 92]]], ["Suctioning should be limited once the tracheotomy is made.", [["Suctioning", "TREATMENT", 0, 10], ["the tracheotomy", "TREATMENT", 34, 49], ["tracheotomy", "OBSERVATION", 38, 49]]], ["If a bronchoscopy is needed after tracheostomy tube placement, we recommend using a side port and holding ventilation.", [["tube", "TISSUE", 47, 51], ["a bronchoscopy", "TEST", 3, 17], ["tracheostomy tube placement", "TREATMENT", 34, 61], ["a side port", "TREATMENT", 82, 93], ["ventilation", "TREATMENT", 106, 117]]], ["A two\u2010filter system is suggested by the Anesthesia Patient Safety Foundation; this involves using a viral filter at the ETT (or tracheostomy tube) and another at the expiratory limb of the ventilator circuit to prevent machine contamination.8Additionally, a filter may be placed at the inspiratory circuit limb if there is concern that the machine itself may become contaminated in\u2010between patient use.", [["limb", "ANATOMY", 177, 181], ["inspiratory circuit limb", "ANATOMY", 286, 310], ["tube", "TISSUE", 141, 145], ["limb", "ORGANISM_SUBDIVISION", 177, 181], ["limb", "ORGANISM_SUBDIVISION", 306, 310], ["patient", "ORGANISM", 390, 397], ["patient", "SPECIES", 390, 397], ["A two\u2010filter system", "TREATMENT", 0, 19], ["a viral filter at the ETT", "TREATMENT", 98, 123], ["tracheostomy tube", "TREATMENT", 128, 145], ["the ventilator circuit", "TREATMENT", 185, 207], ["machine contamination", "PROBLEM", 219, 240], ["a filter", "TREATMENT", 256, 264], ["viral filter", "OBSERVATION", 100, 112], ["tracheostomy tube", "OBSERVATION", 128, 145], ["ventilator circuit", "OBSERVATION", 189, 207], ["filter", "OBSERVATION", 258, 264]]], ["Permitting availability, we recommend that viral filters be placed on the patient's airway, ETT or tracheostomy tube, as well as both limbs of the respiratory circuit, inspiratory, and expiratory.", [["airway", "ANATOMY", 84, 90], ["limbs", "ANATOMY", 134, 139], ["respiratory", "ANATOMY", 147, 158], ["patient", "ORGANISM", 74, 81], ["airway", "MULTI-TISSUE_STRUCTURE", 84, 90], ["tube", "TISSUE", 112, 116], ["limbs", "ORGANISM_SUBDIVISION", 134, 139], ["patient", "SPECIES", 74, 81], ["viral filters", "TREATMENT", 43, 56], ["ETT", "TREATMENT", 92, 95], ["tracheostomy tube", "TREATMENT", 99, 116], ["the respiratory circuit", "TREATMENT", 143, 166], ["airway", "ANATOMY", 84, 90], ["tracheostomy tube", "OBSERVATION", 99, 116], ["respiratory circuit", "OBSERVATION", 147, 166], ["inspiratory", "ANATOMY", 168, 179]]], ["When transitioning from the ETT to tracheostomy circuit, the contaminated ETT viral filter should be discarded and a new filter should be placed at the tracheostomy tube.", [["tube", "TISSUE", 165, 169], ["the ETT", "TREATMENT", 24, 31], ["tracheostomy circuit", "TREATMENT", 35, 55], ["the contaminated ETT viral filter", "TREATMENT", 57, 90], ["a new filter", "TREATMENT", 115, 127], ["the tracheostomy tube", "TREATMENT", 148, 169], ["viral filter", "OBSERVATION", 78, 90], ["new", "OBSERVATION_MODIFIER", 117, 120], ["filter", "OBSERVATION", 121, 127], ["tracheostomy tube", "OBSERVATION", 152, 169]]], ["Once the patient can be weaned off the ventilator, an HME\u2010filter should be used rather than leaving the tracheostomy tube open to trach mask.", [["patient", "ORGANISM", 9, 16], ["tube", "TISSUE", 117, 121], ["patient", "SPECIES", 9, 16], ["the ventilator", "TREATMENT", 35, 49], ["an HME\u2010filter", "TREATMENT", 51, 64], ["the tracheostomy tube", "TREATMENT", 100, 121], ["trach mask", "TREATMENT", 130, 140], ["tracheostomy tube", "OBSERVATION", 104, 121]]]], "PMC7122270": [["IntroductionApoptosis, or programmed cell death, plays a pivotal role in development, organ homeostasis, and immunosurveillance.", [["cell", "ANATOMY", 37, 41], ["organ", "ANATOMY", 86, 91], ["IntroductionApoptosis", "DISEASE", 0, 21], ["cell", "CELL", 37, 41], ["organ", "ORGAN", 86, 91], ["IntroductionApoptosis", "PROBLEM", 0, 21], ["programmed cell death", "PROBLEM", 26, 47], ["immunosurveillance", "TREATMENT", 109, 127], ["cell death", "OBSERVATION", 37, 47]]], ["The term apoptosis was coined by Kerr et al. in 1972 [1] to describe the process of cell death associated with morphological changes, including nucleus and cytoplasm condensation and protuberances from the plasma membrane producing apoptotic bodies, so-called blebs, which are rapidly phagocytosed [1, 2].", [["cell", "ANATOMY", 84, 88], ["nucleus", "ANATOMY", 144, 151], ["cytoplasm", "ANATOMY", 156, 165], ["plasma membrane", "ANATOMY", 206, 221], ["bodies", "ANATOMY", 242, 248], ["blebs", "ANATOMY", 260, 265], ["death", "DISEASE", 89, 94], ["cell", "CELL", 84, 88], ["nucleus", "CELLULAR_COMPONENT", 144, 151], ["cytoplasm", "ORGANISM_SUBSTANCE", 156, 165], ["plasma membrane", "CELLULAR_COMPONENT", 206, 221], ["apoptotic bodies", "CELLULAR_COMPONENT", 232, 248], ["blebs", "CELLULAR_COMPONENT", 260, 265], ["The term apoptosis", "PROBLEM", 0, 18], ["cell death", "PROBLEM", 84, 94], ["morphological changes", "PROBLEM", 111, 132], ["nucleus and cytoplasm condensation", "PROBLEM", 144, 178], ["protuberances", "PROBLEM", 183, 196], ["the plasma membrane", "TEST", 202, 221], ["apoptotic bodies", "PROBLEM", 232, 248], ["blebs", "PROBLEM", 260, 265], ["nucleus", "ANATOMY", 144, 151], ["cytoplasm condensation", "OBSERVATION", 156, 178], ["plasma membrane", "OBSERVATION_MODIFIER", 206, 221], ["apoptotic bodies", "OBSERVATION", 232, 248], ["blebs", "OBSERVATION", 260, 265]]], ["Inhibition of this cellular process is observed in different pathologies, such as cancer and autoimmunity, while amplification of the apoptotic signal was reported in neurodegenerative disorders including Alzheimer\u2019s and Parkinson\u2019s diseases [3, 4], as well as infection by human immunodeficiency virus (HIV).IntroductionThe origin of the apoptotic signal has been used to distinguish two main signaling pathways.", [["cellular", "ANATOMY", 19, 27], ["cancer", "ANATOMY", 82, 88], ["cancer", "DISEASE", 82, 88], ["autoimmunity", "DISEASE", 93, 105], ["neurodegenerative disorders", "DISEASE", 167, 194], ["Alzheimer\u2019s and Parkinson\u2019s diseases", "DISEASE", 205, 241], ["infection", "DISEASE", 261, 270], ["human immunodeficiency virus (HIV)", "DISEASE", 274, 308], ["cellular", "CELL", 19, 27], ["cancer", "CANCER", 82, 88], ["human immunodeficiency virus", "ORGANISM", 274, 302], ["HIV", "ORGANISM", 304, 307], ["human", "SPECIES", 274, 279], ["immunodeficiency virus", "SPECIES", 280, 302], ["HIV", "SPECIES", 304, 307], ["human immunodeficiency virus", "SPECIES", 274, 302], ["HIV", "SPECIES", 304, 307], ["this cellular process", "PROBLEM", 14, 35], ["different pathologies", "PROBLEM", 51, 72], ["cancer", "PROBLEM", 82, 88], ["autoimmunity", "PROBLEM", 93, 105], ["the apoptotic signal", "TEST", 130, 150], ["neurodegenerative disorders", "PROBLEM", 167, 194], ["Alzheimer\u2019s", "PROBLEM", 205, 216], ["Parkinson\u2019s diseases", "PROBLEM", 221, 241], ["infection", "PROBLEM", 261, 270], ["human immunodeficiency virus", "PROBLEM", 274, 302], ["cellular process", "OBSERVATION", 19, 35], ["different", "OBSERVATION_MODIFIER", 51, 60], ["pathologies", "OBSERVATION", 61, 72], ["cancer", "OBSERVATION", 82, 88], ["neurodegenerative disorders", "OBSERVATION", 167, 194], ["infection", "OBSERVATION", 261, 270], ["origin", "ANATOMY_MODIFIER", 325, 331], ["apoptotic signal", "OBSERVATION", 339, 355]]], ["The intrinsic pathway stems from accumulation of DNA damage, deregulation of mitochondrial function, or virus infection and induces the release of proapoptotic factors from the mitochondria, whereas extrinsic signals are transmitted by the binding of apoptotic ligands to death receptors present at the cell surface.", [["mitochondrial", "ANATOMY", 77, 90], ["mitochondria", "ANATOMY", 177, 189], ["cell surface", "ANATOMY", 303, 315], ["infection", "DISEASE", 110, 119], ["death", "DISEASE", 272, 277], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["mitochondrial", "CELLULAR_COMPONENT", 77, 90], ["mitochondria", "CELLULAR_COMPONENT", 177, 189], ["cell surface", "CELLULAR_COMPONENT", 303, 315], ["proapoptotic factors", "PROTEIN", 147, 167], ["death receptors", "PROTEIN", 272, 287], ["DNA damage", "PROBLEM", 49, 59], ["mitochondrial function", "PROBLEM", 77, 99], ["virus infection", "PROBLEM", 104, 119], ["proapoptotic factors", "PROBLEM", 147, 167], ["the mitochondria", "PROBLEM", 173, 189], ["pathway stems", "OBSERVATION", 14, 27], ["accumulation", "OBSERVATION_MODIFIER", 33, 45], ["DNA damage", "OBSERVATION", 49, 59], ["mitochondrial function", "OBSERVATION", 77, 99], ["virus infection", "OBSERVATION", 104, 119], ["apoptotic ligands", "OBSERVATION", 251, 268], ["cell", "OBSERVATION_MODIFIER", 303, 307], ["surface", "OBSERVATION_MODIFIER", 308, 315]]], ["Interconnections exist between these two signaling pathways: both leading to the activation of a family of cysteine proteases specific for aspartic acid residues, called caspases [5].", [["aspartic acid", "CHEMICAL", 139, 152], ["cysteine", "CHEMICAL", 107, 115], ["aspartic acid", "CHEMICAL", 139, 152], ["aspartic acid", "AMINO_ACID", 139, 152], ["caspases", "GENE_OR_GENE_PRODUCT", 170, 178], ["cysteine proteases", "PROTEIN", 107, 125], ["caspases", "PROTEIN", 170, 178], ["cysteine proteases", "TREATMENT", 107, 125], ["aspartic acid residues", "PROBLEM", 139, 161]]], ["The apoptotic role of mitochondria is associated with reduction in its transmembrane potential and the loss of its extracellular membrane integrity, leading to the release of different apoptogenic factors in the cytosol.", [["mitochondria", "ANATOMY", 22, 34], ["transmembrane", "ANATOMY", 71, 84], ["extracellular membrane", "ANATOMY", 115, 137], ["cytosol", "ANATOMY", 212, 219], ["mitochondria", "CELLULAR_COMPONENT", 22, 34], ["extracellular membrane", "CELLULAR_COMPONENT", 115, 137], ["cytosol", "CELLULAR_COMPONENT", 212, 219], ["apoptogenic factors", "PROTEIN", 185, 204], ["the loss of its extracellular membrane integrity", "PROBLEM", 99, 147], ["different apoptogenic factors", "PROBLEM", 175, 204], ["apoptotic", "OBSERVATION_MODIFIER", 4, 13], ["is associated with", "UNCERTAINTY", 35, 53], ["reduction", "OBSERVATION_MODIFIER", 54, 63], ["loss", "OBSERVATION_MODIFIER", 103, 107], ["extracellular membrane integrity", "OBSERVATION", 115, 147]]], ["Among them, cytochrome c associates with the caspase-9/APAF-1 complex to form the apoptosome and trigger apoptosis [6].IntroductionThese two signaling pathways share common features, and both require the aggregation of initiator caspases as their preliminary events.", [["apoptosome", "ANATOMY", 82, 92], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 12, 24], ["caspase-9", "GENE_OR_GENE_PRODUCT", 45, 54], ["APAF-1", "GENE_OR_GENE_PRODUCT", 55, 61], ["apoptosome", "GENE_OR_GENE_PRODUCT", 82, 92], ["caspases", "GENE_OR_GENE_PRODUCT", 229, 237], ["cytochrome c", "PROTEIN", 12, 24], ["caspase-9/APAF-1 complex", "PROTEIN", 45, 69], ["apoptosome", "PROTEIN", 82, 92], ["initiator caspases", "PROTEIN", 219, 237], ["the caspase", "TEST", 41, 52], ["initiator caspases", "TREATMENT", 219, 237]]], ["During interactions with respective ligands, members of the death receptor superfamily recruit adaptor proteins such as Fas-associated protein with a death domain (FADD) [7, 8] or tumor necrosis factor (TNF) receptor 1-associated death domain protein (TRADD) [9], resulting in the aggregation and activation of the initiators caspase-8 and caspase-10 to form the death-inducing signaling complex (DISC) [10].", [["death", "DISEASE", 60, 65], ["death", "DISEASE", 150, 155], ["tumor", "DISEASE", 180, 185], ["death", "DISEASE", 363, 368], ["FADD", "GENE_OR_GENE_PRODUCT", 164, 168], ["tumor necrosis factor (TNF) receptor 1-associated death domain", "GENE_OR_GENE_PRODUCT", 180, 242], ["TRADD", "GENE_OR_GENE_PRODUCT", 252, 257], ["caspase-8", "GENE_OR_GENE_PRODUCT", 326, 335], ["caspase-10", "GENE_OR_GENE_PRODUCT", 340, 350], ["death-inducing signaling complex", "GENE_OR_GENE_PRODUCT", 363, 395], ["DISC", "GENE_OR_GENE_PRODUCT", 397, 401], ["death receptor superfamily", "PROTEIN", 60, 86], ["adaptor proteins", "PROTEIN", 95, 111], ["Fas-associated protein", "PROTEIN", 120, 142], ["death domain (FADD) [7, 8", "PROTEIN", 150, 175], ["tumor necrosis factor (TNF) receptor 1-associated death domain protein", "PROTEIN", 180, 250], ["TRADD", "PROTEIN", 252, 257], ["caspase-8", "PROTEIN", 326, 335], ["caspase-10", "PROTEIN", 340, 350], ["death-inducing signaling complex", "PROTEIN", 363, 395], ["DISC", "PROTEIN", 397, 401], ["adaptor proteins", "TREATMENT", 95, 111], ["a death domain (FADD)", "PROBLEM", 148, 169], ["tumor necrosis factor", "PROBLEM", 180, 201], ["TNF", "TEST", 203, 206], ["receptor", "TEST", 208, 216], ["associated death domain protein", "PROBLEM", 219, 250], ["the aggregation", "PROBLEM", 277, 292], ["the initiators caspase", "TREATMENT", 311, 333], ["caspase", "TREATMENT", 340, 347], ["the death", "PROBLEM", 359, 368], ["signaling complex (DISC)", "PROBLEM", 378, 402], ["tumor", "OBSERVATION_MODIFIER", 180, 185], ["necrosis", "OBSERVATION", 186, 194], ["DISC", "ANATOMY", 397, 401]]], ["In a similar manner, release of cytochrome c and ATP by mitochondria promotes the formation of the apoptosome with the cytosolic APAF-1, thereby aggregating and activating the initiator caspase-9, which in turn cleaves caspase-3 [11].IntroductionIt should be kept in mind that death receptors CD95 [12], TNFR1 [13], DR4 [14], DR5 [15], and DR6 [16] have been cloned based on their ability to elicit apoptosis.", [["mitochondria", "ANATOMY", 56, 68], ["cytosolic", "ANATOMY", 119, 128], ["ATP", "CHEMICAL", 49, 52], ["death", "DISEASE", 277, 282], ["ATP", "CHEMICAL", 49, 52], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 32, 44], ["ATP", "SIMPLE_CHEMICAL", 49, 52], ["mitochondria", "CELLULAR_COMPONENT", 56, 68], ["APAF-1", "GENE_OR_GENE_PRODUCT", 129, 135], ["caspase-9", "GENE_OR_GENE_PRODUCT", 186, 195], ["caspase-3", "GENE_OR_GENE_PRODUCT", 219, 228], ["CD95", "GENE_OR_GENE_PRODUCT", 293, 297], ["TNFR1", "GENE_OR_GENE_PRODUCT", 304, 309], ["DR4", "GENE_OR_GENE_PRODUCT", 316, 319], ["DR5", "GENE_OR_GENE_PRODUCT", 326, 329], ["DR6", "GENE_OR_GENE_PRODUCT", 340, 343], ["cytochrome c", "PROTEIN", 32, 44], ["apoptosome", "PROTEIN", 99, 109], ["cytosolic APAF-1", "PROTEIN", 119, 135], ["initiator caspase-9", "PROTEIN", 176, 195], ["caspase", "PROTEIN", 219, 226], ["death receptors", "PROTEIN", 277, 292], ["CD95", "PROTEIN", 293, 297], ["TNFR1", "PROTEIN", 304, 309], ["DR4", "PROTEIN", 316, 319], ["DR5", "PROTEIN", 326, 329], ["cytochrome c and ATP", "TREATMENT", 32, 52], ["the cytosolic APAF", "TEST", 115, 133], ["the initiator caspase", "TREATMENT", 172, 193], ["caspase", "TEST", 219, 226], ["CD95", "TEST", 293, 297], ["TNFR1", "TEST", 304, 309], ["DR4", "TEST", 316, 319], ["DR5", "TEST", 326, 329], ["DR6", "TEST", 340, 343], ["apoptosis", "PROBLEM", 399, 408], ["apoptosis", "OBSERVATION", 399, 408]]], ["Although studies have revealed the ability of Fas/CD95, DR4, and DR5 in triggering non-apoptotic signaling pathways even immediately after their cloning [17, 18], most, if not all, studies have been focused on characterizing the molecular events leading to cell death.", [["cell", "ANATOMY", 257, 261], ["death", "DISEASE", 262, 267], ["Fas", "GENE_OR_GENE_PRODUCT", 46, 49], ["CD95", "GENE_OR_GENE_PRODUCT", 50, 54], ["DR4", "GENE_OR_GENE_PRODUCT", 56, 59], ["DR5", "GENE_OR_GENE_PRODUCT", 65, 68], ["cell", "CELL", 257, 261], ["Fas", "PROTEIN", 46, 49], ["CD95", "PROTEIN", 50, 54], ["DR4", "PROTEIN", 56, 59], ["DR5", "PROTEIN", 65, 68], ["studies", "TEST", 9, 16], ["Fas", "TEST", 46, 49], ["DR4", "TEST", 56, 59], ["DR5", "TREATMENT", 65, 68], ["the molecular events", "PROBLEM", 225, 245], ["cell death", "PROBLEM", 257, 267], ["non-apoptotic signaling", "OBSERVATION", 83, 106], ["cell death", "OBSERVATION", 257, 267]]], ["Accordingly, several agonistic molecules were developed in order to kill cancer cells, neglecting the impact of non-apoptotic signals in pathophysiological contexts.", [["cancer cells", "ANATOMY", 73, 85], ["cancer", "DISEASE", 73, 79], ["cancer cells", "CELL", 73, 85], ["cancer cells", "CELL_TYPE", 73, 85], ["several agonistic molecules", "PROBLEM", 13, 40], ["kill cancer cells", "PROBLEM", 68, 85], ["non-apoptotic signals", "OBSERVATION", 112, 133]]], ["More recent data changed this vision by evaluating the biological role of death receptor-mediated non-apoptotic signaling pathways in chronic inflammatory disorders and carcinogenesis.IntroductionIn this chapter, apoptotic signaling pathways induced by death receptors are discussed.", [["death", "DISEASE", 74, 79], ["inflammatory disorders", "DISEASE", 142, 164], ["carcinogenesis", "DISEASE", 169, 183], ["death", "DISEASE", 253, 258], ["death receptor", "PROTEIN", 74, 88], ["death receptors", "PROTEIN", 253, 268], ["non-apoptotic signaling pathways", "PROBLEM", 98, 130], ["chronic inflammatory disorders", "PROBLEM", 134, 164], ["carcinogenesis", "PROBLEM", 169, 183], ["chronic", "OBSERVATION_MODIFIER", 134, 141], ["inflammatory", "OBSERVATION", 142, 154]]], ["Moreover, recent evidences pointing to the non-apoptotic signals transmitted by the same receptors are brought up, which may imply their tremendous impact on tumor progression and the design of therapeutic tools.TNFR1 Signaling Pathways ::: TNF Receptor FamilyTNF-\u03b1 exerts its effects by binding to two receptors, TNFR1 and TNFR2 [20].", [["tumor", "ANATOMY", 158, 163], ["tumor", "DISEASE", 158, 163], ["tumor", "CANCER", 158, 163], ["TNFR1", "GENE_OR_GENE_PRODUCT", 212, 217], ["TNF", "GENE_OR_GENE_PRODUCT", 241, 244], ["FamilyTNF-\u03b1", "GENE_OR_GENE_PRODUCT", 254, 265], ["TNFR1", "GENE_OR_GENE_PRODUCT", 314, 319], ["TNFR2", "GENE_OR_GENE_PRODUCT", 324, 329], ["TNFR1", "PROTEIN", 212, 217], ["TNF Receptor FamilyTNF-\u03b1", "PROTEIN", 241, 265], ["TNFR1", "PROTEIN", 314, 319], ["TNFR2", "PROTEIN", 324, 329], ["tumor progression", "PROBLEM", 158, 175], ["TNF", "TEST", 241, 244], ["FamilyTNF", "TEST", 254, 263], ["tremendous", "OBSERVATION_MODIFIER", 137, 147], ["tumor", "OBSERVATION", 158, 163]]], ["Recently, progranulin was identified as a ligand of TNFR with a higher affinity than TNF-\u03b1.", [["progranulin", "GENE_OR_GENE_PRODUCT", 10, 21], ["TNFR", "GENE_OR_GENE_PRODUCT", 52, 56], ["TNF-\u03b1.", "GENE_OR_GENE_PRODUCT", 85, 91], ["progranulin", "PROTEIN", 10, 21], ["TNFR", "PROTEIN", 52, 56], ["TNF", "PROTEIN", 85, 88], ["a ligand of TNFR", "TEST", 40, 56], ["TNF", "TEST", 85, 88]]], ["Progranulin antagonizes TNF-\u03b1 signaling and plays a critical role in the pathogenesis of inflammatory arthritis in mice [27].", [["Progranulin", "CHEMICAL", 0, 11], ["inflammatory arthritis", "DISEASE", 89, 111], ["Progranulin", "CHEMICAL", 0, 11], ["Progranulin", "SIMPLE_CHEMICAL", 0, 11], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 24, 29], ["mice", "ORGANISM", 115, 119], ["TNF", "PROTEIN", 24, 27], ["mice", "SPECIES", 115, 119], ["mice", "SPECIES", 115, 119], ["Progranulin antagonizes TNF", "TEST", 0, 27], ["inflammatory arthritis", "PROBLEM", 89, 111], ["inflammatory", "OBSERVATION_MODIFIER", 89, 101], ["arthritis", "OBSERVATION", 102, 111]]], ["TNFR1, a 55 kDa protein expressed in almost all cell types, presents a DD in its intracellular region, whereas TNFR2, a 75 kDa protein, is mainly detected in oligodendrocytes, astrocytes, T-cells, myocytes, thymocytes, endothelial cells, and human mesenchymal stem cells [28].", [["cell", "ANATOMY", 48, 52], ["intracellular region", "ANATOMY", 81, 101], ["oligodendrocytes", "ANATOMY", 158, 174], ["astrocytes", "ANATOMY", 176, 186], ["T-cells", "ANATOMY", 188, 195], ["myocytes", "ANATOMY", 197, 205], ["thymocytes", "ANATOMY", 207, 217], ["endothelial cells", "ANATOMY", 219, 236], ["mesenchymal stem cells", "ANATOMY", 248, 270], ["TNFR1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 48, 52], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 94], ["TNFR2", "GENE_OR_GENE_PRODUCT", 111, 116], ["oligodendrocytes", "CELL", 158, 174], ["astrocytes", "CELL", 176, 186], ["T-cells", "CELL", 188, 195], ["myocytes", "CELL", 197, 205], ["thymocytes", "CELL", 207, 217], ["endothelial cells", "CELL", 219, 236], ["human", "ORGANISM", 242, 247], ["mesenchymal stem cells", "CELL", 248, 270], ["TNFR1", "PROTEIN", 0, 5], ["55 kDa protein", "PROTEIN", 9, 23], ["DD", "PROTEIN", 71, 73], ["TNFR2", "PROTEIN", 111, 116], ["75 kDa protein", "PROTEIN", 120, 134], ["oligodendrocytes", "CELL_TYPE", 158, 174], ["astrocytes", "CELL_TYPE", 176, 186], ["T-cells", "CELL_TYPE", 188, 195], ["myocytes", "CELL_TYPE", 197, 205], ["thymocytes", "CELL_TYPE", 207, 217], ["endothelial cells", "CELL_TYPE", 219, 236], ["human mesenchymal stem cells", "CELL_TYPE", 242, 270], ["human", "SPECIES", 242, 247], ["human", "SPECIES", 242, 247], ["TNFR1", "TEST", 0, 5], ["a 55 kDa protein", "TEST", 7, 23], ["a DD in its intracellular region", "PROBLEM", 69, 101], ["TNFR2", "TEST", 111, 116], ["a 75 kDa protein", "TEST", 118, 134], ["oligodendrocytes", "TEST", 158, 174], ["astrocytes", "TEST", 176, 186], ["myocytes", "TEST", 197, 205], ["thymocytes", "TEST", 207, 217], ["endothelial cells", "TEST", 219, 236], ["human mesenchymal stem cells", "TEST", 242, 270], ["almost all", "OBSERVATION_MODIFIER", 37, 47], ["cell types", "OBSERVATION", 48, 58], ["intracellular", "ANATOMY_MODIFIER", 81, 94], ["astrocytes", "ANATOMY", 176, 186], ["myocytes", "ANATOMY", 197, 205], ["thymocytes", "ANATOMY", 207, 217], ["endothelial cells", "OBSERVATION", 219, 236], ["mesenchymal stem cells", "OBSERVATION", 248, 270]]], ["Uncertainty remains on the TNFR2 signaling pathway, which has been previously reviewed [28].", [["TNFR2", "GENE_OR_GENE_PRODUCT", 27, 32], ["TNFR2", "PROTEIN", 27, 32]]], ["The CRD1 of CD95, TNFR1, and TNFR2 is involved in homotypic interactions, leading to pre-association of the receptor as a homotrimer in the absence of ligand [23, 24, 29].", [["CRD1", "GENE_OR_GENE_PRODUCT", 4, 8], ["CD95", "GENE_OR_GENE_PRODUCT", 12, 16], ["TNFR1", "GENE_OR_GENE_PRODUCT", 18, 23], ["TNFR2", "GENE_OR_GENE_PRODUCT", 29, 34], ["CRD1", "PROTEIN", 4, 8], ["CD95", "PROTEIN", 12, 16], ["TNFR1", "PROTEIN", 18, 23], ["TNFR2", "PROTEIN", 29, 34], ["homotrimer", "PROTEIN", 122, 132], ["CD95", "TEST", 12, 16], ["TNFR1", "TEST", 18, 23], ["TNFR2", "TEST", 29, 34], ["homotypic interactions", "OBSERVATION", 50, 72]]], ["This domain has been designated as the pre-ligand binding assembly domain (PLAD) [29].", [["pre-ligand binding assembly domain", "PROTEIN", 39, 73], ["PLAD", "PROTEIN", 75, 79]]], ["Receptors of the TNFR superfamily do not possess any enzymatic activity on their own and rely on the recruitment of adaptor proteins for signaling.", [["TNFR", "GENE_OR_GENE_PRODUCT", 17, 21], ["TNFR superfamily", "PROTEIN", 17, 33], ["adaptor proteins", "PROTEIN", 116, 132]]], ["Among these adaptor proteins, TRADD or FADD is instrumental in the implementation of cell death processes [7\u201310].TNFR1 Signaling Pathways ::: TNF Receptor FamilyTNF is synthesized as a 26 kDa transmembrane type II protein (m-TNF) of 233 amino acids [30] which can be cleaved by the metalloprotease TACE [31, 32] to release the 17 kDa soluble form of the cytokine (cl-TNF).", [["cell", "ANATOMY", 85, 89], ["death", "DISEASE", 90, 95], ["amino acids", "CHEMICAL", 237, 248], ["amino acids", "CHEMICAL", 237, 248], ["TRADD", "GENE_OR_GENE_PRODUCT", 30, 35], ["FADD", "GENE_OR_GENE_PRODUCT", 39, 43], ["cell", "CELL", 85, 89], ["TNFR1", "GENE_OR_GENE_PRODUCT", 113, 118], ["TNF Receptor FamilyTNF", "GENE_OR_GENE_PRODUCT", 142, 164], ["m-TNF", "GENE_OR_GENE_PRODUCT", 223, 228], ["amino acids", "AMINO_ACID", 237, 248], ["cl-TNF", "GENE_OR_GENE_PRODUCT", 364, 370], ["adaptor proteins", "PROTEIN", 12, 28], ["TRADD", "PROTEIN", 30, 35], ["FADD", "PROTEIN", 39, 43], ["TNFR1", "PROTEIN", 113, 118], ["TNF", "PROTEIN", 142, 145], ["FamilyTNF", "PROTEIN", 155, 164], ["26 kDa transmembrane type II protein", "PROTEIN", 185, 221], ["m", "PROTEIN", 223, 224], ["TNF", "PROTEIN", 225, 228], ["metalloprotease TACE", "PROTEIN", 282, 302], ["17 kDa soluble form", "PROTEIN", 327, 346], ["cytokine", "PROTEIN", 354, 362], ["cl", "PROTEIN", 364, 366], ["TNF", "PROTEIN", 367, 370], ["these adaptor proteins", "TREATMENT", 6, 28], ["cell death processes", "PROBLEM", 85, 105], ["a 26 kDa transmembrane type II protein", "TEST", 183, 221], ["TNF", "TEST", 225, 228], ["amino acids", "TEST", 237, 248], ["the metalloprotease TACE", "TREATMENT", 278, 302], ["the cytokine", "TEST", 350, 362]]], ["In contrast to cl-TNF, which only activates TNFR1, m-TNF can bind and activate both TNFR1 and TNFR2 [33].TNFR1 Signaling Pathways ::: TNF Receptor FamilyActivation of TNFR1 leads to the induction of cellular processes ranging from cell death (apoptosis or necroptosis) to cell proliferation, migration, and differentiation; the implementation of such different cellular responses reflects the formation of different molecular complexes after receptor activation [28].", [["cellular", "ANATOMY", 199, 207], ["cell", "ANATOMY", 231, 235], ["cell", "ANATOMY", 272, 276], ["cellular", "ANATOMY", 361, 369], ["m-", "CHEMICAL", 51, 53], ["death", "DISEASE", 236, 241], ["cl-TNF", "GENE_OR_GENE_PRODUCT", 15, 21], ["TNFR1", "GENE_OR_GENE_PRODUCT", 44, 49], ["m-TNF", "GENE_OR_GENE_PRODUCT", 51, 56], ["TNFR1", "GENE_OR_GENE_PRODUCT", 84, 89], ["TNFR2", "GENE_OR_GENE_PRODUCT", 94, 99], ["TNFR1", "GENE_OR_GENE_PRODUCT", 105, 110], ["TNF Receptor", "GENE_OR_GENE_PRODUCT", 134, 146], ["TNFR1", "GENE_OR_GENE_PRODUCT", 167, 172], ["cellular", "CELL", 199, 207], ["cell", "CELL", 231, 235], ["cell", "CELL", 272, 276], ["cellular", "CELL", 361, 369], ["cl", "PROTEIN", 15, 17], ["TNF", "PROTEIN", 18, 21], ["TNFR1", "PROTEIN", 44, 49], ["TNF", "PROTEIN", 53, 56], ["TNFR1", "PROTEIN", 84, 89], ["TNFR2", "PROTEIN", 94, 99], ["TNFR1", "PROTEIN", 105, 110], ["TNF", "PROTEIN", 134, 137], ["TNFR1", "PROTEIN", 167, 172], ["molecular complexes", "PROTEIN", 416, 435], ["TNFR1", "TEST", 44, 49], ["TNFR2", "TEST", 94, 99], ["TNF", "TREATMENT", 134, 137], ["TNFR1", "TREATMENT", 167, 172], ["cellular processes", "PROBLEM", 199, 217], ["cell death", "PROBLEM", 231, 241], ["apoptosis", "PROBLEM", 243, 252], ["necroptosis", "PROBLEM", 256, 267], ["cell proliferation", "PROBLEM", 272, 290], ["TNF", "ANATOMY", 18, 21], ["cell death", "OBSERVATION", 231, 241], ["cell", "OBSERVATION", 272, 276], ["proliferation", "OBSERVATION_MODIFIER", 277, 290], ["migration", "OBSERVATION_MODIFIER", 292, 301]]], ["Binding of TNF to TNFR1 causes the formation of two consecutive complexes.", [["TNF", "GENE_OR_GENE_PRODUCT", 11, 14], ["TNFR1", "GENE_OR_GENE_PRODUCT", 18, 23], ["TNF", "PROTEIN", 11, 14], ["TNFR1", "PROTEIN", 18, 23], ["TNF", "ANATOMY", 11, 14]]], ["While the plasma membrane complex (complex I) elicits a non-apoptotic signaling pathway, a second, internalized complex (complex II or DISC) triggers cell death [2].", [["plasma membrane", "ANATOMY", 10, 25], ["cell", "ANATOMY", 150, 154], ["death", "DISEASE", 155, 160], ["plasma membrane", "CELLULAR_COMPONENT", 10, 25], ["complex I", "GENE_OR_GENE_PRODUCT", 35, 44], ["complex II", "GENE_OR_GENE_PRODUCT", 121, 131], ["DISC", "GENE_OR_GENE_PRODUCT", 135, 139], ["cell", "CELL", 150, 154], ["plasma membrane complex", "PROTEIN", 10, 33], ["complex I", "PROTEIN", 35, 44], ["internalized complex", "PROTEIN", 99, 119], ["complex II", "PROTEIN", 121, 131], ["DISC", "PROTEIN", 135, 139], ["a non-apoptotic signaling pathway", "PROBLEM", 54, 87], ["a second, internalized complex (complex II or DISC) triggers cell death", "PROBLEM", 89, 160], ["non-apoptotic signaling pathway", "OBSERVATION", 56, 87], ["internalized", "OBSERVATION_MODIFIER", 99, 111], ["complex", "OBSERVATION_MODIFIER", 112, 119], ["DISC", "ANATOMY", 135, 139], ["cell death", "OBSERVATION", 150, 160]]], ["In the presence of TNF, the adaptor protein TRADD interacts with TNFR1 and recruits other proteins involved in the signaling of the receptor, such as TRAF2, cIAP1, cIAP2, and RIP1, to form complex I. At the plasma membrane, this complex activates the NF-\u03baB signaling pathway, which in turn promotes the transcription of antiapoptotic genes such as cIAP1, cIAP2, and c-FLIP [34].", [["plasma membrane", "ANATOMY", 207, 222], ["TNF", "GENE_OR_GENE_PRODUCT", 19, 22], ["TRADD", "GENE_OR_GENE_PRODUCT", 44, 49], ["TNFR1", "GENE_OR_GENE_PRODUCT", 65, 70], ["TRAF2", "GENE_OR_GENE_PRODUCT", 150, 155], ["cIAP1", "GENE_OR_GENE_PRODUCT", 157, 162], ["cIAP2", "GENE_OR_GENE_PRODUCT", 164, 169], ["RIP1", "GENE_OR_GENE_PRODUCT", 175, 179], ["complex I", "GENE_OR_GENE_PRODUCT", 189, 198], ["plasma membrane", "CELLULAR_COMPONENT", 207, 222], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 251, 256], ["cIAP1", "GENE_OR_GENE_PRODUCT", 348, 353], ["cIAP2", "GENE_OR_GENE_PRODUCT", 355, 360], ["c-FLIP", "GENE_OR_GENE_PRODUCT", 366, 372], ["TNF", "PROTEIN", 19, 22], ["adaptor protein", "PROTEIN", 28, 43], ["TRADD", "PROTEIN", 44, 49], ["TNFR1", "PROTEIN", 65, 70], ["TRAF2", "PROTEIN", 150, 155], ["cIAP1", "PROTEIN", 157, 162], ["cIAP2", "PROTEIN", 164, 169], ["RIP1", "PROTEIN", 175, 179], ["complex I", "PROTEIN", 189, 198], ["NF-\u03baB", "PROTEIN", 251, 256], ["antiapoptotic genes", "DNA", 320, 339], ["cIAP1", "PROTEIN", 348, 353], ["cIAP2", "PROTEIN", 355, 360], ["c", "DNA", 366, 367], ["FLIP", "DNA", 368, 372], ["TNF", "PROBLEM", 19, 22], ["the adaptor protein TRADD", "TREATMENT", 24, 49], ["TNFR1", "TREATMENT", 65, 70], ["cIAP1", "TREATMENT", 157, 162], ["cIAP2", "TREATMENT", 164, 169], ["RIP1", "TREATMENT", 175, 179], ["antiapoptotic genes", "TREATMENT", 320, 339], ["cIAP1", "TEST", 348, 353], ["cIAP2", "TEST", 355, 360], ["TNF", "OBSERVATION", 19, 22], ["plasma membrane", "ANATOMY", 207, 222]]], ["The linear ubiquitin chain assembly complex (LUBAC) is also recruited to complex I via cIAP-generated ubiquitin chains [35].", [["ubiquitin chain assembly complex", "GENE_OR_GENE_PRODUCT", 11, 43], ["LUBAC", "GENE_OR_GENE_PRODUCT", 45, 50], ["complex I", "GENE_OR_GENE_PRODUCT", 73, 82], ["cIAP", "GENE_OR_GENE_PRODUCT", 87, 91], ["linear ubiquitin chain assembly complex", "PROTEIN", 4, 43], ["LUBAC", "PROTEIN", 45, 50], ["complex I", "PROTEIN", 73, 82], ["cIAP", "PROTEIN", 87, 91], ["ubiquitin chains", "PROTEIN", 102, 118], ["The linear ubiquitin chain assembly complex (LUBAC)", "PROBLEM", 0, 51], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["ubiquitin", "OBSERVATION_MODIFIER", 11, 20], ["chain", "OBSERVATION_MODIFIER", 21, 26], ["complex", "OBSERVATION_MODIFIER", 36, 43]]], ["HOIL-1, HOIP, and sharpin constitute the LUBAC complex.", [["sharpin", "CHEMICAL", 18, 25], ["HOIL-1", "GENE_OR_GENE_PRODUCT", 0, 6], ["HOIP", "SIMPLE_CHEMICAL", 8, 12], ["sharpin", "SIMPLE_CHEMICAL", 18, 25], ["LUBAC", "GENE_OR_GENE_PRODUCT", 41, 46], ["HOIL-1, HOIP, and sharpin", "DNA", 0, 25], ["LUBAC complex", "PROTEIN", 41, 54]]], ["HOIL-1 and HOIP add a linear ubiquitin chain by catalyzing the head-to-tail ligation of ubiquitin [36] to RIP1 and NEMO (IKK-\u03b3) in complex I [37], thereby activating NF-\u03baB.TNFR1 Signaling Pathways ::: TNF Receptor FamilyTNF-induced caspase activation is mediated by a second, intracellular complex II, which is formed when complex I dissociates from the receptor, along with FADD and caspase-8 recruitment [2].", [["head", "ANATOMY", 63, 67], ["intracellular", "ANATOMY", 276, 289], ["HOIL-1", "GENE_OR_GENE_PRODUCT", 0, 6], ["HOIP", "SIMPLE_CHEMICAL", 11, 15], ["RIP1", "GENE_OR_GENE_PRODUCT", 106, 110], ["NEMO", "GENE_OR_GENE_PRODUCT", 115, 119], ["IKK-\u03b3", "GENE_OR_GENE_PRODUCT", 121, 126], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 166, 170], ["TNF", "GENE_OR_GENE_PRODUCT", 201, 204], ["FamilyTNF", "GENE_OR_GENE_PRODUCT", 214, 223], ["caspase", "GENE_OR_GENE_PRODUCT", 232, 239], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 276, 289], ["complex II", "GENE_OR_GENE_PRODUCT", 290, 300], ["complex I", "GENE_OR_GENE_PRODUCT", 323, 332], ["FADD", "GENE_OR_GENE_PRODUCT", 375, 379], ["caspase-8", "GENE_OR_GENE_PRODUCT", 384, 393], ["HOIL", "PROTEIN", 0, 4], ["HOIP", "PROTEIN", 11, 15], ["ubiquitin chain", "PROTEIN", 29, 44], ["ubiquitin [36]", "PROTEIN", 88, 102], ["RIP1", "PROTEIN", 106, 110], ["NEMO", "PROTEIN", 115, 119], ["IKK", "PROTEIN", 121, 124], ["\u03b3", "PROTEIN", 125, 126], ["NF-\u03baB.TNFR1", "PROTEIN", 166, 177], ["TNF", "PROTEIN", 201, 204], ["FamilyTNF", "PROTEIN", 214, 223], ["caspase", "PROTEIN", 232, 239], ["intracellular complex II", "PROTEIN", 276, 300], ["complex I", "PROTEIN", 323, 332], ["FADD", "PROTEIN", 375, 379], ["caspase-8", "PROTEIN", 384, 393], ["a linear ubiquitin chain", "TREATMENT", 20, 44], ["the head-to-tail ligation of ubiquitin", "TREATMENT", 59, 97], ["IKK", "TEST", 121, 124], ["activating NF", "TEST", 155, 168], ["TNF", "TEST", 201, 204], ["caspase activation", "PROBLEM", 232, 250], ["FADD", "TREATMENT", 375, 379], ["caspase", "TREATMENT", 384, 391], ["head", "ANATOMY", 63, 67]]], ["NF-\u03baB activation leads to c-FLIP overexpression, preventing formation of complex II.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["c-FLIP", "GENE_OR_GENE_PRODUCT", 26, 32], ["complex II", "GENE_OR_GENE_PRODUCT", 73, 83], ["NF-\u03baB", "PROTEIN", 0, 5], ["FLIP", "PROTEIN", 28, 32], ["complex II", "PROTEIN", 73, 83], ["c-FLIP overexpression", "TREATMENT", 26, 47]]], ["Contrariwise, when NF-\u03baB activation is blocked, c-FLIP, whose protein half-life is short [38], is absent, and cells experience death [2].", [["cells", "ANATOMY", 110, 115], ["death", "DISEASE", 127, 132], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 19, 24], ["c-FLIP", "GENE_OR_GENE_PRODUCT", 48, 54], ["cells", "CELL", 110, 115], ["NF-\u03baB", "PROTEIN", 19, 24], ["c-FLIP", "PROTEIN", 48, 54], ["NF", "TEST", 19, 21], ["c-FLIP", "TEST", 48, 54]]], ["RIP1 is deubiquitinated by enzymes such as Cezanne [39] and CYLD [40], and the complex composed of TRADD and RIP1 moves to the cytosol to form complex II.", [["cytosol", "ANATOMY", 127, 134], ["RIP1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Cezanne [39]", "GENE_OR_GENE_PRODUCT", 43, 55], ["CYLD [40]", "SIMPLE_CHEMICAL", 60, 69], ["TRADD", "GENE_OR_GENE_PRODUCT", 99, 104], ["RIP1", "GENE_OR_GENE_PRODUCT", 109, 113], ["cytosol", "CELLULAR_COMPONENT", 127, 134], ["complex II", "GENE_OR_GENE_PRODUCT", 143, 153], ["RIP1", "PROTEIN", 0, 4], ["CYLD", "PROTEIN", 60, 64], ["TRADD", "PROTEIN", 99, 104], ["RIP1", "PROTEIN", 109, 113], ["complex II", "PROTEIN", 143, 153], ["enzymes", "TEST", 27, 34], ["Cezanne", "TEST", 43, 50], ["CYLD", "TEST", 60, 64], ["TRADD", "TREATMENT", 99, 104], ["RIP1", "TREATMENT", 109, 113], ["TRADD", "OBSERVATION", 99, 104]]], ["FADD is recruited to TRADD by DD-DD interaction and binds caspase-8 [2].", [["FADD", "GENE_OR_GENE_PRODUCT", 0, 4], ["TRADD", "GENE_OR_GENE_PRODUCT", 21, 26], ["caspase-8", "GENE_OR_GENE_PRODUCT", 58, 67], ["FADD", "PROTEIN", 0, 4], ["TRADD", "PROTEIN", 21, 26], ["DD", "PROTEIN", 30, 32], ["binds caspase", "TEST", 52, 65]]], ["Noteworthy, when caspase-8 activity is inhibited or its expression is extinguished, DISC is unable to trigger the apoptotic signaling pathway; but TNFR1 or CD95 stimulation leads to the activation of another cell death signal, namely, necroptosis [41, 42].", [["cell", "ANATOMY", 208, 212], ["death", "DISEASE", 213, 218], ["caspase-8", "GENE_OR_GENE_PRODUCT", 17, 26], ["DISC", "GENE_OR_GENE_PRODUCT", 84, 88], ["TNFR1", "GENE_OR_GENE_PRODUCT", 147, 152], ["CD95", "GENE_OR_GENE_PRODUCT", 156, 160], ["cell", "CELL", 208, 212], ["caspase-8", "PROTEIN", 17, 26], ["DISC", "PROTEIN", 84, 88], ["TNFR1", "PROTEIN", 147, 152], ["CD95", "PROTEIN", 156, 160], ["caspase", "TEST", 17, 24], ["TNFR1", "PROBLEM", 147, 152], ["CD95 stimulation", "TREATMENT", 156, 172], ["another cell death signal", "PROBLEM", 200, 225], ["necroptosis", "PROBLEM", 235, 246]]], ["To prevent the induction of the necroptotic signal, caspase-8 cleaves and inactivates RIP1 and RIP3 [43].", [["caspase-8", "GENE_OR_GENE_PRODUCT", 52, 61], ["RIP1", "GENE_OR_GENE_PRODUCT", 86, 90], ["RIP3 [43]", "GENE_OR_GENE_PRODUCT", 95, 104], ["caspase-8", "PROTEIN", 52, 61], ["RIP1", "PROTEIN", 86, 90], ["RIP3", "PROTEIN", 95, 99], ["the necroptotic signal", "TREATMENT", 28, 50], ["caspase", "TREATMENT", 52, 59]]], ["The fine-tuned control of necroptosis by members of the apoptotic signaling pathway in the organism has been elegantly confirmed by experiments showing that the embryonic lethality of mice harboring the single KO of caspase-8 or FADD is rescued by an additional KO of the RIP3 gene [44\u201346].TNF/TNFR: A Gold Mine for Therapeutic Tools ::: TNF Receptor FamilyMany studies on TNF demonstrated its pivotal role in fueling inflammation, a multistep process that promotes autoimmunity (e.g., rheumatoid arthritis, ankylosing spondylitis, Crohn\u2019s disease, psoriasis, and refractory asthma) and cancer.", [["embryonic", "ANATOMY", 161, 170], ["cancer", "ANATOMY", 587, 593], ["inflammation", "DISEASE", 418, 430], ["autoimmunity", "DISEASE", 466, 478], ["rheumatoid arthritis", "DISEASE", 486, 506], ["ankylosing spondylitis", "DISEASE", 508, 530], ["Crohn\u2019s disease", "DISEASE", 532, 547], ["psoriasis", "DISEASE", 549, 558], ["asthma", "DISEASE", 575, 581], ["cancer", "DISEASE", 587, 593], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 161, 170], ["mice", "ORGANISM", 184, 188], ["caspase-8", "GENE_OR_GENE_PRODUCT", 216, 225], ["FADD", "GENE_OR_GENE_PRODUCT", 229, 233], ["RIP3", "GENE_OR_GENE_PRODUCT", 272, 276], ["TNF", "GENE_OR_GENE_PRODUCT", 290, 293], ["TNFR", "GENE_OR_GENE_PRODUCT", 294, 298], ["TNF Receptor", "GENE_OR_GENE_PRODUCT", 338, 350], ["TNF", "GENE_OR_GENE_PRODUCT", 373, 376], ["cancer", "CANCER", 587, 593], ["caspase-8", "PROTEIN", 216, 225], ["FADD", "PROTEIN", 229, 233], ["RIP3 gene", "DNA", 272, 281], ["TNF", "PROTEIN", 290, 293], ["TNFR", "PROTEIN", 294, 298], ["TNF", "PROTEIN", 338, 341], ["TNF", "PROTEIN", 373, 376], ["mice", "SPECIES", 184, 188], ["mice", "SPECIES", 184, 188], ["necroptosis", "PROBLEM", 26, 37], ["the embryonic lethality", "PROBLEM", 157, 180], ["caspase", "TEST", 216, 223], ["Many studies", "TEST", 357, 369], ["TNF", "TEST", 373, 376], ["fueling inflammation", "PROBLEM", 410, 430], ["rheumatoid arthritis", "PROBLEM", 486, 506], ["ankylosing spondylitis", "PROBLEM", 508, 530], ["Crohn\u2019s disease", "PROBLEM", 532, 547], ["psoriasis", "PROBLEM", 549, 558], ["refractory asthma)", "PROBLEM", 564, 582], ["cancer", "PROBLEM", 587, 593], ["fine", "OBSERVATION_MODIFIER", 4, 8], ["-tuned", "OBSERVATION_MODIFIER", 8, 14], ["necroptosis", "OBSERVATION", 26, 37], ["fueling inflammation", "OBSERVATION", 410, 430], ["rheumatoid arthritis", "OBSERVATION", 486, 506], ["ankylosing spondylitis", "OBSERVATION", 508, 530], ["psoriasis", "OBSERVATION", 549, 558], ["refractory", "OBSERVATION_MODIFIER", 564, 574], ["asthma", "OBSERVATION", 575, 581], ["cancer", "OBSERVATION", 587, 593]]], ["Many TNF inhibitors, such as neutralizing monoclonal antibodies (mAbs) (e.g., infliximab, adalimumab, and golimumab), have been developed to treat these chronic inflammatory disorders, demonstrating that altering ligand/receptor interactions with neutralizing mAbs is an invaluable opportunity to treat certain chronic inflammatory disorders.", [["infliximab", "CHEMICAL", 78, 88], ["adalimumab", "CHEMICAL", 90, 100], ["golimumab", "CHEMICAL", 106, 115], ["inflammatory disorders", "DISEASE", 161, 183], ["golimumab", "CHEMICAL", 106, 115], ["TNF", "GENE_OR_GENE_PRODUCT", 5, 8], ["infliximab", "SIMPLE_CHEMICAL", 78, 88], ["adalimumab", "SIMPLE_CHEMICAL", 90, 100], ["golimumab", "SIMPLE_CHEMICAL", 106, 115], ["TNF", "PROTEIN", 5, 8], ["neutralizing monoclonal antibodies", "PROTEIN", 29, 63], ["mAbs", "PROTEIN", 65, 69], ["neutralizing mAbs", "PROTEIN", 247, 264], ["Many TNF inhibitors", "TREATMENT", 0, 19], ["neutralizing monoclonal antibodies", "TREATMENT", 29, 63], ["infliximab", "TREATMENT", 78, 88], ["adalimumab", "TREATMENT", 90, 100], ["golimumab", "TREATMENT", 106, 115], ["these chronic inflammatory disorders", "PROBLEM", 147, 183], ["altering ligand/receptor interactions", "PROBLEM", 204, 241], ["neutralizing mAbs", "TREATMENT", 247, 264], ["certain chronic inflammatory disorders", "PROBLEM", 303, 341], ["TNF inhibitors", "OBSERVATION", 5, 19], ["chronic", "OBSERVATION_MODIFIER", 153, 160], ["inflammatory", "OBSERVATION", 161, 173], ["chronic", "OBSERVATION_MODIFIER", 311, 318], ["inflammatory", "OBSERVATION", 319, 331]]], ["Other TNF-\u03b1 antagonists, such as etanercept, a TNFR2-immunoglobulin Fc fusion protein, can improve the clinical course of rheumatoid arthritis [47].TNF/TNFR: A Gold Mine for Therapeutic Tools ::: TNF Receptor FamilyWhile findings accumulate to decipher the molecular mechanisms involved in the induction of apoptotic and non-apoptotic signaling pathways by TNFR1 and to elucidate how the receptor can switch from one signal to the other, the mechanistic links involved in the implementation of non-apoptotic signaling pathways by CD95 remain elusive.", [["etanercept", "CHEMICAL", 33, 43], ["rheumatoid arthritis", "DISEASE", 122, 142], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 6, 11], ["etanercept", "SIMPLE_CHEMICAL", 33, 43], ["TNFR2", "GENE_OR_GENE_PRODUCT", 47, 52], ["immunoglobulin Fc", "GENE_OR_GENE_PRODUCT", 53, 70], ["TNF", "GENE_OR_GENE_PRODUCT", 148, 151], ["TNFR", "GENE_OR_GENE_PRODUCT", 152, 156], ["TNF Receptor", "GENE_OR_GENE_PRODUCT", 196, 208], ["TNFR1", "GENE_OR_GENE_PRODUCT", 357, 362], ["CD95", "GENE_OR_GENE_PRODUCT", 530, 534], ["TNF", "PROTEIN", 6, 9], ["TNFR2", "PROTEIN", 47, 52], ["immunoglobulin Fc fusion protein", "PROTEIN", 53, 85], ["TNF", "PROTEIN", 148, 151], ["TNFR", "PROTEIN", 152, 156], ["TNF", "PROTEIN", 196, 199], ["TNFR1", "PROTEIN", 357, 362], ["CD95", "PROTEIN", 530, 534], ["Other TNF-\u03b1 antagonists", "TREATMENT", 0, 23], ["etanercept", "TREATMENT", 33, 43], ["a TNFR2", "TREATMENT", 45, 52], ["immunoglobulin Fc fusion protein", "TREATMENT", 53, 85], ["rheumatoid arthritis", "PROBLEM", 122, 142], ["TNFR1", "TEST", 357, 362], ["non-apoptotic signaling pathways", "PROBLEM", 494, 526], ["rheumatoid arthritis", "OBSERVATION", 122, 142]]], ["However, recent findings have revealed its proinflammatory effects [48\u201354].Structure/Function ::: CD95: A Death Receptor?The CD95 gene (APT-1) consists of nine exons, with exon 6 encoding the transmembrane domain [66] (Fig. 11.1).", [["transmembrane", "ANATOMY", 192, 205], ["CD95", "GENE_OR_GENE_PRODUCT", 98, 102], ["CD95", "GENE_OR_GENE_PRODUCT", 125, 129], ["APT-1", "GENE_OR_GENE_PRODUCT", 136, 141], ["Structure/Function ::: CD95: A Death Receptor", "PROTEIN", 75, 120], ["CD95 gene", "DNA", 125, 134], ["APT", "DNA", 136, 139], ["exons", "DNA", 160, 165], ["exon 6", "DNA", 172, 178], ["transmembrane domain", "PROTEIN", 192, 212], ["its proinflammatory effects", "PROBLEM", 39, 66], ["The CD95 gene", "TEST", 121, 134], ["APT", "TEST", 136, 139], ["the transmembrane domain", "TEST", 188, 212], ["proinflammatory", "OBSERVATION_MODIFIER", 43, 58]]], ["CD95 can be resolved under denaturing conditions between 40 and 50 kDa by SDS-PAGE.", [["CD95", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD95", "PROTEIN", 0, 4], ["CD95", "PROBLEM", 0, 4]]], ["The receptor is a type I transmembrane protein harboring three CRDs.", [["CRDs", "GENE_OR_GENE_PRODUCT", 63, 67], ["type I transmembrane protein", "PROTEIN", 18, 46], ["CRDs", "PROTEIN", 63, 67]]], ["Similar to the TNF receptor [29], CD95 is pre-associated at the plasma membrane as a homotrimer, and this quaternary structure is mandatory for transmission of the apoptotic signals in the presence of CD95L [23, 24].", [["plasma membrane", "ANATOMY", 64, 79], ["TNF receptor", "GENE_OR_GENE_PRODUCT", 15, 27], ["CD95", "GENE_OR_GENE_PRODUCT", 34, 38], ["plasma membrane", "CELLULAR_COMPONENT", 64, 79], ["CD95L", "GENE_OR_GENE_PRODUCT", 201, 206], ["TNF receptor", "PROTEIN", 15, 27], ["CD95", "PROTEIN", 34, 38], ["CD95L", "PROTEIN", 201, 206], ["the TNF receptor", "TEST", 11, 27], ["CD95", "TEST", 34, 38], ["the apoptotic signals", "TEST", 160, 181], ["plasma membrane", "ANATOMY", 64, 79]]], ["Homotrimerization of CD95 occurs mainly through homotypic interactions of the CD95-CRD1 [22\u201324].", [["CD95", "GENE_OR_GENE_PRODUCT", 21, 25], ["CD95", "GENE_OR_GENE_PRODUCT", 78, 82], ["CD95", "PROTEIN", 21, 25], ["CD95", "PROTEIN", 78, 82], ["CRD1", "PROTEIN", 83, 87], ["Homotrimerization of CD95", "TREATMENT", 0, 25], ["the CD95", "TEST", 74, 82], ["CD95", "OBSERVATION", 21, 25]]], ["Binding of CD95L or agonistic anti-CD95 mAbs to CD95 alters both the conformation and the extent to which the receptor is multimerized at the plasma membrane.", [["plasma membrane", "ANATOMY", 142, 157], ["CD95L", "GENE_OR_GENE_PRODUCT", 11, 16], ["anti-CD95 mAbs", "GENE_OR_GENE_PRODUCT", 30, 44], ["CD95", "GENE_OR_GENE_PRODUCT", 48, 52], ["plasma membrane", "CELLULAR_COMPONENT", 142, 157], ["CD95L", "PROTEIN", 11, 16], ["anti-CD95 mAbs", "PROTEIN", 30, 44], ["CD95", "PROTEIN", 48, 52], ["CD95L", "TREATMENT", 11, 16], ["agonistic anti-CD95 mAbs", "TREATMENT", 20, 44], ["plasma membrane", "ANATOMY", 142, 157]]], ["The intracellular region of CD95 encompasses an 80-amino acid stretch designated as the DD (Fig. 11.1), which consists of six antiparallel \u03b1-helices [67].", [["intracellular", "ANATOMY", 4, 17], ["amino acid", "CHEMICAL", 51, 61], ["amino acid", "CHEMICAL", 51, 61], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["CD95", "GENE_OR_GENE_PRODUCT", 28, 32], ["amino acid", "AMINO_ACID", 51, 61], ["CD95", "PROTEIN", 28, 32], ["DD", "PROTEIN", 88, 90], ["antiparallel \u03b1-helices", "PROTEIN", 126, 148], ["the DD (Fig.", "TEST", 84, 96], ["CD95", "OBSERVATION", 28, 32]]], ["Upon addition of CD95L, CD95 undergoes conformational modification of its DD, which induces a shift of helix 6 and fusion with helix 5, promoting both oligomerization of the receptor and recruitment of the adaptor protein FADD [68].", [["CD95L", "GENE_OR_GENE_PRODUCT", 17, 22], ["CD95", "GENE_OR_GENE_PRODUCT", 24, 28], ["FADD", "GENE_OR_GENE_PRODUCT", 222, 226], ["CD95L", "PROTEIN", 17, 22], ["CD95", "PROTEIN", 24, 28], ["DD", "PROTEIN", 74, 76], ["helix 6", "PROTEIN", 103, 110], ["helix 5", "PROTEIN", 127, 134], ["adaptor protein", "PROTEIN", 206, 221], ["FADD", "PROTEIN", 222, 226], ["CD95L", "TREATMENT", 17, 22], ["its DD", "PROBLEM", 70, 76], ["helix 6 and fusion with helix 5", "TREATMENT", 103, 134]]], ["A consequence of the opening of the globular structure of CD95 is that the receptor becomes connected through this bridge, which increases the magnitude of its homo-aggregation.", [["CD95", "GENE_OR_GENE_PRODUCT", 58, 62], ["globular structure", "PROTEIN", 36, 54], ["CD95", "PROTEIN", 58, 62], ["globular", "OBSERVATION_MODIFIER", 36, 44], ["CD95", "OBSERVATION", 58, 62], ["magnitude", "OBSERVATION_MODIFIER", 143, 152], ["homo-aggregation", "OBSERVATION", 160, 176]]], ["This long helix allows the stabilization of the complex by recruiting FADD.", [["long helix", "CELLULAR_COMPONENT", 5, 15], ["FADD", "GENE_OR_GENE_PRODUCT", 70, 74], ["FADD", "PROTEIN", 70, 74], ["This long helix", "PROBLEM", 0, 15], ["stabilization", "OBSERVATION", 27, 40]]], ["Overall, the CD95-DD/FADD-DD crystal structure provides some insights into the formation of the large CD95 clusters observed using imaging or biochemical methods in cells stimulated with CD95L.", [["cells", "ANATOMY", 165, 170], ["CD95", "GENE_OR_GENE_PRODUCT", 13, 17], ["FADD", "GENE_OR_GENE_PRODUCT", 21, 25], ["CD95", "GENE_OR_GENE_PRODUCT", 102, 106], ["cells", "CELL", 165, 170], ["CD95L", "GENE_OR_GENE_PRODUCT", 187, 192], ["CD95", "PROTEIN", 13, 17], ["DD", "PROTEIN", 18, 20], ["FADD", "PROTEIN", 21, 25], ["CD95 clusters", "PROTEIN", 102, 115], ["CD95L", "PROTEIN", 187, 192], ["the CD95", "TEST", 9, 17], ["DD/FADD-DD crystal structure", "PROBLEM", 18, 46], ["the large CD95 clusters", "PROBLEM", 92, 115], ["imaging", "TEST", 131, 138], ["CD95L", "TREATMENT", 187, 192], ["large", "OBSERVATION_MODIFIER", 96, 101], ["CD95", "OBSERVATION", 102, 106]]], ["In addition, it also confirms that alteration in the CD95 conformation plays an instrumental role during signal induction [68].", [["CD95", "GENE_OR_GENE_PRODUCT", 53, 57], ["CD95", "PROTEIN", 53, 57], ["alteration in the CD95 conformation", "PROBLEM", 35, 70], ["alteration", "OBSERVATION", 35, 45]]], ["However, this elongated C-terminal \u03b1-helix favoring the cis-dimerization of CD95-DD was challenged by Driscoll et al. who did not observe the fusion of the last two helices at a more neutral pH (pH 6.2), compared to the acidic condition (pH 4) used in the initial study to resolve the CD95-DD/FADD-DD structure [68].", [["C", "CHEMICAL", 24, 25], ["CD95", "GENE_OR_GENE_PRODUCT", 76, 80], ["CD95", "GENE_OR_GENE_PRODUCT", 285, 289], ["FADD", "GENE_OR_GENE_PRODUCT", 293, 297], ["elongated C-terminal \u03b1-helix", "PROTEIN", 14, 42], ["CD95", "PROTEIN", 76, 80], ["DD", "PROTEIN", 81, 83], ["CD95", "PROTEIN", 285, 289], ["DD", "PROTEIN", 290, 292], ["FADD", "PROTEIN", 293, 297], ["this elongated C-terminal \u03b1-helix", "PROBLEM", 9, 42], ["DD", "PROBLEM", 81, 83], ["pH", "TEST", 195, 197], ["pH", "TEST", 238, 240], ["the initial study", "TEST", 252, 269], ["the CD95", "TEST", 281, 289]]], ["Consequently, at pH 6.2, association of CD95 with FADD predominantly consisted of a 5:5 complex, which occurred via a polymerization mechanism involving three types of asymmetric interactions but without major alteration of the DD globular structure [69, 70].", [["CD95", "GENE_OR_GENE_PRODUCT", 40, 44], ["FADD", "GENE_OR_GENE_PRODUCT", 50, 54], ["CD95", "PROTEIN", 40, 44], ["FADD", "PROTEIN", 50, 54], ["5:5 complex", "PROTEIN", 84, 95], ["DD globular structure", "PROTEIN", 228, 249], ["pH", "TEST", 17, 19], ["CD95", "PROBLEM", 40, 44], ["FADD", "TEST", 50, 54], ["a polymerization mechanism", "PROBLEM", 116, 142], ["asymmetric interactions", "PROBLEM", 168, 191], ["major alteration of the DD globular structure", "PROBLEM", 204, 249], ["polymerization mechanism", "OBSERVATION", 118, 142], ["asymmetric", "OBSERVATION_MODIFIER", 168, 178], ["interactions", "OBSERVATION", 179, 191], ["without", "UNCERTAINTY", 196, 203], ["globular", "OBSERVATION_MODIFIER", 231, 239]]], ["It is likely that the low pH condition used in the study performed by Scott et al. altered CD95 conformation and resulted in the formation of nonphysiological CD95/FADD oligomers [68].", [["CD95", "GENE_OR_GENE_PRODUCT", 91, 95], ["CD95", "GENE_OR_GENE_PRODUCT", 159, 163], ["FADD", "GENE_OR_GENE_PRODUCT", 164, 168], ["CD95", "PROTEIN", 91, 95], ["CD95", "PROTEIN", 159, 163], ["FADD", "PROTEIN", 164, 168], ["the low pH condition", "PROBLEM", 18, 38], ["the study", "TEST", 47, 56], ["altered CD95 conformation", "PROBLEM", 83, 108], ["nonphysiological CD95/FADD oligomers", "PROBLEM", 142, 178], ["is likely", "UNCERTAINTY", 3, 12], ["CD95", "OBSERVATION", 91, 95], ["nonphysiological CD95", "OBSERVATION", 142, 163]]], ["Nonetheless, it cannot be excluded that a local decrease in the intracellular pH affects the initial steps of the CD95 signaling pathway in vivo, through promoting the opening of the CD95-DD and eventually contributing to the formation of a complex eliciting a sequence of events different from the one occurring at physiologic pH.Structure/Function ::: CD95: A Death Receptor?Once docked on CD95-DD, FADD self-associates [71] and binds procaspase-8 and procaspase-10, which are auto-processed and released in the cytosol as active caspases, which cleave many substrates leading to the execution of the apoptotic program and cell death.", [["intracellular", "ANATOMY", 64, 77], ["cytosol", "ANATOMY", 514, 521], ["cell", "ANATOMY", 625, 629], ["death", "DISEASE", 630, 635], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 77], ["CD95", "GENE_OR_GENE_PRODUCT", 114, 118], ["CD95", "GENE_OR_GENE_PRODUCT", 183, 187], ["CD95", "GENE_OR_GENE_PRODUCT", 354, 358], ["CD95", "GENE_OR_GENE_PRODUCT", 392, 396], ["FADD", "GENE_OR_GENE_PRODUCT", 401, 405], ["procaspase-8", "GENE_OR_GENE_PRODUCT", 437, 449], ["procaspase-10", "GENE_OR_GENE_PRODUCT", 454, 467], ["cytosol", "CELLULAR_COMPONENT", 514, 521], ["caspases", "GENE_OR_GENE_PRODUCT", 532, 540], ["cell", "CELL", 625, 629], ["CD95", "PROTEIN", 114, 118], ["CD95", "PROTEIN", 183, 187], ["DD", "PROTEIN", 188, 190], ["Structure/Function ::: CD95: A Death Receptor", "PROTEIN", 331, 376], ["CD95", "PROTEIN", 392, 396], ["DD", "PROTEIN", 397, 399], ["FADD", "PROTEIN", 401, 405], ["procaspase-8", "PROTEIN", 437, 449], ["procaspase-10", "PROTEIN", 454, 467], ["caspases", "PROTEIN", 532, 540], ["a local decrease in the intracellular pH", "PROBLEM", 40, 80], ["CD95", "TEST", 392, 396], ["binds procaspase", "TEST", 431, 447], ["procaspase", "TEST", 454, 464], ["the apoptotic program", "TREATMENT", 599, 620], ["cell death", "PROBLEM", 625, 635], ["cannot be excluded", "UNCERTAINTY", 16, 34], ["local", "OBSERVATION_MODIFIER", 42, 47], ["decrease", "OBSERVATION_MODIFIER", 48, 56], ["intracellular pH", "OBSERVATION", 64, 80], ["CD95", "ANATOMY", 183, 187], ["cell death", "OBSERVATION", 625, 635]]], ["The complex CD95/FADD/caspase-8/caspase-10 is called DISC (Fig. 11.2) [10].", [["CD95", "GENE_OR_GENE_PRODUCT", 12, 16], ["FADD", "GENE_OR_GENE_PRODUCT", 17, 21], ["caspase-8", "GENE_OR_GENE_PRODUCT", 22, 31], ["caspase-10", "GENE_OR_GENE_PRODUCT", 32, 42], ["DISC", "GENE_OR_GENE_PRODUCT", 53, 57], ["CD95", "PROTEIN", 12, 16], ["FADD", "PROTEIN", 17, 21], ["caspase-8", "PROTEIN", 22, 31], ["caspase-10", "PROTEIN", 32, 42], ["DISC", "PROTEIN", 53, 57], ["The complex CD95/FADD/caspase", "TREATMENT", 0, 29], ["caspase", "TREATMENT", 32, 39], ["DISC", "ANATOMY", 53, 57]]], ["Due to the importance of DISC formation in the fate of cells, it is not surprising that numerous cellular and viral proteins were reported to hamper the formation of this structure, such as FLIP [72, 73] and PED/PEA-15 [74], which interfere with the recruitment of caspase-8/caspase-10 (Fig. 11.2).Type I/II Signaling Pathways ::: CD95: A Death Receptor?Following the discovery of CD95 and the first steps of its signaling pathway, Peter and colleagues described that cells can be divided in two groups with regard to the kinetics through which they respond to CD95-mediated apoptotic signals, the magnitude of DISC formation, and the role played by the mitochondrion in this pathway [75].", [["cells", "ANATOMY", 55, 60], ["cellular", "ANATOMY", 97, 105], ["cells", "ANATOMY", 468, 473], ["mitochondrion", "ANATOMY", 654, 667], ["PEA", "CHEMICAL", 212, 215], ["PEA-15", "CHEMICAL", 212, 218], ["DISC", "GENE_OR_GENE_PRODUCT", 25, 29], ["cells", "CELL", 55, 60], ["cellular", "CELL", 97, 105], ["FLIP", "GENE_OR_GENE_PRODUCT", 190, 194], ["caspase-8", "GENE_OR_GENE_PRODUCT", 265, 274], ["caspase-10", "GENE_OR_GENE_PRODUCT", 275, 285], ["Type I/II", "GENE_OR_GENE_PRODUCT", 298, 307], ["CD95", "GENE_OR_GENE_PRODUCT", 331, 335], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 337, 353], ["CD95", "GENE_OR_GENE_PRODUCT", 381, 385], ["cells", "CELL", 468, 473], ["CD95", "GENE_OR_GENE_PRODUCT", 561, 565], ["DISC", "GENE_OR_GENE_PRODUCT", 611, 615], ["mitochondrion", "CELLULAR_COMPONENT", 654, 667], ["DISC", "PROTEIN", 25, 29], ["viral proteins", "PROTEIN", 110, 124], ["FLIP", "PROTEIN", 190, 194], ["caspase-8", "PROTEIN", 265, 274], ["caspase-10", "PROTEIN", 275, 285], ["CD95", "PROTEIN", 331, 335], ["CD95", "PROTEIN", 381, 385], ["CD95", "PROTEIN", 561, 565], ["DISC", "PROTEIN", 611, 615], ["DISC formation", "PROBLEM", 25, 39], ["numerous cellular and viral proteins", "PROBLEM", 88, 124], ["PED/PEA", "TEST", 208, 215], ["caspase", "TEST", 265, 272], ["caspase", "TEST", 275, 282], ["Type I/II Signaling Pathways", "PROBLEM", 298, 326], ["CD95", "PROBLEM", 381, 385], ["DISC formation", "PROBLEM", 611, 625], ["DISC", "OBSERVATION", 25, 29], ["not surprising", "UNCERTAINTY", 68, 82], ["viral proteins", "OBSERVATION", 110, 124], ["apoptotic signals", "OBSERVATION", 575, 592], ["DISC", "ANATOMY", 611, 615]]], ["DISC formation occurs rapidly and efficiently in type I cells releasing a large amount of activated caspase-8 in the cytosol, while type II cells have difficulty forming this complex, and the amount of active caspase-8 is insufficient to directly activate the effectors caspase-3 and caspase-7 [75].", [["type I cells", "ANATOMY", 49, 61], ["cytosol", "ANATOMY", 117, 124], ["type II cells", "ANATOMY", 132, 145], ["DISC", "GENE_OR_GENE_PRODUCT", 0, 4], ["type I cells", "CELL", 49, 61], ["caspase-8", "GENE_OR_GENE_PRODUCT", 100, 109], ["cytosol", "ORGANISM_SUBSTANCE", 117, 124], ["type II cells", "CELL", 132, 145], ["caspase-8", "GENE_OR_GENE_PRODUCT", 209, 218], ["caspase-3", "GENE_OR_GENE_PRODUCT", 270, 279], ["caspase-7", "GENE_OR_GENE_PRODUCT", 284, 293], ["DISC", "PROTEIN", 0, 4], ["type I cells", "CELL_TYPE", 49, 61], ["caspase-8", "PROTEIN", 100, 109], ["type II cells", "CELL_TYPE", 132, 145], ["caspase-8", "PROTEIN", 209, 218], ["caspase-3", "PROTEIN", 270, 279], ["DISC formation", "PROBLEM", 0, 14], ["type I cells", "PROBLEM", 49, 61], ["activated caspase", "TREATMENT", 90, 107], ["type II cells", "PROBLEM", 132, 145], ["active caspase", "TREATMENT", 202, 216], ["the effectors caspase", "TEST", 256, 277], ["caspase", "TEST", 284, 291], ["rapidly", "OBSERVATION_MODIFIER", 22, 29], ["large", "OBSERVATION_MODIFIER", 74, 79], ["amount", "OBSERVATION_MODIFIER", 80, 86], ["active", "OBSERVATION_MODIFIER", 202, 208], ["caspase", "OBSERVATION", 209, 216]]], ["Nonetheless, type II cells experience cell death upon CD95 engagement and are even more sensitive to the CD95-mediated apoptotic signal compared to type I cells [75\u201377].", [["type II cells", "ANATOMY", 13, 26], ["cell", "ANATOMY", 38, 42], ["type I cells", "ANATOMY", 148, 160], ["death", "DISEASE", 43, 48], ["type II cells", "CELL", 13, 26], ["cell", "CELL", 38, 42], ["CD95", "GENE_OR_GENE_PRODUCT", 54, 58], ["CD95", "GENE_OR_GENE_PRODUCT", 105, 109], ["cells", "CELL", 155, 160], ["type II cells", "CELL_TYPE", 13, 26], ["CD95", "PROTEIN", 54, 58], ["CD95", "PROTEIN", 105, 109], ["type I cells", "CELL_TYPE", 148, 160], ["type II cells", "PROBLEM", 13, 26], ["cell death", "PROBLEM", 38, 48], ["CD95 engagement", "TEST", 54, 69], ["the CD95", "TEST", 101, 109], ["apoptotic signal", "TEST", 119, 135]]], ["This discrepancy can be partly explained by the fact that the low amount of activated caspase-8 in type II cells is sufficient to cleave BID, a BH3-only protein, which constitutes the molecular link between caspase-8 activation and the apoptotic activity of mitochondria.", [["type II cells", "ANATOMY", 99, 112], ["mitochondria", "ANATOMY", 258, 270], ["caspase-8", "GENE_OR_GENE_PRODUCT", 86, 95], ["type II cells", "CELL", 99, 112], ["BID", "GENE_OR_GENE_PRODUCT", 137, 140], ["caspase-8", "GENE_OR_GENE_PRODUCT", 207, 216], ["mitochondria", "CELLULAR_COMPONENT", 258, 270], ["activated caspase-8", "PROTEIN", 76, 95], ["type II cells", "CELL_TYPE", 99, 112], ["BID", "PROTEIN", 137, 140], ["BH3", "PROTEIN", 144, 147], ["caspase-8", "PROTEIN", 207, 216], ["activated caspase", "TREATMENT", 76, 93], ["type II cells", "TREATMENT", 99, 112], ["a BH3", "TEST", 142, 147], ["caspase", "TEST", 207, 214], ["apoptotic activity", "OBSERVATION", 236, 254]]], ["Indeed, after cleavage by caspase-8, truncated BID (tBID) translocates to mitochondria, where it triggers the release of proapoptotic factors (Fig. 11.2) [78, 79].", [["mitochondria", "ANATOMY", 74, 86], ["caspase-8", "GENE_OR_GENE_PRODUCT", 26, 35], ["BID", "GENE_OR_GENE_PRODUCT", 47, 50], ["BID", "GENE_OR_GENE_PRODUCT", 53, 56], ["mitochondria", "CELLULAR_COMPONENT", 74, 86], ["caspase-8", "PROTEIN", 26, 35], ["truncated BID", "PROTEIN", 37, 50], ["tBID", "PROTEIN", 52, 56], ["proapoptotic factors", "PROTEIN", 121, 141], ["proapoptotic factors", "PROBLEM", 121, 141]]], ["Although CD95 stimulation activates the mitochondrion-dependent apoptotic signal in type I and type II cells, it seems that only type II cells are addicted to this signal as they display a higher amount of the caspase-3 inhibitor XIAP compared to type I cells [80].", [["mitochondrion", "ANATOMY", 40, 53], ["type II cells", "ANATOMY", 95, 108], ["type II cells", "ANATOMY", 129, 142], ["type I cells", "ANATOMY", 247, 259], ["CD95", "GENE_OR_GENE_PRODUCT", 9, 13], ["mitochondrion", "CELLULAR_COMPONENT", 40, 53], ["type II cells", "CELL", 95, 108], ["type II cells", "CELL", 129, 142], ["caspase-3", "GENE_OR_GENE_PRODUCT", 210, 219], ["XIAP", "GENE_OR_GENE_PRODUCT", 230, 234], ["CD95", "PROTEIN", 9, 13], ["type I and type II cells", "CELL_TYPE", 84, 108], ["type II cells", "CELL_TYPE", 129, 142], ["caspase-3 inhibitor", "PROTEIN", 210, 229], ["XIAP", "PROTEIN", 230, 234], ["type I cells", "CELL_TYPE", 247, 259], ["CD95 stimulation", "TEST", 9, 25], ["dependent apoptotic signal", "PROBLEM", 54, 80], ["type I and type II cells", "PROBLEM", 84, 108], ["type II cells", "PROBLEM", 129, 142], ["the caspase-3 inhibitor XIAP", "TREATMENT", 206, 234], ["type I cells", "PROBLEM", 247, 259], ["dependent", "OBSERVATION_MODIFIER", 54, 63], ["apoptotic signal", "OBSERVATION", 64, 80]]], ["Among the inhibitor of apoptosis protein (IAP) family, XIAP, cIAP1, and cIAP2 inhibit caspase-3, caspase-7 [81, 82], and procaspase-9 [83] activity by direct binding, thereby preventing access to substrates.", [["inhibitor of apoptosis protein", "GENE_OR_GENE_PRODUCT", 10, 40], ["IAP", "GENE_OR_GENE_PRODUCT", 42, 45], ["XIAP", "GENE_OR_GENE_PRODUCT", 55, 59], ["cIAP1", "GENE_OR_GENE_PRODUCT", 61, 66], ["cIAP2", "GENE_OR_GENE_PRODUCT", 72, 77], ["caspase-3", "GENE_OR_GENE_PRODUCT", 86, 95], ["caspase-7", "GENE_OR_GENE_PRODUCT", 97, 106], ["procaspase-9", "GENE_OR_GENE_PRODUCT", 121, 133], ["inhibitor of apoptosis protein (IAP) family", "PROTEIN", 10, 53], ["XIAP", "PROTEIN", 55, 59], ["cIAP1", "PROTEIN", 61, 66], ["cIAP2", "PROTEIN", 72, 77], ["caspase-3", "PROTEIN", 86, 95], ["apoptosis protein", "PROBLEM", 23, 40], ["XIAP", "TEST", 55, 59], ["cIAP1", "TEST", 61, 66], ["caspase", "TEST", 86, 93], ["caspase", "TEST", 97, 104], ["procaspase", "TEST", 121, 131]]], ["Furthermore, XIAP can function as an E3 ligase whose activity is involved in the ubiquitination of active caspase-3 and its subsequent degradation through the proteasome [84].", [["XIAP", "GENE_OR_GENE_PRODUCT", 13, 17], ["E3", "GENE_OR_GENE_PRODUCT", 37, 39], ["caspase-3", "GENE_OR_GENE_PRODUCT", 106, 115], ["XIAP", "PROTEIN", 13, 17], ["E3 ligase", "PROTEIN", 37, 46], ["caspase-3", "PROTEIN", 106, 115], ["proteasome", "PROTEIN", 159, 169], ["an E3 ligase", "TEST", 34, 46], ["active caspase", "TREATMENT", 99, 113], ["active caspase", "OBSERVATION", 99, 113]]], ["To detach XIAP from caspase-3 and restore the apoptotic signal, cells require the release of SMAC/DIABLO (second mitochondria-derived activator of caspase/direct IAP-binding protein with low PI) by the mitochondrion [85, 86], explaining why type II cells are more addicted to this organelle compared to type I cells (Fig. 11.2).Type I/II Signaling Pathways ::: CD95: A Death Receptor?To summarize, DISC formation and IAP amount are two cellular markers allowing a clear discrimination between type I and type II cells.", [["cells", "ANATOMY", 64, 69], ["mitochondria", "ANATOMY", 113, 125], ["mitochondrion", "ANATOMY", 202, 215], ["type II cells", "ANATOMY", 241, 254], ["organelle", "ANATOMY", 281, 290], ["type I cells", "ANATOMY", 303, 315], ["cellular", "ANATOMY", 436, 444], ["type II cells", "ANATOMY", 504, 517], ["XIAP", "GENE_OR_GENE_PRODUCT", 10, 14], ["caspase-3", "GENE_OR_GENE_PRODUCT", 20, 29], ["cells", "CELL", 64, 69], ["SMAC", "GENE_OR_GENE_PRODUCT", 93, 97], ["DIABLO", "GENE_OR_GENE_PRODUCT", 98, 104], ["mitochondria", "CELLULAR_COMPONENT", 113, 125], ["caspase", "GENE_OR_GENE_PRODUCT", 147, 154], ["IAP-binding protein", "GENE_OR_GENE_PRODUCT", 162, 181], ["PI", "GENE_OR_GENE_PRODUCT", 191, 193], ["mitochondrion", "CELLULAR_COMPONENT", 202, 215], ["type II cells", "CELL", 241, 254], ["organelle", "CELLULAR_COMPONENT", 281, 290], ["cells", "CELL", 310, 315], ["Type I/II", "GENE_OR_GENE_PRODUCT", 328, 337], ["CD95", "GENE_OR_GENE_PRODUCT", 361, 365], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 367, 383], ["DISC", "GENE_OR_GENE_PRODUCT", 398, 402], ["IAP", "GENE_OR_GENE_PRODUCT", 417, 420], ["cellular", "CELL", 436, 444], ["type II cells", "CELL", 504, 517], ["XIAP", "PROTEIN", 10, 14], ["caspase-3", "PROTEIN", 20, 29], ["SMAC", "PROTEIN", 93, 97], ["DIABLO", "PROTEIN", 98, 104], ["caspase", "PROTEIN", 147, 154], ["IAP-binding protein", "PROTEIN", 162, 181], ["low PI", "PROTEIN", 187, 193], ["type II cells", "CELL_TYPE", 241, 254], ["type I cells", "CELL_TYPE", 303, 315], ["CD95", "PROTEIN", 361, 365], ["DISC", "PROTEIN", 398, 402], ["IAP", "PROTEIN", 417, 420], ["type I and type II cells", "CELL_TYPE", 493, 517], ["caspase", "TEST", 20, 27], ["SMAC/DIABLO (second mitochondria", "TREATMENT", 93, 125], ["caspase/direct IAP-binding protein", "TREATMENT", 147, 181], ["type II cells", "PROBLEM", 241, 254], ["DISC formation and IAP amount", "PROBLEM", 398, 427], ["type I and type II cells", "PROBLEM", 493, 517], ["DISC", "ANATOMY", 398, 402], ["IAP", "OBSERVATION_MODIFIER", 417, 420], ["amount", "OBSERVATION_MODIFIER", 421, 427], ["cellular markers", "OBSERVATION", 436, 452]]], ["Even though IAP overexpression can account for the mitochondrion dependency observed in type II cells, it remains unclear why DISC formation is hampered in type II cells and/or enhanced in their type I counterparts.", [["mitochondrion", "ANATOMY", 51, 64], ["type II cells", "ANATOMY", 88, 101], ["type II cells", "ANATOMY", 156, 169], ["IAP", "GENE_OR_GENE_PRODUCT", 12, 15], ["mitochondrion", "CELLULAR_COMPONENT", 51, 64], ["type II cells", "CELL", 88, 101], ["DISC", "GENE_OR_GENE_PRODUCT", 126, 130], ["type II cells", "CELL", 156, 169], ["IAP", "PROTEIN", 12, 15], ["type II cells", "CELL_TYPE", 88, 101], ["DISC", "PROTEIN", 126, 130], ["type II cells", "CELL_TYPE", 156, 169], ["type I counterparts", "CELL_TYPE", 195, 214], ["IAP overexpression", "PROBLEM", 12, 30], ["the mitochondrion dependency", "PROBLEM", 47, 75], ["type II cells", "PROBLEM", 88, 101], ["DISC formation", "PROBLEM", 126, 140], ["type II cells", "PROBLEM", 156, 169], ["can account for", "UNCERTAINTY", 31, 46], ["type II", "OBSERVATION_MODIFIER", 88, 95], ["cells", "OBSERVATION", 96, 101], ["type II", "OBSERVATION_MODIFIER", 156, 163]]], ["Recently, high activity of the lipid kinase phosphoinositide 3-kinase (PI3K) or downregulation of its neutralizing phosphatase, phosphatase and tensin homologue on chromosome 10 (PTEN), was found in type II cells, while this signal is blocked in type I cell lines [87, 88].", [["type II cells", "ANATOMY", 199, 212], ["type I cell lines", "ANATOMY", 246, 263], ["lipid kinase phosphoinositide 3-kinase", "GENE_OR_GENE_PRODUCT", 31, 69], ["PI3K", "GENE_OR_GENE_PRODUCT", 71, 75], ["phosphatase and tensin homologue on chromosome 10", "GENE_OR_GENE_PRODUCT", 128, 177], ["PTEN", "GENE_OR_GENE_PRODUCT", 179, 183], ["type II cells", "CELL", 199, 212], ["type I cell lines", "CELL", 246, 263], ["lipid kinase phosphoinositide 3-kinase", "PROTEIN", 31, 69], ["PI3K", "PROTEIN", 71, 75], ["neutralizing phosphatase", "PROTEIN", 102, 126], ["phosphatase and tensin homologue", "PROTEIN", 128, 160], ["chromosome 10", "DNA", 164, 177], ["PTEN", "PROTEIN", 179, 183], ["type II cells", "CELL_TYPE", 199, 212], ["type I cell lines", "CELL_LINE", 246, 263], ["the lipid kinase phosphoinositide", "TEST", 27, 60], ["kinase (PI3K", "TEST", 63, 75], ["its neutralizing phosphatase", "TEST", 98, 126], ["phosphatase", "TEST", 128, 139], ["tensin homologue", "TEST", 144, 160], ["type II cells", "PROBLEM", 199, 212], ["high activity", "OBSERVATION_MODIFIER", 10, 23], ["cell lines", "OBSERVATION", 253, 263]]], ["The PI3K signaling pathway was reported to prevent the aggregation of CD95 [89], probably by retaining the receptor outside of lipid rafts [87, 90].", [["lipid rafts", "ANATOMY", 127, 138], ["PI3K", "GENE_OR_GENE_PRODUCT", 4, 8], ["CD95", "GENE_OR_GENE_PRODUCT", 70, 74], ["lipid rafts", "CELLULAR_COMPONENT", 127, 138], ["PI3K", "PROTEIN", 4, 8], ["CD95", "PROTEIN", 70, 74], ["The PI3K signaling pathway", "TEST", 0, 26], ["the aggregation of CD95", "PROBLEM", 51, 74], ["lipid rafts", "TEST", 127, 138]]], ["PEA-15, also known as PED, is a protein containing a death effector domain (DED) that has been shown to inhibit the CD95 and TNFR1 apoptotic signals (Fig. 11.2) [74].", [["PEA-15", "CHEMICAL", 0, 6], ["death", "DISEASE", 53, 58], ["PEA-15", "CHEMICAL", 0, 6], ["PEA-15", "GENE_OR_GENE_PRODUCT", 0, 6], ["CD95", "GENE_OR_GENE_PRODUCT", 116, 120], ["TNFR1", "GENE_OR_GENE_PRODUCT", 125, 130], ["death effector domain", "PROTEIN", 53, 74], ["DED", "PROTEIN", 76, 79], ["CD95", "PROTEIN", 116, 120], ["TNFR1", "PROTEIN", 125, 130], ["PEA", "TEST", 0, 3], ["a protein containing a death effector domain", "PROBLEM", 30, 74], ["the CD95", "TEST", 112, 120], ["apoptotic signals", "TEST", 131, 148]]], ["Activation of PI3K and its downstream effector, serine-threonine kinase Akt, leads to phosphorylation of PEA-15 at serine 116 [87, 90]; this posttranslational modification promotes its interaction with FADD, ultimately inhibiting DISC formation [91, 92].Type I/II Signaling Pathways ::: CD95: A Death Receptor?Notably, the existence of type I and type II cells is not only an in vitro observation, but has been identified physiologically in the human body.", [["type II cells", "ANATOMY", 347, 360], ["body", "ANATOMY", 451, 455], ["PEA", "CHEMICAL", 105, 108], ["serine", "CHEMICAL", 48, 54], ["threonine", "CHEMICAL", 55, 64], ["PEA-15", "CHEMICAL", 105, 111], ["serine", "CHEMICAL", 115, 121], ["PI3K", "GENE_OR_GENE_PRODUCT", 14, 18], ["serine-threonine kinase", "GENE_OR_GENE_PRODUCT", 48, 71], ["Akt", "GENE_OR_GENE_PRODUCT", 72, 75], ["PEA-15", "GENE_OR_GENE_PRODUCT", 105, 111], ["serine 116", "AMINO_ACID", 115, 125], ["FADD", "GENE_OR_GENE_PRODUCT", 202, 206], ["DISC", "GENE_OR_GENE_PRODUCT", 230, 234], ["Type I/II", "GENE_OR_GENE_PRODUCT", 254, 263], ["CD95", "GENE_OR_GENE_PRODUCT", 287, 291], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 293, 309], ["type II cells", "CELL", 347, 360], ["human", "ORGANISM", 445, 450], ["body", "ORGANISM_SUBDIVISION", 451, 455], ["PI3K", "PROTEIN", 14, 18], ["serine-threonine kinase", "PROTEIN", 48, 71], ["Akt", "PROTEIN", 72, 75], ["FADD", "PROTEIN", 202, 206], ["DISC", "PROTEIN", 230, 234], ["CD95", "PROTEIN", 287, 291], ["type I and type II cells", "CELL_TYPE", 336, 360], ["human", "SPECIES", 445, 450], ["human", "SPECIES", 445, 450], ["Activation of PI3K", "TREATMENT", 0, 18], ["serine-threonine kinase Akt", "TEST", 48, 75], ["PEA", "TEST", 105, 108], ["this posttranslational modification", "TREATMENT", 136, 171], ["Type I/II Signaling Pathways", "PROBLEM", 254, 282], ["type I and type II cells", "PROBLEM", 336, 360], ["DISC", "ANATOMY", 230, 234], ["human", "ANATOMY", 445, 450], ["body", "ANATOMY_MODIFIER", 451, 455]]], ["CD95-mediated apoptotic signal cannot be altered in thymocytes or activated T-cells expressing a Bcl-2 transgene, conferring to their type I nature [93], whereas hepatocytes expressing the same transgene resist CD95-induced apoptosis and thus behave as type II cells [94, 95].What Can We Learn from CD95 Mutations? ::: CD95: A Death Receptor?Germinal mutations in APT-1 have been reported in patients developing a syndrome termed autoimmune lymphoproliferative syndrome type Ia (ALPS, also called Canale-Smith syndrome) [96\u201398].", [["thymocytes", "ANATOMY", 52, 62], ["T-cells", "ANATOMY", 76, 83], ["hepatocytes", "ANATOMY", 162, 173], ["type II cells", "ANATOMY", 253, 266], ["autoimmune lymphoproliferative syndrome type Ia", "DISEASE", 430, 477], ["ALPS", "DISEASE", 479, 483], ["Canale-Smith syndrome", "DISEASE", 497, 518], ["CD95", "GENE_OR_GENE_PRODUCT", 0, 4], ["thymocytes", "CELL", 52, 62], ["T-cells", "CELL", 76, 83], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 97, 102], ["hepatocytes", "CELL", 162, 173], ["CD95", "GENE_OR_GENE_PRODUCT", 211, 215], ["type II cells", "CELL", 253, 266], ["CD95", "GENE_OR_GENE_PRODUCT", 299, 303], ["CD95", "GENE_OR_GENE_PRODUCT", 319, 323], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 325, 341], ["APT-1", "GENE_OR_GENE_PRODUCT", 364, 369], ["patients", "ORGANISM", 392, 400], ["autoimmune lymphoproliferative syndrome type Ia", "CANCER", 430, 477], ["CD95", "PROTEIN", 0, 4], ["thymocytes", "CELL_TYPE", 52, 62], ["activated T-cells", "CELL_TYPE", 66, 83], ["Bcl-2 transgene", "DNA", 97, 112], ["hepatocytes", "CELL_TYPE", 162, 173], ["CD95", "PROTEIN", 211, 215], ["type II cells", "CELL_TYPE", 253, 266], ["CD95", "PROTEIN", 299, 303], ["CD95", "PROTEIN", 319, 323], ["APT-1", "DNA", 364, 369], ["patients", "SPECIES", 392, 400], ["CD95", "TEST", 0, 4], ["apoptotic signal", "PROBLEM", 14, 30], ["apoptosis", "PROBLEM", 224, 233], ["Germinal mutations in APT", "PROBLEM", 342, 367], ["a syndrome termed autoimmune lymphoproliferative syndrome type Ia", "PROBLEM", 412, 477], ["apoptotic signal", "OBSERVATION", 14, 30], ["cannot be", "UNCERTAINTY", 31, 40], ["mutations", "OBSERVATION", 351, 360], ["autoimmune lymphoproliferative syndrome", "OBSERVATION", 430, 469]]], ["ALPS patients show chronic lymphadenopathy and splenomegaly, expanded populations of double-negative \u03b1/\u03b2-\u03a4-lymphocytes (CD3+CD4\u2212CD8\u2212), and often develop autoimmunity [96, 97, 99, 100].", [["\u03b1/\u03b2-\u03a4-lymphocytes", "ANATOMY", 101, 118], ["CD3+CD4\u2212CD8\u2212", "ANATOMY", 120, 132], ["ALPS", "DISEASE", 0, 4], ["lymphadenopathy", "DISEASE", 27, 42], ["splenomegaly", "DISEASE", 47, 59], ["autoimmunity", "DISEASE", 153, 165], ["patients", "ORGANISM", 5, 13], ["\u03b1", "GENE_OR_GENE_PRODUCT", 101, 102], ["\u03b2", "GENE_OR_GENE_PRODUCT", 103, 104], ["CD3", "GENE_OR_GENE_PRODUCT", 120, 123], ["CD4", "GENE_OR_GENE_PRODUCT", 124, 127], ["CD8", "GENE_OR_GENE_PRODUCT", 128, 131], ["double-negative \u03b1/\u03b2-\u03a4-lymphocytes", "CELL_TYPE", 85, 118], ["CD3", "PROTEIN", 120, 123], ["CD4", "PROTEIN", 124, 127], ["CD8", "PROTEIN", 128, 131], ["patients", "SPECIES", 5, 13], ["chronic lymphadenopathy", "PROBLEM", 19, 42], ["splenomegaly", "PROBLEM", 47, 59], ["double", "TEST", 85, 91], ["\u03b2", "TEST", 103, 104], ["lymphocytes", "TEST", 107, 118], ["CD3", "TEST", 120, 123], ["CD4", "TEST", 124, 127], ["CD8\u2212", "TEST", 128, 132], ["autoimmunity", "TEST", 153, 165], ["chronic", "OBSERVATION_MODIFIER", 19, 26], ["lymphadenopathy", "OBSERVATION", 27, 42], ["splenomegaly", "OBSERVATION", 47, 59], ["expanded", "OBSERVATION_MODIFIER", 61, 69], ["populations", "OBSERVATION_MODIFIER", 70, 81], ["lymphocytes", "ANATOMY", 107, 118]]], ["In agreement with the notion that CD95 behaves as a tumor suppressor, ALPS patients display an increased risk of Hodgkin and non-Hodgkin lymphoma [101].", [["tumor", "ANATOMY", 52, 57], ["Hodgkin", "ANATOMY", 113, 120], ["non-Hodgkin lymphoma", "ANATOMY", 125, 145], ["tumor", "DISEASE", 52, 57], ["ALPS", "DISEASE", 70, 74], ["Hodgkin and non-Hodgkin lymphoma", "DISEASE", 113, 145], ["CD95", "GENE_OR_GENE_PRODUCT", 34, 38], ["tumor", "CANCER", 52, 57], ["patients", "ORGANISM", 75, 83], ["Hodgkin", "CANCER", 113, 120], ["non-Hodgkin lymphoma", "CANCER", 125, 145], ["CD95", "PROTEIN", 34, 38], ["patients", "SPECIES", 75, 83], ["a tumor suppressor", "TREATMENT", 50, 68], ["Hodgkin and non-Hodgkin lymphoma", "PROBLEM", 113, 145], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["Hodgkin", "OBSERVATION", 113, 120], ["non-Hodgkin lymphoma", "OBSERVATION", 125, 145]]], ["Predominance of post-germinal center (GC) lymphomas in patients exhibiting either germ line or somatic CD95 mutations can be explained by the fact that, inside germinal centers of the secondary lymphoid follicles, the CD95 signal plays a pivotal role in the deletion of self-reactive maturating B-lymphocytes [102], in addition to the fact that APT-1 belongs to a set of rare genes (i.e., PIM1, c-myc, PAX5, RhoH/TTF, and Bcl-6) subject to somatic hypermutation [103, 104], which may affect biological function.", [["post-germinal center (GC) lymphomas", "ANATOMY", 16, 51], ["germ line", "ANATOMY", 82, 91], ["germinal centers", "ANATOMY", 160, 176], ["lymphoid follicles", "ANATOMY", 194, 212], ["B-lymphocytes", "ANATOMY", 295, 308], ["lymphomas", "DISEASE", 42, 51], ["post-germinal center (GC) lymphomas", "CANCER", 16, 51], ["patients", "ORGANISM", 55, 63], ["germ line", "CELL", 82, 91], ["CD95", "GENE_OR_GENE_PRODUCT", 103, 107], ["lymphoid follicles", "MULTI-TISSUE_STRUCTURE", 194, 212], ["CD95", "GENE_OR_GENE_PRODUCT", 218, 222], ["B-lymphocytes [102]", "CELL", 295, 314], ["APT-1", "GENE_OR_GENE_PRODUCT", 345, 350], ["PIM1", "GENE_OR_GENE_PRODUCT", 389, 393], ["c-myc", "GENE_OR_GENE_PRODUCT", 395, 400], ["PAX5", "GENE_OR_GENE_PRODUCT", 402, 406], ["RhoH", "GENE_OR_GENE_PRODUCT", 408, 412], ["TTF", "GENE_OR_GENE_PRODUCT", 413, 416], ["Bcl-6", "GENE_OR_GENE_PRODUCT", 422, 427], ["CD95", "PROTEIN", 103, 107], ["CD95", "PROTEIN", 218, 222], ["self-reactive maturating B-lymphocytes", "CELL_TYPE", 270, 308], ["APT-1", "DNA", 345, 350], ["PIM1", "DNA", 389, 393], ["c-myc", "DNA", 395, 400], ["PAX5", "DNA", 402, 406], ["RhoH", "DNA", 408, 412], ["TTF", "DNA", 413, 416], ["Bcl-6", "DNA", 422, 427], ["patients", "SPECIES", 55, 63], ["post-germinal center (GC) lymphomas", "PROBLEM", 16, 51], ["germ line", "PROBLEM", 82, 91], ["somatic CD95 mutations", "PROBLEM", 95, 117], ["PIM1", "TEST", 389, 393], ["myc", "TEST", 397, 400], ["PAX5", "TEST", 402, 406], ["RhoH", "TEST", 408, 412], ["TTF", "TEST", 413, 416], ["Bcl", "TEST", 422, 425], ["somatic hypermutation", "PROBLEM", 440, 461], ["post-germinal center", "OBSERVATION_MODIFIER", 16, 36], ["germ line", "OBSERVATION", 82, 91], ["somatic CD95 mutations", "OBSERVATION", 95, 117], ["secondary lymphoid follicles", "OBSERVATION", 184, 212]]], ["In addition to post-GC lymphomas, significant amounts of mutations in the CD95 gene were found in tumors of various histological origins (reviewed in [54]).", [["GC lymphomas", "ANATOMY", 20, 32], ["tumors", "ANATOMY", 98, 104], ["lymphomas", "DISEASE", 23, 32], ["tumors", "DISEASE", 98, 104], ["GC lymphomas", "CANCER", 20, 32], ["CD95", "GENE_OR_GENE_PRODUCT", 74, 78], ["tumors", "CANCER", 98, 104], ["CD95 gene", "DNA", 74, 83], ["post-GC lymphomas", "PROBLEM", 15, 32], ["mutations in the CD95 gene", "PROBLEM", 57, 83], ["GC lymphomas", "OBSERVATION", 20, 32], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["amounts", "OBSERVATION_MODIFIER", 46, 53]]], ["Extensive analysis of CD95 mutations and their distribution in APT-1 reveals that, with some exceptions, most are gathered in exons 8 and 9 encoding the CD95 intracellular region (Fig. 11.3) [105].", [["intracellular", "ANATOMY", 158, 171], ["CD95", "GENE_OR_GENE_PRODUCT", 22, 26], ["APT-1", "GENE_OR_GENE_PRODUCT", 63, 68], ["CD95", "GENE_OR_GENE_PRODUCT", 153, 157], ["CD95", "PROTEIN", 22, 26], ["APT-1", "DNA", 63, 68], ["exons 8 and 9", "DNA", 126, 139], ["CD95 intracellular region", "PROTEIN", 153, 178], ["Extensive analysis", "TEST", 0, 18], ["CD95 mutations", "PROBLEM", 22, 36], ["APT", "TEST", 63, 66], ["CD95 mutations", "OBSERVATION", 22, 36]]], ["Remarkably, most of these mutations are heterozygous, mainly localized in CD95-DD, and lead to inhibition of the CD95-mediated apoptotic signal.", [["CD95", "GENE_OR_GENE_PRODUCT", 74, 78], ["CD95", "GENE_OR_GENE_PRODUCT", 113, 117], ["CD95", "PROTEIN", 74, 78], ["CD95", "PROTEIN", 113, 117], ["these mutations", "PROBLEM", 20, 35], ["heterozygous", "PROBLEM", 40, 52], ["the CD95", "TEST", 109, 117], ["heterozygous", "OBSERVATION", 40, 52], ["apoptotic signal", "OBSERVATION", 127, 143]]], ["Indeed, in agreement with the notion that CD95 is expressed at the plasma membrane as a pre-associated homotrimer [23, 24], formation of heterocomplexes containing wild-type and mutated CD95 prevents FADD recruitment and abrogates the ignition of the apoptotic signal in a dominant manner.What Can We Learn from CD95 Mutations? ::: CD95: A Death Receptor?Extensive analysis and positioning of various CD95 mutations described in the literature seem to highlight mutation \u201chot spots\u201d in the CD95 sequence (Fig. 11.3).", [["plasma membrane", "ANATOMY", 67, 82], ["CD95", "GENE_OR_GENE_PRODUCT", 42, 46], ["plasma membrane", "CELLULAR_COMPONENT", 67, 82], ["heterocomplexes", "GENE_OR_GENE_PRODUCT", 137, 152], ["CD95", "GENE_OR_GENE_PRODUCT", 186, 190], ["FADD", "GENE_OR_GENE_PRODUCT", 200, 204], ["CD95", "GENE_OR_GENE_PRODUCT", 312, 316], ["CD95", "GENE_OR_GENE_PRODUCT", 332, 336], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 338, 354], ["CD95", "GENE_OR_GENE_PRODUCT", 401, 405], ["CD95", "GENE_OR_GENE_PRODUCT", 490, 494], ["CD95", "PROTEIN", 42, 46], ["heterocomplexes", "PROTEIN", 137, 152], ["wild-type and mutated CD95", "PROTEIN", 164, 190], ["FADD", "PROTEIN", 200, 204], ["CD95", "PROTEIN", 312, 316], ["CD95", "PROTEIN", 332, 336], ["CD95", "PROTEIN", 401, 405], ["CD95 sequence", "DNA", 490, 503], ["heterocomplexes", "PROBLEM", 137, 152], ["FADD recruitment", "TREATMENT", 200, 216], ["Extensive analysis", "TEST", 355, 373], ["various CD95 mutations", "PROBLEM", 393, 415], ["mutation \u201chot spots", "PROBLEM", 462, 481], ["the CD95 sequence", "TEST", 486, 503], ["apoptotic signal", "OBSERVATION", 251, 267], ["various CD95 mutations", "OBSERVATION", 393, 415]]], ["Among these hot spots, arginine 234, aspartic acid 244, and valine 251 account for a significant amount of the documented CD95 mutations.", [["arginine 234", "CHEMICAL", 23, 35], ["aspartic acid 244", "CHEMICAL", 37, 54], ["valine 251", "CHEMICAL", 60, 70], ["arginine", "CHEMICAL", 23, 31], ["aspartic acid", "CHEMICAL", 37, 50], ["valine", "CHEMICAL", 60, 66], ["arginine", "AMINO_ACID", 23, 31], ["234", "AMINO_ACID", 32, 35], ["aspartic acid 244", "AMINO_ACID", 37, 54], ["valine", "AMINO_ACID", 60, 66], ["251", "AMINO_ACID", 67, 70], ["CD95", "GENE_OR_GENE_PRODUCT", 122, 126], ["CD95", "PROTEIN", 122, 126], ["these hot spots", "TEST", 6, 21], ["arginine", "TEST", 23, 31], ["aspartic acid", "TEST", 37, 50], ["valine", "TEST", 60, 66], ["the documented CD95 mutations", "PROBLEM", 107, 136], ["CD95 mutations", "OBSERVATION", 122, 136]]], ["Indeed, among the 189 mutations annotated in the 335 amino acids of CD95, 30 (~16%) are localized on these three amino acids (Fig. 11.3).", [["amino acids", "CHEMICAL", 53, 64], ["amino acids", "CHEMICAL", 113, 124], ["amino acids", "CHEMICAL", 53, 64], ["amino acids", "CHEMICAL", 113, 124], ["amino acids", "AMINO_ACID", 53, 64], ["CD95", "GENE_OR_GENE_PRODUCT", 68, 72], ["amino acids", "AMINO_ACID", 113, 124], ["CD95", "PROTEIN", 68, 72], ["amino acids", "TEST", 53, 64], ["CD95", "TEST", 68, 72], ["these three amino acids", "TEST", 101, 124], ["Fig.", "TEST", 126, 130]]], ["Strikingly, the pivotal role played by these amino acids in stabilization or formation of intra- and inter-bridges between CD95 and FADD may explain these hot spots.", [["amino acids", "CHEMICAL", 45, 56], ["amino acids", "CHEMICAL", 45, 56], ["amino acids", "AMINO_ACID", 45, 56], ["CD95", "GENE_OR_GENE_PRODUCT", 123, 127], ["FADD", "GENE_OR_GENE_PRODUCT", 132, 136], ["CD95", "PROTEIN", 123, 127], ["FADD", "PROTEIN", 132, 136], ["these amino acids", "TREATMENT", 39, 56], ["intra- and inter-bridges between CD95", "TREATMENT", 90, 127], ["FADD", "TREATMENT", 132, 136], ["these hot spots", "PROBLEM", 149, 164]]], ["For instance, both R234 and D244 contribute to the homotypic aggregation of the receptor and FADD recruitment [67].", [["D244", "GENE_OR_GENE_PRODUCT", 28, 32], ["FADD", "GENE_OR_GENE_PRODUCT", 93, 97], ["FADD", "PROTEIN", 93, 97]]], ["Nevertheless, the observation of death domain hot spots is in contradiction with the study of Scott and colleagues demonstrating that the region of the CD95-DD interacting with the FADD-DD extends over a disperse surface through weak binding affinity [68].What Can We Learn from CD95 Mutations? ::: CD95: A Death Receptor?Most ALPS type Ia patients affected by malignancies do not undergo loss of heterozygosity (LOH), which formed the hypothesis that preservation of a wild-type allele may contribute to carcinogenesis [106, 107].", [["surface", "ANATOMY", 213, 220], ["malignancies", "ANATOMY", 361, 373], ["death", "DISEASE", 33, 38], ["ALPS", "DISEASE", 327, 331], ["malignancies", "DISEASE", 361, 373], ["loss of heterozygosity", "DISEASE", 389, 411], ["carcinogenesis", "DISEASE", 505, 519], ["CD95", "GENE_OR_GENE_PRODUCT", 152, 156], ["DD", "GENE_OR_GENE_PRODUCT", 157, 159], ["FADD", "GENE_OR_GENE_PRODUCT", 181, 185], ["surface", "CELLULAR_COMPONENT", 213, 220], ["CD95", "GENE_OR_GENE_PRODUCT", 279, 283], ["CD95", "GENE_OR_GENE_PRODUCT", 299, 303], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 305, 321], ["patients", "ORGANISM", 340, 348], ["malignancies", "CANCER", 361, 373], ["death domain", "PROTEIN", 33, 45], ["CD95", "PROTEIN", 152, 156], ["DD", "PROTEIN", 157, 159], ["FADD", "PROTEIN", 181, 185], ["DD", "PROTEIN", 186, 188], ["CD95", "PROTEIN", 279, 283], ["CD95", "PROTEIN", 299, 303], ["wild-type allele", "DNA", 470, 486], ["patients", "SPECIES", 340, 348], ["death domain hot spots", "PROBLEM", 33, 55], ["the study", "TEST", 81, 90], ["DD", "PROBLEM", 186, 188], ["weak binding affinity", "PROBLEM", 229, 250], ["malignancies", "PROBLEM", 361, 373], ["loss of heterozygosity (LOH)", "PROBLEM", 389, 417], ["a wild-type allele", "PROBLEM", 468, 486], ["CD95", "ANATOMY", 152, 156], ["malignancies", "OBSERVATION", 361, 373]]], ["In the same line, it was demonstrated that expression of a unique mutated CD95 allele blocks the induction of apoptotic signals, while it fails to prevent non-apoptotic signals such as NF-\u03baB and MAPK [106, 107], whose induction promotes invasiveness in tumor cells [105, 108].", [["tumor cells", "ANATOMY", 253, 264], ["tumor", "DISEASE", 253, 258], ["CD95", "GENE_OR_GENE_PRODUCT", 74, 78], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 185, 190], ["MAPK", "GENE_OR_GENE_PRODUCT", 195, 199], ["tumor cells", "CELL", 253, 264], ["mutated CD95 allele", "DNA", 66, 85], ["NF-\u03baB", "PROTEIN", 185, 190], ["MAPK", "PROTEIN", 195, 199], ["tumor cells", "CELL_TYPE", 253, 264], ["a unique mutated CD95 allele blocks", "TREATMENT", 57, 92], ["apoptotic signals", "TEST", 110, 127], ["non-apoptotic signals", "PROBLEM", 155, 176], ["NF", "TEST", 185, 187], ["MAPK", "TEST", 195, 199], ["tumor cells", "TEST", 253, 264], ["line", "OBSERVATION", 12, 16], ["invasiveness", "OBSERVATION_MODIFIER", 237, 249]]], ["In addition, mutations found in the intracellular CD95-DD exhibit a higher penetrance of ALPS phenotype features in mutation-bearing relatives compared to extracellular mutations.", [["intracellular", "ANATOMY", 36, 49], ["extracellular", "ANATOMY", 155, 168], ["ALPS", "DISEASE", 89, 93], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 36, 49], ["CD95", "GENE_OR_GENE_PRODUCT", 50, 54], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 155, 168], ["CD95", "PROTEIN", 50, 54], ["DD", "PROTEIN", 55, 57], ["mutations", "PROBLEM", 13, 22], ["the intracellular CD95", "TEST", 32, 54], ["a higher penetrance of ALPS phenotype features", "PROBLEM", 66, 112], ["extracellular mutations", "PROBLEM", 155, 178], ["intracellular CD95", "ANATOMY", 36, 54], ["ALPS phenotype", "OBSERVATION", 89, 103]]], ["These results suggest that unlike DD mutations, CD95 mutations localized outside the DD somehow prevent the apoptotic signal but may fail to promote non-apoptotic pathways, which may contribute to disease aggressiveness.Lipid Rafts ::: Regulation of the\u00a0Initial Steps of CD95-Mediated Signaling ::: CD95: A Death Receptor?In addition to CD95 downregulation or expression of the mutated allele of the receptor, the plasma membrane distribution of CD95 represents an additional pathway for tumor cells to develop resistance to CD95L-expressing immune cells.", [["plasma membrane", "ANATOMY", 414, 429], ["tumor cells", "ANATOMY", 488, 499], ["immune cells", "ANATOMY", 542, 554], ["aggressiveness", "DISEASE", 205, 219], ["tumor", "DISEASE", 488, 493], ["DD", "GENE_OR_GENE_PRODUCT", 34, 36], ["CD95", "GENE_OR_GENE_PRODUCT", 48, 52], ["Lipid", "SIMPLE_CHEMICAL", 220, 225], ["CD95", "GENE_OR_GENE_PRODUCT", 271, 275], ["CD95", "GENE_OR_GENE_PRODUCT", 299, 303], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 305, 321], ["CD95", "GENE_OR_GENE_PRODUCT", 337, 341], ["plasma membrane", "CELLULAR_COMPONENT", 414, 429], ["CD95", "GENE_OR_GENE_PRODUCT", 446, 450], ["tumor cells", "CELL", 488, 499], ["CD95L", "GENE_OR_GENE_PRODUCT", 525, 530], ["immune cells", "CELL", 542, 554], ["CD95", "PROTEIN", 48, 52], ["CD95", "PROTEIN", 271, 275], ["CD95", "PROTEIN", 299, 303], ["CD95", "PROTEIN", 337, 341], ["mutated allele", "DNA", 378, 392], ["CD95", "PROTEIN", 446, 450], ["tumor cells", "CELL_TYPE", 488, 499], ["CD95L", "PROTEIN", 525, 530], ["expressing immune cells", "CELL_TYPE", 531, 554], ["unlike DD mutations", "PROBLEM", 27, 46], ["CD95 mutations", "PROBLEM", 48, 62], ["the apoptotic signal", "PROBLEM", 104, 124], ["disease aggressiveness", "PROBLEM", 197, 219], ["CD95 downregulation", "PROBLEM", 337, 356], ["tumor cells", "PROBLEM", 488, 499], ["CD95L", "TEST", 525, 530], ["immune cells", "PROBLEM", 542, 554], ["CD95 downregulation", "OBSERVATION", 337, 356], ["tumor", "OBSERVATION", 488, 493], ["immune cells", "OBSERVATION", 542, 554]]], ["Indeed, the plasma membrane is a heterogeneous lipid bilayer comprising compacted or liquid-ordered domains, called microdomains, lipid rafts, or detergent-resistant microdomains (DRMs).", [["plasma membrane", "ANATOMY", 12, 27], ["lipid bilayer", "ANATOMY", 47, 60], ["microdomains", "ANATOMY", 116, 128], ["lipid rafts", "ANATOMY", 130, 141], ["microdomains", "ANATOMY", 166, 178], ["DRMs", "ANATOMY", 180, 184], ["plasma membrane", "CELLULAR_COMPONENT", 12, 27], ["lipid bilayer", "CELLULAR_COMPONENT", 47, 60], ["microdomains", "CELLULAR_COMPONENT", 116, 128], ["lipid rafts", "CELLULAR_COMPONENT", 130, 141], ["DRMs", "CELLULAR_COMPONENT", 180, 184], ["a heterogeneous lipid bilayer", "PROBLEM", 31, 60], ["lipid rafts", "TREATMENT", 130, 141], ["plasma membrane", "OBSERVATION", 12, 27], ["heterogeneous", "OBSERVATION_MODIFIER", 33, 46], ["lipid bilayer", "OBSERVATION", 47, 60], ["resistant microdomains", "OBSERVATION", 156, 178]]], ["These domains are described as floating in a more fluid or liquid-disordered 2D lipid bilayer and are enriched in ceramides [109].", [["ceramides", "CHEMICAL", 114, 123], ["ceramides", "CHEMICAL", 114, 123], ["ceramides", "SIMPLE_CHEMICAL", 114, 123], ["liquid-disordered 2D lipid bilayer", "TREATMENT", 59, 93], ["floating", "OBSERVATION_MODIFIER", 31, 39]]], ["It has been elegantly shown that while CD95 is mostly excluded from lipid rafts in activated T-lymphocytes, TCR-dependent reactivation of these cells leads to rapid distribution of the death receptor into lipid rafts [110].", [["lipid rafts", "ANATOMY", 68, 79], ["T-lymphocytes", "ANATOMY", 93, 106], ["cells", "ANATOMY", 144, 149], ["lipid rafts", "ANATOMY", 205, 216], ["TCR", "CHEMICAL", 108, 111], ["death", "DISEASE", 185, 190], ["CD95", "GENE_OR_GENE_PRODUCT", 39, 43], ["lipid rafts", "CELLULAR_COMPONENT", 68, 79], ["T-lymphocytes", "CELL", 93, 106], ["TCR", "GENE_OR_GENE_PRODUCT", 108, 111], ["cells", "CELL", 144, 149], ["CD95", "PROTEIN", 39, 43], ["activated T-lymphocytes", "CELL_TYPE", 83, 106], ["TCR", "PROTEIN", 108, 111], ["death receptor", "PROTEIN", 185, 199], ["CD95", "TEST", 39, 43], ["lipid rafts", "TEST", 68, 79], ["TCR-dependent reactivation of these cells", "PROBLEM", 108, 149], ["mostly excluded", "UNCERTAINTY", 47, 62], ["dependent", "OBSERVATION_MODIFIER", 112, 121], ["reactivation", "OBSERVATION", 122, 134], ["rapid", "OBSERVATION_MODIFIER", 159, 164], ["distribution", "OBSERVATION_MODIFIER", 165, 177]]], ["This CD95 compartmentalization contributes to reducing the apoptotic threshold leading to the clonotypic elimination of activated T-lymphocytes through activation of the CD95-mediated apoptotic signal [110].", [["T-lymphocytes", "ANATOMY", 130, 143], ["CD95", "GENE_OR_GENE_PRODUCT", 5, 9], ["T-lymphocytes", "CELL", 130, 143], ["CD95", "GENE_OR_GENE_PRODUCT", 170, 174], ["CD95", "PROTEIN", 5, 9], ["activated T-lymphocytes", "CELL_TYPE", 120, 143], ["CD95", "PROTEIN", 170, 174], ["the apoptotic threshold", "PROBLEM", 55, 78], ["the CD95", "TEST", 166, 174]]], ["Similarly, the reorganization of CD95 into DRMs can occur independent from ligand upon addition of certain chemotherapeutic drugs (e.g., rituximab [111], resveratrol [112, 113], edelfosine [87, 114, 115], aplidin [116], perifosine [115], cisplatin [117]).", [["DRMs", "ANATOMY", 43, 47], ["rituximab", "CHEMICAL", 137, 146], ["resveratrol", "CHEMICAL", 154, 165], ["edelfosine", "CHEMICAL", 178, 188], ["aplidin", "CHEMICAL", 205, 212], ["perifosine", "CHEMICAL", 220, 230], ["cisplatin", "CHEMICAL", 238, 247], ["resveratrol", "CHEMICAL", 154, 165], ["edelfosine", "CHEMICAL", 178, 188], ["aplidin", "CHEMICAL", 205, 212], ["perifosine", "CHEMICAL", 220, 230], ["cisplatin", "CHEMICAL", 238, 247], ["CD95", "GENE_OR_GENE_PRODUCT", 33, 37], ["DRMs", "CELLULAR_COMPONENT", 43, 47], ["rituximab", "SIMPLE_CHEMICAL", 137, 146], ["resveratrol", "SIMPLE_CHEMICAL", 154, 165], ["edelfosine", "SIMPLE_CHEMICAL", 178, 188], ["aplidin [116]", "SIMPLE_CHEMICAL", 205, 218], ["perifosine", "SIMPLE_CHEMICAL", 220, 230], ["cisplatin", "SIMPLE_CHEMICAL", 238, 247], ["CD95", "PROTEIN", 33, 37], ["certain chemotherapeutic drugs", "TREATMENT", 99, 129], ["rituximab", "TREATMENT", 137, 146], ["resveratrol", "TREATMENT", 154, 165], ["edelfosine", "TREATMENT", 178, 188], ["aplidin", "TREATMENT", 205, 212], ["perifosine", "TREATMENT", 220, 230], ["cisplatin", "TREATMENT", 238, 247]]], ["The molecular cascades that underlie this process remain elusive.", [["The molecular cascades", "PROBLEM", 0, 22], ["molecular cascades", "OBSERVATION", 4, 22]]], ["Nevertheless, a growing body of evidence leads us to postulate that alteration of intracellular signaling pathway(s), such as the aforementioned PI3K signal [87, 90], may change biophysical properties of the plasma membrane, such as membrane fluidity, which in turn may facilitate CD95 clustering into large lipid raft-enriched platforms, favoring DISC formation and induction of the apoptotic program [118].Posttranslational Modifications ::: Regulation of the\u00a0Initial Steps of CD95-Mediated Signaling ::: CD95: A Death Receptor?Accumulation of CD95 mutations is not the only mechanism by which malignant cells inhibit the extrinsic signaling pathway.", [["intracellular", "ANATOMY", 82, 95], ["plasma membrane", "ANATOMY", 208, 223], ["membrane", "ANATOMY", 233, 241], ["lipid raft", "ANATOMY", 308, 318], ["malignant cells", "ANATOMY", 596, 611], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 82, 95], ["PI3K", "GENE_OR_GENE_PRODUCT", 145, 149], ["plasma membrane", "CELLULAR_COMPONENT", 208, 223], ["membrane", "CELLULAR_COMPONENT", 233, 241], ["CD95", "GENE_OR_GENE_PRODUCT", 281, 285], ["lipid raft", "CELLULAR_COMPONENT", 308, 318], ["DISC", "GENE_OR_GENE_PRODUCT", 348, 352], ["CD95", "GENE_OR_GENE_PRODUCT", 479, 483], ["CD95", "GENE_OR_GENE_PRODUCT", 507, 511], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 513, 529], ["CD95", "GENE_OR_GENE_PRODUCT", 546, 550], ["malignant cells", "CELL", 596, 611], ["PI3K", "PROTEIN", 145, 149], ["CD95", "PROTEIN", 281, 285], ["DISC", "PROTEIN", 348, 352], ["CD95", "PROTEIN", 479, 483], ["CD95", "PROTEIN", 507, 511], ["CD95", "PROTEIN", 546, 550], ["malignant cells", "CELL_TYPE", 596, 611], ["the aforementioned PI3K signal", "TEST", 126, 156], ["membrane fluidity", "PROBLEM", 233, 250], ["DISC formation", "PROBLEM", 348, 362], ["the apoptotic program", "TREATMENT", 380, 401], ["CD95 mutations", "PROBLEM", 546, 560], ["malignant cells", "PROBLEM", 596, 611], ["plasma membrane", "OBSERVATION", 208, 223], ["large", "OBSERVATION_MODIFIER", 302, 307], ["lipid raft", "OBSERVATION", 308, 318], ["DISC formation", "OBSERVATION", 348, 362], ["CD95 mutations", "OBSERVATION", 546, 560]]], ["Posttranslational modifications in the intracellular tail of CD95, such as reversible oxidation or covalent attachment of a palmitic acid, were reported to alter the plasma membrane distribution of CD95 and thereby its subsequent signaling pathway.", [["intracellular tail", "ANATOMY", 39, 57], ["plasma membrane", "ANATOMY", 166, 181], ["palmitic acid", "CHEMICAL", 124, 137], ["palmitic acid", "CHEMICAL", 124, 137], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 52], ["CD95", "GENE_OR_GENE_PRODUCT", 61, 65], ["palmitic acid", "SIMPLE_CHEMICAL", 124, 137], ["plasma membrane", "CELLULAR_COMPONENT", 166, 181], ["CD95", "GENE_OR_GENE_PRODUCT", 198, 202], ["intracellular tail", "PROTEIN", 39, 57], ["CD95", "PROTEIN", 61, 65], ["CD95", "PROTEIN", 198, 202], ["Posttranslational modifications", "PROBLEM", 0, 31], ["reversible oxidation", "TREATMENT", 75, 95], ["a palmitic acid", "TEST", 122, 137], ["intracellular", "ANATOMY_MODIFIER", 39, 52], ["tail", "ANATOMY_MODIFIER", 53, 57], ["reversible oxidation", "OBSERVATION", 75, 95], ["palmitic acid", "OBSERVATION", 124, 137]]], ["For instance, S-glutathionylation of mouse CD95 at cysteine 294 promotes clustering of CD95 and its distribution into lipid rafts [119].", [["lipid rafts", "ANATOMY", 118, 129], ["cysteine 294", "CHEMICAL", 51, 63], ["cysteine", "CHEMICAL", 51, 59], ["mouse", "ORGANISM", 37, 42], ["CD95", "GENE_OR_GENE_PRODUCT", 43, 47], ["cysteine", "AMINO_ACID", 51, 59], ["294", "AMINO_ACID", 60, 63], ["CD95", "GENE_OR_GENE_PRODUCT", 87, 91], ["mouse CD95", "PROTEIN", 37, 47], ["CD95", "PROTEIN", 87, 91], ["mouse", "SPECIES", 37, 42], ["mouse", "SPECIES", 37, 42], ["S-glutathionylation of mouse CD95 at cysteine", "TREATMENT", 14, 59], ["CD95", "TREATMENT", 87, 91]]], ["This amino acid is conserved in the human CD95 sequence and corresponds to cysteine 304 (or C288 when subtraction of the 16-amino acid signal peptide is taken into consideration [12, 120]).", [["amino acid", "CHEMICAL", 5, 15], ["cysteine 304", "CHEMICAL", 75, 87], ["amino acid", "CHEMICAL", 124, 134], ["amino acid", "CHEMICAL", 5, 15], ["cysteine", "CHEMICAL", 75, 83], ["amino acid", "CHEMICAL", 124, 134], ["amino acid", "AMINO_ACID", 5, 15], ["human", "ORGANISM", 36, 41], ["CD95", "GENE_OR_GENE_PRODUCT", 42, 46], ["cysteine 304", "AMINO_ACID", 75, 87], ["amino acid", "AMINO_ACID", 124, 134], ["human CD95 sequence", "DNA", 36, 55], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["This amino acid", "TEST", 0, 15], ["the human CD95 sequence", "TEST", 32, 55], ["cysteine", "TEST", 75, 83], ["subtraction", "TEST", 102, 113], ["amino acid signal peptide", "TREATMENT", 124, 149]]], ["Interestingly, Janssen-Heininger and colleagues emphasize that death receptor glutathionylation occurs downstream of caspase-8 and caspase-3 activation whose catalytic activity damages the thioltransferase glutaredoxin 1 (Grx1), an enzyme implicated in the denitrosylation of proteins [119].", [["death", "DISEASE", 63, 68], ["caspase-8", "GENE_OR_GENE_PRODUCT", 117, 126], ["caspase-3", "GENE_OR_GENE_PRODUCT", 131, 140], ["thioltransferase glutaredoxin 1", "GENE_OR_GENE_PRODUCT", 189, 220], ["Grx1", "GENE_OR_GENE_PRODUCT", 222, 226], ["caspase-8", "PROTEIN", 117, 126], ["caspase-3", "PROTEIN", 131, 140], ["thioltransferase glutaredoxin 1", "PROTEIN", 189, 220], ["Grx1", "PROTEIN", 222, 226], ["death receptor glutathionylation", "TREATMENT", 63, 95], ["caspase", "TEST", 117, 124], ["caspase", "TREATMENT", 131, 138], ["the thioltransferase glutaredoxin", "TREATMENT", 185, 218], ["an enzyme", "TEST", 229, 238]]], ["The consequence of Grx1 inactivation is the accumulation of glutathionylated CD95, which clusters into lipid rafts, sensitizing cells to the CD95-mediated apoptotic signal.", [["lipid rafts", "ANATOMY", 103, 114], ["cells", "ANATOMY", 128, 133], ["Grx1", "GENE_OR_GENE_PRODUCT", 19, 23], ["CD95", "GENE_OR_GENE_PRODUCT", 77, 81], ["lipid rafts", "CELLULAR_COMPONENT", 103, 114], ["cells", "CELL", 128, 133], ["CD95", "GENE_OR_GENE_PRODUCT", 141, 145], ["Grx1", "PROTEIN", 19, 23], ["glutathionylated CD95", "PROTEIN", 60, 81], ["CD95", "PROTEIN", 141, 145], ["Grx1 inactivation", "PROBLEM", 19, 36], ["the accumulation of glutathionylated CD95", "PROBLEM", 40, 81], ["the CD95", "TEST", 137, 145], ["Grx1 inactivation", "OBSERVATION", 19, 36], ["accumulation", "OBSERVATION_MODIFIER", 44, 56], ["glutathionylated CD95", "OBSERVATION", 60, 81], ["lipid rafts", "OBSERVATION", 103, 114], ["sensitizing cells", "OBSERVATION", 116, 133], ["CD95", "ANATOMY", 141, 145], ["apoptotic signal", "OBSERVATION", 155, 171]]], ["Based on these findings, caspase-8 activation occurs prior to aggregation of CD95 and redistribution into lipid rafts, both of which are requisite to form the DISC and subsequently activate larger amounts of caspase-8.", [["lipid rafts", "ANATOMY", 106, 117], ["caspase-8", "GENE_OR_GENE_PRODUCT", 25, 34], ["CD95", "GENE_OR_GENE_PRODUCT", 77, 81], ["lipid rafts", "CELLULAR_COMPONENT", 106, 117], ["DISC", "GENE_OR_GENE_PRODUCT", 159, 163], ["caspase-8", "GENE_OR_GENE_PRODUCT", 208, 217], ["caspase-8", "PROTEIN", 25, 34], ["CD95", "PROTEIN", 77, 81], ["DISC", "PROTEIN", 159, 163], ["caspase-8", "PROTEIN", 208, 217], ["caspase-8 activation", "TREATMENT", 25, 45], ["CD95", "TREATMENT", 77, 81], ["redistribution into lipid rafts", "TREATMENT", 86, 117], ["the DISC", "TREATMENT", 155, 163], ["caspase", "TEST", 208, 215], ["redistribution", "OBSERVATION_MODIFIER", 86, 100], ["lipid rafts", "OBSERVATION", 106, 117], ["DISC", "ANATOMY", 159, 163], ["larger", "OBSERVATION_MODIFIER", 190, 196]]], ["In agreement with these observations, activation of caspase-8 was reported to occur in a two-step process.", [["caspase-8", "GENE_OR_GENE_PRODUCT", 52, 61], ["caspase-8", "PROTEIN", 52, 61], ["caspase", "TEST", 52, 59]]], ["That is, an immediate and small amount of activated caspase-8 (<1%) is generated when CD95L interacts with CD95 that orchestrates acid sphingomyelinase (ASM) activation, ceramide production, and CD95 clustering, which in turn promote DISC formation and the outburst of caspase-8 processing essential to mount the apoptotic signal [121].Posttranslational Modifications ::: Regulation of the\u00a0Initial Steps of CD95-Mediated Signaling ::: CD95: A Death Receptor?S-Glutathionylation consists in a bond between a reactive Cys-thiol and reduced glutathione (GSH), a tripeptide consisting of glycine, cysteine, and glutamate; its attachment to the protein will alter its structure and function in a manner similar to the addition of a phosphate [122].", [["ceramide", "CHEMICAL", 170, 178], ["Cys-thiol", "CHEMICAL", 516, 525], ["glutathione", "CHEMICAL", 538, 549], ["GSH", "CHEMICAL", 551, 554], ["glycine", "CHEMICAL", 584, 591], ["cysteine", "CHEMICAL", 593, 601], ["glutamate", "CHEMICAL", 607, 616], ["phosphate", "CHEMICAL", 727, 736], ["ceramide", "CHEMICAL", 170, 178], ["Cys", "CHEMICAL", 516, 519], ["thiol", "CHEMICAL", 520, 525], ["reduced glutathione", "CHEMICAL", 530, 549], ["GSH", "CHEMICAL", 551, 554], ["tripeptide", "CHEMICAL", 559, 569], ["glycine", "CHEMICAL", 584, 591], ["cysteine", "CHEMICAL", 593, 601], ["glutamate", "CHEMICAL", 607, 616], ["phosphate", "CHEMICAL", 727, 736], ["caspase-8", "GENE_OR_GENE_PRODUCT", 52, 61], ["CD95L", "GENE_OR_GENE_PRODUCT", 86, 91], ["CD95", "GENE_OR_GENE_PRODUCT", 107, 111], ["acid sphingomyelinase", "GENE_OR_GENE_PRODUCT", 130, 151], ["ASM", "GENE_OR_GENE_PRODUCT", 153, 156], ["ceramide", "SIMPLE_CHEMICAL", 170, 178], ["CD95", "GENE_OR_GENE_PRODUCT", 195, 199], ["DISC", "GENE_OR_GENE_PRODUCT", 234, 238], ["caspase-8", "GENE_OR_GENE_PRODUCT", 269, 278], ["CD95", "GENE_OR_GENE_PRODUCT", 407, 411], ["CD95", "GENE_OR_GENE_PRODUCT", 435, 439], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 441, 457], ["reactive Cys-thiol", "SIMPLE_CHEMICAL", 507, 525], ["glutathione", "SIMPLE_CHEMICAL", 538, 549], ["GSH", "SIMPLE_CHEMICAL", 551, 554], ["glycine", "SIMPLE_CHEMICAL", 584, 591], ["cysteine", "AMINO_ACID", 593, 601], ["glutamate", "SIMPLE_CHEMICAL", 607, 616], ["activated caspase-8", "PROTEIN", 42, 61], ["CD95L", "PROTEIN", 86, 91], ["CD95", "PROTEIN", 107, 111], ["acid sphingomyelinase", "PROTEIN", 130, 151], ["CD95", "PROTEIN", 195, 199], ["DISC", "PROTEIN", 234, 238], ["caspase-8", "PROTEIN", 269, 278], ["CD95", "PROTEIN", 407, 411], ["CD95", "PROTEIN", 435, 439], ["activated caspase", "TREATMENT", 42, 59], ["acid sphingomyelinase (ASM) activation", "PROBLEM", 130, 168], ["ceramide production", "PROBLEM", 170, 189], ["CD95 clustering", "PROBLEM", 195, 210], ["DISC formation", "PROBLEM", 234, 248], ["caspase", "TREATMENT", 269, 276], ["Glutathionylation", "PROBLEM", 460, 477], ["a reactive Cys", "TEST", 505, 519], ["a tripeptide consisting of glycine, cysteine", "TREATMENT", 557, 601], ["glutamate", "TREATMENT", 607, 616], ["a phosphate", "TREATMENT", 725, 736], ["small", "OBSERVATION_MODIFIER", 26, 31], ["amount", "OBSERVATION_MODIFIER", 32, 38], ["DISC", "ANATOMY", 234, 238], ["Glutathionylation", "OBSERVATION", 460, 477], ["reactive Cys", "OBSERVATION", 507, 519]]], ["S-Glutathionylation is not the only posttranslational modification of CD95 on a cysteine.", [["cysteine", "CHEMICAL", 80, 88], ["cysteine", "CHEMICAL", 80, 88], ["CD95", "GENE_OR_GENE_PRODUCT", 70, 74], ["cysteine", "AMINO_ACID", 80, 88], ["CD95", "PROTEIN", 70, 74], ["a cysteine", "TREATMENT", 78, 88], ["Glutathionylation", "OBSERVATION", 2, 19]]], ["S-Nitrosylation of cysteine 199 (corresponding to C183 after subtraction of signal peptide sequence) and 304 (C288) in colon and breast tumor cells also promotes the redistribution of CD95 into DRMs, the formation of the DISC, and the transmission of the apoptotic signal [123].Posttranslational Modifications ::: Regulation of the\u00a0Initial Steps of CD95-Mediated Signaling ::: CD95: A Death Receptor?Two reports have brought into light that covalent coupling of a 16-carbon fatty acid (palmitic acid) to cysteine 199 (C183) elicits the redistribution of CD95 into DRMs, the formation of SDS-stable CD95 microaggregates resistant to denaturing and reducing treatments, and the internalization of the receptor [124, 125].", [["colon", "ANATOMY", 119, 124], ["breast tumor cells", "ANATOMY", 129, 147], ["DRMs", "ANATOMY", 194, 198], ["DRMs", "ANATOMY", 564, 568], ["S-Nitrosylation", "CHEMICAL", 0, 15], ["cysteine 199", "CHEMICAL", 19, 31], ["breast tumor", "DISEASE", 129, 141], ["16-carbon fatty acid", "CHEMICAL", 464, 484], ["palmitic acid", "CHEMICAL", 486, 499], ["cysteine 199", "CHEMICAL", 504, 516], ["C183", "CHEMICAL", 518, 522], ["cysteine", "CHEMICAL", 19, 27], ["C183", "CHEMICAL", 50, 54], ["16-carbon fatty acid", "CHEMICAL", 464, 484], ["palmitic acid", "CHEMICAL", 486, 499], ["cysteine", "CHEMICAL", 504, 512], ["C183", "CHEMICAL", 518, 522], ["cysteine", "AMINO_ACID", 19, 27], ["199", "AMINO_ACID", 28, 31], ["colon", "CELL", 119, 124], ["breast tumor cells", "CELL", 129, 147], ["CD95", "GENE_OR_GENE_PRODUCT", 184, 188], ["DRMs", "CELLULAR_COMPONENT", 194, 198], ["DISC", "GENE_OR_GENE_PRODUCT", 221, 225], ["CD95", "GENE_OR_GENE_PRODUCT", 349, 353], ["CD95", "GENE_OR_GENE_PRODUCT", 377, 381], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 383, 399], ["16-carbon fatty acid", "SIMPLE_CHEMICAL", 464, 484], ["palmitic acid", "SIMPLE_CHEMICAL", 486, 499], ["cysteine 199", "SIMPLE_CHEMICAL", 504, 516], ["C183", "AMINO_ACID", 518, 522], ["CD95", "GENE_OR_GENE_PRODUCT", 554, 558], ["DRMs", "CELLULAR_COMPONENT", 564, 568], ["CD95", "GENE_OR_GENE_PRODUCT", 598, 602], ["C183", "PROTEIN", 50, 54], ["colon and breast tumor cells", "CELL_TYPE", 119, 147], ["CD95", "PROTEIN", 184, 188], ["DISC", "PROTEIN", 221, 225], ["CD95", "PROTEIN", 349, 353], ["Mediated Signaling ::: CD95: A Death Receptor", "PROTEIN", 354, 399], ["CD95", "PROTEIN", 554, 558], ["CD95 microaggregates", "PROTEIN", 598, 618], ["Nitrosylation of cysteine", "TREATMENT", 2, 27], ["signal peptide sequence", "TEST", 76, 99], ["colon and breast tumor cells", "PROBLEM", 119, 147], ["CD95 into DRMs", "PROBLEM", 184, 198], ["the apoptotic signal", "TEST", 251, 271], ["a 16-carbon fatty acid (palmitic acid", "TREATMENT", 462, 499], ["cysteine", "TEST", 504, 512], ["the redistribution of CD95 into DRMs", "PROBLEM", 532, 568], ["SDS", "TEST", 587, 590], ["denaturing", "TREATMENT", 632, 642], ["reducing treatments", "TREATMENT", 647, 666], ["colon", "ANATOMY", 119, 124], ["breast", "ANATOMY", 129, 135], ["tumor", "OBSERVATION", 136, 141], ["redistribution", "OBSERVATION_MODIFIER", 166, 180], ["DISC", "ANATOMY", 221, 225], ["redistribution", "OBSERVATION_MODIFIER", 536, 550], ["stable", "OBSERVATION_MODIFIER", 591, 597]]], ["Although their order remains to be fine-tuned, these molecular steps play a critical role in the implementation of apoptotic signals.Posttranslational Modifications ::: Regulation of the\u00a0Initial Steps of CD95-Mediated Signaling ::: CD95: A Death Receptor?Of note, similar to S-nitrosylation, both the aforementioned S-glutathionylation at C304 (C288) and palmitoylation at C199 (C183) promote the partition of CD95 into lipid rafts and enhance the subsequent apoptotic signal.", [["lipid rafts", "ANATOMY", 420, 431], ["CD95", "GENE_OR_GENE_PRODUCT", 204, 208], ["CD95", "GENE_OR_GENE_PRODUCT", 232, 236], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 238, 254], ["C304", "SIMPLE_CHEMICAL", 339, 343], ["CD95", "GENE_OR_GENE_PRODUCT", 410, 414], ["lipid rafts", "CELLULAR_COMPONENT", 420, 431], ["CD95", "PROTEIN", 204, 208], ["Mediated Signaling ::: CD95: A Death Receptor", "PROTEIN", 209, 254], ["CD95", "PROTEIN", 410, 414], ["apoptotic signals", "TEST", 115, 132], ["S-nitrosylation", "TREATMENT", 275, 290], ["palmitoylation", "TEST", 355, 369], ["S-glutathionylation", "OBSERVATION", 316, 335], ["apoptotic signal", "OBSERVATION", 459, 475]]], ["Further investigation is required to address whether these posttranslational modifications are redundant and occur simultaneously in dying cells or are elicited in a cell-specific and/or in a microenvironment-specific manner.", [["cells", "ANATOMY", 139, 144], ["cell", "ANATOMY", 166, 170], ["cells", "CELL", 139, 144], ["cell", "CELL", 166, 170], ["dying cells", "CELL_TYPE", 133, 144], ["Further investigation", "TEST", 0, 21], ["these posttranslational modifications", "PROBLEM", 53, 90]]], ["Understanding the molecular mechanisms controlling these posttranslational modifications would be of great interest in order to identify the mechanism by which tumor cells block them, leading to their resistance to the extrinsic signaling pathway.CD95 Internalization ::: Regulation of the\u00a0Initial Steps of CD95-Mediated Signaling ::: CD95: A Death Receptor?Using a powerful magnetic method to isolate receptor-containing endocytic vesicles, it has been shown that CD95 promptly associates with endosomal and lysosomal markers when incubated with an agonistic anti-CD95 mAb [126].", [["tumor cells", "ANATOMY", 160, 171], ["endocytic vesicles", "ANATOMY", 422, 440], ["endosomal", "ANATOMY", 495, 504], ["lysosomal", "ANATOMY", 509, 518], ["tumor", "DISEASE", 160, 165], ["tumor cells", "CELL", 160, 171], ["CD95", "GENE_OR_GENE_PRODUCT", 247, 251], ["CD95", "GENE_OR_GENE_PRODUCT", 307, 311], ["CD95", "GENE_OR_GENE_PRODUCT", 335, 339], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 341, 357], ["endocytic vesicles", "CELLULAR_COMPONENT", 422, 440], ["CD95", "GENE_OR_GENE_PRODUCT", 465, 469], ["endosomal", "CELLULAR_COMPONENT", 495, 504], ["lysosomal", "CELLULAR_COMPONENT", 509, 518], ["tumor cells", "CELL_TYPE", 160, 171], ["CD95", "PROTEIN", 247, 251], ["CD95", "PROTEIN", 307, 311], ["CD95", "PROTEIN", 335, 339], ["CD95", "PROTEIN", 465, 469], ["endosomal and lysosomal markers", "PROTEIN", 495, 526], ["anti-CD95 mAb", "PROTEIN", 560, 573], ["tumor cells block", "PROBLEM", 160, 177], ["a powerful magnetic method", "TREATMENT", 364, 390], ["an agonistic anti-CD95 mAb", "TREATMENT", 547, 573], ["endocytic vesicles", "OBSERVATION", 422, 440]]], ["In addition, expression of a CD95 mutant in which the DD-located tyrosine 291 (Y275) is changed to phenylalanine does not seem to alter the capacity to bind FADD but compromises CD95L-mediated CD95 internalization occurring through an AP2/clathrin-driven endocytic pathway [126].", [["tyrosine", "CHEMICAL", 65, 73], ["phenylalanine", "CHEMICAL", 99, 112], ["tyrosine", "CHEMICAL", 65, 73], ["phenylalanine", "CHEMICAL", 99, 112], ["CD95", "GENE_OR_GENE_PRODUCT", 29, 33], ["DD-located tyrosine 291", "GENE_OR_GENE_PRODUCT", 54, 77], ["Y275", "AMINO_ACID", 79, 83], ["phenylalanine", "AMINO_ACID", 99, 112], ["FADD", "GENE_OR_GENE_PRODUCT", 157, 161], ["CD95L", "GENE_OR_GENE_PRODUCT", 178, 183], ["CD95", "GENE_OR_GENE_PRODUCT", 193, 197], ["AP2", "GENE_OR_GENE_PRODUCT", 235, 238], ["clathrin", "GENE_OR_GENE_PRODUCT", 239, 247], ["CD95 mutant", "PROTEIN", 29, 40], ["DD", "PROTEIN", 54, 56], ["FADD", "PROTEIN", 157, 161], ["CD95L", "PROTEIN", 178, 183], ["CD95", "PROTEIN", 193, 197], ["AP2", "PROTEIN", 235, 238], ["clathrin", "PROTEIN", 239, 247], ["a CD95 mutant", "PROBLEM", 27, 40], ["phenylalanine", "TREATMENT", 99, 112], ["CD95L", "TEST", 178, 183], ["CD95 internalization", "PROBLEM", 193, 213], ["an AP2/clathrin", "TREATMENT", 232, 247]]], ["More strikingly, expression of the internalization-defective CD95 mutant Y291F abrogates the transmission of apoptotic signals, but fails to alter the non-apoptotic signaling pathways (i.e., NF-\u03baB and ERK), and even promotes them (Fig. 11.3).", [["CD95", "GENE_OR_GENE_PRODUCT", 61, 65], ["Y291F", "GENE_OR_GENE_PRODUCT", 73, 78], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 191, 196], ["ERK", "GENE_OR_GENE_PRODUCT", 201, 204], ["CD95 mutant Y291F", "PROTEIN", 61, 78], ["NF-\u03baB", "PROTEIN", 191, 196], ["ERK", "PROTEIN", 201, 204], ["the internalization", "TEST", 31, 50], ["apoptotic signals", "PROBLEM", 109, 126], ["NF", "TEST", 191, 193]]], ["These findings provide insight into the presence of a region in the DD, interacting with AP2 and promoting a clathrin-dependent endocytic pathway in a FADD-independent manner.", [["DD", "GENE_OR_GENE_PRODUCT", 68, 70], ["AP2", "GENE_OR_GENE_PRODUCT", 89, 92], ["clathrin", "GENE_OR_GENE_PRODUCT", 109, 117], ["FADD", "GENE_OR_GENE_PRODUCT", 151, 155], ["DD", "PROTEIN", 68, 70], ["AP2", "PROTEIN", 89, 92], ["clathrin", "PROTEIN", 109, 117], ["FADD", "PROTEIN", 151, 155]]], ["Regarding the role of palmitoylation in receptor internalization, the interplay between lipid alteration and the AP2/clathrin-driven internalization of CD95 remains to be elucidated.Ca2+ Response ::: Regulation of the\u00a0Initial Steps of CD95-Mediated Signaling ::: CD95: A Death Receptor?It has been recently demonstrated that CD95 engagement evokes a rapid and transient Ca2+ signaling , which stimulates the recruitment of protein kinase C-\u03b22 (PKC-\u03b22) from the cytosol to the DISC [127].", [["cytosol", "ANATOMY", 461, 468], ["Ca2", "CHEMICAL", 182, 185], ["Ca2", "CHEMICAL", 370, 373], ["Ca2+", "CHEMICAL", 182, 186], ["Ca2+", "CHEMICAL", 370, 374], ["lipid", "SIMPLE_CHEMICAL", 88, 93], ["AP2", "GENE_OR_GENE_PRODUCT", 113, 116], ["clathrin", "GENE_OR_GENE_PRODUCT", 117, 125], ["CD95", "GENE_OR_GENE_PRODUCT", 152, 156], ["Ca2+", "SIMPLE_CHEMICAL", 182, 186], ["CD95", "GENE_OR_GENE_PRODUCT", 235, 239], ["CD95", "GENE_OR_GENE_PRODUCT", 263, 267], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 269, 285], ["CD95", "GENE_OR_GENE_PRODUCT", 325, 329], ["Ca2+", "SIMPLE_CHEMICAL", 370, 374], ["protein kinase C-\u03b22", "GENE_OR_GENE_PRODUCT", 423, 442], ["PKC-\u03b22", "GENE_OR_GENE_PRODUCT", 444, 450], ["cytosol", "CELLULAR_COMPONENT", 461, 468], ["DISC", "GENE_OR_GENE_PRODUCT", 476, 480], ["AP2", "PROTEIN", 113, 116], ["clathrin", "PROTEIN", 117, 125], ["CD95", "PROTEIN", 152, 156], ["Ca2", "PROTEIN", 182, 185], ["CD95", "PROTEIN", 235, 239], ["Mediated Signaling ::: CD95: A Death Receptor", "PROTEIN", 240, 285], ["CD95", "PROTEIN", 325, 329], ["Ca2", "PROTEIN", 370, 373], ["protein kinase C", "PROTEIN", 423, 439], ["\u03b22", "PROTEIN", 440, 442], ["PKC", "PROTEIN", 444, 447], ["\u03b22", "PROTEIN", 448, 450], ["DISC", "PROTEIN", 476, 480], ["palmitoylation in receptor internalization", "TREATMENT", 22, 64], ["lipid alteration", "TREATMENT", 88, 104], ["the AP2/clathrin", "TREATMENT", 109, 125], ["a rapid and transient Ca2+ signaling", "PROBLEM", 348, 384], ["protein kinase C", "TEST", 423, 439], ["PKC", "TEST", 444, 447], ["DISC", "ANATOMY", 476, 480]]], ["This kinase transiently brakes DISC formation, providing a checkpoint before the irreversible commitment to cell death [128].", [["cell", "ANATOMY", 108, 112], ["death", "DISEASE", 113, 118], ["DISC", "GENE_OR_GENE_PRODUCT", 31, 35], ["cell", "CELL", 108, 112], ["DISC", "PROTEIN", 31, 35], ["This kinase transiently brakes DISC formation", "PROBLEM", 0, 45], ["brakes DISC", "OBSERVATION", 24, 35]]], ["These findings raised the following questions: what are the Ca2+-dependent molecular mechanisms transiently inhibiting DISC formation, and do tumor cells use this signal to escape the immune response and/or resist chemotherapy?Programmed Necrosis also known as Necroptosis ::: CD95: A Death Receptor?In 1998, inhibition of caspase activity was shown to sensitize fibroblastic L929 cell line to TNF-mediated necrotic cell death [42].", [["tumor cells", "ANATOMY", 142, 153], ["fibroblastic L929 cell line", "ANATOMY", 363, 390], ["cell", "ANATOMY", 416, 420], ["Ca2", "CHEMICAL", 60, 63], ["tumor", "DISEASE", 142, 147], ["necrotic", "DISEASE", 407, 415], ["death", "DISEASE", 421, 426], ["Ca2+-", "CHEMICAL", 60, 65], ["Ca2+-", "SIMPLE_CHEMICAL", 60, 65], ["DISC", "GENE_OR_GENE_PRODUCT", 119, 123], ["tumor cells", "CELL", 142, 153], ["CD95", "GENE_OR_GENE_PRODUCT", 277, 281], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 283, 299], ["caspase", "GENE_OR_GENE_PRODUCT", 323, 330], ["fibroblastic L929 cell line", "CELL", 363, 390], ["TNF", "GENE_OR_GENE_PRODUCT", 394, 397], ["necrotic cell", "CELL", 407, 420], ["Ca2", "PROTEIN", 60, 63], ["DISC", "PROTEIN", 119, 123], ["tumor cells", "CELL_TYPE", 142, 153], ["Necroptosis ::: CD95: A Death Receptor", "PROTEIN", 261, 299], ["caspase", "PROTEIN", 323, 330], ["fibroblastic L929 cell line", "CELL_LINE", 363, 390], ["TNF", "PROTEIN", 394, 397], ["DISC formation", "PROBLEM", 119, 133], ["tumor cells", "PROBLEM", 142, 153], ["resist chemotherapy", "TREATMENT", 207, 226], ["Programmed Necrosis", "PROBLEM", 227, 246], ["caspase activity", "PROBLEM", 323, 339], ["fibroblastic L929 cell line", "TREATMENT", 363, 390], ["TNF", "TEST", 394, 397], ["necrotic cell death", "PROBLEM", 407, 426], ["DISC", "ANATOMY", 119, 123], ["Necrosis", "OBSERVATION", 238, 246], ["Necroptosis", "OBSERVATION", 261, 272], ["fibroblastic L929 cell line", "OBSERVATION", 363, 390], ["necrotic cell death", "OBSERVATION", 407, 426]]], ["With respect to CD95 signal, Tschopp et al. showed that FADD and RIP1 participate in the implementation of a non-apoptotic signaling pathway, which leads to a necrotic morphology without chromatin condensation and with loss of plasma membrane integrity [41].", [["chromatin", "ANATOMY", 187, 196], ["plasma membrane", "ANATOMY", 227, 242], ["necrotic", "DISEASE", 159, 167], ["CD95", "GENE_OR_GENE_PRODUCT", 16, 20], ["FADD", "GENE_OR_GENE_PRODUCT", 56, 60], ["RIP1", "GENE_OR_GENE_PRODUCT", 65, 69], ["chromatin", "CELLULAR_COMPONENT", 187, 196], ["plasma membrane", "CELLULAR_COMPONENT", 227, 242], ["CD95", "PROTEIN", 16, 20], ["FADD", "PROTEIN", 56, 60], ["RIP1", "PROTEIN", 65, 69], ["CD95 signal", "TEST", 16, 27], ["FADD", "PROBLEM", 56, 60], ["RIP1", "TREATMENT", 65, 69], ["a non-apoptotic signaling pathway", "PROBLEM", 107, 140], ["a necrotic morphology", "PROBLEM", 157, 178], ["chromatin condensation", "PROBLEM", 187, 209], ["loss of plasma membrane integrity", "PROBLEM", 219, 252], ["necrotic", "OBSERVATION_MODIFIER", 159, 167], ["without", "UNCERTAINTY", 179, 186], ["chromatin condensation", "OBSERVATION", 187, 209]]], ["Of note, BID cleavage was not observed in this necrotic signal.", [["necrotic", "DISEASE", 47, 55], ["BID", "CHEMICAL", 9, 12], ["BID", "GENE_OR_GENE_PRODUCT", 9, 12], ["BID cleavage", "PROBLEM", 9, 21], ["this necrotic signal", "PROBLEM", 42, 62], ["necrotic", "OBSERVATION", 47, 55]]], ["While FADD plays a crucial role in both apoptotic and necrotic pathways, RIP1 recruitment to CD95 occurs independently of this adaptor protein.", [["necrotic", "DISEASE", 54, 62], ["FADD", "GENE_OR_GENE_PRODUCT", 6, 10], ["RIP1", "GENE_OR_GENE_PRODUCT", 73, 77], ["CD95", "GENE_OR_GENE_PRODUCT", 93, 97], ["FADD", "PROTEIN", 6, 10], ["RIP1", "PROTEIN", 73, 77], ["CD95", "PROTEIN", 93, 97], ["adaptor protein", "PROTEIN", 127, 142], ["necrotic pathways", "PROBLEM", 54, 71], ["RIP1 recruitment", "TREATMENT", 73, 89], ["this adaptor protein", "TREATMENT", 122, 142], ["necrotic", "OBSERVATION_MODIFIER", 54, 62]]], ["Indeed, yeast two-hybrid experiments showed that RIP1 can bind directly to the CD95-DD, while this interaction is lost when a bait corresponding to mutated CD95-DD (replacement of Val 238 to Asn) is used [129].", [["Val", "CHEMICAL", 180, 183], ["Asn", "CHEMICAL", 191, 194], ["RIP1", "GENE_OR_GENE_PRODUCT", 49, 53], ["CD95", "GENE_OR_GENE_PRODUCT", 79, 83], ["DD", "GENE_OR_GENE_PRODUCT", 84, 86], ["CD95", "GENE_OR_GENE_PRODUCT", 156, 160], ["Asn", "AMINO_ACID", 191, 194], ["RIP1", "PROTEIN", 49, 53], ["CD95", "PROTEIN", 79, 83], ["DD", "PROTEIN", 84, 86], ["CD95", "PROTEIN", 156, 160], ["DD", "PROTEIN", 161, 163], ["yeast", "SPECIES", 8, 13], ["yeast", "SPECIES", 8, 13], ["RIP1", "PROBLEM", 49, 53], ["DD (replacement of Val", "TREATMENT", 161, 183]]], ["In addition, RIP3 (RIPK3, a member of the RIP kinase family) is an indispensable factor for the induction of the necrotic signaling pathway [78\u201380].", [["necrotic", "DISEASE", 113, 121], ["RIP3", "GENE_OR_GENE_PRODUCT", 13, 17], ["RIPK3", "GENE_OR_GENE_PRODUCT", 19, 24], ["RIP", "GENE_OR_GENE_PRODUCT", 42, 45], ["RIP3", "PROTEIN", 13, 17], ["RIPK3", "PROTEIN", 19, 24], ["RIP kinase family", "PROTEIN", 42, 59], ["the necrotic signaling pathway", "PROBLEM", 109, 139], ["necrotic", "OBSERVATION_MODIFIER", 113, 121]]], ["A growing body of evidence supports the existence of necroptosis (programmed necrosis).", [["necroptosis", "DISEASE", 53, 64], ["necrosis", "DISEASE", 77, 85], ["necroptosis", "PROBLEM", 53, 64], ["programmed necrosis", "PROBLEM", 66, 85], ["evidence supports the existence of", "UNCERTAINTY", 18, 52], ["necroptosis", "OBSERVATION", 53, 64], ["necrosis", "OBSERVATION_MODIFIER", 77, 85]]], ["In addition, identification of necrostatin, a chemical inhibitor of necroptosis [130], which specifically inhibits RIP1 kinase activity [131], has accelerated the pace of discovery in this field of cell death.", [["cell", "ANATOMY", 198, 202], ["necrostatin", "CHEMICAL", 31, 42], ["death", "DISEASE", 203, 208], ["necrostatin", "CHEMICAL", 31, 42], ["necrostatin", "GENE_OR_GENE_PRODUCT", 31, 42], ["RIP1", "GENE_OR_GENE_PRODUCT", 115, 119], ["cell", "CELL", 198, 202], ["RIP1 kinase", "PROTEIN", 115, 126], ["necrostatin", "TREATMENT", 31, 42], ["a chemical inhibitor", "TREATMENT", 44, 64], ["necroptosis", "PROBLEM", 68, 79], ["RIP1 kinase activity", "TEST", 115, 135], ["cell death", "PROBLEM", 198, 208], ["cell death", "OBSERVATION", 198, 208]]], ["Interplays exist between apoptosis and necroptosis; for instance, caspase-8, a potent inhibitor of necroptosis for both CD95 and TNFR1 [132], plays a critical role in necroptosis by its ability to process and inactivate RIP1 and RIP3 [133, 134].", [["caspase-8", "GENE_OR_GENE_PRODUCT", 66, 75], ["CD95", "GENE_OR_GENE_PRODUCT", 120, 124], ["TNFR1 [132]", "GENE_OR_GENE_PRODUCT", 129, 140], ["RIP1", "GENE_OR_GENE_PRODUCT", 220, 224], ["RIP3", "GENE_OR_GENE_PRODUCT", 229, 233], ["caspase-8", "PROTEIN", 66, 75], ["CD95", "PROTEIN", 120, 124], ["TNFR1", "PROTEIN", 129, 134], ["RIP1", "PROTEIN", 220, 224], ["RIP3", "PROTEIN", 229, 233], ["apoptosis", "PROBLEM", 25, 34], ["necroptosis", "PROBLEM", 39, 50], ["caspase", "TEST", 66, 73], ["a potent inhibitor", "TREATMENT", 77, 95], ["necroptosis", "PROBLEM", 99, 110], ["necroptosis", "PROBLEM", 167, 178], ["RIP3", "TEST", 229, 233], ["apoptosis", "OBSERVATION", 25, 34], ["necroptosis", "OBSERVATION", 39, 50], ["necroptosis", "OBSERVATION", 167, 178]]], ["At least for TNF signaling, the necrotic signal relies on the activity of CYLD, a deubiquitinating enzyme that is also cleaved and inactivated by caspase-8 [135].Programmed Necrosis also known as Necroptosis ::: CD95: A Death Receptor?Overall, these findings suggest that the apoptotic machinery controls the necrotic one.", [["necrotic", "DISEASE", 32, 40], ["necrotic", "DISEASE", 309, 317], ["TNF", "GENE_OR_GENE_PRODUCT", 13, 16], ["CYLD", "GENE_OR_GENE_PRODUCT", 74, 78], ["caspase-8", "GENE_OR_GENE_PRODUCT", 146, 155], ["CD95", "GENE_OR_GENE_PRODUCT", 212, 216], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 218, 234], ["TNF", "PROTEIN", 13, 16], ["CYLD", "PROTEIN", 74, 78], ["deubiquitinating enzyme", "PROTEIN", 82, 105], ["caspase", "PROTEIN", 146, 153], ["CD95", "PROTEIN", 212, 216], ["TNF signaling", "PROBLEM", 13, 26], ["the necrotic signal", "PROBLEM", 28, 47], ["a deubiquitinating enzyme", "TEST", 80, 105], ["caspase", "TEST", 146, 153], ["Programmed Necrosis", "PROBLEM", 162, 181], ["necrotic", "OBSERVATION_MODIFIER", 32, 40], ["Necrosis", "OBSERVATION", 173, 181], ["Necroptosis", "OBSERVATION", 196, 207], ["necrotic", "OBSERVATION_MODIFIER", 309, 317]]], ["The KO of FADD or caspase-8 is deleterious in mice mainly by the fact that these two apoptotic factors are beneficial in inhibiting a RIP1-/RIP3-dependent necrotic signal; thus, their loss unleashes the necroptotic program and leads to embryonic lethality.", [["embryonic", "ANATOMY", 236, 245], ["necrotic", "DISEASE", 155, 163], ["embryonic lethality", "DISEASE", 236, 255], ["FADD", "GENE_OR_GENE_PRODUCT", 10, 14], ["caspase-8", "GENE_OR_GENE_PRODUCT", 18, 27], ["mice", "ORGANISM", 46, 50], ["RIP1", "GENE_OR_GENE_PRODUCT", 134, 138], ["RIP3", "GENE_OR_GENE_PRODUCT", 140, 144], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 236, 245], ["FADD", "PROTEIN", 10, 14], ["caspase-8", "PROTEIN", 18, 27], ["apoptotic factors", "PROTEIN", 85, 102], ["RIP1", "PROTEIN", 134, 138], ["RIP3", "PROTEIN", 140, 144], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50], ["caspase", "TEST", 18, 25], ["these two apoptotic factors", "PROBLEM", 75, 102], ["a RIP1", "TEST", 132, 138], ["dependent necrotic signal", "PROBLEM", 145, 170], ["embryonic lethality", "PROBLEM", 236, 255], ["dependent", "OBSERVATION_MODIFIER", 145, 154], ["necrotic", "OBSERVATION_MODIFIER", 155, 163], ["embryonic lethality", "OBSERVATION", 236, 255]]], ["Yet, most studies on necroptosis have focused on the TNF signaling pathway, whereas the mechanism by which CD95 can elicit this cell death pathway, and how the switch in this receptor occurs between non-apoptotic, apoptotic, and necroptotic signals remains unclear.", [["cell", "ANATOMY", 128, 132], ["TNF", "GENE_OR_GENE_PRODUCT", 53, 56], ["CD95", "GENE_OR_GENE_PRODUCT", 107, 111], ["cell", "CELL", 128, 132], ["TNF", "PROTEIN", 53, 56], ["CD95", "PROTEIN", 107, 111], ["necroptosis", "PROBLEM", 21, 32], ["the TNF signaling pathway", "TEST", 49, 74], ["necroptotic signals", "PROBLEM", 229, 248], ["apoptotic", "OBSERVATION_MODIFIER", 214, 223]]], ["Importantly, the impact of each cell death on antigen presentation, and on the efficiency of immune response after elimination of infected or transformed cells, remains unclear.A Ligand to Create Immune Privileges ::: CD95L, an Inflammatory/Oncogenic Cytokine? ::: CD95: A Death Receptor?The transmembrane CD95L (CD178/FasL) is present at the surface of activated lymphocytes [64] and NK cells [137] where it orchestrates the elimination of transformed and infected cells.", [["cell", "ANATOMY", 32, 36], ["cells", "ANATOMY", 154, 159], ["transmembrane", "ANATOMY", 292, 305], ["surface", "ANATOMY", 343, 350], ["lymphocytes", "ANATOMY", 364, 375], ["NK cells", "ANATOMY", 385, 393], ["cells", "ANATOMY", 466, 471], ["death", "DISEASE", 37, 42], ["cell", "CELL", 32, 36], ["cells", "CELL", 154, 159], ["CD95L", "GENE_OR_GENE_PRODUCT", 218, 223], ["CD95", "GENE_OR_GENE_PRODUCT", 265, 269], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 271, 287], ["transmembrane", "CELLULAR_COMPONENT", 292, 305], ["CD95L", "GENE_OR_GENE_PRODUCT", 306, 311], ["CD178", "GENE_OR_GENE_PRODUCT", 313, 318], ["FasL", "GENE_OR_GENE_PRODUCT", 319, 323], ["surface", "CELLULAR_COMPONENT", 343, 350], ["lymphocytes", "CELL", 364, 375], ["NK cells", "CELL", 385, 393], ["cells", "CELL", 466, 471], ["transformed cells", "CELL_LINE", 142, 159], ["CD95L", "PROTEIN", 218, 223], ["Inflammatory/Oncogenic Cytokine", "PROTEIN", 228, 259], ["CD95", "PROTEIN", 265, 269], ["transmembrane CD95L", "PROTEIN", 292, 311], ["CD178", "PROTEIN", 313, 318], ["FasL", "PROTEIN", 319, 323], ["activated lymphocytes", "CELL_TYPE", 354, 375], ["NK cells", "CELL_TYPE", 385, 393], ["transformed and infected cells", "CELL_TYPE", 441, 471], ["each cell death", "PROBLEM", 27, 42], ["immune response", "PROBLEM", 93, 108], ["infected or transformed cells", "PROBLEM", 130, 159], ["CD95L", "TREATMENT", 218, 223], ["The transmembrane CD95L", "TEST", 288, 311], ["activated lymphocytes", "TEST", 354, 375], ["NK cells", "TEST", 385, 393], ["transformed and infected cells", "PROBLEM", 441, 471], ["infected", "OBSERVATION", 130, 138], ["transformed cells", "OBSERVATION", 142, 159], ["Inflammatory", "OBSERVATION_MODIFIER", 228, 240], ["Oncogenic Cytokine", "OBSERVATION", 241, 259], ["infected cells", "OBSERVATION", 457, 471]]], ["In addition, CD95L is expressed on the surface of neurons [138], corneal epithelia and endothelia [58, 139], and Sertoli cells [59] to prevent the infiltration of immune cells and thus to prohibit the spread of inflammation in these sensitive organs (i.e., brain, eyes, and testis, respectively), commonly called \u201cimmune-privileged\u201d sites.", [["surface", "ANATOMY", 39, 46], ["neurons", "ANATOMY", 50, 57], ["corneal epithelia", "ANATOMY", 65, 82], ["endothelia", "ANATOMY", 87, 97], ["Sertoli cells", "ANATOMY", 113, 126], ["immune cells", "ANATOMY", 163, 175], ["organs", "ANATOMY", 243, 249], ["brain", "ANATOMY", 257, 262], ["eyes", "ANATOMY", 264, 268], ["testis", "ANATOMY", 274, 280], ["sites", "ANATOMY", 333, 338], ["inflammation", "DISEASE", 211, 223], ["CD95L", "GENE_OR_GENE_PRODUCT", 13, 18], ["surface", "CELLULAR_COMPONENT", 39, 46], ["neurons", "CELL", 50, 57], ["corneal epithelia", "TISSUE", 65, 82], ["endothelia", "TISSUE", 87, 97], ["Sertoli cells", "CELL", 113, 126], ["immune cells", "CELL", 163, 175], ["organs", "ORGAN", 243, 249], ["brain", "ORGAN", 257, 262], ["eyes", "ORGAN", 264, 268], ["testis", "ORGAN", 274, 280], ["\u201d sites", "TISSUE", 331, 338], ["CD95L", "PROTEIN", 13, 18], ["Sertoli cells", "CELL_TYPE", 113, 126], ["immune cells", "CELL_TYPE", 163, 175], ["CD95L", "TREATMENT", 13, 18], ["corneal epithelia", "TEST", 65, 82], ["endothelia", "TEST", 87, 97], ["Sertoli cells", "TEST", 113, 126], ["the infiltration of immune cells", "PROBLEM", 143, 175], ["inflammation in these sensitive organs (i.e., brain, eyes, and testis", "PROBLEM", 211, 280], ["CD95L", "OBSERVATION", 13, 18], ["corneal epithelia", "ANATOMY", 65, 82], ["endothelia", "ANATOMY", 87, 97], ["infiltration", "OBSERVATION", 147, 159], ["immune cells", "OBSERVATION", 163, 175], ["inflammation", "OBSERVATION", 211, 223], ["brain", "ANATOMY", 257, 262], ["eyes", "ANATOMY", 264, 268], ["testis", "ANATOMY", 274, 280]]], ["The description of physiological immune privilege was followed by tumor-mediated immune privilege, since two groups reported that the ectopic expression of CD95L by malignant cells participated in the elimination of infiltrating T-lymphocytes and thus could play a role in the establishment of a tumor site whose access was denied to immune cells [140, 141].", [["tumor", "ANATOMY", 66, 71], ["malignant cells", "ANATOMY", 165, 180], ["infiltrating T-lymphocytes", "ANATOMY", 216, 242], ["tumor site", "ANATOMY", 296, 306], ["immune cells", "ANATOMY", 334, 346], ["tumor", "DISEASE", 66, 71], ["tumor", "DISEASE", 296, 301], ["tumor", "CANCER", 66, 71], ["CD95L", "GENE_OR_GENE_PRODUCT", 156, 161], ["malignant cells", "CELL", 165, 180], ["T-lymphocytes", "CELL", 229, 242], ["tumor", "CANCER", 296, 301], ["immune cells", "CELL", 334, 346], ["CD95L", "PROTEIN", 156, 161], ["malignant cells", "CELL_TYPE", 165, 180], ["infiltrating T-lymphocytes", "CELL_TYPE", 216, 242], ["immune cells", "CELL_TYPE", 334, 346], ["malignant cells", "PROBLEM", 165, 180], ["infiltrating T-lymphocytes", "PROBLEM", 216, 242], ["a tumor site", "PROBLEM", 294, 306], ["infiltrating", "OBSERVATION", 216, 228], ["tumor", "OBSERVATION", 296, 301]]], ["However, these observations are controversial since ectopic expression of CD95L in allogenic transplant of \u03b2-islets [142, 143] and in tumor cell lines [144] led to a more rapid elimination of these cells than control cells, due to increased infiltration of neutrophils and macrophages endowed with antitumor activity.At Least Two Different Ligands and Two Different Signals ::: CD95L, an Inflammatory/Oncogenic Cytokine? ::: CD95: A Death Receptor?Among the weapons at the disposal of immune cells, transmembrane CD95L contributes to the elimination of pre-tumor cells.", [["\u03b2-islets", "ANATOMY", 107, 115], ["tumor cell lines", "ANATOMY", 134, 150], ["cells", "ANATOMY", 198, 203], ["cells", "ANATOMY", 217, 222], ["neutrophils", "ANATOMY", 257, 268], ["macrophages", "ANATOMY", 273, 284], ["antitumor", "ANATOMY", 298, 307], ["immune cells", "ANATOMY", 485, 497], ["transmembrane", "ANATOMY", 499, 512], ["pre-tumor cells", "ANATOMY", 553, 568], ["tumor", "DISEASE", 134, 139], ["CD95L", "GENE_OR_GENE_PRODUCT", 74, 79], ["\u03b2-islets", "CELL", 107, 115], ["tumor cell lines [144]", "CELL", 134, 156], ["cells", "CELL", 198, 203], ["cells", "CELL", 217, 222], ["neutrophils", "CELL", 257, 268], ["macrophages", "CELL", 273, 284], ["antitumor", "CANCER", 298, 307], ["CD95L", "GENE_OR_GENE_PRODUCT", 378, 383], ["CD95", "GENE_OR_GENE_PRODUCT", 425, 429], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 431, 447], ["immune cells", "CELL", 485, 497], ["transmembrane", "CELLULAR_COMPONENT", 499, 512], ["CD95L", "GENE_OR_GENE_PRODUCT", 513, 518], ["pre-tumor cells", "CELL", 553, 568], ["CD95L", "PROTEIN", 74, 79], ["tumor cell lines", "CELL_LINE", 134, 150], ["control cells", "CELL_TYPE", 209, 222], ["neutrophils", "CELL_TYPE", 257, 268], ["macrophages", "CELL_TYPE", 273, 284], ["CD95L", "PROTEIN", 378, 383], ["Inflammatory/Oncogenic Cytokine", "PROTEIN", 388, 419], ["CD95", "PROTEIN", 425, 429], ["immune cells", "CELL_TYPE", 485, 497], ["transmembrane CD95L", "PROTEIN", 499, 518], ["pre-tumor cells", "CELL_TYPE", 553, 568], ["ectopic expression", "PROBLEM", 52, 70], ["CD95L in allogenic transplant", "TREATMENT", 74, 103], ["\u03b2-islets", "TEST", 107, 115], ["tumor cell lines", "TEST", 134, 150], ["these cells", "PROBLEM", 192, 203], ["increased infiltration of neutrophils", "PROBLEM", 231, 268], ["macrophages", "PROBLEM", 273, 284], ["antitumor activity", "TREATMENT", 298, 316], ["CD95L", "TEST", 378, 383], ["immune cells", "TREATMENT", 485, 497], ["transmembrane CD95L", "TREATMENT", 499, 518], ["pre-tumor cells", "PROBLEM", 553, 568], ["tumor cell lines", "OBSERVATION", 134, 150], ["increased", "OBSERVATION_MODIFIER", 231, 240], ["infiltration", "OBSERVATION", 241, 253], ["neutrophils", "ANATOMY", 257, 268], ["Different Ligands", "OBSERVATION", 330, 347], ["Inflammatory", "OBSERVATION_MODIFIER", 388, 400], ["Oncogenic Cytokine", "OBSERVATION", 401, 419], ["pre-tumor cells", "OBSERVATION", 553, 568]]], ["Therefore, pre-tumor cells that escape the immunosurveillance will be shaped to develop resistance to CD95, a process termed immunoediting [145].", [["pre-tumor cells", "ANATOMY", 11, 26], ["pre-tumor cells", "CELL", 11, 26], ["CD95", "GENE_OR_GENE_PRODUCT", 102, 106], ["pre-tumor cells", "CELL_TYPE", 11, 26], ["CD95", "PROTEIN", 102, 106], ["pre-tumor cells", "PROBLEM", 11, 26]]], ["In other words, imprinting of the immune system on pre-tumor cells will select malignant cells with increased resistance toward the CD95L-induced signal.", [["immune system", "ANATOMY", 34, 47], ["pre-tumor cells", "ANATOMY", 51, 66], ["malignant cells", "ANATOMY", 79, 94], ["pre-tumor cells", "CELL", 51, 66], ["malignant cells", "CELL", 79, 94], ["CD95L", "GENE_OR_GENE_PRODUCT", 132, 137], ["pre-tumor cells", "CELL_TYPE", 51, 66], ["malignant cells", "CELL_TYPE", 79, 94], ["CD95L", "PROTEIN", 132, 137], ["pre-tumor cells", "PROBLEM", 51, 66], ["malignant cells", "PROBLEM", 79, 94], ["increased resistance", "PROBLEM", 100, 120], ["the CD95L", "TEST", 128, 137], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["resistance", "OBSERVATION_MODIFIER", 110, 120]]], ["As previously mentioned, these alterations of the CD95 signal not only block the CD95-mediated apoptotic signal but also promote the transmission of non-apoptotic signals by CD95L, which may play a critical role in carcinogenesis [106\u2013108, 146].", [["carcinogenesis", "DISEASE", 215, 229], ["CD95", "GENE_OR_GENE_PRODUCT", 50, 54], ["CD95", "GENE_OR_GENE_PRODUCT", 81, 85], ["CD95L", "GENE_OR_GENE_PRODUCT", 174, 179], ["CD95", "PROTEIN", 50, 54], ["CD95", "PROTEIN", 81, 85], ["CD95L", "PROTEIN", 174, 179], ["the CD95 signal", "TEST", 46, 61]]], ["In agreement with this hypothesis, a complete loss of CD95 expression is rarely observed in malignant cells [147].At Least Two Different Ligands and Two Different Signals ::: CD95L, an Inflammatory/Oncogenic Cytokine? ::: CD95: A Death Receptor?Accumulating evidence indicates that the apoptotic ligand CD95L behaves as a chemoattractant for neutrophils, macrophages [50, 143, 144], T-lymphocytes [53], and malignant cells in which the CD95-mediated apoptotic signal is nonproductive [108, 148].", [["malignant cells", "ANATOMY", 92, 107], ["neutrophils", "ANATOMY", 342, 353], ["macrophages", "ANATOMY", 355, 366], ["T-lymphocytes", "ANATOMY", 383, 396], ["malignant cells", "ANATOMY", 407, 422], ["CD95", "GENE_OR_GENE_PRODUCT", 54, 58], ["malignant cells", "CELL", 92, 107], ["CD95L", "GENE_OR_GENE_PRODUCT", 175, 180], ["CD95", "GENE_OR_GENE_PRODUCT", 222, 226], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 228, 244], ["CD95L", "GENE_OR_GENE_PRODUCT", 303, 308], ["neutrophils", "CELL", 342, 353], ["macrophages", "CELL", 355, 366], ["T-lymphocytes", "CELL", 383, 396], ["malignant cells", "CELL", 407, 422], ["CD95", "GENE_OR_GENE_PRODUCT", 436, 440], ["CD95", "PROTEIN", 54, 58], ["malignant cells", "CELL_TYPE", 92, 107], ["CD95L", "PROTEIN", 175, 180], ["Inflammatory/Oncogenic Cytokine", "PROTEIN", 185, 216], ["CD95", "PROTEIN", 222, 226], ["apoptotic ligand CD95L", "PROTEIN", 286, 308], ["neutrophils", "CELL_TYPE", 342, 353], ["macrophages", "CELL_TYPE", 355, 366], ["T-lymphocytes", "CELL_TYPE", 383, 396], ["malignant cells", "CELL_TYPE", 407, 422], ["CD95", "PROTEIN", 436, 440], ["a complete loss of CD95 expression", "PROBLEM", 35, 69], ["malignant cells", "PROBLEM", 92, 107], ["CD95L", "TEST", 175, 180], ["the apoptotic ligand CD95L", "TEST", 282, 308], ["a chemoattractant for neutrophils", "TEST", 320, 353], ["macrophages", "TEST", 355, 366], ["T-lymphocytes", "TEST", 383, 396], ["malignant cells", "PROBLEM", 407, 422], ["the CD95", "TEST", 432, 440], ["apoptotic signal", "TEST", 450, 466], ["Different Ligands", "OBSERVATION", 127, 144], ["Inflammatory", "OBSERVATION_MODIFIER", 185, 197], ["Oncogenic Cytokine", "OBSERVATION", 198, 216], ["malignant cells", "OBSERVATION", 407, 422], ["CD95", "ANATOMY", 436, 440], ["apoptotic signal", "OBSERVATION", 450, 466], ["nonproductive", "OBSERVATION_MODIFIER", 470, 483]]], ["Nonetheless, the biological role of CD95L has to be clarified due to the fact that pathophysiologically the ligand is present in at least two forms with different stoichiometries.", [["CD95L", "GENE_OR_GENE_PRODUCT", 36, 41], ["CD95L", "PROTEIN", 36, 41], ["ligand", "OBSERVATION", 108, 114], ["different stoichiometries", "OBSERVATION", 153, 178]]], ["Indeed, CD95L is a transmembrane cytokine whose ectodomain can be cleaved by metalloproteases such as MMP3 [149], MMP7 [150], MMP9 [151], and ADAM-10 (a disintegrin and metalloproteinase 10) [152, 153] and released as a soluble ligand in the bloodstream.", [["transmembrane", "ANATOMY", 19, 32], ["bloodstream", "ANATOMY", 242, 253], ["CD95L", "GENE_OR_GENE_PRODUCT", 8, 13], ["MMP3 [149]", "GENE_OR_GENE_PRODUCT", 102, 112], ["MMP7 [150]", "GENE_OR_GENE_PRODUCT", 114, 124], ["MMP9", "GENE_OR_GENE_PRODUCT", 126, 130], ["ADAM-10", "GENE_OR_GENE_PRODUCT", 142, 149], ["disintegrin and metalloproteinase 10", "GENE_OR_GENE_PRODUCT", 153, 189], ["CD95L", "PROTEIN", 8, 13], ["transmembrane cytokine", "PROTEIN", 19, 41], ["ectodomain", "PROTEIN", 48, 58], ["metalloproteases", "PROTEIN", 77, 93], ["MMP3", "PROTEIN", 102, 106], ["MMP7", "PROTEIN", 114, 118], ["MMP9", "PROTEIN", 126, 130], ["ADAM-10", "PROTEIN", 142, 149], ["disintegrin and metalloproteinase 10", "PROTEIN", 153, 189], ["MMP3", "TEST", 102, 106], ["MMP7", "TEST", 114, 118], ["MMP9", "TEST", 126, 130], ["ADAM", "TEST", 142, 146], ["a disintegrin and metalloproteinase", "TEST", 151, 186], ["a soluble ligand", "TEST", 218, 234], ["bloodstream", "ANATOMY", 242, 253]]], ["Based on the data demonstrating that a hexameric CD95L represents the minimal level of self-association required to signal apoptosis [154] and that cleavage by metalloproteases releases an homotrimeric ligand [154, 155], this soluble ligand has long been considered as an inert ligand competing with its membrane-bound counterpart for CD95 binding, thus acting as an antagonist of the death signal [155, 156].", [["membrane", "ANATOMY", 304, 312], ["death", "DISEASE", 385, 390], ["CD95L", "GENE_OR_GENE_PRODUCT", 49, 54], ["membrane", "CELLULAR_COMPONENT", 304, 312], ["CD95", "GENE_OR_GENE_PRODUCT", 335, 339], ["hexameric CD95L", "PROTEIN", 39, 54], ["metalloproteases", "PROTEIN", 160, 176], ["CD95", "PROTEIN", 335, 339], ["the data", "TEST", 9, 17], ["a hexameric CD95L", "TREATMENT", 37, 54], ["signal apoptosis", "PROBLEM", 116, 132], ["this soluble ligand", "TREATMENT", 221, 240], ["an inert ligand", "TREATMENT", 269, 284], ["CD95 binding", "PROBLEM", 335, 347], ["the death signal", "TEST", 381, 397], ["minimal", "OBSERVATION_MODIFIER", 70, 77]]], ["It has been recently demonstrated that this metalloprotease-cleaved CD95L (cl-CD95L) actively participates in the aggravation of inflammation and autoimmunity in patients affected by systemic lupus erythematosus (SLE) by inducing the non-apoptotic NF-\u03baB and PI3K [51, 53] signaling pathways (Fig. 11.4).", [["inflammation", "DISEASE", 129, 141], ["autoimmunity", "DISEASE", 146, 158], ["systemic lupus erythematosus", "DISEASE", 183, 211], ["SLE", "DISEASE", 213, 216], ["metalloprotease", "GENE_OR_GENE_PRODUCT", 44, 59], ["CD95L", "GENE_OR_GENE_PRODUCT", 68, 73], ["cl-CD95L", "GENE_OR_GENE_PRODUCT", 75, 83], ["patients", "ORGANISM", 162, 170], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 248, 253], ["PI3K [51, 53", "GENE_OR_GENE_PRODUCT", 258, 270], ["metalloprotease", "PROTEIN", 44, 59], ["cleaved CD95L", "PROTEIN", 60, 73], ["cl", "PROTEIN", 75, 77], ["CD95L", "PROTEIN", 78, 83], ["PI3K", "PROTEIN", 258, 262], ["patients", "SPECIES", 162, 170], ["this metalloprotease", "TEST", 39, 59], ["inflammation", "PROBLEM", 129, 141], ["autoimmunity", "PROBLEM", 146, 158], ["systemic lupus erythematosus", "PROBLEM", 183, 211], ["the non-apoptotic NF", "TEST", 230, 250], ["PI3K", "TEST", 258, 262], ["signaling pathways", "TEST", 272, 290], ["Fig.", "TEST", 292, 296], ["inflammation", "OBSERVATION", 129, 141], ["systemic", "OBSERVATION_MODIFIER", 183, 191], ["lupus erythematosus", "OBSERVATION", 192, 211]]], ["Unlike transmembrane CD95L, induction of the PI3K signaling pathway by its metalloprotease-cleaved counterpart occurs through the formation of a complex devoid of FADD and caspase-8 which recruits the src kinase c-yes instead [53, 148]; this unconventional receptosome was designated motility-inducing signaling complex (MISC) [53, 157] (Fig. 11.4).", [["transmembrane", "ANATOMY", 7, 20], ["transmembrane", "CELLULAR_COMPONENT", 7, 20], ["CD95L", "GENE_OR_GENE_PRODUCT", 21, 26], ["PI3K", "GENE_OR_GENE_PRODUCT", 45, 49], ["FADD", "GENE_OR_GENE_PRODUCT", 163, 167], ["caspase-8", "GENE_OR_GENE_PRODUCT", 172, 181], ["src", "GENE_OR_GENE_PRODUCT", 201, 204], ["receptosome", "CANCER", 257, 268], ["motility-inducing signaling complex", "GENE_OR_GENE_PRODUCT", 284, 319], ["transmembrane CD95L", "PROTEIN", 7, 26], ["PI3K", "PROTEIN", 45, 49], ["metalloprotease-cleaved counterpart", "PROTEIN", 75, 110], ["FADD", "PROTEIN", 163, 167], ["caspase-8", "PROTEIN", 172, 181], ["src kinase c", "PROTEIN", 201, 213], ["motility-inducing signaling complex", "PROTEIN", 284, 319], ["MISC", "PROTEIN", 321, 325], ["transmembrane CD95L", "TREATMENT", 7, 26], ["its metalloprotease", "TEST", 71, 90], ["caspase", "TEST", 172, 179], ["the src kinase c", "TEST", 197, 213], ["transmembrane CD95L", "OBSERVATION", 7, 26]]], ["Even though experiments by the authors did not detect any trace of caspase-8 in the MISC, this enzyme has been shown to participate in cell migration.", [["cell", "ANATOMY", 135, 139], ["caspase-8", "GENE_OR_GENE_PRODUCT", 67, 76], ["MISC", "CANCER", 84, 88], ["cell", "CELL", 135, 139], ["caspase-8", "PROTEIN", 67, 76], ["MISC", "PROTEIN", 84, 88], ["caspase", "TEST", 67, 74], ["this enzyme", "TEST", 90, 101], ["cell migration", "OBSERVATION", 135, 149]]], ["The protease activity of caspase-8 can be abolished by its phosphorylation at tyrosine 380 by src kinase [158].", [["tyrosine", "CHEMICAL", 78, 86], ["tyrosine", "CHEMICAL", 78, 86], ["caspase-8", "GENE_OR_GENE_PRODUCT", 25, 34], ["tyrosine", "AMINO_ACID", 78, 86], ["380", "AMINO_ACID", 87, 90], ["src", "GENE_OR_GENE_PRODUCT", 94, 97], ["protease", "PROTEIN", 4, 12], ["caspase-8", "PROTEIN", 25, 34], ["src kinase", "PROTEIN", 94, 104], ["The protease activity of caspase", "TREATMENT", 0, 32]]], ["This posttranslational modification was observed in cells stimulated with EGF and in colon cancer cells exhibiting constitutive activation of src; from a molecular standpoint, this modification does not alter caspase homodimerization or recruitment in DISC [158].", [["cells", "ANATOMY", 52, 57], ["colon cancer cells", "ANATOMY", 85, 103], ["colon cancer", "DISEASE", 85, 97], ["cells", "CELL", 52, 57], ["EGF", "GENE_OR_GENE_PRODUCT", 74, 77], ["colon cancer cells", "CELL", 85, 103], ["src", "GENE_OR_GENE_PRODUCT", 142, 145], ["caspase", "GENE_OR_GENE_PRODUCT", 209, 216], ["DISC", "GENE_OR_GENE_PRODUCT", 252, 256], ["EGF", "PROTEIN", 74, 77], ["colon cancer cells", "CELL_TYPE", 85, 103], ["src", "PROTEIN", 142, 145], ["caspase", "PROTEIN", 209, 216], ["DISC", "PROTEIN", 252, 256], ["This posttranslational modification", "TREATMENT", 0, 35], ["colon cancer cells", "PROBLEM", 85, 103], ["constitutive activation of src", "PROBLEM", 115, 145], ["caspase homodimerization", "TREATMENT", 209, 233], ["recruitment in DISC", "PROBLEM", 237, 256], ["colon", "ANATOMY", 85, 90], ["cancer", "OBSERVATION", 91, 97], ["constitutive activation", "OBSERVATION", 115, 138], ["DISC", "ANATOMY", 252, 256]]], ["Moreover, the EGFR-driven phosphorylation of caspase-8 at Y380 turns out to be a potent inducer of the PI3K signaling pathway by recruiting the PI3K adaptor p85 alpha subunit [159].", [["EGFR", "GENE_OR_GENE_PRODUCT", 14, 18], ["caspase-8", "GENE_OR_GENE_PRODUCT", 45, 54], ["Y380", "GENE_OR_GENE_PRODUCT", 58, 62], ["PI3K", "GENE_OR_GENE_PRODUCT", 103, 107], ["PI3K", "GENE_OR_GENE_PRODUCT", 144, 148], ["p85", "GENE_OR_GENE_PRODUCT", 157, 160], ["EGFR", "PROTEIN", 14, 18], ["caspase-8", "PROTEIN", 45, 54], ["PI3K", "PROTEIN", 103, 107], ["PI3K adaptor p85 alpha subunit", "PROTEIN", 144, 174], ["the EGFR", "TEST", 10, 18], ["caspase", "TEST", 45, 52]]], ["Ultimately, caspase-8 phosphorylation triggers cell migration.", [["cell", "ANATOMY", 47, 51], ["caspase-8", "GENE_OR_GENE_PRODUCT", 12, 21], ["cell", "CELL", 47, 51], ["caspase-8", "PROTEIN", 12, 21], ["caspase", "TREATMENT", 12, 19], ["phosphorylation triggers cell migration", "TREATMENT", 22, 61], ["cell migration", "OBSERVATION", 47, 61]]], ["Nonetheless, it is noteworthy that CD95-induced migration and invasion do not appear to require an intact DD (reviewed in [160]), suggesting that either the caspase-8-dependent mode of cell migration occurs as an alternative signal for death receptors or that it only participates in non-death receptor-induced cell motility.", [["cell", "ANATOMY", 185, 189], ["cell", "ANATOMY", 311, 315], ["death", "DISEASE", 236, 241], ["CD95", "GENE_OR_GENE_PRODUCT", 35, 39], ["caspase-8", "GENE_OR_GENE_PRODUCT", 157, 166], ["cell", "CELL", 185, 189], ["non-death receptor", "GENE_OR_GENE_PRODUCT", 284, 302], ["cell", "CELL", 311, 315], ["CD95", "PROTEIN", 35, 39], ["caspase-8", "PROTEIN", 157, 166], ["death receptors", "PROTEIN", 236, 251], ["non-death receptor", "PROTEIN", 284, 302], ["CD95", "PROBLEM", 35, 39], ["invasion", "PROBLEM", 62, 70], ["the caspase", "TEST", 153, 164], ["cell migration", "PROBLEM", 185, 199], ["death receptors", "PROBLEM", 236, 251], ["induced cell motility", "PROBLEM", 303, 324], ["migration", "OBSERVATION_MODIFIER", 48, 57], ["intact", "OBSERVATION", 99, 105], ["cell migration", "OBSERVATION", 185, 199], ["cell motility", "OBSERVATION", 311, 324]]], ["To date, it can only be surmised that phosphorylation of caspase-8 at Y380 upon EGFR stimulation may prime certain cancer cells to become unresponsive to the apoptotic signal triggered by cytotoxic CD95L and meanwhile promote cell migration, an essential event in the course of cancer cell metastasis (Fig. 11.4).At Least Two Different Ligands and Two Different Signals ::: CD95L, an Inflammatory/Oncogenic Cytokine? ::: CD95: A Death Receptor?It is noteworthy that in a similar manner, a decrease in the plasma membrane level of CD95 or expression of a mutated CD95 allele, as observed in ALPS patients and malignant cells, inhibits the implementation of the apoptotic signal but does not affect the transmission of non-apoptotic signals, such as NF-\u03baB, MAPK, and PI3K [106, 107, 147], suggesting that these signals may stem from a different domain than CD95-DD or rely on different thresholds to be elicited.", [["cancer cells", "ANATOMY", 115, 127], ["cell", "ANATOMY", 226, 230], ["cancer cell", "ANATOMY", 278, 289], ["plasma membrane", "ANATOMY", 505, 520], ["malignant cells", "ANATOMY", 608, 623], ["cancer", "DISEASE", 115, 121], ["cancer", "DISEASE", 278, 284], ["ALPS", "DISEASE", 590, 594], ["caspase-8", "GENE_OR_GENE_PRODUCT", 57, 66], ["Y380", "GENE_OR_GENE_PRODUCT", 70, 74], ["EGFR", "GENE_OR_GENE_PRODUCT", 80, 84], ["cancer cells", "CELL", 115, 127], ["CD95L", "GENE_OR_GENE_PRODUCT", 198, 203], ["cell", "CELL", 226, 230], ["cancer cell", "CELL", 278, 289], ["CD95L", "GENE_OR_GENE_PRODUCT", 374, 379], ["CD95", "GENE_OR_GENE_PRODUCT", 421, 425], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 427, 443], ["plasma membrane", "CELLULAR_COMPONENT", 505, 520], ["CD95", "GENE_OR_GENE_PRODUCT", 530, 534], ["CD95", "GENE_OR_GENE_PRODUCT", 562, 566], ["patients", "ORGANISM", 595, 603], ["malignant cells", "CELL", 608, 623], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 748, 753], ["MAPK", "GENE_OR_GENE_PRODUCT", 755, 759], ["PI3K", "GENE_OR_GENE_PRODUCT", 765, 769], ["CD95", "GENE_OR_GENE_PRODUCT", 855, 859], ["caspase-8", "PROTEIN", 57, 66], ["EGFR", "PROTEIN", 80, 84], ["cancer cells", "CELL_TYPE", 115, 127], ["cytotoxic CD95L", "PROTEIN", 188, 203], ["CD95L", "PROTEIN", 374, 379], ["Inflammatory/Oncogenic Cytokine", "PROTEIN", 384, 415], ["CD95", "PROTEIN", 421, 425], ["CD95", "PROTEIN", 530, 534], ["mutated CD95 allele", "DNA", 554, 573], ["malignant cells", "CELL_TYPE", 608, 623], ["NF-\u03baB", "PROTEIN", 748, 753], ["MAPK", "PROTEIN", 755, 759], ["PI3K", "PROTEIN", 765, 769], ["CD95", "PROTEIN", 855, 859], ["patients", "SPECIES", 595, 603], ["caspase", "TEST", 57, 64], ["EGFR stimulation", "TREATMENT", 80, 96], ["certain cancer cells", "PROBLEM", 107, 127], ["unresponsive", "PROBLEM", 138, 150], ["the apoptotic signal", "PROBLEM", 154, 174], ["cytotoxic CD95L", "TREATMENT", 188, 203], ["promote cell migration", "TREATMENT", 218, 240], ["cancer cell metastasis", "PROBLEM", 278, 300], ["CD95L", "TEST", 374, 379], ["a decrease", "PROBLEM", 487, 497], ["the plasma membrane level", "TEST", 501, 526], ["a mutated CD95 allele", "PROBLEM", 552, 573], ["malignant cells", "PROBLEM", 608, 623], ["the apoptotic signal", "TEST", 656, 676], ["non-apoptotic signals", "TEST", 717, 738], ["NF", "TEST", 748, 750], ["PI3K", "TEST", 765, 769], ["DD", "PROBLEM", 860, 862], ["cell migration", "OBSERVATION", 226, 240], ["cancer cell metastasis", "OBSERVATION", 278, 300], ["Different Ligands", "OBSERVATION", 326, 343], ["Inflammatory", "OBSERVATION_MODIFIER", 384, 396], ["Oncogenic Cytokine", "OBSERVATION", 397, 415], ["decrease", "OBSERVATION_MODIFIER", 489, 497], ["malignant cells", "OBSERVATION", 608, 623]]], ["In summary, although the CD95/CD95L interaction can eliminate malignant cells by implementation of the DISC or can promote carcinogenesis by sustaining inflammation and/or by inducing metastatic dissemination [50, 51, 53, 108, 147, 148, 161], the molecular mechanisms underlying the switch between these different signaling pathways remain enigmatic.", [["malignant cells", "ANATOMY", 62, 77], ["carcinogenesis", "DISEASE", 123, 137], ["inflammation", "DISEASE", 152, 164], ["CD95", "GENE_OR_GENE_PRODUCT", 25, 29], ["CD95L", "GENE_OR_GENE_PRODUCT", 30, 35], ["malignant cells", "CELL", 62, 77], ["DISC", "GENE_OR_GENE_PRODUCT", 103, 107], ["CD95", "PROTEIN", 25, 29], ["CD95L", "PROTEIN", 30, 35], ["malignant cells", "CELL_TYPE", 62, 77], ["DISC", "PROTEIN", 103, 107], ["the CD95/CD95L interaction", "TREATMENT", 21, 47], ["malignant cells", "PROBLEM", 62, 77], ["the DISC", "PROBLEM", 99, 107], ["sustaining inflammation", "PROBLEM", 141, 164], ["metastatic dissemination", "PROBLEM", 184, 208], ["DISC", "ANATOMY", 103, 107], ["inflammation", "OBSERVATION", 152, 164], ["metastatic", "OBSERVATION_MODIFIER", 184, 194]]], ["An important question to be addressed is how the magnitude of CD95 aggregation controls the formation of \u201cdeath\u201d- vs. \u201cmotility\u201d-ISCs.", [["ISCs", "ANATOMY", 129, 133], ["death", "DISEASE", 106, 111], ["CD95", "GENE_OR_GENE_PRODUCT", 62, 66], ["ISCs", "CELL", 129, 133], ["CD95", "PROTEIN", 62, 66], ["ISCs", "CELL_TYPE", 129, 133], ["CD95 aggregation", "PROBLEM", 62, 78], ["\u201cdeath", "PROBLEM", 105, 111]]], ["Addressing these questions will lead to the development of new therapeutic agents with the ability to contain the spread of inflammation or impede carcinogenesis at least in pathologies involving increased soluble CD95L such as cancers (e.g., pancreatic cancer [162], large granular lymphocytic leukemia, breast cancer [157], and NK cell lymphoma [163]) or autoimmune disorders (e.g., rheumatoid arthritis and osteoarthritis [164], graft-versus-host-disease (GVHD) [165, 166], or SLE [53, 167]).", [["cancers", "ANATOMY", 228, 235], ["pancreatic cancer", "ANATOMY", 243, 260], ["granular lymphocytic leukemia", "ANATOMY", 274, 303], ["breast cancer", "ANATOMY", 305, 318], ["NK cell lymphoma", "ANATOMY", 330, 346], ["graft", "ANATOMY", 432, 437], ["inflammation", "DISEASE", 124, 136], ["carcinogenesis", "DISEASE", 147, 161], ["cancers", "DISEASE", 228, 235], ["pancreatic cancer", "DISEASE", 243, 260], ["granular lymphocytic leukemia", "DISEASE", 274, 303], ["breast cancer", "DISEASE", 305, 318], ["NK cell lymphoma", "DISEASE", 330, 346], ["autoimmune disorders", "DISEASE", 357, 377], ["rheumatoid arthritis", "DISEASE", 385, 405], ["osteoarthritis", "DISEASE", 410, 424], ["graft-versus-host-disease", "DISEASE", 432, 457], ["GVHD", "DISEASE", 459, 463], ["SLE", "DISEASE", 480, 483], ["CD95L", "GENE_OR_GENE_PRODUCT", 214, 219], ["cancers", "CANCER", 228, 235], ["pancreatic cancer", "CANCER", 243, 260], ["large granular lymphocytic leukemia", "CANCER", 268, 303], ["breast cancer", "CANCER", 305, 318], ["NK cell lymphoma", "CANCER", 330, 346], ["graft-versus-host-disease", "CANCER", 432, 457], ["CD95L", "PROTEIN", 214, 219], ["new therapeutic agents", "TREATMENT", 59, 81], ["inflammation", "PROBLEM", 124, 136], ["impede carcinogenesis", "PROBLEM", 140, 161], ["pathologies", "PROBLEM", 174, 185], ["increased soluble CD95L", "TREATMENT", 196, 219], ["cancers", "PROBLEM", 228, 235], ["pancreatic cancer", "PROBLEM", 243, 260], ["large granular lymphocytic leukemia", "PROBLEM", 268, 303], ["breast cancer", "PROBLEM", 305, 318], ["NK cell lymphoma", "PROBLEM", 330, 346], ["autoimmune disorders", "PROBLEM", 357, 377], ["rheumatoid arthritis", "PROBLEM", 385, 405], ["osteoarthritis", "PROBLEM", 410, 424], ["graft", "TREATMENT", 432, 437], ["host-disease", "PROBLEM", 445, 457], ["GVHD", "PROBLEM", 459, 463], ["SLE", "TEST", 480, 483], ["inflammation", "OBSERVATION", 124, 136], ["pancreatic", "ANATOMY", 243, 253], ["cancer", "OBSERVATION", 254, 260], ["large", "OBSERVATION_MODIFIER", 268, 273], ["granular lymphocytic leukemia", "OBSERVATION", 274, 303], ["breast", "ANATOMY", 305, 311], ["cancer", "OBSERVATION", 312, 318], ["NK cell lymphoma", "OBSERVATION", 330, 346], ["rheumatoid arthritis", "OBSERVATION", 385, 405], ["osteoarthritis", "OBSERVATION", 410, 424], ["graft", "OBSERVATION", 432, 437]]], ["Altogether, these studies support the notion that the death function of CD95 may correspond to its \u201cday job,\u201d while the receptor may act as \u201ca night killer\u201d by fueling inflammation in certain pathophysiological contexts.At Least Two Different Ligands and Two Different Signals ::: CD95L, an Inflammatory/Oncogenic Cytokine? ::: CD95: A Death Receptor?Strikingly, while the soluble form of CD95L generated by MMP7 (cleavage site inside the 113ELR115 sequence, Fig. 11.5) induces apoptosis [150], its counterpart processed between serine 126 and leucine 127 does not [51, 53, 155].", [["death", "DISEASE", 54, 59], ["inflammation", "DISEASE", 168, 180], ["serine 126", "CHEMICAL", 529, 539], ["leucine 127", "CHEMICAL", 544, 555], ["serine", "CHEMICAL", 529, 535], ["leucine", "CHEMICAL", 544, 551], ["CD95", "GENE_OR_GENE_PRODUCT", 72, 76], ["CD95L", "GENE_OR_GENE_PRODUCT", 281, 286], ["CD95", "GENE_OR_GENE_PRODUCT", 328, 332], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 334, 350], ["CD95L", "GENE_OR_GENE_PRODUCT", 389, 394], ["MMP7", "GENE_OR_GENE_PRODUCT", 408, 412], ["serine 126", "AMINO_ACID", 529, 539], ["leucine", "AMINO_ACID", 544, 551], ["CD95", "PROTEIN", 72, 76], ["CD95L", "PROTEIN", 281, 286], ["Inflammatory/Oncogenic Cytokine", "PROTEIN", 291, 322], ["CD95", "PROTEIN", 328, 332], ["CD95L", "PROTEIN", 389, 394], ["MMP7", "PROTEIN", 408, 412], ["113ELR115 sequence", "DNA", 439, 457], ["these studies", "TEST", 12, 25], ["the death function of CD95", "PROBLEM", 50, 76], ["fueling inflammation", "PROBLEM", 160, 180], ["CD95L", "TEST", 281, 286], ["MMP7 (cleavage site", "TREATMENT", 408, 427], ["apoptosis", "PROBLEM", 478, 487], ["leucine", "TEST", 544, 551], ["inflammation", "OBSERVATION", 168, 180], ["Different Ligands", "OBSERVATION", 233, 250], ["Inflammatory", "OBSERVATION_MODIFIER", 291, 303], ["Oncogenic Cytokine", "OBSERVATION", 304, 322]]], ["To explain this discrepancy, one may speculate that the different quaternary structures of the naturally processed CD95L underlie the implementation of \u201cdeath\u201d- vs. \u201cnon-death\u201d-inducing signaling complexes and downstream signals.", [["death", "DISEASE", 153, 158], ["death", "DISEASE", 170, 175], ["CD95L", "GENE_OR_GENE_PRODUCT", 115, 120], ["CD95L", "PROTEIN", 115, 120], ["signaling complexes", "PROTEIN", 186, 205], ["non-death", "PROBLEM", 166, 175], ["signaling complexes and downstream signals", "PROBLEM", 186, 228]]], ["In agreement with this notion, soluble CD95L bathed in the bronchoalveolar lavage (BALs) of patients suffering from acute respiratory distress syndrome (ARDS) undergoes oxidation at methionines 224 and 225 (Fig. 11.5), which enhances the aggregation level of the soluble ligand followed by its cytotoxic activity [168].", [["bronchoalveolar lavage", "ANATOMY", 59, 81], ["BALs", "ANATOMY", 83, 87], ["acute respiratory distress syndrome", "DISEASE", 116, 151], ["ARDS", "DISEASE", 153, 157], ["methionines 224 and 225", "CHEMICAL", 182, 205], ["methionines", "CHEMICAL", 182, 193], ["CD95L", "GENE_OR_GENE_PRODUCT", 39, 44], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 59, 81], ["BALs", "MULTI-TISSUE_STRUCTURE", 83, 87], ["patients", "ORGANISM", 92, 100], ["CD95L", "PROTEIN", 39, 44], ["patients", "SPECIES", 92, 100], ["soluble CD95L", "TREATMENT", 31, 44], ["the bronchoalveolar lavage", "TEST", 55, 81], ["acute respiratory distress syndrome", "PROBLEM", 116, 151], ["ARDS", "PROBLEM", 153, 157], ["bronchoalveolar lavage", "OBSERVATION", 59, 81], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["respiratory distress syndrome", "OBSERVATION", 122, 151]]], ["The same authors observed that the stalk region of CD95L, corresponding to amino acids 103\u2013136 and encompassing the metalloprotease cleavage sites (Fig. 11.5), participates in the multimerization of CD95L, which accounts for the damage of the lung epithelium in ARDS [168].", [["stalk region", "ANATOMY", 35, 47], ["lung epithelium", "ANATOMY", 243, 258], ["amino acids 103\u2013136", "CHEMICAL", 75, 94], ["ARDS", "DISEASE", 262, 266], ["amino acids", "CHEMICAL", 75, 86], ["CD95L", "GENE_OR_GENE_PRODUCT", 51, 56], ["amino acids 103\u2013136", "AMINO_ACID", 75, 94], ["CD95L", "GENE_OR_GENE_PRODUCT", 199, 204], ["lung epithelium", "TISSUE", 243, 258], ["stalk region", "PROTEIN", 35, 47], ["CD95L", "PROTEIN", 51, 56], ["amino acids 103\u2013136", "PROTEIN", 75, 94], ["metalloprotease cleavage sites", "PROTEIN", 116, 146], ["CD95L", "PROTEIN", 199, 204], ["amino acids", "TEST", 75, 86], ["the metalloprotease cleavage sites", "PROBLEM", 112, 146], ["the damage of the lung epithelium", "PROBLEM", 225, 258], ["ARDS", "PROBLEM", 262, 266], ["damage", "OBSERVATION", 229, 235], ["lung", "ANATOMY", 243, 247], ["epithelium", "ANATOMY_MODIFIER", 248, 258], ["ARDS", "OBSERVATION", 262, 266]]], ["Of note, in ARDS BALs, additional oxidation occurs at methionine 121 (Fig. 11.5), which in turn prevents the processing of CD95L by MMP7, and explains why this cytotoxic ligand keeps its stalk region [168].", [["ARDS", "DISEASE", 12, 16], ["methionine 121", "CHEMICAL", 54, 68], ["methionine", "CHEMICAL", 54, 64], ["methionine 121", "SIMPLE_CHEMICAL", 54, 68], ["CD95L", "GENE_OR_GENE_PRODUCT", 123, 128], ["MMP7", "GENE_OR_GENE_PRODUCT", 132, 136], ["CD95L", "PROTEIN", 123, 128], ["MMP7", "PROTEIN", 132, 136], ["ARDS BALs", "TEST", 12, 21], ["methionine", "TREATMENT", 54, 64], ["this cytotoxic ligand", "PROBLEM", 155, 176]]], ["Nonetheless, preservation of this region in soluble CD95L raises the question that whether an unidentified MMP7-independent cleavage site exists in the juxtamembrane region of CD95L, near the plasma membrane, or the ligand detected in ARDS patients corresponds to the full-length CD95L embedded in exosomes [169, 170].", [["juxtamembrane region", "ANATOMY", 152, 172], ["plasma membrane", "ANATOMY", 192, 207], ["exosomes", "ANATOMY", 298, 306], ["ARDS", "DISEASE", 235, 239], ["CD95L", "GENE_OR_GENE_PRODUCT", 52, 57], ["MMP7", "GENE_OR_GENE_PRODUCT", 107, 111], ["CD95L", "GENE_OR_GENE_PRODUCT", 176, 181], ["plasma membrane", "CELLULAR_COMPONENT", 192, 207], ["patients", "ORGANISM", 240, 248], ["CD95L", "GENE_OR_GENE_PRODUCT", 280, 285], ["exosomes", "CELL", 298, 306], ["CD95L", "PROTEIN", 52, 57], ["MMP7", "PROTEIN", 107, 111], ["juxtamembrane region", "PROTEIN", 152, 172], ["CD95L", "PROTEIN", 176, 181], ["CD95L", "PROTEIN", 280, 285], ["exosomes", "CELL_TYPE", 298, 306], ["patients", "SPECIES", 240, 248], ["this region in soluble CD95L", "TREATMENT", 29, 57], ["an unidentified MMP7", "PROBLEM", 91, 111], ["independent cleavage site", "PROBLEM", 112, 137], ["ARDS", "PROBLEM", 235, 239], ["MMP7", "OBSERVATION", 107, 111], ["CD95L", "OBSERVATION", 176, 181], ["plasma membrane", "ANATOMY", 192, 207], ["ARDS", "OBSERVATION", 235, 239]]], ["Indeed, this peculiar exosome-bound CD95L can be expressed by human prostate cancer cells (i.e., LNCaP) and evokes apoptosis in activated T-lymphocytes [171].At Least Two Different Ligands and Two Different Signals ::: CD95L, an Inflammatory/Oncogenic Cytokine? ::: CD95: A Death Receptor?Overall, these findings emphasize that it will be of great interest in the future to finely characterize the quaternary structure of the naturally processed CD95L from the sera of patients affected by cancers or chronic/acute inflammatory disorders, to better understand the molecular mechanisms implemented by this ligand and thus predict its subsequent biological functions.Concluding RemarksApoptosis is a fundamental process contributing to tissue homeostasis, immune response, and development.", [["exosome", "ANATOMY", 22, 29], ["prostate cancer cells", "ANATOMY", 68, 89], ["LNCaP", "ANATOMY", 97, 102], ["T-lymphocytes", "ANATOMY", 138, 151], ["sera", "ANATOMY", 461, 465], ["cancers", "ANATOMY", 490, 497], ["tissue", "ANATOMY", 734, 740], ["prostate cancer", "DISEASE", 68, 83], ["cancers", "DISEASE", 490, 497], ["RemarksApoptosis", "DISEASE", 676, 692], ["exosome", "CELLULAR_COMPONENT", 22, 29], ["CD95L", "GENE_OR_GENE_PRODUCT", 36, 41], ["human", "ORGANISM", 62, 67], ["prostate cancer cells", "CELL", 68, 89], ["LNCaP", "CELL", 97, 102], ["T-lymphocytes [171]", "CELL", 138, 157], ["CD95L", "GENE_OR_GENE_PRODUCT", 219, 224], ["CD95", "GENE_OR_GENE_PRODUCT", 266, 270], ["A Death Receptor", "GENE_OR_GENE_PRODUCT", 272, 288], ["CD95L", "GENE_OR_GENE_PRODUCT", 446, 451], ["sera", "ORGANISM_SUBSTANCE", 461, 465], ["patients", "ORGANISM", 469, 477], ["cancers", "CANCER", 490, 497], ["tissue", "TISSUE", 734, 740], ["exosome", "PROTEIN", 22, 29], ["CD95L", "PROTEIN", 36, 41], ["human prostate cancer cells", "CELL_TYPE", 62, 89], ["LNCaP", "CELL_LINE", 97, 102], ["activated T-lymphocytes", "CELL_TYPE", 128, 151], ["CD95L", "PROTEIN", 219, 224], ["Inflammatory/Oncogenic Cytokine", "PROTEIN", 229, 260], ["CD95", "PROTEIN", 266, 270], ["CD95L", "PROTEIN", 446, 451], ["human", "SPECIES", 62, 67], ["patients", "SPECIES", 469, 477], ["human", "SPECIES", 62, 67], ["human prostate cancer cells", "PROBLEM", 62, 89], ["LNCaP", "TEST", 97, 102], ["apoptosis", "PROBLEM", 115, 124], ["CD95L", "TEST", 219, 224], ["cancers", "PROBLEM", 490, 497], ["chronic/acute inflammatory disorders", "PROBLEM", 501, 537], ["a fundamental process", "PROBLEM", 696, 717], ["tissue homeostasis", "PROBLEM", 734, 752], ["-bound CD95L", "OBSERVATION", 29, 41], ["prostate", "ANATOMY", 68, 76], ["cancer", "OBSERVATION", 77, 83], ["Different Ligands", "OBSERVATION", 171, 188], ["Inflammatory", "OBSERVATION_MODIFIER", 229, 241], ["Oncogenic Cytokine", "OBSERVATION", 242, 260], ["cancers", "OBSERVATION", 490, 497], ["chronic", "OBSERVATION_MODIFIER", 501, 508], ["acute", "OBSERVATION_MODIFIER", 509, 514], ["inflammatory", "OBSERVATION", 515, 527]]], ["CD95, also called Fas, is a member of the tumor necrosis factor receptor (TNFR) superfamily.", [["tumor", "DISEASE", 42, 47], ["CD95", "GENE_OR_GENE_PRODUCT", 0, 4], ["Fas", "GENE_OR_GENE_PRODUCT", 18, 21], ["tumor necrosis factor receptor", "GENE_OR_GENE_PRODUCT", 42, 72], ["TNFR", "GENE_OR_GENE_PRODUCT", 74, 78], ["CD95", "PROTEIN", 0, 4], ["Fas", "PROTEIN", 18, 21], ["tumor necrosis factor receptor (TNFR) superfamily", "PROTEIN", 42, 91], ["the tumor necrosis", "PROBLEM", 38, 56], ["tumor", "OBSERVATION_MODIFIER", 42, 47], ["necrosis", "OBSERVATION", 48, 56]]], ["Its ligand, CD95L, was initially detected at the plasma membrane of activated T-lymphocytes and natural killer (NK) cells where it contributes to the elimination of transformed and infected cells.", [["plasma membrane", "ANATOMY", 49, 64], ["T-lymphocytes", "ANATOMY", 78, 91], ["natural killer (NK) cells", "ANATOMY", 96, 121], ["cells", "ANATOMY", 190, 195], ["CD95L", "GENE_OR_GENE_PRODUCT", 12, 17], ["plasma membrane", "CELLULAR_COMPONENT", 49, 64], ["T-lymphocytes", "CELL", 78, 91], ["natural killer (NK) cells", "CELL", 96, 121], ["cells", "CELL", 190, 195], ["CD95L", "PROTEIN", 12, 17], ["activated T-lymphocytes", "CELL_TYPE", 68, 91], ["natural killer (NK) cells", "CELL_TYPE", 96, 121], ["transformed and infected cells", "CELL_TYPE", 165, 195], ["natural killer (NK) cells", "TREATMENT", 96, 121], ["transformed and infected cells", "PROBLEM", 165, 195], ["infected cells", "OBSERVATION", 181, 195]]], ["Given its implication in immune homeostasis and immune surveillance combined with the fact that various lineages of malignant cells exhibit loss-of-function mutations, CD95 was initially classified as a tumor suppressor gene.", [["malignant cells", "ANATOMY", 116, 131], ["tumor", "ANATOMY", 203, 208], ["tumor", "DISEASE", 203, 208], ["malignant cells", "CELL", 116, 131], ["CD95", "GENE_OR_GENE_PRODUCT", 168, 172], ["tumor", "CANCER", 203, 208], ["malignant cells", "CELL_TYPE", 116, 131], ["CD95", "PROTEIN", 168, 172], ["tumor suppressor gene", "DNA", 203, 224], ["immune homeostasis", "TREATMENT", 25, 43], ["immune surveillance", "TREATMENT", 48, 67], ["malignant cells", "PROBLEM", 116, 131], ["loss-of-function mutations", "PROBLEM", 140, 166], ["a tumor suppressor gene", "TREATMENT", 201, 224], ["immune homeostasis", "OBSERVATION", 25, 43], ["malignant cells", "OBSERVATION", 116, 131], ["tumor suppressor", "OBSERVATION", 203, 219]]], ["Nonetheless, in different pathophysiological contexts, this receptor is able to transmit non-apoptotic signals and promote inflammation and carcinogenesis.", [["inflammation", "DISEASE", 123, 135], ["carcinogenesis", "DISEASE", 140, 154], ["inflammation", "PROBLEM", 123, 135], ["carcinogenesis", "PROBLEM", 140, 154], ["inflammation", "OBSERVATION", 123, 135]]], ["Although the different non-apoptotic signaling pathways (NF-\u03baB, MAPK, and PI3K) triggered by CD95 are known, the initial molecular events leading to these signals, the mechanisms by which the receptor switches from an apoptotic function to an inflammatory role, and, more importantly, the biological functions of these signals remain elusive.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 57, 62], ["MAPK", "GENE_OR_GENE_PRODUCT", 64, 68], ["PI3K", "GENE_OR_GENE_PRODUCT", 74, 78], ["CD95", "GENE_OR_GENE_PRODUCT", 93, 97], ["NF-\u03baB", "PROTEIN", 57, 62], ["MAPK", "PROTEIN", 64, 68], ["PI3K", "PROTEIN", 74, 78], ["CD95", "PROTEIN", 93, 97], ["NF", "TEST", 57, 59], ["MAPK", "TEST", 64, 68], ["PI3K", "TEST", 74, 78], ["the initial molecular events", "PROBLEM", 109, 137], ["apoptotic function", "OBSERVATION", 218, 236], ["inflammatory", "OBSERVATION_MODIFIER", 243, 255]]]], "PMC7251258": [["The terrestrial mobile hospital is the most common type, which includes tent hospital, vehicle hospital, shelter hospital, and so forth.", [["terrestrial", "OBSERVATION_MODIFIER", 4, 15], ["mobile", "OBSERVATION_MODIFIER", 16, 22], ["most common", "OBSERVATION_MODIFIER", 39, 50]]], ["The terrestrial mobile hospital is modular.", [["terrestrial", "OBSERVATION_MODIFIER", 4, 15], ["mobile", "OBSERVATION_MODIFIER", 16, 22], ["modular", "OBSERVATION", 35, 42]]], ["From the point of view of spatial structure, the shelter hospital could respond immediately to disaster calls and immediate departure from the disaster zone when the situation worsens, and it must meet the requirements of flatness for supporting terrain.", [["spatial structure", "OBSERVATION", 26, 43]]], ["While the tent hospital has a large available space and low requirements for terrain, its disadvantages are long in deployment and withdrawal time.", [["a large available space", "PROBLEM", 28, 51], ["large", "OBSERVATION_MODIFIER", 30, 35], ["low requirements", "OBSERVATION_MODIFIER", 56, 72]]], ["At present, the configuration forms of terrestrial mobile hospitals in various countries include mainly the shelter combination represented by the United States and France, the tent combination represented by Russia and Italy, and the shelter and tent combination represented by Germany and China.3,4", [["3,4", "CHEMICAL", 297, 300], ["the tent combination", "TREATMENT", 173, 193], ["tent combination", "TREATMENT", 247, 263], ["terrestrial", "OBSERVATION_MODIFIER", 39, 50], ["mobile", "OBSERVATION_MODIFIER", 51, 57]]]], "5baefca7a143be6267b7c98ab40c440ef0cd15c5": [["Despite some encouraging preliminary clinical data (2,3), major concerns have been raised about the use of HCQ to treat COVID-19 (5), particularly regarding potential cardiac toxicity (i.e. QTc increase and risk of torsade de pointe).", [["cardiac", "ANATOMY", 167, 174], ["HCQ", "CHEMICAL", 107, 110], ["COVID", "DISEASE", 120, 125], ["cardiac toxicity", "DISEASE", 167, 183], ["torsade de pointe", "DISEASE", 215, 232], ["HCQ", "CHEMICAL", 107, 110], ["COVID-19", "CHEMICAL", 120, 128], ["HCQ", "SIMPLE_CHEMICAL", 107, 110], ["cardiac", "ORGAN", 167, 174], ["HCQ", "TREATMENT", 107, 110], ["COVID", "TEST", 120, 125], ["potential cardiac toxicity", "PROBLEM", 157, 183], ["QTc increase", "PROBLEM", 190, 202], ["torsade", "PROBLEM", 215, 222], ["cardiac", "ANATOMY", 167, 174], ["toxicity", "OBSERVATION", 175, 183]]], ["Because HCQ has been safely used for many years for various indications (e.a. connective tissue diseases) (6), we decided to follow interim Belgian guidance for all eligible patients hospitalized in our COVID-19 wards.", [["connective tissue", "ANATOMY", 78, 95], ["HCQ", "CHEMICAL", 8, 11], ["connective tissue diseases", "DISEASE", 78, 104], ["HCQ", "CHEMICAL", 8, 11], ["HCQ", "SIMPLE_CHEMICAL", 8, 11], ["connective tissue", "TISSUE", 78, 95], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["HCQ", "TREATMENT", 8, 11], ["various indications (e.a. connective tissue diseases", "PROBLEM", 52, 104], ["connective tissue", "OBSERVATION_MODIFIER", 78, 95]]], ["Repeat ECG was not systematically performed during HCQ treatment, except in case of drug-drug interaction which could potentially increase QTc (see foot note of Table1).", [["HCQ", "CHEMICAL", 51, 54], ["HCQ", "CHEMICAL", 51, 54], ["HCQ", "SIMPLE_CHEMICAL", 51, 54], ["Table1", "PROTEIN", 161, 167], ["Repeat ECG", "TEST", 0, 10], ["HCQ treatment", "TREATMENT", 51, 64], ["QTc", "TEST", 139, 142]]], ["The main drug-drug interaction was driven by addition of AZM (n=28).", [["AZM", "CHEMICAL", 57, 60], ["AZM", "CHEMICAL", 57, 60], ["AZM", "SIMPLE_CHEMICAL", 57, 60], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["In this group, QTc was controlled at day 2 of combination therapy (n=24).", [["QTc", "TEST", 15, 18], ["combination therapy", "TREATMENT", 46, 65]]], ["We observed a significant increase in mean QTc, from 418 to 433 msec (p< 0,01 with paired t-test), but none of the patients showed a QTc over 500 msec.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["mean QTc", "TEST", 38, 46], ["paired t-test", "TEST", 83, 96], ["a QTc", "TEST", 131, 136], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["mean QTc", "OBSERVATION", 38, 46]]]], "PMC7484669": [["IntroductionSince the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan in December 2019, it has spread worldwide and infected more than 3 855 788 people by 9 May 2020 1.", [["coronavirus disease", "DISEASE", 34, 53], ["COVID-19", "CHEMICAL", 60, 68], ["coronavirus", "ORGANISM", 34, 45], ["people", "ORGANISM", 154, 160], ["people", "SPECIES", 154, 160], ["coronavirus disease", "PROBLEM", 34, 53], ["coronavirus disease", "OBSERVATION", 34, 53]]], ["With the high rate of human transmission and a mortality rate of 2.9% in Hubei province compared to that of 0.4% outside of the region 2, the disease has been recognized as a pandemic by the WHO on Mar 11, 2020 3.IntroductionIn Wuhan, 16 fangcang shelter hospitals have been built-up to hospitalize, treat and monitor the patients with confirmed COVID-19, such that the limited medical resources could distribute for mild-type, common-type, severe-type, and fatal severe-type patients.", [["human", "ORGANISM", 22, 27], ["patients", "ORGANISM", 322, 330], ["patients", "ORGANISM", 476, 484], ["human", "SPECIES", 22, 27], ["patients", "SPECIES", 322, 330], ["patients", "SPECIES", 476, 484], ["human", "SPECIES", 22, 27], ["a mortality rate", "TEST", 45, 61], ["the disease", "PROBLEM", 138, 149], ["COVID", "TEST", 346, 351], ["mild-type, common-type, severe-type, and fatal severe-type patients", "PROBLEM", 417, 484], ["high", "OBSERVATION_MODIFIER", 9, 13], ["disease", "OBSERVATION", 142, 149], ["severe", "OBSERVATION_MODIFIER", 441, 447], ["fatal", "OBSERVATION_MODIFIER", 458, 463], ["severe", "OBSERVATION_MODIFIER", 464, 470]]], ["By March 10, more than 12,000 patients 4 had been treated uniformly according to the standard protocols 5, and all the fangcang shelter hospitals in Wuhan had been closed due to the recent relief of the epidemics.IntroductionPrevious studies have revealed the typical radiological imaging features of COVID-19 6-12.", [["patients", "ORGANISM", 30, 38], ["COVID-19 6-12", "DNA", 301, 314], ["patients", "SPECIES", 30, 38], ["the epidemics", "PROBLEM", 199, 212], ["IntroductionPrevious studies", "TEST", 213, 241], ["COVID", "TEST", 301, 306]]], ["However, it remains understudied how the chest CT manifestations evolve in the patients of fangcang shelter hospitals, who were hospitalized according to uniform criteria 5 and who went through more regular examinations and uniform treatments 5.", [["chest", "ANATOMY", 41, 46], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["the chest CT", "TEST", 37, 49], ["regular examinations", "TEST", 199, 219], ["uniform treatments", "TREATMENT", 224, 242], ["chest", "ANATOMY", 41, 46]]], ["In the meanwhile, as will be introduced below, the medical intervention in the fangcang shelter hospitals could be potentially practiced in a self-isolation environment such as at home.", [["the medical intervention", "TREATMENT", 47, 71]]], ["Therefore, the purpose of this study was to determine the temporal patterns of CT manifestations in COVID-19 patients from a single fangcang shelter hospital and to facilitate the understanding of the disease course.Admission to, treatment at, and discharge from the Fangcang Shelter Hospitals ::: MethodsThe admission criteria for fangcang shelter hospitals were13: 1) patients with confirmed COVID-19; 2) Clinical classifications were mild-type (clinical symptoms without CT abnormity) or common-type (clinical symptoms with CT abnormity); 3) no respiratory, cardio, or mental diseases, no other basic diseases; 4) 16-65 years old with self-care ability; 5) negative test results of influenza virus assays.Admission to, treatment at, and discharge from the Fangcang Shelter Hospitals ::: MethodsThe treatment protocol and discharge criteria followed 'The 6th Edition of Pneumonia diagnosis and treatment plan for new coronavirus infection' formulated by National Health Commission of the People's Republic of China 5.Admission to, treatment at, and discharge from the Fangcang Shelter Hospitals ::: MethodsFor treatment: 1) Oseltamivir: 75 mg/tablet, 2 tablets each time, 2 times a day, less than 10 days; 2) Abidor 14: 200 mg for adults, 3 times a day, less than 10 days; 3) Moxifloxacin: 0.4 g for adults, once a day, less than 7 days; 4) LianHua QingWen Formular: 1.4 g each time, three times a day, less than 10 days.Admission to, treatment at, and discharge from the Fangcang Shelter Hospitals ::: MethodsFor discharge: 1) afebrile for more than 3 days; 2) respiratory symptoms markedly improved; 3) improvement in the radiological abnormalities on chest CT (Reduction in density and range of lesions); 4) two successive negative PCR tests with at least 24 h interval.Patients ::: MethodsWe retrospectively reviewed the clinical records of patients for Jianghan fangcang shelter hospital who were admitted between February 05, 2020, and February 09, 2020, and the initial symptoms and symptom onset time were recorded.", [["respiratory", "ANATOMY", 548, 559], ["cardio", "ANATOMY", 561, 567], ["respiratory", "ANATOMY", 1564, 1575], ["chest", "ANATOMY", 1656, 1661], ["lesions", "ANATOMY", 1700, 1707], ["abnormity", "DISEASE", 477, 486], ["respiratory, cardio, or mental diseases", "DISEASE", 548, 587], ["Pneumonia", "DISEASE", 872, 881], ["coronavirus infection", "DISEASE", 919, 940], ["Oseltamivir", "CHEMICAL", 1126, 1137], ["Moxifloxacin", "CHEMICAL", 1278, 1290], ["Oseltamivir", "CHEMICAL", 1126, 1137], ["Moxifloxacin", "CHEMICAL", 1278, 1290], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 370, 378], ["Oseltamivir", "SIMPLE_CHEMICAL", 1126, 1137], ["lesions", "PATHOLOGICAL_FORMATION", 1700, 1707], ["Patients", "ORGANISM", 1775, 1783], ["patients", "ORGANISM", 1847, 1855], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 370, 378], ["Patients", "SPECIES", 1775, 1783], ["patients", "SPECIES", 1847, 1855], ["this study", "TEST", 26, 36], ["CT manifestations", "TEST", 79, 96], ["treatment", "TREATMENT", 230, 239], ["Methods", "TREATMENT", 298, 305], ["COVID", "TEST", 394, 399], ["mild-type (clinical symptoms", "PROBLEM", 437, 465], ["CT abnormity", "PROBLEM", 474, 486], ["common-type (clinical symptoms", "PROBLEM", 491, 521], ["CT abnormity", "TEST", 527, 539], ["respiratory, cardio, or mental diseases", "PROBLEM", 548, 587], ["other basic diseases", "PROBLEM", 592, 612], ["influenza virus assays", "PROBLEM", 685, 707], ["treatment", "TREATMENT", 722, 731], ["Methods", "TREATMENT", 790, 797], ["The treatment protocol", "TREATMENT", 797, 819], ["Pneumonia", "PROBLEM", 872, 881], ["treatment plan", "TREATMENT", 896, 910], ["new coronavirus infection", "PROBLEM", 915, 940], ["treatment", "TREATMENT", 1033, 1042], ["Methods", "TREATMENT", 1101, 1108], ["Oseltamivir", "TREATMENT", 1126, 1137], ["Abidor", "TREATMENT", 1211, 1217], ["Moxifloxacin", "TREATMENT", 1278, 1290], ["LianHua QingWen Formular", "TREATMENT", 1343, 1367], ["treatment", "TREATMENT", 1437, 1446], ["Methods", "TREATMENT", 1505, 1512], ["afebrile", "PROBLEM", 1530, 1538], ["respiratory symptoms", "PROBLEM", 1564, 1584], ["the radiological abnormalities", "PROBLEM", 1622, 1652], ["chest CT", "TEST", 1656, 1664], ["lesions", "PROBLEM", 1700, 1707], ["PCR tests", "TEST", 1737, 1746], ["the initial symptoms", "PROBLEM", 1967, 1987], ["mild", "OBSERVATION_MODIFIER", 437, 441], ["no", "UNCERTAINTY", 545, 547], ["respiratory", "ANATOMY", 548, 559], ["cardio", "ANATOMY", 561, 567], ["Pneumonia", "OBSERVATION", 872, 881], ["coronavirus", "OBSERVATION_MODIFIER", 919, 930], ["infection", "OBSERVATION", 931, 940], ["chest", "ANATOMY", 1656, 1661], ["density", "OBSERVATION", 1679, 1686], ["lesions", "OBSERVATION", 1700, 1707]]], ["The inclusion criteria were: 1) patients had initial chest CT at our hospital (hence the integrity of the clinical and imaging records) were included in the study; 2) patients had been discharged from Jianghan fangcang shelter hospital by the censored date (March 09, 2020).CT image acquisition ::: MethodsTo minimize motion artifacts, patients were instructed on breath-holding in the supine position.", [["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 167, 175], ["patients", "ORGANISM", 336, 344], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 167, 175], ["patients", "SPECIES", 336, 344], ["initial chest CT", "TEST", 45, 61], ["the study", "TEST", 153, 162], ["CT image acquisition", "TEST", 274, 294], ["MethodsTo", "TREATMENT", 299, 308], ["motion artifacts", "PROBLEM", 318, 334], ["breath", "TEST", 364, 370], ["chest", "ANATOMY", 53, 58], ["motion artifacts", "OBSERVATION", 318, 334]]], ["All chest CT scans were performed within a single inspiratory phase on two commercial multi-detector CT scanners (uCT550, Shanghai, China, Shanghai United Imaging Healthcare; Aquilion16-slice, Toshiba Medical Systems, Tochigi, Japan).", [["chest", "ANATOMY", 4, 9], ["All chest CT scans", "TEST", 0, 18], ["a single inspiratory phase", "TEST", 41, 67], ["chest", "ANATOMY", 4, 9]]], ["For CT acquisition, the tube voltage was fixed at 120 kVp, the pitch of 1.075, scanning interval of 0.55 mm, rotation time of 0.6s, and collimator width of 22 mm.", [["tube", "ANATOMY", 24, 28], ["tube", "TISSUE", 24, 28], ["CT acquisition", "TEST", 4, 18], ["the tube voltage", "TEST", 20, 36], ["the pitch", "TEST", 59, 68], ["scanning interval", "TEST", 79, 96], ["rotation time", "TEST", 109, 122], ["collimator width", "TEST", 136, 152], ["22 mm", "OBSERVATION_MODIFIER", 156, 161]]], ["Low-dose scanning mode with an automatic tube current of 40 mAs and dose level at 1 was performed to reduce the radiation risk of the patients.", [["tube", "ANATOMY", 41, 45], ["tube", "TISSUE", 41, 45], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["Low-dose scanning mode", "TREATMENT", 0, 22], ["an automatic tube", "TREATMENT", 28, 45], ["dose level", "TEST", 68, 78]]], ["CT images were reconstructed with a matrix size of 512 \u00d7 512 (thickness of 1.5 mm and increment of 1.5 mm) in transverse slice orientation.", [["matrix", "ANATOMY", 36, 42], ["slice", "ANATOMY", 121, 126], ["CT images", "TEST", 0, 9], ["a matrix size", "TEST", 34, 47], ["thickness", "TEST", 62, 71], ["transverse slice orientation", "TEST", 110, 138], ["size", "OBSERVATION_MODIFIER", 43, 47]]], ["The images were acquired for lung (window width, 1,000-1,500 HU; window level, -700 HU) and mediastinal (window width, 350 HU; window level, 35-40 HU) settings.CT Image Interpretation ::: MethodsImage analysis was reviewed by three radiologists (H. S, L. Y, and M. D who had 30, 22 and 10 years of experience in thoracic radiology, respectively), using the institutional digital database system (Vue PACS, version 11.3.5.8902, Carestream Health, Canada).", [["lung", "ANATOMY", 29, 33], ["mediastinal", "ANATOMY", 92, 103], ["thoracic", "ANATOMY", 312, 320], ["lung", "ORGAN", 29, 33], ["The images", "TEST", 0, 10], ["window level", "TEST", 65, 77], ["mediastinal (window width", "TREATMENT", 92, 117], ["window level", "TEST", 127, 139], ["MethodsImage analysis", "TEST", 188, 209], ["version", "TEST", 406, 413], ["lung", "ANATOMY", 29, 33], ["700 HU", "OBSERVATION_MODIFIER", 80, 86], ["mediastinal", "ANATOMY", 92, 103], ["350 HU", "OBSERVATION_MODIFIER", 119, 125], ["thoracic", "ANATOMY", 312, 320]]], ["Decisions were reached by consensus when there was a disagreement between the three radiologists.CT Image Interpretation ::: MethodsDepending on the time between symptoms onset and the CT scan, all the CT scans were divided into 5 groups: Group 1 (scans obtained the first week from symptom onset), Group 2 (2nd week), Group 3 (3rd week), Group 4 (4th week), and Group 5 (>week 4).CT Image Interpretation ::: MethodsPredominantly CT pattern, including ground-glass opacity (GGO), consolidation pattern, reticular pattern, and the mixed pattern (the combination of GGO, consolidation, and reticulation) 6, 8, 9, 15.", [["reticular", "ANATOMY", 503, 512], ["GGO", "DISEASE", 564, 567], ["symptoms", "PROBLEM", 162, 170], ["the CT scan", "TEST", 181, 192], ["all the CT scans", "TEST", 194, 210], ["CT Image", "TEST", 381, 389], ["MethodsPredominantly CT pattern", "TEST", 409, 440], ["ground-glass opacity (GGO)", "PROBLEM", 452, 478], ["consolidation pattern", "PROBLEM", 480, 501], ["reticular pattern", "PROBLEM", 503, 520], ["GGO", "PROBLEM", 564, 567], ["consolidation", "PROBLEM", 569, 582], ["ground", "OBSERVATION_MODIFIER", 452, 458], ["glass opacity", "OBSERVATION", 459, 472], ["GGO", "OBSERVATION_MODIFIER", 474, 477], ["consolidation", "OBSERVATION", 480, 493], ["reticular", "OBSERVATION_MODIFIER", 503, 512], ["pattern", "OBSERVATION_MODIFIER", 513, 520], ["mixed", "OBSERVATION_MODIFIER", 530, 535], ["pattern", "OBSERVATION_MODIFIER", 536, 543], ["GGO", "OBSERVATION", 564, 567], ["consolidation", "OBSERVATION", 569, 582], ["reticulation", "OBSERVATION_MODIFIER", 588, 600]]], ["Distribution of abnormal opacities was recorded mainly as three types: subpleural (involving mainly the peripheral one-third of the lung), random (without predilection for subpleural or central regions), and diffuse (continuous involvement without respect to lung segments) 6.", [["subpleural", "ANATOMY", 71, 81], ["lung", "ANATOMY", 132, 136], ["subpleural", "ANATOMY", 172, 182], ["lung", "ANATOMY", 259, 263], ["abnormal opacities", "DISEASE", 16, 34], ["subpleural", "MULTI-TISSUE_STRUCTURE", 71, 81], ["lung", "ORGAN", 132, 136], ["subpleural", "MULTI-TISSUE_STRUCTURE", 172, 182], ["lung", "ORGAN", 259, 263], ["abnormal opacities", "PROBLEM", 16, 34], ["subpleural", "PROBLEM", 71, 81], ["subpleural or central regions)", "PROBLEM", 172, 202], ["diffuse (continuous involvement", "PROBLEM", 208, 239], ["abnormal", "OBSERVATION_MODIFIER", 16, 24], ["opacities", "OBSERVATION", 25, 34], ["subpleural", "ANATOMY_MODIFIER", 71, 81], ["peripheral", "ANATOMY_MODIFIER", 104, 114], ["one-", "ANATOMY_MODIFIER", 115, 119], ["third", "ANATOMY_MODIFIER", 119, 124], ["lung", "ANATOMY", 132, 136], ["subpleural", "ANATOMY_MODIFIER", 172, 182], ["central", "ANATOMY_MODIFIER", 186, 193], ["regions", "ANATOMY_MODIFIER", 194, 201], ["diffuse", "OBSERVATION_MODIFIER", 208, 215], ["lung", "ANATOMY", 259, 263], ["segments", "ANATOMY_MODIFIER", 264, 272]]], ["Additionally, the presence of pleura effusion, mediastinal lymphadenopathy (axil diameter >1.0 cm) was also noted.CT Image Interpretation ::: MethodsA total score of 0-25 was obtained as the summation of 5 lobes (score 0-5 for each lobe: score 0, no involvement; score 1, <5% involvement; score 2, 6%-25% involvement; score 3, 26%-49% involvement; score 4, 50%-75% involvement; score 5, >75% involvement) 16.Statistical analysis ::: MethodsThe median values of total CT scores were plotted against time since symptom onset.", [["pleura effusion", "ANATOMY", 30, 45], ["mediastinal lymphadenopathy", "ANATOMY", 47, 74], ["axil", "ANATOMY", 76, 80], ["pleura effusion", "DISEASE", 30, 45], ["mediastinal lymphadenopathy", "DISEASE", 47, 74], ["pleura", "ORGAN", 30, 36], ["lobe", "MULTI-TISSUE_STRUCTURE", 232, 236], ["pleura effusion", "PROBLEM", 30, 45], ["mediastinal lymphadenopathy", "PROBLEM", 47, 74], ["axil diameter", "TEST", 76, 89], ["MethodsA total score", "TEST", 142, 162], ["score", "TEST", 263, 268], ["score", "TEST", 289, 294], ["score", "TEST", 318, 323], ["score", "TEST", 348, 353], ["score", "TEST", 378, 383], ["Methods", "TREATMENT", 433, 440], ["total CT scores", "TEST", 461, 476], ["symptom onset", "PROBLEM", 509, 522], ["pleura", "ANATOMY", 30, 36], ["effusion", "OBSERVATION", 37, 45], ["mediastinal", "ANATOMY", 47, 58], ["lymphadenopathy", "OBSERVATION", 59, 74], ["diameter", "OBSERVATION_MODIFIER", 81, 89], ["1.0 cm", "OBSERVATION_MODIFIER", 91, 97], ["no", "UNCERTAINTY", 247, 249]]], ["The temporal changes in CT abnormity patterns and the distribution of lung abnormalities were analyzed.", [["lung", "ANATOMY", 70, 74], ["lung abnormalities", "DISEASE", 70, 88], ["lung", "ORGAN", 70, 74], ["The temporal changes in CT abnormity patterns", "PROBLEM", 0, 45], ["lung abnormalities", "PROBLEM", 70, 88], ["temporal", "OBSERVATION_MODIFIER", 4, 12], ["distribution", "OBSERVATION_MODIFIER", 54, 66], ["lung", "ANATOMY", 70, 74], ["abnormalities", "OBSERVATION", 75, 88]]], ["Manne-Whitney U test was used for the difference between the median values of CT lung quantification in different groups, and the Chi-square test was applied to compare the frequency of CT patterns in different groups.", [["lung", "ANATOMY", 81, 85], ["lung", "ORGAN", 81, 85], ["Whitney U test", "TEST", 6, 20], ["CT lung quantification", "TEST", 78, 100], ["the Chi-square test", "TEST", 126, 145], ["CT patterns", "TEST", 186, 197], ["lung", "ANATOMY", 81, 85]]], ["A P-value of < 0.05 was considered statistically significant.", [["A P-value", "TEST", 0, 9]]], ["Statistical analysis was performed by using statistical software (SPSS version 18, IBM, New York, USA).Patients ::: ResultsBetween February 05, 2020, and February 09, 2020, a total of 125 patients for Jianghan fangcang shelter hospital who performed the initial CT scans in our hospital were conducted.", [["Patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 188, 196], ["Patients", "SPECIES", 103, 111], ["patients", "SPECIES", 188, 196], ["Statistical analysis", "TEST", 0, 20], ["SPSS version", "TEST", 66, 78], ["the initial CT scans", "TEST", 250, 270]]], ["Another 27 patients were excluded because they were transferred to designated hospitals due to failure to meet discharge criteria.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["failure", "PROBLEM", 95, 102]]], ["The remaining 98 patients (43 males and 55 females) with confirmed COVID-19 were included in this study, all of whom had been discharged by the censored date.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["COVID", "TEST", 67, 72], ["this study", "TEST", 93, 103]]], ["The mean age of the patients was 49 \u00b1 12 years old (range 15-67 years).", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["The most common symptoms at the onset of illness were fever (82%) and cough (52%).", [["illness", "DISEASE", 41, 48], ["fever", "DISEASE", 54, 59], ["cough", "DISEASE", 70, 75], ["The most common symptoms", "PROBLEM", 0, 24], ["illness", "PROBLEM", 41, 48], ["fever", "PROBLEM", 54, 59], ["cough", "PROBLEM", 70, 75], ["most common", "OBSERVATION_MODIFIER", 4, 15]]], ["Most fever patients had either low-grade (38%, 37.4-38 \u00b0C) or moderate fever (32%, 38.1-39.0 \u00b0C).", [["fever", "DISEASE", 5, 10], ["fever", "DISEASE", 71, 76], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["Most fever", "PROBLEM", 0, 10], ["low-grade", "PROBLEM", 31, 40], ["moderate fever", "PROBLEM", 62, 76], ["low-grade", "OBSERVATION_MODIFIER", 31, 40], ["moderate", "OBSERVATION_MODIFIER", 62, 70], ["fever", "OBSERVATION", 71, 76]]], ["All patients were discharged with a median hospitalized period of 18 (interquartile range: 14-22) days, range 9-33 days.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["The demographic characteristics, initial symptoms, and clinical records were summarized in Table 1.General CT manifestations ::: ResultsAmong the 98 patients, 40 had twice CT scans, 45 had three CT scans, and the other 13 had four CT scans.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["initial symptoms", "PROBLEM", 33, 49], ["CT scans", "TEST", 172, 180], ["three CT scans", "TEST", 189, 203], ["four CT scans", "TEST", 226, 239]]], ["A total of 267 CT scans was acquired and evaluated.", [["CT scans", "TEST", 15, 23]]], ["For Group 1, the predominant demonstrations were subpleural (39%, 28/71 patients) and diffuse (35%, 25/71) lung abnormalities.", [["subpleural", "ANATOMY", 49, 59], ["lung", "ANATOMY", 107, 111], ["lung abnormalities", "DISEASE", 107, 125], ["subpleural", "MULTI-TISSUE_STRUCTURE", 49, 59], ["patients", "ORGANISM", 72, 80], ["lung", "ORGAN", 107, 111], ["patients", "SPECIES", 72, 80], ["subpleural", "TEST", 49, 59], ["diffuse (35%, 25/71) lung abnormalities", "PROBLEM", 86, 125], ["subpleural", "ANATOMY_MODIFIER", 49, 59], ["diffuse", "OBSERVATION_MODIFIER", 86, 93], ["lung", "ANATOMY", 107, 111], ["abnormalities", "OBSERVATION", 112, 125]]], ["Lung abnormalities tended to be most diffuse (64%, 34/53) in Group 2 (Fig. 1).", [["Lung", "ANATOMY", 0, 4], ["Lung abnormalities", "DISEASE", 0, 18], ["Lung", "ORGAN", 0, 4], ["Lung abnormalities", "PROBLEM", 0, 18], ["abnormalities", "OBSERVATION", 5, 18], ["diffuse", "OBSERVATION_MODIFIER", 37, 44]]], ["Bilateral lung involvement was commonly observed during the whole course of the disease (lung involvement 76%-90%) with the highest percentage of 90% (36/40 patients) in Group 3 (Table 2).Temporal changes in CT scores ::: ResultsThe median values of total CT score were 7 (interquartile range: 3-10) for the first week (Group 1), higher than reported in the literatures (6, 10, 16), which slowly increased to a peak value of 10 (interquartile range: 4-14, p< 0.05, compared to that of within the first week) at the second week (Group 2) and started to decrease substantially afterward.", [["lung", "ANATOMY", 10, 14], ["lung", "ANATOMY", 89, 93], ["lung", "ORGAN", 10, 14], ["lung", "ORGAN", 89, 93], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["Bilateral lung involvement", "PROBLEM", 0, 26], ["the disease", "PROBLEM", 76, 87], ["lung involvement", "TEST", 89, 105], ["Temporal changes in CT scores", "PROBLEM", 188, 217], ["The median values", "TEST", 229, 246], ["total CT score", "TEST", 250, 264], ["a peak value", "TEST", 409, 421], ["lung", "ANATOMY", 10, 14], ["involvement", "OBSERVATION", 15, 26], ["disease", "OBSERVATION", 80, 87], ["lung", "ANATOMY", 89, 93]]], ["The median values of total CT scores were 9.5 (7, 14), 7 (4, 10), and 7 (4, 11) for the Groups 3, 4, and 5, respectively.", [["total CT scores", "TEST", 21, 36], ["median", "OBSERVATION_MODIFIER", 4, 10]]], ["Radiological improvement occurs after the third week, with a statistically significant decrease in median scores between Group 3 and Group 4 (p=0.006) (Table 2, Fig. 2).Temporal changes of predominant imaging patterns ::: ResultsPredominant CT image patterns changed over time as the disease progressed.", [["a statistically significant decrease in median scores", "PROBLEM", 59, 112], ["Predominant CT image patterns", "TEST", 229, 258], ["the disease", "PROBLEM", 280, 291], ["improvement", "OBSERVATION", 13, 24], ["significant", "OBSERVATION_MODIFIER", 75, 86], ["decrease", "OBSERVATION_MODIFIER", 87, 95], ["disease", "OBSERVATION", 284, 291]]], ["Within the first week (Group 1) after symptom onset, the GGO pattern was the earliest and most common imaging finding (58%, 41/71 patients).", [["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["symptom onset", "PROBLEM", 38, 51]]], ["In the second week (Group 2), consolidation and mixed pattern developed to the predominant patterns with demonstration frequencies of 26% (14/53) and 40% (21/53).", [["consolidation", "PROBLEM", 30, 43], ["consolidation", "OBSERVATION", 30, 43], ["mixed pattern", "OBSERVATION", 48, 61]]], ["In the third week of illness (Group 3), imaging patterns became more diverse, including GGO (38%, 15/40 patients), reticular pattern (28%, 11/40), and mixed pattern (23%, 9/40).", [["reticular", "ANATOMY", 115, 124], ["GGO", "DISEASE", 88, 91], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["imaging patterns", "TEST", 40, 56], ["GGO", "TEST", 88, 91], ["reticular pattern", "TEST", 115, 132], ["reticular", "ANATOMY_MODIFIER", 115, 124], ["mixed", "OBSERVATION_MODIFIER", 151, 156], ["pattern", "OBSERVATION_MODIFIER", 157, 164]]], ["GGO and reticular patterns were the main imaging patterns in Group 4 (4th week) and Group 5 (>4 weeks) (Table 2, Fig. 3).Temporal changes of predominant imaging patterns ::: ResultsAmong the 71 CT scans in Group 1 who had their initial CT taken within the 1st week of symptom onset, 8 patients with repeated examinations or no lesions were excluded, hence, 63 patients demonstrated CT abnormalities, including GGO in 38 patients, consolidation in 15 patients, and mix pattern for 10 patients.", [["reticular", "ANATOMY", 8, 17], ["lesions", "ANATOMY", 327, 334], ["GGO", "DISEASE", 410, 413], ["patients", "ORGANISM", 285, 293], ["lesions", "CANCER", 327, 334], ["patients", "ORGANISM", 360, 368], ["patients", "ORGANISM", 420, 428], ["patients", "ORGANISM", 450, 458], ["patients", "ORGANISM", 483, 491], ["patients", "SPECIES", 285, 293], ["patients", "SPECIES", 360, 368], ["patients", "SPECIES", 420, 428], ["patients", "SPECIES", 450, 458], ["patients", "SPECIES", 483, 491], ["GGO and reticular patterns", "PROBLEM", 0, 26], ["CT scans", "TEST", 194, 202], ["their initial CT", "TEST", 222, 238], ["repeated examinations", "TEST", 299, 320], ["lesions", "PROBLEM", 327, 334], ["CT abnormalities", "PROBLEM", 382, 398], ["GGO", "PROBLEM", 410, 413], ["consolidation", "PROBLEM", 430, 443], ["reticular", "ANATOMY_MODIFIER", 8, 17], ["no", "UNCERTAINTY", 324, 326], ["lesions", "OBSERVATION", 327, 334], ["GGO", "OBSERVATION", 410, 413], ["consolidation", "OBSERVATION", 430, 443], ["15 patients", "OBSERVATION_MODIFIER", 447, 458]]], ["For the 38 patients with initial GGO, 37 presented varying residual lesions in the final scans, including GGO pattern [17 patients, median CT score: 3 (1, 7)] (Fig. 4), reticular pattern [18 patients, 9 (5, 13)] and mixed pattern [2 patients, 8 (5, 11)].", [["lesions", "ANATOMY", 68, 75], ["reticular", "ANATOMY", 169, 178], ["GGO", "DISEASE", 33, 36], ["patients", "ORGANISM", 11, 19], ["residual lesions", "CANCER", 59, 75], ["patients", "ORGANISM", 122, 130], ["patients", "ORGANISM", 191, 199], ["patients", "ORGANISM", 233, 241], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 122, 130], ["patients", "SPECIES", 191, 199], ["patients", "SPECIES", 233, 241], ["initial GGO", "TEST", 25, 36], ["varying residual lesions", "PROBLEM", 51, 75], ["the final scans", "TEST", 79, 94], ["GGO pattern", "TEST", 106, 117], ["median CT score", "TEST", 132, 147], ["reticular pattern", "TEST", 169, 186], ["varying", "OBSERVATION_MODIFIER", 51, 58], ["residual", "OBSERVATION_MODIFIER", 59, 67], ["lesions", "OBSERVATION", 68, 75], ["reticular", "ANATOMY_MODIFIER", 169, 178]]], ["Noticeably, the median CT score of patients with the final reticular pattern was higher than that of patients with final GGO (p=0.004).", [["reticular", "ANATOMY", 59, 68], ["GGO", "DISEASE", 121, 124], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 101, 109], ["the median CT score", "TEST", 12, 31], ["final GGO", "TEST", 115, 124], ["reticular", "OBSERVATION_MODIFIER", 59, 68], ["higher", "OBSERVATION_MODIFIER", 81, 87], ["GGO", "OBSERVATION", 121, 124]]], ["Among the 38 patients with initial predominant GGO, 17 had final CT scan at discharge also demonstrated predominant GGO, while the median CT scores had significant differences between the initial [median CT score: 5 (3, 9)] and final CTs [median CT score: 3 (1, 7)] (p=0.033).", [["GGO", "DISEASE", 47, 50], ["patients", "ORGANISM", 13, 21], ["GGO", "CANCER", 47, 50], ["patients", "SPECIES", 13, 21], ["initial predominant GGO", "PROBLEM", 27, 50], ["final CT scan", "TEST", 59, 72], ["predominant GGO", "PROBLEM", 104, 119], ["the median CT scores", "TEST", 127, 147], ["median CT score", "TEST", 197, 212], ["final CTs", "TEST", 228, 237], ["median CT score", "TEST", 239, 254], ["predominant", "OBSERVATION_MODIFIER", 104, 115], ["GGO", "OBSERVATION", 116, 119]]], ["On the other hand, 18 of the 38 patients had their initial predominant GGO turned to the reticular pattern in the final scans, for whom no significant differences were observed between the initial [median CT score: 8.5 (3.75,10.25)] and the final CT scores [median CT score: 9 (5,13)] (p=0.253).", [["reticular", "ANATOMY", 89, 98], ["patients", "ORGANISM", 32, 40], ["GGO", "CANCER", 71, 74], ["patients", "SPECIES", 32, 40], ["their initial predominant GGO", "PROBLEM", 45, 74], ["the final scans", "TEST", 110, 125], ["significant differences", "PROBLEM", 139, 162], ["median CT score", "TEST", 198, 213], ["the final CT scores", "TEST", 237, 256], ["median CT score", "TEST", 258, 273], ["GGO", "OBSERVATION", 71, 74], ["reticular", "ANATOMY_MODIFIER", 89, 98]]], ["For the 15 patients with initial consolidation, residual lesions in the final scans were GGO in 9 patients [median CT score: 4 (2, 7)] and reticular in 4 patients [median CT score: 7 (3, 9.5)] (Fig. 5).", [["lesions", "ANATOMY", 57, 64], ["reticular", "ANATOMY", 139, 148], ["GGO", "DISEASE", 89, 92], ["patients", "ORGANISM", 11, 19], ["lesions", "CANCER", 57, 64], ["patients", "ORGANISM", 98, 106], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 98, 106], ["patients", "SPECIES", 154, 162], ["initial consolidation", "PROBLEM", 25, 46], ["residual lesions", "PROBLEM", 48, 64], ["the final scans", "TEST", 68, 83], ["GGO", "TEST", 89, 92], ["median CT score", "TEST", 108, 123], ["median CT score", "TEST", 164, 179], ["consolidation", "OBSERVATION", 33, 46], ["residual", "OBSERVATION_MODIFIER", 48, 56], ["lesions", "OBSERVATION", 57, 64], ["reticular", "ANATOMY", 139, 148]]], ["For the 10 patients with initially mixed patterns, residual lesions in the final scans were GGO in 2 patients and reticulation in 7 patients [median CT score: 8 (2, 11)] (Table 3).Temporal changes of predominant imaging patterns ::: Results94 out of 98 patients had their last CT scans obtained within 3 days from the twice PCR test that turned negative.", [["lesions", "ANATOMY", 60, 67], ["GGO", "DISEASE", 92, 95], ["patients", "ORGANISM", 11, 19], ["residual lesions", "CANCER", 51, 67], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 132, 140], ["patients", "SPECIES", 253, 261], ["residual lesions", "PROBLEM", 51, 67], ["the final scans", "TEST", 71, 86], ["GGO", "TEST", 92, 95], ["reticulation", "PROBLEM", 114, 126], ["median CT score", "TEST", 142, 157], ["Results", "TEST", 233, 240], ["their last CT scans", "TEST", 266, 285], ["the twice PCR test", "TEST", 314, 332], ["residual", "OBSERVATION_MODIFIER", 51, 59], ["lesions", "OBSERVATION", 60, 67], ["reticulation", "OBSERVATION_MODIFIER", 114, 126]]], ["The last CT scans were obtained more than 3 days from the PCR turning negative for the other 4 patients.", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["The last CT scans", "TEST", 0, 17], ["the PCR", "TEST", 54, 61]]], ["Among the last CT scans for these 94 patients, the mixed pattern was mainly presented in patients with a disease duration of 2-3 weeks, for whom GGO and reticular were consistently the most common CT abnormalities during the whole course.", [["reticular", "ANATOMY", 153, 162], ["GGO", "DISEASE", 145, 148], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 89, 97], ["reticular", "CELLULAR_COMPONENT", 153, 162], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 89, 97], ["the last CT scans", "TEST", 6, 23], ["GGO", "PROBLEM", 145, 148], ["the most common CT abnormalities", "PROBLEM", 181, 213], ["reticular", "ANATOMY_MODIFIER", 153, 162], ["abnormalities", "OBSERVATION", 200, 213]]], ["Complete lesion absorption was observed for 4 (4/94) patients only.", [["lesion", "ANATOMY", 9, 15], ["lesion", "PATHOLOGICAL_FORMATION", 9, 15], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Complete lesion absorption", "PROBLEM", 0, 26], ["lesion", "OBSERVATION", 9, 15]]], ["Substantial residual lesions (median CT score \u22655) mainly existed in patients with the disease course of greater than 3 weeks (Table 4).Temporal changes of predominant imaging patterns ::: ResultsFour of the 98 patients (4%) developed mild unilateral (3/4 patients) and bilateral (1/4) pleural effusion at 6, 10, 23, and 27 days since symptom onset.", [["lesions", "ANATOMY", 21, 28], ["pleural", "ANATOMY", 285, 292], ["pleural effusion", "DISEASE", 285, 301], ["residual lesions", "PATHOLOGICAL_FORMATION", 12, 28], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 210, 218], ["patients", "ORGANISM", 255, 263], ["pleural", "ORGAN", 285, 292], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 210, 218], ["patients", "SPECIES", 255, 263], ["Substantial residual lesions", "PROBLEM", 0, 28], ["median CT score", "TEST", 30, 45], ["mild unilateral (3/4 patients)", "PROBLEM", 234, 264], ["bilateral (1/4) pleural effusion", "PROBLEM", 269, 301], ["symptom onset", "PROBLEM", 334, 347], ["residual", "OBSERVATION_MODIFIER", 12, 20], ["lesions", "OBSERVATION", 21, 28], ["disease", "OBSERVATION", 86, 93], ["mild", "OBSERVATION_MODIFIER", 234, 238], ["unilateral", "OBSERVATION_MODIFIER", 239, 249], ["bilateral", "ANATOMY_MODIFIER", 269, 278], ["pleural", "ANATOMY", 285, 292], ["effusion", "OBSERVATION", 293, 301]]], ["Mediastinal lymphadenopathy was not observed in our study.DiscussionIn this study, serial CT scans obtained in the cohort of Jianghan fangcang shelter hospital were analyzed to explore the temporal imaging changes from symptom onset.", [["Mediastinal lymphadenopathy", "ANATOMY", 0, 27], ["Mediastinal lymphadenopathy", "DISEASE", 0, 27], ["Mediastinal lymphadenopathy", "PROBLEM", 0, 27], ["our study", "TEST", 48, 57], ["this study", "TEST", 71, 81], ["serial CT scans", "TEST", 83, 98], ["the temporal imaging", "TEST", 185, 205], ["symptom onset", "PROBLEM", 219, 232], ["lymphadenopathy", "OBSERVATION", 12, 27]]], ["Lung injury in CT demonstrations developed remarkably after symptom onset and peaked in the second week, followed by a slow decrease of total CT scores.", [["Lung", "ANATOMY", 0, 4], ["Lung injury", "DISEASE", 0, 11], ["Lung", "ORGAN", 0, 4], ["Lung injury", "PROBLEM", 0, 11], ["CT demonstrations", "TEST", 15, 32], ["symptom onset", "PROBLEM", 60, 73], ["a slow decrease of total CT scores", "PROBLEM", 117, 151], ["injury", "OBSERVATION", 5, 11], ["slow", "OBSERVATION_MODIFIER", 119, 123], ["decrease", "OBSERVATION_MODIFIER", 124, 132]]], ["Remarkably, the median CT score in the 1st week from symptom onset was higher than those reported previously for COVID-19 patients 10, 16 and even SARS 6 patients.", [["SARS", "DISEASE", 147, 151], ["patients", "ORGANISM", 122, 130], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 122, 130], ["patients", "SPECIES", 154, 162], ["the median CT score", "TEST", 12, 31], ["symptom onset", "PROBLEM", 53, 66], ["COVID", "TEST", 113, 118]]], ["The peak of the CT score appeared in the 2nd week since symptom onset in our cohort, which was consistent with 6-11 days reported by Pan et al. 16 and Wang et al. 10 with COVID-19 patients and the 2nd week reported by Ooi et al. 6 for SARS patients, and which was, however, controversial to the rapid lung injury as presented for SARS and MERS 6, 17.", [["lung", "ANATOMY", 301, 305], ["SARS", "DISEASE", 235, 239], ["lung injury", "DISEASE", 301, 312], ["SARS", "DISEASE", 330, 334], ["patients", "ORGANISM", 180, 188], ["patients", "ORGANISM", 240, 248], ["lung", "ORGAN", 301, 305], ["patients", "SPECIES", 180, 188], ["patients", "SPECIES", 240, 248], ["the CT score", "TEST", 12, 24], ["symptom", "PROBLEM", 56, 63], ["COVID", "TEST", 171, 176], ["SARS", "PROBLEM", 235, 239], ["the rapid lung injury", "PROBLEM", 291, 312], ["SARS", "PROBLEM", 330, 334], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["rapid", "OBSERVATION_MODIFIER", 295, 300], ["lung", "ANATOMY", 301, 305], ["injury", "OBSERVATION", 306, 312]]], ["The high median CT score in the 1st week from symptom onset in our cohort was accompanied by longer median disease duration of 30 (26,36) days and hospitalized 18 (14,22) days, in contrast to the median disease duration of 25 (10, 56) days and hospitalized period of 18 (5, 43) days reported by Wang et al. 10 and the mean disease duration of 19 \u00b1 4 days and hospitalized period of 17\u00b14 days as reported in Pan et al. 16.", [["The high median CT score", "PROBLEM", 0, 24], ["longer median disease duration", "PROBLEM", 93, 123], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["These observations of high initial CT score and longer disease duration might be attributed to the older cohort in our study (49 \u00b1 12 years) as compared to the cohort ages of 40 \u00b1 9 years in Pan et al. 16 and 45 \u00b1 14 years in wang et al. 6, 10.", [["high initial CT score", "PROBLEM", 22, 43], ["longer disease duration", "PROBLEM", 48, 71]]], ["The patients reported in SARS 6 and MERS 17 studies were 42.5 \u00b1 12.2 years old and 44.2 \u00b1 16.1 years old, respectively, which might have led to a shorter disease course and, hence, the earlier CT score peak when compared to the cases in our cohort.", [["SARS", "DISEASE", 25, 29], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["SARS", "TEST", 25, 29], ["MERS 17 studies", "TEST", 36, 51], ["a shorter disease course", "PROBLEM", 144, 168], ["the earlier CT score", "TEST", 181, 201]]], ["The differences in treatments may be another cause of varying disease course.", [["treatments", "TREATMENT", 19, 29], ["varying disease course", "PROBLEM", 54, 76], ["varying", "OBSERVATION_MODIFIER", 54, 61], ["disease", "OBSERVATION", 62, 69]]], ["Oral antiviral agents, complaint management and symptomatic treatment were the main treatments in fangcang shelter hospitals 5, while oxygen treatment/high-flow nasal cannula, mechanical ventilation, glucocorticoids therapy and emergency extracorporeal membrane oxygenation (ECMO) were commonly used for severe patients in designated hospitals 2, 18.", [["Oral", "ANATOMY", 0, 4], ["nasal", "ANATOMY", 161, 166], ["extracorporeal membrane", "ANATOMY", 238, 261], ["oxygen", "CHEMICAL", 134, 140], ["glucocorticoids", "CHEMICAL", 200, 215], ["oxygen", "CHEMICAL", 134, 140], ["oxygen", "SIMPLE_CHEMICAL", 134, 140], ["patients", "ORGANISM", 311, 319], ["patients", "SPECIES", 311, 319], ["Oral antiviral agents", "TREATMENT", 0, 21], ["complaint management", "TREATMENT", 23, 43], ["symptomatic treatment", "TREATMENT", 48, 69], ["oxygen treatment", "TREATMENT", 134, 150], ["high-flow nasal cannula", "TREATMENT", 151, 174], ["mechanical ventilation", "TREATMENT", 176, 198], ["glucocorticoids therapy", "TREATMENT", 200, 223], ["emergency extracorporeal membrane oxygenation", "TREATMENT", 228, 273], ["ECMO", "TREATMENT", 275, 279], ["antiviral agents", "OBSERVATION", 5, 21], ["nasal cannula", "ANATOMY", 161, 174], ["mechanical ventilation", "OBSERVATION", 176, 198]]], ["Therefore, the similar peak time, despite the higher initial CT score, when compared to the previous reports might have revealed the progressive nature of the disease at the absence of complicated treatments in the fangcang shelter hospitals, which was also evidenced by the slow decrease and persistent high CT scores after the 2nd week in our study that was suggestive of the slow absorption of the COVID-19 lung lesions.", [["COVID-19 lung lesions", "ANATOMY", 401, 422], ["COVID-19 lung lesions", "CANCER", 401, 422], ["the disease", "PROBLEM", 155, 166], ["the slow decrease", "PROBLEM", 271, 288], ["persistent high CT scores", "PROBLEM", 293, 318], ["our study", "TEST", 341, 350], ["the slow absorption of the COVID-19 lung lesions", "PROBLEM", 374, 422], ["progressive", "OBSERVATION_MODIFIER", 133, 144], ["disease", "OBSERVATION", 159, 166], ["complicated", "OBSERVATION", 185, 196], ["slow", "OBSERVATION_MODIFIER", 275, 279], ["decrease", "OBSERVATION_MODIFIER", 280, 288], ["persistent", "OBSERVATION_MODIFIER", 293, 303], ["high", "OBSERVATION_MODIFIER", 304, 308], ["suggestive of", "UNCERTAINTY", 360, 373], ["slow", "OBSERVATION_MODIFIER", 378, 382], ["absorption", "OBSERVATION_MODIFIER", 383, 393], ["lung", "ANATOMY", 410, 414], ["lesions", "OBSERVATION", 415, 422]]], ["To confirm this speculation, we will review the data from multiple fangcang shelter hospitals for larger sample size and extended monitoring.DiscussionIn this work, predominant GGO was the commonest and earliest imaging finding within the first week after symptom onset, while consolidation became predominant in the second week.", [["GGO", "DISEASE", 177, 180], ["GGO", "CANCER", 177, 180], ["larger sample size", "TREATMENT", 98, 116], ["extended monitoring", "TEST", 121, 140], ["earliest imaging", "TEST", 203, 219], ["symptom onset", "PROBLEM", 256, 269], ["consolidation", "PROBLEM", 277, 290], ["size", "OBSERVATION_MODIFIER", 112, 116], ["consolidation", "OBSERVATION", 277, 290], ["predominant", "OBSERVATION_MODIFIER", 298, 309]]], ["Predominant GGO and consolidation have also been widely reported in previous studies as the common lung abnormalities within the first 2 weeks after symptom onset in COVID-19, SARS or MERS 6, 9-11, 16, 17, 19.", [["lung", "ANATOMY", 99, 103], ["lung abnormalities", "DISEASE", 99, 117], ["SARS", "DISEASE", 176, 180], ["lung", "ORGAN", 99, 103], ["Predominant GGO", "PROBLEM", 0, 15], ["consolidation", "PROBLEM", 20, 33], ["previous studies", "TEST", 68, 84], ["the common lung abnormalities", "PROBLEM", 88, 117], ["symptom", "PROBLEM", 149, 156], ["COVID", "TEST", 166, 171], ["SARS", "PROBLEM", 176, 180], ["MERS", "TEST", 184, 188], ["GGO", "OBSERVATION", 12, 15], ["consolidation", "OBSERVATION", 20, 33], ["widely", "OBSERVATION_MODIFIER", 49, 55], ["common", "ANATOMY_MODIFIER", 92, 98], ["lung", "ANATOMY", 99, 103], ["abnormalities", "OBSERVATION", 104, 117]]], ["A recent postmortem pathology study 20 for a patient with a 15-day disease course revealed the exudative change in the lung and the absence of severe fibrosis, suggesting diffuse alveolar damage in response to acute lung injury, which was supportive to the observed CT manifestations in the first 2 weeks.", [["lung", "ANATOMY", 119, 123], ["alveolar", "ANATOMY", 179, 187], ["lung", "ANATOMY", 216, 220], ["fibrosis", "DISEASE", 150, 158], ["alveolar damage", "DISEASE", 179, 194], ["acute lung injury", "DISEASE", 210, 227], ["patient", "ORGANISM", 45, 52], ["lung", "ORGAN", 119, 123], ["alveolar", "TISSUE", 179, 187], ["lung", "ORGAN", 216, 220], ["patient", "SPECIES", 45, 52], ["A recent postmortem pathology study", "TEST", 0, 35], ["the exudative change in the lung", "PROBLEM", 91, 123], ["severe fibrosis", "PROBLEM", 143, 158], ["diffuse alveolar damage", "PROBLEM", 171, 194], ["acute lung injury", "PROBLEM", 210, 227], ["the observed CT manifestations", "PROBLEM", 253, 283], ["exudative", "OBSERVATION_MODIFIER", 95, 104], ["change", "OBSERVATION", 105, 111], ["lung", "ANATOMY", 119, 123], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["fibrosis", "OBSERVATION", 150, 158], ["suggesting", "UNCERTAINTY", 160, 170], ["diffuse", "OBSERVATION_MODIFIER", 171, 178], ["alveolar damage", "OBSERVATION", 179, 194], ["acute", "OBSERVATION_MODIFIER", 210, 215], ["lung", "ANATOMY", 216, 220], ["injury", "OBSERVATION", 221, 227]]], ["The severity and distribution of gray-white patch lesions in the lung in the pathology had explained the predominant GGO in the early stage.", [["gray-white patch lesions", "ANATOMY", 33, 57], ["lung", "ANATOMY", 65, 69], ["GGO", "DISEASE", 117, 120], ["patch lesions", "PATHOLOGICAL_FORMATION", 44, 57], ["lung", "ORGAN", 65, 69], ["GGO", "CANCER", 117, 120], ["gray-white patch lesions", "PROBLEM", 33, 57], ["the predominant GGO", "PROBLEM", 101, 120], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["distribution", "OBSERVATION_MODIFIER", 17, 29], ["gray", "OBSERVATION_MODIFIER", 33, 37], ["white", "OBSERVATION_MODIFIER", 38, 43], ["patch", "OBSERVATION_MODIFIER", 44, 49], ["lesions", "OBSERVATION", 50, 57], ["lung", "ANATOMY", 65, 69], ["predominant", "OBSERVATION_MODIFIER", 105, 116], ["GGO", "OBSERVATION", 117, 120], ["early stage", "OBSERVATION_MODIFIER", 128, 139]]], ["The eventual consolidation was considered a result of cellular fibro-myxoid exudates in alveoli 21.DiscussionRadiological improvement occurred after the third week.", [["cellular fibro-myxoid exudates", "ANATOMY", 54, 84], ["alveoli 21", "ANATOMY", 88, 98], ["cellular", "CELL", 54, 62], ["myxoid exudates", "TISSUE", 69, 84], ["The eventual consolidation", "PROBLEM", 0, 26], ["cellular fibro-myxoid exudates", "PROBLEM", 54, 84], ["consolidation", "OBSERVATION", 13, 26], ["cellular fibro", "OBSERVATION", 54, 68], ["myxoid exudates", "OBSERVATION", 69, 84], ["alveoli", "ANATOMY_MODIFIER", 88, 95]]], ["For later stages (\u22654 weeks), predominant GGO and reticular pattern became common findings, inconsistency with the CT demonstrations of SARS 6, 22, 23 or ARDS 24.", [["reticular", "ANATOMY", 49, 58], ["SARS", "DISEASE", 135, 139], ["ARDS", "DISEASE", 153, 157], ["GGO", "CANCER", 41, 44], ["predominant GGO", "PROBLEM", 29, 44], ["the CT", "TEST", 110, 116], ["SARS", "TEST", 135, 139], ["ARDS", "TEST", 153, 157], ["predominant", "OBSERVATION_MODIFIER", 29, 40], ["GGO", "OBSERVATION", 41, 44], ["reticular", "ANATOMY_MODIFIER", 49, 58]]], ["However, Wang et al. 10 indicated GGO and mixed pattern were the common findings in the later stage of COVID-19 pneumonia, the cause of this difference remaining unclear.", [["pneumonia", "DISEASE", 112, 121], ["GGO", "CANCER", 34, 37], ["Wang et al.", "TEST", 9, 20], ["GGO", "PROBLEM", 34, 37], ["COVID-19 pneumonia", "PROBLEM", 103, 121], ["pneumonia", "OBSERVATION", 112, 121]]], ["Particularly, the reticular pattern experienced a persistent increase since the 2nd week in our study, and the lung involvement of GGO had an obvious decrease in the second week and increased after that.", [["reticular", "ANATOMY", 18, 27], ["lung", "ANATOMY", 111, 115], ["GGO", "DISEASE", 131, 134], ["lung", "ORGAN", 111, 115], ["our study", "TEST", 92, 101], ["the lung involvement of GGO", "PROBLEM", 107, 134], ["reticular", "ANATOMY_MODIFIER", 18, 27], ["persistent", "OBSERVATION_MODIFIER", 50, 60], ["increase", "OBSERVATION_MODIFIER", 61, 69], ["lung", "ANATOMY", 111, 115], ["GGO", "OBSERVATION", 131, 134], ["obvious", "OBSERVATION_MODIFIER", 142, 149], ["decrease", "OBSERVATION_MODIFIER", 150, 158], ["increased", "OBSERVATION_MODIFIER", 182, 191]]], ["Besides, GGO and reticular were the main patterns of later phase CT scans in patients with relatively advanced diseases who had longer illness duration (\u22654 weeks).", [["reticular", "ANATOMY", 17, 26], ["illness", "DISEASE", 135, 142], ["reticular", "CELLULAR_COMPONENT", 17, 26], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["GGO", "PROBLEM", 9, 12], ["later phase CT scans", "TEST", 53, 73], ["relatively advanced diseases", "PROBLEM", 91, 119], ["GGO", "OBSERVATION", 9, 12], ["reticular", "ANATOMY_MODIFIER", 17, 26], ["main", "OBSERVATION_MODIFIER", 36, 40]]], ["Elevation of GGO in later stages had also been reported before for both COVID-19 10 and SARS 6.", [["GGO", "DISEASE", 13, 16], ["SARS", "DISEASE", 88, 92], ["Elevation of GGO", "PROBLEM", 0, 16], ["COVID", "TEST", 72, 77], ["GGO", "OBSERVATION", 13, 16]]], ["Noticeably, patients with predominant reticular pattern in the late stages had significantly higher late-stage CT scores than those with late-stage predominant GGO, implying the appearance of GGO in later stage suggestive of better recovery of the illness 6, 10.", [["reticular", "ANATOMY", 38, 47], ["GGO", "DISEASE", 160, 163], ["GGO", "DISEASE", 192, 195], ["illness", "DISEASE", 248, 255], ["patients", "ORGANISM", 12, 20], ["GGO", "CANCER", 160, 163], ["patients", "SPECIES", 12, 20], ["predominant reticular pattern", "PROBLEM", 26, 55], ["significantly higher late-stage CT scores", "PROBLEM", 79, 120], ["late-stage predominant GGO", "PROBLEM", 137, 163], ["GGO", "PROBLEM", 192, 195], ["predominant", "OBSERVATION_MODIFIER", 26, 37], ["reticular", "OBSERVATION_MODIFIER", 38, 47], ["pattern", "OBSERVATION_MODIFIER", 48, 55], ["late stages", "OBSERVATION_MODIFIER", 63, 74], ["significantly", "OBSERVATION_MODIFIER", 79, 92], ["higher", "OBSERVATION_MODIFIER", 93, 99], ["late", "OBSERVATION_MODIFIER", 100, 104], ["-stage", "OBSERVATION_MODIFIER", 104, 110], ["stage predominant", "OBSERVATION_MODIFIER", 142, 159], ["GGO", "OBSERVATION", 160, 163], ["GGO", "OBSERVATION", 192, 195], ["suggestive of", "UNCERTAINTY", 211, 224], ["better", "OBSERVATION_MODIFIER", 225, 231], ["recovery", "OBSERVATION_MODIFIER", 232, 240]]], ["In contrast, substantial residual reticular pattern in later stage might indicate the possible development of fibrosis 25 or secondary organizing pneumonia 26.", [["reticular", "ANATOMY", 34, 43], ["fibrosis", "DISEASE", 110, 118], ["pneumonia", "DISEASE", 146, 155], ["substantial residual reticular pattern", "PROBLEM", 13, 51], ["fibrosis", "PROBLEM", 110, 118], ["secondary organizing pneumonia", "PROBLEM", 125, 155], ["substantial", "OBSERVATION_MODIFIER", 13, 24], ["residual", "OBSERVATION_MODIFIER", 25, 33], ["reticular pattern", "OBSERVATION", 34, 51], ["later stage", "OBSERVATION_MODIFIER", 55, 66], ["might indicate the possible", "UNCERTAINTY", 67, 94], ["fibrosis", "OBSERVATION", 110, 118], ["secondary", "OBSERVATION_MODIFIER", 125, 134], ["organizing", "OBSERVATION_MODIFIER", 135, 145], ["pneumonia", "OBSERVATION", 146, 155]]], ["Irreversible fibrosis might be too early to label due to uncharted nature history 6.", [["fibrosis", "DISEASE", 13, 21], ["Irreversible fibrosis", "PROBLEM", 0, 21], ["fibrosis", "OBSERVATION", 13, 21]]], ["Our observation raised the necessity of long-term follow-up in chest CT and concomitant functional tests to determine the long-term pulmonary sequelae of COVID-19 22.DiscussionAlthough all the patients in this cohort matched with the discharge criteria by the end of the study, varying residual lesions were still observed via CT.", [["chest", "ANATOMY", 63, 68], ["pulmonary", "ANATOMY", 132, 141], ["lesions", "ANATOMY", 295, 302], ["COVID-19", "CHEMICAL", 154, 162], ["pulmonary", "ORGAN", 132, 141], ["patients", "ORGANISM", 193, 201], ["lesions", "CANCER", 295, 302], ["patients", "SPECIES", 193, 201], ["chest CT", "TEST", 63, 71], ["concomitant functional tests", "TEST", 76, 104], ["COVID", "TEST", 154, 159], ["the study", "TEST", 267, 276], ["varying residual lesions", "PROBLEM", 278, 302], ["CT", "TEST", 327, 329], ["chest", "ANATOMY", 63, 68], ["pulmonary", "ANATOMY", 132, 141], ["residual", "OBSERVATION_MODIFIER", 286, 294], ["lesions", "OBSERVATION", 295, 302]]], ["In light of a recent report of 4 discharged patients with recurrent positive RT-PCR results 27, follow up of these patients is also necessary from the perspective of epidemic prevention.DiscussionThe current study was mainly limited as no severe patients were included.DiscussionIn conclusion, our study showed a high median total CT score of 7 within the first week from symptom onset, peaked at 2nd week, followed by persistence of high levels and a prolonged median disease course.", [["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 115, 123], ["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 246, 254], ["recurrent positive RT-PCR", "PROBLEM", 58, 83], ["epidemic prevention", "TREATMENT", 166, 185], ["The current study", "TEST", 196, 213], ["our study", "TEST", 294, 303], ["a high median total CT score", "PROBLEM", 311, 339], ["high levels", "PROBLEM", 434, 445], ["a prolonged median disease course", "PROBLEM", 450, 483], ["high levels", "OBSERVATION", 434, 445], ["median disease", "OBSERVATION", 462, 476]]], ["GGO was the predominant pattern in week 1, consolidation and mixed pattern in 2nd week, whereas GGO and reticular patterns in later stages (\u22654 weeks).HighlightsA high median total CT score of 7 within the first week from symptom onset, peaked at 2nd week, followed by persistence of high levels and a prolonged median disease course;Ground-glass opacity (GGO) was the earliest and most frequent finding in week 1.", [["reticular", "ANATOMY", 104, 113], ["GGO", "PROBLEM", 0, 3], ["consolidation", "PROBLEM", 43, 56], ["GGO", "PROBLEM", 96, 99], ["high levels", "PROBLEM", 283, 294], ["a prolonged median disease course", "PROBLEM", 299, 332], ["Ground-glass opacity", "PROBLEM", 333, 353], ["predominant", "OBSERVATION_MODIFIER", 12, 23], ["pattern", "OBSERVATION_MODIFIER", 24, 31], ["consolidation", "OBSERVATION", 43, 56], ["mixed", "OBSERVATION_MODIFIER", 61, 66], ["pattern", "OBSERVATION_MODIFIER", 67, 74], ["reticular", "OBSERVATION_MODIFIER", 104, 113], ["patterns", "OBSERVATION_MODIFIER", 114, 122], ["high levels", "OBSERVATION", 283, 294], ["glass opacity", "OBSERVATION", 340, 353]]], ["Consolidation and mixed pattern were predominant patterns in 2nd week.", [["Consolidation", "PROBLEM", 0, 13], ["mixed", "OBSERVATION_MODIFIER", 18, 23], ["pattern", "OBSERVATION_MODIFIER", 24, 31], ["predominant", "OBSERVATION_MODIFIER", 37, 48], ["patterns", "OBSERVATION_MODIFIER", 49, 57]]], ["GGO and reticular were the main patterns in the later stages of the disease;Among the 94 patients with CT abnormities obtained within 3 days from the twice RT-PCR test turned negative, GGO and reticular were common during the whole course.", [["reticular", "ANATOMY", 8, 17], ["reticular", "ANATOMY", 193, 202], ["reticular", "CELLULAR_COMPONENT", 8, 17], ["patients", "ORGANISM", 89, 97], ["reticular", "MULTI-TISSUE_STRUCTURE", 193, 202], ["patients", "SPECIES", 89, 97], ["GGO", "PROBLEM", 0, 3], ["the disease", "PROBLEM", 64, 75], ["CT abnormities", "TEST", 103, 117], ["the twice RT-PCR test", "TEST", 146, 167], ["GGO", "PROBLEM", 185, 188], ["reticular", "ANATOMY_MODIFIER", 8, 17], ["main", "OBSERVATION_MODIFIER", 27, 31], ["patterns", "OBSERVATION_MODIFIER", 32, 40], ["disease", "OBSERVATION", 68, 75], ["reticular", "ANATOMY_MODIFIER", 193, 202]]]], "PMC2361307": [["Cell culture ::: MATERIALS AND METHODSThe human melanoma cell lines BLM, Mel57, M14 and 1F6 were a kind gift of Dr JR Westphal and Dr W Leenders, University Medical Centre, St Radboud Nijmegen, Netherlands, and have been established from surgically removed melanoma metastases (Van Muijen et al, 1991).", [["Cell", "ANATOMY", 0, 4], ["melanoma cell lines BLM", "ANATOMY", 48, 71], ["Mel57", "ANATOMY", 73, 78], ["M14", "ANATOMY", 80, 83], ["melanoma metastases", "ANATOMY", 257, 276], ["melanoma", "DISEASE", 48, 56], ["melanoma", "DISEASE", 257, 265], ["Cell", "CELL", 0, 4], ["human", "ORGANISM", 42, 47], ["melanoma cell lines BLM", "CELL", 48, 71], ["Mel57", "CELL", 73, 78], ["M14", "CELL", 80, 83], ["1F6", "CELL", 88, 91], ["Dr JR Westphal", "CELL", 112, 126], ["Dr W Leenders", "CELL", 131, 144], ["melanoma", "CANCER", 257, 265], ["human melanoma cell lines", "CELL_LINE", 42, 67], ["BLM", "CELL_LINE", 68, 71], ["Mel57", "CELL_LINE", 73, 78], ["M14", "CELL_LINE", 80, 83], ["1F6", "CELL_LINE", 88, 91], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["Cell culture", "TEST", 0, 12], ["METHODSThe human melanoma cell lines BLM", "TREATMENT", 31, 71], ["surgically removed melanoma metastases", "PROBLEM", 238, 276], ["melanoma cell lines", "OBSERVATION", 48, 67], ["melanoma", "OBSERVATION_MODIFIER", 257, 265], ["metastases", "OBSERVATION", 266, 276]]], ["The BRO cell line has been derived from a highly malignant and aggressive primary melanoma (Lockshin et al, 1985).", [["BRO cell line", "ANATOMY", 4, 17], ["primary melanoma", "ANATOMY", 74, 90], ["primary melanoma", "DISEASE", 74, 90], ["BRO cell line", "CELL", 4, 17], ["primary melanoma", "CANCER", 74, 90], ["BRO cell line", "CELL_LINE", 4, 17], ["The BRO cell line", "TREATMENT", 0, 17], ["a highly malignant and aggressive primary melanoma", "PROBLEM", 40, 90], ["BRO cell line", "OBSERVATION", 4, 17], ["highly", "OBSERVATION_MODIFIER", 42, 48], ["malignant", "OBSERVATION_MODIFIER", 49, 58], ["aggressive", "OBSERVATION_MODIFIER", 63, 73], ["primary", "OBSERVATION_MODIFIER", 74, 81], ["melanoma", "OBSERVATION", 82, 90]]], ["Hep3B human hepatocellular carcinoma cells, HL60 human promyelocytic leukaemia cells and U937 human histiocytic lymphoma cells were obtained from American Type Culture Collection (ATCC, Manassa, VA, USA).", [["Hep3B", "ANATOMY", 0, 5], ["hepatocellular carcinoma cells", "ANATOMY", 12, 42], ["HL60", "ANATOMY", 44, 48], ["promyelocytic leukaemia cells", "ANATOMY", 55, 84], ["U937", "ANATOMY", 89, 93], ["histiocytic lymphoma cells", "ANATOMY", 100, 126], ["hepatocellular carcinoma", "DISEASE", 12, 36], ["promyelocytic leukaemia", "DISEASE", 55, 78], ["histiocytic lymphoma", "DISEASE", 100, 120], ["Hep3B", "CELL", 0, 5], ["human", "ORGANISM", 6, 11], ["hepatocellular carcinoma cells", "CELL", 12, 42], ["HL60", "CELL", 44, 48], ["human", "ORGANISM", 49, 54], ["promyelocytic leukaemia cells", "CELL", 55, 84], ["U937", "CELL", 89, 93], ["human", "ORGANISM", 94, 99], ["histiocytic lymphoma cells", "CELL", 100, 126], ["Hep3B human hepatocellular carcinoma cells", "CELL_LINE", 0, 42], ["HL60 human promyelocytic leukaemia cells", "CELL_LINE", 44, 84], ["U937 human histiocytic lymphoma cells", "CELL_LINE", 89, 126], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 94, 99], ["ATCC", "SPECIES", 180, 184], ["Hep3B human hepatocellular carcinoma cells", "PROBLEM", 0, 42], ["HL60 human promyelocytic leukaemia cells", "PROBLEM", 44, 84], ["U937 human histiocytic lymphoma cells", "PROBLEM", 89, 126], ["hepatocellular", "ANATOMY", 12, 26], ["carcinoma cells", "OBSERVATION", 27, 42], ["HL60 human promyelocytic leukaemia cells", "OBSERVATION", 44, 84], ["U937 human", "OBSERVATION", 89, 99], ["histiocytic lymphoma", "OBSERVATION", 100, 120]]], ["Cell lines and 1F6 clones highly (H) or lowly (L) overexpressing the 18kD isoform of human bFGF (1F6-18kD-H and 1F6-18kD-L), all isoforms of bFGF (1F6-ALL-H and 1F6-ALL-L) or control empty vector cells (1F6-pcDNA3) have been described (Fontijn et al, unpublished data).", [["Cell lines", "ANATOMY", 0, 10], ["1F6 clones", "ANATOMY", 15, 25], ["1F6-ALL-L", "ANATOMY", 161, 170], ["cells", "ANATOMY", 196, 201], ["Cell lines", "CELL", 0, 10], ["1F6 clones", "CELL", 15, 25], ["human", "ORGANISM", 85, 90], ["bFGF", "GENE_OR_GENE_PRODUCT", 91, 95], ["bFGF", "GENE_OR_GENE_PRODUCT", 141, 145], ["1F6-ALL-L", "CELL", 161, 170], ["cells", "CELL", 196, 201], ["1F6-pcDNA3", "GENE_OR_GENE_PRODUCT", 203, 213], ["Cell lines", "CELL_LINE", 0, 10], ["1F6 clones", "CELL_LINE", 15, 25], ["18kD isoform", "PROTEIN", 69, 81], ["human bFGF", "PROTEIN", 85, 95], ["1F6", "PROTEIN", 97, 100], ["18kD", "PROTEIN", 101, 105], ["H", "PROTEIN", 106, 107], ["1F6", "PROTEIN", 112, 115], ["18kD", "PROTEIN", 116, 120], ["bFGF", "PROTEIN", 141, 145], ["1F6", "PROTEIN", 147, 150], ["1F6", "PROTEIN", 161, 164], ["1F6", "PROTEIN", 203, 206], ["pcDNA3", "DNA", 207, 213], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["Cell lines", "TREATMENT", 0, 10], ["1F6 clones", "TEST", 15, 25], ["human bFGF", "TEST", 85, 95], ["1F6", "TEST", 112, 115], ["bFGF", "TEST", 141, 145], ["1F6", "TEST", 161, 164], ["vector cells", "OBSERVATION", 189, 201]]], ["Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Bio Whittaker, Verviers, Belgium) supplemented with 10% heat-inactivated fetal calf serum (FCS; Gibco Invitrogen, Breda, the Netherlands), 50 U ml\u22121 penicillin (ICN Biochemicals, Zoetermeer, the Netherlands) and 50 \u03bcg ml\u22121 streptomycin (ICN Biochemicals).", [["Cells", "ANATOMY", 0, 5], ["fetal calf serum", "ANATOMY", 138, 154], ["penicillin", "CHEMICAL", 214, 224], ["streptomycin", "CHEMICAL", 288, 300], ["penicillin", "CHEMICAL", 214, 224], ["streptomycin", "CHEMICAL", 288, 300], ["Cells", "CELL", 0, 5], ["calf", "ORGANISM", 144, 148], ["serum", "ORGANISM_SUBSTANCE", 149, 154], ["penicillin", "SIMPLE_CHEMICAL", 214, 224], ["streptomycin", "SIMPLE_CHEMICAL", 288, 300], ["calf", "SPECIES", 144, 148], ["Cells", "TEST", 0, 5], ["Dulbecco", "TEST", 23, 31], ["fetal calf serum", "TEST", 138, 154], ["FCS", "TEST", 156, 159], ["1 penicillin", "TREATMENT", 212, 224], ["Zoetermeer", "TREATMENT", 244, 254], ["1 streptomycin", "TREATMENT", 286, 300], ["fetal calf", "ANATOMY", 138, 148]]], ["In addition, bFGF-overexpressing 1F6 clones were cultured in the presence of 500 \u03bcg ml\u22121 geneticin (Gibco/Invitrogen) to maintain selection for bFGF overexpression.", [["1F6 clones", "ANATOMY", 33, 43], ["geneticin", "CHEMICAL", 89, 98], ["geneticin", "CHEMICAL", 89, 98], ["bFGF", "GENE_OR_GENE_PRODUCT", 13, 17], ["1F6 clones", "CELL", 33, 43], ["bFGF", "GENE_OR_GENE_PRODUCT", 144, 148], ["bFGF", "PROTEIN", 13, 17], ["1F6 clones", "CELL_LINE", 33, 43], ["bFGF", "PROTEIN", 144, 148], ["bFGF", "TEST", 13, 17], ["overexpressing 1F6 clones", "PROBLEM", 18, 43], ["Gibco/Invitrogen", "TREATMENT", 100, 116], ["bFGF overexpression", "PROBLEM", 144, 163]]], ["All cells were grown at 37\u00b0C in humidified air containing 5% CO2.Isolation of RNA and RT\u2013PCR ::: MATERIALS AND METHODSTotal RNA of cell lines was isolated using Trizol reagent (Gibco/Invitrogen) according to the manufacturer's protocol.", [["cells", "ANATOMY", 4, 9], ["cell lines", "ANATOMY", 131, 141], ["CO2", "CHEMICAL", 61, 64], ["CO2", "CHEMICAL", 61, 64], ["cells", "CELL", 4, 9], ["CO2", "SIMPLE_CHEMICAL", 61, 64], ["cell lines", "CELL", 131, 141], ["cell lines", "CELL_LINE", 131, 141], ["All cells", "PROBLEM", 0, 9], ["5% CO2", "TREATMENT", 58, 64], ["Isolation of RNA", "TREATMENT", 65, 81], ["RT\u2013PCR", "TEST", 86, 92], ["cell lines", "TREATMENT", 131, 141], ["Trizol reagent", "TREATMENT", 161, 175], ["Gibco/Invitrogen)", "TREATMENT", 177, 194], ["the manufacturer's protocol", "TREATMENT", 208, 235], ["cell lines", "OBSERVATION", 131, 141]]], ["RNA (3 \u03bcg) was reverse-transcribed with 50 U MMLV reverse transcriptase (Invitrogen) in the presence of 1.2 \u03bcl 0.5 \u03bcg ml\u22121 random primers.Isolation of RNA and RT\u2013PCR ::: MATERIALS AND METHODSQuantitative Light Cycler RT\u2013PCR was used to determine bFGF and CD13 mRNA in melanoma cells and bFGF-overexpressing 1F6 clones (Van Hensbergen et al, 2003) mRNA was analysed with the LightCycler-Faststart DNA Master Hybridization Probes kSYBR Green 1 kit (Roche Diagnostics, Mannheim, Germany).", [["melanoma cells", "ANATOMY", 268, 282], ["1F6 clones", "ANATOMY", 307, 317], ["melanoma", "DISEASE", 268, 276], ["MMLV reverse transcriptase", "GENE_OR_GENE_PRODUCT", 45, 71], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 73, 83], ["bFGF", "GENE_OR_GENE_PRODUCT", 246, 250], ["CD13", "GENE_OR_GENE_PRODUCT", 255, 259], ["melanoma cells", "CELL", 268, 282], ["bFGF", "GENE_OR_GENE_PRODUCT", 287, 291], ["1F6 clones", "CELL", 307, 317], ["DNA", "CELLULAR_COMPONENT", 396, 399], ["RNA", "RNA", 0, 3], ["50 U MMLV reverse transcriptase", "PROTEIN", 40, 71], ["bFGF and CD13 mRNA", "RNA", 246, 264], ["melanoma cells", "CELL_TYPE", 268, 282], ["bFGF-overexpressing 1F6 clones", "CELL_LINE", 287, 317], ["2003) mRNA", "RNA", 341, 351], ["RNA", "TEST", 0, 3], ["50 U MMLV reverse transcriptase", "TREATMENT", 40, 71], ["Isolation of RNA", "TREATMENT", 138, 154], ["RT\u2013PCR", "TEST", 159, 165], ["Cycler RT\u2013PCR", "TEST", 210, 223], ["bFGF", "TEST", 246, 250], ["CD13 mRNA in melanoma cells", "PROBLEM", 255, 282], ["bFGF", "TEST", 287, 291], ["the LightCycler", "TEST", 370, 385], ["melanoma cells", "OBSERVATION", 268, 282]]], ["The human bFGF (sense: 5\u2032-TGTGCTAACCGTTACCTGGC-3\u2032, antisense: 5\u2032-ATAGCTTTCCCAGGTCC-3\u2032), CD13 (sense: 5\u2032-GTAATACGACTCACTATAGGGCCAGGGGCCTGTACGTTTTTA-3\u2032, antisense: 5\u2032-AATTAACCCTCACTAAAGGGCCACCAGCTCAGTCTTGTCA-3\u2032) and, as internal controls, human \u03b22-microglobulin (sense: 5\u2032-GATGAGTATGCCTGCCGTGTG-3\u2032, antisense: 5\u2032-CAATCCAAATGCGGCATCT-3\u2032), GAPDH (sense: 5\u2032-ACCACAGTCCATGCCATCAC-3\u2032, antisense: 5\u2032-TCCACCACCCTGTTGCTGTA-3\u2032) and PDGB (sense: 5\u2032-TCCAAGCGGAGCCATGTCTG-3\u2032, antisense: AGAATCTTGTCCCCTGTGGTGGA-3\u2032) genes were amplified according to the manufacturer's protocol.", [["human", "ORGANISM", 4, 9], ["bFGF", "GENE_OR_GENE_PRODUCT", 10, 14], ["CD13", "GENE_OR_GENE_PRODUCT", 88, 92], ["human", "ORGANISM", 237, 242], ["\u03b22-microglobulin", "GENE_OR_GENE_PRODUCT", 243, 259], ["GAPDH", "GENE_OR_GENE_PRODUCT", 336, 341], ["PDGB", "GENE_OR_GENE_PRODUCT", 421, 425], ["AGAATCTTGTCCCCTGTGGTGGA-3\u2032", "GENE_OR_GENE_PRODUCT", 473, 499], ["human bFGF", "PROTEIN", 4, 14], ["CD13", "PROTEIN", 88, 92], ["human \u03b22-microglobulin", "DNA", 237, 259], ["GAPDH", "DNA", 336, 341], ["PDGB", "DNA", 421, 425], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 237, 242], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 237, 242], ["The human bFGF", "TEST", 0, 14], ["TGTGCTAACCGTTACCTGGC", "TEST", 26, 46], ["antisense", "TEST", 51, 60], ["ATAGCTTTCCCAGGTCC", "TEST", 65, 82], ["CD13", "TEST", 88, 92], ["sense", "TEST", 94, 99], ["GTAATACGACTCACTATAGGGCCAGGGGCCTGTACGTTTTTA", "TEST", 104, 146], ["antisense", "TEST", 151, 160], ["AATTAACCCTCACTAAAGGGCCACCAGCTCAGTCTTGTCA", "TEST", 165, 205], ["GATGAGTATGCCTGCCGTGTG", "TEST", 271, 292], ["antisense", "TEST", 297, 306], ["CAATCCAAATGCGGCATCT", "TEST", 311, 330], ["GAPDH", "TEST", 336, 341], ["sense", "TEST", 343, 348], ["\u2032", "TEST", 351, 352], ["ACCACAGTCCATGCCATCAC", "TEST", 353, 373], ["antisense", "TEST", 378, 387], ["TCCACCACCCTGTTGCTGTA", "TEST", 392, 412], ["PDGB", "TEST", 421, 425], ["sense", "TEST", 427, 432], ["TCCAAGCGGAGCCATGTCTG", "TEST", 437, 457], ["AGAATCTTGTCCCCTGTGGTGGA", "TEST", 473, 496], ["CD13", "ANATOMY", 88, 92]]], ["In short, the reaction mix contained 4 mM MgCl2, 0.5 \u03bcM sense and antisense primer, 1 \u00d7 FastStart DNA Master SYBR Green 1 mix (containing LightCycler-Faststart Enzyme, FastStart Taq DNA polymerase, SYBR green dye, dNTPs and reaction buffer) and 2 \u03bcl cDNA.", [["MgCl2", "CHEMICAL", 42, 47], ["SYBR green dye", "CHEMICAL", 198, 212], ["dNTPs", "CHEMICAL", 214, 219], ["MgCl2", "CHEMICAL", 42, 47], ["dNTPs", "CHEMICAL", 214, 219], ["MgCl2", "SIMPLE_CHEMICAL", 42, 47], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["DNA", "CELLULAR_COMPONENT", 182, 185], ["SYBR green dye", "GENE_OR_GENE_PRODUCT", 198, 212], ["dNTPs", "SIMPLE_CHEMICAL", 214, 219], ["FastStart Taq DNA polymerase", "PROTEIN", 168, 196], ["\u03bcl cDNA", "DNA", 247, 254], ["4 mM MgCl2", "TREATMENT", 37, 47], ["antisense primer", "TREATMENT", 66, 82], ["LightCycler", "TEST", 138, 149], ["Enzyme", "TEST", 160, 166], ["FastStart", "TEST", 168, 177], ["Taq DNA polymerase", "TEST", 178, 196], ["dNTPs and reaction buffer", "TREATMENT", 214, 239]]], ["Polymerase chain reaction conditions were as follows: 95\u00b0C for 10 min followed by 40 cycles at 95\u00b0C for 10 s, 60\u00b0C for 10 s and 72\u00b0C for 22 s. cDNA was replaced by PCR-grade water as a negative control.", [["Polymerase chain reaction conditions", "PROBLEM", 0, 36], ["cDNA", "TEST", 143, 147], ["PCR", "TEST", 164, 167]]], ["Relative expression levels of different samples were calculated from bFGF crossing points normalised to \u03b22-microglobulin.", [["samples", "ANATOMY", 40, 47], ["bFGF", "GENE_OR_GENE_PRODUCT", 69, 73], ["\u03b22-microglobulin", "GENE_OR_GENE_PRODUCT", 104, 120], ["bFGF", "PROTEIN", 69, 73], ["\u03b22", "PROTEIN", 104, 106], ["Relative expression levels of different samples", "PROBLEM", 0, 47]]], ["Relative mRNA expression was calculated by: (E\u0394Cp target gene)/(E\u0394Cp reference gene), in which E=efficiency and \u0394Cp=crossing point when compared to 1F6 or 1F6-pcDNA3 cells.", [["1F6-pcDNA3 cells", "ANATOMY", 155, 171], ["1F6-pcDNA3 cells", "CELL", 155, 171], ["E\u0394Cp target gene", "DNA", 45, 61], ["E\u0394Cp reference gene", "DNA", 64, 83], ["1F6", "CELL_LINE", 148, 151], ["1F6", "CELL_LINE", 155, 158], ["pcDNA3 cells", "CELL_LINE", 159, 171], ["\u0394Cp", "PROBLEM", 112, 115]]], ["Primer efficiencies were determined using pooled cDNAs.Isolation of RNA and RT\u2013PCR ::: MATERIALS AND METHODSIn experiments designed to investigate the effect of bFGF overexpression on CD13 mRNA stability, cells were made quiescent in serum-free medium for 24 h.", [["cells", "ANATOMY", 205, 210], ["serum", "ANATOMY", 234, 239], ["bFGF", "GENE_OR_GENE_PRODUCT", 161, 165], ["CD13", "GENE_OR_GENE_PRODUCT", 184, 188], ["cells", "CELL", 205, 210], ["serum", "ORGANISM_SUBSTANCE", 234, 239], ["cDNAs", "DNA", 49, 54], ["bFGF", "PROTEIN", 161, 165], ["CD13 mRNA", "RNA", 184, 193], ["Primer efficiencies", "PROBLEM", 0, 19], ["Isolation of RNA", "TREATMENT", 55, 71], ["RT\u2013PCR", "TEST", 76, 82], ["METHODSIn experiments", "TREATMENT", 101, 122], ["bFGF overexpression", "TREATMENT", 161, 180], ["CD13 mRNA stability", "TEST", 184, 203]]], ["Next, cells were preincubated with 1 \u03bcg ml\u22121 actinomycin D (Sigma-Aldrich chemie, Zwijndrecht, the Netherlands) for 1 h in serum-free medium (time point=0 h) and, thereafter, harvested after incubation for 1, 2, 3 and 5 h with 1 \u03bcg ml\u22121 actinomycin D in serum-free medium.", [["cells", "ANATOMY", 6, 11], ["serum", "ANATOMY", 123, 128], ["serum", "ANATOMY", 254, 259], ["actinomycin D", "CHEMICAL", 45, 58], ["actinomycin D", "CHEMICAL", 237, 250], ["actinomycin D", "CHEMICAL", 45, 58], ["actinomycin D", "CHEMICAL", 237, 250], ["cells", "CELL", 6, 11], ["actinomycin D", "SIMPLE_CHEMICAL", 45, 58], ["Sigma-Aldrich chemie", "SIMPLE_CHEMICAL", 60, 80], ["serum", "ORGANISM_SUBSTANCE", 123, 128], ["actinomycin D", "SIMPLE_CHEMICAL", 237, 250], ["serum", "ORGANISM_SUBSTANCE", 254, 259], ["1 \u03bcg ml\u22121 actinomycin D", "TREATMENT", 227, 250]]], ["At each time \u2013point, CD13 mRNA levels were determined by Light Cycler RT\u2013PCR.Isolation of RNA and RT\u2013PCR ::: MATERIALS AND METHODSExpression of fragments derived from activity of the myeloid (MP) or both the myeloid and epithelial (MP/EP) promoters of CD13 was determined by RT\u2013PCR.", [["fragments", "ANATOMY", 144, 153], ["myeloid", "ANATOMY", 183, 190], ["MP", "ANATOMY", 192, 194], ["myeloid", "ANATOMY", 208, 215], ["epithelial", "ANATOMY", 220, 230], ["CD13", "GENE_OR_GENE_PRODUCT", 21, 25], ["myeloid", "CELL", 183, 190], ["MP", "CELL", 192, 194], ["myeloid", "CELL", 208, 215], ["epithelial", "TISSUE", 220, 230], ["CD13", "GENE_OR_GENE_PRODUCT", 252, 256], ["CD13 mRNA", "RNA", 21, 30], ["myeloid and epithelial (MP/EP) promoters", "DNA", 208, 248], ["CD13", "PROTEIN", 252, 256], ["CD13 mRNA levels", "TEST", 21, 37], ["Light Cycler RT\u2013PCR", "TEST", 57, 76], ["Isolation of RNA", "TREATMENT", 77, 93], ["RT\u2013PCR", "TEST", 98, 104], ["fragments", "PROBLEM", 144, 153], ["epithelial (MP/EP) promoters", "TREATMENT", 220, 248], ["CD13", "TEST", 252, 256], ["RT\u2013PCR", "TEST", 275, 281], ["fragments", "OBSERVATION", 144, 153], ["myeloid", "ANATOMY", 183, 190], ["myeloid", "ANATOMY", 208, 215], ["epithelial", "ANATOMY_MODIFIER", 220, 230]]], ["In total, 2 \u03bcl cDNA was subjected to 38 PCR cycles with the sense primers CD13 MP: 5\u2032-AGTCCAGGGTCCAGGTTCCA-3\u2032 and CD13 MP/EP: 5\u2032-ATGGCCAAGGGCTTCTATAT-3\u2032 and the shared antisense primer CD13 MP/EP: 5\u2032-ACGCTTTACTTTGGTCCAA-3\u2032.", [["CD13", "GENE_OR_GENE_PRODUCT", 74, 78], ["CD13 MP", "GENE_OR_GENE_PRODUCT", 114, 121], ["CD13", "GENE_OR_GENE_PRODUCT", 185, 189], ["\u03bcl cDNA", "DNA", 12, 19], ["CD13 MP", "DNA", 114, 121], ["EP", "DNA", 122, 124], ["antisense primer CD13 MP", "DNA", 168, 192], ["EP: 5\u2032-ACGCTTTACTTTGGTCCAA-3\u2032", "DNA", 193, 222], ["2 \u03bcl cDNA", "TREATMENT", 10, 19], ["PCR cycles", "TEST", 40, 50], ["the sense primers", "TEST", 56, 73], ["MP", "TEST", 79, 81], ["\u2032", "TEST", 84, 85], ["AGTCCAGGGTCCAGGTTCCA", "TEST", 86, 106], ["CD13", "TEST", 114, 118], ["MP", "TEST", 119, 121], ["EP", "TEST", 122, 124], ["\u2032", "TEST", 127, 128], ["ATGGCCAAGGGCTTCTATAT", "TEST", 129, 149], ["MP", "TEST", 190, 192], ["EP", "TEST", 193, 195], ["ACGCTTTACTTTGGTCCAA", "TEST", 200, 219]]], ["As an internal control, \u03b22-microglobulin expression was detected in the same samples.", [["samples", "ANATOMY", 77, 84], ["\u03b22-microglobulin", "GENE_OR_GENE_PRODUCT", 24, 40], ["\u03b22", "PROTEIN", 24, 26], ["an internal control", "TREATMENT", 3, 22], ["\u03b22-microglobulin expression", "TREATMENT", 24, 51]]], ["Polymerase chain reaction conditions were as follows: 3 min hotstart at 94\u00b0C followed by a 30 s denaturation step at 94\u00b0C, annealing at 56\u00b0C for 30 s, elongation at 72\u00b0C for 30 s.", [["Polymerase chain reaction conditions", "PROBLEM", 0, 36]]], ["Amplification products were separated on a 1% agarose gel containing 1 \u03bcg ml\u22121 ethidium bromide (Invitrogen) and analysed in a qualitative way using a Geldoc system (Bio-rad Laboratories, Veenendaal, the Netherlands).Western blot ::: MATERIALS AND METHODSMelanoma cell lines and bFGF-overexpressing 1F6 clones were lysed in ice-cold FOS-RIPA lysis buffer (10 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 0.1% NP-40 and 0.1% sodium deoxycholate) supplemented with 0.5 mM trypsin inhibitor (Sigma-Aldrich), 0.5 \u03bcg ml\u22121 leupeptin (Sigma-Aldrich), 1 mM PMSF (Merck, Amsterdam, the Netherlands), 0.1 mM sodium ortho vanadate (Sigma-Aldrich) and 50 mM sodium fluoride (Baker Chemicals, Deventer, the Netherlands) for 10 min on ice.", [["METHODSMelanoma cell lines", "ANATOMY", 248, 274], ["1F6 clones", "ANATOMY", 299, 309], ["ethidium bromide", "CHEMICAL", 79, 95], ["Tris-HCl", "CHEMICAL", 362, 370], ["NaCl", "CHEMICAL", 379, 383], ["NP-40", "CHEMICAL", 400, 405], ["sodium deoxycholate", "CHEMICAL", 415, 434], ["sodium ortho vanadate", "CHEMICAL", 589, 610], ["Sigma-Aldrich", "CHEMICAL", 612, 625], ["sodium fluoride", "CHEMICAL", 637, 652], ["ethidium bromide", "CHEMICAL", 79, 95], ["Tris-HCl", "CHEMICAL", 362, 370], ["NaCl", "CHEMICAL", 379, 383], ["sodium deoxycholate", "CHEMICAL", 415, 434], ["leupeptin", "CHEMICAL", 508, 517], ["PMSF", "CHEMICAL", 540, 544], ["sodium ortho vanadate", "CHEMICAL", 589, 610], ["sodium fluoride", "CHEMICAL", 637, 652], ["agarose", "SIMPLE_CHEMICAL", 46, 53], ["ethidium bromide", "SIMPLE_CHEMICAL", 79, 95], ["Invitrogen", "SIMPLE_CHEMICAL", 97, 107], ["METHODSMelanoma cell lines", "CELL", 248, 274], ["bFGF", "GENE_OR_GENE_PRODUCT", 279, 283], ["1F6 clones", "CELL", 299, 309], ["Tris-HCl", "SIMPLE_CHEMICAL", 362, 370], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 415, 434], ["trypsin", "GENE_OR_GENE_PRODUCT", 461, 468], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 480, 493], ["leupeptin", "SIMPLE_CHEMICAL", 508, 517], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 519, 532], ["PMSF", "SIMPLE_CHEMICAL", 540, 544], ["sodium ortho vanadate", "SIMPLE_CHEMICAL", 589, 610], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 612, 625], ["sodium fluoride", "SIMPLE_CHEMICAL", 637, 652], ["METHODSMelanoma cell lines", "CELL_LINE", 248, 274], ["bFGF-overexpressing 1F6 clones", "CELL_LINE", 279, 309], ["Amplification products", "TREATMENT", 0, 22], ["a 1% agarose gel", "TREATMENT", 41, 57], ["1 \u03bcg ml\u22121 ethidium bromide", "TREATMENT", 69, 95], ["a Geldoc system", "TREATMENT", 149, 164], ["METHODSMelanoma cell lines", "TREATMENT", 248, 274], ["bFGF", "TEST", 279, 283], ["overexpressing 1F6 clones", "TREATMENT", 284, 309], ["RIPA lysis buffer", "TREATMENT", 337, 354], ["mM NaCl", "TREATMENT", 376, 383], ["0.1% sodium deoxycholate)", "TREATMENT", 410, 435], ["0.5 mM trypsin inhibitor", "TREATMENT", 454, 478], ["Sigma-Aldrich)", "TREATMENT", 480, 494], ["0.1 mM sodium ortho vanadate", "TREATMENT", 582, 610], ["Sigma-Aldrich)", "TREATMENT", 612, 626], ["50 mM sodium fluoride", "TREATMENT", 631, 652], ["cell lines", "OBSERVATION", 264, 274]]], ["Lysates were centrifuged for 15 min at 13 000 r.p.m. at 4\u00b0C to remove debris.", [["Lysates", "ANATOMY", 0, 7], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["C", "SIMPLE_CHEMICAL", 58, 59], ["Lysates", "TEST", 0, 7], ["debris", "PROBLEM", 70, 76], ["debris", "OBSERVATION", 70, 76]]], ["Protein concentrations of cell lysates were measured according to Bradford (1976).Western blot ::: MATERIALS AND METHODSProteins were denatured by addition of sample buffer containing \u03b2-mercapto ethanol and incubation at 95\u00b0C for 5 min.", [["cell lysates", "ANATOMY", 26, 38], ["\u03b2-mercapto ethanol", "CHEMICAL", 184, 202], ["\u03b2-mercapto ethanol", "CHEMICAL", 184, 202], ["cell lysates", "ORGANISM_SUBSTANCE", 26, 38], ["\u03b2-mercapto ethanol", "SIMPLE_CHEMICAL", 184, 202], ["Protein concentrations", "TEST", 0, 22], ["cell lysates", "TEST", 26, 38], ["METHODSProteins", "TREATMENT", 113, 128], ["sample buffer containing \u03b2-mercapto ethanol", "TREATMENT", 159, 202], ["cell lysates", "OBSERVATION", 26, 38]]], ["Proteins were subjected to SDS\u2013PAGE on a 12% polyacrylamide gel and electrophoretically transferred to a polyvinylidene difluoride membrane (Immobilon; Millipore, Etten-Leur, the Netherlands).", [["polyacrylamide", "CHEMICAL", 45, 59], ["polyvinylidene", "CHEMICAL", 105, 119], ["difluoride", "CHEMICAL", 120, 130], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["a 12% polyacrylamide gel", "TREATMENT", 39, 63], ["a polyvinylidene difluoride membrane", "TREATMENT", 103, 139], ["Millipore", "TREATMENT", 152, 161]]], ["Membranes were blocked for 1 h in TBST (10 mM Tris pH 8, 150 mM l\u22121 NaCl and 0.025% Tween 20)/5% milk and incubated overnight with 0.2 \u03bcg ml\u22121 rabbit polyclonal human bFGF-directed antiserum (sc-79; Santa Cruz Biotechnology, Heerhugowaard, the Netherlands) or 0.5 \u03bcg ml\u22121 mouse polyclonal human CD13-directed antiserum (3D8; Santa Cruz Biotechnology) in TBST/5% milk.", [["Membranes", "ANATOMY", 0, 9], ["milk", "ANATOMY", 97, 101], ["milk", "ANATOMY", 362, 366], ["NaCl", "CHEMICAL", 68, 72], ["NaCl", "CHEMICAL", 68, 72], ["Tween 20", "CHEMICAL", 84, 92], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["milk", "ORGANISM_SUBSTANCE", 97, 101], ["rabbit", "ORGANISM", 143, 149], ["human", "ORGANISM", 161, 166], ["bFGF", "GENE_OR_GENE_PRODUCT", 167, 171], ["mouse", "ORGANISM", 272, 277], ["human", "ORGANISM", 289, 294], ["CD13", "GENE_OR_GENE_PRODUCT", 295, 299], ["milk", "ORGANISM_SUBSTANCE", 362, 366], ["bFGF", "PROTEIN", 167, 171], ["ml\u22121 mouse polyclonal human CD13-directed antiserum (3D8; Santa Cruz Biotechnology", "PROTEIN", 267, 349], ["rabbit", "SPECIES", 143, 149], ["human", "SPECIES", 161, 166], ["mouse", "SPECIES", 272, 277], ["human", "SPECIES", 289, 294], ["rabbit", "SPECIES", 143, 149], ["human", "SPECIES", 161, 166], ["mouse", "SPECIES", 272, 277], ["human", "SPECIES", 289, 294], ["TBST", "TEST", 34, 38], ["Tris pH", "TEST", 46, 53], ["150 mM l\u22121 NaCl", "TREATMENT", 57, 72], ["mouse polyclonal human CD13-directed antiserum", "TREATMENT", 272, 318]]], ["After washing with TBST, bFGF and CD13 membranes were incubated for 1 h at room temperature with, respectively, horseradish peroxidase-conjugated mouse anti-rabbit IgG (1 : 2000 dilution; Cell Signalling Technology, Heerhugowaard, the Netherlands) or with horseradish peroxidase-conjugated rabbit anti-mouse IgG (dilution 1 : 500; DAKO Cytomation, Heverlee, the Netherlands) in TBST/5% milk.", [["CD13 membranes", "ANATOMY", 34, 48], ["Cell", "ANATOMY", 188, 192], ["milk", "ANATOMY", 386, 390], ["bFGF", "GENE_OR_GENE_PRODUCT", 25, 29], ["CD13", "GENE_OR_GENE_PRODUCT", 34, 38], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 112, 134], ["mouse", "ORGANISM", 146, 151], ["Cell", "CELL", 188, 192], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 256, 278], ["rabbit", "ORGANISM", 290, 296], ["milk", "ORGANISM_SUBSTANCE", 386, 390], ["bFGF", "PROTEIN", 25, 29], ["CD13", "PROTEIN", 34, 38], ["horseradish peroxidase", "PROTEIN", 112, 134], ["conjugated mouse anti-rabbit IgG", "PROTEIN", 135, 167], ["horseradish peroxidase", "PROTEIN", 256, 278], ["conjugated rabbit anti-mouse IgG", "PROTEIN", 279, 311], ["horseradish", "SPECIES", 112, 123], ["mouse", "SPECIES", 146, 151], ["anti-rabbit", "SPECIES", 152, 163], ["horseradish", "SPECIES", 256, 267], ["rabbit", "SPECIES", 290, 296], ["anti-mouse", "SPECIES", 297, 307], ["mouse", "SPECIES", 146, 151], ["anti-rabbit", "SPECIES", 152, 163], ["rabbit", "SPECIES", 290, 296], ["TBST", "TREATMENT", 19, 23], ["bFGF", "TREATMENT", 25, 29], ["CD13 membranes", "PROBLEM", 34, 48], ["horseradish peroxidase-conjugated mouse anti-rabbit IgG", "TREATMENT", 112, 167], ["horseradish peroxidase", "TREATMENT", 256, 278], ["conjugated rabbit anti-mouse IgG (dilution", "TREATMENT", 279, 321], ["CD13 membranes", "ANATOMY", 34, 48]]], ["Membranes were washed and proteins were visualized by electro-chemiluminescence.Fluorescence-activated cell sorter analysis ::: MATERIALS AND METHODSCells at 70% confluence were harvested by short trypsinisation, washed and resuspended in phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin (BSA) and 0.05% NaNO3.", [["Membranes", "ANATOMY", 0, 9], ["cell", "ANATOMY", 103, 107], ["serum", "ANATOMY", 294, 299], ["phosphate", "CHEMICAL", 239, 248], ["NaNO3", "CHEMICAL", 324, 329], ["phosphate", "CHEMICAL", 239, 248], ["NaNO3", "CHEMICAL", 324, 329], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["cell", "CELL", 103, 107], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 239, 264], ["bovine", "ORGANISM", 287, 293], ["serum", "ORGANISM_SUBSTANCE", 294, 299], ["albumin", "SIMPLE_CHEMICAL", 300, 307], ["BSA", "SIMPLE_CHEMICAL", 309, 312], ["NaNO3", "SIMPLE_CHEMICAL", 324, 329], ["bovine", "SPECIES", 287, 293], ["Fluorescence", "TEST", 80, 92], ["METHODSCells", "TREATMENT", 142, 154], ["phosphate-buffered saline (PBS)", "TREATMENT", 239, 270], ["0.1% bovine serum albumin (BSA)", "TREATMENT", 282, 313], ["0.05% NaNO3", "TREATMENT", 318, 329]]], ["1 \u00d7 105 cells were incubated at room temperature for 30 min with 1 : 20 diluted phycoerythrin (PE)-conjugated anti-human CD13 monoclonal antibody L-138 (BD biosciences, Alphen aanden Rijn, the Netherlands), PE-conjugated mouse IgG1 or PBS.", [["cells", "ANATOMY", 8, 13], ["PE", "CHEMICAL", 95, 97], ["L-138", "CHEMICAL", 146, 151], ["PE", "CHEMICAL", 207, 209], ["1 \u00d7 105 cells", "CELL", 0, 13], ["phycoerythrin", "SIMPLE_CHEMICAL", 80, 93], ["PE", "SIMPLE_CHEMICAL", 95, 97], ["CD13", "GENE_OR_GENE_PRODUCT", 121, 125], ["L-138", "SIMPLE_CHEMICAL", 146, 151], ["PE", "SIMPLE_CHEMICAL", 207, 209], ["mouse", "ORGANISM", 221, 226], ["IgG1", "GENE_OR_GENE_PRODUCT", 227, 231], ["1 \u00d7 105 cells", "CELL_LINE", 0, 13], ["CD13", "PROTEIN", 121, 125], ["conjugated mouse IgG1", "PROTEIN", 210, 231], ["mouse", "SPECIES", 221, 226], ["mouse", "SPECIES", 221, 226], ["20 diluted phycoerythrin", "TREATMENT", 69, 93], ["PE", "TEST", 95, 97], ["conjugated anti-human CD13", "TEST", 99, 125], ["monoclonal antibody L", "TEST", 126, 147], ["BD biosciences", "TEST", 153, 167], ["Alphen", "TEST", 169, 175], ["PE", "PROBLEM", 207, 209], ["PE", "OBSERVATION", 95, 97], ["PE", "OBSERVATION", 207, 209]]], ["Cells were washed and analysed on a FACS calibur flow cytometer (BD biosciences).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["a FACS", "TEST", 34, 40]]], ["Results were expressed as the ratio of the mean fluorescence of L-138 divided by that of IgG1.Aminopeptidase activity assay ::: MATERIALS AND METHODSSurface aminopeptidase activity was measured by plating 5000 cells in 10% serum in a 96-well plate according to Van Hensbergen et al (2002).", [["cells", "ANATOMY", 210, 215], ["serum", "ANATOMY", 223, 228], ["L-138", "CHEMICAL", 64, 69], ["L-138", "CHEMICAL", 64, 69], ["L-138", "GENE_OR_GENE_PRODUCT", 64, 69], ["IgG1", "GENE_OR_GENE_PRODUCT", 89, 93], ["Aminopeptidase", "GENE_OR_GENE_PRODUCT", 94, 108], ["METHODSSurface aminopeptidase", "GENE_OR_GENE_PRODUCT", 142, 171], ["cells", "CELL", 210, 215], ["serum", "ORGANISM_SUBSTANCE", 223, 228], ["IgG1", "PROTEIN", 89, 93], ["the mean fluorescence", "TEST", 39, 60], ["Aminopeptidase activity assay", "TEST", 94, 123], ["METHODSSurface aminopeptidase activity", "TEST", 142, 180], ["serum", "TEST", 223, 228]]], ["After a 6-h incubation period, medium was removed and fresh serum-free medium containing 0.1% BSA was added.", [["serum", "ANATOMY", 60, 65], ["BSA", "CHEMICAL", 94, 97], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["BSA", "SIMPLE_CHEMICAL", 94, 97], ["fresh serum-free medium containing", "TREATMENT", 54, 88]]], ["After 16 h, cells were washed with PBS and incubated with 100 \u03bcl alanine-AMC (L-alanine-4-methyl-7-coumarinylamide trifluoroacetate; Sigma-Aldrich) in the absence or presence of 350 \u03bcM bestatin (Sigma-Aldrich) or 10 \u03bcg ml\u22121 CD13-neutralising mouse monoclonal antibody WM15 (BD biosciences).", [["cells", "ANATOMY", 12, 17], ["alanine", "CHEMICAL", 65, 72], ["AMC", "CHEMICAL", 73, 76], ["L-alanine-4-methyl-7-coumarinylamide trifluoroacetate", "CHEMICAL", 78, 131], ["Sigma-Aldrich", "CHEMICAL", 133, 146], ["bestatin", "CHEMICAL", 185, 193], ["alanine", "CHEMICAL", 65, 72], ["L-alanine-4-methyl-7-coumarinylamide trifluoroacetate", "CHEMICAL", 78, 131], ["Sigma-Aldrich", "CHEMICAL", 133, 146], ["bestatin", "CHEMICAL", 185, 193], ["cells", "CELL", 12, 17], ["\u03bcl alanine-AMC", "SIMPLE_CHEMICAL", 62, 76], ["L-alanine-4-methyl-7-coumarinylamide trifluoroacetate", "SIMPLE_CHEMICAL", 78, 131], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 133, 146], ["bestatin", "SIMPLE_CHEMICAL", 185, 193], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 195, 208], ["CD13", "GENE_OR_GENE_PRODUCT", 224, 228], ["mouse", "ORGANISM", 242, 247], ["CD13", "PROTEIN", 224, 228], ["neutralising mouse monoclonal antibody WM15", "PROTEIN", 229, 272], ["BD biosciences", "PROTEIN", 274, 288], ["mouse", "SPECIES", 242, 247], ["mouse", "SPECIES", 242, 247], ["PBS", "TREATMENT", 35, 38], ["L-alanine", "TEST", 78, 87], ["methyl", "TREATMENT", 90, 96], ["coumarinylamide trifluoroacetate", "TREATMENT", 99, 131], ["bestatin (Sigma-Aldrich)", "TREATMENT", 185, 209], ["CD13", "TEST", 224, 228], ["neutralising mouse monoclonal antibody", "TREATMENT", 229, 267]]], ["Release of the fluorescent product 7-AMC was monitored every 5 min during 1 h in a Spectrafluor multiplate reader (Tecan, Salzburg, Austria) with excitation wavelength \u03bb360 nm and emission wavelength \u03bb465 nm.", [["7-AMC", "CHEMICAL", 35, 40], ["7-AMC", "SIMPLE_CHEMICAL", 35, 40], ["the fluorescent product", "TREATMENT", 11, 34]]], ["The neutral aminopeptidase activity was calculated from the slope of the fluorescence\u2013time curve, using a calibration curve of 7-AMC (Sigma-Aldrich).Migration assay ::: MATERIALS AND METHODSCells were seeded in 24-well plates and grown to confluence.", [["7-AMC", "CHEMICAL", 127, 132], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 12, 26], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 134, 147], ["aminopeptidase", "PROTEIN", 12, 26], ["The neutral aminopeptidase activity", "TEST", 0, 35], ["the fluorescence\u2013time curve", "TEST", 69, 96], ["a calibration curve", "TEST", 104, 123], ["METHODSCells", "TREATMENT", 183, 195], ["confluence", "OBSERVATION_MODIFIER", 239, 249]]], ["A wound was scratched in the confluent cell layer with a sterile pipette tip in two directions.", [["wound", "ANATOMY", 2, 7], ["cell layer", "ANATOMY", 39, 49], ["wound", "PATHOLOGICAL_FORMATION", 2, 7], ["A wound", "PROBLEM", 0, 7], ["a sterile pipette tip", "TREATMENT", 55, 76], ["wound", "ANATOMY", 2, 7], ["scratched", "OBSERVATION_MODIFIER", 12, 21], ["confluent", "OBSERVATION_MODIFIER", 29, 38], ["cell", "OBSERVATION", 39, 43], ["layer", "OBSERVATION_MODIFIER", 44, 49], ["sterile pipette", "OBSERVATION", 57, 72]]], ["Medium was replaced by medium without or with 10 \u03bcg ml\u22121 mouse IgG, 10 \u03bcg ml\u22121 WM15 or 350 \u03bcM bestatin.", [["bestatin", "CHEMICAL", 94, 102], ["bestatin", "CHEMICAL", 94, 102], ["mouse", "ORGANISM", 57, 62], ["IgG", "GENE_OR_GENE_PRODUCT", 63, 66], ["bestatin", "SIMPLE_CHEMICAL", 94, 102], ["mouse IgG", "PROTEIN", 57, 66], ["mouse", "SPECIES", 57, 62], ["mouse", "SPECIES", 57, 62], ["1 mouse IgG", "TREATMENT", 55, 66], ["bestatin", "TREATMENT", 94, 102]]], ["Immediately after wounding and at time points 6, 12 and 24 h, wounds were photographed at \u00d7 25 magnification with a confocal laserscan microscope (Leica TCS 4D; Leica, Jena, Germany) and a video camera attached to a computer with Leica Q500MC software (Leica).", [["wounds", "ANATOMY", 62, 68], ["wounds", "PATHOLOGICAL_FORMATION", 62, 68], ["Leica Q500MC software", "DNA", 230, 251], ["wounds", "PROBLEM", 62, 68], ["a confocal laserscan microscope", "TEST", 114, 145], ["wounds", "ANATOMY", 62, 68]]], ["The width of the wounds was measured in four areas at all time points and compared to the original wound at time point 0 h.", [["wounds", "ANATOMY", 17, 23], ["wound", "ANATOMY", 99, 104], ["wounds", "PATHOLOGICAL_FORMATION", 17, 23], ["wound", "PATHOLOGICAL_FORMATION", 99, 104], ["the wounds", "PROBLEM", 13, 23], ["width", "OBSERVATION_MODIFIER", 4, 9], ["wounds", "OBSERVATION", 17, 23], ["four", "OBSERVATION_MODIFIER", 40, 44], ["areas", "OBSERVATION_MODIFIER", 45, 50], ["wound", "OBSERVATION", 99, 104]]], ["Possible toxicity of IgG, WM15 and bestatin was determined by performing a parallel MTT (3-(4,5-dimetylthiazol-2-yl)-2,6-dimethyl-morpholino)-2,5-diphenyl-tetrazolium bromide; Sigma-Aldrich) assay (Mosmann, 1983) using four replicate wells and an exposure time of 24 h.", [["toxicity", "DISEASE", 9, 17], ["WM15", "CHEMICAL", 26, 30], ["bestatin", "CHEMICAL", 35, 43], ["MTT", "CHEMICAL", 84, 87], ["3-(4,5-dimetylthiazol-2-yl)-2,6-dimethyl-morpholino)-2,5-diphenyl-tetrazolium bromide", "CHEMICAL", 89, 174], ["bestatin", "CHEMICAL", 35, 43], ["MTT", "CHEMICAL", 84, 87], ["3-(4,5-dimetylthiazol-2-yl)-2,6-dimethyl-morpholino)-2,5-diphenyl-tetrazolium bromide", "CHEMICAL", 89, 174], ["IgG", "GENE_OR_GENE_PRODUCT", 21, 24], ["WM15", "SIMPLE_CHEMICAL", 26, 30], ["bestatin", "SIMPLE_CHEMICAL", 35, 43], ["3-(4,5-dimetylthiazol-2-yl)-2,6-dimethyl-morpholino)-2,5-diphenyl-tetrazolium bromide", "SIMPLE_CHEMICAL", 89, 174], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 176, 189], ["IgG", "PROTEIN", 21, 24], ["toxicity of IgG", "PROBLEM", 9, 24], ["bestatin", "TREATMENT", 35, 43], ["a parallel MTT", "TREATMENT", 73, 87], ["dimetylthiazol", "TREATMENT", 96, 110], ["dimethyl-morpholino)", "TREATMENT", 121, 141], ["diphenyl-tetrazolium bromide", "TREATMENT", 146, 174]]], ["Cell growth of untreated cells was set at 100% and growth of treated cells was expressed as a percentage of control cell growth.Matrigel invasion assay ::: MATERIALS AND METHODSThe Matrigel invasion assay was performed in a 24-well plate transwell system (Van Hensbergen et al, 2003).", [["Cell", "ANATOMY", 0, 4], ["cells", "ANATOMY", 25, 30], ["cells", "ANATOMY", 69, 74], ["cell", "ANATOMY", 116, 120], ["Cell", "CELL", 0, 4], ["cells", "CELL", 25, 30], ["cells", "CELL", 69, 74], ["cell", "CELL", 116, 120], ["treated cells", "CELL_LINE", 61, 74], ["untreated cells", "PROBLEM", 15, 30], ["treated cells", "PROBLEM", 61, 74], ["METHODSThe Matrigel invasion assay", "TEST", 170, 204], ["untreated cells", "OBSERVATION", 15, 30], ["cell growth", "OBSERVATION", 116, 127], ["invasion", "OBSERVATION", 137, 145], ["Matrigel invasion", "OBSERVATION", 181, 198]]], ["Filters with 8 \u03bcm pore size (HTS Fluoroblok Insert; Becton Dickinson labware, Le Pont de Claix, France) were coated on the lower side with 1% fibronectin (Merck) for 2 h and washed with PBS before coating the upper side of the filter with Matrigel (5 or 20 \u03bcg filter\u22121; Sigma-Aldrich).", [["pore", "ANATOMY", 18, 22], ["Matrigel", "CHEMICAL", 239, 247], ["fibronectin", "GENE_OR_GENE_PRODUCT", 142, 153], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 270, 283], ["fibronectin", "PROTEIN", 142, 153], ["Filters", "TREATMENT", 0, 7], ["8 \u03bcm pore size", "TREATMENT", 13, 27], ["HTS Fluoroblok Insert", "TREATMENT", 29, 50], ["Le Pont de Claix", "TREATMENT", 78, 94], ["1% fibronectin (Merck)", "TREATMENT", 139, 161], ["PBS", "TREATMENT", 186, 189], ["the filter", "TREATMENT", 223, 233], ["Matrigel (5 or 20 \u03bcg filter", "TREATMENT", 239, 266], ["8 \u03bcm pore", "OBSERVATION_MODIFIER", 13, 22], ["size", "OBSERVATION_MODIFIER", 23, 27], ["upper", "ANATOMY_MODIFIER", 209, 214], ["filter", "OBSERVATION", 227, 233]]], ["DMEM containing 10% FCS was added to the lower compartment.", [["lower compartment", "ANATOMY", 41, 58], ["FCS", "ORGANISM_SUBSTANCE", 20, 23], ["DMEM", "TREATMENT", 0, 4], ["10% FCS", "TREATMENT", 16, 23], ["lower", "ANATOMY_MODIFIER", 41, 46], ["compartment", "ANATOMY", 47, 58]]], ["2 \u00d7 105 cells in DMEM containing 0.5% FCS in a volume of 200 \u03bcl were added to the upper compartment.", [["cells", "ANATOMY", 8, 13], ["upper compartment", "ANATOMY", 82, 99], ["FCS", "CHEMICAL", 38, 41], ["2 \u00d7 105 cells", "CELL", 0, 13], ["upper compartment", "MULTI-TISSUE_STRUCTURE", 82, 99], ["DMEM", "TREATMENT", 17, 21], ["0.5% FCS", "TREATMENT", 33, 41], ["a volume", "TREATMENT", 45, 53], ["upper", "ANATOMY_MODIFIER", 82, 87], ["compartment", "ANATOMY", 88, 99]]], ["In control wells, 0.5% FCS was added to both the lower and the upper compartment.", [["upper compartment", "ANATOMY", 63, 80], ["FCS", "ORGANISM_SUBSTANCE", 23, 26], ["upper compartment", "MULTI-TISSUE_STRUCTURE", 63, 80], ["0.5% FCS", "TREATMENT", 18, 26], ["lower", "ANATOMY_MODIFIER", 49, 54], ["upper", "ANATOMY_MODIFIER", 63, 68], ["compartment", "ANATOMY", 69, 80]]], ["For inhibition of invasion, 350 \u03bcM bestatin was added to both the upper and the lower compartment.", [["lower compartment", "ANATOMY", 80, 97], ["bestatin", "CHEMICAL", 35, 43], ["bestatin", "CHEMICAL", 35, 43], ["bestatin", "SIMPLE_CHEMICAL", 35, 43], ["upper", "ORGANISM_SUBDIVISION", 66, 71], ["invasion", "PROBLEM", 18, 26], ["350 \u03bcM bestatin", "TREATMENT", 28, 43], ["invasion", "OBSERVATION", 18, 26], ["upper", "ANATOMY_MODIFIER", 66, 71], ["lower", "ANATOMY_MODIFIER", 80, 85], ["compartment", "ANATOMY_MODIFIER", 86, 97]]], ["WM15 (10\u03bcg ml\u22121) was present in the upper compartment only, and this included a 1-h preincubation period before the cells were seeded.", [["upper compartment", "ANATOMY", 36, 53], ["cells", "ANATOMY", 116, 121], ["WM15", "CHEMICAL", 0, 4], ["WM15", "CHEMICAL", 0, 4], ["WM15", "SIMPLE_CHEMICAL", 0, 4], ["upper compartment", "ORGANISM_SUBDIVISION", 36, 53], ["cells", "CELL", 116, 121], ["a 1-h preincubation period", "TREATMENT", 78, 104], ["the cells", "TREATMENT", 112, 121], ["upper", "ANATOMY_MODIFIER", 36, 41]]], ["Cells were allowed to invade for 48 h at 37\u00b0C. Invasion was quantified by exposing the cells in the lower compartment to 5 \u03bcM calcein-AM (Molecular Probes, Leiden, the Netherlands) at 37\u00b0C during the final 30 min of the assay.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 87, 92], ["lower compartment", "ANATOMY", 100, 117], ["calcein", "CHEMICAL", 126, 133], ["calcein-AM", "CHEMICAL", 126, 136], ["Cells", "CELL", 0, 5], ["cells", "CELL", 87, 92], ["calcein-AM", "SIMPLE_CHEMICAL", 126, 136], ["C", "GENE_OR_GENE_PRODUCT", 187, 188], ["Invasion", "PROBLEM", 47, 55], ["calcein", "TEST", 126, 133], ["the assay", "TEST", 216, 225], ["lower", "ANATOMY_MODIFIER", 100, 105]]], ["Calcein-AM is the acetoxy-methyl ester of calcein, which diffuses readily through the cell membrane.", [["cell membrane", "ANATOMY", 86, 99], ["Calcein", "CHEMICAL", 0, 7], ["acetoxy-methyl ester", "CHEMICAL", 18, 38], ["calcein", "CHEMICAL", 42, 49], ["Calcein-AM", "CHEMICAL", 0, 10], ["acetoxy-methyl ester", "CHEMICAL", 18, 38], ["calcein", "CHEMICAL", 42, 49], ["Calcein-AM", "SIMPLE_CHEMICAL", 0, 10], ["acetoxy-methyl ester", "SIMPLE_CHEMICAL", 18, 38], ["calcein", "SIMPLE_CHEMICAL", 42, 49], ["cell membrane", "CELLULAR_COMPONENT", 86, 99], ["Calcein", "TEST", 0, 7], ["the acetoxy-methyl ester of calcein", "TREATMENT", 14, 49], ["cell membrane", "OBSERVATION", 86, 99]]], ["In the cytosol, calcein-AM is converted into the fluorochrome calcein by esterases.", [["cytosol", "ANATOMY", 7, 14], ["calcein", "CHEMICAL", 16, 23], ["calcein", "CHEMICAL", 62, 69], ["calcein-AM", "CHEMICAL", 16, 26], ["calcein", "CHEMICAL", 62, 69], ["cytosol", "ORGANISM_SUBSTANCE", 7, 14], ["calcein-AM", "SIMPLE_CHEMICAL", 16, 26], ["fluorochrome", "SIMPLE_CHEMICAL", 49, 61], ["calcein", "SIMPLE_CHEMICAL", 62, 69], ["the fluorochrome calcein", "TREATMENT", 45, 69]]], ["Calcein fluorescence in the lower compartment was measured in a Spectrafluor multiplate reader (Tecan) with excitation wavelength \u03bb492 nm and emission wavelength \u03bb535 nm.", [["lower compartment", "ANATOMY", 28, 45], ["Calcein", "CHEMICAL", 0, 7], ["Calcein", "CHEMICAL", 0, 7], ["Calcein", "SIMPLE_CHEMICAL", 0, 7], ["Calcein fluorescence", "TEST", 0, 20], ["lower", "ANATOMY_MODIFIER", 28, 33]]], ["Cytotoxicity of WM15 and bestatin was determined by performing a parallel MTT assay with an exposure time of 48 h in a similar way as described for the migration assay.Transient transfection and dual luciferase assay ::: MATERIALS AND METHODSThe CD13 promoter-luciferase reporter constructs BstXI-luciferase, encoding the epithelial promoter and CD13-1.15-luciferase, encoding the myeloid promoter, were a kind gift of Dr LH Shapiro and have been described previously (Bhagwat et al, 2001). pGL2 basic-luciferase and pRenilla luciferase-CMV were purchased from Promega (Leiden, the Netherlands).", [["epithelial", "ANATOMY", 322, 332], ["myeloid", "ANATOMY", 381, 388], ["WM15", "CHEMICAL", 16, 20], ["bestatin", "CHEMICAL", 25, 33], ["WM15", "CHEMICAL", 16, 20], ["bestatin", "CHEMICAL", 25, 33], ["MTT", "CHEMICAL", 74, 77], ["WM15", "SIMPLE_CHEMICAL", 16, 20], ["bestatin", "SIMPLE_CHEMICAL", 25, 33], ["luciferase", "GENE_OR_GENE_PRODUCT", 200, 210], ["CD13", "GENE_OR_GENE_PRODUCT", 246, 250], ["luciferase", "GENE_OR_GENE_PRODUCT", 260, 270], ["BstXI", "GENE_OR_GENE_PRODUCT", 291, 296], ["luciferase", "GENE_OR_GENE_PRODUCT", 297, 307], ["epithelial", "TISSUE", 322, 332], ["CD13", "GENE_OR_GENE_PRODUCT", 346, 350], ["luciferase", "GENE_OR_GENE_PRODUCT", 356, 366], ["myeloid", "CELL", 381, 388], ["LH", "GENE_OR_GENE_PRODUCT", 422, 424], ["pGL2", "GENE_OR_GENE_PRODUCT", 491, 495], ["luciferase", "GENE_OR_GENE_PRODUCT", 502, 512], ["luciferase", "GENE_OR_GENE_PRODUCT", 526, 536], ["CMV", "ORGANISM", 537, 540], ["luciferase", "PROTEIN", 200, 210], ["CD13 promoter", "DNA", 246, 259], ["luciferase reporter constructs", "DNA", 260, 290], ["BstXI", "DNA", 291, 296], ["luciferase", "PROTEIN", 297, 307], ["epithelial promoter", "DNA", 322, 341], ["CD13-1.15-luciferase", "DNA", 346, 366], ["myeloid promoter", "DNA", 381, 397], ["pGL2 basic-luciferase and pRenilla luciferase", "DNA", 491, 536], ["Cytotoxicity of WM15", "PROBLEM", 0, 20], ["bestatin", "TREATMENT", 25, 33], ["a parallel MTT assay", "TEST", 63, 83], ["the migration assay", "TEST", 148, 167], ["dual luciferase assay", "TEST", 195, 216], ["METHODSThe CD13 promoter", "TREATMENT", 235, 259], ["BstXI", "TEST", 291, 296], ["CD13", "TEST", 346, 350], ["the myeloid promoter", "TREATMENT", 377, 397], ["pRenilla luciferase", "PROBLEM", 517, 536], ["CMV", "PROBLEM", 537, 540], ["transfection", "OBSERVATION", 178, 190], ["myeloid promoter", "OBSERVATION", 381, 397], ["luciferase", "OBSERVATION", 502, 512], ["CMV", "OBSERVATION", 537, 540]]], ["Exponentially growing 1F6 cells and bFGF-overexpressing 1F6 clones in duplicate wells of six-well plates were transiently transfected with 0.5 \u03bcg of each reporter plasmid for 48 h using Fugene 6 transfection reagent (Roche Diagnostics) following the manufacturer's protocol.", [["Exponentially", "ANATOMY", 0, 13], ["1F6 cells", "ANATOMY", 22, 31], ["1F6 clones", "ANATOMY", 56, 66], ["plasmid", "ANATOMY", 163, 170], ["1F6 cells", "CELL", 22, 31], ["bFGF", "GENE_OR_GENE_PRODUCT", 36, 40], ["1F6 clones", "CELL", 56, 66], ["1F6 cells", "CELL_LINE", 22, 31], ["bFGF-overexpressing 1F6 clones", "CELL_LINE", 36, 66], ["reporter plasmid", "DNA", 154, 170], ["Exponentially growing 1F6 cells", "PROBLEM", 0, 31], ["bFGF", "TEST", 36, 40], ["overexpressing 1F6 clones", "PROBLEM", 41, 66], ["six-well plates", "TREATMENT", 89, 104], ["each reporter plasmid", "TREATMENT", 149, 170], ["Fugene 6 transfection reagent", "TREATMENT", 186, 215], ["the manufacturer's protocol", "TREATMENT", 246, 273], ["1F6 cells", "OBSERVATION", 22, 31]]], ["Cotransfection with 5 ng pRenilla luciferase-CMV (pRL-CMV) was performed to correct for possible differences in transfection efficiency.", [["luciferase", "GENE_OR_GENE_PRODUCT", 34, 44], ["CMV", "ORGANISM", 45, 48], ["pRL-CMV", "ORGANISM", 50, 57], ["luciferase", "PROTEIN", 34, 44], ["pRL", "PROTEIN", 50, 53], ["Cotransfection", "TEST", 0, 14], ["5 ng pRenilla luciferase", "TEST", 20, 44], ["CMV (pRL-CMV)", "TEST", 45, 58], ["differences in transfection efficiency", "PROBLEM", 97, 135], ["transfection efficiency", "OBSERVATION", 112, 135]]], ["The activities of firefly and Renilla luciferase were determined with the dual luciferase reporter assay (Promega) following the manufacturer's protocol.", [["firefly", "GENE_OR_GENE_PRODUCT", 18, 25], ["Renilla", "GENE_OR_GENE_PRODUCT", 30, 37], ["luciferase", "GENE_OR_GENE_PRODUCT", 38, 48], ["luciferase", "GENE_OR_GENE_PRODUCT", 79, 89], ["firefly", "DNA", 18, 25], ["luciferase", "PROTEIN", 38, 48], ["Renilla luciferase", "TEST", 30, 48], ["the manufacturer's protocol", "TREATMENT", 125, 152]]], ["In short, cells were lysed by scraping in the presence of 250 \u03bcl 1 \u00d7 passive lysis buffer.", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15], ["passive lysis buffer", "TREATMENT", 69, 89], ["short", "OBSERVATION_MODIFIER", 3, 8]]], ["In total, 20 \u03bcl of cell lysate was transferred into the luminometer tube containing 100 ml LAR II buffer (Promega), and firefly luciferase activity was measured.", [["cell lysate", "ANATOMY", 19, 30], ["cell lysate", "CELL", 19, 30], ["luciferase", "GENE_OR_GENE_PRODUCT", 128, 138], ["luciferase", "PROTEIN", 128, 138], ["cell lysate", "TREATMENT", 19, 30], ["the luminometer tube", "TREATMENT", 52, 72], ["LAR II buffer (Promega)", "TREATMENT", 91, 114], ["firefly luciferase activity", "TEST", 120, 147]]], ["Consecutively, Renilla luciferase activity was measured after adding 100 ml of Stop & Glo Reagent (Promega).", [["luciferase", "GENE_OR_GENE_PRODUCT", 23, 33], ["luciferase", "PROTEIN", 23, 33], ["Renilla luciferase activity", "TEST", 15, 42], ["Glo Reagent (Promega)", "TREATMENT", 86, 107]]], ["Relative CD13 promoter activity in 1F6 cells and bFGF-transfected clones was calculated by the formula:Statistical analysis ::: MATERIALS AND METHODSStatistical analysis of possible differences between mean values was performed with a two-tailed Student's t-test.", [["1F6 cells", "ANATOMY", 35, 44], ["clones", "ANATOMY", 66, 72], ["CD13", "GENE_OR_GENE_PRODUCT", 9, 13], ["1F6 cells", "CELL", 35, 44], ["bFGF", "GENE_OR_GENE_PRODUCT", 49, 53], ["clones", "CELL", 66, 72], ["CD13 promoter", "DNA", 9, 22], ["1F6 cells", "CELL_LINE", 35, 44], ["bFGF", "PROTEIN", 49, 53], ["transfected clones", "CELL_LINE", 54, 72], ["Relative CD13 promoter activity in 1F6 cells", "TREATMENT", 0, 44], ["bFGF", "TREATMENT", 49, 53], ["transfected clones", "PROBLEM", 54, 72], ["METHODSStatistical analysis", "TEST", 142, 169], ["mean values", "TEST", 202, 213], ["Student's t-test", "TEST", 246, 262], ["CD13 promoter", "OBSERVATION", 9, 22]]], ["P<0.05 was considered significant.Characteristics of bFGF-overexpressing 1F6 cells ::: RESULTSRecently, we characterised 1F6 melanoma cells stably transfected with the 18kD isoform of bFGF, ALL isoforms of bFGF or a control empty vector pcDNA3 (Fontijn et al, unpublished data).", [["bFGF-overexpressing 1F6 cells", "ANATOMY", 53, 82], ["1F6 melanoma cells", "ANATOMY", 121, 139], ["melanoma", "DISEASE", 125, 133], ["ALL", "DISEASE", 190, 193], ["bFGF", "GENE_OR_GENE_PRODUCT", 53, 57], ["1F6 cells", "CELL", 73, 82], ["1F6 melanoma cells", "CELL", 121, 139], ["bFGF", "GENE_OR_GENE_PRODUCT", 184, 188], ["ALL", "CANCER", 190, 193], ["bFGF", "GENE_OR_GENE_PRODUCT", 206, 210], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 237, 243], ["bFGF", "PROTEIN", 53, 57], ["1F6 cells", "CELL_LINE", 73, 82], ["1F6 melanoma cells", "CELL_LINE", 121, 139], ["18kD isoform", "PROTEIN", 168, 180], ["bFGF", "PROTEIN", 184, 188], ["ALL isoforms", "PROTEIN", 190, 202], ["bFGF", "PROTEIN", 206, 210], ["pcDNA3", "DNA", 237, 243], ["bFGF", "TEST", 53, 57], ["overexpressing 1F6 cells", "PROBLEM", 58, 82], ["melanoma cells", "PROBLEM", 125, 139], ["bFGF", "TREATMENT", 184, 188], ["bFGF", "TREATMENT", 206, 210], ["a control empty vector pcDNA3", "TREATMENT", 214, 243], ["bFGF", "OBSERVATION", 53, 57], ["overexpressing 1F6 cells", "OBSERVATION", 58, 82], ["melanoma cells", "OBSERVATION", 125, 139]]], ["The overexpressed bFGF was biologically active in a human umbilical vein endothelial cell (HUVEC) proliferation assay.", [["human umbilical vein endothelial cell", "ANATOMY", 52, 89], ["HUVEC", "ANATOMY", 91, 96], ["bFGF", "GENE_OR_GENE_PRODUCT", 18, 22], ["human umbilical vein endothelial cell", "CELL", 52, 89], ["HUVEC", "CELL", 91, 96], ["bFGF", "PROTEIN", 18, 22], ["human umbilical vein endothelial cell", "CELL_LINE", 52, 89], ["HUVEC", "CELL_LINE", 91, 96], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["a human umbilical vein endothelial cell", "TREATMENT", 50, 89], ["proliferation assay", "TEST", 98, 117], ["bFGF", "OBSERVATION", 18, 22], ["active", "OBSERVATION_MODIFIER", 40, 46], ["umbilical vein", "ANATOMY", 58, 72], ["endothelial cell", "OBSERVATION", 73, 89]]], ["Changes in cell morphology were observed in 1F6 cells overexpressing both the 18kD and ALL bFGF isoforms.", [["cell", "ANATOMY", 11, 15], ["1F6 cells", "ANATOMY", 44, 53], ["ALL", "DISEASE", 87, 90], ["cell", "CELL", 11, 15], ["1F6 cells", "CELL", 44, 53], ["18kD", "GENE_OR_GENE_PRODUCT", 78, 82], ["bFGF", "GENE_OR_GENE_PRODUCT", 91, 95], ["1F6 cells", "CELL_LINE", 44, 53], ["18kD and ALL bFGF isoforms", "PROTEIN", 78, 104], ["Changes in cell morphology", "PROBLEM", 0, 26], ["ALL bFGF isoforms", "TREATMENT", 87, 104], ["cell morphology", "OBSERVATION", 11, 26]]], ["In contrast to 1F6 cells, which are large cells with numerous dendritic cell processes, 1F6-18kD and 1F6-ALL cells appeared smaller, were more rounded and formed less dendritic cell processes.", [["1F6 cells", "ANATOMY", 15, 24], ["cells", "ANATOMY", 42, 47], ["dendritic cell", "ANATOMY", 62, 76], ["1F6-18kD", "ANATOMY", 88, 96], ["1F6-ALL cells", "ANATOMY", 101, 114], ["dendritic cell", "ANATOMY", 167, 181], ["ALL", "DISEASE", 105, 108], ["1F6 cells", "CELL", 15, 24], ["cells", "CELL", 42, 47], ["dendritic cell", "CELL", 62, 76], ["1F6-18kD", "CELL", 88, 96], ["1F6-ALL cells", "CELL", 101, 114], ["dendritic cell", "CELL", 167, 181], ["1F6 cells", "CELL_LINE", 15, 24], ["1F6-18kD and 1F6-ALL cells", "CELL_LINE", 88, 114], ["large cells", "PROBLEM", 36, 47], ["numerous dendritic cell processes", "PROBLEM", 53, 86], ["1F6", "TEST", 88, 91], ["1F6 cells", "OBSERVATION_MODIFIER", 15, 24], ["large cells", "OBSERVATION", 36, 47], ["numerous", "OBSERVATION_MODIFIER", 53, 61], ["dendritic cell processes", "OBSERVATION", 62, 86], ["smaller", "OBSERVATION_MODIFIER", 124, 131], ["more rounded", "OBSERVATION_MODIFIER", 138, 150], ["less", "OBSERVATION_MODIFIER", 162, 166], ["dendritic cell processes", "OBSERVATION", 167, 191]]], ["In addition, significantly accelerated in vitro and in vivo growth rates up to, respectively, two- and three-fold were observed in 1F6 cells and tumours overexpressing either 18kD or ALL bFGF isoforms (Fontijn et al, unpublished data).", [["1F6 cells", "ANATOMY", 131, 140], ["tumours", "ANATOMY", 145, 152], ["ALL", "DISEASE", 183, 186], ["1F6 cells", "CELL", 131, 140], ["tumours", "CANCER", 145, 152], ["18kD", "GENE_OR_GENE_PRODUCT", 175, 179], ["bFGF", "GENE_OR_GENE_PRODUCT", 187, 191], ["1F6 cells", "CELL_LINE", 131, 140], ["18kD", "PROTEIN", 175, 179], ["ALL bFGF isoforms", "PROTEIN", 183, 200], ["significantly accelerated in vitro", "PROBLEM", 13, 47], ["vivo growth rates", "TEST", 55, 72], ["ALL bFGF isoforms", "TEST", 183, 200], ["significantly", "OBSERVATION_MODIFIER", 13, 26]]], ["Since these changes in morphology and growth rate might be indicative for increased aggressive behaviour, we determined whether CD13 expression was upregulated in bFGF-overexpressing 1F6 cells.CD13 expression and activity is increased in 1F6 cells overexpressing 18kD or ALL isoforms of bFGF ::: RESULTSbFGF mRNA and protein expression in 1F6-pcDNA3 cells and 1F6 clones lowly or highly overexpressing 18kD (18kD-L, 18kD-H) or ALL (ALL-L, ALL-H) isoforms of bFGF are visualised in Figure 1.", [["1F6 cells", "ANATOMY", 183, 192], ["1F6 cells", "ANATOMY", 238, 247], ["ALL", "ANATOMY", 271, 274], ["1F6-pcDNA3 cells", "ANATOMY", 339, 355], ["1F6 clones", "ANATOMY", 360, 370], ["ALL", "ANATOMY", 427, 430], ["ALL-L", "ANATOMY", 432, 437], ["ALL", "DISEASE", 271, 274], ["ALL", "DISEASE", 427, 430], ["ALL", "DISEASE", 432, 435], ["ALL", "DISEASE", 439, 442], ["CD13", "GENE_OR_GENE_PRODUCT", 128, 132], ["bFGF", "GENE_OR_GENE_PRODUCT", 163, 167], ["1F6 cells", "CELL", 183, 192], ["CD13", "GENE_OR_GENE_PRODUCT", 193, 197], ["1F6 cells", "CELL", 238, 247], ["18kD", "GENE_OR_GENE_PRODUCT", 263, 267], ["ALL", "CANCER", 271, 274], ["bFGF", "GENE_OR_GENE_PRODUCT", 287, 291], ["RESULTSbFGF", "GENE_OR_GENE_PRODUCT", 296, 307], ["1F6-pcDNA3 cells", "CELL", 339, 355], ["1F6 clones", "CELL", 360, 370], ["18kD", "CELL", 402, 406], ["ALL", "CANCER", 427, 430], ["ALL-H", "GENE_OR_GENE_PRODUCT", 439, 444], ["bFGF", "GENE_OR_GENE_PRODUCT", 458, 462], ["CD13", "PROTEIN", 128, 132], ["bFGF", "PROTEIN", 163, 167], ["1F6 cells", "CELL_LINE", 183, 192], ["CD13", "PROTEIN", 193, 197], ["1F6 cells", "CELL_LINE", 238, 247], ["18kD", "PROTEIN", 263, 267], ["ALL isoforms", "PROTEIN", 271, 283], ["bFGF", "PROTEIN", 287, 291], ["RESULTSbFGF mRNA", "RNA", 296, 312], ["1F6-pcDNA3 cells", "CELL_LINE", 339, 355], ["1F6 clones", "CELL_LINE", 360, 370], ["18kD", "PROTEIN", 402, 406], ["18kD", "PROTEIN", 408, 412], ["bFGF", "PROTEIN", 458, 462], ["growth rate", "TEST", 38, 49], ["increased aggressive behaviour", "PROBLEM", 74, 104], ["CD13 expression", "PROBLEM", 128, 143], ["overexpressing 1F6 cells", "PROBLEM", 168, 192], ["CD13 expression", "TEST", 193, 208], ["mRNA", "TEST", 308, 312], ["protein expression", "TEST", 317, 335], ["pcDNA3 cells", "TEST", 343, 355], ["clones", "TEST", 364, 370], ["ALL", "TEST", 427, 430], ["bFGF", "PROBLEM", 458, 462], ["might be indicative for", "UNCERTAINTY", 50, 73], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["aggressive", "OBSERVATION_MODIFIER", 84, 94], ["1F6 cells", "OBSERVATION", 183, 192], ["activity", "OBSERVATION_MODIFIER", 213, 221], ["increased", "OBSERVATION_MODIFIER", 225, 234], ["protein expression", "OBSERVATION", 317, 335]]], ["Increased CD13 mRNA expression up to 150-fold was observed in 1F6-18kD as well as in 1F6-ALL clones as compared to the expression level in 1F6-pcDNA3 (Figure 2A).", [["1F6-18kD", "ANATOMY", 62, 70], ["1F6-ALL clones", "ANATOMY", 85, 99], ["ALL", "DISEASE", 89, 92], ["CD13", "GENE_OR_GENE_PRODUCT", 10, 14], ["1F6-ALL clones", "CELL", 85, 99], ["1F6-pcDNA3", "GENE_OR_GENE_PRODUCT", 139, 149], ["Figure 2A", "GENE_OR_GENE_PRODUCT", 151, 160], ["CD13 mRNA", "RNA", 10, 19], ["1F6-18kD", "CELL_LINE", 62, 70], ["1F6-ALL clones", "CELL_LINE", 85, 99], ["1F6", "PROTEIN", 139, 142], ["pcDNA3", "DNA", 143, 149], ["Increased CD13 mRNA expression", "PROBLEM", 0, 30], ["the expression level", "TEST", 115, 135], ["CD13 mRNA", "OBSERVATION", 10, 19]]], ["Figure 2B shows CD13 mRNA expression in the same clones, but normalised for two other reference genes GAPDH and PDGB.", [["clones", "ANATOMY", 49, 55], ["CD13", "GENE_OR_GENE_PRODUCT", 16, 20], ["clones", "CELL", 49, 55], ["GAPDH", "GENE_OR_GENE_PRODUCT", 102, 107], ["PDGB", "GENE_OR_GENE_PRODUCT", 112, 116], ["CD13 mRNA", "RNA", 16, 25], ["reference genes", "DNA", 86, 101], ["GAPDH", "DNA", 102, 107], ["PDGB", "PROTEIN", 112, 116], ["Figure 2B", "TEST", 0, 9], ["CD13 mRNA expression in the same clones", "PROBLEM", 16, 55], ["PDGB", "PROBLEM", 112, 116], ["CD13 mRNA expression", "OBSERVATION", 16, 36]]], ["A similar pattern of CD13 upregulation was observed, although the absolute fold increase over 1F6-pcDNA3 CD13 expression levels varied with the reference gene of choice.", [["CD13", "GENE_OR_GENE_PRODUCT", 21, 25], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 98, 104], ["CD13", "GENE_OR_GENE_PRODUCT", 105, 109], ["CD13", "PROTEIN", 21, 25], ["1F6", "PROTEIN", 94, 97], ["CD13", "PROTEIN", 105, 109], ["CD13 upregulation", "PROBLEM", 21, 38], ["the absolute fold increase", "PROBLEM", 62, 88], ["CD13 expression levels", "TEST", 105, 127], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["pattern", "OBSERVATION_MODIFIER", 10, 17], ["CD13 upregulation", "OBSERVATION", 21, 38], ["absolute fold", "OBSERVATION_MODIFIER", 66, 79], ["increase", "OBSERVATION_MODIFIER", 80, 88]]], ["GeNorm analysis (Vandesompele et al, 2002) indicated that among the reference genes, human \u03b22-microglobulin and GAPDH were the most stable in our model (data not shown).", [["human", "ORGANISM", 85, 90], ["\u03b22-microglobulin", "GENE_OR_GENE_PRODUCT", 91, 107], ["GAPDH", "GENE_OR_GENE_PRODUCT", 112, 117], ["reference genes", "DNA", 68, 83], ["human \u03b22-microglobulin", "PROTEIN", 85, 107], ["GAPDH", "PROTEIN", 112, 117], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["GeNorm analysis", "TEST", 0, 15], ["GAPDH", "TEST", 112, 117], ["most stable", "OBSERVATION_MODIFIER", 127, 138]]], ["High expression of CD13 in bFGF-transfected 1F6 clones was confirmed on the protein level by Western blot (Figure 2C).", [["1F6 clones", "ANATOMY", 44, 54], ["CD13", "GENE_OR_GENE_PRODUCT", 19, 23], ["bFGF", "GENE_OR_GENE_PRODUCT", 27, 31], ["1F6 clones", "CELL", 44, 54], ["CD13", "PROTEIN", 19, 23], ["bFGF", "PROTEIN", 27, 31], ["1F6 clones", "CELL_LINE", 44, 54], ["CD13 in bFGF", "TREATMENT", 19, 31], ["the protein level", "TEST", 72, 89], ["CD13", "ANATOMY", 19, 23]]], ["Fluorescence-activated cell sorter analysis also confirmed high CD13 protein expression, which was increased up to 450-fold in bFGF-overexpressing 1F6 clones (Figure 2D).", [["cell", "ANATOMY", 23, 27], ["1F6 clones", "ANATOMY", 147, 157], ["cell", "CELL", 23, 27], ["CD13", "GENE_OR_GENE_PRODUCT", 64, 68], ["bFGF", "GENE_OR_GENE_PRODUCT", 127, 131], ["1F6 clones", "CELL", 147, 157], ["CD13", "PROTEIN", 64, 68], ["bFGF", "PROTEIN", 127, 131], ["1F6 clones", "CELL_LINE", 147, 157], ["Fluorescence", "TEST", 0, 12], ["activated cell sorter analysis", "TEST", 13, 43], ["high CD13 protein expression", "PROBLEM", 59, 87]]], ["CD13 expression in 1F6 clones was up to two-fold higher than that in the BRO cell line, which contains high levels of endogenous CD13.CD13 expression and activity is increased in 1F6 cells overexpressing 18kD or ALL isoforms of bFGF ::: RESULTSTo test whether the overexpressed CD13 had enzymatic activity, aminopeptidase-activated release of 7-AMC from alanine-AMC was measured in 1F6, 1F6-pcDNA3 and clones highly overexpressing 18kD or ALL bFGF isoform proteins (Figure 3).", [["1F6 clones", "ANATOMY", 19, 29], ["BRO cell line", "ANATOMY", 73, 86], ["1F6 cells", "ANATOMY", 179, 188], ["ALL", "ANATOMY", 212, 215], ["ALL", "DISEASE", 212, 215], ["alanine", "CHEMICAL", 354, 361], ["ALL", "DISEASE", 439, 442], ["7-AMC", "CHEMICAL", 343, 348], ["alanine", "CHEMICAL", 354, 361], ["CD13", "GENE_OR_GENE_PRODUCT", 0, 4], ["1F6 clones", "CELL", 19, 29], ["BRO cell line", "CELL", 73, 86], ["CD13", "GENE_OR_GENE_PRODUCT", 129, 133], ["CD13", "GENE_OR_GENE_PRODUCT", 134, 138], ["1F6 cells", "CELL", 179, 188], ["18kD", "GENE_OR_GENE_PRODUCT", 204, 208], ["ALL", "CANCER", 212, 215], ["bFGF", "GENE_OR_GENE_PRODUCT", 228, 232], ["CD13", "GENE_OR_GENE_PRODUCT", 278, 282], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 307, 321], ["7-AMC", "SIMPLE_CHEMICAL", 343, 348], ["alanine-AMC", "SIMPLE_CHEMICAL", 354, 365], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 391, 397], ["clones", "CELL", 402, 408], ["18kD", "CELL", 431, 435], ["bFGF", "GENE_OR_GENE_PRODUCT", 443, 447], ["CD13", "PROTEIN", 0, 4], ["1F6 clones", "CELL_LINE", 19, 29], ["BRO cell line", "CELL_LINE", 73, 86], ["endogenous CD13", "PROTEIN", 118, 133], ["CD13", "PROTEIN", 134, 138], ["1F6 cells", "CELL_LINE", 179, 188], ["18kD", "PROTEIN", 204, 208], ["ALL isoforms", "PROTEIN", 212, 224], ["bFGF", "PROTEIN", 228, 232], ["CD13", "PROTEIN", 278, 282], ["aminopeptidase", "PROTEIN", 307, 321], ["1F6, 1F6-pcDNA3", "CELL_LINE", 382, 397], ["18kD", "PROTEIN", 431, 435], ["ALL bFGF isoform proteins", "PROTEIN", 439, 464], ["CD13 expression in 1F6 clones", "PROBLEM", 0, 29], ["endogenous CD13", "PROBLEM", 118, 133], ["CD13 expression", "TEST", 134, 149], ["RESULTSTo test", "TEST", 237, 251], ["enzymatic activity", "TEST", 287, 305], ["aminopeptidase", "TEST", 307, 321], ["alanine-AMC", "TEST", 354, 365], ["ALL bFGF isoform proteins", "PROBLEM", 439, 464], ["higher", "OBSERVATION_MODIFIER", 49, 55], ["BRO cell line", "OBSERVATION", 73, 86], ["high", "OBSERVATION_MODIFIER", 103, 107], ["levels", "OBSERVATION_MODIFIER", 108, 114], ["endogenous CD13", "OBSERVATION", 118, 133], ["activity", "OBSERVATION_MODIFIER", 154, 162], ["increased", "OBSERVATION_MODIFIER", 166, 175]]], ["In line with mRNA and protein expression, aminopeptidase activity was increased up to five-fold in bFGF-overexpressing clones.", [["clones", "ANATOMY", 119, 125], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 42, 56], ["bFGF", "GENE_OR_GENE_PRODUCT", 99, 103], ["clones", "CELL", 119, 125], ["mRNA", "RNA", 13, 17], ["aminopeptidase", "PROTEIN", 42, 56], ["bFGF", "PROTEIN", 99, 103], ["overexpressing clones", "CELL_LINE", 104, 125], ["mRNA and protein expression", "TREATMENT", 13, 40], ["aminopeptidase activity", "TREATMENT", 42, 65], ["overexpressing clones", "PROBLEM", 104, 125], ["overexpressing clones", "OBSERVATION", 104, 125]]], ["Addition of 350 \u03bcM bestatin, a nonspecific aminopeptidase inhibitor, resulted in a more than 90% inhibition of enzyme activity in all cell lines (P<0.05).", [["cell lines", "ANATOMY", 134, 144], ["bestatin", "CHEMICAL", 19, 27], ["bestatin", "CHEMICAL", 19, 27], ["bestatin", "SIMPLE_CHEMICAL", 19, 27], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 43, 57], ["cell lines", "CELL", 134, 144], ["enzyme", "PROTEIN", 111, 117], ["cell lines", "CELL_LINE", 134, 144], ["350 \u03bcM bestatin", "TREATMENT", 12, 27], ["a nonspecific aminopeptidase inhibitor", "TREATMENT", 29, 67], ["enzyme activity", "PROBLEM", 111, 126], ["cell lines", "OBSERVATION", 134, 144]]], ["In contrast, the specific CD13-neutralising antibody WM15 (10 \u03bcg ml\u22121) did not inhibit the enzymatic activity in 1F6 and 1F6-pcDNA3 cells, suggesting that CD13 is not involved in the basal neutral aminopeptidase activity.", [["1F6", "ANATOMY", 113, 116], ["1F6-pcDNA3 cells", "ANATOMY", 121, 137], ["WM15", "CHEMICAL", 53, 57], ["CD13", "GENE_OR_GENE_PRODUCT", 26, 30], ["1F6", "CELL", 113, 116], ["1F6-pcDNA3 cells", "CELL", 121, 137], ["CD13", "GENE_OR_GENE_PRODUCT", 155, 159], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 197, 211], ["CD13", "PROTEIN", 26, 30], ["1F6", "CELL_LINE", 113, 116], ["1F6", "CELL_LINE", 121, 124], ["pcDNA3 cells", "CELL_LINE", 125, 137], ["CD13", "PROTEIN", 155, 159], ["aminopeptidase", "PROTEIN", 197, 211], ["the specific CD13", "TEST", 13, 30], ["neutralising antibody WM15", "TEST", 31, 57], ["the enzymatic activity", "TEST", 87, 109], ["CD13", "TEST", 155, 159], ["enzymatic activity", "OBSERVATION", 91, 109], ["aminopeptidase activity", "OBSERVATION", 197, 220]]], ["In 1F6-18kD and 1F6-ALL cells, however, exposure to WM15 resulted in a three-fold reduction of total aminopeptidase activity, indicating that the increased enzymatic activity in 1F6-18kD and 1F6-ALL cells is mainly due to increased CD13 levels.High CD13 expression in bFGF-overexpressing 1F6 clones facilitates invasion, but not migration ::: RESULTSCD13 has been implicated to be required for melanoma cell invasion in ECM in vitro as well as in vivo (Menrad et al, 1993; Fujii et al, 1995).", [["1F6-18kD", "ANATOMY", 3, 11], ["1F6-ALL cells", "ANATOMY", 16, 29], ["1F6-18kD", "ANATOMY", 178, 186], ["1F6-ALL cells", "ANATOMY", 191, 204], ["1F6 clones", "ANATOMY", 288, 298], ["melanoma cell", "ANATOMY", 394, 407], ["ECM", "ANATOMY", 420, 423], ["ALL", "DISEASE", 20, 23], ["WM15", "CHEMICAL", 52, 56], ["ALL", "DISEASE", 195, 198], ["RESULTSCD13", "CHEMICAL", 343, 354], ["melanoma", "DISEASE", 394, 402], ["WM15", "CHEMICAL", 52, 56], ["1F6-18kD", "CELL", 3, 11], ["1F6-ALL cells", "CELL", 16, 29], ["WM15", "SIMPLE_CHEMICAL", 52, 56], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 101, 115], ["1F6-18kD", "CELL", 178, 186], ["1F6-ALL cells", "CELL", 191, 204], ["CD13", "GENE_OR_GENE_PRODUCT", 232, 236], ["CD13", "GENE_OR_GENE_PRODUCT", 249, 253], ["bFGF", "GENE_OR_GENE_PRODUCT", 268, 272], ["1F6 clones", "CELL", 288, 298], ["RESULTSCD13", "GENE_OR_GENE_PRODUCT", 343, 354], ["melanoma cell", "CELL", 394, 407], ["ECM", "CELLULAR_COMPONENT", 420, 423], ["1F6-18kD and 1F6-ALL cells", "CELL_LINE", 3, 29], ["aminopeptidase", "PROTEIN", 101, 115], ["1F6-18kD and 1F6-ALL cells", "CELL_LINE", 178, 204], ["CD13", "PROTEIN", 232, 236], ["CD13", "PROTEIN", 249, 253], ["bFGF", "PROTEIN", 268, 272], ["1F6 clones", "CELL_LINE", 288, 298], ["RESULTSCD13", "PROTEIN", 343, 354], ["total aminopeptidase activity", "TREATMENT", 95, 124], ["the increased enzymatic activity", "PROBLEM", 142, 174], ["increased CD13 levels", "PROBLEM", 222, 243], ["High CD13 expression in bFGF", "PROBLEM", 244, 272], ["invasion", "PROBLEM", 311, 319], ["melanoma cell invasion", "PROBLEM", 394, 416], ["aminopeptidase activity", "OBSERVATION", 101, 124], ["increased", "OBSERVATION_MODIFIER", 146, 155], ["enzymatic activity", "OBSERVATION", 156, 174], ["mainly due to", "UNCERTAINTY", 208, 221], ["increased", "OBSERVATION_MODIFIER", 222, 231], ["CD13 levels", "OBSERVATION", 232, 243], ["CD13 expression", "OBSERVATION", 249, 264], ["melanoma cell invasion", "OBSERVATION", 394, 416]]], ["Therefore, we determined whether the increased CD13 expression observed in the highly bFGF-overexpressing 1F6 clones resulted in a higher invasive capacity.", [["1F6 clones", "ANATOMY", 106, 116], ["CD13", "GENE_OR_GENE_PRODUCT", 47, 51], ["bFGF", "GENE_OR_GENE_PRODUCT", 86, 90], ["1F6 clones", "CELL", 106, 116], ["CD13", "PROTEIN", 47, 51], ["bFGF", "PROTEIN", 86, 90], ["1F6 clones", "CELL_LINE", 106, 116], ["the increased CD13 expression", "PROBLEM", 33, 62], ["overexpressing 1F6 clones", "PROBLEM", 91, 116], ["a higher invasive capacity", "PROBLEM", 129, 155], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["CD13 expression", "OBSERVATION", 47, 62]]], ["In contrast to 1F6 and 1F6-pcDNA3 cells, which did not show any invasion through Matrigel 5 \u03bcg filter\u22121 in the presence of 10% FCS used as a chemoattractant, highly increased invasion was observed for both 1F6-18kD and 1F6-ALL clones (Figure 4A).", [["1F6-pcDNA3 cells", "ANATOMY", 23, 39], ["1F6-18kD", "ANATOMY", 206, 214], ["1F6-ALL clones", "ANATOMY", 219, 233], ["ALL", "DISEASE", 223, 226], ["1F6", "CELL", 15, 18], ["1F6-pcDNA3 cells", "CELL", 23, 39], ["1F6-ALL clones", "CELL", 219, 233], ["1F6 and 1F6-pcDNA3 cells", "CELL_LINE", 15, 39], ["1F6-18kD and 1F6-ALL clones", "CELL_LINE", 206, 233], ["any invasion", "PROBLEM", 60, 72], ["10% FCS", "TREATMENT", 123, 130], ["highly increased invasion", "PROBLEM", 158, 183], ["invasion", "OBSERVATION", 64, 72], ["increased", "OBSERVATION_MODIFIER", 165, 174], ["invasion", "OBSERVATION", 175, 183]]], ["Figure 4B shows that 1F6-18kD and 1F6-ALL clones even invaded through Matrigel 20 \u03bcg filter\u22121.", [["1F6-ALL clones", "ANATOMY", 34, 48], ["ALL", "DISEASE", 38, 41], ["1F6-18kD", "SIMPLE_CHEMICAL", 21, 29], ["1F6-ALL clones", "CELL", 34, 48], ["1F6-18kD and 1F6-ALL clones", "CELL_LINE", 21, 48], ["Figure 4B", "TEST", 0, 9], ["ALL clones", "PROBLEM", 38, 48], ["Matrigel 20 \u03bcg filter", "TREATMENT", 70, 91]]], ["Addition of 350 \u03bcM bestatin resulted in complete inhibition of the FCS-induced invasion (P<0.05).", [["bestatin", "CHEMICAL", 19, 27], ["bestatin", "CHEMICAL", 19, 27], ["bestatin", "SIMPLE_CHEMICAL", 19, 27], ["FCS", "SIMPLE_CHEMICAL", 67, 70], ["350 \u03bcM bestatin", "TREATMENT", 12, 27], ["the FCS", "TEST", 63, 70], ["induced invasion", "PROBLEM", 71, 87], ["invasion", "OBSERVATION", 79, 87]]], ["Exposure to 10 \u03bcg ml\u22121 of the CD13-neutralising antibody WM15 also resulted in a significant reduction of invasion (P<0.05).", [["WM15", "CHEMICAL", 57, 61], ["CD13", "GENE_OR_GENE_PRODUCT", 30, 34], ["CD13", "PROTEIN", 30, 34], ["WM15", "PROTEIN", 57, 61], ["the CD13", "TEST", 26, 34], ["neutralising antibody", "TEST", 35, 56], ["a significant reduction of invasion", "PROBLEM", 79, 114], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["reduction", "OBSERVATION_MODIFIER", 93, 102], ["invasion", "OBSERVATION", 106, 114]]], ["Toxicity of bestatin and WM15 was determined by an MTT assay.", [["Toxicity", "DISEASE", 0, 8], ["bestatin", "CHEMICAL", 12, 20], ["WM15", "CHEMICAL", 25, 29], ["bestatin", "CHEMICAL", 12, 20], ["WM15", "CHEMICAL", 25, 29], ["MTT", "CHEMICAL", 51, 54], ["bestatin", "SIMPLE_CHEMICAL", 12, 20], ["WM15", "SIMPLE_CHEMICAL", 25, 29], ["bestatin", "TREATMENT", 12, 20], ["an MTT assay", "TEST", 48, 60]]], ["Bestatin at 350 \u03bcM resulted in a growth inhibition of approximately 10%, while WM15 at 10 \u03bcg ml\u22121 did not affect cell growth (data not shown).High CD13 expression in bFGF-overexpressing 1F6 clones facilitates invasion, but not migration ::: RESULTSThe migratory capacity of 1F6 cells and bFGF-overexpressing clones was determined by a wound assay.", [["cell", "ANATOMY", 113, 117], ["1F6 clones", "ANATOMY", 186, 196], ["1F6 cells", "ANATOMY", 274, 283], ["clones", "ANATOMY", 308, 314], ["wound", "ANATOMY", 335, 340], ["Bestatin", "CHEMICAL", 0, 8], ["WM15", "CHEMICAL", 79, 83], ["Bestatin", "CHEMICAL", 0, 8], ["Bestatin", "SIMPLE_CHEMICAL", 0, 8], ["WM15", "SIMPLE_CHEMICAL", 79, 83], ["cell", "CELL", 113, 117], ["CD13", "GENE_OR_GENE_PRODUCT", 147, 151], ["bFGF", "GENE_OR_GENE_PRODUCT", 166, 170], ["1F6 clones", "CELL", 186, 196], ["1F6 cells", "CELL", 274, 283], ["bFGF", "GENE_OR_GENE_PRODUCT", 288, 292], ["clones", "CELL", 308, 314], ["wound", "PATHOLOGICAL_FORMATION", 335, 340], ["CD13", "PROTEIN", 147, 151], ["bFGF", "PROTEIN", 166, 170], ["1F6 clones", "CELL_LINE", 186, 196], ["1F6 cells", "CELL_LINE", 274, 283], ["bFGF-overexpressing clones", "CELL_LINE", 288, 314], ["Bestatin", "TREATMENT", 0, 8], ["a growth inhibition", "PROBLEM", 31, 50], ["High CD13 expression in bFGF", "PROBLEM", 142, 170], ["invasion", "PROBLEM", 209, 217], ["1F6 cells", "TREATMENT", 274, 283], ["bFGF", "PROBLEM", 288, 292], ["overexpressing clones", "PROBLEM", 293, 314], ["a wound assay", "TEST", 333, 346], ["overexpressing clones", "OBSERVATION", 293, 314], ["wound", "ANATOMY", 335, 340]]], ["Figure 5A illustrates that clones 1F6-18kD and 1F6-ALL clearly had a higher rate of migration as compared to that of parent 1F6 and 1F6-pcDNA3 cells (P<0.05).", [["1F6-ALL", "ANATOMY", 47, 54], ["1F6", "ANATOMY", 124, 127], ["1F6-pcDNA3 cells", "ANATOMY", 132, 148], ["ALL", "DISEASE", 51, 54], ["1F6-18kD", "CELL", 34, 42], ["1F6-ALL", "CANCER", 47, 54], ["1F6", "CELL", 124, 127], ["1F6-pcDNA3 cells", "CELL", 132, 148], ["1F6", "PROTEIN", 34, 37], ["1F6", "CELL_LINE", 47, 50], ["1F6", "CELL_LINE", 124, 127], ["1F6", "CELL_LINE", 132, 135], ["pcDNA3 cells", "CELL_LINE", 136, 148], ["clones", "TEST", 27, 33], ["migration", "OBSERVATION", 84, 93]]], ["Exposure to 10 \u03bcg ml\u22121 WM15 did not inhibit the migration rate (Figure 5B and C) indicating that CD13 activity is not involved in this process.Basic fibroblast growth factor-induced CD13 expression is not due to increased mRNA stability ::: RESULTSOne possible mechanism for the increased CD13 expression observed in bFGF-overexpressing 1F6 cells is an increase in CD13 mRNA stability.", [["bFGF-overexpressing 1F6 cells", "ANATOMY", 317, 346], ["WM15", "CHEMICAL", 23, 27], ["CD13", "GENE_OR_GENE_PRODUCT", 97, 101], ["Basic fibroblast growth factor", "GENE_OR_GENE_PRODUCT", 143, 173], ["CD13", "GENE_OR_GENE_PRODUCT", 182, 186], ["CD13", "GENE_OR_GENE_PRODUCT", 289, 293], ["bFGF", "GENE_OR_GENE_PRODUCT", 317, 321], ["1F6 cells", "CELL", 337, 346], ["CD13", "GENE_OR_GENE_PRODUCT", 365, 369], ["CD13", "PROTEIN", 97, 101], ["fibroblast growth factor", "PROTEIN", 149, 173], ["CD13", "PROTEIN", 182, 186], ["CD13", "PROTEIN", 289, 293], ["bFGF", "PROTEIN", 317, 321], ["1F6 cells", "CELL_LINE", 337, 346], ["CD13 mRNA", "RNA", 365, 374], ["the migration rate", "TEST", 44, 62], ["CD13 activity", "PROBLEM", 97, 110], ["Basic fibroblast growth factor", "TEST", 143, 173], ["CD13 expression", "TEST", 182, 197], ["increased mRNA stability", "PROBLEM", 212, 236], ["the increased CD13 expression", "PROBLEM", 275, 304], ["overexpressing 1F6 cells", "PROBLEM", 322, 346], ["an increase in CD13 mRNA stability", "PROBLEM", 350, 384], ["CD13 activity", "OBSERVATION", 97, 110], ["fibroblast growth", "OBSERVATION", 149, 166], ["mRNA stability", "OBSERVATION", 222, 236], ["increase", "OBSERVATION_MODIFIER", 353, 361], ["CD13 mRNA stability", "OBSERVATION", 365, 384]]], ["To test this possibility, we determined the degradation of CD13 mRNA in 1F6-pcDNA3 and bFGF-transfected 1F6 clones after incubation with the transcription inhibitor actinomycin D for different time periods by Light-Cycler PCR.", [["1F6 clones", "ANATOMY", 104, 114], ["actinomycin D", "CHEMICAL", 165, 178], ["actinomycin D", "CHEMICAL", 165, 178], ["CD13", "GENE_OR_GENE_PRODUCT", 59, 63], ["1F6-pcDNA3", "GENE_OR_GENE_PRODUCT", 72, 82], ["bFGF", "GENE_OR_GENE_PRODUCT", 87, 91], ["1F6 clones", "CELL", 104, 114], ["actinomycin D", "SIMPLE_CHEMICAL", 165, 178], ["CD13 mRNA", "RNA", 59, 68], ["1F6", "PROTEIN", 72, 75], ["bFGF", "PROTEIN", 87, 91], ["1F6 clones", "CELL_LINE", 104, 114], ["CD13 mRNA", "TEST", 59, 68], ["bFGF", "TREATMENT", 87, 91], ["the transcription inhibitor actinomycin D", "TREATMENT", 137, 178], ["Light-Cycler PCR", "TEST", 209, 225]]], ["From Figure 6 it can be seen that CD13 mRNA in 1F6-pcDNA3, 1F6-18kD and 1F6-ALL cells was degraded with similar half-lifes of approximately 18 h.Basic fibroblast growth factor can induce expression of CD13 transcripts from the myeloid promoter ::: RESULTSCD13 transcriptional regulation can be mediated by the distal, myeloid promoter, and a proximal, epithelial promoter (Shapiro et al, 1991).", [["1F6-18kD", "ANATOMY", 59, 67], ["1F6-ALL cells", "ANATOMY", 72, 85], ["myeloid", "ANATOMY", 227, 234], ["myeloid", "ANATOMY", 318, 325], ["epithelial", "ANATOMY", 352, 362], ["ALL", "DISEASE", 76, 79], ["CD13", "GENE_OR_GENE_PRODUCT", 34, 38], ["1F6-pcDNA3", "GENE_OR_GENE_PRODUCT", 47, 57], ["1F6", "GENE_OR_GENE_PRODUCT", 59, 62], ["1F6-ALL cells", "CELL", 72, 85], ["Basic fibroblast growth factor", "GENE_OR_GENE_PRODUCT", 145, 175], ["CD13", "GENE_OR_GENE_PRODUCT", 201, 205], ["myeloid", "CELL", 227, 234], ["RESULTSCD13", "GENE_OR_GENE_PRODUCT", 248, 259], ["myeloid", "CELL", 318, 325], ["epithelial", "TISSUE", 352, 362], ["CD13 mRNA", "RNA", 34, 43], ["1F6-pcDNA3, 1F6-18kD and 1F6-ALL cells", "CELL_LINE", 47, 85], ["CD13 transcripts", "RNA", 201, 217], ["myeloid promoter", "DNA", 227, 243], ["RESULTSCD13", "PROTEIN", 248, 259], ["distal, myeloid promoter", "DNA", 310, 334], ["proximal, epithelial promoter", "DNA", 342, 371], ["CD13 mRNA", "TEST", 34, 43], ["pcDNA3", "TEST", 51, 57], ["Basic fibroblast growth factor", "PROBLEM", 145, 175], ["myeloid promoter", "OBSERVATION", 227, 243], ["distal", "ANATOMY_MODIFIER", 310, 316], ["myeloid promoter", "OBSERVATION", 318, 334], ["proximal", "ANATOMY_MODIFIER", 342, 350]]], ["We designed a primer set to specifically detect CD13 mRNA expression resulting from activity of the myeloid promoter (CD13 MP).", [["myeloid", "ANATOMY", 100, 107], ["CD13", "GENE_OR_GENE_PRODUCT", 48, 52], ["myeloid", "CELL", 100, 107], ["CD13 MP", "GENE_OR_GENE_PRODUCT", 118, 125], ["CD13 mRNA", "RNA", 48, 57], ["myeloid promoter", "DNA", 100, 116], ["CD13 MP", "PROTEIN", 118, 125], ["CD13 mRNA expression", "PROBLEM", 48, 68], ["myeloid promoter", "OBSERVATION", 100, 116]]], ["U937 and HL60 cells were included as positive controls for myeloid CD13 promoter activity.", [["U937", "ANATOMY", 0, 4], ["HL60 cells", "ANATOMY", 9, 19], ["myeloid", "ANATOMY", 59, 66], ["U937", "CELL", 0, 4], ["HL60 cells", "CELL", 9, 19], ["myeloid", "CELL", 59, 66], ["CD13", "GENE_OR_GENE_PRODUCT", 67, 71], ["U937", "CELL_LINE", 0, 4], ["HL60 cells", "CELL_LINE", 9, 19], ["myeloid CD13 promoter", "DNA", 59, 80], ["U937", "TEST", 0, 4], ["HL60 cells", "TEST", 9, 19], ["myeloid CD13 promoter activity", "PROBLEM", 59, 89], ["HL60 cells", "OBSERVATION", 9, 19], ["myeloid CD13", "OBSERVATION", 59, 71], ["promoter activity", "OBSERVATION", 72, 89]]], ["As a negative control, Hep3B cells were used, since CD13 expression in this cell line is the result of activity of the epithelial promoter only.", [["Hep3B cells", "ANATOMY", 23, 34], ["cell line", "ANATOMY", 76, 85], ["epithelial", "ANATOMY", 119, 129], ["Hep3B cells", "CELL", 23, 34], ["CD13", "GENE_OR_GENE_PRODUCT", 52, 56], ["cell line", "CELL", 76, 85], ["epithelial", "TISSUE", 119, 129], ["Hep3B cells", "CELL_LINE", 23, 34], ["CD13", "PROTEIN", 52, 56], ["epithelial promoter", "DNA", 119, 138], ["Hep3B cells", "TREATMENT", 23, 34], ["CD13 expression", "PROBLEM", 52, 67], ["this cell line", "TREATMENT", 71, 85], ["negative", "OBSERVATION", 5, 13], ["cell line", "OBSERVATION", 76, 85], ["epithelial promoter", "OBSERVATION", 119, 138]]], ["While no myeloid promoter fragment could be detected in Hep3B, 1F6 and 1F6-pcDNA3 cells (Figure 7, lanes 4\u20136), high levels of myeloid promoter fragments were observed in 1F6 clones overexpressing 18kD and ALL bFGF isoforms (Figure 7, lanes 7\u201310).", [["myeloid", "ANATOMY", 9, 16], ["Hep3B", "ANATOMY", 56, 61], ["1F6", "ANATOMY", 63, 66], ["1F6-pcDNA3 cells", "ANATOMY", 71, 87], ["myeloid promoter fragments", "ANATOMY", 126, 152], ["1F6 clones", "ANATOMY", 170, 180], ["ALL", "DISEASE", 205, 208], ["myeloid", "CELL", 9, 16], ["fragment", "CELLULAR_COMPONENT", 26, 34], ["Hep3B", "CELL", 56, 61], ["1F6", "CELL", 63, 66], ["1F6-pcDNA3 cells", "CELL", 71, 87], ["myeloid", "CELL", 126, 133], ["1F6 clones", "CELL", 170, 180], ["18kD", "CELL", 196, 200], ["bFGF", "GENE_OR_GENE_PRODUCT", 209, 213], ["myeloid promoter fragment", "DNA", 9, 34], ["Hep3B", "CELL_LINE", 56, 61], ["1F6", "CELL_LINE", 63, 66], ["1F6", "CELL_LINE", 71, 74], ["pcDNA3 cells", "CELL_LINE", 75, 87], ["myeloid promoter fragments", "DNA", 126, 152], ["1F6 clones", "CELL_LINE", 170, 180], ["18kD", "PROTEIN", 196, 200], ["ALL bFGF isoforms", "PROTEIN", 205, 222], ["myeloid promoter fragment", "PROBLEM", 9, 34], ["Hep3B", "TEST", 56, 61], ["Figure", "TEST", 89, 95], ["lanes", "TEST", 99, 104], ["high levels of myeloid promoter fragments", "PROBLEM", 111, 152], ["ALL bFGF isoforms", "TREATMENT", 205, 222], ["no", "UNCERTAINTY", 6, 8], ["myeloid", "OBSERVATION", 9, 16], ["promoter fragment", "OBSERVATION", 17, 34], ["Hep3B", "ANATOMY", 56, 61], ["myeloid promoter fragments", "OBSERVATION", 126, 152]]], ["A second primer set (CD13 MP/EP) was used to amplify fragments resulting from activity of both the epithelial and the myeloid promoter.", [["fragments", "ANATOMY", 53, 62], ["epithelial", "ANATOMY", 99, 109], ["myeloid", "ANATOMY", 118, 125], ["CD13 MP", "GENE_OR_GENE_PRODUCT", 21, 28], ["epithelial", "TISSUE", 99, 109], ["myeloid", "CELL", 118, 125], ["primer set", "DNA", 9, 19], ["CD13 MP", "PROTEIN", 21, 28], ["EP", "DNA", 29, 31], ["myeloid promoter", "DNA", 118, 134], ["A second primer set (CD13 MP/EP)", "TREATMENT", 0, 32], ["fragments", "PROBLEM", 53, 62], ["epithelial", "ANATOMY", 99, 109], ["myeloid promoter", "OBSERVATION", 118, 134]]], ["As expected, positive bands were observed in all cell lines using this primer set.Increased CD13 expression is mediated by enhanced activity of both the myeloid and epithelial promoter ::: RESULTSOur RT\u2013PCR analysis indicated that at least the CD13 myeloid promoter is involved in the increased CD13 expression observed in bFGF-overexpressing 1F6 clones.", [["cell lines", "ANATOMY", 49, 59], ["myeloid", "ANATOMY", 153, 160], ["epithelial", "ANATOMY", 165, 175], ["CD13 myeloid", "ANATOMY", 244, 256], ["1F6 clones", "ANATOMY", 343, 353], ["cell lines", "CELL", 49, 59], ["CD13", "GENE_OR_GENE_PRODUCT", 92, 96], ["myeloid", "CELL", 153, 160], ["epithelial", "TISSUE", 165, 175], ["CD13", "GENE_OR_GENE_PRODUCT", 244, 248], ["CD13", "GENE_OR_GENE_PRODUCT", 295, 299], ["bFGF", "GENE_OR_GENE_PRODUCT", 323, 327], ["1F6 clones", "CELL", 343, 353], ["cell lines", "CELL_LINE", 49, 59], ["CD13", "PROTEIN", 92, 96], ["myeloid and epithelial promoter", "DNA", 153, 184], ["CD13 myeloid promoter", "DNA", 244, 265], ["CD13", "PROTEIN", 295, 299], ["bFGF", "PROTEIN", 323, 327], ["1F6 clones", "CELL_LINE", 343, 353], ["positive bands", "PROBLEM", 13, 27], ["all cell lines", "TREATMENT", 45, 59], ["this primer set", "TREATMENT", 66, 81], ["Increased CD13 expression", "PROBLEM", 82, 107], ["RESULTSOur RT\u2013PCR analysis", "TEST", 189, 215], ["the CD13 myeloid promoter", "TREATMENT", 240, 265], ["the increased CD13 expression", "PROBLEM", 281, 310], ["positive bands", "OBSERVATION", 13, 27], ["cell lines", "OBSERVATION", 49, 59], ["CD13 expression", "OBSERVATION", 92, 107], ["myeloid", "ANATOMY", 153, 160], ["epithelial promoter", "OBSERVATION", 165, 184], ["CD13 myeloid promoter", "OBSERVATION", 244, 265], ["increased", "OBSERVATION_MODIFIER", 285, 294], ["CD13 expression", "OBSERVATION", 295, 310]]], ["To further examine whether only the myeloid or both the myeloid and epithelial CD13 promoters were activated, transient transfections were performed using reporter gene constructs encoding for either the myeloid promoter (BstXI-luc) or the epithelial promoter (CD13-1.15-luc).", [["myeloid", "ANATOMY", 36, 43], ["myeloid", "ANATOMY", 56, 63], ["epithelial CD13", "ANATOMY", 68, 83], ["myeloid", "ANATOMY", 204, 211], ["epithelial", "ANATOMY", 240, 250], ["myeloid", "CELL", 36, 43], ["myeloid", "CELL", 56, 63], ["epithelial", "CELL", 68, 78], ["CD13", "GENE_OR_GENE_PRODUCT", 79, 83], ["myeloid", "CELL", 204, 211], ["BstXI-luc", "GENE_OR_GENE_PRODUCT", 222, 231], ["epithelial", "TISSUE", 240, 250], ["CD13", "GENE_OR_GENE_PRODUCT", 261, 265], ["myeloid and epithelial CD13 promoters", "DNA", 56, 93], ["reporter gene constructs", "DNA", 155, 179], ["myeloid promoter", "DNA", 204, 220], ["BstXI", "DNA", 222, 227], ["luc", "DNA", 228, 231], ["epithelial promoter", "DNA", 240, 259], ["CD13", "DNA", 261, 265], ["luc", "DNA", 271, 274], ["the myeloid", "PROBLEM", 32, 43], ["transient transfections", "PROBLEM", 110, 133], ["reporter gene constructs", "TREATMENT", 155, 179], ["the myeloid promoter", "TREATMENT", 200, 220], ["the epithelial promoter", "TREATMENT", 236, 259], ["CD13", "TEST", 261, 265], ["myeloid", "OBSERVATION", 36, 43], ["myeloid", "ANATOMY", 56, 63], ["epithelial CD13", "ANATOMY", 68, 83]]], ["To correct for possible differences in transfection efficiency between parent 1F6 cells and bFGF-overexpressing clones, cotransfections were performed with pRenilla-CMV.", [["1F6 cells", "ANATOMY", 78, 87], ["clones", "ANATOMY", 112, 118], ["1F6 cells", "CELL", 78, 87], ["bFGF", "GENE_OR_GENE_PRODUCT", 92, 96], ["clones", "CELL", 112, 118], ["pRenilla-CMV", "ORGANISM", 156, 168], ["1F6 cells", "CELL_LINE", 78, 87], ["bFGF-overexpressing clones", "CELL_LINE", 92, 118], ["differences in transfection efficiency", "PROBLEM", 24, 62], ["bFGF", "TEST", 92, 96], ["overexpressing clones", "PROBLEM", 97, 118], ["cotransfections", "TEST", 120, 135], ["pRenilla", "TEST", 156, 164], ["transfection efficiency", "OBSERVATION", 39, 62]]], ["CD13 myeloid promoter activity in clones 1F6-18kD-H and 1F6-ALL-H was, respectively, 4.5- and 2.8-fold induced.", [["myeloid", "ANATOMY", 5, 12], ["1F6-ALL-H", "ANATOMY", 56, 65], ["1F6-18kD-H", "CHEMICAL", 41, 51], ["ALL", "DISEASE", 60, 63], ["CD13", "GENE_OR_GENE_PRODUCT", 0, 4], ["1F6-ALL-H", "CELL", 56, 65], ["CD13", "PROTEIN", 0, 4], ["CD13 myeloid promoter activity", "TEST", 0, 30], ["clones", "TEST", 34, 40], ["myeloid promoter", "OBSERVATION", 5, 21], ["activity", "OBSERVATION_MODIFIER", 22, 30]]], ["Interestingly, the activity of the epithelial promoter was also induced up to 2.5-fold in both bFGF-overexpressing clones (Figure 8).", [["epithelial", "ANATOMY", 35, 45], ["clones", "ANATOMY", 115, 121], ["epithelial", "TISSUE", 35, 45], ["bFGF", "GENE_OR_GENE_PRODUCT", 95, 99], ["epithelial promoter", "DNA", 35, 54], ["bFGF", "PROTEIN", 95, 99], ["overexpressing clones", "CELL_LINE", 100, 121], ["overexpressing clones", "PROBLEM", 100, 121], ["activity", "OBSERVATION_MODIFIER", 19, 27], ["epithelial promoter", "OBSERVATION", 35, 54], ["overexpressing clones", "OBSERVATION", 100, 121]]], ["These data clearly indicate that, although basal activity of the myeloid promoter in 1F6 cells was about 2.5-fold higher as compared to the activity of the epithelial promoter, both CD13 promoters are activated in bFGF-overexpressing 1F6 cells.CD13 expression correlates with bFGF expression in a panel of human melanoma cell lines ::: RESULTSSince we observed that bFGF overexpression can induce CD13 expression in human melanoma cells, we determined whether there was a correlation between bFGF and CD13 mRNA expression in a panel of melanoma cell lines.", [["myeloid", "ANATOMY", 65, 72], ["1F6 cells", "ANATOMY", 85, 94], ["epithelial", "ANATOMY", 156, 166], ["1F6 cells", "ANATOMY", 234, 243], ["melanoma cell lines", "ANATOMY", 312, 331], ["melanoma cells", "ANATOMY", 422, 436], ["melanoma cell lines", "ANATOMY", 536, 555], ["melanoma", "DISEASE", 312, 320], ["melanoma", "DISEASE", 422, 430], ["melanoma", "DISEASE", 536, 544], ["myeloid", "CELL", 65, 72], ["1F6 cells", "CELL", 85, 94], ["epithelial", "CELL", 156, 166], ["CD13", "GENE_OR_GENE_PRODUCT", 182, 186], ["bFGF", "GENE_OR_GENE_PRODUCT", 214, 218], ["1F6 cells", "CELL", 234, 243], ["CD13", "GENE_OR_GENE_PRODUCT", 244, 248], ["bFGF", "GENE_OR_GENE_PRODUCT", 276, 280], ["human", "ORGANISM", 306, 311], ["melanoma cell lines", "CELL", 312, 331], ["bFGF", "GENE_OR_GENE_PRODUCT", 366, 370], ["CD13", "GENE_OR_GENE_PRODUCT", 397, 401], ["human", "ORGANISM", 416, 421], ["melanoma cells", "CELL", 422, 436], ["bFGF", "GENE_OR_GENE_PRODUCT", 492, 496], ["CD13", "GENE_OR_GENE_PRODUCT", 501, 505], ["melanoma cell lines", "CELL", 536, 555], ["myeloid promoter", "DNA", 65, 81], ["1F6 cells", "CELL_LINE", 85, 94], ["epithelial promoter", "DNA", 156, 175], ["CD13 promoters", "DNA", 182, 196], ["bFGF", "PROTEIN", 214, 218], ["1F6 cells", "CELL_LINE", 234, 243], ["CD13", "PROTEIN", 244, 248], ["bFGF", "PROTEIN", 276, 280], ["human melanoma cell lines", "CELL_LINE", 306, 331], ["bFGF", "PROTEIN", 366, 370], ["CD13", "PROTEIN", 397, 401], ["human melanoma cells", "CELL_TYPE", 416, 436], ["bFGF", "PROTEIN", 492, 496], ["CD13 mRNA", "RNA", 501, 510], ["melanoma cell lines", "CELL_LINE", 536, 555], ["human", "SPECIES", 306, 311], ["human", "SPECIES", 416, 421], ["human", "SPECIES", 306, 311], ["human", "SPECIES", 416, 421], ["basal activity of the myeloid promoter in 1F6 cells", "PROBLEM", 43, 94], ["CD13 expression", "TEST", 244, 259], ["bFGF overexpression", "PROBLEM", 366, 385], ["CD13 expression in human melanoma cells", "PROBLEM", 397, 436], ["CD13 mRNA expression", "PROBLEM", 501, 521], ["melanoma cell lines", "TREATMENT", 536, 555], ["myeloid promoter", "OBSERVATION", 65, 81], ["epithelial promoter", "OBSERVATION", 156, 175], ["1F6 cells", "OBSERVATION", 234, 243], ["melanoma cell lines", "OBSERVATION", 312, 331], ["melanoma cells", "OBSERVATION", 422, 436], ["melanoma cell lines", "OBSERVATION", 536, 555]]], ["Indeed, the two cell lines, BRO and BLM, with high bFGF expression also contained a high level of CD13 mRNA, while low CD13 mRNA content was present in Mel57, M14 and 1F6 cells expressing low levels of bFGF mRNA (Figure 9A).", [["cell lines", "ANATOMY", 16, 26], ["BRO", "ANATOMY", 28, 31], ["BLM", "ANATOMY", 36, 39], ["Mel57", "ANATOMY", 152, 157], ["M14", "ANATOMY", 159, 162], ["1F6 cells", "ANATOMY", 167, 176], ["cell lines", "CELL", 16, 26], ["BRO", "CELL", 28, 31], ["BLM", "CELL", 36, 39], ["bFGF", "GENE_OR_GENE_PRODUCT", 51, 55], ["CD13", "GENE_OR_GENE_PRODUCT", 98, 102], ["CD13", "GENE_OR_GENE_PRODUCT", 119, 123], ["Mel57", "GENE_OR_GENE_PRODUCT", 152, 157], ["M14", "CELL", 159, 162], ["1F6 cells", "CELL", 167, 176], ["bFGF", "GENE_OR_GENE_PRODUCT", 202, 206], ["cell lines", "CELL_LINE", 16, 26], ["BRO", "CELL_LINE", 28, 31], ["BLM", "CELL_LINE", 36, 39], ["bFGF", "PROTEIN", 51, 55], ["CD13 mRNA", "RNA", 98, 107], ["CD13 mRNA", "RNA", 119, 128], ["Mel57", "CELL_LINE", 152, 157], ["M14", "CELL_LINE", 159, 162], ["1F6 cells", "CELL_LINE", 167, 176], ["bFGF mRNA", "RNA", 202, 211], ["BLM", "PROBLEM", 36, 39], ["high bFGF expression", "PROBLEM", 46, 66], ["a high level of CD13 mRNA", "PROBLEM", 82, 107], ["low CD13 mRNA content", "PROBLEM", 115, 136], ["Mel57", "TEST", 152, 157], ["low levels of bFGF mRNA", "PROBLEM", 188, 211], ["cell lines", "OBSERVATION", 16, 26], ["high", "OBSERVATION_MODIFIER", 46, 50], ["bFGF expression", "OBSERVATION", 51, 66], ["high", "OBSERVATION_MODIFIER", 84, 88], ["CD13 mRNA", "OBSERVATION", 98, 107], ["low levels", "OBSERVATION_MODIFIER", 188, 198], ["bFGF mRNA", "OBSERVATION", 202, 211]]], ["A significantly positive correlation was calculated between CD13 and bFGF mRNA expression (P< 0.05, R2=0.883).", [["CD13", "GENE_OR_GENE_PRODUCT", 60, 64], ["bFGF", "GENE_OR_GENE_PRODUCT", 69, 73], ["CD13", "PROTEIN", 60, 64], ["bFGF mRNA", "RNA", 69, 78], ["CD13", "TEST", 60, 64], ["bFGF mRNA expression", "TEST", 69, 89], ["P", "TEST", 91, 92], ["R2", "TEST", 100, 102]]], ["In accordance with mRNA data, CD13 protein expression was only observed in BRO and BLM cell lines containing high levels of bFGF proteins (Figure 9B).DISCUSSIONWe report for the first time that overexpression of bFGF in human melanoma cells mediates highly increased expression of CD13 mRNA and protein, which indicates that bFGF is involved in the induction of an invasive cellular phenotype.", [["BRO", "ANATOMY", 75, 78], ["BLM cell lines", "ANATOMY", 83, 97], ["melanoma cells", "ANATOMY", 226, 240], ["cellular", "ANATOMY", 374, 382], ["melanoma", "DISEASE", 226, 234], ["CD13", "GENE_OR_GENE_PRODUCT", 30, 34], ["BRO", "CELL", 75, 78], ["BLM cell lines", "CELL", 83, 97], ["bFGF", "GENE_OR_GENE_PRODUCT", 124, 128], ["bFGF", "GENE_OR_GENE_PRODUCT", 212, 216], ["human", "ORGANISM", 220, 225], ["melanoma cells", "CELL", 226, 240], ["CD13", "GENE_OR_GENE_PRODUCT", 281, 285], ["bFGF", "GENE_OR_GENE_PRODUCT", 325, 329], ["cellular", "CELL", 374, 382], ["CD13", "PROTEIN", 30, 34], ["BRO", "CELL_LINE", 75, 78], ["BLM cell lines", "CELL_LINE", 83, 97], ["bFGF proteins", "PROTEIN", 124, 137], ["Figure 9B", "PROTEIN", 139, 148], ["bFGF", "PROTEIN", 212, 216], ["human melanoma cells", "CELL_TYPE", 220, 240], ["CD13 mRNA", "RNA", 281, 290], ["bFGF", "PROTEIN", 325, 329], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 220, 225], ["mRNA data", "TEST", 19, 28], ["CD13 protein expression", "TEST", 30, 53], ["BLM cell lines", "TREATMENT", 83, 97], ["high levels of bFGF proteins", "PROBLEM", 109, 137], ["overexpression of bFGF in human melanoma cells", "PROBLEM", 194, 240], ["CD13 mRNA", "TEST", 281, 290], ["protein", "TEST", 295, 302], ["bFGF", "PROBLEM", 325, 329], ["an invasive cellular phenotype", "PROBLEM", 362, 392], ["BLM cell lines", "OBSERVATION", 83, 97], ["high levels", "OBSERVATION_MODIFIER", 109, 120], ["melanoma cells", "OBSERVATION", 226, 240], ["increased", "OBSERVATION_MODIFIER", 257, 266], ["bFGF", "OBSERVATION", 325, 329], ["invasive", "OBSERVATION_MODIFIER", 365, 373], ["cellular phenotype", "OBSERVATION", 374, 392]]], ["The increased invasiveness of bFGF-overexpressing clones through Matrigel could be attributed to high CD13 expression, since the specific monoclonal antibody WM15 inhibited this process.", [["clones", "ANATOMY", 50, 56], ["WM15", "CHEMICAL", 158, 162], ["bFGF", "GENE_OR_GENE_PRODUCT", 30, 34], ["clones", "CELL", 50, 56], ["CD13", "GENE_OR_GENE_PRODUCT", 102, 106], ["WM15", "GENE_OR_GENE_PRODUCT", 158, 162], ["bFGF", "PROTEIN", 30, 34], ["overexpressing clones", "CELL_LINE", 35, 56], ["CD13", "PROTEIN", 102, 106], ["monoclonal antibody", "PROTEIN", 138, 157], ["WM15", "PROTEIN", 158, 162], ["The increased invasiveness of bFGF", "PROBLEM", 0, 34], ["overexpressing clones through Matrigel", "PROBLEM", 35, 73], ["high CD13 expression", "PROBLEM", 97, 117], ["the specific monoclonal antibody", "TEST", 125, 157], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["invasiveness", "OBSERVATION_MODIFIER", 14, 26], ["overexpressing clones", "OBSERVATION", 35, 56], ["high CD13 expression", "OBSERVATION", 97, 117]]], ["In accordance with these effects of bFGF overexpression, we found in a panel of human melanoma cell lines a highly significant correlation between endogenous bFGF and CD13 mRNA expression as well as spontaneous metastasis formation.", [["melanoma cell lines", "ANATOMY", 86, 105], ["melanoma", "DISEASE", 86, 94], ["metastasis", "DISEASE", 211, 221], ["bFGF", "GENE_OR_GENE_PRODUCT", 36, 40], ["human", "ORGANISM", 80, 85], ["melanoma cell lines", "CELL", 86, 105], ["bFGF", "GENE_OR_GENE_PRODUCT", 158, 162], ["CD13", "GENE_OR_GENE_PRODUCT", 167, 171], ["bFGF", "PROTEIN", 36, 40], ["human melanoma cell lines", "CELL_LINE", 80, 105], ["bFGF", "PROTEIN", 158, 162], ["CD13 mRNA", "RNA", 167, 176], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["bFGF overexpression", "PROBLEM", 36, 55], ["human melanoma cell lines", "PROBLEM", 80, 105], ["endogenous bFGF", "PROBLEM", 147, 162], ["CD13 mRNA expression", "PROBLEM", 167, 187], ["spontaneous metastasis formation", "PROBLEM", 199, 231], ["melanoma cell lines", "OBSERVATION", 86, 105], ["endogenous bFGF", "OBSERVATION", 147, 162], ["CD13 mRNA expression", "OBSERVATION", 167, 187], ["spontaneous", "OBSERVATION_MODIFIER", 199, 210], ["metastasis", "OBSERVATION", 211, 221]]], ["These findings point towards an important role for bFGF in the high metastatic potential of melanomas in patients.DISCUSSIONFor our experiments, we made use of 1F6 cells with low endogenous bFGF levels that were transfected with vectors either encoding the 18kD isoform or ALL isoforms in an attempt to distinguish between the variation in phenotypic behaviour induced by the different proteins.", [["melanomas", "ANATOMY", 92, 101], ["1F6 cells", "ANATOMY", 160, 169], ["melanomas", "DISEASE", 92, 101], ["ALL", "DISEASE", 273, 276], ["bFGF", "GENE_OR_GENE_PRODUCT", 51, 55], ["melanomas", "CANCER", 92, 101], ["patients", "ORGANISM", 105, 113], ["1F6 cells", "CELL", 160, 169], ["bFGF", "GENE_OR_GENE_PRODUCT", 190, 194], ["18kD", "GENE_OR_GENE_PRODUCT", 257, 261], ["bFGF", "PROTEIN", 51, 55], ["1F6 cells", "CELL_LINE", 160, 169], ["bFGF", "PROTEIN", 190, 194], ["18kD isoform", "PROTEIN", 257, 269], ["ALL isoforms", "PROTEIN", 273, 285], ["patients", "SPECIES", 105, 113], ["bFGF", "TREATMENT", 51, 55], ["melanomas", "PROBLEM", 92, 101], ["1F6 cells", "TREATMENT", 160, 169], ["low endogenous bFGF levels", "PROBLEM", 175, 201], ["vectors", "TREATMENT", 229, 236], ["the variation in phenotypic behaviour", "PROBLEM", 323, 360], ["high", "OBSERVATION_MODIFIER", 63, 67], ["metastatic", "OBSERVATION_MODIFIER", 68, 78], ["melanomas", "OBSERVATION", 92, 101]]], ["The 18kD bFGF isoform functions as an autocrine and paracrine growth factor and is mainly found in the cytoplasm of cells and bound to heparan sulphate proteoglycans (HSPGs) on the cell membrane.", [["cytoplasm", "ANATOMY", 103, 112], ["cells", "ANATOMY", 116, 121], ["cell membrane", "ANATOMY", 181, 194], ["heparan sulphate", "CHEMICAL", 135, 151], ["bFGF", "GENE_OR_GENE_PRODUCT", 9, 13], ["cytoplasm", "ORGANISM_SUBSTANCE", 103, 112], ["cells", "CELL", 116, 121], ["heparan sulphate proteoglycans", "GENE_OR_GENE_PRODUCT", 135, 165], ["HSPGs", "GENE_OR_GENE_PRODUCT", 167, 172], ["cell membrane", "CELLULAR_COMPONENT", 181, 194], ["18kD bFGF isoform", "PROTEIN", 4, 21], ["heparan sulphate proteoglycans", "PROTEIN", 135, 165], ["HSPGs", "PROTEIN", 167, 172], ["paracrine growth factor", "PROBLEM", 52, 75], ["heparan sulphate proteoglycans", "TREATMENT", 135, 165], ["the cell membrane", "TREATMENT", 177, 194], ["cell membrane", "OBSERVATION", 181, 194]]], ["In contrast, the high molecular weight (HMW) isoforms are located in the nucleus and are thought to play a role in transcriptional regulation (Renko et al, 1990; Bugler et al, 1991; Florkiewicz et al, 1991; Quarto et al, 1991).", [["nucleus", "ANATOMY", 73, 80], ["high molecular weight (HMW)", "GENE_OR_GENE_PRODUCT", 17, 44], ["nucleus", "CELLULAR_COMPONENT", 73, 80], ["high molecular weight (HMW) isoforms", "PROTEIN", 17, 53], ["nucleus", "ANATOMY", 73, 80]]], ["Upon transfection, however, both 1F6-18kD and 1F6-ALL clones expressed similar amounts of CD13, which suggests that expression of the 18kD protein alone is sufficient for the induction of CD13.", [["1F6-18kD", "ANATOMY", 33, 41], ["1F6-ALL clones", "ANATOMY", 46, 60], ["1F6-ALL clones", "CELL", 46, 60], ["CD13", "GENE_OR_GENE_PRODUCT", 90, 94], ["18kD", "GENE_OR_GENE_PRODUCT", 134, 138], ["CD13", "GENE_OR_GENE_PRODUCT", 188, 192], ["1F6-18kD and 1F6-ALL clones", "CELL_LINE", 33, 60], ["CD13", "PROTEIN", 90, 94], ["18kD protein", "PROTEIN", 134, 146], ["CD13", "PROTEIN", 188, 192], ["CD13", "TEST", 90, 94], ["CD13", "TEST", 188, 192], ["transfection", "OBSERVATION", 5, 17]]], ["Moreover, changes in morphology and growth rate were similar between 1F6-18kD and 1F6-ALL clones.DISCUSSIONInduction of CD13 expression by exogenous bFGF has previously been described in human endothelial cells and is required for vasculogenesis.", [["1F6-18kD", "ANATOMY", 69, 77], ["1F6-ALL clones", "ANATOMY", 82, 96], ["endothelial cells", "ANATOMY", 193, 210], ["ALL", "DISEASE", 86, 89], ["bFGF", "CHEMICAL", 149, 153], ["1F6-18kD", "CELL", 69, 77], ["1F6-ALL clones", "CELL", 82, 96], ["CD13", "GENE_OR_GENE_PRODUCT", 120, 124], ["bFGF", "GENE_OR_GENE_PRODUCT", 149, 153], ["human", "ORGANISM", 187, 192], ["endothelial cells", "CELL", 193, 210], ["1F6-18kD and 1F6-ALL clones", "CELL_LINE", 69, 96], ["CD13", "PROTEIN", 120, 124], ["bFGF", "PROTEIN", 149, 153], ["human endothelial cells", "CELL_TYPE", 187, 210], ["human", "SPECIES", 187, 192], ["human", "SPECIES", 187, 192], ["growth rate", "TEST", 36, 47], ["exogenous bFGF", "PROBLEM", 139, 153], ["vasculogenesis", "PROBLEM", 231, 245]]], ["In the study by Bhagwat et al (2001), addition of the 18kD bFGF protein to serum-starved HUVECs upregulated CD13 mRNA expression up to 2.5-fold.", [["serum", "ANATOMY", 75, 80], ["HUVECs", "ANATOMY", 89, 95], ["bFGF", "GENE_OR_GENE_PRODUCT", 59, 63], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["HUVECs", "CELL", 89, 95], ["CD13", "GENE_OR_GENE_PRODUCT", 108, 112], ["18kD bFGF protein", "PROTEIN", 54, 71], ["HUVECs", "CELL_LINE", 89, 95], ["CD13 mRNA", "RNA", 108, 117], ["the study", "TEST", 3, 12], ["the 18kD bFGF protein", "TEST", 50, 71], ["serum", "TEST", 75, 80], ["CD13", "TEST", 108, 112], ["mRNA expression", "TEST", 113, 128], ["HUVECs", "ANATOMY", 89, 95]]], ["Although bFGF was the most potent stimulator of CD13 expression in that study, induction of CD13 protein was also observed when endothelial cells were cultured under hypoxic conditions or were treated with the angiogenic growth factors VEGF, TNF\u03b1 or IGF-1.", [["endothelial cells", "ANATOMY", 128, 145], ["bFGF", "GENE_OR_GENE_PRODUCT", 9, 13], ["CD13", "GENE_OR_GENE_PRODUCT", 48, 52], ["CD13", "GENE_OR_GENE_PRODUCT", 92, 96], ["endothelial cells", "CELL", 128, 145], ["VEGF", "GENE_OR_GENE_PRODUCT", 236, 240], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 242, 246], ["IGF-1", "GENE_OR_GENE_PRODUCT", 250, 255], ["bFGF", "PROTEIN", 9, 13], ["CD13", "PROTEIN", 48, 52], ["CD13 protein", "PROTEIN", 92, 104], ["endothelial cells", "CELL_TYPE", 128, 145], ["angiogenic growth factors", "PROTEIN", 210, 235], ["VEGF", "PROTEIN", 236, 240], ["TNF\u03b1", "PROTEIN", 242, 246], ["IGF-1", "PROTEIN", 250, 255], ["bFGF", "PROBLEM", 9, 13], ["that study", "TEST", 67, 77], ["CD13 protein", "TEST", 92, 104], ["endothelial cells", "PROBLEM", 128, 145], ["hypoxic conditions", "PROBLEM", 166, 184], ["the angiogenic growth factors VEGF", "PROBLEM", 206, 240], ["TNF", "TEST", 242, 245], ["IGF", "TEST", 250, 253], ["most potent", "OBSERVATION_MODIFIER", 22, 33]]], ["Inhibition of CD13 expression by bestatin, amastatin or the monoclonal-anti CD13 antibody MY7 resulted in a clear reduction of capillary tube formation of HUVECs, while there was no effect of these inhibitors on proliferation (Bhagwat et al, 2001).", [["capillary tube", "ANATOMY", 127, 141], ["HUVECs", "ANATOMY", 155, 161], ["bestatin", "CHEMICAL", 33, 41], ["amastatin", "CHEMICAL", 43, 52], ["MY7", "CHEMICAL", 90, 93], ["bestatin", "CHEMICAL", 33, 41], ["amastatin", "CHEMICAL", 43, 52], ["CD13", "GENE_OR_GENE_PRODUCT", 14, 18], ["bestatin", "SIMPLE_CHEMICAL", 33, 41], ["amastatin", "SIMPLE_CHEMICAL", 43, 52], ["CD13", "GENE_OR_GENE_PRODUCT", 76, 80], ["capillary tube", "TISSUE", 127, 141], ["HUVECs", "CELL", 155, 161], ["CD13", "PROTEIN", 14, 18], ["monoclonal-anti CD13 antibody MY7", "PROTEIN", 60, 93], ["HUVECs", "CELL_LINE", 155, 161], ["CD13 expression", "TREATMENT", 14, 29], ["bestatin", "TREATMENT", 33, 41], ["amastatin", "TREATMENT", 43, 52], ["the monoclonal-anti CD13 antibody", "TEST", 56, 89], ["capillary tube formation of HUVECs", "TREATMENT", 127, 161], ["these inhibitors", "TREATMENT", 192, 208], ["CD13 expression", "OBSERVATION", 14, 29], ["clear", "OBSERVATION_MODIFIER", 108, 113], ["reduction", "OBSERVATION_MODIFIER", 114, 123], ["capillary tube formation", "OBSERVATION", 127, 151], ["HUVECs", "ANATOMY", 155, 161]]], ["The authors have also reported that exogenous bFGF could induce CD13 expression in KS1767 Kaposi sarcoma cells (Bhagwat et al, 2001).", [["KS1767 Kaposi sarcoma cells", "ANATOMY", 83, 110], ["bFGF", "CHEMICAL", 46, 50], ["Kaposi sarcoma", "DISEASE", 90, 104], ["bFGF", "GENE_OR_GENE_PRODUCT", 46, 50], ["CD13", "GENE_OR_GENE_PRODUCT", 64, 68], ["KS1767 Kaposi sarcoma cells", "CELL", 83, 110], ["bFGF", "PROTEIN", 46, 50], ["CD13", "PROTEIN", 64, 68], ["KS1767 Kaposi sarcoma cells", "CELL_LINE", 83, 110], ["exogenous bFGF", "PROBLEM", 36, 50], ["Kaposi sarcoma cells", "PROBLEM", 90, 110], ["Kaposi sarcoma", "OBSERVATION", 90, 104]]], ["Recently, Kehlen et al (2003) have shown induction of CD13 expression upon stimulation of serum-starved 1736 thyroid carcinoma cells with bFGF.DISCUSSIONRepeatedly, we were not able to increase CD13 expression by stimulating serum-starved 1F6 cells with exogenous recombinant human bFGF, regardless efficient stimulation of cell proliferation (data not shown).", [["serum", "ANATOMY", 90, 95], ["thyroid carcinoma cells", "ANATOMY", 109, 132], ["serum", "ANATOMY", 225, 230], ["1F6 cells", "ANATOMY", 239, 248], ["cell", "ANATOMY", 324, 328], ["thyroid carcinoma", "DISEASE", 109, 126], ["CD13", "GENE_OR_GENE_PRODUCT", 54, 58], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["1736 thyroid carcinoma cells", "CELL", 104, 132], ["bFGF", "GENE_OR_GENE_PRODUCT", 138, 142], ["CD13", "GENE_OR_GENE_PRODUCT", 194, 198], ["serum", "ORGANISM_SUBSTANCE", 225, 230], ["1F6 cells", "CELL", 239, 248], ["human", "ORGANISM", 276, 281], ["bFGF", "GENE_OR_GENE_PRODUCT", 282, 286], ["cell", "CELL", 324, 328], ["CD13", "PROTEIN", 54, 58], ["serum-starved 1736 thyroid carcinoma cells", "CELL_LINE", 90, 132], ["bFGF", "PROTEIN", 138, 142], ["CD13", "PROTEIN", 194, 198], ["1F6 cells", "CELL_LINE", 239, 248], ["exogenous recombinant human bFGF", "PROTEIN", 254, 286], ["human", "SPECIES", 276, 281], ["human", "SPECIES", 276, 281], ["CD13 expression", "PROBLEM", 54, 69], ["serum", "TEST", 90, 95], ["thyroid carcinoma cells", "PROBLEM", 109, 132], ["bFGF", "PROBLEM", 138, 142], ["stimulating serum", "TEST", 213, 230], ["exogenous recombinant human bFGF", "TREATMENT", 254, 286], ["cell proliferation", "PROBLEM", 324, 342], ["thyroid", "ANATOMY", 109, 116], ["carcinoma cells", "OBSERVATION", 117, 132], ["cell proliferation", "OBSERVATION", 324, 342]]], ["This finding indicates that the bFGF-mediated induction of CD13 in 1F6 cells is an indirect effect of the transformation process in itself, rather than a direct effect on CD13 promoter activity.", [["1F6 cells", "ANATOMY", 67, 76], ["bFGF", "GENE_OR_GENE_PRODUCT", 32, 36], ["CD13", "GENE_OR_GENE_PRODUCT", 59, 63], ["1F6 cells", "CELL", 67, 76], ["CD13", "GENE_OR_GENE_PRODUCT", 171, 175], ["bFGF", "PROTEIN", 32, 36], ["CD13", "PROTEIN", 59, 63], ["1F6 cells", "CELL_LINE", 67, 76], ["CD13 promoter", "DNA", 171, 184], ["the bFGF", "TEST", 28, 36], ["CD13 in 1F6 cells", "TREATMENT", 59, 76], ["the transformation process", "PROBLEM", 102, 128], ["transformation process", "OBSERVATION", 106, 128]]], ["Since CD13 can be detected on melanoma cells (Elder et al, 1989; Menrad et al, 1993; Fujii et al, 1995), we are the first to report that endogenous bFGF can mediate the expression and activity of this protein.DISCUSSIONBestatin is a well-known chemical inhibitor of CD13 aminopeptidase activity, which blocks the catalytic site of the enzyme in a competitive manner.", [["melanoma cells", "ANATOMY", 30, 44], ["melanoma", "DISEASE", 30, 38], ["DISCUSSIONBestatin", "CHEMICAL", 209, 227], ["CD13", "GENE_OR_GENE_PRODUCT", 6, 10], ["melanoma cells", "CELL", 30, 44], ["bFGF", "GENE_OR_GENE_PRODUCT", 148, 152], ["CD13 aminopeptidase", "GENE_OR_GENE_PRODUCT", 266, 285], ["CD13", "PROTEIN", 6, 10], ["melanoma cells", "CELL_TYPE", 30, 44], ["bFGF", "PROTEIN", 148, 152], ["CD13 aminopeptidase", "PROTEIN", 266, 285], ["catalytic site", "PROTEIN", 313, 327], ["enzyme", "PROTEIN", 335, 341], ["CD13", "TEST", 6, 10], ["melanoma cells", "PROBLEM", 30, 44], ["endogenous bFGF", "PROBLEM", 137, 152], ["CD13 aminopeptidase activity", "TREATMENT", 266, 294], ["melanoma cells", "OBSERVATION", 30, 44]]], ["Although bestatin is often considered to be specific for CD13, it also inhibits other aminopeptidases, such as aminopeptidase B and leucine aminopeptidases (Scornik and Botbol, 2001).", [["bestatin", "CHEMICAL", 9, 17], ["leucine", "CHEMICAL", 132, 139], ["bestatin", "CHEMICAL", 9, 17], ["leucine", "CHEMICAL", 132, 139], ["bestatin", "SIMPLE_CHEMICAL", 9, 17], ["CD13", "GENE_OR_GENE_PRODUCT", 57, 61], ["aminopeptidase B", "GENE_OR_GENE_PRODUCT", 111, 127], ["leucine aminopeptidases", "SIMPLE_CHEMICAL", 132, 155], ["CD13", "PROTEIN", 57, 61], ["aminopeptidases", "PROTEIN", 86, 101], ["aminopeptidase B", "PROTEIN", 111, 127], ["leucine aminopeptidases", "PROTEIN", 132, 155], ["CD13", "PROBLEM", 57, 61], ["other aminopeptidases", "PROBLEM", 80, 101], ["aminopeptidase B and leucine aminopeptidases", "TEST", 111, 155]]], ["High concentrations of bestatin (150\u2013300 \u03bcM) clearly reduced invasion of HT1080 fibrosarcoma cells and WM1158 melanoma cells through Matrigel (Menrad et al, 1993; Fujii et al, 1996).", [["HT1080 fibrosarcoma cells", "ANATOMY", 73, 98], ["WM1158 melanoma cells", "ANATOMY", 103, 124], ["bestatin", "CHEMICAL", 23, 31], ["fibrosarcoma", "DISEASE", 80, 92], ["melanoma", "DISEASE", 110, 118], ["bestatin", "CHEMICAL", 23, 31], ["bestatin", "SIMPLE_CHEMICAL", 23, 31], ["HT1080 fibrosarcoma cells", "CELL", 73, 98], ["WM1158 melanoma cells", "CELL", 103, 124], ["HT1080 fibrosarcoma cells", "CELL_LINE", 73, 98], ["WM1158 melanoma cells", "CELL_LINE", 103, 124], ["bestatin (150\u2013300 \u03bcM)", "TREATMENT", 23, 44], ["HT1080 fibrosarcoma cells", "PROBLEM", 73, 98], ["concentrations", "OBSERVATION_MODIFIER", 5, 19], ["reduced", "OBSERVATION_MODIFIER", 53, 60], ["invasion", "OBSERVATION_MODIFIER", 61, 69], ["HT1080 fibrosarcoma cells", "OBSERVATION", 73, 98], ["melanoma cells", "OBSERVATION", 110, 124]]], ["WM15 is a monoclonal antibody that specifically neutralises CD13 activity.", [["WM15", "CHEMICAL", 0, 4], ["WM15", "SIMPLE_CHEMICAL", 0, 4], ["CD13", "GENE_OR_GENE_PRODUCT", 60, 64], ["WM15", "PROTEIN", 0, 4], ["monoclonal antibody", "PROTEIN", 10, 29], ["CD13", "PROTEIN", 60, 64], ["a monoclonal antibody", "TEST", 8, 29], ["monoclonal antibody", "OBSERVATION", 10, 29], ["CD13 activity", "OBSERVATION", 60, 73]]], ["WM15 has been shown to inhibit invasion through Matrigel, as described for SN12M renal-cell carcinoma, HT1080 fibrosarcoma and A375 melanoma cells (Saiki et al, 1993).", [["SN12M renal-cell carcinoma", "ANATOMY", 75, 101], ["HT1080 fibrosarcoma", "ANATOMY", 103, 122], ["A375 melanoma cells", "ANATOMY", 127, 146], ["WM15", "CHEMICAL", 0, 4], ["renal-cell carcinoma", "DISEASE", 81, 101], ["fibrosarcoma", "DISEASE", 110, 122], ["melanoma", "DISEASE", 132, 140], ["WM15", "GENE_OR_GENE_PRODUCT", 0, 4], ["SN12M renal-cell carcinoma", "CELL", 75, 101], ["HT1080 fibrosarcoma", "CELL", 103, 122], ["A375 melanoma cells", "CELL", 127, 146], ["WM15", "PROTEIN", 0, 4], ["SN12M renal-cell carcinoma, HT1080 fibrosarcoma", "CELL_LINE", 75, 122], ["A375 melanoma cells", "CELL_LINE", 127, 146], ["SN12M renal-cell carcinoma", "PROBLEM", 75, 101], ["HT1080 fibrosarcoma", "PROBLEM", 103, 122], ["A375 melanoma cells", "PROBLEM", 127, 146], ["invasion", "OBSERVATION", 31, 39], ["renal", "ANATOMY", 81, 86], ["cell carcinoma", "OBSERVATION", 87, 101], ["HT1080 fibrosarcoma", "OBSERVATION", 103, 122], ["A375 melanoma cells", "OBSERVATION", 127, 146]]], ["In our bFGF-overexpressing 1F6 clones, both bestatin and WM15 almost completely abrogated the enhanced invasive capacity.", [["1F6 clones", "ANATOMY", 27, 37], ["bestatin", "CHEMICAL", 44, 52], ["WM15", "CHEMICAL", 57, 61], ["bestatin", "CHEMICAL", 44, 52], ["WM15", "CHEMICAL", 57, 61], ["bFGF", "GENE_OR_GENE_PRODUCT", 7, 11], ["1F6 clones", "CELL", 27, 37], ["bestatin", "SIMPLE_CHEMICAL", 44, 52], ["WM15", "SIMPLE_CHEMICAL", 57, 61], ["bFGF", "PROTEIN", 7, 11], ["1F6 clones", "CELL_LINE", 27, 37], ["both bestatin", "TREATMENT", 39, 52], ["the enhanced invasive capacity", "PROBLEM", 90, 120], ["invasive capacity", "OBSERVATION", 103, 120]]], ["This observation indicates that the increased CD13 expression and activity in the bFGF-overexpressing clones is mainly responsible for the facilitated invasive potential.DISCUSSIONThe activity of the myeloid and the epithelial promoters of CD13 is believed to be mutually exclusive (Shapiro et al, 1991).", [["clones", "ANATOMY", 102, 108], ["myeloid", "ANATOMY", 200, 207], ["epithelial", "ANATOMY", 216, 226], ["CD13", "GENE_OR_GENE_PRODUCT", 46, 50], ["bFGF", "GENE_OR_GENE_PRODUCT", 82, 86], ["myeloid", "CELL", 200, 207], ["epithelial", "CELL", 216, 226], ["CD13", "GENE_OR_GENE_PRODUCT", 240, 244], ["CD13", "PROTEIN", 46, 50], ["bFGF", "PROTEIN", 82, 86], ["overexpressing clones", "CELL_LINE", 87, 108], ["myeloid and the epithelial promoters", "DNA", 200, 236], ["CD13", "PROTEIN", 240, 244], ["This observation", "TEST", 0, 16], ["the increased CD13 expression", "PROBLEM", 32, 61], ["overexpressing clones", "PROBLEM", 87, 108], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["CD13 expression", "OBSERVATION", 46, 61], ["overexpressing clones", "OBSERVATION", 87, 108], ["activity", "OBSERVATION_MODIFIER", 184, 192], ["myeloid", "OBSERVATION", 200, 207], ["epithelial", "ANATOMY_MODIFIER", 216, 226]]], ["As a result, expression of CD13 protein in a particular cell type is thought to be mediated by activation of either the myeloid or the epithelial promoter.", [["cell", "ANATOMY", 56, 60], ["myeloid", "ANATOMY", 120, 127], ["epithelial", "ANATOMY", 135, 145], ["CD13", "GENE_OR_GENE_PRODUCT", 27, 31], ["cell type", "CELL", 56, 65], ["myeloid", "CELL", 120, 127], ["epithelial", "TISSUE", 135, 145], ["CD13 protein", "PROTEIN", 27, 39], ["epithelial promoter", "DNA", 135, 154], ["CD13 protein", "PROBLEM", 27, 39], ["CD13 protein", "OBSERVATION", 27, 39], ["thought to be", "UNCERTAINTY", 69, 82], ["myeloid", "OBSERVATION", 120, 127], ["epithelial promoter", "OBSERVATION", 135, 154]]], ["We now show that both CD13 promoters can be activated in response to bFGF overexpression.", [["CD13", "GENE_OR_GENE_PRODUCT", 22, 26], ["bFGF", "GENE_OR_GENE_PRODUCT", 69, 73], ["CD13 promoters", "DNA", 22, 36], ["bFGF", "PROTEIN", 69, 73], ["both CD13 promoters", "TREATMENT", 17, 36], ["bFGF overexpression", "TREATMENT", 69, 88]]], ["Although in 1F6 cells the basal expression of the myeloid promoter was consistently found to be higher than the activity of the epithelial promoter, both activities were increased to the same extent, up to four-fold in clones 1F6-18kD and 1F6-ALL.", [["1F6 cells", "ANATOMY", 12, 21], ["myeloid", "ANATOMY", 50, 57], ["epithelial", "ANATOMY", 128, 138], ["1F6-18kD", "ANATOMY", 226, 234], ["1F6-ALL", "ANATOMY", 239, 246], ["ALL", "DISEASE", 243, 246], ["1F6 cells", "CELL", 12, 21], ["myeloid", "CELL", 50, 57], ["epithelial", "TISSUE", 128, 138], ["1F6-18kD", "CELL", 226, 234], ["1F6-ALL", "CANCER", 239, 246], ["1F6 cells", "CELL_LINE", 12, 21], ["myeloid promoter", "DNA", 50, 66], ["epithelial promoter", "DNA", 128, 147], ["1F6", "CELL_LINE", 239, 242], ["the myeloid promoter", "PROBLEM", 46, 66], ["clones", "TEST", 219, 225], ["basal", "ANATOMY_MODIFIER", 26, 31], ["myeloid promoter", "OBSERVATION", 50, 66], ["higher", "OBSERVATION_MODIFIER", 96, 102], ["epithelial promoter", "OBSERVATION", 128, 147], ["increased", "OBSERVATION_MODIFIER", 170, 179]]], ["We do not know if the current results are specific for melanoma cells, or whether the use of the more sensitive techniques would also allow to detect upregulation of both promoters in other cell types.", [["melanoma cells", "ANATOMY", 55, 69], ["cell", "ANATOMY", 190, 194], ["melanoma", "DISEASE", 55, 63], ["melanoma cells", "CELL", 55, 69], ["cell", "CELL", 190, 194], ["melanoma cells", "CELL_TYPE", 55, 69], ["promoters", "DNA", 171, 180], ["melanoma cells", "PROBLEM", 55, 69], ["both promoters", "OBSERVATION", 166, 180], ["cell types", "OBSERVATION", 190, 200]]], ["While initial CD13 promoter studies were performed with chloramphenicol acetyl transferase (CAT) assays and Northern blots (Shapiro et al, 1991), we made use of RT\u2013PCR and promoter-luciferase assays allowing us to detect the activities of both promoters in 1F6 melanoma cells and clones.DISCUSSIONRecently, induction of CD13 expression by bFGF in endothelial cells was shown to be regulated by two Ras-mediated signalling pathways that have been implicated in the transition of quiescent to active endothelium: the mitogen-activated protein kinase (MAPK) and phosphoinositide-3 kinase/AKT (PI-3K/AKT) pathways (Bhagwat et al, 2003).", [["1F6 melanoma cells", "ANATOMY", 257, 275], ["clones", "ANATOMY", 280, 286], ["endothelial cells", "ANATOMY", 347, 364], ["endothelium", "ANATOMY", 498, 509], ["chloramphenicol", "CHEMICAL", 56, 71], ["melanoma", "DISEASE", 261, 269], ["chloramphenicol acetyl", "CHEMICAL", 56, 78], ["CD13", "GENE_OR_GENE_PRODUCT", 14, 18], ["chloramphenicol acetyl transferase", "GENE_OR_GENE_PRODUCT", 56, 90], ["CAT", "GENE_OR_GENE_PRODUCT", 92, 95], ["luciferase", "GENE_OR_GENE_PRODUCT", 181, 191], ["1F6 melanoma cells", "CELL", 257, 275], ["clones", "CELL", 280, 286], ["CD13", "GENE_OR_GENE_PRODUCT", 320, 324], ["bFGF", "GENE_OR_GENE_PRODUCT", 339, 343], ["endothelial cells", "CELL", 347, 364], ["endothelium", "TISSUE", 498, 509], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 515, 547], ["MAPK", "GENE_OR_GENE_PRODUCT", 549, 553], ["phosphoinositide-3 kinase", "GENE_OR_GENE_PRODUCT", 559, 584], ["AKT", "GENE_OR_GENE_PRODUCT", 585, 588], ["PI-3K", "GENE_OR_GENE_PRODUCT", 590, 595], ["AKT", "GENE_OR_GENE_PRODUCT", 596, 599], ["CD13 promoter", "DNA", 14, 27], ["chloramphenicol acetyl transferase", "PROTEIN", 56, 90], ["CAT", "PROTEIN", 92, 95], ["luciferase", "PROTEIN", 181, 191], ["promoters", "DNA", 244, 253], ["1F6 melanoma cells", "CELL_LINE", 257, 275], ["CD13", "PROTEIN", 320, 324], ["bFGF", "PROTEIN", 339, 343], ["endothelial cells", "CELL_TYPE", 347, 364], ["mitogen-activated protein kinase", "PROTEIN", 515, 547], ["MAPK", "PROTEIN", 549, 553], ["phosphoinositide-3 kinase", "PROTEIN", 559, 584], ["AKT (PI-3K", "PROTEIN", 585, 595], ["AKT", "PROTEIN", 596, 599], ["initial CD13 promoter studies", "TEST", 6, 35], ["chloramphenicol acetyl transferase", "TREATMENT", 56, 90], ["RT\u2013PCR", "TREATMENT", 161, 167], ["promoter-luciferase assays", "TEST", 172, 198], ["CD13 expression", "TREATMENT", 320, 335], ["the mitogen", "TEST", 511, 522], ["activated protein kinase", "TEST", 523, 547], ["MAPK", "TEST", 549, 553], ["phosphoinositide", "TEST", 559, 575], ["kinase", "TEST", 578, 584], ["AKT", "TEST", 585, 588], ["PI", "TEST", 590, 592], ["melanoma cells", "OBSERVATION", 261, 275], ["endothelial", "ANATOMY", 347, 358]]], ["Petrovic et al (2003) have demonstrated in activated endothelial cells that CD13 transcription was induced by RAS/MAPK-mediated phosphorylation of the transcription factor Ets-2 resulting in increased activity of the epithelial CD13 promoter.", [["endothelial cells", "ANATOMY", 53, 70], ["epithelial", "ANATOMY", 217, 227], ["endothelial cells", "CELL", 53, 70], ["CD13", "GENE_OR_GENE_PRODUCT", 76, 80], ["RAS", "GENE_OR_GENE_PRODUCT", 110, 113], ["MAPK", "GENE_OR_GENE_PRODUCT", 114, 118], ["Ets-2", "GENE_OR_GENE_PRODUCT", 172, 177], ["epithelial CD13", "GENE_OR_GENE_PRODUCT", 217, 232], ["endothelial cells", "CELL_TYPE", 53, 70], ["CD13", "PROTEIN", 76, 80], ["RAS", "PROTEIN", 110, 113], ["MAPK", "PROTEIN", 114, 118], ["transcription factor Ets-2", "PROTEIN", 151, 177], ["epithelial CD13 promoter", "DNA", 217, 241], ["activated endothelial cells", "PROBLEM", 43, 70], ["CD13 transcription", "TREATMENT", 76, 94], ["the transcription factor Ets", "TEST", 147, 175], ["increased activity of the epithelial CD13 promoter", "PROBLEM", 191, 241], ["endothelial", "ANATOMY", 53, 64], ["increased activity", "OBSERVATION", 191, 209], ["epithelial CD13 promoter", "OBSERVATION", 217, 241]]], ["In our bFGF-overexpressing 1F6 clones, phospho-AKT and phospho-p38 MAPK levels were increased as compared to basal levels in parent 1F6 cells, while basal phospho-ERK1/2 MAPK was not further increased (Fontijn et al, unpublished data).", [["1F6 clones", "ANATOMY", 27, 37], ["1F6 cells", "ANATOMY", 132, 141], ["phospho", "CHEMICAL", 39, 46], ["phospho", "CHEMICAL", 55, 62], ["bFGF", "GENE_OR_GENE_PRODUCT", 7, 11], ["1F6 clones", "CELL", 27, 37], ["phospho-AKT", "GENE_OR_GENE_PRODUCT", 39, 50], ["phospho-p38 MAPK", "GENE_OR_GENE_PRODUCT", 55, 71], ["1F6 cells", "CELL", 132, 141], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 163, 169], ["MAPK", "GENE_OR_GENE_PRODUCT", 170, 174], ["bFGF", "PROTEIN", 7, 11], ["1F6 clones", "CELL_LINE", 27, 37], ["AKT", "PROTEIN", 47, 50], ["p38 MAPK", "PROTEIN", 63, 71], ["1F6 cells", "CELL_LINE", 132, 141], ["ERK1/2 MAPK", "PROTEIN", 163, 174], ["our bFGF", "TEST", 3, 11], ["phospho", "TEST", 39, 46], ["phospho-p38 MAPK levels", "TEST", 55, 78], ["basal levels", "TEST", 109, 121], ["basal phospho-ERK1/2 MAPK", "TEST", 149, 174], ["increased", "OBSERVATION_MODIFIER", 84, 93]]], ["We are further investigating the possible contribution of the PI-3K/AKT and p38 MAPK signalling pathways in the increased CD13 expression in bFGF-overexpressing 1F6 clones.DISCUSSIONIn general, high CD13 expression in solid tumours in patients is considered as an unfavourable factor.", [["1F6 clones", "ANATOMY", 161, 171], ["solid tumours", "ANATOMY", 218, 231], ["solid tumours", "DISEASE", 218, 231], ["PI-3K", "GENE_OR_GENE_PRODUCT", 62, 67], ["AKT", "GENE_OR_GENE_PRODUCT", 68, 71], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 76, 84], ["CD13", "GENE_OR_GENE_PRODUCT", 122, 126], ["bFGF", "GENE_OR_GENE_PRODUCT", 141, 145], ["1F6 clones", "CELL", 161, 171], ["CD13", "GENE_OR_GENE_PRODUCT", 199, 203], ["solid tumours", "CANCER", 218, 231], ["patients", "ORGANISM", 235, 243], ["3K", "PROTEIN", 65, 67], ["AKT", "PROTEIN", 68, 71], ["MAPK", "PROTEIN", 80, 84], ["CD13", "PROTEIN", 122, 126], ["bFGF", "PROTEIN", 141, 145], ["1F6 clones", "CELL_LINE", 161, 171], ["CD13", "PROTEIN", 199, 203], ["patients", "SPECIES", 235, 243], ["the PI", "TEST", 58, 64], ["p38 MAPK signalling pathways", "TEST", 76, 104], ["the increased CD13 expression in bFGF", "PROBLEM", 108, 145], ["overexpressing 1F6 clones", "PROBLEM", 146, 171], ["high CD13 expression in solid tumours", "PROBLEM", 194, 231], ["an unfavourable factor", "PROBLEM", 261, 283], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["CD13 expression", "OBSERVATION", 122, 137], ["solid tumours", "OBSERVATION", 218, 231]]], ["Few clinical studies are available, among which are observations in pancreatic carcinoma, colon carcinoma and thyroid carcinoma, which will be described shortly.", [["pancreatic carcinoma", "ANATOMY", 68, 88], ["colon carcinoma", "ANATOMY", 90, 105], ["thyroid carcinoma", "ANATOMY", 110, 127], ["pancreatic carcinoma", "DISEASE", 68, 88], ["colon carcinoma", "DISEASE", 90, 105], ["thyroid carcinoma", "DISEASE", 110, 127], ["pancreatic carcinoma", "CANCER", 68, 88], ["colon carcinoma", "CANCER", 90, 105], ["thyroid carcinoma", "CANCER", 110, 127], ["Few clinical studies", "TEST", 0, 20], ["pancreatic carcinoma", "PROBLEM", 68, 88], ["colon carcinoma", "PROBLEM", 90, 105], ["thyroid carcinoma", "PROBLEM", 110, 127], ["pancreatic", "ANATOMY", 68, 78], ["carcinoma", "OBSERVATION", 79, 88], ["colon", "ANATOMY", 90, 95], ["carcinoma", "OBSERVATION", 96, 105], ["thyroid", "ANATOMY", 110, 117], ["carcinoma", "OBSERVATION", 118, 127]]], ["CD13 protein expression was detected in 48% of pancreatic carcinoma patients and was significantly associated with a shorter median survival (Ikeda et al, 2003).", [["pancreatic carcinoma", "ANATOMY", 47, 67], ["pancreatic carcinoma", "DISEASE", 47, 67], ["CD13", "GENE_OR_GENE_PRODUCT", 0, 4], ["pancreatic carcinoma", "CANCER", 47, 67], ["patients", "ORGANISM", 68, 76], ["CD13", "PROTEIN", 0, 4], ["patients", "SPECIES", 68, 76], ["CD13 protein expression", "TEST", 0, 23], ["pancreatic carcinoma", "PROBLEM", 47, 67], ["pancreatic", "ANATOMY", 47, 57], ["carcinoma", "OBSERVATION", 58, 67]]], ["The disease-free and overall survival rate for patients with CD13-positive colon carcinoma was significantly lower than that for patients without CD13 expression (Hashida et al, 2002).", [["CD13-positive colon carcinoma", "ANATOMY", 61, 90], ["colon carcinoma", "DISEASE", 75, 90], ["patients", "ORGANISM", 47, 55], ["CD13", "GENE_OR_GENE_PRODUCT", 61, 65], ["patients", "ORGANISM", 129, 137], ["CD13", "GENE_OR_GENE_PRODUCT", 146, 150], ["CD13", "PROTEIN", 61, 65], ["CD13", "PROTEIN", 146, 150], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 129, 137], ["The disease", "PROBLEM", 0, 11], ["CD13", "TEST", 61, 65], ["positive colon carcinoma", "PROBLEM", 66, 90], ["CD13 expression", "PROBLEM", 146, 161], ["disease", "OBSERVATION", 4, 11], ["free", "OBSERVATION_MODIFIER", 12, 16], ["colon", "ANATOMY", 75, 80], ["carcinoma", "OBSERVATION", 81, 90]]], ["Kehlen et al (2003) have shown that CD13 expression in undifferentiated thyroid carcinomas was higher than that in papillary or follicular thyroid carcinomas, suggesting that it is a marker for differentiation.", [["undifferentiated thyroid carcinomas", "ANATOMY", 55, 90], ["papillary", "ANATOMY", 115, 124], ["follicular thyroid carcinomas", "ANATOMY", 128, 157], ["thyroid carcinomas", "DISEASE", 72, 90], ["follicular thyroid carcinomas", "DISEASE", 128, 157], ["CD13", "GENE_OR_GENE_PRODUCT", 36, 40], ["undifferentiated thyroid carcinomas", "CANCER", 55, 90], ["papillary", "CANCER", 115, 124], ["follicular thyroid carcinomas", "CANCER", 128, 157], ["CD13", "PROTEIN", 36, 40], ["CD13 expression", "PROBLEM", 36, 51], ["undifferentiated thyroid carcinomas", "PROBLEM", 55, 90], ["papillary or follicular thyroid carcinomas", "PROBLEM", 115, 157], ["undifferentiated", "OBSERVATION_MODIFIER", 55, 71], ["thyroid", "ANATOMY", 72, 79], ["carcinomas", "OBSERVATION", 80, 90], ["papillary", "ANATOMY", 115, 124], ["follicular thyroid carcinomas", "OBSERVATION", 128, 157]]], ["Clinical studies on CD13 expression in cutaneous melanoma are yet to be carried out.DISCUSSIONIt can be hypothesized that the presence of CD13 in melanoma patients will also be associated with poor prognosis.", [["cutaneous melanoma", "ANATOMY", 39, 57], ["melanoma", "ANATOMY", 146, 154], ["cutaneous melanoma", "DISEASE", 39, 57], ["melanoma", "DISEASE", 146, 154], ["CD13", "GENE_OR_GENE_PRODUCT", 20, 24], ["cutaneous melanoma", "CANCER", 39, 57], ["CD13", "GENE_OR_GENE_PRODUCT", 138, 142], ["melanoma", "CANCER", 146, 154], ["patients", "ORGANISM", 155, 163], ["CD13", "PROTEIN", 20, 24], ["CD13", "PROTEIN", 138, 142], ["patients", "SPECIES", 155, 163], ["Clinical studies", "TEST", 0, 16], ["CD13 expression", "TEST", 20, 35], ["cutaneous melanoma", "PROBLEM", 39, 57], ["CD13 in melanoma", "PROBLEM", 138, 154], ["cutaneous", "ANATOMY", 39, 48], ["melanoma", "OBSERVATION", 49, 57], ["melanoma", "OBSERVATION", 146, 154]]], ["As a rationale, it has been shown in vitro that inhibition of CD13 aminopeptidase activity can reduce the invasive capacity of WM1158 and A375M melanoma cells through Matrigel (Menrad et al, 1993; Saiki et al, 1993).", [["WM1158", "ANATOMY", 127, 133], ["A375M melanoma cells", "ANATOMY", 138, 158], ["melanoma", "DISEASE", 144, 152], ["CD13 aminopeptidase", "GENE_OR_GENE_PRODUCT", 62, 81], ["WM1158", "CELL", 127, 133], ["A375M melanoma cells", "CELL", 138, 158], ["CD13 aminopeptidase", "PROTEIN", 62, 81], ["WM1158 and A375M melanoma cells", "CELL_LINE", 127, 158], ["WM1158", "SPECIES", 127, 133], ["CD13 aminopeptidase activity", "TREATMENT", 62, 90], ["the invasive capacity", "PROBLEM", 102, 123], ["A375M melanoma cells", "PROBLEM", 138, 158], ["invasive", "OBSERVATION_MODIFIER", 106, 114], ["melanoma cells", "OBSERVATION", 144, 158]]], ["Upon transfection of CD13 into A375M and A2058 melanoma cells, increased degradation of type IV collagen and invasion in ECM have been observed (Fujii et al, 1995).", [["A375M", "ANATOMY", 31, 36], ["A2058 melanoma cells", "ANATOMY", 41, 61], ["ECM", "ANATOMY", 121, 124], ["melanoma", "DISEASE", 47, 55], ["CD13", "GENE_OR_GENE_PRODUCT", 21, 25], ["A375M", "CELL", 31, 36], ["A2058 melanoma cells", "CELL", 41, 61], ["type IV collagen", "GENE_OR_GENE_PRODUCT", 88, 104], ["ECM", "CELLULAR_COMPONENT", 121, 124], ["CD13", "PROTEIN", 21, 25], ["A375M and A2058 melanoma cells", "CELL_LINE", 31, 61], ["type IV collagen", "PROTEIN", 88, 104], ["ECM", "PROTEIN", 121, 124], ["CD13", "TEST", 21, 25], ["A2058 melanoma cells", "PROBLEM", 41, 61], ["increased degradation", "PROBLEM", 63, 84], ["type IV collagen", "TREATMENT", 88, 104], ["invasion in ECM", "PROBLEM", 109, 124], ["melanoma cells", "OBSERVATION", 47, 61], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["degradation", "OBSERVATION_MODIFIER", 73, 84], ["type IV collagen", "OBSERVATION_MODIFIER", 88, 104], ["invasion", "OBSERVATION", 109, 117]]], ["These CD13-transfected cells showed a significantly augmented lung-colonising potential in nude mice (Fujii et al, 1995).", [["cells", "ANATOMY", 23, 28], ["lung", "ANATOMY", 62, 66], ["CD13", "GENE_OR_GENE_PRODUCT", 6, 10], ["cells", "CELL", 23, 28], ["lung", "ORGAN", 62, 66], ["nude mice", "ORGANISM", 91, 100], ["CD13", "PROTEIN", 6, 10], ["transfected cells", "CELL_LINE", 11, 28], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 96, 100], ["These CD13", "TEST", 0, 10], ["transfected cells", "TEST", 11, 28], ["a significantly augmented lung", "PROBLEM", 36, 66], ["significantly", "OBSERVATION_MODIFIER", 38, 51], ["augmented", "OBSERVATION_MODIFIER", 52, 61], ["lung", "ANATOMY", 62, 66]]], ["The observations are in agreement with our data that 1F6 cells could hardly invade through Matrigel, but their invasive capacity is greatly facilitated in the case of CD13 overexpression.", [["1F6 cells", "ANATOMY", 53, 62], ["1F6 cells", "CELL", 53, 62], ["CD13", "GENE_OR_GENE_PRODUCT", 167, 171], ["1F6 cells", "CELL_LINE", 53, 62], ["CD13", "PROTEIN", 167, 171], ["1F6 cells", "PROBLEM", 53, 62], ["CD13 overexpression", "PROBLEM", 167, 186]]], ["As proof of concept, in our panel of human melanoma cell lines, we found a clear correlation between bFGF and CD13 mRNA and protein expression (Figure 9).", [["melanoma cell lines", "ANATOMY", 43, 62], ["melanoma", "DISEASE", 43, 51], ["human", "ORGANISM", 37, 42], ["melanoma cell lines", "CELL", 43, 62], ["bFGF", "GENE_OR_GENE_PRODUCT", 101, 105], ["CD13", "GENE_OR_GENE_PRODUCT", 110, 114], ["human melanoma cell lines", "CELL_LINE", 37, 62], ["bFGF", "PROTEIN", 101, 105], ["CD13 mRNA", "RNA", 110, 119], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["bFGF", "TEST", 101, 105], ["CD13 mRNA", "TEST", 110, 119], ["protein expression", "TEST", 124, 142], ["melanoma cell lines", "OBSERVATION", 43, 62]]], ["High bFGF and CD13 protein expression could be detected in melanoma cell lines BRO and BLM, being aggressive cell lines on the basis of a high in vitro and in vivo growth rate.", [["melanoma cell lines BRO", "ANATOMY", 59, 82], ["BLM", "ANATOMY", 87, 90], ["cell lines", "ANATOMY", 109, 119], ["melanoma", "DISEASE", 59, 67], ["bFGF", "GENE_OR_GENE_PRODUCT", 5, 9], ["CD13", "GENE_OR_GENE_PRODUCT", 14, 18], ["melanoma cell lines BRO", "CELL", 59, 82], ["BLM", "CELL", 87, 90], ["cell lines", "CELL", 109, 119], ["bFGF", "PROTEIN", 5, 9], ["CD13", "PROTEIN", 14, 18], ["melanoma cell lines", "CELL_LINE", 59, 78], ["BRO", "CELL_LINE", 79, 82], ["BLM", "CELL_LINE", 87, 90], ["aggressive cell lines", "CELL_LINE", 98, 119], ["High bFGF", "PROBLEM", 0, 9], ["CD13 protein expression", "TEST", 14, 37], ["melanoma cell lines BRO", "PROBLEM", 59, 82], ["aggressive cell lines", "TREATMENT", 98, 119], ["a high in vitro", "TREATMENT", 136, 151], ["melanoma cell lines", "OBSERVATION", 59, 78], ["aggressive", "OBSERVATION_MODIFIER", 98, 108], ["cell lines", "OBSERVATION", 109, 119], ["high", "OBSERVATION_MODIFIER", 138, 142]]], ["Furthermore, BLM and BRO cells grown as subcutaneous xenografts in nude mice have a very high rate of spontaneous metastasis formation (Lockshin et al, 1985; Van Muijen et al, 1991).DISCUSSIONBestatin has been studied for its therapeutic usefulness in the clinic in the past, since the compound was considered to have immunopotentiating activity (Ota, 1991).", [["BLM", "ANATOMY", 13, 16], ["BRO cells", "ANATOMY", 21, 30], ["subcutaneous xenografts", "ANATOMY", 40, 63], ["metastasis", "DISEASE", 114, 124], ["DISCUSSIONBestatin", "CHEMICAL", 182, 200], ["BLM", "CELL", 13, 16], ["BRO cells", "CELL", 21, 30], ["subcutaneous xenografts", "CANCER", 40, 63], ["nude mice", "ORGANISM", 67, 76], ["BLM", "CELL_TYPE", 13, 16], ["BRO cells", "CELL_LINE", 21, 30], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["BLM and BRO cells", "PROBLEM", 13, 30], ["subcutaneous xenografts in nude mice", "TREATMENT", 40, 76], ["spontaneous metastasis formation", "PROBLEM", 102, 134], ["BRO cells", "OBSERVATION", 21, 30], ["subcutaneous", "ANATOMY", 40, 52], ["xenografts", "OBSERVATION", 53, 63], ["very", "OBSERVATION_MODIFIER", 84, 88], ["high", "OBSERVATION_MODIFIER", 89, 93], ["spontaneous", "OBSERVATION_MODIFIER", 102, 113], ["metastasis", "OBSERVATION", 114, 124]]], ["In a prospective randomised trial in adult nonlymphocytic leukaemia, prolongation of remission duration and survival was achieved with bestatin added to maintenance chemotherapy in elderly patients (Ota et al, 1986).", [["adult nonlymphocytic leukaemia", "ANATOMY", 37, 67], ["nonlymphocytic leukaemia", "DISEASE", 43, 67], ["bestatin", "CHEMICAL", 135, 143], ["bestatin", "CHEMICAL", 135, 143], ["adult nonlymphocytic leukaemia", "CANCER", 37, 67], ["bestatin", "SIMPLE_CHEMICAL", 135, 143], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["a prospective randomised trial", "TREATMENT", 3, 33], ["adult nonlymphocytic leukaemia", "PROBLEM", 37, 67], ["survival", "TREATMENT", 108, 116], ["bestatin", "TREATMENT", 135, 143], ["maintenance chemotherapy", "TREATMENT", 153, 177], ["nonlymphocytic leukaemia", "OBSERVATION", 43, 67]]], ["Prospective randomised clinical trials in various solid tumours contained either too few patients or were negative to demonstrate a beneficial effect on survival (Ota, 1991).", [["solid tumours", "ANATOMY", 50, 63], ["solid tumours", "CANCER", 50, 63], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["Prospective randomised clinical trials", "TREATMENT", 0, 38], ["various solid tumours", "PROBLEM", 42, 63]]], ["In a recent, randomised double-blind placebo-controlled trial by Ichinose et al (2003), bestatin was given for its aminopeptidase inhibiting, immunostimulant and antitumour activity to patients with completely resected stage I squamous-cell lung carcinoma.", [["squamous-cell lung carcinoma", "ANATOMY", 227, 255], ["bestatin", "CHEMICAL", 88, 96], ["squamous-cell lung carcinoma", "DISEASE", 227, 255], ["bestatin", "CHEMICAL", 88, 96], ["bestatin", "SIMPLE_CHEMICAL", 88, 96], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 115, 129], ["antitumour", "CANCER", 162, 172], ["patients", "ORGANISM", 185, 193], ["squamous-cell lung carcinoma", "CANCER", 227, 255], ["patients", "SPECIES", 185, 193], ["randomised double-blind placebo", "TREATMENT", 13, 44], ["Ichinose et al", "TREATMENT", 65, 79], ["bestatin", "TREATMENT", 88, 96], ["its aminopeptidase inhibiting", "TREATMENT", 111, 140], ["immunostimulant", "TREATMENT", 142, 157], ["completely resected stage I squamous-cell lung carcinoma", "PROBLEM", 199, 255], ["resected", "OBSERVATION_MODIFIER", 210, 218], ["stage I", "OBSERVATION_MODIFIER", 219, 226], ["squamous-cell", "OBSERVATION", 227, 240], ["lung", "ANATOMY", 241, 245], ["carcinoma", "OBSERVATION", 246, 255]]], ["Of the 402 patients that entered the study, it appeared that the overall survival and cancer-free survival were both significantly different in favour of the bestatin-treated group.", [["cancer", "ANATOMY", 86, 92], ["cancer", "DISEASE", 86, 92], ["bestatin", "CHEMICAL", 158, 166], ["bestatin", "CHEMICAL", 158, 166], ["patients", "ORGANISM", 11, 19], ["cancer", "CANCER", 86, 92], ["bestatin", "SIMPLE_CHEMICAL", 158, 166], ["patients", "SPECIES", 11, 19], ["the study", "TEST", 33, 42], ["cancer-free survival", "PROBLEM", 86, 106], ["the bestatin", "TREATMENT", 154, 166]]], ["Since we found a clear correlation between bFGF and CD13 expression and invasiveness of melanoma cells, the incorporation of bestatin in a clinical trial in stage II melanoma patients should be considered with the aim of preventing the development of metastases and to improve survival.DISCUSSIONIn conclusion, our data indicate that high bFGF expression in human melanoma cells is a major mechanism of the upregulation of CD13 resulting in enhanced invasive capacity and metastatic behaviour.", [["melanoma cells", "ANATOMY", 88, 102], ["stage II melanoma", "ANATOMY", 157, 174], ["metastases", "ANATOMY", 251, 261], ["melanoma cells", "ANATOMY", 364, 378], ["melanoma", "DISEASE", 88, 96], ["bestatin", "CHEMICAL", 125, 133], ["melanoma", "DISEASE", 166, 174], ["metastases", "DISEASE", 251, 261], ["melanoma", "DISEASE", 364, 372], ["bestatin", "CHEMICAL", 125, 133], ["bFGF", "GENE_OR_GENE_PRODUCT", 43, 47], ["CD13", "GENE_OR_GENE_PRODUCT", 52, 56], ["melanoma cells", "CELL", 88, 102], ["bestatin", "SIMPLE_CHEMICAL", 125, 133], ["stage II melanoma", "CANCER", 157, 174], ["patients", "ORGANISM", 175, 183], ["bFGF", "GENE_OR_GENE_PRODUCT", 339, 343], ["human", "ORGANISM", 358, 363], ["melanoma cells", "CELL", 364, 378], ["CD13", "GENE_OR_GENE_PRODUCT", 423, 427], ["bFGF", "PROTEIN", 43, 47], ["CD13", "PROTEIN", 52, 56], ["melanoma cells", "CELL_TYPE", 88, 102], ["bFGF", "PROTEIN", 339, 343], ["human melanoma cells", "CELL_TYPE", 358, 378], ["CD13", "PROTEIN", 423, 427], ["patients", "SPECIES", 175, 183], ["human", "SPECIES", 358, 363], ["human", "SPECIES", 358, 363], ["melanoma cells", "PROBLEM", 88, 102], ["bestatin", "TREATMENT", 125, 133], ["stage II melanoma", "PROBLEM", 157, 174], ["metastases", "PROBLEM", 251, 261], ["high bFGF expression in human melanoma cells", "PROBLEM", 334, 378], ["CD13", "PROBLEM", 423, 427], ["enhanced invasive capacity", "PROBLEM", 441, 467], ["metastatic behaviour", "PROBLEM", 472, 492], ["invasiveness", "OBSERVATION_MODIFIER", 72, 84], ["melanoma cells", "OBSERVATION", 88, 102], ["stage II", "OBSERVATION_MODIFIER", 157, 165], ["melanoma", "OBSERVATION", 166, 174], ["metastases", "OBSERVATION", 251, 261], ["melanoma cells", "OBSERVATION", 364, 378], ["invasive", "OBSERVATION_MODIFIER", 450, 458], ["metastatic", "OBSERVATION", 472, 482]]], ["Selective inhibition of CD13, or even of bFGF itself, should therefore be an attractive strategy for the treatment of advanced melanoma, but likely also for adjuvant treatment in stage II disease.", [["melanoma", "ANATOMY", 127, 135], ["melanoma", "DISEASE", 127, 135], ["CD13", "GENE_OR_GENE_PRODUCT", 24, 28], ["bFGF", "GENE_OR_GENE_PRODUCT", 41, 45], ["melanoma", "CANCER", 127, 135], ["stage II disease", "CANCER", 179, 195], ["CD13", "PROTEIN", 24, 28], ["bFGF", "PROTEIN", 41, 45], ["Selective inhibition of CD13", "TREATMENT", 0, 28], ["an attractive strategy", "TREATMENT", 74, 96], ["the treatment", "TREATMENT", 101, 114], ["advanced melanoma", "PROBLEM", 118, 135], ["adjuvant treatment", "TREATMENT", 157, 175], ["stage II disease", "PROBLEM", 179, 195], ["advanced", "OBSERVATION_MODIFIER", 118, 126], ["melanoma", "OBSERVATION", 127, 135], ["stage II", "OBSERVATION_MODIFIER", 179, 187], ["disease", "OBSERVATION", 188, 195]]]], "5e27b0fecc965b71e8b29c955ba4aa06fa888d08": [["Stature at 12 monthsgirls (cm) 74.9 \u00b1 3.8 Systolic blood pressure (mmHg) 88.3 \u00b1 1.08 Diastolic blood pressure (mmHg) 53.4 \u00b1 2.99 Biomarker Mean / SD p value Albuminuria (mg/g urine creatinine)", [["blood", "ANATOMY", 51, 56], ["blood", "ANATOMY", 95, 100], ["urine", "ANATOMY", 175, 180], ["Stature", "DISEASE", 0, 7], ["Albuminuria", "DISEASE", 157, 168], ["creatinine", "CHEMICAL", 181, 191], ["creatinine", "CHEMICAL", 181, 191], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["blood", "ORGANISM_SUBSTANCE", 95, 100], ["urine", "ORGANISM_SUBSTANCE", 175, 180], ["creatinine", "SIMPLE_CHEMICAL", 181, 191], ["Systolic blood pressure", "TEST", 42, 65], ["mmHg", "TEST", 67, 71], ["Diastolic blood pressure", "TEST", 85, 109], ["mmHg", "TEST", 111, 115], ["Biomarker", "TEST", 129, 138], ["Mean", "TEST", 139, 143], ["SD", "TEST", 146, 148], ["value", "TEST", 151, 156], ["Albuminuria", "TEST", 157, 168], ["mg/g urine", "TEST", 170, 180], ["creatinine", "TEST", 181, 191]]]], "1be0e0b85312fb2bf7e2f6914fb89dec82ff29d8": [["internalization into cells.", [["cells", "ANATOMY", 21, 26], ["cells", "CELL", 21, 26], ["internalization into cells", "PROBLEM", 0, 26], ["cells", "ANATOMY", 21, 26]]], ["Consistent with these findings, Mxra8-Fc protein or anti-Mxra8 monoclonal antibodies blocked CHIKV infection in multiple cell types including primary human synovial fibroblasts, osteoblasts, chondrocytes, and skeletal muscle cells.", [["cell", "ANATOMY", 121, 125], ["synovial fibroblasts", "ANATOMY", 156, 176], ["osteoblasts", "ANATOMY", 178, 189], ["chondrocytes", "ANATOMY", 191, 203], ["skeletal muscle cells", "ANATOMY", 209, 230], ["CHIKV infection", "DISEASE", 93, 108], ["Mxra8-Fc", "GENE_OR_GENE_PRODUCT", 32, 40], ["anti-Mxra8", "GENE_OR_GENE_PRODUCT", 52, 62], ["CHIKV", "ORGANISM", 93, 98], ["cell", "CELL", 121, 125], ["human", "ORGANISM", 150, 155], ["synovial fibroblasts", "CELL", 156, 176], ["osteoblasts", "CELL", 178, 189], ["chondrocytes", "CELL", 191, 203], ["skeletal muscle cells", "CELL", 209, 230], ["Mxra8", "PROTEIN", 32, 37], ["Fc protein", "PROTEIN", 38, 48], ["anti-Mxra8 monoclonal antibodies", "PROTEIN", 52, 84], ["primary human synovial fibroblasts", "CELL_TYPE", 142, 176], ["osteoblasts", "CELL_TYPE", 178, 189], ["chondrocytes", "CELL_TYPE", 191, 203], ["skeletal muscle cells", "CELL_TYPE", 209, 230], ["human", "SPECIES", 150, 155], ["CHIKV", "SPECIES", 93, 98], ["human", "SPECIES", 150, 155], ["these findings", "TEST", 16, 30], ["Mxra8", "TEST", 32, 37], ["Fc protein", "TEST", 38, 48], ["anti-Mxra8 monoclonal antibodies", "PROBLEM", 52, 84], ["CHIKV infection", "PROBLEM", 93, 108], ["multiple cell types", "PROBLEM", 112, 131], ["primary human synovial fibroblasts", "PROBLEM", 142, 176], ["osteoblasts", "PROBLEM", 178, 189], ["chondrocytes", "PROBLEM", 191, 203], ["skeletal muscle cells", "PROBLEM", 209, 230], ["CHIKV infection", "OBSERVATION", 93, 108], ["multiple cell types", "OBSERVATION", 112, 131], ["primary", "OBSERVATION_MODIFIER", 142, 149], ["human", "OBSERVATION", 150, 155], ["synovial fibroblasts", "OBSERVATION", 156, 176], ["osteoblasts", "ANATOMY", 178, 189], ["chondrocytes", "ANATOMY", 191, 203], ["skeletal muscle", "ANATOMY", 209, 224], ["cells", "OBSERVATION", 225, 230]]], ["Mutagenesis experiments suggest that Mxra8 binds to a surface-exposed region across the A and B domains of CHIKV E2, a speculated site of attachment.", [["surface", "ANATOMY", 54, 61], ["Mxra8", "CHEMICAL", 37, 42], ["E2", "CHEMICAL", 113, 115], ["Mxra8", "GENE_OR_GENE_PRODUCT", 37, 42], ["CHIKV", "ORGANISM", 107, 112], ["E2", "GENE_OR_GENE_PRODUCT", 113, 115], ["Mxra8", "PROTEIN", 37, 42], ["A and B domains", "DNA", 88, 103], ["CHIKV", "SPECIES", 107, 112], ["Mutagenesis experiments", "TEST", 0, 23], ["Mxra8 binds", "PROBLEM", 37, 48], ["CHIKV E2", "PROBLEM", 107, 115], ["CHIKV", "OBSERVATION", 107, 112], ["attachment", "OBSERVATION", 138, 148]]], ["Finally, administration of Mxr8a-Fc protein or anti-Mxra8 blocking antibodies reduced CHIKV or ONNV infection and associated foot swelling in mice.", [["foot", "ANATOMY", 125, 129], ["infection", "DISEASE", 100, 109], ["foot swelling", "DISEASE", 125, 138], ["Mxr8a-Fc", "GENE_OR_GENE_PRODUCT", 27, 35], ["anti-Mxra8", "GENE_OR_GENE_PRODUCT", 47, 57], ["CHIKV", "ORGANISM", 86, 91], ["ONNV", "GENE_OR_GENE_PRODUCT", 95, 99], ["foot", "ORGANISM_SUBDIVISION", 125, 129], ["mice", "ORGANISM", 142, 146], ["Mxr8a", "PROTEIN", 27, 32], ["Fc protein", "PROTEIN", 33, 43], ["anti-Mxra8 blocking antibodies", "PROTEIN", 47, 77], ["mice", "SPECIES", 142, 146], ["CHIKV", "SPECIES", 86, 91], ["ONNV", "SPECIES", 95, 99], ["mice", "SPECIES", 142, 146], ["Mxr8a-Fc protein", "TREATMENT", 27, 43], ["anti-Mxra8 blocking antibodies", "TREATMENT", 47, 77], ["CHIKV", "PROBLEM", 86, 91], ["ONNV infection", "PROBLEM", 95, 109], ["foot swelling", "PROBLEM", 125, 138], ["infection", "OBSERVATION", 100, 109], ["foot", "ANATOMY", 125, 129], ["swelling", "OBSERVATION", 130, 138]]], ["Pharmacological targeting of Mxra8 could form a strategy for mitigating infection and disease by multiple arthritogenic alphaviruses.", [["infection", "DISEASE", 72, 81], ["Mxra8", "GENE_OR_GENE_PRODUCT", 29, 34], ["Mxra8", "PROTEIN", 29, 34], ["Mxra8", "TREATMENT", 29, 34], ["mitigating infection", "PROBLEM", 61, 81], ["disease", "PROBLEM", 86, 93], ["multiple arthritogenic alphaviruses", "PROBLEM", 97, 132], ["infection", "OBSERVATION", 72, 81], ["multiple", "OBSERVATION_MODIFIER", 97, 105], ["arthritogenic alphaviruses", "OBSERVATION", 106, 132]]]]}